NIPA Inc

3411 Silverside Road
104 Hagley Building
Wilmington,
DE 19810 USA
Tel: (302) 478-1522
Fax: (302) 478-4097
www.nipa.com

Clariant

4693 '00 AUG 29 P4:31

August 22, 2000

Ms. Debbie Lumpkins
Dockets Management Branch (HFA-305)
Food and Drug Administration
5600 Fishers Lane, Room 1060
Rockville, MD 20852

Re: Docket No. 75N-183H
Topical Antimicrobial Drug Products
For Over-The-Counter Human Use:
Tentative Final Monograph for
Health-Care Antiseptic Drug Products
Chloroxylenol (PCMX) – ADME Study / 13 Week Dermal Draft Protocol

Dear Ms. Lumpkins:

Enclosed please find two (2) copies each of the following for Agency review:

- **Dermal Absorption With [14C]-Labeled PCMX in Mice**
- **Draft Protocol – 13 Week Dermal Toxicity Study in Mice**

The dermal Absorption study was done in accordance with the Agency's review of and comments on our previously submitted draft protocol. This study is being submitted under the mandates set forth by the Agency to meet requirements for classification of chloroxylenol (PCMX) as a Category I active ingredient for topical handwash applications.

The Draft Protocol For The 13 Week Dermal Toxicity Study In Mice is based on the results of the ADME study and is being submitted for the Agency's review and approval.

We request a meeting with you, the reviewers and other appropriate personnel to discuss both submissions. It is our intention to obtain the earliest approval of the draft protocol so that we may begin data development as soon as possible. I would propose a meeting date in early to mid November 2000 (or earlier if possible) to discuss the results and finalize the draft protocol. Please advise a meeting date convenient for all Agency personnel involved.

Sincerely,

Irving Gottlieb
Director Sales and Marketing, Biocides

cc: D. Andrews, File, Dr. W. Guess

75N-183H

PR 8

NIPA
BIOCIDES

DRAFT

PROTOCOL

A 13-WEEK DERMAL TOXICITY STUDY OF PCMX IN MICE

Submitted To:

NIPA Laboratories, Inc.
3411 Silverside
Wilmington, DE 19180

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

I. Objective:

The objective of this study is to evaluate the possible toxic effects of the test article when dermally administered daily for 13 weeks. Results will be used to design a two year dermal study in mice.

This protocol has been designed and the study will be conducted in general accordance with the United States Food and Drug Administration (FDA), Japanese Ministry of Health and Welfare (MOHW) and the International Conference on Harmonization (ICH).

The study will be conducted in compliance with the U.S. FDA Good Laboratory Practice Standards, 21 CFR Part 58.

II. Personnel Involved in the Study:

A. Sponsor Representative:

Mr. Irving Gottlieb
Tel: (302) 478-1522

B. Sponsor Monitor:

Wallace R. Guess
Consultant
Tel: (601) 234-4064

C. WIL Study Director:

Christopher P. Chengelis, Ph.D., D.A.B.T.
Director, Toxicology

D. WIL Deputy Director:

Thomas P. O'Neill, B.S.
Associate Toxicologist

E. WIL Departmental Responsibilities:

Jozef J.W.M. Mertens, Ph.D., D.A.B.T.
Assistant Director, Toxicology

Jonathan M. Hurley, B.S.
Manager I, General Toxicology

Sally A. Keets, A.S.
Manager II, Vivarium

Ronald E. Wilson, B.S.
Director, Informational Systems

Daniel W. Sved, Ph.D.
Director, Metabolism and Analytical Chemistry

Susan Haley, B.S.
Unit Supervisor, Clinical Pathology

Carol A. Kopp, B.S.
Group Supervisor, Gross Pathology and
Developmental Toxicology Laboratory

Lynn E. Myers, A.S.
Group Supervisor, Histology

Barbara L. Smith, D.V.M., M.S., Ph.D., D.A.C.V.S.
Director, Laboratory Animal Resources

Karen S. Regan, D.V.M., D.A.C.V.P., D.A.B.T.
Director, Pathology and Veterinary Medicine

Philip L. Stetson, M.D., Ph.D.
Associate Director, Analytical Chemistry

Charlene A. Weygandt, B.S.
Manager, Technical Report Writing

Deborah L. Little, B.S., RQAP-GLP
Manager II, Quality Assurance

III. Study Schedule:

Proposed Animal Receipt Date:

Proposed Experimental Start Date:

Proposed Necropsy Date(s):

Proposed Audited Draft Report Date:

IV. Test Article Information:

A. Test Article:

1. Identification:	PCMX (Chloroxylenol) (also known as Nipacide)
2. Supplier:	Sponsor
3. Lot Number:	To be documented in the raw data.
4. Purity:	Assumed to be 100% (based on information provided by the Sponsor).
5. Stability:	Stability data are the responsibility of the Sponsor.
6. Physical Description:	To be documented by WIL Research Laboratories, Inc.
7. Storage Conditions:	Room temperature, protected from light.
8. Reserve Samples:	Retention samples will be collected and stored in accordance with Standard Operating Procedures.
9. Personnel Safety Data:	A dust respirator, safety glasses, appropriate protective clothing and latex gloves will be worn when preparing or handling the solutions and neat test article. A material safety data sheet or equivalent will be requested from the client.
10. Vehicle:	Test article will be dissolved in acetone. Solvent will be purchased by WIL Research Laboratories, Inc. Lot number and supplier will be documented.

V. Test System:

A. Species:	Mouse

B. Strain: CD® -1 (ICR) BR

C. Source: Charles River Laboratories
Raleigh, NC 27610

D. Number of Animals: Seventy males and seventy females will be ordered; Fifty animals of each sex will be placed on study.

E. Approximate Age and Weight: Animals will be approximately 4 weeks of age at receipt. Animals will be approximately 6 weeks of age at initiation of dosing and are expected to weigh approximately 20 to 30 g.

F. Identification System: Each animal will be uniquely identified by a tail tattoo displaying the animal number. Individual cage cards will be affixed to each cage and will display the animal number, group number and study number.

G. Justification for Selection: This species and strain of animal is recognized to be appropriate for subchronic dermal toxicity studies. The CD® -1 mouse will be used because it is a widely used strain for which significant historical control data are available. It was the species and strain used for the preliminary studies on PCMX conducted at WIL Research.

VI. Specific Maintenance Schedule:

A. Animal Housing:

Animals will be housed in an environmentally-controlled room, three per cage by sex, in clean, suspended, wire-mesh cages for approximately three days following receipt. Thereafter, all animals will be housed individually. The cages will be elevated above cage-board or other suitable material, which will be changed at least three times each week. The facilities at WIL Research Laboratories, Inc. are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

B. Environmental Conditions:

Controls will be set to maintain temperature at 72 ± 5°F (22 ± 3°C) and relative humidity at approximately 30-70%. Fluorescent lighting will provide illumination for 12 hours per day. The light/dark period may be interrupted, however, to allow for protocol specified activities. Temperature and relative humidity will be monitored continuously and recorded once daily. Ventilation rate will be set at 10 to 15 room changes per hour, 100% fresh air.

C. Drinking Water:

Reverse osmosis-treated tap water will be available *ad libitum*. Filters servicing the automatic watering system will be changed regularly according to Standard Operating Procedures. Municipal water supplying the laboratory will be analyzed for contaminants according to WIL Standard Operating Procedures to ascertain that none are present at concentrations that would be expected to affect the outcome of the study.

D. Diet:

PMI Nutrition International, Inc. Certified Rodent LabDiet® 5002 will be offered *ad libitum* during the study. Analyses of the certified feed for the presence of heavy metals and pesticides will be provided by the manufacturer to ensure that none are present at concentrations that would be expected to affect the outcome of the study. Feeders will be changed and sanitized once per week.

VII. Experimental Design:

A. Animal Receipt and Acclimation:

Each animal will be inspected by a qualified technician upon receipt. Animals judged to be in good health will be placed immediately in acclimation for at least seven days. All animals will be weighed and assigned a permanent animal number. During the acclimation period, each animal will be observed twice daily for changes in general appearance and behavior. The animals will be allowed a pretreatment week (as part of the acclimation period) during which body weights and food consumption will be determined and general health will be monitored, but they will not receive the test article. All animals will receive a detailed physical examination one week prior to the initiation of dosing and at the time of animal selection for randomization.

B. Randomization:

At the conclusion of the acclimation period, animals judged to be suitable for testing will be assigned to groups at random using a computer program. At the time of randomization, the animal numbers will be entered into the WIL Toxicology Data Management System (WTDMS™). A printout containing the animal numbers and individual group assignments will be generated, based on body weight stratification, into a block design. Animals will then be arranged into the groups according to the printout. Body weights at randomization will be within ± 20% of the mean for each sex.

C. Route and Rationale of Test Article Administration:

The route of administration will be dermal since the intended use of the test article indicated that dermal contact is the route of exposure to human beings.

D. Organization of Test Groups, Dosage Levels and Treatment Regimen:

1. Organization of Test Groups:

The following table presents the study group arrangement:

Group Number	Treatment	Approximate* Dosage (mg/kg/day)	Dose Concentration (%)	Dose Volume (µl)	Number of Animals	
					Male	Female
1	Naïve Control	0	0	50	10	10
2	Acetone (vehicle control)	0	0	50	10	10
3	PCMX	100	6	50	10	10
4	PCMX	333	20	50	10	10
5	PCMX	1000	60	50	10	10

* - Based on 30 gram mouse.

2. Treatment Regimen:

The test article will be applied seven days per week for 13 weeks for a minimum of 91 applications. Test article will be given at a constant 50 µl per mouse. Animals in the naive control group will be maintained and observed in the same manner as the test group animals, but will not be dosed with test article. Vehicle control group animals will be dosed with acetone. The first day of dosing is day 0. Day 91 will be first day of necropsy.

Dosages were selected on the basis of preliminary studies (WIL-304001 and WIL-304002) which together demonstrated appropriate bioavailability and irritation characteristics for a 40% PCMX solution in acetone.

3. **Administration:**

The hair will be clipped from the back of each animal, from the scapula (shoulder) to the wing of the ileum (hipbone) and halfway down the flank on each side of the animal. This will be done the day before initiation of dosing and as often as needed thereafter (at least one time each week).

The test article solutions will be taken up in an appropriate size calibrated pippett. The application sites will be dried with a gentle stream of unheated air if necessary and will not be dressed or wrapped. The test article will slowly and evenly discharge from the pipette while "painting" the target dose area.

The test article will be applied to a single site on each animal. The area covered by test article will be measured and recorded once per week for 1 representative (close to the mean body weight) animal of each sex in each group. In addition, the corners of the application site will be marked with indelible ink to allow proper identification of the treated and untreated skin.

The test sites will be washed with acetone and gauze swabs once per week.

4. **Test Article Preparation:**

The test article will be dissolved in vehicle on a weight to volume basis, using routine methods, on a weekly basis.

5. **Analysis:**

Based on information provided by the Sponsor, homogeneity testing will not be conducted for this study. Test article preparation will be assayed to confirm concentrations once per month (Weeks 0, 4, 8, 12). On sampling days, duplicate samples (5 ml) of each preparation will be transferred to the WIL Research Analytical Chemistry Laboratory where they will be analyzed for test article contents. The results will be summarized in a report that will be appended to the main study report.

VIII. <u>Parameters to be Evaluated</u>:

A. Viability Observations:

All animals will be observed for mortality/moribundity twice daily, once in the morning and once in the afternoon. Moribund animals will be euthanized to ensure that tissues will not be lost due to autolysis.

B. Clinical Observations:

1. Daily Observations:

A clinical examination will be performed for all animals once daily approximately three hours after dosing. Observations will include but are not limited to changes in the skin, fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous systems function, somatomotor activity and behavior patterns. Findings noted at the clinical observation will be recorded for individual animals; the condition of the animals without signs will be documented as a general comment. Clinical observations will not be performed on the days detailed physical examinations are conducted.

2. Dermal Observations:

Application sites will be examined for erythema, edema and other dermal findings once per week at the time of a detailed physical examination. Erythema and edema will be evaluated in accordance with the method of Draize (Appendix A) based on the four-step grading system of very slight, slight, moderate and severe. Other dermal findings, if present, will be noted.

3. Detailed Physical Observations:

All animals will receive a detailed physical examination once weekly. The first examination will occur one week prior to test article administration. Animals will be removed from the home cages and placed in a standard arena for observation and signs will be carefully recorded. Where appropriate, signs will be scored (minimal, mild, moderate, severe) if, in the opinion of the study director, doing so increases the utility of the data. Signs noted should include, but are not limited to, changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g., lacrimation, piloerection, pupil size, unusual respiratory pattern). Change in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypies (e.g., excessive grooming, repetitive circling) or bizarre behavior (e.g., self-mutilation, walking backwards) should be recorded.

C. Individual Body Weights:

Individual body weights will be recorded weekly, beginning at least one week prior to test article administration.

D. Individual Food Consumption:

Individual food consumption will be recorded weekly, beginning at least one week prior to test article administration.

E. Ophthalmic Examinations:

A board-certified veterinary ophthalmologist, using an indirect ophthalmoscope (or other equivalent suitable equipment) will examine all animals. An appropriate mydriatic agent will be administered prior to examination. The examinations will be performed before initiation of dosing and near the end of the dosing period.

F. Clinical Pathology:

The following clinical pathology parameters will be evaluated on all surviving animals at the end of the dosing period. Blood samples will be collected from the vena cava at the time of necropsy from animals euthanized under Isoflurane anesthesia.

1. Hematology (5/sex/group):

Differential leukocyte count	MCHC
Erythrocyte count	MCV
Hematocrit	Platelet count
Hemoglobin	Reticulocyte count[a]
MCH	Total leukocyte count

[a] To be evaluated initially only, on control and high dose groups, if warranted by other erythrocyte parameters. If a potential effect is noted, this evaluation may be extended to the low and mid dose groups.

2. Serum Chemistry (5/sex/group):

A/G ratio	Globulin (by calculation)
Alanine aminotransferase	Glucose
Albumin	Phosphorus
Alkaline phosphatase	Potassium
Aspartate aminotransferase	Sodium
Calcium	Total bilirubin
Chloride	Total cholesterol
Creatine kinase	Total protein
Creatinine	Triglycerides
Gamma glutamyltransferase	Urea nitrogen

G. Anatomic Pathology:

1. Macroscopic Examination

A complete necropsy examination will be conducted on all animals. Animals *in extremis* or at the scheduled necropsy will be euthanized by Isoflurane anesthesia followed by exsanguination. Necropsy will include examination of the external surface; all orifices; and the cranial, thoracic, abdominal and pelvic cavities including viscera. Tissues listed below will be collected and placed in 10% neutral buffered formalin (except as noted):

- Adrenal (2)
- Aorta
- Bone with marrow
  - Sternum
  - Femur
- Bone Marrow Smear[a]
- Brain
  - Forebrain
  - Midbrain
  - Hindbrain
- Epididymides(2)[c]
- Eyes with optic nerve (2)[b]
- Gall Bladder
- Gastrointestinal tract
  - Esophagus
  - Stomach
  - Duodenum
  - Jejunum
  - Ileum
  - Cecum
  - Colon
  - Rectum
- Harderian gland (2)
- Heart
- Kidneys (2)
- Liver (sections of two lobes)
- Lungs (including bronchi, fixed by inflation with fixative)
- Lymph node (mesenteric)
- Mammary gland (females only)
- Ovaries (2)
- Pancreas
- Parathyroids (if present)
- Peripheral nerve (sciatic)
- Pituitary
- Prostate
- Salivary glands [mandibular (2)]
- Seminal vesicles (2)
- Skeletal muscle (rectus femoris)
- Skin
  - Treated
  - Untreated
- Spinal Cord
  - Cervical
  - Midthoracic
  - Lumbar
- Spleen
- Testes (2)[c]
- Thymus
- Thyroid
- Tongue
- Trachea
- Urinary bladder
- Uterus with cervix
- Vagina
- All gross lesions (when possible)

[a] = Not taken from animals found dead, not placed in formalin; to be examined only if scientifically warranted.
[b] = To be placed in Davidson's Solution
[c] = To be placed in Bouin's Solution

2. **Organ Weights:**

The following organs from all animals euthanized at the scheduled necropsy will be weighed:

Adrenals	Ovaries
Brain	Spleen
Epididymides	Testes
Heart	Thyroid*
Kidneys	Thymus
Liver	Uterus

Paired organs will be weighed together. Organ to body weight and organ to brain weight ratios will be calculated.

* Weighed after fixation.

3. **Microscopic Examination:**

All tissues will be processed to paraffin block stage. Microscopic examination of hematoxylin-eosin stained paraffin sections will be performed on a) all mice found dead or euthanized *in extremis*, b) All tissues of the vehicle control and high dose group animals and c) skin (treated and untreated) and gross lesions from all other animals. Other organs will be examined by amendment. Special stains may be used at the discretion of the pathologist to further characterize lesions and changes. Any special stains used will be documented in the individual animal data and interpretation of results will be included in the final report.

IX. Statistical Methods:

Analyses will be two-tailed for significance levels of 5% and 1%. All means will be presented with standard deviations. Statistical tests will be performed using appropriate computing devices or programs. Body weights, body weight changes and food consumption, organ weights, and clinical pathology (excluding differential white counts other than neutrophils and lymphocytes) will be subjected to a one-way analysis of variance[1]. If a statistical significant difference exists, a comparison of the control group to each treated group by Dunnett's test[2] will be performed.

X. Quality Assurance:

The study will be audited by the WIL Quality Assurance Unit while in progress to assure compliance with Good Laboratory Practice regulations, adherence to the protocol and to WIL Standard Operating Procedures. The raw data and draft report

will be audited by the WIL Quality Assurance Unit to assure that the final report accurately describes the conduct and the findings of the study.

This is an FDA regulated study and will be included on the WIL master list of regulated studies.

XI. Records to be Maintained:

All original raw data records, as defined by WIL SOPs and the applicable GLPs, will be stored in the Archives at WIL Research Laboratories, Inc., as described in protocol section XII.

XII. Work Product:

Sponsor will have title to all documentation records, raw data, slides, specimens or other work product generated during the performance of the study. All work product including: raw paper data, magnetically encoded records and specimens, will be retained at no charge for a period of 5 years following issuance of the final report in the Archives at WIL Research Laboratories, Inc. Thereafter, WIL Research will charge a monthly archiving fee for retention of all work product, which will be stored in compliance with regulatory requirements.

XIII. Reports:

The final report will contain a summary, test article data, methods and procedures, appropriate individual animal and summary data tables, a copy of the protocol and amendments (if any) and an interpretation and discussion of the study results. The report will contain all information necessary to conform with current FDA, MOHW and ICH specifications. The report will be comprehensive and shall attempt to define the level(s) inducing toxic effects, as well as "no-effect" level(s) under the conditions of this investigation.

WIL Research Laboratories will provide one (1) copy of an Audited Draft Report, submitted in a timely manner upon completion of the study phase, prior to issuance of the final report. One (1) revision will be permitted as part of the cost of the study, from which Sponsor's reasonable revisions and suggestions will be incorporated into the Final Report as appropriate. Additional changes or revisions may be made, at extra cost. It is expected that the Sponsor will review the draft report and provide comments to WIL within a two (2) month time frame following submission. WIL will submit the Final Report within one (1) month following receipt of comments. Two (2) copies of the Final Report (1 bound, 1 unbound) will be provided; requests for additional copies of the Final Report may result in additional charges.

XIV. Protocol Modification:

Modification of the protocol may be accomplished during the course of this investigation. However, no changes will be made in the study design without the verbal or written permission of the Sponsor. In the event that the Sponsor verbally requests or approves changes in the protocol, such changes will be made by appropriate documentation in the form of protocol amendments. All alterations of the protocol and reasons for the modification(s) will be signed by the Study Director and the Sponsor Representative.

XV. Animal Welfare Act Compliance:

This study will comply with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR). The Sponsor should make particular note of the following:

- The Sponsor signature on this protocol documents for the Study Director the Sponsor's assurance that the study described does not unnecessarily duplicate previous experiments

- Whenever possible, procedures used in this study have been designed to avoid or minimize discomfort, distress or pain to animals. All methods are described in this study protocol or in written laboratory Standard Operating Procedures.

- Animals that experience severe or chronic pain or distress that cannot be relieved will be painlessly euthanized, as deemed appropriate by the veterinary staff and Study Director. The Sponsor will be advised by the Study Director of all circumstances which could lead to this action, in as timely a manner as possible.

- Methods of euthanasia used during this study are in conformance with the above-referenced regulation.

XVI. References:

1. Snedecor, G.W. and Cochran, W.G. (1980) One way classifications: analysis of variance. In: Statistical Methods, Seventh Edition. Iowa State University Press, Ames, IA, pp. 215-237.

2. Dunnett, C.W. (1964) New Tables for Multiple Comparisons with a Control. Biometrics, 20:482-491.

XVII. Protocol Approval:

NIPA Laboratories, Inc. DRAFT

_____ _____
Irving Gottlieb Date
Sponsor Representative

WIL Research Laboratories, Inc.

_____ _____
Christopher P. Chengelis, Ph.D., D.A.B.T. Date
Study Director

_____ _____
Joseph F. Holson, Ph.D. Date
President, Director

APPENDIX A

SCORING CRITERIA FOR DERMAL REACTIONS

Evaluation of Dermal Reactions*

Value	Erythema and Eschar Formation	Computer Designation
0	No erythema	No erythema
1	Very slight erythema (barely perceptible, edges of area not well defined)	Very slight erythema
2	Slight erythema (pale red in color and edges definable)	Slight erythema
3	Moderate to severe erythema (definite red in color and area well defined)	Moderate erythema
4	Severe erythema (beet or crimson red) to slight eschar formation (injuries in depth)	Severe erythema

	Edema Formation	Computer Designation
0	No edema	No edema
1	Very slight edema (barely perceptible, edges of area not well defined)	Very slight edema
2	Slight edema (edges of area well defined by definite raising)	Slight edema
3	Moderate edema (raised approximately 1 mm)	Moderate edema
4	Severe edema (raised more than 1 mm and extending beyond area of exposure)	Severe edema

*Draize, J.H., 1965. The Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics. Dermal Toxicity, pp. 46-59. Assoc. of Food and Drug Officials of the U.S., Topeka, Kansas.

Unaudited Draft Report

STUDY TITLE

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

AUTHOR

Daniel W. Sved, Ph.D.

STUDY COMPLETION DATE

PERFORMING LABORATORY

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805

LABORATORY STUDY NUMBER

Study No.: WIL–304002

SPONSOR

NIPA, Inc.
3411 Silverside Road
Wilmington, DE 19810

COMPLIANCE STATEMENT

This study, "A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice" (WIL Study No.: WIL–304002) was performed in compliance with current FDA Good Laboratory Practice regulations (21 CFR Part 58) by WIL Research Laboratories, Inc. Synthesis and characterization of the radiolabeled test article was performed by Wizard Laboratories, Inc. and it is not known whether this was performed in accordance with the Good Laboratory Practice regulations. Characterization of the nonradiolabeled test article and compliance with Good Laboratory Practice regulations for this aspect was the responsibility of the sponsor.

Submitted By:

_____ _____

Daniel W. Sved, Ph.D.
Study Director
Director, Metabolism and Analytical Chemistry
WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805

Date

I. QUALITY ASSURANCE UNIT STATEMENT

Dates of Inspections	Phase Inspected	Dates Findings Reported to Study Director	Dates Findings Reported to WIL Research Management

This study was conducted and inspected in accordance with Good Laboratory Practice Regulations, the Standard Operating Procedures of WIL Research Laboratories, Inc., and the protocol and protocol amendment(s) as approved by the sponsor, with the following exception. The data located in Appendix B were provided by Wizard Laboratories, Inc. or the sponsor. Quality Assurance findings, derived from the inspections during the conduct of the study and from the inspections of the raw data and the draft report, are documented and have been reported to the study director. A status report is submitted to management monthly.

QUALITY ASSURANCE UNIT STATEMENT (Cont.)

This report accurately reflects the data generated during the study. The methods and procedures used in the study were those specified in the protocol, its amendments, and the Standard Operating Procedures of WIL Research Laboratories, Inc.

All original raw data and the final report will be stored in the Archives at WIL Research Laboratories, Inc. or another location specified by the sponsor.

_____ _____

Deborah L. Little, B.S., RQAP-GLP
Manager II, Quality Assurance

Date

II. KEY PERSONNEL AND REPORT SUBMISSION

Key Study Personnel:

Jennifer E. Moore, B.S.
Biologist I, Metabolism

Marlene M. Parker, B.S.
Biologist I, Metabolism

David A. Mandich, B.A.
Biologist I, Metabolism

Aimee C. Mahoney, B.S.
Biologist II, Metabolism

Peter Resnis, B.S.
Senior Research Chemist, Metabolism

Sally A. Keets, A.S.
Manager II, Vivarium

Karen S. Regan, D.V.M., D.A.C.V.P., D.A.B.T.
Director of Pathology and Veterinary Medicine

Report Prepared By:

_____ _____
Daniel W. Sved, Ph.D. Date
Director of Metabolism and Analytical Chemistry

Report Reviewed By:

_____ _____
Christopher P. Chengelis, Ph.D., D.A.B.T. Date
Director of Toxicology

III. TABLE OF CONTENTS

COMPLIANCE STATEMENT 2
I. QUALITY ASSURANCE UNIT STATEMENT 3
II. KEY PERSONNEL AND REPORT SUBMISSION 5
III. TABLE OF CONTENTS 6
IV. SUMMARY 14
V. OBJECTIVES 18
VI. OVERVIEW OF EXPERIMENTAL DESIGN 18
VII. TEST ARTICLE AND DOSING FORMULATIONS 21
A. Test Article: Description and Source 21
B. Preparation of the Dosing Formulations 22
C. Analysis of the Dosing Formulations 23
1. Radioconcentration and Uniformity 23
2. Radiopurity 24
VIII. BIOLOGICAL PROCEDURES 25
A. Animal Receipt and Housing 25
B. Diet and Drinking Water 26
C. Selection Procedures and Group Assignments 26
D. Dose Site Preparation and Dose Administration 27
E. Exposure Termination and Sample Collection 28
IX. ANALYTICAL PROCEDURES 30
A. Sample Processing 30
B. Sample Analysis 31
C. Sample Combustion 31
D. Validation and Sensitivity of Analytical Techniques 32
E. Liquid Scintillation Counting (LSC) 33
F. Radio-High Performance Liquid Chromatography (HPLC) 34
G. Calculations 35
X. RESULTS AND DISCUSSION 35
A. Actual Doses Applied 35
B. Recovery of Applied Radioactivity 36

TABLE OF CONTENTS (Cont.)

C. Dermal Absorption 37
1. Percent of Dose Absorbed 38
2. Amount Absorbed 39
D. Dermal Penetration and Migration 40
E. Amount in the Blood 41
F. Tissue Concentrations 43
G. Elimination 44
XI. CONCLUSIONS 45
XII. PROTOCOL DEVIATIONS 47
XIII. RETENTION OF RECORDS, RAW DATA AND SPECIMENS 48
XIV. REFERENCES 48

INDEX OF TABLES

1. Mean Applied Dermal Doses of PCMX 50
2. Mean Distribution of PCMX Equivalents in Male Mice following a Single Dermal Administration of ^{14}C-PCMX (as Percent of Dose) 51
3. Mean Distribution of PCMX Equivalents in Female Mice following a Single Dermal Administration of ^{14}C-PCMX (as Percent of Dose) 52
4. Mean Distribution of PCMX Equivalents in Male Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Percent of Dose) 53
5. Mean Distribution of PCMX Equivalents in Female Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Percent of Dose) 54
6. Mean Distribution of PCMX Equivalents in Male Mice following a Single Dermal Administration of ^{14}C-PCMX (as Total Micrograms) 55
7. Mean Distribution of PCMX Equivalents in Female Mice following a Single Dermal Administration of ^{14}C-PCMX (as Total Micrograms) 56

TABLE OF CONTENTS (Cont.)

INDEX OF TABLES (Cont.)

8. Mean Distribution of PCMX Equivalents in Male Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Total Micrograms) 57
9. Mean Distribution of PCMX Equivalents in Female Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Total Micrograms) 58
10. Kinetics of the Absorption of PCMX Equivalents in Male Mice following Dermal Administration of ^{14}C-PCMX 59
11. Kinetics of the Absorption of PCMX Equivalents in Female Mice following Dermal Administration of ^{14}C-PCMX 60
12. Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 2.4 mg ^{14}C-PCMX 61
13. Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 8.0 mg ^{14}C-PCMX 62
14. Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 24 mg ^{14}C-PCMX 63
15. Kinetics of the Concentration of PCMX Equivalents in Skin following Dermal Administration of ^{14}C-PCMX 64
16. Kinetics of the Concentration of PCMX Equivalents in Plasma following Dermal Administration of ^{14}C-PCMX 65
17. Mean Concentration of PCMX Equivalents in Tissues following Dermal Administration of ^{14}C-PCMX 66
18. Elimination of PCMX Equivalents as a Percent of the Total Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice 67
19. Elimination of PCMX Equivalents as a Percent of the Total Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice 68
20. Kinetics of the Elimination of PCMX Equivalents following Dermal Administration of ^{14}C-PCMX to Male Mice 69
21. Kinetics of the Elimination of PCMX Equivalents following Dermal Administration of ^{14}C-PCMX to Female Mice 70

TABLE OF CONTENTS (Cont.)

INDEX OF FIGURES

1. Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Direct Calculation) 72
2. Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Direct Calculation) 73
3. Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Indirect Calculation) 74
4. Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Indirect Calculation) 75
5. PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Direct Calculation) 76
6. PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Direct Calculation) 77
7. PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Indirect Calculation) 78
8. PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Indirect Calculation) 79
9. Amount of PCMX Equivalents Absorbed in 24 Hours following a Single Dermal Administration of ^{14}C-PCMX 80
10. Amount of PCMX Equivalents Absorbed in 14 Days following Daily Dermal Administration of ^{14}C-PCMX 81
11. Amount of PCMX Equivalents Absorbed in 28 Days following Daily Dermal Administration of ^{14}C-PCMX 82
12. Concentration of PCMX Equivalents in Application Site Skin following Dermal Administration of ^{14}C-PCMX to Male Mice 83
13. Concentration of PCMX Equivalents in Application Site Skin following Dermal Administration of ^{14}C-PCMX to Female Mice 84
14. Concentration of PCMX Equivalents in Application Site Skin as a Function of Dose following a Single Dermal Administration of ^{14}C-PCMX 85

TABLE OF CONTENTS (Cont.)

INDEX OF FIGURES (Cont.)

15. Concentration of PCMX Equivalents in Plasma following Dermal Administration of ^{14}C-PCMX to Male Mice 86
16. Concentration of PCMX Equivalents in Plasma following Dermal Administration of ^{14}C-PCMX to Female Mice 87
17. Concentration of PCMX Equivalents in Plasma as a Function of Dose following a Single Dermal Administration of ^{14}C-PCMX 88
18. Concentration of PCMX Equivalents in the Blood Cellular Fraction following Dermal Administration of ^{14}C-PCMX to Male Mice 89
19. Concentration of PCMX Equivalents in the Blood Cellular Fraction following Dermal Administration of ^{14}C-PCMX to Female Mice 90
20. Concentration of PCMX Equivalents in Liver following Dermal Administration of ^{14}C-PCMX 91
21. Concentration of PCMX Equivalents in Kidney following Dermal Administration of ^{14}C-PCMX 92
22. Concentration of PCMX Equivalents in Brain following Dermal Administration of ^{14}C-PCMX 93
23. Concentration of PCMX Equivalents in Tongue following Dermal Administration of ^{14}C-PCMX 94
24. Percent of Absorbed Dose Eliminated following Dermal Administration of ^{14}C-PCMX to Male Mice 95
25. Percent of Absorbed Dose Eliminated following Dermal Administration of ^{14}C-PCMX to Female Mice 96
26. Amount Remaining To Be Eliminated (ARE) following Dermal Administration of ^{14}C-PCMX to Male Mice 97
27. Amount Remaining To Be Eliminated (ARE) following Dermal Administration of ^{14}C-PCMX to Female Mice 98

TABLE OF CONTENTS (Cont.)

INDEX OF APPENDICES

A. Protocol and Amendments 99
B. Test Article Information 119
C. Calculation of Final Specific Activity and Analysis of the Dosing Formulations 122
TABLE C1. Calculations for Preparation of Dosing Formulations and Final Specific Activity – Acute Test 123
TABLE C2. Calculations for Preparation of Dosing Formulations and Final Specific Activity – Repeated Dose Test 124
TABLE C3. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-5-1) Used for Group 1 125
TABLE C4. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-36-1) Used for Group 2 126
TABLE C5. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-23-1) Used for Group 3 127
TABLE C6. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-28-1) Used for Group 4 128
TABLE C7. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 5 129
TABLE C8. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 6 130
TABLE C9. Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 7 131
FIGURE C1. Representative Radio-High Performance Liquid Chromatography of a Dosing Formulation 132

TABLE OF CONTENTS (Cont.)

INDEX OF APPENDICES (Cont.)

D. Animal Body Weights and Group Assignments 133
TABLE D1. Animal Identification, Group Assignment, and Body Weights for Male Animals Received September 14, 1999 134
TABLE D2. Animal Identification, Group Assignment, and Body Weights for Female Animals Received September 14, 1999 135
TABLE D3. Animal Identification, Group Assignment, and Body Weights for Male Animals Received October 5, 1999 136
TABLE D4. Animal Identification, Group Assignment, and Body Weights for Female Animals Received October 5, 1999 137
TABLE D5. Animal Identification, Group Assignment, and Body Weights for Male Animals Received September 28, 1999 138
TABLE D6. Animal Identification, Group Assignment, and Body Weights for Female Animals Received September 28, 1999 139
TABLE D7. Animal Identification, Group Assignment, and Body Weights for Male Animals Received October 12, 1999 140
TABLE D8. Animal Identification, Group Assignment, and Body Weights for Female Animals Received October 12, 1999 141
E. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied 142
TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test) 144
TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test) 154
TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test) 183
F. Liquid Scintillation Analyses of Individual Samples 240
TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples 242
TABLE F2. Liquid Scintillation Analyses of Water Wash Samples 256

TABLE OF CONTENTS (Cont.)

INDEX OF APPENDICES (Cont.)

TABLE F3. Liquid Scintillation Analyses of Skin Samples.....270
TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples.....281
TABLE F5. Liquid Scintillation Analyses of Plasma Samples 295
TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples 301
TABLE F7. Liquid Scintillation Analyses of Liver Samples 307
TABLE F8. Liquid Scintillation Analyses of Kidney Samples 314
TABLE F9. Liquid Scintillation Analyses of Brain Samples 317
TABLE F10. Liquid Scintillation Analyses of Tongue Samples.....320
TABLE F11. Liquid Scintillation Analyses of Urine Samples.....323
TABLE F12. Liquid Scintillation Analyses of Feces Samples.....340
TABLE F13. Liquid Scintillation Analyses of Carcass Samples.....358

G. Analysis of Fortified Samples, Estimation of Quantitation Limits, and Volatility Results 379
TABLE G1. Analysis of Fortified Samples.....380
TABLE G2. Solutions Used for Matrix Fortifications 383
TABLE G3. Calculation of Approximate Quantitation Limits 384
TABLE G4. Volatility of PCMX.....386

H. Summaries of Individual Animal Data 387
TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose).....389
TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms) 411
TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries) 433

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

IV. SUMMARY

PCMX was applied to the shaved skin on the back of male and female CD-1® mice at target doses of 2.4, 8.0, and 24 mg/dose. The study consisted of an acute (single dose) test and a repeated dose test. In the single dose test, each animal received a single dermal dose of PCMX in acetone at one of three target dosage levels or a single dermal dose of PCMX in dimethylsulfoxide (DMSO) at the highest dosage level. Approximately 5 μCi of [^{14}C]-PCMX was added per dose. Mean actual applied doses in acetone were 2.6, 8.7, and 25 mg. The mean actual applied dose in DMSO was 23 mg. In the repeated dose test, each animal received a daily dose of PCMX in acetone at one of three target dosage levels for 14 or 28 consecutive days. Approximately 2 μCi of [^{14}C]-PCMX was added per dose. Mean actual applied doses were 2.5, 8.3, and 25 mg/dose. All doses were applied in a dosage volume of 40 μL.

For the single dose test, sub-groups of three males and three females at each dosage level using acetone were euthanized at 3, 6, 12, and 48 hours after dosing. For all dose groups, a sub-group of four males and four females were euthanized at 24 hours after dosing. The dose site was washed with soap and water and the washes retained for analysis. Skin from the dose site and a blood sample (separated into plasma and cellular fractions) were collected. Urine remaining in the bladder was removed and added to the urine collection. For the animals euthanized at 24 hours after dosing, liver, kidney, brain, and tongue were removed for analysis. All carcasses were retained for analysis. The metabolism cages were washed with ethanol, which was retained for analysis. All samples were analyzed for total ^{14}C using liquid scintillation techniques.

For the repeated dose test, animals were prepared and dosed as in the single dose test except that sub-groups of four males and four females were dosed daily for 14 or 28 consecutive days. Animals were maintained in individual metabolism cages where urine and feces were collected separately over 24-hour

intervals. Urine and feces samples up until the final dose were pooled for analysis. For the animals dosed for 28 days, the application site was washed with soap and water prior to applying the 15th dose; the washes were retained for analysis. Approximately 24 hours after receiving the final dose, the animals were euthanized. The dose site was washed and samples, including tissues, were collected as in the single dose test. The metabolism cages were washed with ethanol, which was retained for analysis. All samples were analyzed for total ^{14}C using liquid scintillation techniques.

The overall mean recovery of applied radioactivity for all the animals used in the study was 65.5%. In the single dose test, recovery tended to decrease with increasing length of exposure; in the repeated dose test, recovery tended to be intermediate to the values obtained during the single dose test. The methodology used in this study was not designed to recover a volatile component, which may explain the low and time-dependent recoveries. At body temperature, PCMX is volatile, losing approximately 20% in 24 hours. The possibility that there was a volatile metabolite, either in expired air or the excreta, also exists, but was not investigated in this study.

Mean percent of dose absorbed at 24 hours after a single dermal dose of PCMX was 51.0, 51.4, and 49.9% for male mice and 51.0, 51.5, and 45.2% for female mice, for the low, mid, and high dosage levels, respectively, using a direct calculation procedure, which sums the amounts absorbed. The mean percent of dose absorbed using DMSO as the vehicle was 66.0% for males and 65.6% for females. Using an indirect calculation procedure, which subtracts the amounts not absorbed from the applied dose, nearly 100% of dose was absorbed with either vehicle. The direct calculation procedure may underestimate absorption owing to loss of the test article via volatilization from the skin surface or the loss of a volatile metabolite. Following 14 days of repeated daily dermal applications, mean percent of dose absorbed (using a direct calculation procedure) was 62.5, 82.2, and 63.4% for males and 67.0, 70.8, and 68.1% for female mice, respectively. Dosing for 28 days did not further increase the percent of dose that was absorbed.

PCMX equivalents rapidly penetrated the skin. The percent of dose associated with the skin was highest 3 hours after a single dose and decreased with increasing length of exposure. After a 3-hr exposure, the percent of dose in the skin at the lowest dosage level (≈15%) was higher than at the two higher dosage levels (≈10%). The rate at which the concentration of PCMX equivalents decreased in the skin appeared to be biphasic at the two lowest dosage levels, but monophasic at the highest dosage level. Along with the lower percent of dose absorbed at the highest dosage level than at the lowest dosage level, these results suggest that the initial rate of absorption may have been limited at the highest dosage level. The extent of penetration, however, was not saturated as evidenced by a dose-proportional relationship of the concentration of PCMX equivalents in the skin. Repeated dosing had little effect on the percent of dose in the skin, although the concentration of PCMX equivalents in skin was typically higher after 14 days of repeated dosing than after a single dose, indicating some accumulation. The percent of dose retained in the skin at 24 hours after dosing when using DMSO as the vehicle was lower in male mice, but higher in female mice, than when acetone was used as the vehicle. These differences may reflect differences in the time course of absorption, which was not investigated with the use of DMSO.

PCMX equivalents in the skin moved rapidly into the systemic circulation as evidenced by initially high amounts associated with the blood and carcass. The concentration of PCMX equivalents in plasma was highest 3 hours after a single dose and decreased with increasing length of exposure. Initial concentrations of PCMX equivalents in plasma were higher for females than for males. The rate at which the concentration of PCMX equivalents decreased in the plasma appeared to be biphasic at the lowest dosage level, but monophasic at the highest dosage level. The concentration of PCMX equivalents in plasma, however, were proportional to the dosage level, suggesting that the rate, but not the extent, of migration into the systemic circulation was saturated at the highest dosage level. Except at the lowest dosage level for females, the half-life for PCMX equivalents in plasma was approximately 10–20 hr. In general, the concentration of PCMX equivalents in the blood cellular fraction was lower than

the concentration in plasma following a single dose, but similar to the concentration in plasma following repeated dosing. PCMX equivalents in plasma and the blood cellular fraction were at or near steady-state within 14 days of repeated dosing at the dosage levels tested. There did not appear to be an effect of the use of DMSO as a vehicle on the concentration of PCMX equivalents in the plasma or blood cellular fraction.

The concentration of PCMX equivalents in liver, kidney, and brain typically increased slightly between 1 and 14 days of dosing, but typically did not increase further upon 28 days of dosing, indicating that these tissues are not sites of deposition. The concentration of PCMX equivalents in tongue typically increased between 1, 14, and 28 days of dosing, suggesting that there may have been continued oral ingestion of the test article. When DMSO was used as a vehicle, the concentration of PCMX equivalents in the tissues was typically less than when acetone was used as a vehicle.

Elimination occurred primarily via the urine. Dosage level did not appear to affect the route of elimination, however, a greater percentage of the absorbed dose was eliminated within 24 hours of a single dose at the lowest dosage level than at the highest dosage level. A greater percent of the absorbed dose was eliminated following repeated dosing than following a single dose. The use of DMSO as a vehicle did not affect the route or extent of elimination. Elimination appeared to follow first-order kinetics, with a urinary elimination half-life of approximately 10 hr. There appeared to be sex-related and dose-related differences in the rates of elimination.

V. OBJECTIVES

The objectives of this study were:

1. To determine the absorption of [^{14}C]-PCMX after single and repeated dermal administration,

2. To ascertain the pharmacokinetics of [^{14}C]-PCMX after single and repeated after dermal administration,

3. To determine if there are dose dependent differences in the absorption and pharmacokinetics of [^{14}C]-PCMX after dermal administration, and

4. To determine the distribution of [^{14}C]-PCMX in select tissues after single and repeated administration.

VI. OVERVIEW OF EXPERIMENTAL DESIGN

The study was performed at WIL Research Laboratories, Inc. (WIL), Ashland, Ohio as study number WIL-304002. The study director was Daniel W. Sved, Ph.D., Director of Metabolism and Analytical Chemistry. The protocol for the study is presented in Appendix A.

The study consisted of an acute (single dose) test and a repeated dose test. In the single dose test, each animal received a single dermal dose of PCMX in acetone at one of three target dosage levels or a single dermal dose of PCMX in dimethylsulfoxide (DMSO) at the highest dosage level. In the repeated dose test, each animal received a daily dose of PCMX in acetone at one of three target dosage levels for 14 or 28 consecutive days. [^{14}C]-PCMX was added to each dose to trace the absorption, distribution, and elimination of PCMX. The target dosage levels are outlined in the following table:

Dose Groups

SINGLE DOSE TEST			
Group	Vehicle	Concentration	mg/dose
1	Acetone	6%	2.4
2	Acetone	20%	8.0
3	Acetone	60%	24
4	DMSO	60%	24
REPEATED DOSE TEST			
5	Acetone	6%	2.4
6	Acetone	20%	8.0
7	Acetone	60%	24

For the single dose test, the back of each animal was shaved and then washed with acetone on the day prior to dosing. The dose was applied in a dose volume of 40 µL. Radioactivity retained on the dosing pipet was measured in order to calculate the actual dose applied. Following dosing, the animals were placed in individual metabolism cages where urine and feces were collected separately. For the animals receiving the dose with acetone as the vehicle, sub-groups of three males and three females at each dosage level were euthanized at 3, 6, 12, and 48 hours after dosing. For all dose groups, a sub-group of four males and four females were euthanized at 24 hours after dosing. The dose site was washed with soap and water and the washes retained for analysis. Skin from the dose site and a blood sample (separated into plasma and cellular fractions) were collected. Urine remaining in the bladder was removed and added to the urine collection. For the animals euthanized at 24 hours after dosing, liver, kidney, brain, and tongue were removed for analysis. All carcasses were retained for analysis. The metabolism cages were washed with ethanol, which was retained for analysis. All samples were analyzed for total ^{14}C using liquid scintillation techniques.

For the repeated dose test, animals were prepared and dosed as in the single dose test except that sub-groups of four males and four females were dosed daily

for 14 or 28 consecutive days. Animals were maintained in individual metabolism cages where urine and feces were collected separately over 24-hour intervals. Urine and feces samples up until the final dose were pooled for analysis. For the animals dosed for 28 days, the application site was washed with soap and water prior to applying the 15th dose; the washes were retained for analysis. Approximately 24 hours after receiving the final dose, the animals were euthanized. The dose site was washed and samples, including tissues, were collected as in the single dose test. The metabolism cages were washed with ethanol, which was retained for analysis. All samples were analyzed for total ^{14}C using liquid scintillation techniques.

Principal study activities were conducted according to the following schedule:

Principal Study Dates

March 11, 1997	Receipt of Unlabeled Test Article
August 11, 1999	Receipt of Radiolabeled Test Substance
September 14, 28 & October 5, 1999	Receipt of Animals for Single Dose Test
September 22-23 & October 6-7 & 13-14, 1999	Dose Administration for Single Dose Test
October 12, 1999	Receipt of Animals for Repeated Dose Test
October 19 – November 17, 1999	Dosing Administration for Repeated Dose Test
March 7, 2000	Completion of Analyses

VII. TEST ARTICLE AND DOSING FORMULATIONS

A. Test Article: Description and Source

The test article used for this study was chloroxylenol, or 4-chloro-3,5-dimethylphenol. The compound is also known as parachlorometaxylenol, hence the abbreviation PCMX. Unlabeled PCMX was provided by the sponsor; a Certificate of Analysis is provided in Appendix B. Radiolabeled PCMX ([^{14}C]-PCMX) was prepared by Wizard Laboratories, Inc. (2785B Del Monte St., West Sacramento, CA 95691). A product information sheet for the radiolabeled PCMX is presented in Appendix B.

Based on information provided by the supplier, the radiolabeled PCMX was uniformly labeled with ^{14}C in the phenyl (*) ring as shown in the following figure:



Where appropriate, results were expressed in terms of PCMX equivalents based on the specific activity of the test article.

A plastic bottle containing unlabeled PCMX was received at WIL from Nipa Laboratories Ltd., Lancashire, United Kingdom on March 11, 1997. The material was assigned WIL log number 3304A and was stored at room temperature. The test article was labeled with the following information:

Nipacide Px-R
4-Chloro-3,5-dimethylphenol
Batch E22-1

A glass vial containing radiolabeled PCMX was received at WIL from Wizard Laboratories, Inc. on August 11, 1999. The material was assigned WIL log number MET-0120A and was stored purged with nitrogen, protected from light in a freezer. The vial was labeled with the following information:

4-Chloro-3,5-dimethylphenol-UL-Ring-^{14}C
Lot #990809
26.2 mCi
15.44 mCi/mm

Samples of the unlabeled test article and the radiolabeled test article were retained in the archives at WIL Research Laboratories.

B. Preparation of the Dosing Formulations

The dosing formulations were prepared by combining radiolabeled PCMX with unlabeled PCMX in a volumetric flask and diluting to the proper volume with acetone or dimethylsulfoxide (DMSO). A magnetic stir bar was added to the flask and the formulations were stirred until the PCMX was completely dissolved. The target concentrations of the formulations were 6% for Groups 1 and 5, 20% for Groups 2 and 6, and 60% for Groups 3, 4, and 7. Formulations for the single dose test were prepared once; formulations for the repeated dose test were prepared weekly and divided into aliquots for daily use. Formulations were stored refrigerated when not in use. The specific activity of PCMX in the formulations was calculated using the supplied specific activity of the radiolabeled PCMX and the amount of unlabeled PCMX added. Weights,

volumes, and calculations for each of the formulations are presented in Tables C1 and C2 (Appendix C).

C. Analysis of the Dosing Formulations

1. Radioconcentration and Uniformity

The radioconcentration and uniformity of the dosing formulations for the single dose test were assessed prior to and after use on each day of dosing. The radioconcentration and uniformity of the dosing formulations for the repeated dose test were assessed at the time of preparation. For the analyses, triplicate aliquots of the dosing formulations were removed, diluted in acetone, and analyzed by liquid scintillation counting (LSC). The results of the LSC analyses are presented in Tables C3–C9 (Appendix C). The formulations were uniform with respect to radioconcentration as indicated by the low (<2%) coefficients of variation for each analysis. The grand mean radioconcentration of the formulations are summarized in the following table:

Radioconcentration of the Dosing Formulations

	µCi/mL	% of Target
Group 1	142	113
Group 2	142	113
Group 3	138	110
Group 4	128	101
Group 5	55.9	111
Group 6	55.9	112
Group 7	55.1	110

For the single dose test, the grand mean radioconcentration for each formulation was used in the calculation of individual doses, whereas for the repeated dose test, the radioconcentration of each weekly preparation was used (see Section VIII.D.).

2. Radiopurity

For the single dose test, the radiopurity of the dosing formulations were assessed prior to and after use. Additionally, the formulations for Groups 1 and 3 were stored refrigerated for 8 days and then reanalyzed to assess stability prior to determining preparation frequency for the repeated dose test. For the analyses, an aliquot of the dosing formulation was diluted in acetone and then analyzed in duplicate by radio-high performance liquid chromatography (HPLC). The HPLC method used for the analyses is described in Section IX.F. Representative chromatograms are presented in Figure C1 (Appendix C). No impurities were evident in any of the chromatograms. The mean radiochemical purities of the dosing formulations are summarized in the following table:

Radiopurity of the Dosing Formulations

	Pre-Dosing (%)	Post-Dosing (%)	8-Day Storage (%)
Group 1	99.1	99.1	98.9
Group 2	98.7	99.3	N/A
Group 3	99.0	98.8	99.1
Group 4	99.1	98.9	N/A
Group 5	98.7	N/A	N/A
Group 6	99.0	N/A	N/A
Group 7	99.1	N/A	N/A

The similarity of the pre-dosing, post-dosing, and 8-day storage radiopurity values indicated stability of the radiolabel over the time course of use.

VIII. BIOLOGICAL PROCEDURES

A. Animal Receipt and Housing

Four shipments of CD-1® mice were used for this study. The mice were obtained from Charles River Laboratories (Raleigh, NC facility) and, according to the supplier, were approximately 7 weeks old at the time of receipt. The shipments and use are summarized in the following table:

Shipments of Animals

Receipt Date	Number Received (Males / Females)	Use
September 14, 1999	20 / 20	Group 1*
September 28, 1999	25 / 25	Groups 3 & 4**
October 5, 1999	19 / 19	Group 2
October 12, 1999	28 / 28	Groups 5, 6, & 7

* Additional animals used for matrix samples.
** Additional male animals also used for Group 2.

Upon arrival at the laboratory, each animal was inspected by a qualified technician and placed in quarantine in an environmentally controlled room with at least 10 fresh air changes per hour. The animals initially were group-housed for a few days and then uniquely identified by tail tattoo displaying a permanent animal number, weighed, and individually housed. The males ranged in weight from 18.8 to 31.0 g and the females ranged in weight from 14.6 to 29.2 g (Tables D1–D8, Appendix D). The animals were judged to be in good health. Acclimation lasted for approximately 1 week.

During the quarantine/acclimation period, animals were housed in suspended wire-mesh cages. The cages were elevated above cage-board or other suitable material, which was changed at least three times each week. Following administration of the radiolabeled dose, the animals were placed in individual plastic metabolism units designed for the separate collection of urine and feces. Individual cage cards were affixed to each cage displaying the permanent animal number, study number, and, when appropriate, the group number. Except on two occasions, all animals were observed for mortality and morbidity twice daily.

Temperature and humidity in the animal rooms used for the study were recorded once daily during animal occupancy, except on two occasions. Temperature ranged from 68-81°F. Relative humidity ranged from 28-56 percent. Light timers were used to provide a daily photoperiod of 12 hours of light followed by 12 hours of darkness.

B. Diet and Drinking Water

PMI Nutrition International, Inc. Certified Rodent LabDiet® 5002 was made available *ad libitum* during acclimation and the in-life portions of the study. Each lot used was documented. Analyses of the certified feed for the presence of heavy metals and pesticides were provided by the manufacturer. Feeders were changed and sanitized at least once per week.

Tap water was made available *ad libitum*. Tap water was supplied via an automatic watering system during acclimation and via water bottles while the animals were in metabolism units. The municipal water supplying the laboratory is analyzed once yearly for contaminants.

C. Selection Procedures and Group Assignments

On the day prior to initiation of dosing for each group, the animals were weighed. The males ranged in weight from 16.5 to 32.9 g and the females ranged in weight from 15.8 to 29.3 g (Tables D1–D8, Appendix D). Animals deemed unsuitable for testing (e.g., abraded skin or other

significant clinical condition) were eliminated from use in the study. The remaining animals were randomly assigned to the dose groups and/or sub-groups using a computer program. The sub-group selections are indicated in Tables D1–D8 (Appendix D).

D. Dose Site Preparation and Dose Administration

On the day prior to receiving the first (or only) dose, the anterior dorsal hair from the shoulders to the rump and halfway down each side was removed from each animal using a small electric animal clipper. The shaved area was wiped with acetone to remove oily secretions. The dose application site was demarcated on the shaved area with a permanent felt tip marker. If necessary during the repeated dose test, animals were re-shaved prior to being dosed on that day; any hair removed after the initiation of dosing was retained for analysis.

The dosing formulations were applied using a 40-µL positive displacement pipet with a glass capillary tip. The dose was spread evenly over the entire application site using the pipet tip. The pipet tip was then washed internally and externally with 15 mL of ethanol. Aliquots of the pipet wash were analyzed by LSC and the amount of radioactivity in the pipet wash was subtracted from the amount of radioactivity in 40 µL of dosing formulation to determine the actual dose applied for each animal (Tables E1–E3, Appendix E). Dosing for each of the groups occurred according to the following table:

Dosing Schedule

	Dates of Dosing
Group 1	September 22 and 23, 1999
Group 2	October 13 and 14, 1999
Group 3	October 6 and 7, 1999
Group 4	October 7, 1999
Group 5	October 19 to November 15, 1999
Group 6	October 20 to November 16, 1999
Group 7	October 21 to November 17, 1999

E. Exposure Termination and Sample Collection

For the single dose test, exposure was terminated for a sub-group of animals in each dose group at the appropriate time after dose administration. The length of exposure for each sub-group and the number of animals in each sub-group are provided in the following table:

Designation of Sub-Groups for Single Dose Test

Sub-Group	Length of Exposure (hr)	Number of Animals (Males / Females)
1	3	3 / 3
2	6	3 / 3
3	12	3 / 3
4	24	4 / 4
5	48	3 / 3

There were no sub-groups for Group 4. This dose group, which consisted of four males and four females, received a single dose using DMSO as the vehicle. The group was exposed for 24 hours, with sample collection performed as per sub-groups 4.

For the repeated dose test, exposure was terminated for a sub-group of animals in each dose group approximately 24 hours following the last dose.

The length of exposure for each sub-group and the number of animals in each sub-group are provided in the following table:

Designation of Sub-Groups for Repeated Dose Test

Sub-Group	Length of Exposure (days)	Number of Animals (Males / Females)
1	14	4 / 4
2	28	4 / 4

Urine and feces were collected separately for each animal. For animals in sub-groups 1–4 of the single dose test, a single collection of urine and feces was made during the course of exposure. For animals in sub-groups 5 of the single dose test, and sub-groups 1 and 2 of the repeated dose test, urine and feces were collected in 24-hr intervals. A small amount of deionized water was used to rinse the inside of the metabolism units and included in the urine collections to ensure that any urine that dried on the inside of the unit was also collected. Except on one occasion during the reated dose test, the weight of each collection was recorded. The samples were retained for analysis. For the repeated dose test, urine and feces collected up until the last dose were pooled for analysis; the urine and feces collected between the last dose and exposure termination were kept separate.

At exposure termination, each animal was removed from its metabolism unit and the dose site was then washed four times: twice with gauze soaked in dilute detergent (Dove Dishwashing Detergent:deionized water; 1:50) and twice with gauze soaked in deionized water. The gauzes were retained for analysis. Additionally, the animals exposed for 28 days were washed as previously described prior to receiving the 15th dose.

Animals were euthanized by asphyxiation with carbon dioxide. After euthanasia, each animal was weighed. The males ranged in weight from 22.1 to 34.8 g and the females ranged in weight from 18.5 to 28.1 g (Tables D1–D8, Appendix D). The abdominal cavity was opened and a sample of

whole blood (using heparin as the anticoagulant) was removed from the inferior vena cava or the heart and separated into plasma and cellular fractions by centrifugation. The skin at the application site was dissected from the carcass, weighed, and retained for analysis. Urine remaining in the urinary bladder was removed and added to the final (or only) urine collection. For the animals in sub-groups 4 of the single dose test and all animals in the repeated dose test, the liver, kidneys, brain, and tongue were also collected. The remaining carcass was weighed and retained for analysis. The metabolism units were washed with ethanol and the wash was weighed and retained for analysis. All biological samples were stored frozen (≈-20°C) pending analysis.

IX. ANALYTICAL PROCEDURES

A. Sample Processing

Skin wash gauzes were digested in 50% H_2SO_4 containing approximately 10% methanol. Skin samples were solubilized in Soluene®-350 (Packard Instrument Co., Meriden, CT). Hair samples were also to be solubilized in Soluene®-350, however, only one hair sample was collected and analysis was deemed unnecessary. For the single dose test, fecal samples >1 g were homogenized using a spatula; for the repeated dose test, fecal samples were homogenized with deionized water (2:1) using an electronic tissue homogenizer. Liver samples were homogenized using a spatula. Carcass samples were chopped into small pieces using a knife and then homogenized in a Waring® blender. Fecal samples <1 g and kidney, brain, and tongue samples were analyzed in entirety.

B. Sample Analysis

Each sample or processed sample was prepared for analysis of total ^{14}C radioactivity in duplicate, if possible. Aliquots of known size of each

pipet wash, cage wash, plasma, and urine sample and each skin wash gauze and skin digest were mixed with 10 mL of Ultima Gold™ liquid scintillation cocktail (Packard Instrument Co., Meriden, CT) for direct analysis by LSC. Aliquots of each blood cellular fraction, feces, liver, kidney, brain, tongue, and carcass sample were combusted prior to LSC analysis (see Section IX.C.). The results of the LSC analyses for the pipet wash samples are presented in Tables E1–E3 (Appendix E). The results of the LSC analyses for the other sample types are presented in Tables F1–F13 (Appendix F).

C. Sample Combustion

Aliquots of samples analyzed by combustion were weighed into combustion boats and combusted in a Harvey Biological Materials Oxidizer (Model OX500, R. J. Harvey Instrument Co., Hillsdale, NJ). Each aliquot was combusted for 4 min. The liberated $^{14}CO_2$ was trapped in 15 mL of Permafluor E+:Carbosorb E (2:1) combined liquid scintillation cocktail and carbon dioxide absorber (Packard Instrument Co., Meriden, CT). A solution of the radiolabeled test substance was used as an oxidation standard. On each day that samples were processed by combustion, the efficiency of the oxidizer was evaluated using the oxidation standard. Prior to sample combustion, two aliquots of the oxidation standard were mixed with scintillation media without being oxidized and two aliquots were combusted. An aliquot of oxidation standard was also combusted after at least every ten oxidations. A preliminary LSC analysis of the standards was performed to determine if the oxidizer was functioning properly. The standards were then recounted in a single run and the results used to calculate the F-factor (inverse oxidizer efficiency) for the day using the following formula:

$$\text{F-factor} = \frac{\text{Mean dpm of unoxidized standards}}{\text{Mean dpm of oxidized standards}}$$

The LSC results for combusted samples were corrected for the efficiency of the oxidizer determined for the day the samples were combusted.

The standards oxidized after the tongue samples from Group 7, Sub-group 1 (high dose, 14-day exposure) and after the kidney samples from Group 6, Sub-group 1 (mid dose, 14-day exposure) were unacceptable. This would warrant reanalysis of the samples; however, the samples were consumed during the original analysis. Therefore, values for the samples were calculated based on the acceptable preceding standards. As the results for these samples were intermediate to the values following 1 and 28 days of exposure at the respective dosage levels, these incidents would not be expected to affect the quality or integrity of the study.

D. Validation and Sensitivity of Analytical Techniques

For each sample type analyzed, samples or aliquots of samples from an untreated animal were fortified with dosing formulation (or a dilution thereof). The samples were then analyzed as previously described. The results of the fortification analyses are presented in Table G1 (Appendix G), with the analyses of the solutions used for the fortifications presented in Table G2 (Appendix G). The initial determination of recovery for the soap wash gauze digest was lower than expected (87.6%); additional soap gauzes were fortified with a mean recovery of 95.4%. Initial assessments of recovery for liver, brain, and tongue were also lower than expected (69.5%, 55.6%, and 67.0%, respectively); additional fortifications of these sample types were conducted with mean recoveries of 98.6%, 94.3%, and 100%, respectively. One recovery determination for blood cellular fraction was 87.4%; two other determinations had a mean recovery of 98.3%. All other recovery determinations ranged from 90.6% to 106%.

The sensitivity of each analytical procedure was estimated assuming that a minimum of 50 dpm (above a background of approximately 50 dpm) per aliquot assayed was required for quantitation. Approximate mean sample and aliquot sizes were used in the calculations. The results of the calculations are presented in Table G3 (Appendix G). Sensitivity, in terms

of percent of dose, was constant among dose groups within each of the tests because the same amount of radioactivity was used for all groups in each test. Approximate quantitation limits were <0.1% of dose for the single dose test and <0.25% of dose for the repeated dose test. For the repeated dose test, the quantitation limit in terms of percent of dose is an overestimation because the calculation was based on the amount of a single dose rather than the cumulative dose administered. Mean values below the approximate quantitation limits are noted on summary tables, however, calculations were not censored for these values (see Section IX.G).

E. Liquid Scintillation Counting (LSC)

Radioactivity was determined using a Beckman Model LS 6000TA liquid scintillation spectrophotometer (Beckman Instruments Inc., Fullerton, CA). Background radioactivity was determined for each day of analysis using the same scintillation media used for the preparation of the samples. Background radioactivity was automatically subtracted. Count data were automatically corrected for chemiluminescence and chemical quench. Chemical quench was determined using a ^{137}Cs external standard with Horrock's number (H#) as the quench indicating parameter. The H# was related to counting efficiency using quench curves prepared with the same scintillation media used for the preparation of the samples. All samples were counted for 10 minutes or until a 2-σ error of 1% was achieved.

Analyses were considered acceptable if the duplicate dpm/g or dpm/mL values were within 10% of the mean value, provided the mean per aliquot analyzed was >100 dpm. Analyses not meeting the acceptance criteria were repeated and the values from the repeat analyses were used for the sample provided that the results met the acceptance criteria. If acceptable duplication could not be achieved after several attempts, extraneous values were eliminated using Dean and Dixon's Q-test[1] and all remaining values were used in subsequent calculations.

Two pipet wash samples (Days 5 and 6 for Animal 5905) had duplicate values that differed from the mean value by more than 10% and were inadvertently not reanalyzed promptly. Upon subsequent evaluation of the samples, too much evaporation had occurred to warrant reanalysis. This incident would not be expected to affect the quality or integrity of the study because the mean values for these samples were within the range of values for this sample type and affected quantitation of the administered dose on only two out of 28 days.

F. Radio-High Performance Liquid Chromatography (HPLC)

Radio-HPLC analyses were preformed using a Hitachi HPLC system (Hitachi Ltd., Tokyo, Japan) equipped with a 655A-40 autosampler, L-2000 pump, L-4000 variable wavelength UV detector set at 254 nm, and a D-2500 integrator. Radioactivity in the effluent was monitored using a Packard Radiomatic A-515A FLO-ONE/Beta Radioactive Flow Detector (Packard Instrument Co., Meriden, CT) with a 0.5-mL cell. Prior to entering the radioactive flow detector, the column effluent was mixed with Ultima-Flo M scintillation cocktail (Packard Instrument Co.) pumped at a rate of 3 mL/min. The radio-HPLC conditions were as follows:

Column:	Rexchrom S5-100-ODS Octadecyl, 5 µm, 250 mm x 4.6 mm I.D.
Mobile Phase:	Isocratic delivery (1 mL/min) of acetonitrile:water (1:1)
Injection Volume:	50 µL

Radio-chromatograms were processed using the Radiomatic flow detector software package. Peaks were automatically selected and integrated using the following parameters:

Threshold:	+1.0000; -1.0000
Filter:	5

The amount of radioactivity in each peak was reported as a percent of the total radioactivity in the selected peaks.

G. Calculations

All calculations for this report were performed with Microsoft® Excel spreadsheets using full floating decimal point calculations. Calculations were performed on the data as collected or as displayed or output by instruments, with no censoring for quantitation limits or significant figures. Equations used for calculations (other than mean, standard deviation [SD], percent coefficient of variation [%CV], and linear regression) are presented with the tables. Slightly different results can be expected if calculations are based on the values as presented in the tables because some numbers have been rounded for display.

X. RESULTS AND DISCUSSION

A. Actual Doses Applied

The test article, PCMX, was applied in acetone at concentrations of 6%, 20%, and 60% and in DMSO at a concentration of 60%. [^{14}C]-PCMX was added to the dosing formulations to achieve approximately 5 µCi/dose for the single dose test and approximately 2 µCi/dose for the repeated dose test. Based on the radioactive concentration of the dosing formulations and the amount of radioactivity retained on the capillary pipet tip used for dosing, the mean (±SD) actual doses of radioactivity in the single dose test were 5.5 (±0.057), 5.5 (±0.059), 5.3 (±0.073), and 4.9 (±0.046) µCi/mouse for Group 1, Group 2, Group 3, and Group 4, respectively (Table 1). For the repeated dose test, the mean (±SD) actual doses of radioactivity were 2.1 (±0.070), 2.1 (±0.060), and 2.1 (±0.060) µCi/dose for Group 5, Group 6, and Group 7, respectively.

Using the calculated specific activity of the test substance in the dosing formulations to convert radioactivity to PCMX equivalents, the mean (±SD) actual doses of PCMX applied in the single dose test were 2.6 (±0.027), 8.7 (±0.094), 25 (±0.35), and 23 (±0.22) mg/mouse for Group 1, Group 2, Group 3, and Group 4, respectively. For the repeated dose test, the mean (±SD) actual doses of PCMX were 2.5 (±0.083), 8.3 (±0.24), and 25 (±0.72) mg/dose for Group 5, Group 6, and Group 7, respectively. These values are equivalent to 109, 108, 106, 96.6, 105, 104, and 103 percent of the target dosage levels for Groups 1–7, respectively. For males, these doses were approximately 84.9, 294, 892, 786, 84.2, 275, and 856 mg/kg for Groups 1–7, respectively. For females, these doses were approximately 107, 373, 1061, 929, 104, 340, and 1022 mg/kg for Groups 1–7, respectively.

B. Recovery of Applied Radioactivity

Percent recovery of the actual applied dose was calculated for each animal by summing the percent of actual dose found in each of the sample types analyzed. The individual results are presented in Table H1 (Appendix H) with recoveries summarized on the last page. The mean for each sub-group is summarized in Tables 2–5. For males, individual recoveries ranged from 38.9% to 88.8% with a mean (±SD) recovery of 65.8 (±11)%. For females, individual recoveries ranged from 36.7% to 92.6% with a mean (±SD) recovery of 65.2 (±11)%.

In the single dose test, recovery tended to decrease with increasing length of exposure. In the repeated dose test, recovery tended to be intermediate to the values obtained during the single dose test. One possible explanation for these results is that the test article and/or a metabolite are volatile. The methodology used in this study was not designed to recover a volatile component. To test this hypothesis, the volatility of PCMX was measured at room temperature and body temperature (37°C). At room temperature, there was a 4% decrease in the amount of PCMX during 24 hours, but at 37°C there was almost a 20%

decrease (Table G4, Appendix G). These results indicate that there was probably some loss of PCMX from the skin surface during exposure. The possibility that there was a volatile metabolite, either in expired air or the excreta, also exists, but was not investigated.

C. Dermal Absorption

The percent of dose, amount of PCMX equivalents, and total radioactivity absorbed for each individual animal was calculated by two procedures (Tables H1–H3, Appendix H). The direct procedure involved summing the values for the cage wash, blood fractions, tissues, urine, feces, and carcass samples. The indirect procedure involved summing the values for all the remaining sample types (soap wash, water wash, and skin samples) and subtracting the total from the actual dose applied. The percent of dose and amount of PCMX equivalents are summarized in Tables 2–5 and 6–9, respectively.

The indirect procedure for calculating absorption yielded higher values than the direct procedure because of the low recoveries. Using the direct calculation method as a measure of absorption assumes that none of the unaccounted for radioactivity was absorbed, e.g., if all of the unaccounted for radioactivity had volatilized from the skin surface. Using the indirect calculation method as a measure of absorption assumes that all of the unaccounted for radioactivity was absorbed, e.g., if all of the unaccounted for radioactivity was lost via a volatile metabolite. As either approach, or a combination of the two, may be correct, absorption was evaluated using both procedures.

1. Percent of Dose Absorbed

In terms of percent of dose, absorption generally increased with increasing length of exposure following a single dose of PCMX (Figures 1–4). Percent of dose absorbed was typically higher following 14 days of repeated dosing than after one day of dosing (24-hr single dose data), but did not increase further with 28 days of

repeated dosing. Percent of dose absorbed was similar between males and females. Using the direct calculation method, percent of dose absorbed was generally similar among dose groups, suggesting that the absorption process was not saturated at the dosage levels tested. Using the indirect calculation method, percent of dose absorbed was generally inversely proportional to the dosage level for 24 hours following a single dose, but was similar among dose groups at 48 hours following a single dose and after repeated dosing. These results suggest that the rate of absorption may be limiting at the highest dose. Using the direct calculation method, the percent of dose absorbed when DMSO was used as a vehicle was higher than when acetone was used as the vehicle, but this difference was not evident using the indirect calculation method.

For male mice, mean (±SD) percent of dose absorbed after a 24-hr exposure as calculated using the direct procedure was 51.0 (±9.3), 51.4 (±5.9), 49.9 (±6.3), and 66.0 (±3.0)% for Groups 1, 2, 3, and 4, respectively. For female mice, mean (±SD) percent of dose absorbed after a 24-hr exposure as calculated using the direct procedure was 51.0 (±11), 51.5 (±3.9), 45.2 (±5.7), and 65.6 (±6.5)% for Groups 1, 2, 3, and 4, respectively. After a 48-hr exposure, percent of dose absorbed was slightly higher than after a 24-hr exposure as radioactivity associated with the skin continued to move into the systemic circulation and be eliminated. Using the indirect calculation method, the percent of dose absorbed approached 100% within 24 hours.

After 28 days of repeated dosing, the mean (±SD) percent of dose absorbed for male mice using the direct calculation method was 64.2 (±5.1), 68.6 (±1.0), and 66.4 (±5.8)% for Groups 5, 6, and 7, respectively. For female mice, the mean (±SD) percent of dose absorbed using the direct calculation method was 65.3 (±6.5), 69.7 (±3.2), and 69.1 (±2.9)% for Groups 5, 6, and 7, respectively. Using

the indirect calculation method, the percent of dose absorbed was approximately 100%.

2. Amount Absorbed

In terms of total PCMX equivalents absorbed, absorption proceeded in a biphasic manner (Figures 5–8). The initial phase increased in duration with increasing dosage level. At a dose of 2.4 mg, the initial phase occurred from 3–6 hr for male mice and from 3–12 hr for female mice, whereas at a dose of 24 mg, the initial phase lasted from 3–24 hr regardless of sex. The absorption rate constant for the initial phase decreased with increasing dosage level (Table 10). At a dose of 2.4 mg, the absorption rate constant for the initial phase was approximately 0.15 hr^{-1} for male mice and approximately 0.07 hr^{-1} for female mice. At a dose of 24 mg, the absorption rate constant for the initial phase was approximately 0.03 hr^{-1} regardless of sex. During the terminal phase (end of initial phase–48 hr), the rate of absorption was similar among the dose groups, with an absorption rate constant of approximately 0.005 hr^{-1} or less regardless of sex. These results again suggest that the rate of absorption may initially be limited at the highest dosage level, but that the absorption process was not saturated over the range of doses tested. Further evidence of a lack of saturation was the dose-proportionality of the amount of PCMX equivalents absorbed after 1, 14, or 28 days of exposure (Figures 9–11).

For male mice, mean (±SD) amount absorbed after a 24-hr exposure as calculated using the direct procedure was 1.3 (±0.23), 4.5 (±0.50), 13 (±1.6), and 15 (±0.76) mg for Groups 1, 2, 3, and 4, respectively. For female mice, mean (±SD) amount absorbed after a 24-hr exposure as calculated using the direct procedure was 1.3 (±0.30), 4.5 (±0.33), 11 (±1.4), and 15 (±1.6) mg for Groups 1, 2, 3, and 4, respectively.

After 28 days of repeated dosing, the mean (±SD) amount absorbed for male mice using the direct calculation method was 45 (±3.6), 160 (±1.8), and 459 (±39) mg for Groups 5, 6, and 7, respectively. For female mice, the mean (±SD) amount absorbed using the direct calculation method was 46 (±4.5), 164 (±7.9), and 476 (±11) mg for Groups 5, 6, and 7, respectively.

D. Dermal Penetration and Migration

Measurable amounts of radioactivity were associated with the application site skin at all time points. The concentration of PCMX equivalents in the skin was highest 3 hours after a single dose and decreased with increasing length of exposure (Tables 12–14; Figures 12 and 13). After a 3-hr exposure, the percent of dose in the skin at the lowest dosage level (≈15%) was higher than at the two higher dosage levels (≈10%). Less than 0.5% of dose remained in the skin by 48 hours after dosing. The rate at which the concentration of PCMX equivalents decreased in the skin appeared to be biphasic at the two lowest dosage levels. The initial phase occurred from 3–24 hr and was similar between the sexes. The initial elimination rate constants at the two lowest dosage levels were on the order of 0.1–0.2 hr^{-1} (Table 15). At the highest dosage level, depletion of PCMX equivalents appeared to be monophasic, which is consistent with the rate of absorption being limiting at this dosage level. However, the concentration of PCMX equivalents in the skin was proportional to the dosage level at both 3 and 48 hours after dosing (Figure 14), suggesting that the rate, but not the extent of absorption was saturated at the highest dosage level. The terminal elimination rate constants increased with increasing dosage level and differed between the sexes at the two lowest dosages. For males, the half-lives for PCMX equivalents in the skin were 47, 44, and 8.5 hr for Groups 1, 2, and 3, respectively; for females, the half-lives were 27, 14, and 8.5 hr, respectively.

Repeated dosing had little effect on the percent of dose in the skin. Approximately 0.2% of the dose typically remained associated with the

skin at 24 hours following either 14 or 28 days of repeated dosing. These values are slightly lower than the percent of dose remaining in the skin at 24 hours after a single administration. The concentration of PCMX equivalents in skin was typically higher after 14 days of repeated dosing than after a single dose indicating some accumulation of PCMX equivalents in the skin. However, the concentration of PCMX equivalents in the skin typically did not increase further after 28 days of repeated dosing.

The effect of DMSO as a vehicle on the percent of dose in the skin at 24 hours post-dosing differed between the sexes. For males, the percent of dose in the skin was approximately 4-fold lower when DMSO was used as a vehicle than when acetone was used as a vehicle. For females, the percent of dose in the skin was approximately 2-fold higher using DMSO. These differences may reflect differences in the time course of absorption, which was not investigated with the use of DMSO.

E. Amount in the Blood

Measurable amounts of radioactivity were found in the plasma at all time points; mean concentrations for the blood cellular fraction were below quantitation levels for Groups 2 and 3 at 48 hours post-dosing (Tables 12–14). In terms of percent of dose, most blood values (plasma + cellular fraction) from the repeated dose test were considered to be below the quantitation limit (Tables 4 and 5) even though the concentrations were above the quantitation limit. This apparent discrepancy is an artifact of calculating a quantitation limit based on the percent of a single dose rather than the total of all doses administered.

The concentration of PCMX equivalents in plasma was highest 3 hours after a single dose and decreased with increasing length of exposure (Tables 12–14; Figures 15 and 16). Initial concentrations of PCMX equivalents in plasma were higher for females than for males. The rate at which the concentration of PCMX equivalents decreased in the plasma appeared to be biphasic at the two lowest dosage levels in males, but only

at the lowest dosage level in females. The initial phase occurred from 3–24 hr and was similar between the sexes. The initial elimination rate constants were approximately 0.15 hr^{-1} (Table 16). At the highest dosage level for males and at the two highest dosage levels for females, elimination appeared to be monophasic, which is consistent with the rate of absorption being limiting at least at the highest dosage level. However, the concentration of PCMX equivalents in plasma was proportional to the dosage level at both 3 and 48 hours after dosing (Figure 17), again suggesting that any saturation at the highest dosage level was minimal and rate-related. The terminal elimination rate constants were similar among dosage levels and between the sexes except at the lowest dosage level for females. For males, the half-lives for PCMX equivalents in plasma were 18, 22, and 12 hr for Groups 1, 2, and 3, respectively; for females, the half-lives were 70, 9.1, and 12 hr, respectively.

The concentration of PCMX equivalents in the blood cellular fraction was more variable than the concentration in plasma (Tables 12–14; Figures 18 and 19). The kinetics of changes in the concentration of PCMX equivalents in the blood cellular fraction were not calculated because of this variability. In general, the concentration of PCMX equivalents in the blood cellular fraction was lower than the concentration in plasma following a single dose. Following repeated dosing, the concentration of PCMX equivalents were similar in the two blood fractions.

Except at the lowest dosage level, repeated dosing had little effect on the concentration of PCMX equivalents in plasma. At the two highest dosage levels, plasma concentrations of PCMX equivalents were similar following 1, 14, and 28 days of dosing. At the lowest dosage level, plasma concentrations of PCMX equivalents increased between 1 and 14 days of dosing, but did not increase further upon 28 days of dosing. The concentration of PCMX equivalents in the blood cellular fraction increased between 1 and 14 days of dosing. Between 14 and 28 days of dosing, the concentration of PCMX equivalents in the blood cellular fraction increased slightly at the lowest dosage level, but remained essentially unchanged at

the highest two dosage levels. These results indicate that PCMX equivalents in plasma and the blood cellular fraction were at or near steady-state within 14 days of repeated dosing at the dosage levels tested.

There did not appear to be an effect of the use of DMSO as a vehicle on the concentration of PCMX equivalents in the plasma or blood cellular fraction.

F. Tissue Concentrations

The concentration of PCMX equivalents in liver, kidney, and brain typically increased slightly between 1 and 14 days of dosing, but typically did not increase further upon 28 days of dosing (Table 17; Figures 20–22). At the highest dosage level, variability in the data made this assessment uncertain, however, the data clearly indicate that these tissues are not sites of deposition. Of these three tissues, the highest concentrations of PCMX equivalents were found in the kidney.

The concentration of PCMX equivalents in tongue typically increased between 1, 14, and 28 days of dosing (Table 17; Figure 23), suggesting that there may have been continued oral ingestion of the test article. Concentrations of PCMX equivalents in the tongue were typically higher than in any of the other tissues examined.

When DMSO was used as a vehicle, the concentration of PCMX equivalents in the tissues was typically less than when acetone was used as a vehicle. Without more data on the kinetics of the absorption process when DMSO is used as a vehicle the significance of these differences cannot be evaluated.

G. Elimination

Radioactivity that was absorbed was eliminated primarily in the urine (Tables 18 and 19). Dosage level did not appear to affect the route of elimination. Following a single dose of PCMX, the percent of the absorbed dose that was eliminated increased as the length of exposure increased

(Figures 24 and 25). A greater percentage of the absorbed dose was eliminated within 24 hours at the lowest dosage level than at the highest dosage level. The mean (±SD) percent of absorbed dose that was eliminated in the urine within 24 hours was 82 (±2.5), 72 (±6.3), and 62 (±6.0)% for male mice and 71 (±7.1), 70 (±6.6), and 54 (±3.5)% for female mice for Groups 1, 2, and 3, respectively. The mean (±SD) percent of absorbed dose eliminated in the feces within 24 hours was 1.6 (±0.27), 1.5 (±0.44), and 6.1 (±3.1)% for male mice and 1.6 (±1.1), 3.2 (±3.0), and 5.7 (±1.2)% for female mice for Groups 1, 2, and 3, respectively. The use of DMSO as a vehicle did not affect the route or extent of elimination. Approximately 90–95% of the absorbed dose was eliminated following repeated dosing.

Elimination appeared to follow first-order kinetics as evidenced by the general linear decrease in the log amount remaining to be eliminated (Figures 26 and 27). For males, elimination rate constants for urinary elimination were similar among dosage groups, but elimination rate constants for fecal elimination increased with dosage level (Table 20). Urinary elimination half-lives were approximately 10 hr, whereas fecal elimination half-lives were 50, 33, and 15 hr for Groups 1, 2, and 3, respectively. For females elimination rate constants for fecal elimination were similar among dosage groups, but elimination rate constants for urinary elimination decreased with dosage level. Fecal elimination half-lives were approximately 25 hr, whereas urinary elimination half-lives were 5.8, 7.0, and 13 hr for Groups 1, 2, and 3, respectively.

XI. CONCLUSIONS

Following a single dermal application of [^{14}C]-PCMX in acetone at mean actual doses of 2.6, 8.7, and 25 mg, PCMX equivalents were absorbed and eliminated primarily in the urine. Mean percent of dose absorbed after a 24-hr exposure was 51.0, 51.4, and 49.9% for male mice and 51.0, 51.5, and 45.2% for

female mice, for the low, mid, and high dosage levels, respectively, using a direct calculation procedure. At a mean actual dose of 23 mg, the mean percent of dose absorbed using DMSO as the vehicle was 66.0% for males and 65.6% for females. Using an indirect calculation procedure, nearly 100% of dose was absorbed with either vehicle. The direct calculation procedure may underestimate absorption owing to loss of the test article via volatilization from the skin surface or the loss of a volatile metabolite.

Following 14 days of repeated daily dermal applications of [^{14}C]-PCMX in acetone at mean actual doses of 2.5, 8.3, and 25 mg/dose, mean percent of dose absorbed (using a direct calculation procedure) was 62.5, 82.2, and 63.4% for males and 67.0, 70.8, and 68.1% for female mice, respectively. Dosing for 28 days did not further increase the percent of dose that was absorbed.

PCMX equivalents rapidly penetrated the skin. The percent of dose associated with the skin was highest 3 hours after a single dose and decreased with increasing exposure. The percent of dose in the skin at the lowest dosage level was higher than at the two higher dosage levels. There were dose-dependent differences in the rate at which the concentration of PCMX equivalents decreased in the skin, but the concentration of PCMX equivalents in the skin was dose-proportional. These results suggest that the rate of absorption, but not the extent of absorption, may be limited at the highest dosage level. Repeated dosing had little effect on the percent of dose in the skin, although the concentration of PCMX equivalents in skin was typically higher after 14 days of repeated dosing than after a single dose, indicating some accumulation. The percent of dose retained in the skin at 24 hours after dosing when using DMSO as the vehicle was lower in male mice, but higher in female mice, than when acetone was used as the vehicle. These differences may reflect differences in the time course of absorption, which was not investigated with the use of DMSO.

PCMX equivalents in the skin moved rapidly into the systemic circulation as evidenced by initially high amounts associated with the blood and carcass. The concentration of PCMX equivalents in plasma was highest 3 hours after a single dose and decreased with increasing length of exposure. Initial concentrations of PCMX equivalents in plasma were higher for females than for

males. There were dose-dependent differences in the rate at which the concentration of PCMX equivalents decreased in the plasma, but the concentration of PCMX equivalents in plasma was dose-proportional. These results again suggest the possibility that the rate of the absorption process was limited at the highest dosage level. Except at the lowest dosage level for females, the half-life for PCMX equivalents in plasma was approximately 10–20 hr. In general, the concentration of PCMX equivalents in the blood cellular fraction was lower than the concentration in plasma following a single dose, but similar to the concentration in plasma following repeated dosing. PCMX equivalents in plasma and the blood cellular fraction were at or near steady-state within 14 days of repeated dosing at the dosage levels tested. There was no effect of the use of DMSO as a vehicle on the concentration of PCMX equivalents in the plasma or blood cellular fraction.

The concentration of PCMX equivalents in liver, kidney, and brain typically increased slightly between 1 and 14 days of dosing, but typically did not increase further upon 28 days of dosing, indicating that these tissues are not sites of deposition. The concentration of PCMX equivalents in tongue typically increased between 1, 14, and 28 days of dosing, suggesting that there may have been continued oral ingestion of the test article. When DMSO was used as a vehicle, the concentration of PCMX equivalents in the tissues was typically less than when acetone was used as a vehicle.

Elimination occurred primarily via the urine. Dosage level did not appear to affect the route of elimination, however, a greater percentage of the absorbed dose was eliminated within 24 hours of a single dose at the lowest dosage level than at the highest dosage level. A greater percent of the absorbed dose was eliminated following repeated dosing than following a single dose. The use of DMSO as a vehicle did not affect the route or extent of elimination. Elimination appeared to follow first-order kinetics, with a urinary elimination half-life of approximately 10 hr. There appeared to be sex-related and dose-related differences in the rates of elimination.

XII. PROTOCOL DEVIATIONS

Four protocol deviations occurred during the study:

1. The protocol stated that documentation concerning the synthesis of the ^{14}C-PCMX was to be provided by Wizard Laboratories, Inc. However, the synthesis procedure was designed by Wizard Laboratories, Inc. and considered to be proprietary. The ^{14}C-PCMX, however, was characterized by Wizard Laboratories, Inc. and the results of the characterization provided to WIL Research Laboratories, Inc. and included in the study file. Therefore this deviation would not be expected to adversely affect the quality or integrity of the study.

2. The protocol stated that each animal will be observed twice daily during the quarantine period. The observations were inadvertently not performed on two days. As this deviation occurred during the quarantine period, the deviation would not be expected to adversely affect the quality or integrity of the study.

3. The protocol stated that during the repeated dose test, individual urine collections would be measured. The urine weight for Animal #5919 (Group 6, Sub-group 2) was inadvertently not recorded for the Day 26 collection. The individual daily weights were only needed to calculate a sum for the pooled urine weight. Instead, the urine pool for this animal was thawed and weighed. As the weight of the pooled sample was obtained, this deviation would not be expected to adversely affect the quality or integrity of the study.

4. The protocol stated that hair removed following the initiation of dosing would be analyzed. Only one animal needed to be re-shaved and only on one occasion. Therefore, the sample was not considered to be material to the objectives of the study and was not analyzed. This deviation would not be expected to adversely affect the quality or integrity of the study

XIII. RETENTION OF RECORDS, RAW DATA AND SPECIMENS

The original raw data, including pertinent facility records, and the final report for this study are stored in the archives of WIL Research Laboratories, Inc. Following quality assurance verification and approval of the Sponsor, wet specimens, extracts, and digests will be discarded.

XIV. REFERENCES

1. Dean, R.B. & W.J. Dixon. 1951. Simplified statistics for small numbers of observations. Anal. Chem.: 23(4), 636-638.

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Tables 1–21

TABLE 1

Mean Applied Dermal Doses of PCMX

	Target Dose		Actual Dosage Applied				Approximate Dose		
			nCi/dose*		mg/dose*		mg/kg**		% of Target†
	(Concentration)	(mg/dose)	Mean	SD	Mean	SD	Males	Females	
GROUP 1									
	6 %	2.4	5476	57.4	2.61	0.027	84.9	107	**109**
GROUP 2									
	20 %	8.0	5452	59.4	8.67	0.094	294	373	**108**
GROUP 3									
	60 %	24	5326	73.0	25.4	0.348	892	1061	**106**
GROUP 4									
	60 %	24	4939	46.4	23.2	0.218	786	929	**96.6**
GROUP 5									
	6 %	2.4	2097	69.7	2.51	0.083	84.2	104	**105**
GROUP 6									
	20 %	8.0	2093	59.9	8.35	0.239	275	340	**104**
GROUP 7									
	60 %	24	2057	60.5	24.6	0.724	856	1022	**103**

* Data were derived from Tables E1-E3 (Appendix E).

** Approx. Dose (mg / kg) $= \frac{\text{mg / dose}}{\text{Body Wt. (g)}} \times \frac{1000\text{ g}}{\text{kg}}$, where Body Wt. is the average of the randomization and euthanasia body weights (see Tables D1- D8 [Appendix D]).

† % of Target $= 100 \times \frac{\text{Actual mg / dose}}{\text{Target mg / dose}}$

TABLE 2

Mean Distribution of PCMX Equivalents in Male Mice following a Single Dermal Administration of ^{14}C-PCMX (as Percent of Dose)*

		NOT ABSORBED		ABSORBABLE	ABSORBED								
Sub-Grp.	Length of Exp. (hr)	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1 (2.4 mg/mouse)													
1	3	25.11	3.99	17.34	9.45	0.05	N/A	11.99	0.27	10.48	78.7	32.24	53.56
2	6	6.43	0.94	5.23	9.53	0.02	N/A	32.76	0.04	5.33	60.3	47.68	87.41
3	12	0.50	1.00	2.36	10.58	0.01	N/A	37.83	0.32	3.22	55.8	51.96	96.13
4	24	0.02	0.00	0.39	6.35	0.003	0.06	42.15	0.83	1.64	51.4	51.03	99.59
5	48	0.01	0.00	0.29	6.01	0.002	N/A	50.98	2.81	0.78	60.9	60.59	99.70
GROUP 2 (8.0 mg/mouse)													
1	3	40.89	5.09	10.95	7.63	0.04	N/A	8.71	0.50	10.29	84.1	27.16	43.07
2	6	30.84	4.02	9.98	9.08	0.03	N/A	15.83	0.08	6.25	76.1	31.27	55.17
3	12	10.37	1.59	5.34	11.26	0.02	N/A	28.37	0.53	5.31	62.8	45.48	82.69
4	24	0.03	0.01	0.57	11.28	0.003	0.05	37.41	0.78	1.86	52.0	51.39	99.39
5	48	0.00	0.01	0.37	8.25	0.001	N/A	45.30	1.82	1.17	56.9	56.54	99.63
GROUP 3 (24 mg/mouse)													
1	3	36.10	6.51	11.08	15.45	0.01	N/A	4.45	0.91	5.99	80.5	26.82	46.31
2	6	41.27	3.67	5.85	14.41	0.01	N/A	8.26	2.33	5.00	80.8	30.02	49.21
3	12	27.93	3.24	6.68	8.16	0.01	N/A	15.07	2.64	1.91	65.6	27.79	62.16
4	24	6.69	0.89	2.29	14.02	0.01	0.08	31.11	3.00	1.71	59.8	49.93	90.13
5	48	0.02	0.01	0.20	8.21	0.00	N/A	39.81	4.41	1.00	53.7	53.43	99.77
GROUP 4 (24 mg/mouse - DMSO)													
N/A	24	0.06	0.03	0.58	13.96	0.004	0.05	47.15	1.24	3.54	66.6	65.95	99.34

* Data were obtained from Table H1 (Appendix H).

☐ = Below the approximate quantitation limit. For blood, below the sum of the applicable approximate quantitation limits.

TABLE 3

Mean Distribution of PCMX Equivalents in Female Mice following a Single Dermal Administration of ^{14}C-PCMX (as Percent of Dose)*

		NOT ABSORBED		ABSORBABLE	ABSORBED								
Sub-Grp.	Length of Exp. (hr)	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1 (2.4 mg/mouse)													
1	3	27.25	3.31	16.17	12.86	0.05	N/A	15.71	0.04	4.99	80.4	33.64	53.26
2	6	15.37	2.53	13.39	7.14	0.04	N/A	16.93	0.08	4.02	59.5	28.21	68.71
3	12	0.92	0.18	1.36	14.67	0.01	N/A	24.97	1.51	1.90	45.5	43.06	97.53
4	24	0.04	0.02	0.97	12.43	0.002	0.02	36.31	0.80	1.38	52.0	50.96	98.97
5	48	0.01	0.01	0.49	19.19	0.003	N/A	32.14	0.46	1.09	53.4	52.88	99.50
GROUP 2 (8.0 mg/mouse)													
1	3	35.99	4.69	8.90	10.56	0.05	N/A	8.69	0.12	9.84	78.8	29.27	50.42
2	6	32.85	3.33	8.52	11.02	0.02	N/A	14.03	0.42	6.73	76.9	32.22	55.31
3	12	12.76	1.39	5.46	10.39	0.01	N/A	31.93	0.47	5.46	67.9	48.27	80.39
4	24	0.56	0.18	0.76	11.76	0.01	0.05	35.78	1.56	2.38	53.0	51.54	98.50
5	48	0.00	0.00	0.28	9.61	0.003	N/A	39.92	3.46	1.06	54.3	54.05	99.71
GROUP 3 (24 mg/mouse)													
1	3	39.11	4.25	10.65	10.64	0.02	N/A	4.52	1.08	5.48	75.8	21.74	45.98
2	6	33.76	3.68	6.01	19.70	0.01	N/A	11.37	0.76	5.95	81.2	37.79	56.55
3	12	23.80	3.28	7.62	10.75	0.01	N/A	13.58	2.96	2.17	64.2	29.46	65.30
4	24	9.33	1.08	2.05	16.50	0.01	0.05	24.43	2.58	1.61	57.6	45.17	87.54
5	48	0.01	0.01	0.25	10.89	0.002	N/A	33.68	6.07	0.98	51.9	51.63	99.73
GROUP 4 (24 mg/mouse - DMSO)													
N/A	24	1.04	0.23	4.63	19.79	0.01	0.05	36.70	2.03	7.02	71.5	65.60	94.10

* Data were obtained from Table H1 (Appendix H).
☐ = Below the approximate quantitation limit.

TABLE 4

Mean Distribution of PCMX Equivalents in Male Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Percent of Dose)*

		NOT ABSORBED		ABSORBABLE	ABSORBED								
Sub-Grp.	Length of Exp. (days)	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5 (2.4 mg/mouse/day)													
1	14	0.01	0.01	0.27	4.32	0.00	0.011	52.27	5.37	0.57	62.8	62.54	99.70
2	28	0.01	0.01	0.21	4.41	0.00	0.00	56.84	2.64	0.29	64.4	64.19	99.76
GROUP 6 (8.0 mg/mouse/day)													
1	14	0.00	0.00	0.21	2.49	0.00	0.006	73.08	6.20	0.46	82.4	82.23	99.78
2	28	0.06	0.03	0.18	2.71	0.00	0.00	62.21	3.42	0.29	68.9	68.64	99.73
GROUP 7 (24 mg/mouse/day)													
1	14	0.01	0.01	0.13	5.21	0.00	0.00	52.20	5.31	0.66	63.5	63.39	99.85
2	28	0.09	0.05	0.28	2.99	0.00	0.00	56.34	6.62	0.42	66.8	66.38	99.58

* Data were obtained from Table H1 (Appendix H).

☐ = Below the approximate quantitation limit. For blood and tissues, below the sum of the applicable approximate quantitation limits.

TABLE 5

Mean Distribution of PCMX Equivalents in Female Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Percent of Dose)*

		NOT ABSORBED		ABSORBABLE	ABSORBED								
Sub-Grp.	Length of Exp. (days)	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5 (2.4 mg/mouse/day)													
1	14	0.01	0.00	0.25	4.49	0.00	0.005	56.27	5.84	0.41	67.3	67.01	99.74
2	28	0.01	0.01	0.22	5.26	0.00	0.00	55.64	4.13	0.27	65.6	65.31	99.76
GROUP 6 (8.0 mg/mouse/day)													
1	14	0.00	0.00	0.20	3.11	0.00	0.00	62.67	4.57	0.43	71.0	70.78	99.80
2	28	0.01	0.01	0.17	2.48	0.00	0.00	63.09	3.91	0.23	69.9	69.71	99.81
GROUP 7 (24 mg/mouse/day)													
1	14	0.47	0.17	0.58	5.87	0.00	0.007	55.51	5.82	0.92	69.4	68.13	98.78
2	28	0.01	0.02	0.09	3.49	0.00	0.00	58.80	6.54	0.27	69.2	69.10	99.88

* Data were obtained from Table H1 (Appendix H).

☐ = Below the approximate quantitation limit. For blood and tissues, below the sum of the applicable approximate quantitation limits.

TABLE 6

Mean Distribution of PCMX Equivalents in Male Mice following a Single Dermal Administration of ^{14}C-PCMX (as Total Micrograms)*

			NOT ABSORBED		ABSORBABLE	ABSORBED							
Sub-Grp.	Length of Exp. (hr)	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1 (2.4 mg/mouse)													
1	3	2588	650	103	448	244	1.34	N/A	312	7.05	271	836	1387
2	6	2638	317	24.6	138	251	0.53	N/A	865	1.09	141	1259	2159
3	12	2616	13.1	26.2	61.8	277	0.34	N/A	990	8.43	84.3	1360	2515
4	24	2615	0.56	0.13	10.2	166	0.07	1.44	1101	21.6	42.8	1333	2605
5	48	2589	0.14	0.07	7.57	156	0.05	N/A	1319	73.0	20.3	1568	2581
GROUP 2 (8.0 mg/mouse)													
1	3	8617	3522	438	944	658	3.38	N/A	751	43.1	887	2342	3713
2	6	8631	2661	347	861	784	2.30	N/A	1366	7.15	540	2699	4762
3	12	8679	901	138	464	977	1.35	N/A	2461	46.40	461	3946	7175
4	24	8764	2.36	1.07	50.4	989	0.26	4.80	3278	68.15	163	4503	8711
5	48	8655	0.06	0.45	31.7	714	0.12	N/A	3920	157.33	101	4893	8623
GROUP 3 (24 mg/mouse)													
1	3	25507	9200	1659	2831	3941	3.12	N/A	1136	232	1530	6842	11816
2	6	25373	10476	932	1485	3655	3.66	N/A	2094	590	1269	7612	12480
3	12	25369	7090	823	1699	2064	2.07	N/A	3829	666	485	7047	15758
4	24	25539	1705	227	583	3581	1.41	21.2	7947	764	437	12752	23024
5	48	25361	5.70	2.44	50.2	2084	0.22	N/A	10090	1116	253	13543	25303
GROUP 4 (24 mg/mouse - DMSO)													
N/A	24	23064	13.9	6.02	132	3223	0.83	12.2	10875	286	816	15213	22912

* Data were obtained from Table H2 (Appendix H).

☐ = Below the approximate quantitation limit. For blood, below the sum of the applicable approximate quantitation limits.

TABLE 7

Mean Distribution of PCMX Equivalents in Female Mice following a Single Dermal Administration of ^{14}C-PCMX (as Total Micrograms)*

			NOT ABSORBED		ABSORBABLE	ABSORBED							
Sub-Grp.	Length of Exp. (hr)	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1 (2.4 mg/mouse)													
1	3	2586	707	85.8	418	332	1.31	N/A	405	0.91	129	868	1375
2	6	2609	401	66.0	348	186	1.05	N/A	442	2.11	105	737	1794
3	12	2623	24.2	4.75	35.7	385	0.21	N/A	655	39.8	49.8	1130	2559
4	24	2633	1.08	0.45	25.5	328	0.05	0.65	957	21.1	36.4	1343	2606
5	48	2607	0.21	0.13	12.7	501	0.07	N/A	837	12.0	28.4	1379	2594
GROUP 2 (8.0 mg/mouse)													
1	3	8568	3088	402	762	901	4.24	N/A	740	10.6	844	2501	4315
2	6	8671	2848	289	738	955	1.73	N/A	1216	36.8	584	2794	4796
3	12	8728	1114	121	477	907	1.25	N/A	2786	40.8	477	4213	7016
4	24	8693	49.0	15.5	65.5	1018	0.51	4.13	3099	135	206	4463	8531
5	48	8675	0.00	0.05	24.7	833	0.24	N/A	3465	299	91.6	4688	8650
GROUP 3 (24 mg/mouse)													
1	3	25658	10036	1091	2731	2730	6.18	N/A	1158	277	1406	5577	11799
2	6	24931	8402	919	1501	4891	3.08	N/A	2831	191	1478	9393	14109
3	12	25527	6084	839	1949	2742	2.13	N/A	3459	754	555	7512	16655
4	24	25459	2382	277	523	4202	1.48	13.9	6213	655	410	11494	22277
5	48	25194	3.70	2.42	62.1	2735	0.58	N/A	8479	1530	247	12992	25126
GROUP 4 (24 mg/mouse - DMSO)													
N/A	24	23319	242	54.3	1079	4612	1.62	12.5	8565	474	1637	15304	21944

* Data were obtained from Table H2 (Appendix H).
☐ = Below the approximate quantitation limit.

TABLE 8

Mean Distribution of PCMX Equivalents in Male Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Total Micrograms)*

			NOT ABSORBED		ABSORBABLE	ABSORBED							
Sub-Grp.	Length of Exp. (days)	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5 (2.4 mg/mouse/day)													
1	14	34831	4.87	4.35	95.1	1507	0.30	3.90	18203	1871	198	21783	34727
2	28	69980	8.53	6.72	149	3083	0.14	2.72	39780	1849	205	44920	69815
GROUP 6 (8.0 mg/mouse/day)													
1	14	115714	3.93	4.96	241	2884	0.52	7.38	84539	7187	534	95152	115465
2	28	233553	139	63.7	422	6318	0.70	9.70	145292	7985	687	160293	232928
GROUP 7 (24 mg/mouse/day)													
1	14	339233	38.9	23.3	438	17655	2.17	16.7	177154	18001	2236	215065	338734
2	28	691213	611	369	1949	20692	2.79	31.4	389422	45721	2929	458798	688284

* Data were obtained from Table H2 (Appendix H).

☐ = Below the approximate quantitation limit.

TABLE 9

Mean Distribution of PCMX Equivalents in Female Mice following Repeated Dermal Administration of ^{14}C-PCMX (as Total Micrograms)*

			NOT ABSORBED		ABSORBABLE	ABSORBED							
Sub-Grp.	Length of Exp. (days)	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5 (2.4 mg/mouse/day)													
1	14	35386	2.15	1.62	87.4	1590	0.27	1.93	19906	2066	145	23709	35295
2	28	70599	6.62	5.37	159	3712	0.38	1.87	39274	2920	194	46102	70428
GROUP 6 (8.0 mg/mouse/day)													
1	14	122929	0.54	3.15	236	3678	0.52	5.70	74476	5451	512	84122	122689
2	28	235176	24.8	21.9	392	5824	0.84	5.36	148393	9189	547	163959	234737
GROUP 7 (24 mg/mouse/day)													
1	14	336940	1571	581	1964	19883	4.29	25.0	186825	19630	3055	229423	332823
2	28	688490	80.9	137	626	24084	1.61	14.2	404560	44979	1875	475514	687647

* Data were obtained from Table H2 (Appendix H).
☐ = Below the approximate quantitation limit.

TABLE 10

Kinetics of the Absorption of PCMX Equivalents in Male Mice following Dermal Administration of ^{14}C-PCMX

	DIRECT CALCULATION			INDIRECT CALCULATION		
	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)
Mean Amount Absorbed (µg)						
3 hr	836	2342	6842	1387	3713	11816
6 hr	1259	2699	7612	2159	4762	12480
12 hr	1360	3946	7047	2515	7175	15758
24 hr	1333	4503	12752	2605	8711	23024
48 hr	1568	4893	13543	2581	8623	25303
Absorption Kinetics						
Initial Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	3-6	3-12	3-24	3-6	3-12	3-24
Slope (b)	0.059	0.026	0.012	0.064	0.031	0.014
Y-Intercept (µg)	555	1937	5996	891	3025	10540
Coefficient of Determination (r^2)	1.00	0.995	0.827	1.00	0.998	0.996
Absorption Rate Constant (hr^{-1})*	0.14	0.059	0.029	0.15	0.072	0.033
Terminal Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	6-48	12-48	24-48	6-48	12-48	24-48
Slope (b)	0.0020	0.0024	0.0011	0.0014	0.0019	0.0017
Y-Intercept (µg)	1237	3786	12008	2291	7212	20951
Coefficient of Determination (r^2)	0.879	0.900	1.00	0.436	0.525	1.00
Absorption Rate Constant (hr^{-1})*	0.0047	0.0056	0.0025	0.0031	0.0043	0.0039

* Absorption Rate Constant = ln(10)xb

TABLE 11

Kinetics of the Absorption of PCMX Equivalents in Female Mice following Dermal Administration of ^{14}C-PCMX

	DIRECT CALCULATION			INDIRECT CALCULATION		
	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)
Mean Amount Absorbed (µg)						
3 hr	868	2501	5577	1375	4315	11799
6 hr	737	2794	9393	1794	4796	14109
12 hr	1130	4213	7512	2559	7016	16655
24 hr	1343	4463	11494	2606	8531	22277
48 hr	1379	4688	12992	2594	8650	25126
Absorption Kinetics						
Initial Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	6-12**	3-12	3-24	3-12	3-12	3-24
Slope (b)	0.031	0.026	0.011	0.029	0.024	0.012
Y-Intercept (µg)	481	2036	6127	1152	3567	11417
Coefficient of Determination (r^2)	1.00	0.983	0.602	0.989	0.984	0.973
Absorption Rate Constant (hr^{-1})*	0.071	0.059	0.026	0.068	0.055	0.029
Terminal Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	12-48	12-48	24-48	12-48	12-48	24-48
Slope (b)	0.0021	0.0012	0.0022	0.00013	0.0022	0.0022
Y-Intercept (µg)	1115	4110	10169	2564	6967	19751
Coefficient of Determination (r^2)	0.689	0.946	1.00	0.338	0.630	1.00
Absorption Rate Constant (hr^{-1})*	0.0049	0.0028	0.0051	0.00030	0.0051	0.0050

* Absorption Rate Constant = ln(10)xb

** 3-hr point excluded owing to higher absorption than at 6 hours.

TABLE 12

Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 2.4 mg ^{14}C-PCMX*

Sub-Group	Length of Exposure (hr)	Skin** (µg/g)	Skin** (SD)	Plasma (µg/g)	Plasma (SD)		Blood Cellular Fraction (µg/g)	Blood Cellular Fraction (SD)
GROUP 1 (Single Dose)								
Males								
1	3	680.50	243.12	4.93	0.73		1.90	0.45
2	6	158.64	84.78	2.04	0.82		0.71	0.30
3	12	81.79	65.54	1.11	0.72		0.32	0.22
4	24	13.14	0.82	0.19	0.03		0.10	0.04
5	48	9.24	0.59	0.08	0.01		0.09	0.04
Females								
1	3	665.84	201.46	5.36	1.38		1.66	0.38
2	6	500.47	323.33	4.40	0.25		1.69	0.12
3	12	45.92	16.65	0.84	0.45		0.33	0.11
4	24	29.26	12.74	0.26	0.08		0.14	0.07
5	48	15.79	4.06	0.20	0.08		0.23	0.05
GROUP 5 (Repeated Daily Dosing)								
Males								
1	14 days	100.12	37.13	0.86	0.26		0.39	0.18
2	28 days	101.66	29.41	0.51	0.09	†	0.66	0.64
Females								
1	14 days	90.96	17.61	0.76	0.16		0.62	0.42
2	28 days	117.61	32.53	0.67	0.11		0.89	0.75

* Data were derived from Tables F3, F5, and F6 (Appendix F); N=3, except for Sub-Group 4 (Group 1) and Group 5 where N=4.

** Skin from the application site.

† Plasma value does not include Animal #5893 owing to limited blood volume collected.

TABLE 13

Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 8.0 mg ^{14}C-PCMX*

Sub-Group	Length of Exposure (hr)	Skin** (µg/g)	Skin** (SD)	Plasma (µg/g)	Plasma (SD)	Blood Cellular Fraction (µg/g)	Blood Cellular Fraction (SD)
GROUP 2 (Single Dose)							
Males							
1	3	1063.33	238.11	10.21	3.58	3.87	1.40
2	6	825.65	200.37	7.45	2.74	2.18	0.43
3	12	653.17	395.55	4.55	1.44	2.13	0.46
4	24	49.79	12.74	0.78	0.20	0.47	0.20
5	48	34.10	15.86	0.36	0.09	0.14	0.10
Females							
1	3	1024.89	200.65	16.36	5.33	5.01	0.93
2	6	1466.91	958.88	7.46	0.98	2.18	0.20
3	12	690.72	391.30	6.15	0.97	2.31	0.33
4	24	116.11	38.82	2.81	1.22	0.86	0.54
5	48	34.26	3.52	0.40	0.04	0.55	0.10
GROUP 6 (Repeated Daily Dosing)							
Males							
1	14 days	281.38	67.06	1.14	0.28	1.25	0.83
2	28 days	275.36	67.37	1.77	0.82	1.16	0.54
Females							
1	14 days	278.40	69.56	1.58	0.19	1.68	1.00
2	28 days	302.93	92.27	1.83	0.41	1.86	0.85

* Data were derived from Tables F3, F5, and F6 (Appendix F); N=3, except for Sub-Group 4 (Group 2) and Group 6 where N=4.

** Skin from the application site.

☐ = Below the approximate quantitation limit.

TABLE 14

Mean Concentration of PCMX Equivalents in Skin and Blood following Dermal Administration of 24 mg ^{14}C-PCMX*

Sub-Group	Length of Exposure (hr)	Skin** (µg/g)	Skin** (SD)	Plasma (µg/g)	Plasma (SD)	Blood Cellular Fraction (µg/g)	Blood Cellular Fraction (SD)
GROUP 3 (Single Dose)							
Males							
1	3	3381.54	1334.32	16.09	8.45	5.47	2.67
2	6	1517.09	363.48	12.95	5.89	4.26	1.35
3	12	1750.37	394.81	6.64	0.67	3.52	0.33
4	24	548.29	347.05	5.67	2.58	2.31	1.07
5	48	70.71	35.23	1.14	0.68	0.42	0.11
Females							
1	3	3574.90	1584.08	24.59	15.05	7.31	3.71
2	6	1806.61	701.34	16.96	4.36	8.72	4.65
3	12	2844.55	1377.68	8.72	1.29	3.08	0.75
4	24	746.08	486.38	7.83	2.05	3.08	0.88
5	48	83.35	22.21	1.64	0.31	1.65	0.56
GROUP 4 (Single Dose; DMSO as vehicle)							
Males							
N/A	24	150.52	119.79	2.59	0.75	1.33	0.57
Females							
N/A	24	1472.13	853.46	7.27	1.43	3.40	0.39
GROUP 7 (Repeated Daily Dosing)							
Males							
1	14 days	465.50	455.01	5.01	4.10	3.82	2.99
2	28 days	1548.51	1409.93	8.31	6.03	4.83	2.12
Females							
1	14 days	1741.22	883.54	11.27	6.21	5.38	2.96
2	28 days	574.17	75.85	4.55	0.89	2.20	1.31

* Data were derived from Tables F3, F5, and F6 (Appendix F); N=3, except for Sub-Group 4 (Group 3) and Groups 4 and 7 where N=4.

** Skin from the application site.

N/A = Not applicable

[ ] = Below the approximate quantitation limit.

TABLE 15

Kinetics of the Concentration of PCMX Equivalents in Skin following Dermal Administration of ^{14}C-PCMX

	MALES			FEMALES		
	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)
Mean Concentration (µg/g)						
3 hr	681	1063	3382	666	1025	3575
6 hr	159	826	1517	500	1467	1807
12 hr	82	653	1750	46	691	2845
24 hr	13	50	548	29	116	746
48 hr	9	34	71	16	34	83
Depletion Kinetics						
Initial Phase (Linear Regression of log Amount vs. Time from 3–24 hr)						
Slope (b)	-0.074	-0.064	N/A	-0.068	-0.050	N/A
Y-Intercept (µg)	711	2152	N/A	841	2166	N/A
Coefficient of Determination (r^2)	0.942	0.924	N/A	0.813	0.912	N/A
Elimination Rate Constant (hr^{-1})*	0.17	0.15	N/A	0.16	0.12	N/A
Terminal Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	24-48	24-48	3-48	24-48	24-48	3-48
Slope (b)	-0.0064	-0.0068	-0.035	-0.011	-0.022	-0.035
Y-Intercept (µg)	19	73	3684	54	394	4658
Coefficient of Determination (r^2)	1.00	1.00	0.973	1.00	1.00	0.949
Elimination Rate Constant (hr^{-1})*	0.015	0.016	0.081	0.026	0.051	0.081
Half-life (hr)**	47	44	8.5	27	14	8.5

* Elimination Rate Constant (k_{el}) = -ln(10)xb

** Half-life = -ln(0.5)/k_{el}

N/A = Not applicable.

TABLE 16

Kinetics of the Concentration of PCMX Equivalents in Plasma following Dermal Administration of ^{14}C-PCMX

	MALES			FEMALES		
	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)	Group 1 (2.4 mg/mouse)	Group 2 (8.0 mg/mouse)	Group 3 (24 mg/mouse)
Mean Concentration (µg/g)						
3 hr	4.93	10.21	16.09	5.36	16.36	24.59
6 hr	2.04	7.45	12.95	4.40	7.46	16.96
12 hr	1.11	4.55	6.64	0.84	6.15	8.72
24 hr	0.19	0.78	5.67	0.26	2.81	7.83
48 hr	0.08	0.36	1.14	0.20	0.40	1.64
Depletion Kinetics						
Initial Phase (Linear Regression of log Amount vs. Time from 3–24 hr)						
Slope (b)	-0.064	-0.053	N/A	-0.066	N/A	N/A
Y-Intercept (µg)	6.29	16.11	N/A	8.21	N/A	N/A
Coefficient of Determination (r^2)	0.982	0.985	N/A	0.947	N/A	N/A
Elimination Rate Constant (hr^{-1})*	0.15	0.12	N/A	0.15	N/A	N/A
Terminal Phase (Linear Regression of log Amount vs. Time)						
Time Frame (hr)	24-48	24-48	3-48	24-48	3-48	3-48
Slope (b)	-0.017	-0.014	-0.024	-0.0043	-0.033	-0.024
Y-Intercept (µg)	0.47	1.68	17.44	0.33	15.90	24.10
Coefficient of Determination (r^2)	1.00	1.00	0.966	1.00	0.98	0.953
Elimination Rate Constant (hr^{-1})*	0.038	0.032	0.056	0.010	0.076	0.056
Half-life (hr)**	18	22	12	70	9.1	12

* Elimination Rate Constant (k_{el}) = -ln(10)xb

** Half-life = -ln(0.5)/k_{el}

N/A = Not applicable.

TABLE 17

Mean Concentration of PCMX Equivalents in Tissues following Dermal Administration of ^{14}C-PCMX*

	Group	Sub-Group	Length of Exposure (days)	Liver (µg/g)	Liver (SD)	Kidney (µg/g)	Kidney (SD)	Brain (µg/g)	Brain (SD)	Tongue (µg/g)	Tongue (SD)
2.4 mg/day											
Males											
	1	4	1	0.19	0.02	1.50	0.57	0.03	0.01	1.25	0.22
	5	1	14	0.83	0.20	3.73	1.35	0.30	0.09	4.44	0.75
	5	2	28	0.73	0.13	2.21	0.35	0.38	0.11	3.08	0.69
Females											
	1	4	1	0.22	0.03	0.67	0.37	0.05	0.00	1.54	0.14
	5	1	14	0.68	0.13	1.83	0.42	0.21	0.11	3.14	0.45
	5	2	28	0.84	0.15	1.60	0.26	0.33	0.06	2.71	0.46
8.0 mg/day											
Males											
	2	4	1	1.03	0.17	4.49	2.63	0.16	0.02	6.42	1.24
	6	1	14	2.08	0.22	5.52	1.97	0.54	0.14	9.39	3.71
	6	2	28	2.54	0.77	7.25	4.04	1.17	1.06	11.09	2.62
Females											
	2	4	1	1.61	0.57	5.02	2.29	0.21	0.09	7.29	1.34
	6	1	14	2.31	0.31	3.50	0.58	0.62	0.08	10.13	2.38
	6	2	28	2.13	0.29	3.82	1.00	0.56	0.19	9.20	1.44
24 mg/day											
Males											
	3	4	1	3.72	0.86	24.99	5.30	0.80	0.07	13.51	1.00
**	4	N/A	1	2.88	0.92	11.87	0.97	0.77	0.28	9.31	3.27
	7	1	14	4.92	1.20	13.49	9.81	1.90	0.70	21.88	6.61
	7	2	28	10.25	4.27	28.85	25.83	1.78	0.29	37.09	10.70
Females											
	3	4	1	5.33	1.10	20.40	2.47	0.97	0.36	12.43	2.35
**	4	N/A	1	4.19	0.90	15.86	3.11	0.83	0.11	17.39	7.98
	7	1	14	7.64	2.37	33.79	20.29	2.13	0.73	26.98	4.60
	7	2	28	5.48	0.35	10.97	3.43	1.23	0.27	46.26	47.31

* Data were derived from Tables F7, F8, F9 and F10 (Appendix F); N=4.
** DMSO as the vehicle.

TABLE 18

Elimination of PCMX Equivalents as a Percent of the Total Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice*

Group	Sub-Group	Length of Exposure (hr)	Urine (Mean %)	Urine (SD)	Feces (Mean %)	Feces (SD)	Total (Mean %)	Total (SD)
2.4 mg/dose								
1	1	3	35.45	15.61	0.87	1.45	36.33	15.14
1	2	6	66.46	8.91	0.08	0.07	66.54	8.95
1	3	12	72.67	2.68	0.61	0.20	73.28	2.87
1	4	24	82.29	2.53	1.63	0.27	83.92	2.38
1	5	48	84.10	5.44	4.67	4.54	88.77	1.40
5	1	14 days	83.70	3.93	8.45	3.60	92.14	1.41
5	2	28 days	88.56	0.60	4.09	1.23	92.65	0.71
8.0 mg/dose								
2	1	3	31.39	9.71	1.97	2.61	33.36	7.12
2	2	6	51.03	6.47	0.27	0.03	51.30	6.48
2	3	12	61.61	6.40	1.23	0.47	62.84	5.97
2	4	24	72.33	6.33	1.52	0.44	73.85	6.31
2	5	48	80.15	2.80	3.19	1.15	83.33	2.42
6	1	14 days	88.99	8.03	7.38	8.12	96.38	0.95
6	2	28 days	90.63	1.49	4.99	1.62	95.62	0.21
24 mg/dose								
3	1	3	16.37	5.26	3.40	0.40	19.77	5.28
3	2	6	26.94	4.09	7.85	2.26	34.80	4.88
3	3	12	54.77	9.30	9.14	4.57	63.91	5.64
3	4	24	61.87	6.02	6.11	3.14	67.98	4.09
3	5	48	74.40	7.42	8.23	2.23	82.63	6.13
7	1	14 days	82.49	5.76	8.26	3.95	90.75	2.54
7	2	28 days	84.82	3.59	9.96	3.24	94.79	0.91
24 mg/mouse - DMSO as vehicle								
4	N/A	24	71.52	1.74	1.88	0.18	73.40	1.89

* Data were derived from Table H2 (Appendix H) using the following equation and the direct calculation method for total absorption.

$$\% \text{ of Total Absorbed} = 100 \times \frac{\mu g \text{ Eliminated}}{\mu g \text{ Absorbed (Direct Calculation)}}$$

TABLE 19

Elimination of PCMX Equivalents as a Percent of the Total Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice*

Group	Sub-Group	Length of Exposure (hr)	Urine (Mean %)	Urine (SD)	Feces (Mean %)	Feces (SD)	Total (Mean %)	Total (SD)
2.4 mg/dose								
1	1	3	46.34	4.30	0.12	0.12	46.45	4.18
1	2	6	60.04	4.45	0.29	0.24	60.33	4.69
1	3	12	58.04	1.52	2.99	4.28	61.03	4.10
1	4	24	71.34	7.13	1.58	1.07	72.92	6.84
1	5	48	60.48	9.45	0.88	0.30	61.35	9.22
5	1	14 days	83.91	4.56	8.74	3.12	92.65	1.57
5	2	28 days	84.96	3.30	6.55	3.02	91.51	0.46
8.0 mg/dose								
2	1	3	28.91	7.75	0.42	0.37	29.33	7.92
2	2	6	43.16	5.34	1.35	1.76	44.51	4.49
2	3	12	66.29	2.80	0.98	0.51	67.26	3.00
2	4	24	69.72	6.60	3.17	2.97	72.89	8.39
2	5	48	74.01	10.76	6.32	6.42	80.33	4.64
6	1	14 days	88.56	1.48	6.43	1.58	94.98	1.24
6	2	28 days	90.42	2.67	5.65	2.03	96.06	1.62
24 mg/dose								
3	1	3	20.01	4.35	5.25	2.51	25.26	2.34
3	2	6	29.31	7.65	2.06	0.55	31.37	7.93
3	3	12	44.91	11.84	10.91	6.84	55.83	17.09
3	4	24	54.00	3.53	5.66	1.21	59.66	4.61
3	5	48	65.30	2.08	11.61	3.83	76.91	5.16
7	1	14 days	81.45	4.91	8.57	1.92	90.03	3.16
7	2	28 days	85.06	1.89	9.44	2.13	94.51	1.66
24 mg/mouse - DMSO as vehicle								
4	N/A	24	55.42	9.58	3.11	1.63	58.53	10.23

* Data were derived from Table H2 (Appendix H) using the following equation and the direct calculation method for total absorption.

$$\% \text{ of Total Absorbed} = 100 \times \frac{\mu g \text{ Eliminated}}{\mu g \text{ Absorbed (Direct Calculation)}}$$

TABLE 20

Kinetics of the Elimination of PCMX Equivalents following Dermal Administration of ^{14}C-PCMX to Male Mice

	URINE			FECES		
	Group 1 (2.4 mg/dose)	Group 2 (8.0 mg/dose)	Group 3 (24 mg/dose)	Group 1 (2.4 mg/dose)	Group 2 (8.0 mg/dose)	Group 3 (24 mg/dose)
Mean Amount Eliminated per Interval (µg)*						
0-3 hr	312	751	1136	7.05	43.1	232
0-6 hr	865	1366	2094	1.09	7.15	590
0-12 hr	990	2461	3829	8.43	46.4	666
0-24 hr	1101	3278	7947	21.6	68.1	764
0-48 hr	1319	3920	10090	73.0	157	1116
Amount Remaining To Be Eliminated (ARE; µg)**						
0 hr	1319	3920	10090	73.0	157	1116
3 hr	1007	3169	8954	66.0	114	884
6 hr	454	2554	7996	71.9	150	526
12 hr	329	1460	6261	64.6	111	450
24 hr	219	642	2143	51.5	89.2	352
Elimination Kinetics (Linear Regression of log ARE vs. Time from 0-24 hr)						
Slope (b)	-0.0317	-0.0332	-0.0281	-0.00599	-0.00905	-0.0198
Y-Intercept (µg)	1031	3923	11216	73.5	147	914
Coefficient of Determination (r^2)	0.844	0.997	0.960	0.870	0.713	0.810
Elimination Rate Constant (hr^{-1}) ***	0.0731	0.0765	0.0646	0.0138	0.0208	0.0455
Half-Life (hr) †	9.5	9.1	11	50	33	15

* Data were obtained from Table 6.

** ARE = Amount Eliminated (0-48 hr) - Amount Eliminated in Interval

*** Elimination Rate Constant (k_{el}) = -ln(10) x b

† Half-Life = $-\ln(0.5)/k_{el}$

TABLE 21

Kinetics of the Elimination of PCMX Equivalents following Dermal Administration of ^{14}C-PCMX to Female Mice

	URINE			FECES		
	Group 1 (2.4 mg/dose)	Group 2 (8.0 mg/dose)	Group 3 (24 mg/dose)	Group 1 (2.4 mg/dose)	Group 2 (8.0 mg/dose)	Group 3 (24 mg/dose)
Mean Amount Eliminated per Interval (µg)*						
0-3 hr	405	740	1158	0.91	10.6	277
0-6 hr	442	1216	2831	2.11	36.8	191
0-12 hr	655	2786	3459	39.8	40.8	754
0-24 hr	957	3099	6213	21.1	135	655
0-48 hr	837	3465	8479	12.0	299	1530
Amount Remaining To Be Eliminated (ARE; µg)**						
0 hr	837	3465	8479	12.0	299	1530
3 hr	432	2724	7320	11.1	288	1253
6 hr	395	2248	5648	9.93	262	1340
12 hr	182	678	5020	-27.8	258	776
24 hr	-120	366	2266	-9.1	164	876
Elimination Kinetics (Linear Regression of log ARE vs. Time from 0 hr-last positive value)						
Slope (b)	-0.0518	-0.0433	-0.0232	-0.01393	-0.01063	-0.0106
Y-Intercept (µg)	750	3419	8498	12.1	310	1394
Coefficient of Determination (r^2)	0.953	0.937	0.979	0.989	0.930	0.640
Elimination Rate Constant (hr^{-1}) ***	0.1192	0.0997	0.0535	0.0321	0.0245	0.0245
Half-Life (hr) †	5.8	7.0	13	22	28	28

* Data were obtained from Table 7.

** ARE = Amount Eliminated (0-48 hr) - Amount Eliminated in Interval

*** Elimination Rate Constant (k_{el}) = -ln(10) x b

† Half-Life = $-\ln(0.5)/k_{el}$

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Figures 1–27

FIGURE 1

Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Direct Calculation)*



* Data were obtained from Table H1 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 2

Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Direct Calculation)*



* Data were obtained from Table H1 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 3

Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Indirect Calculation)*



* Data were obtained from Table H1 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 4

Percent of Dose Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Indirect Calculation)*



* Data were obtained from Table H1 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 5

PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Direct Calculation)*



* Data were obtained from Table H2 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 6

PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Direct Calculation)*



* Data were obtained from Table H2 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 7

PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Male Mice (Indirect Calculation)*



* Data were obtained from Table H2 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 8

PCMX Equivalents Absorbed following Dermal Administration of ^{14}C-PCMX to Female Mice (Indirect Calculation)*



* Data were obtained from Table H2 (Appendix H).

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 9

Amount of PCMX Equivalents Absorbed in 24 Hours following a Single Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table H2 (Appendix H).

** N=4. Lines are least-squares linear regressions.

FIGURE 10
Amount of PCMX Equivalents Absorbed in 14 Days following Daily Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table H2 (Appendix H).

** N=4. Lines are lest-squares linear regressions.

FIGURE 11

Amount of PCMX Equivalents Absorbed in 28 Days following Daily Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table H2 (Appendix H).

** N=4. Lines are least-squares linear regressions.

FIGURE 12
Concentration of PCMX Equivalents in Application Site Skin following Dermal Administration of ^{14}C-PCMX to Male Mice*



* Data were obtained from Tables 12-14.

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 13
Concentration of PCMX Equivalents in Application Site Skin following Dermal Administration of ^{14}C-PCMX to Female Mice*



* Data were obtained from Tables 12-14

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 14

Concentration of PCMX Equivalents in Application Site Skin as a Function of Dose following a Single Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 12-14.

** N=3. Lines are least-squares linear regressions.

FIGURE 15

Concentration of PCMX in Plasma following Dermal Administration of ^{14}C-PCMX to Male Mice*



* Data were obtained from Tables 12-14.

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 16

Concentration of PCMX in Plasma following Dermal Administration of ^{14}C-PCMX to Female Mice*



* Data were obtained from Tables 12-14.

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 17

Concentration of PCMX Equivalents in Plasma as a Function of Dose following a Single Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 12-14.

** N=3. Lines are least-squares linear regressions.

FIGURE 18

Concentration of PCMX in the Blood Cellular Fraction following Dermal Administration of ^{14}C-PCMX to Male Mice*



* Data were obtained from Tables 12-14.

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 19

Concentration of PCMX in the Blood Cellular Fraction following Dermal Administration of ^{14}C-PCMX to Female Mice*



* Data were obtained from Tables 12-14.

** N=3 except at 1 (24 hr), 14, and 28 days where N=4.

FIGURE 20

Concentration of PCMX Equivalents in Liver following Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 17.

** N=4.

FIGURE 21

Concentration of PCMX Equivalents in Kidney following Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 17.

** N=4.

FIGURE 22

Concentration of PCMX Equivalents in Brain following Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 17.

** N=4.

FIGURE 23

Concentration of PCMX Equivalents in Tongue following Dermal Administration of ^{14}C-PCMX*



* Data were obtained from Table 17.

** N=4.

FIGURE 24

Percent of Absorbed Dose Eliminated following Dermal Administration of ^{14}C-PCMX to Male Mice*



* Data were obtained from Table 18.

** N=3 except at 1 (24 hr), 7, and 14 days where N=4.

FIGURE 25

Percent of Absorbed Dose Eliminated following Dermal Administration of ^{14}C-PCMX to Female Mice*



* Data were obtained from Table 19.

** N=3 except at 1 (24 hr), 7, and 14 days where N=4.

FIGURE 26

Amount Remaining To Be Eliminated (ARE) following Dermal Administration of ^{14}C-PCMX to Male Mice*



* Data were obtained from Table 20.

FIGURE 27

Amount Remaining To Be Eliminated (ARE) following Dermal Administration of ^{14}C-PCMX to Female Mice*



* Data were obtained from Table 21.

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix A

Protocol and Amendments

Study Number: WIL-304002

PROTOCOL AMENDMENT I

Sponsor: NIPA, Inc.

A. Title of Study:

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

B. Protocol Modifications:

III. STUDY SCHEDULE DATA:

1) **A. Proposed Experimental Start Date:** September 22, 1999

B. Proposed Experimental Termination Date: December 31, 1999

C. Proposed Audited Draft Report Date: March 31, 2000

IV. TEST ARTICLE DATA:

E. Dose Formulation Analysis:

2) Second sentence should read: "Dose formulations will be analyzed prior to and after use by high performance liquid chromatography to assess radiopurity and stability."

Dose formulations refer to those used for the acute test. Stability (radiopurity) of the Group 1 and Group 3 formulations for the acute test will also be assessed after 8-days refrigerated storage. Formulations for the repeated dose test will be prepared at a frequency dictated by the stability data generated during the acute test and divided into aliquots for daily use if applicable. Formulations for the repeated dose test will be analyzed prior to use by liquid scintillation counting to assess radiochemical concentration and homogeneity.

VI. **SPECIFIC MAINTENANCE SCHEDULE:**

A. **Animal Housing:**

3) Animals may be group-housed for the first few days of the quarantine/acclimation period.

VII. **EXPERIMENTAL DESIGN:**

B. **Animal Receipt and Acclimation:**

4) Permanent animal numbers will be assigned at the time animals are individually housed.

F. **Biological Phases:**

5) 1.d. A sub-sample of whole blood will not be taken. The entire blood sample will be centrifuged.

6) 2.d. A sub-sample of whole blood will not be taken. The entire blood sample will be centrifuged.

G. **Analytical Phases:**

7) 4. Whole blood will not be analyzed.

C. **Reason for Protocol Modifications:**

1) Add dates to protocol.

2) Correct typographical error and clarify dose formulation analyses.

3) Allow for group housing during acclimation.

4) Clarify when permanent animal numbers will be assigned.

5) An insufficient volume of blood can be collected to analyze whole blood as well as plasma and the cellular fraction.

6) Same as reason 5.

7) Remove sample type from analysis (see reason 5).

Approved By:

NIPA, Inc.

Irving Gottlieb
Sponsor Representative

9/29/99
Date

WIL Research Laboratories, Inc.

Daniel W. Sved, Ph.D.
Study Director

9/20/99
Date

Study Number: WIL-304002

PROTOCOL AMENDMENT II

Sponsor: NIPA, Inc.

A. Title of Study:

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

B. Protocol Modifications:

VII. EXPERIMENTAL DESIGN

E. Dosage Levels and Group Assignments

1) Length of exposure for Sub-Groups 1 and 2 of the repeated dose test should be 14 and 28 days, respectively.

F. Biological Phases

2) 2.a. Any hair removed following the initiation of exposure will be weighed, pooled by animal, and retained for analysis. For the animals exposed for 28 days, the dosing area will be washed prior to treatment on Day 14.

G. Analytical Phases

3) 5. Hair samples will also be analyzed by solubilization.

C. Reason for Protocol Modifications:

1) Clarification. Animals will receive either 14 or 28 daily doses and be euthanized the day following the last dose, which provides 14 or 28 days of exposure.

2) Addition of hair collection to improve mass balance aspect of the study. Clarification of length of exposure and day for washing.

3) Addition of hair analysis.

Approved By:

NIPA, Inc.

Irving Gottlieb
Sponsor Representative

11/1/99
Date

Prepared By:

WIL Research Laboratories, Inc.

Daniel W. Sved, Ph.D.
Study Director

10/13/99
Date

Study Number: WIL-304002

PROTOCOL AMENDMENT III

Sponsor: NIPA, Inc.

A. Title of Study:

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

B. Protocol Modifications:

VII. EXPERIMENTAL DESIGN

H. Additional Investigation (new section)

1) Aliquots of dosing formulation will be added to each of 18 scintillation vials. Scintillation cocktail will be added to three of the vials immediately after preparation. The remaining vials will be allowed to sit open in a hood. At 1, 3, 6, 12, and 24 hours after preparation, scintillation cocktail will be added to three vials. All vials will be analyzed for ^{14}C by LSC.

C. Reason for Protocol Modifications:

1) Recovery of radioactivity from the animals used in the study appears to be approximately 80% at most. Volatility of the test article is one of several possible explanations. This additional investigation is being added to estimate what percent of dose may be lost through volatilization prior to the material being absorbed.

Approved By:

NIPA, Inc.

Irving Gottlieb
Sponsor Representative

Date

Prepared By:

WIL Research Laboratories, Inc.

Daniel W. Sved, Ph.D.
Study Director

1/28/2000
Date

PROTOCOL

A Dermal Absorption
Study with [^{14}C]-labeled PCMX in Mice

WIL Study No.: WIL-304002

For

NIPA [redacted] (1) Inc.
3411 Silverside Road
Wilmington, DE 19810

By

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

(1) Sponsor changed to reflect name as of 4/1/99. DWS 4/29/99

March 30, 1999

A DERMAL ABSORPTION STUDY WITH [^{14}C]-LABELED PCMX IN MICE

WIL Study No.: WIL-304002

I. OBJECTIVES OF THE STUDY:

1. To determine the absorption of [^{14}C]-PCMX after single and repeated dermal administration.
2. To ascertain the pharmacokinetics of [^{14}C]-PCMX after single and repeated dermal administration.
3. To determine if there are dose dependent differences in the absorption and pharmacokinetics of [^{14}C]-PCMX after dermal administration.
4. To determine the distribution of [^{14}C]-PCMX is select tissues after single and repeated dermal administration.

II. PERSONNEL INVOLVED IN THE STUDY:

A. Sponsor Monitor

Wallace Guess, Ph.D.
NIPA [redacted], (1) Inc.

B. WIL Study Director

Daniel W. Sved, Ph.D.
Director of Metabolism and Analytical Chemistry

C. WIL Deputy Director

Peter Resnis, B.S.
Senior Research Chemist - Metabolism

D. WIL Department Responsibilities

1. James L. Schardein, M.S., A.T.S.
   Director of Research
2. Christopher P. Chengelis, Ph.D., D.A.B.T.
   Director, Toxicology
3. Karen S. Regan, D.V.M., D.A.C.V.P., D.A.B.T.
   Director of Pathology and Veterinary Medicine
4. Sally A. Keets, A.S.
   Manager II, Vivarium

(1) Sponsor changed name. DWS 4/25/99

II. PERSONNEL INVOLVED IN THE STUDY: (continued)

5. Deborah L. Little, B.S., RQAP-GLP
Manager II, Quality Assurance

III. STUDY SCHEDULE DATA

A. Proposed Experimental Start Date: To be determined

B. Proposed Experimental Termination Date: To be determined

C. Proposed Audited Draft Report Date: To be determined

IV. TEST ARTICLE DATA

A. Identification: Chloroxylenol (4-chloro-3,5-dimethylphenol; parachlorometaxylenol; PCMX) labeled with ^{14}C in a biologically stable position will be provided by Wizard Laboratories, Inc., West Sacramento, CA. Documentation concerning the synthesis, of the test article will be provided by Wizard Laboratories. The Sponsor will provide an appropriate amount of unlabeled test article for dilution purposes.

B. Radiopurity: Radiopurity of the ^{14}C-PCMX will be determined provided by Wizard Laboratories. Radiopurity of the dosing formulations will be determined by WIL Research using an HPLC method (see Section IV.E.).

C. Specific Activity: The specific activity of the ^{14}C-PCMX will be determined by Wizard Laboratories. Calculations will be based on the supplied specific activity.

D. Dose Formulation: Except for Group 4, the test article will be formulated for dose administration in acetone. For Group 4, the test article will be formulated in dimethylsulfoxide (DMSO).

E. Dose Formulation Analysis: Dose formulations will be analyzed prior to and after use by liquid scintillation counting to assess radiochemical concentration and homogeneity.

Dose formulations will be analyzed prior to and after use by high performance liquid and stability chromatography to assess radiopurity.

IV. TEST ARTICLE DATA (continued)

F. Storage Conditions: The ^{14}C-labeled PCMX will be stored under freezer conditions. Unlabeled PCMX will be stored at room temperature. Dose formulations will be stored under refrigerator conditions when not in use.

G. Reserve Samples: A reserve sample of each batch of test article will be retained at WIL Research according to WIL Research standard operating procedures.

H. Personnel Safety Data: Appropriate safe handling procedures will be used based on available information.

V. TEST SYSTEM

A. Species: Mouse

B. Strain: CD-1®

C. Source: Charles River Laboratories

D. Number on Study: 76 males and 76 females (two additional animals will be used to provide matrix for analytical validation)

E. Approximate Weight: Animals will be about 20 to 35 g at initiation of dosing.

F. Approximate Age: Approximately 7 weeks old at initiation of dosing.

G. Identification System: Animals will be identified uniquely by tail tattoo displaying the animal number. Individual cage cards will be affixed to each cage and will display the animal number, group number and study number.

H. Justification for Selection: The mouse is a preferred species for developing data on the absorption, distribution, and excretion of the test substance. These data will be used, in part, to select dosage levels for a mouse dermal carcinogenicity study.

VI. SPECIFIC MAINTENANCE SCHEDULE

A. Animal Housing

All animals will be housed individually in clean suspended wire-mesh cages during the quarantine/acclimation period. The cages will be elevated above cage-board or other suitable material, which will be changed at least three times each week. After receiving the radiolabeled dose, animals will be housed individually in metabolism units designed for the separate collection of urine and feces.

B. Environmental Conditions

Animals will be kept in an environmentally controlled room designed to maintain a temperature of 72° ± 4°F and a relative humidity of 30% to 70% with at least 10 fresh air changes per hour. Timers will be set to provide a daily photoperiod of 12 hours of fluorescent light followed by 12 hours of darkness. Temperature and relative humidity in the animal room(s) used for the study will be recorded once daily.

C. Drinking Water

Tap water will be available *ad libitum*. Water will be provided using an automatic water system except in metabolism units, where water will be provided using water bottles. Filters servicing the automatic watering system will be changed regularly according to WIL Standard Operating Procedures. The municipal water supplying the laboratory will be analyzed for contaminants according to WIL Standard Operating Procedures to ascertain that none of the analyzed contaminants are present in concentrations that would be expected to affect the outcome of the study.

D. Basal Diet

PMI Nutrition International, Inc. Certified Rodent LabDiet® 5002 will be offered *ad libitum* during acclimation and the in-life portions of the study. Each lot utilized will be identified and recorded. Analyses of the certified feed for the presence of heavy metals and pesticides will be provided by the manufacturer. Feeders will be changed and sanitized at least once per week.

VII. EXPERIMENTAL DESIGN

A. Overview

The study will consist of an acute (single dose) test and a repeated dose test, each with a biological phase and an analytical phase. In the acute test, each animal will receive a single dose of [^{14}C]-PCMX dermally at one of three dose levels. In the repeated dose test, each animal will receive a dose of [^{14}C]-PCMX at one of three dose levels daily for 14 or 28 days. Following treatment, the animals will be placed in individual metabolism cages. In the acute test, sub-groups at each dose level will be periodically euthanized. In the repeated dose test, sub-groups at each dose level will be euthanized 24 hours after the final dose. The disposition of ^{14}C will be determined. All samples will be analyzed for total ^{14}C.

B. Animal Receipt and Acclimation

Each animal will be inspected by qualified personnel upon receipt. Animals judged to be in good health and suitable as test animals will be assigned a permanent animal number and immediately placed in quarantine for approximately 10 days. All animals will be weighed. During the quarantine period, each animal will be observed twice daily for changes in general appearance and behavior.

C. Randomization

Near the end of the quarantine/acclimation period, animals judged to be suitable for testing will be weighed and assigned to groups at random using a computer program. A printout containing the animal numbers and individual group assignments will be generated based on body weight stratification into a block design. Animals will then be arranged into the groups according to the printout.

D. Route and Rationale of Test Substance Administration

The route of administration will be topical because dermal exposure is the anticipated route of human exposure and will be the route of administration used in a carcinogenicity study.

E. Dosage Levels and Group Assignments

Three dose levels will be used. The animals used in the study will be divided into groups (and sub-groups) as outlined in the following table.

VII. EXPERIMENTAL DESIGN (continued)

Group	Dosage Level (40 µL/mouse)	Vehicle	Sub-group	Length of Exposure (hours)	Number of Animals M	Number of Animals F
ACUTE TEST						
1	6%	Acetone	1	3	3	3
			2	6	3	3
			3	12	3	3
			4	24	4	4
			5	48	3	3
2	20%	Acetone	1	3	3	3
			2	6	3	3
			3	12	3	3
			4	24	4	4
			5	48	3	3
3	60%	Acetone	1	3	3	3
			2	6	3	3
			3	12	3	3
			4	24	4	4
			5	48	3	3
4	60%	DMSO	NA (treated as Sub-group 4)	24	4	4
REPEATED DOSE TEST						
5	6%	Acetone	1	15 days	4	4
			2	29 days	4	4
6	20%	Acetone	1	15 days	4	4
			2	29 days	4	4
7	60%	Acetone	1	15 days	4	4
			2	29 days	4	4

NA =Not applicable.

VII. EXPERIMENTAL DESIGN (continued)

F. Biological Phases

1. Acute Test

a. The anterior dorsal hair of the mice will be shaved on the day prior to treatment. The dosing area will be washed with acetone to remove oily secretions found on the skin.

b. The dosing preparation (40 μL) will be applied to the dosing area once using a positive displacement pipet with a glass, capillary tip. Following the dose application, the capillary tip will be washed both internally and externally with a known amount of an appropriate solvent.

c. Each treated animal will be placed in a metabolism unit (Nalgene type), which allows for separate collection of urine and feces. A single urine collection and a single feces collection for each animal of Sub-groups 1 through 4 will be made from the time of application to the time the animal is euthanized. For the animals of Sub-groups 5, urine and feces will be collected over 24-hour intervals. Individual collections of urine and feces from each animal will be measured.

d. Sub-groups 1, 2, 3, and 5: After the appropriate exposure duration, the skin of the application site will be washed vigorously four times to recover unabsorbed radioactivity. The washes will be done in sequence using sterile cotton gauze squares and two liquids: two washes with Dove liquid detergent: deionized water (20:1000) and two washes with deionized water. Gauzes from each type of wash will be combined. Each animal will be euthanized using carbon dioxide. After euthanasia, each animal will be weighed, the abdominal cavity opened and a sample of whole blood removed from the inferior vena cava or the heart using heparin as the anticoagulant. Sub-samples of the whole blood will be taken and the remaining blood separated into plasma and a cellular fraction (labeled as RBC) by centrifugation. Skin from the application site will be dissected from the carcass. Urine will be removed from the bladder and combined with the last urine collection. The carcass of each animal will be retained. Other than skin sections (as mentioned above), no individual organs or tissues will be collected from these sub-groups.

e. Sub-group 4: After the 24-hour exposure period, the animals will be processed as described above, except that the following tissues will also be collected for analysis: tongue, brain, liver, and kidney.

f. Each metabolism cage will be washed with an appropriate solvent. The amount of the cage wash will be measured.

VII. EXPERIMENTAL DESIGN (continued)

g. Two animals that were included in the randomization pool, but not used in the treatment groups will be used to provide samples for the determination of analytical recoveries. These animals will be placed in individual metabolism units until a sufficient amount of urine and feces has been collected. The animals will then be euthanized and processed as per the sub-group 4 animals.

h. All samples will be stored under freezer conditions unless otherwise documented in the raw data.

2. Repeated Dose Test

a. The anterior dorsal hair of the mice will be shaved on the day prior to the first treatment and as needed prior to additional treatments. The dosing area will be washed with acetone after the initial shaving to remove oily secretions found on the skin. For the animals exposed for 29 days, the dosing area will be washed as described in Section VII.F.2.d. prior to treatment on Day 15 (Day 0 is the day of the first treatment).

b. The dosing preparation (40 μL) will be applied to the dosing area once daily, at approximately the same time each day, using a positive displacement pipet with a glass, capillary tip. Following each dose application, the capillary tip will be washed both internally and externally with a known amount of an appropriate solvent. Animals in sub-groups 1 will receive 14 daily doses; animals in sub-groups 2 will receive 28 daily doses.

c. Each treated animal will be placed in a metabolism unit (Nalgene type), which allows for separate collection of urine and feces. Urine and feces will be collected over each 24-hour interval following the initial treatment and pooled until the time of the final dose. Urine and feces collected between the last dose and necropsy will be collected separately. Individual collections from each animal will be measured.

VII. EXPERIMENTAL DESIGN (continued)

d. After the appropriate exposure duration, the skin of the application site will be washed vigorously four times to recover unabsorbed radioactivity. The washes will be done in sequence using sterile cotton gauze squares and two liquids: two washes with Dove liquid detergent: deionized water (20:1000) and two washes with deionized water. Gauzes from each type of wash will be combined. Each animal will be euthanized using carbon dioxide. After euthanasia, each animal will be weighed, the abdominal cavity opened and a sample of whole blood removed from the inferior vena cava or the heart using heparin as the anticoagulant. Sub-samples of the whole blood will be taken and the remaining blood separated into plasma and a cellular fraction (labeled as RBC) by centrifugation. Skin from the application site will be dissected from the carcass. Urine will be removed from the bladder and combined with the last urine collection. Tongue, brain, liver, and kidney will be removed, and the remaining carcass retained.

e. Each metabolism cage will be washed with an appropriate solvent. The amount of the cage wash will be measured.

f. All samples will be stored under freezer conditions unless otherwise documented in the raw data.

G. Analytical Phases

1. Analyses for ^{14}C will be performed by liquid scintillation counting (LSC) in duplicate, when possible, according to WIL standard operating procedures. Liquid scintillation analyses will be corrected for chemical quench using an external standard method, background, and, if possible, chemiluminescence. In general, samples will be counted for 10 minutes, or until a 2-sigma error of 1% is achieved.

2. Aliquots of known size of each pipette wash, urine, cage wash, and plasma sample will be mixed with an appropriate volume of scintillation cocktail and analyzed for ^{14}C by LSC.

3. The soap wash gauzes and water wash gauzes from each animal will be digested in 50% H_2SO_4 and aliquots of the digests will be mixed with an appropriate volume of scintillation cocktail and analyzed for ^{14}C by LSC.

4. Each fecal, tongue, brain, liver, and kidney sample will be homogenized. Methods for processing and homogenizing the samples will be documented in the raw data. Each carcass will be partially thawed and homogenized by passage through a power meat grinder. Aliquots of known size of each fecal, tongue, brain, liver, kidney, carcass, whole blood, and RBC sample will be oxidized according to WIL standard operating procedures. The CO_2 liberated during combustion will be trapped in a suitable medium and analyzed for ^{14}C by LSC.

VII. EXPERIMENTAL DESIGN (continued)

5. Skin samples will be solubilized and aliquots of the digest will be mixed with an appropriate volume of scintillation cocktail and analyzed for ^{14}C by LSC.

6. For each sample type analyzed, aliquots of the sample type from the untreated animal will be fortified with the ^{14}C-test article and analyzed by LSC techniques to establish the validity and sensitivity of the radioanalytical procedures.

VIII. CALCULATIONS AND STATISTICAL EVALUATION

Calculation of the amounts of radioactivity in various materials generated in the study will be performed using programs of the WIL Toxicology Data Management System on a microvax 3400 or spreadsheets on a personal computer according to WIL standard operating procedures. Absorption will be calculated using a direct method (sum of amounts in blood, urine, feces, cage wash, and carcass) and an indirect method (dose amount minus the amounts in skin washes and skin). The total amounts of ^{14}C in all samples will be summed to determine overall recovery of the ^{14}C administered in the dose. When appropriate, kinetic parameters (e.g., area under the concentration-time curves, elimination coefficients) will be calculated using standard equations. Generally, only descriptive statistics (e.g., totals, arithmetic means, standard deviations, standard errors, coefficients of variation, percentages) will be used.

IX. QUALITY ASSURANCE

The study will be audited by the WIL Quality Assurance Unit while in progress to assure compliance with FDA Good Laboratory Practice regulations (21 CFR Part 58) and adherence to the protocol and to WIL Standard Operating Procedures. The raw data and draft report will be audited by the WIL Quality Assurance Unit prior to submission to the Sponsor to assure that the report accurately describes the conduct and the findings of the study.

This study is an FDA regulated study and should be included on the WIL master list of regulated studies.

X. RECORDS TO BE MAINTAINED

All original raw data records, as defined by the applicable GLPs and WIL SOPs, will be stored in the Archives at WIL Research Laboratories, Inc.

XI. WORK PRODUCT

Sponsor will have title to all documentation records, raw data, slides, specimens, or other work product including counted scintillation vials, generated during the performance of the study. All work product including paper raw data, magnetically encoded records and specimens will be retained at no charge for a period of six months following issuance of the final report in the Archives at WIL Research Laboratories, Inc. Thereafter, WIL Research Laboratories will charge a monthly archiving fee for retention of all work product. All work product will be stored in compliance with regulatory requirements.

XII. REPORTS

Following conclusion of experimental activities, WIL Research will prepare a report of the study, which will contain all information necessary to conform with current regulatory agency specifications.

The contents of the report will include, but not be limited to:

1. A description of all experimental procedures and calculations.
2. All results from the scintillation counting of individual sub-samples.
3. The actual quantity of test article administered to each animal, the amount absorbed (direct and indirect methods), and a determination of mass balance.
4. A determination of the limit of detection for each sample type.

WIL Research Laboratories will provide one (1) copy of an Audited Draft Report, submitted in a timely manner upon completion of the study prior to issuance of the final report. One (1) revision will be permitted as part of the cost of the study, from which Sponsor's reasonable revisions and suggestions will be incorporated into the Final Report as appropriate. Additional changes or revisions may be made, at extra cost. It is expected that the Sponsor will review the draft report and provide comments to WIL within a two (2) month time frame following submission. WIL will submit the Final Report within one (1) month following receipt of comments. Two (2) copies of the Final Report (1 bound, 1 unbound) will be provided; requests for additional copies of the Final Report may result in additional charges.

XIII. PROTOCOL MODIFICATION

Modification of the protocol may be accomplished during the course of this investigation. However, no changes will be made in the study design without the verbal or written permission of the Sponsor. In the event that the Sponsor verbally requests or approves changes in the protocol, such changes will be made by appropriate documentation in the form of protocol amendments. All alterations of the protocol and reasons for the modification(s) will be signed by the Study Director.

XIV. ANIMAL WELFARE ACT COMPLIANCE

This study will comply with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR). The Sponsor should make particular note of the following:

1. The Sponsor signature on this protocol documents for the Study Director the Sponsor's assurance that the study described in this protocol does not unnecessarily duplicate previous experiments.

2. Whenever possible, procedures used in this study have been designed to avoid or minimize discomfort, distress or pain to animals. All methods are described in this study protocol or in written laboratory standard operating procedures.

3. Animals that experience severe or chronic pain or distress that cannot be relieved will be painlessly euthanized as deemed appropriate by the veterinary staff and Study Director. The Sponsor will be advised by the Study Director of all circumstances which could lead to this action in as timely a manner as possible.

4. Methods of euthanasia used during this study are in conformance with the above referenced regulation.

XV. PROTOCOL APPROVAL

NIPA ~~[illegible]~~ ① Inc.
3411 Silverside Road
Wilmington, DE 19810

Irving Gottlieb
Sponsor Representative

4/22/99
Date

WIL Research Laboratories, Inc.
Ashland, Ohio 44805-9281

Daniel W. Sved, Ph.D.
Study Director

3/31/99
Date

① Sponsor changed name. DWS 4/29/99

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix B

Test Article Information

3304A

Nipa Laboratories Ltd.

Nook Lane, Oswaldtwistle, Lancashire. BB5 3PQ. United Kingdom.
Telephone: 01254 233621 Fax: 01254 872800

Your Reference;
Our Reference;OSMP 1806
Date; 7 March 1997

WIL RESEARCH LABS INC.,
1407 GEORGE ROAD,
ASHLANDS,
OH 44805-9281,
U.S.A.

attention of; Dr. CHRIS P.CHENGELIS

CERTIFICATE OF ANALYSIS - NIPACIDE PX (PCMX)

Batch no;	E 22-1
Melting Point;	115.4
Purity % ;	99.41

NIPA LABORATORIES LTD.

J.R.Thomas.
Quality Control Manager.

WIL–304002
NIPA Inc.

Wizard Laboratories, Inc.

DATE: 8/9/99

LOT NO.: 990809

PRODUCT INFORMATION

COMPOUND..... 4-Chloro-3,5-dimethylphenol-UL-ring-^{14}C

ACTIVITY..... 26.2 mCi

SPECIFIC ACTIVITY..... 15.44 mCi/mmol

RADIOCHEMICAL PURITY... 99.7%

as determined by high-pressure liquid chromatography:

Column: C18, 10u, 4.6 x 250mm
Mobile Phase: 50:50 CH3CN:H2O, 1.0ml/min, Det. 280nm

Packaging: 1 x 26.2 mCi in screw-cap vial under N2

NOTE: The susceptibility of carbon-14 labeled compounds to radiolysis varies greatly. We urge you to use this product as soon as possible.

WARRANTY: Wizard Laboratories warrants this material to be as stated above. There is no warranty, expressed or implied, as to the fitness of this material for any particular purpose. The customer must notify the company, by registered mail, of any breach of warranty within 20 days of receipt.

2785-B DEL MONTE STREET WEST SACRAMENTO, CA 95691 USA TEL/FAX: (916) 372-2124 E-MAIL: SALES@WIZARDLABS.COM

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix C

Calculation of Final Specific Activity and Analysis of the Dosing Formulations

TABLE C1

Calculations for Preparation of Dosing Formulations and Final Specific Activity - Acute Test

	Group 1	Group 2	Group 3	Group 4
(A) Target Concentration of Dosing Formulation	60 mg/mL	200 mg/mL	600 mg/mL	600 mg/mL
(B) Volume of Dosing Solution Prepared	5.00 mL	5.00 mL	5.00 mL	1.00 mL
(C) Amount of Test Substance Needed	300.0 mg	1000.0 mg	3000.0 mg	600.0 mg
(D) Dose Volume	0.04 mL	0.04 mL	0.04 mL	0.04 mL
(E) Desired Radioactivity/dose	5.0 µCi	5.0 µCi	5.0 µCi	5.0 µCi
(F) Amount of Radioactivity Needed	625 µCi	625 µCi	625 µCi	125 µCi
(G) Amount of Radiolabeled Test Substance Used	6.4 mg	6.4 mg	6.4 mg	1.3 mg
(H) Amount of Nonradiolabeled Test Substance Used	0.2936 g	0.9936 g	2.9936 g	0.5987 g
(I) Total Amount of Test Substance Used	300 mg	1000 mg	3000 mg	600 mg
(J) Initial Specific Activity of Test Substance	15.44 mCi/mmol	15.44 mCi/mmol	15.44 mCi/mmol	15.44 mCi/mmol
(K) Final Specific Activity of Test Substance	**2.10** µCi/mg	**0.63** µCi/mg	**0.21** µCi/mg	**0.21** µCi/mg
(L) Final Specific Activity of Test Substance	**4655** dpm/µg	**1396** dpm/µg	**465** dpm/µg	**473** dpm/µg
(M) Theo. Radioactive Concentration of Dosing Formulation	125808 nCi/mL	125808 nCi/mL	125808 nCi/mL	127774 nCi/mL

Formulae:

(C) = (A)x(B)
(F) = (B)x(E)/(D)
* (G) = (F)/(J)x(Molecular Weight)/(1000 µCi/mCi)
(H) = ((C)-(G))/(1000 mg/g)
(I) = (G)+((H)x1000 mg/g))
* (K) = (J)/(Molecular Weight)x(1000 µCi/mCi)x(G)/(I)
(L) = (K)x(2.22x10^6 dpm/µCi)/(1000 µg/mg)
(M) = (K)x(I)x(1000 nCi/µCi)/(B)

* Molecular weight = 157.09 mg/mmol.

TABLE C2

Calculations for Preparation of Dosing Formulations and Final Specific Activity - Repeated Dose Test

	Group 5	Group 6	Group 7
(A) Target Concentration of Dosing Formulation	60 mg/mL	200 mg/mL	600 mg/mL
(B) Volume of Dosing Solution Prepared	10.00 mL	10.00 mL	10.00 mL
(C) Amount of Test Substance Needed	600.0 mg	2000.0 mg	6000.0 mg
(D) Dose Volume	0.04 mL	0.04 mL	0.04 mL
(E) Desired Radioactivity/dose	2.0 µCi	2.0 µCi	2.0 µCi
(F) Amount of Radioactivity Needed	500 µCi	500 µCi	500 µCi
(G) Amount of Radiolabeled Test Substance Used	5.1 mg	5.1 mg	5.1 mg
(H) Amount of Nonradiolabeled Test Substance Used	0.5949 g	1.9949 g	5.9949 g
(I) Total Amount of Test Substance Used	600 mg	2000 mg	6000 mg
(J) Initial Specific Activity of Test Substance	15.44 mCi/mmol	15.44 mCi/mmol	15.44 mCi/mmol
(K) Final Specific Activity of Test Substance	**0.84** µCi/mg	**0.25** µCi/mg	**0.08** µCi/mg
(L) Final Specific Activity of Test Substance	**1855** dpm/µg	**556** dpm/µg	**185** dpm/µg
(M) Theo. Radioactive Concentration of Dosing Formulation	50127 nCi/mL	50127 nCi/mL	50127 nCi/mL

Formulae:

(C) = (A)x(B)
(F) = (B)x(E)/(D)
* (G) = (F)/(J)x(Molecular Weight)/(1000 µCi/mCi)
(H) = ((C)-(G))/(1000 mg/g)
(I) = (G)+((H)x1000 mg/g))
* (K) = (J)/(Molecular Weight)x(1000 µCi/mCi)x(G)/(I)
(L) = (K)x(2.22x10^6 dpm/µCi)/(1000 µg/mg)
(M) = (K)x(I)x(1000 nCi/µCi)/(B)

* Molecular weight = 157.09 mg/mmol.

TABLE C3

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-5-1) Used for Group 1

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	Volume of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
Pre-Dosing (1st day of use)							
7 - 1	40.0	5.0	40.0	100861	100206	102022	142215
7 - 2	40.0	5.0	40.0	100427	101333	101021	142071
7 - 3	40.0	5.0	40.0	99775	100001	99207	140289
						MEAN =	**141525**
						SD =	1073
						%CV =	**0.76**
						****Percent of Theoretical =**	**112**
Post-Dosing (1st day of use)							
9 - 1	40.0	5.0	40.0	100430	100932	101882	142288
9 - 2	40.0	5.0	40.0	101160	101406	100946	142413
9 - 3	40.0	5.0	40.0	100575	100982	100469	141716
						MEAN =	**142139**
						SD =	371.7
						%CV =	**0.26**
						****Percent of Theoretical =**	**113**
Pre-Dosing (2nd day of use)							
10 - 1	40.0	5.0	40.0	100107	99403	99836	140459
10 - 2	40.0	5.0	40.0	101250	100029	100925	141800
10 - 3	40.0	5.0	40.0	101426	100844	100418	142027
						MEAN =	**141429**
						SD =	847.6
						%CV =	**0.60**
						****Percent of Theoretical =**	**112**
Post-Dosing (2nd day of use)							
11 - 1	40.0	5.0	40.0	104443	102556	103281	145589
11 - 2	40.0	5.0	40.0	101305	101716	101457	142867
11 - 3	40.0	5.0	40.0	100486	100581	101077	141772
						MEAN =	**143409**
						SD =	1966
						%CV =	**1.37**
						****Percent of Theoretical =**	**114**

GRAND MEAN: 142 µCi/mL
OVERALL PERCENT OF THEORETICAL: 113
DOSE PER 40 µL: 5685 nCi

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

TABLE C4

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-36-1) Used for Group 2

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	Volume of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
Pre-Dosing (1st day of use)							
36 - 2	40.0	5.0	40.0	101147	99960	100573	141554
36 - 3	40.0	5.0	40.0	100132	101852	101488	142395
36 - 4	40.0	5.0	40.0	100227	100980	100099	141378
						MEAN =	**141776**
						SD =	543
						%CV =	**0.38**
						****Percent of Theoretical =**	**113**
Post-Dosing (1st day of use)							
39 - 1	40.0	5.0	40.0	101637	101425	101226	142778
39 - 2	40.0	5.0	40.0	102549	100067	101065	142493
39 - 3	40.0	5.0	40.0	99917	99545	100131	140575
						MEAN =	**141949**
						SD =	1198
						%CV =	**0.84**
						****Percent of Theoretical =**	**113**
Pre-Dosing (2nd day of use)							
40 - 1	40.0	5.0	40.0	100805	100108	100404	141383
40 - 2	40.0	5.0	40.0	99198	99777	99217	139917
40 - 3	40.0	5.0	40.0	100512	100100	100528	141300
						MEAN =	**140867**
						SD =	824
						%CV =	**0.58**
						****Percent of Theoretical =**	**112**
Post-Dosing (2nd day of use)							
41 - 1	40.0	5.0	40.0	101043	99320	99896	140887
41 - 2	40.0	5.0	40.0	100415	100234	101471	141760
41 - 3	40.0	5.0	40.0	101086	101422	100426	142143
						MEAN =	**141597**
						SD =	644
						%CV =	**0.45**
						****Percent of Theoretical =**	**113**

GRAND MEAN: 142 µCi/mL
OVERALL PERCENT OF THEORETICAL: 113
DOSE PER 40 µL: 5662 nCi

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

TABLE C5

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-23-1) Used for Group 3

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	Volume of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
Pre-Dosing (1st day of use)							
23 - 2	40.0	5.0	40.0	99281	100331	99038	140132
23 - 3	40.0	5.0	40.0	98014	97868	97847	137823
23 - 4	40.0	5.0	40.0	98804	98922	99497	139462
						MEAN =	**139139**
						SD =	1188
						%CV =	**0.85**
						****Percent of Theoretical =**	**111**
Post-Dosing (1st day of use)							
27 - 1	40.0	5.0	40.0	98811	98838	98249	138841
27 - 2	40.0	5.0	40.0	95684	98226	98470	137190
27 - 3	40.0	5.0	40.0	99152	97904	98699	138774
						MEAN =	**138269**
						SD =	934.2
						%CV =	**0.68**
						****Percent of Theoretical =**	**110**
Pre-Dosing (2nd day of use)							
30 - 1	40.0	5.0	40.0	97753	99117	98886	138775
30 - 2	40.0	5.0	40.0	98116	98887	98791	138792
30 - 3	40.0	5.0	40.0	97976	96189	99295	137697
						MEAN =	**138421**
						SD =	627.3
						%CV =	**0.45**
						****Percent of Theoretical =**	**110**
Post-Dosing (2nd day of use)							
31 - 1	40.0	5.0	40.0	96626	96524	96369	135848
31 - 2	40.0	5.0	40.0	96871	96402	96492	135964
31 - 3	40.0	5.0	40.0	96777	97186	95715	135922
						MEAN =	**135911**
						SD =	58.7
						%CV =	**0.043**
						****Percent of Theoretical =**	**108**

GRAND MEAN: 138 µCi/mL
OVERALL PERCENT OF THEORETICAL: 110
DOSE PER 40 µL: 5517 nCi

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

TABLE C6

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulation (Ref #304002A1-28-1) Used for Group 4

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
Pre-Dosing							
28 - 2	40.0	5.0	40.0	90756	92838	90404	128565
28 - 3	40.0	5.0	40.0	89885	90449	88934	126346
28 - 4	40.0	5.0	40.0	89631	88464	91043	126285
						MEAN =	**127065**
						SD =	1299
						%CV =	**1.02**
						****Percent of Theoretical =**	**99.4**
Post-Dosing							
32 - 1	40.0	5.0	40.0	93351	92659	91704	130309
32 - 2	40.0	5.0	40.0	92122	92268	92769	130048
32 - 3	40.0	5.0	40.0	91488	91925	91798	129134
						MEAN =	**129831**
						SD =	616.7
						%CV =	**0.48**
						****Percent of Theoretical =**	**102**

GRAND MEAN: 128 µCi/mL
OVERALL PERCENT OF THEORETICAL: 101
DOSE PER 40 µL: 5138 nCi

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

TABLE C7

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 5

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
1st Week (Ref #304002A1-46-1)							
46 - 2	40.0	2.0	40.0	100607	99899	99881	56379
46 - 3	40.0	2.0	40.0	100393	99176	100624	56342
46 - 4	40.0	2.0	40.0	99420	99137	100037	56042
						MEAN =	**56255**
						SD =	185
						%CV =	**0.33**
						****Percent of Theoretical =**	**112**
						Dose per 40 µL (nCi) =	**2250**
2nd Week (Ref #304002A1-55-1)							
55 - 2	40.0	2.0	40.0	100101	100314	100059	56395
55 - 3	40.0	2.0	40.0	99988	100385	99971	56371
55 - 4	40.0	2.0	40.0	99955	100852	99866	56433
						MEAN =	**56400**
						SD =	31.1
						%CV =	**0.055**
						****Percent of Theoretical =**	**113**
						Dose per 40 µL (nCi) =	**2256**
3rd Week (Ref #304002A1-66-1)							
66 - 2	40.0	2.0	40.0	98632	99375	98305	55614
66 - 3	40.0	2.0	40.0	99419	99508	97477	55631
66 - 4	40.0	2.0	40.0	98335	99563	98725	55673
						MEAN =	**55639**
						SD =	30.1
						%CV =	**0.054**
						****Percent of Theoretical =**	**111**
						Dose per 40 µL (nCi) =	**2226**
4th Week (Ref #304002A1-79-1)							
79 - 2	40.0	2.0	40.0	97428	96549	97442	54696
79 - 3	40.0	2.0	40.0	99197	99079	97801	55570
79 - 4	40.0	2.0	40.0	97220	98567	97801	55103
						MEAN =	**55123**
						SD =	437
						%CV =	**0.79**
						****Percent of Theoretical =**	**110**
						Dose per 40 µL (nCi) =	**2205**

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C2, Appendix C)

TABLE C8

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 6

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
1st Week (Ref #304002A1-49-1)							
49 - 2	40.0	2.0	40.0	98463	99356	98691	55651
49 - 3	40.0	2.0	40.0	98363	97165	98767	55235
49 - 4	40.0	2.0	40.0	98930	99388	99901	55972
						MEAN =	**55620**
						SD =	369
						%CV =	**0.66**
						****Percent of Theoretical =**	**111**
						Dose per 40 µL (nCi) =	**2225**
2nd Week (Ref #304002A1-58-1)							
58 - 2	40.0	2.0	40.0	100016	100305	99913	56350
58 - 3	40.0	2.0	40.0	101043	100360	100973	56752
58 - 4	40.0	2.0	40.0	99612	100631	100039	56359
						MEAN =	**56487**
						SD =	230
						%CV =	**0.41**
						****Percent of Theoretical =**	**113**
						Dose per 40 µL (nCi) =	**2259**
3rd Week (Ref #304002A1-69-1)							
69 - 2	40.0	2.0	40.0	97162	98987	98414	55286
69 - 3	40.0	2.0	40.0	99755	99670	99025	56016
69 - 4	40.0	2.0	40.0	98233	98862	98730	55523
						MEAN =	**55608**
						SD =	372
						%CV =	**0.67**
						****Percent of Theoretical =**	**111**
						Dose per 40 µL (nCi) =	**2224**
4th Week (Ref #304002A1-82-1)							
82 - 2	40.0	2.0	40.0	98582	97836	98872	55422
82 - 3	40.0	2.0	40.0	99881	100417	99715	56309
82 - 4	40.0	2.0	40.0	99156	100772	99433	56186
						MEAN =	**55973**
						SD =	480
						%CV =	**0.86**
						****Percent of Theoretical =**	**112**
						Dose per 40 µL (nCi) =	**2239**

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

TABLE C9

Radiochemical Concentration and Homogeneity Analysis of the Dosing Formulations Used for Group 7

Dilution Reference (304002A1-)	Volume of Aliquot (µL)	of Dilution (mL)	Sub-Sample Analyzed (µL)	Amount of ^{14}C in Sub-Sample (dpm)	(dpm)	(dpm)	Concentration of ^{14}C in the Dosing (nCi/mL)
1st Week (Ref #304002A1-52-1)							
52 - 2	40.0	2.0	40.0	97156	97117	96290	54535
52 - 3	40.0	2.0	40.0	96174	95663	95928	54010
52 - 4	40.0	2.0	40.0	97251	95884	97110	54475
						MEAN =	**54340**
						SD =	287
						%CV =	**0.53**
						****Percent of Theoretical =**	**108**
						Dose per 40 µL (nCi) =	**2174**
2nd Week (Ref #304002A1-62-1)							
62 - 2	40.0	2.0	40.0	96643	98172	96837	54739
62 - 3	40.0	2.0	40.0	99336	98864	99921	55954
62 - 4	40.0	2.0	40.0	96737	98283	97372	54878
						MEAN =	**55190**
						SD =	665
						%CV =	**1.2**
						****Percent of Theoretical =**	**110**
						Dose per 40 µL (nCi) =	**2208**
3rd Week (Ref #304002A1-74-1)							
74 - 2	40.0	2.0	40.0	98678	99476	97303	55454
74 - 3	40.0	2.0	40.0	98118	98851	98151	55391
74 - 4	40.0	2.0	40.0	99303	97593	98957	55528
						MEAN =	**55457**
						SD =	68.8
						%CV =	**0.12**
						****Percent of Theoretical =**	**111**
						Dose per 40 µL (nCi) =	**2218**
4th Week (Ref #304002A1-85-1)							
85 - 2	40.0	2.0	40.0	98906	98414	95920	55038
85 - 3	40.0	2.0	40.0	99573	99390	99186	55959
85 - 4	40.0	2.0	40.0	98536	98878	99525	55732
						MEAN =	**55576**
						SD =	480
						%CV =	**0.86**
						****Percent of Theoretical =**	**111**
						Dose per 40 µL (nCi) =	**2223**

* Dose Conc. (nCi/mL) = mean dpm x (dilution mL ÷ sub-sample mL) x (1 nCi/2220 dpm) ÷ aliquot mL
** % of Theo. = 100 x Mean Conc./Theo. Conc. (from Table C1, Appendix C)

FIGURE C1
Representative Radio-High Performance Liquid Chromatography of a Dosing Formulation

Group 1 Dosing Formulation (Reference No. 304002A1-5-1)

Pre-Dosing Analysis (Run 0001)



Post-Dosing Analysis (Run 0003)



8-Day Stability Analysis (Run 0005)



A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix D

Animal Body Weights and Group Assignments

TABLE D1

Animal Identification, Group Assignment, and Body Weights for Male Animals Received September 14, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5327	M	1	3	28.3	30.2	28.4
5328	M	1	4	28.9	32.0	32.5
5329	M	1	5	29.2	31.9	31.6
5330	M	1	3	27.9	31.6	28.9
5331	M	1	1	28.5	32.1	30.3
5332	M	1	2	27.0	29.5	29.0
5333	M	1	5	29.8	31.5	30.9
5334	M	1	3	29.0	32.4	31.0
5335	M	**	NA	27.3	29.7	29.2
5336	M	1	4	30.2	32.9	32.3
5337	M	*	NA	28.2	30.5	NA
5338	M	*	NA	28.8	31.1	NA
5339	M	1	1	29.1	31.6	30.2
5340	M	1	1	25.8	28.7	27.7
5341	M	1	5	27.3	30.6	29.9
5342	M	1	2	29.9	31.8	31.3
5343	M	1	2	27.6	30.8	29.7
5344	M	1	4	27.8	31.4	32.3
5345	M	1	4	27.7	30.3	29.2
5346	M	*	NA	27.4	29.5	NA
			MEAN:	**28.3**	**31.0**	**30.3**
			SD:	1.1	1.1	1.4

* Eliminated at time of randomization.
** = Used for matrix samples.
NA = Not applicable.

TABLE D2

Animal Identification, Group Assignment, and Body Weights for Female Animals Received September 14, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5347	F	1	3	24.6	25.7	25.9
5348	F	1	3	21.5	22.9	21.9
5349	F	1	2	20.3	24.4	20.8
5350	F	1	2	22.2	23.7	21.8
5351	F	1	4	21.3	23.4	21.9
5352	F	1	3	22.9	24.0	22.1
5353	F	1	4	23.6	24.7	24.7
5354	F	**	NA	24.0	21.2	NA
5355	F	1	1	21.2	23.3	22.1
5356	F	1	1	22.9	24.8	23.1
5357	F	*	NA	23.5	26.1	NA
5358	F	*	NA	21.8	23.3	NA
5359	F	1	4	27.0	28.9	27.6
5360	F	1	5	21.7	24.4	23.3
5361	F	***	NA	21.6	22.7	22.1
5362	F	1	1	24.1	24.9	23.6
5363	F	1	2	26.7	28.8	27.2
5364	F	1	5	25.0	26.0	26.4
5365	F	1	4	24.3	25.6	24.7
5366	F	1	5	23.4	22.6	23.4
			MEAN:	**23.2**	**24.6**	**23.7**
			SD:	1.8	1.9	2.1

* Eliminated at time of randomization.
** Eliminated after randomization owing to a cut during shaving. Replaced with Animal #5350.
*** = Used for matrix samples.
NA = Not applicable.

TABLE D3

Animal Identification, Group Assignment, and Body Weights for Male Animals Received October 5, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5827	M	*	NA	30.5	32.4	NA
5828	M	2	5	29.1	31.1	30.0
5829	M	2	4	27.4	27.6	27.9
5830	M	2	4	28.5	30.3	29.0
5831	M	2	3	29.9	31.2	31.4
5832	M	2	2	27.2	28.3	26.2
5833	M	**	NA	18.8	16.9	NA
5834	M	2	2	28.8	30.4	28.5
5835	M	**	NA	20.2	16.5	NA
5836	M	2	1	27.7	30.8	28.7
5837	M	2	3	27.8	28.9	28.0
5838	M	*	NA	28.9	29.5	NA
5839	M	2	4	31.0	32.8	31.5
5840	M	2	5	21.6	25.2	28.5
5841	M	2	1	31.0	30.0	31.4
5842	M	***	NA	21.6	NA	NA
5843	M	***	NA	21.8	NA	NA
5844	M	2	1	28.1	27.2	27.8
5845	M	2	2	29.6	31.1	29.2
			MEAN:	**26.8**	**28.2**	**29.1**
			SD:	3.9	4.7	1.6

* Eliminated at time of randomization.
** Euthanized prior to randomization; animal was moribund.
*** Animal died prior to randomization.
NA = Not applicable.

TABLE D4

Animal Identification, Group Assignment, and Body Weights for Female Animals Received October 5, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5846	F	2	2	23.5	25.5	24.1
5847	F	2	3	24.1	25.8	24.1
5848	F	2	5	20.4	22.3	23.0
5849	F	*	NA	24.1	26.2	NA
5850	F	2	3	19.0	19.9	21.2
5851	F	2	4	23.9	24.4	23.3
5852	F	2	4	24.4	26.5	25.2
5853	F	2	1	21.2	21.1	21.2
5854	F	2	5	18.9	22.2	24.4
5855	F	2	1	16.9	24.3	23.0
5856	F	**	NA	16.3	NA	NA
5857	F	2	4	25.1	28.1	26.6
5858	F	2	2	23.1	25.1	23.9
5859	F	***	NA	15.0	17.5	NA
5860	F	2	2	15.8	16.8	18.5
5861	F	2	4	17.8	18.9	19.4
5862	F	2	5	17.4	26.1	24.5
5863	F	2	1	29.2	25.4	23.5
5864	F	2	3	23.0	23.2	22.9
			MEAN:	**21.0**	**23.3**	**23.1**
			SD:	3.9	3.3	2.1

* Eliminated at time of randomization.
** Animal died prior to randomization.
*** Animal excluded from randomization owing to clinical observation (dried yellow material around anogenital area and tail).
NA = Not applicable.

TABLE D5

Animal Identification, Group Assignment, and Body Weights for Male Animals Received September 28, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5713	M	2	4	28.9	31.0	30.7
5714	M	4	NA	26.0	28.1	26.9
5715	M	2	3	26.7	27.7	27.0
5716	M	3	3	23.4	25.9	24.5
5717	M	3	3	26.8	30.2	27.5
5718	M	4	NA	28.9	32.1	30.4
5719	M	4	NA	29.5	31.7	30.4
5720	M	2	5	27.8	32.7	31.3
5721	M	3	5	27.7	30.8	30.0
5722	M	3	2	25.0	28.4	26.9
5723	M	3	1	21.4	28.1	26.6
5724	M	3	4	27.5	30.3	28.6
5725	M	3	4	26.3	29.9	28.5
5726	M	3	3	27.0	29.2	27.2
5727	M	3	4	19.6	28.2	27.0
5728	M	3	5	25.1	27.6	25.9
5729	M	*	NA	26.1	29.2	NA
5730	M	4	NA	20.9	28.4	28.0
5731	M	*	NA	25.6	28.6	NA
5732	M	3	5	26.5	29.0	23.1
5733	M	3	1	26.4	29.0	27.9
5734	M	3	2	28.3	30.1	29.1
5735	M	3	4	28.7	32.0	30.2
5736	M	3	1	28.0	30.5	28.5
5737	M	3	2	27.6	30.9	29.5
			MEAN:	**26.2**	**29.6**	**28.1**
			SD:	2.5	1.7	2.0

* Eliminated at time of randomization.
NA = Not applicable.

TABLE D6

Animal Identification, Group Assignment, and Body Weights for Female Animals Received September 28, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5738	F	3	5	26.6	28.6	26.1
5739	F	3	3	24.9	27.9	25.7
5740	F	3	4	22.2	23.9	22.7
5741	F	3	1	17.5	22.4	21.4
5742	F	3	4	22.4	28.8	24.8
5743	F	4	NA	22.2	23.9	21.7
5744	F	3	1	26.5	28.2	27.1
5745	F	4	NA	22.7	25.2	23.1
5746	F	3	2	23.9	25.3	23.3
5747	F	*	NA	22.7	24.6	NA
5748	F	4	NA	26.4	29.3	28.1
5749	F	*	NA	23.4	26.5	NA
5750	F	3	3	21.8	25.0	22.3
5751	F	3	2	19.2	19.9	19.6
5752	F	3	3	22.6	23.6	21.9
5753	F	3	4	23.7	25.2	22.9
5754	F	4	NA	23.1	25.1	23.4
5755	F	*	NA	22.4	25.0	NA
5756	F	3	4	21.7	24.2	21.8
5757	F	*	NA	24.0	27.5	NA
5758	F	3	5	20.8	21.7	20.9
5759	F	*	NA	21.3	22.7	NA
5760	F	3	5	23.3	24.9	23.3
5761	F	3	2	20.0	24.1	21.7
5762	F	3	1	21.6	24.5	22.3
			MEAN:	**22.7**	**25.1**	**23.2**
			SD:	2.1	2.3	2.2

* Eliminated at time of randomization.
NA = Not applicable.

TABLE D7

Animal Identification, Group Assignment, and Body Weights for Male Animals Received October 12, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5867	M	6	1	26.7	29.4	31.0
5868	M	6	1	29.8	31.9	34.1
5869	M	5	2	28.4	29.6	31.3
5870	M	5	2	27.7	30.3	34.2
5871	M	5	1	27.1	29.6	30.2
5872	M	7	1	28.4	31.8	32.4
5873	M	7	1	25.3	28.5	29.7
5874	M	7	1	26.4	29.8	22.1
5875	M	6	1	27.2	28.5	28.9
5876	M	*	NA	27.7	30.1	NA
5877	M	*	NA	26.4	30.3	NA
5878	M	7	2	24.8	28.4	27.2
5879	M	*	NA	26.7	29.2	NA
5880	M	6	2	27.2	29.1	32.5
5881	M	6	1	24.0	26.6	27.7
5882	M	7	1	24.8	26.7	27.0
5883	M	5	1	27.8	31.7	32.4
5884	M	5	1	22.2	24.9	26.4
5885	M	6	2	25.1	27.1	31.8
5886	M	7	2	27.3	29.9	27.5
5887	M	6	2	28.8	31.9	31.0
5888	M	5	2	24.9	27.5	31.4
5889	M	5	1	24.4	28.2	28.4
5890	M	*	NA	25.2	26.4	NA
5891	M	7	2	28.4	31.2	30.1
5892	M	7	2	26.3	27.8	30.4
5893	M	5	2	26.2	29.2	31.5
5894	M	6	2	26.4	29.3	34.8
			MEAN:	**26.5**	**29.1**	**30.2**
			SD:	1.7	1.8	2.9

* Eliminated at time of randomization.
NA = Not applicable.

TABLE D8

Animal Identification, Group Assignment, and Body Weights for Female Animals Received October 12, 1999

Animal Number	Sex	Group	Sub-Group	Weight at Identification (g)	Weight at Randomization (g)	Weight at Euthanasia (g)
5895	F	6	1	23.0	24.8	26.3
5896	F	5	1	22.7	24.7	25.7
5897	F	*	NA	14.8	22.9	NA
5898	F	*	NA	16.3	23.6	NA
5899	F	5	1	20.4	21.9	23.8
5900	F	5	1	21.1	24.0	24.9
5901	F	7	1	24.4	24.5	27.8
5902	F	7	1	20.1	21.2	19.8
5903	F	6	2	21.7	24.4	27.1
5904	F	*	NA	19.8	21.2	NA
5905	F	7	2	22.2	23.2	25.6
5906	F	7	2	14.6	21.9	25.2
5907	F	6	1	21.6	23.4	23.2
5908	F	7	2	23.7	24.9	27.5
5909	F	6	1	21.6	22.7	23.8
5910	F	5	2	22.6	24.0	27.3
5911	F	5	2	23.7	24.9	24.9
5912	F	6	2	21.9	21.7	26.0
5913	F	7	1	21.6	23.1	24.5
5914	F	7	2	22.5	23.9	25.7
5915	F	5	2	20.8	22.7	23.0
5916	F	5	2	20.5	22.2	24.8
5917	F	6	2	22.2	24.1	26.3
5918	F	6	1	21.1	22.7	25.5
5919	F	6	2	22.4	23.2	28.1
5920	F	7	1	21.1	23.7	22.9
5921	F	5	1	21.4	23.3	23.2
5922	F	*	NA	20.8	15.8	NA
			MEAN:	**21.1**	**23.0**	**25.1**
			SD:	2.4	1.8	1.9

* Eliminated at time of randomization.
NA = Not applicable.

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix E

Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied

Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied

The following equations were used in calculation of the amount of radioactivity in the pipet washes and the actual dose applied:

(1) $$\text{dpm/mL} = \frac{\text{dpm}}{\text{Aliquot Size (mL)}}$$

(2) $$\text{Total Activity (nCi)} = \frac{\text{Mean dpm/mL} \times \text{Sample Size (mL)}}{2220\ \text{dpm/nCi}}$$

(3) $$\text{Actual Dose Appl. (nCi)} = \text{Dose (nCi)}^{*} - \text{Total Activity (nCi)}$$

(4) $$\text{Actual Dose Appl. (mg)} = \frac{\text{Actual Dose Appl. (nCi)} \times \frac{1\ \mu\text{Ci}}{1000\ \text{nCi}}}{\text{Specific Activity } (\mu\text{Ci/mg})^{**}}$$

Abbreviations used in the tables in this appendix include:

Grp. No. = Group Number
Anim.. No. = Animal Number
Nec = Necropsy
Samp. = Sample
Nec = Necropsy
Count. Eff. = Counting Efficiency

* nCi per 40 µL of dosing formulation from Tables C3–C9 (Appendix C).
** Specific Activity from Tables C1 and C2 (Appendix C).

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
1	1	5331	M	164	15	0.25	8874	94.7	9373	37494	251.5	5434	2.591
1	1	5331	M	165	15	0.25	8738	94.6	9235	36942			
1	1	5339	M	166	15	0.25	6195	94.6	6548	26191	176.6	5508	2.627
1	1	5339	M	167	15	0.25	6167	94.6	6518	26071			
1	1	5340	M	168	15	0.25	12188	94.7	12872	51489	349.0	5336	2.545
1	1	5340	M	169	15	0.25	12260	94.6	12954	51816			
1	1	5355	F	170	15	0.25	8656	94.6	9149	36594	245.9	5439	2.594
1	1	5355	F	171	15	0.25	8560	94.6	9047	36187			
1	1	5356	F	172	15	0.25	7326	94.7	7739	30956	209.4	5476	2.611
1	1	5356	F	173	15	0.25	7341	94.7	7754	31017			
1	1	5362	F	174	15	0.25	11609	94.7	12262	49049	330.9	5354	2.553
1	1	5362	F	175	15	0.25	11570	94.6	12225	48899			
1	2	5332	M	214	15	0.25	5223	94.7	5514	22057	147.6	5537	2.641
1	2	5332	M	215	15	0.25	5122	94.8	5405	21618			
1	2	5342	M	216	15	0.25	4842	94.7	5113	20452	139.5	5546	2.645
1	2	5342	M	217	15	0.25	4937	94.8	5210	20840			
1	2	5343	M	218	15	0.25	6068	94.8	6403	25611	173.1	5512	2.629
1	2	5343	M	219	15	0.25	6073	94.8	6409	25635			
1	2	5349	F	220	15	0.25	6665	94.8	7034	28136	189.5	5496	2.621
1	2	5349	F	221	15	0.25	6615	94.7	6987	27949			
1	2	5350	F	222	15	0.25	9636	94.8	10167	40669	275.9	5409	2.580
1	2	5350	F	223	15	0.25	9707	94.7	10248	40990			
1	2	5363	F	224	15	0.25	6204	94.7	6550	26199	175.8	5509	2.627
1	2	5363	F	225	15	0.25	6117	94.7	6461	25844			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
1	3	5327	M	176	15	0.25	6839	94.6	7226	28905	195.1	5490	2.618
1	3	5327	M	177	15	0.25	6826	94.7	7208	28833			
1	3	5330	M	178	15	0.25	7435	94.6	7856	31426	212.8	5472	2.610
1	3	5330	M	179	15	0.25	7470	94.7	7891	31566			
1	3	5334	M	180	15	0.25	6567	94.6	6941	27764	189.2	5496	2.621
1	3	5334	M	181	15	0.25	6682	94.7	7059	28236			
1	3	5347	F	182	15	0.25	5886	94.7	6216	24866	167.5	5518	2.631
1	3	5347	F	183	15	0.25	5845	94.6	6178	24710			
1	3	5348	F	184	15	0.25	8151	94.7	8607	34430	233.6	5451	2.600
1	3	5348	F	185	15	0.25	8212	94.7	8675	34701			
1	3	5352	F	186	15	0.25	5364	94.7	5666	22663	151.8	5533	2.639
1	3	5352	F	187	15	0.25	5273	94.7	5568	22274			
1	4	5328	M	226	15	0.25	5811	94.8	6133	24531	166.1	5519	2.632
1	4	5328	M	227	15	0.25	5835	94.7	6162	24650			
1	4	5336	M	228	15	0.25	9709	94.8	10241	40964	280.1	5405	2.578
1	4	5336	M	229	15	0.25	9938	94.8	10489	41956			
1	4	5344	M	230	15	0.25	8011	94.7	8462	33847	228.0	5457	2.603
1	4	5344	M	231	15	0.25	7965	94.7	8410	33639			
1	4	5345	M	232	15	0.25	4565	94.7	4819	19275	129.4	5556	2.650
1	4	5345	M	233	15	0.25	4502	94.7	4756	19023			
1	4	5351	F	234	15	0.25	7096	94.7	7490	29961	203.0	5482	2.614
1	4	5351	F	235	15	0.25	7133	94.7	7532	30126			
1	4	5353	F	236	15	0.25	4542	94.7	4798	19191	128.7	5556	2.650
1	4	5353	F	237	15	0.25	4477	94.7	4729	18916			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
1	4	5359	F	238	15	0.25	4758	94.7	5026	20104	136.2	5549	2.646
1	4	5359	F	239	15	0.25	4781	94.6	5052	20206			
1	4	5365	F	240	15	0.25	6570	94.7	6937	27747	188.5	5497	2.621
1	4	5365	F	241	15	0.25	6639	94.7	7012	28049			
1	5	5329	M	188	15	0.25	10720	94.7	11326	45304	304.9	5380	2.566
1	5	5329	M	189	15	0.25	10638	94.7	11239	44958			
1	5	5333	M	190	15	0.25	7424	94.7	7838	31353	210.5	5475	2.611
1	5	5333	M	191	15	0.25	7323	94.7	7735	30942			
1	5	5341	M	192	15	0.25	8940	94.6	9455	37819	255.8	5429	2.589
1	5	5341	M	193	15	0.25	8968	94.7	9471	37883			
1	5	5360	F	194	15	0.25	8604	94.7	9088	36353	245.7	5439	2.594
1	5	5360	F	195	15	0.25	8607	94.7	9092	36368			
1	5	5364	F	196	15	0.25	8385	94.7	8856	35424	240.5	5444	2.597
1	5	5364	F	197	15	0.25	8468	94.7	8944	35776			
1	5	5366	F	198	15	0.25	5862	94.7	6193	24770	167.2	5518	2.632
1	5	5366	F	199	15	0.25	5853	94.7	6180	24722			
2	1	5836	M	1290	15	0.25	8095	94.6	8559	34235	231.4	5430	8.633
2	1	5836	M	1291	15	0.25	8102	94.6	8566	34263			
2	1	5841	M	1292	15	0.25	9395	94.6	9931	39723	270.0	5392	8.572
2	1	5841	M	1293	15	0.25	9502	94.5	10052	40207			
2	1	5844	M	1294	15	0.25	7764	94.6	8207	32828	222.2	5440	8.648
2	1	5844	M	1295	15	0.25	7788	94.6	8235	32941			
2	1	5853	F	1296	15	0.25	6518	94.6	6892	27569	184.5	5477	8.707
2	1	5853	F	1297	15	0.25	6396	94.6	6763	27052			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
2	1	5855	F	1298	15	0.25	15041	94.6	15907	63628	431.5	5230	8.315
2	1	5855	F	1299	15	0.25	15156	94.6	16027	64108			
2	1	5863	F	1300	15	0.25	7122	94.6	7529	30116	201.5	5460	8.681
2	1	5863	F	1301	15	0.25	6977	94.6	7379	29518			
2	2	5832	M	1302	15	0.25	9070	94.6	9592	38370	259.6	5402	8.588
2	2	5832	M	1303	15	0.25	9087	94.5	9618	38471			
2	2	5834	M	1304	15	0.25	8297	94.6	8768	35072	235.6	5426	8.626
2	2	5834	M	1305	15	0.25	8198	94.6	8668	34674			
2	2	5845	M	1306	15	0.25	7066	94.6	7472	29889	202.0	5460	8.680
2	2	5845	M	1307	15	0.25	7075	94.6	7479	29916			
2	2	5846	F	1308	15	0.25	7092	94.6	7494	29974	203.5	5458	8.677
2	2	5846	F	1309	15	0.25	7156	94.6	7562	30248			
2	2	5858	F	1310	15	0.25	7166	94.7	7571	30283	204.4	5457	8.676
2	2	5858	F	1311	15	0.25	7153	94.7	7556	30225			
2	2	5860	F	1312	15	0.25	7539	94.6	7971	31885	214.8	5447	8.659
2	2	5860	F	1313	15	0.25	7497	94.6	7922	31688			
2	3	5715	M	1227	15	0.25	6571	94.7	6939	27754	188.1	5474	8.702
2	3	5715	M	1228	15	0.25	6604	94.6	6980	27921			
2	3	5831	M	1229	15	0.25	8127	94.7	8585	34342	229.6	5432	8.636
2	3	5831	M	1230	15	0.25	7951	94.6	8407	33628			
2	3	5837	M	1231	15	0.25	6658	94.6	7037	28147	190.1	5472	8.699
2	3	5837	M	1232	15	0.25	6651	94.6	7032	28128			
2	3	5847	F	1233	15	0.25	5689	94.6	6015	24061	162.6	5499	8.742
2	3	5847	F	1234	15	0.25	5693	94.6	6018	24073			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
2	3	5850	F	1235	15	0.25	5576	94.6	5894	23578	158.9	5503	8.748
2	3	5850	F	1236	15	0.25	5550	94.6	5868	23471			
2	3	5864	F	1237	15	0.25	6790	94.6	7178	28711	193.4	5468	8.693
2	3	5864	F	1238	15	0.25	6749	94.6	7135	28540			
2	4	5713	M	1314	15	0.25	6176	94.6	6529	26116	175.5	5486	8.722
2	4	5713	M	1315	15	0.25	6109	94.6	6457	25830			
2	4	5829	M	1316	15	0.25	1114	94.6	1178	4712	31.6	5630	8.951
2	4	5829	M	1317	15	0.25	1095	94.5	1158	4631			
2	4	5830	M	1318	15	0.25	6828	94.6	7217	28867	196.2	5466	8.689
2	4	5830	M	1319	15	0.25	6899	94.5	7299	29195			
2	4	5839	M	1320	15	0.25	6705	94.6	7092	28368	191.6	5470	8.696
2	4	5839	M	1321	15	0.25	6701	94.6	7085	28341			
2	4	5851	F	4532	15	0.25	9611	94.3	10189	40756	275.3	5387	8.563
2	4	5851	F	4533	15	0.25	9601	94.3	10180	40719			
2	4	5852	F	1324	15	0.25	5451	94.6	5762	23046	165.4	5497	8.738
2	4	5852	F	1325	15	0.25	6123	94.6	6476	25904			
2	4	5857	F	4534	15	0.25	6626	94.3	7024	28097	190.5	5471	8.698
2	4	5857	F	4535	15	0.25	6673	94.4	7071	28284			
2	4	5861	F	1328	15	0.25	7522	94.6	7954	31814	225.0	5437	8.643
2	4	5861	F	1329	15	0.25	8221	94.5	8700	34799			
2	5	5720	M	4528	15	0.25	8366	94.3	8868	35470	239.4	5422	8.620
2	5	5720	M	4529	15	0.25	8344	94.3	8847	35390			
2	5	5828	M	1332	15	0.25	6135	94.6	6488	25954	176.8	5485	8.720
2	5	5828	M	1333	15	0.25	6235	94.6	6595	26379			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
2	5	5840	M	4530	15	0.25	8265	94.3	8763	35051	236.3	5426	8.625
2	5	5840	M	4531	15	0.25	8223	94.3	8722	34889			
2	5	5848	F	1336	15	0.25	7843	94.4	8304	33216	214.6	5447	8.660
2	5	5848	F	1337	15	0.25	7159	94.5	7576	30303			
2	5	5854	F	1338	15	0.25	8236	94.5	8715	34859	234.6	5427	8.628
2	5	5854	F	1339	15	0.25	8170	94.5	8644	34577			
2	5	5862	F	1340	15	0.25	5765	94.5	6099	24398	165.8	5496	8.737
2	5	5862	F	1341	15	0.25	5830	94.5	6168	24672			
3	1	5723	M	483	15	0.25	7580	94.6	8009	32037	217.5	5300	25.276
3	1	5723	M	484	15	0.25	7652	94.6	8089	32357			
3	1	5733	M	485	15	0.25	5583	94.6	5901	23604	157.2	5360	25.564
3	1	5733	M	486	15	0.25	5429	94.7	5734	22936			
3	1	5736	M	487	15	0.25	4688	94.6	4957	19826	132.5	5385	25.681
3	1	5736	M	488	15	0.25	4586	94.6	4849	19394			
3	1	5741	F	489	15	0.25	5196	94.6	5494	21977	147.8	5370	25.609
3	1	5741	F	490	15	0.25	5150	94.7	5440	21762			
3	1	5744	F	491	15	0.25	3951	94.6	4175	16699	112.4	5405	25.777
3	1	5744	F	492	15	0.25	3921	94.6	4146	16583			
3	1	5762	F	493	15	0.25	5342	94.6	5646	22583	152.1	5365	25.588
3	1	5762	F	494	15	0.25	5308	94.6	5610	22439			
3	2	5722	M	535	15	0.25	6852	94.8	7230	28919	197.0	5320	25.374
3	2	5722	M	536	15	0.25	6956	94.7	7346	29384			
3	2	5734	M	537	15	0.25	6358	94.6	6718	26872	179.3	5338	25.458
3	2	5734	M	538	15	0.25	6201	94.7	6548	26190			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
3	2	5737	M	539	15	0.25	7566	94.7	7990	31958	215.6	5302	25.285
3	2	5737	M	540	15	0.25	7540	94.7	7963	31852			
3	2	5746	F	541	15	0.25	15474	94.6	16354	65417	440.0	5077	24.215
3	2	5746	F	542	15	0.25	15350	94.7	16207	64829			
3	2	5751	F	543	15	0.25	8593	94.7	9077	36309	245.9	5271	25.141
3	2	5751	F	544	15	0.25	8635	94.7	9121	36485			
3	2	5761	F	545	15	0.25	6397	94.7	6757	27027	183.7	5334	25.437
3	2	5761	F	546	15	0.25	6474	94.7	6840	27360			
3	3	5716	M	495	15	0.25	10307	94.6	10898	43591	292.8	5225	24.917
3	3	5716	M	496	15	0.25	10185	94.6	10769	43078			
3	3	5717	M	497	15	0.25	5714	94.6	6039	24156	165.0	5352	25.526
3	3	5717	M	498	15	0.25	5840	94.6	6174	24696			
3	3	5726	M	499	15	0.25	4798	94.6	5073	20290	136.1	5381	25.664
3	3	5726	M	500	15	0.25	4729	94.6	5000	20000			
3	3	5739	F	501	15	0.25	6321	94.6	6680	26721	178.8	5339	25.461
3	3	5739	F	502	15	0.25	6191	94.6	6548	26191			
3	3	5750	F	503	15	0.25	4174	94.5	4415	17661	120.6	5397	25.738
3	3	5750	F	504	15	0.25	4268	94.6	4512	18050			
3	3	5752	F	505	15	0.25	6841	94.6	7228	28912	195.1	5322	25.383
3	3	5752	F	506	15	0.25	6816	94.6	7207	28828			
3	4	5724	M	519	15	0.25	5501	94.6	5815	23260	155.4	5362	25.573
3	4	5724	M	520	15	0.25	5376	94.6	5681	22725			
3	4	5725	M	521	15	0.25	6162	94.6	6516	26063	176.2	5341	25.473
3	4	5725	M	522	15	0.25	6175	94.6	6525	26102			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
3	4	5727	M	523	15	0.25	4450	94.6	4705	18821	126.8	5391	25.709
3	4	5727	M	524	15	0.25	4425	94.6	4677	18707			
3	4	5735	M	525	15	0.25	6744	94.6	7128	28512	191.4	5326	25.401
3	4	5735	M	526	15	0.25	6656	94.6	7035	28141			
3	4	5740	F	527	15	0.25	8772	94.6	9270	37081	250.5	5267	25.119
3	4	5740	F	528	15	0.25	8774	94.7	9269	37076			
3	4	5742	F	529	15	0.25	5534	94.6	5852	23410	157.6	5360	25.562
3	4	5742	F	530	15	0.25	5493	94.6	5806	23226			
3	4	5753	F	531	15	0.25	6447	94.7	6811	27244	185.0	5332	25.431
3	4	5753	F	532	15	0.25	6503	94.6	6876	27502			
3	4	5756	F	533	15	0.25	4321	94.6	4569	18277	123.7	5394	25.724
3	4	5756	F	534	15	0.25	4334	94.6	4581	18325			
3	5	5721	M	507	15	0.25	9873	94.6	10436	41743	285.2	5232	24.953
3	5	5721	M	508	15	0.25	10088	94.6	10669	42675			
3	5	5728	M	509	15	0.25	7591	94.6	8023	32093	215.0	5302	25.288
3	5	5728	M	510	15	0.25	7462	94.6	7888	31551			
3	5	5732	M	511	15	0.25	3461	94.6	3657	14627	98.8	5419	25.842
3	5	5732	M	512	15	0.25	3457	94.6	3655	14620			
3	5	5738	F	513	15	0.25	4805	94.6	5081	20325	136.4	5381	25.663
3	5	5738	F	514	15	0.25	4746	94.6	5015	20061			
3	5	5758	F	515	15	0.25	7209	94.7	7615	30459	204.7	5313	25.337
3	5	5758	F	516	15	0.25	7129	94.6	7536	30146			
3	5	5760	F	517	15	0.25	12557	94.6	13270	53079	362.8	5155	24.583
3	5	5760	F	518	15	0.25	12844	94.6	13579	54315			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
4	NA	5714	M	547	15	0.25	8922	94.6	9428	37712	256.4	4881	22.922
4	NA	5714	M	548	15	0.25	9041	94.7	9549	38196			
4	NA	5718	M	549	15	0.25	6949	94.7	7341	29364	198.6	4939	23.194
4	NA	5718	M	550	15	0.25	6963	94.7	7355	29421			
4	NA	5719	M	551	15	0.25	9363	94.6	9893	39572	266.4	4871	22.876
4	NA	5719	M	552	15	0.25	9296	94.6	9823	39291			
4	NA	5730	M	553	15	0.25	6475	94.6	6845	27379	183.8	4954	23.264
4	NA	5730	M	554	15	0.25	6394	94.7	6754	27017			
4	NA	5743	F	555	15	0.25	7414	94.6	7836	31343	210.3	4928	23.139
4	NA	5743	F	556	15	0.25	7319	94.7	7729	30917			
4	NA	5745	F	557	15	0.25	4807	94.7	5079	20315	136.8	5001	23.484
4	NA	5745	F	558	15	0.25	4776	94.7	5045	20181			
4	NA	5748	F	559	15	0.25	6867	94.7	7252	29008	196.5	4941	23.204
4	NA	5748	F	560	15	0.25	6894	94.6	7287	29146			
4	NA	5754	F	561	15	0.25	5068	94.6	5359	21435	144.4	4993	23.448
4	NA	5754	F	562	15	0.25	5044	94.6	5330	21320			

TABLE E1. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (Acute Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
Analyses That Were Not Used for Calculations:													**Reason for Exclusion:**
2	4	5851	F	1322	15	0.25	9311	94.6	9848	39393			Poor replication.
2	4	5851	F	1323	15	0.25	14843	94.2	15758	63031			
2	4	5857	F	1326	15	0.25	6106	94.6	6458	25832			Poor replication.
2	4	5857	F	1327	15	0.25	7573	94.5	8011	32045			
2	5	5720	M	1330	15	0.25	7419	94.6	7847	31387			Poor replication.
2	5	5720	M	1331	15	0.25	6303	94.5	6669	26676			
2	5	5840	M	1334	15	0.25	6148	94.6	6502	26010			Poor replication.
2	5	5840	M	1335	15	0.25	8115	94.6	8582	34328			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5871	M	1620	0	15	0.25	4176	94.5	4419	17676	120.4	2130	2.549
5	1	5871	M	1621	0	15	0.25	4248	94.6	4492	17967			
5	1	5871	M	1672	1	15	0.25	4398	94.5	4654	18616	125.3	2125	2.543
5	1	5871	M	1673	1	15	0.25	4361	94.5	4615	18459			
5	1	5871	M	1736	2	15	0.25	4923	94.7	5200	20802	139.6	2111	2.526
5	1	5871	M	1737	2	15	0.25	4855	94.7	5128	20512			
5	1	5871	M	1834	3	15	0.25	3044	94.7	3214	12857	87.1	2163	2.589
5	1	5871	M	1835	3	15	0.25	3064	94.7	3234	12935			
5	1	5871	M	4536	4	15	0.25	22344	94.4	23679	94714	639.5	1611	1.928
5	1	5871	M	4537	4	15	0.25	22298	94.3	23647	94589			
5	1	5871	M	2026	5	15	0.25	4403	94.6	4653	18611	126.8	2123	2.542
5	1	5871	M	2027	5	15	0.25	4479	94.7	4730	18920			
5	1	5871	M	2122	6	15	0.25	7198	94.6	7607	30427	205.9	2044	2.447
5	1	5871	M	2123	6	15	0.25	7223	94.7	7627	30506			
5	1	5871	M	2229	7	15	0.25	8588	94.7	9071	36285	245.1	2011	2.407
5	1	5871	M	2230	7	15	0.25	8584	94.7	9068	36270			
5	1	5871	M	2325	8	15	0.25	9030	94.6	9548	38191	257.7	1998	2.392
5	1	5871	M	2326	8	15	0.25	9010	94.6	9522	38089			
5	1	5871	M	2421	9	15	0.25	8297	94.6	8769	35075	235.7	2020	2.418
5	1	5871	M	2422	9	15	0.25	8208	94.6	8675	34701			
5	1	5871	M	2519	10	15	0.25	9167	94.6	9687	38747	259.8	1996	2.389
5	1	5871	M	2520	10	15	0.25	9024	94.6	9542	38167			
5	1	5871	M	2615	11	15	0.25	4829	94.6	5106	20422	138.5	2117	2.535
5	1	5871	M	2616	11	15	0.25	4864	94.6	5143	20573			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5871	M	2711	12	15	0.25	4959	94.8	5234	20935	140.9	2115	2.532
5	1	5871	M	2712	12	15	0.25	4919	94.7	5194	20774			
5	1	5871	M	2807	13	15	0.25	3728	94.8	3931	15723	106.7	2149	2.573
5	1	5871	M	2808	13	15	0.25	3760	94.8	3968	15871			
5	1	5883	M	1622	0	15	0.25	4348	94.6	4595	18380	124.2	2126	2.545
5	1	5883	M	1623	0	15	0.25	4347	94.6	4593	18374			
5	1	5883	M	1674	1	15	0.25	4301	94.5	4552	18209	122.7	2127	2.546
5	1	5883	M	1675	1	15	0.25	4281	94.5	4531	18124			
5	1	5883	M	1738	2	15	0.25	5773	94.8	6092	24367	165.1	2085	2.496
5	1	5883	M	1739	2	15	0.25	5800	94.7	6126	24505			
5	1	5883	M	1836	3	15	0.25	6036	94.7	6376	25504	171.7	2078	2.488
5	1	5883	M	1837	3	15	0.25	5993	94.7	6331	25323			
5	1	5883	M	1932	4	15	0.25	3368	94.7	3556	14224	96.8	2153	2.578
5	1	5883	M	1933	4	15	0.25	3419	94.7	3609	14436			
5	1	5883	M	2028	5	15	0.25	4217	94.7	4453	17810	120.2	2130	2.550
5	1	5883	M	2029	5	15	0.25	4201	94.6	4440	17758			
5	1	5883	M	2124	6	15	0.25	9398	94.7	9923	39692	269.1	1981	2.371
5	1	5883	M	2125	6	15	0.25	9460	94.7	9989	39956			
5	1	5883	M	2231	7	15	0.25	5521	94.6	5837	23347	160.4	2096	2.508
5	1	5883	M	2232	7	15	0.25	5706	94.6	6032	24130			
5	1	5883	M	2327	8	15	0.25	5169	94.5	5469	21874	147.5	2109	2.524
5	1	5883	M	2328	8	15	0.25	5146	94.5	5444	21776			
5	1	5883	M	2423	9	15	0.25	5343	94.6	5649	22596	152.1	2104	2.518
5	1	5883	M	2424	9	15	0.25	5304	94.6	5607	22428			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5883	M	2521	10	15	0.25	7437	94.5	7866	31464	209.6	2046	2.449
5	1	5883	M	2522	10	15	0.25	7227	94.6	7642	30567			
5	1	5883	M	2617	11	15	0.25	5623	94.5	5948	23793	159.3	2097	2.510
5	1	5883	M	2618	11	15	0.25	5523	94.6	5838	23353			
5	1	5883	M	2713	12	15	0.25	5757	94.7	6083	24331	162.3	2094	2.506
5	1	5883	M	2714	12	15	0.25	5615	94.7	5927	23707			
5	1	5883	M	2809	13	15	0.25	3369	94.7	3557	14227	95.3	2161	2.586
5	1	5883	M	2810	13	15	0.25	3310	94.7	3496	13982			
5	1	5884	M	1624	0	15	0.25	2995	94.5	3167	12670	84.8	2165	2.592
5	1	5884	M	1625	0	15	0.25	2940	94.6	3107	12430			
5	1	5884	M	1676	1	15	0.25	3880	94.4	4108	16433	110.9	2139	2.561
5	1	5884	M	1677	1	15	0.25	3876	94.5	4102	16409			
5	1	5884	M	1740	2	15	0.25	5406	94.7	5708	22830	155.7	2094	2.507
5	1	5884	M	1741	2	15	0.25	5506	94.6	5817	23270			
5	1	5884	M	1838	3	15	0.25	3469	94.6	3667	14669	98.4	2152	2.576
5	1	5884	M	1839	3	15	0.25	3421	94.7	3613	14452			
5	1	5884	M	1934	4	15	0.25	7103	94.8	7495	29980	200.5	2050	2.453
5	1	5884	M	1935	4	15	0.25	6959	94.8	7340	29362			
5	1	5884	M	2030	5	15	0.25	4302	94.7	4545	18181	123.2	2127	2.546
5	1	5884	M	2031	5	15	0.25	4328	94.7	4572	18287			
5	1	5884	M	2126	6	15	0.25	7220	94.6	7631	30522	206.1	2044	2.447
5	1	5884	M	2127	6	15	0.25	7214	94.7	7620	30481			
5	1	5884	M	2233	7	15	0.25	7894	94.6	8347	33387	226.0	2030	2.430
5	1	5884	M	2234	7	15	0.25	7931	94.7	8379	33518			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5884	M	2329	8	15	0.25	4520	94.5	4781	19125	131.6	2124	2.543
5	1	5884	M	2330	8	15	0.25	4690	94.6	4960	19842			
5	1	5884	M	2425	9	15	0.25	7295	94.6	7708	30832	205.7	2050	2.454
5	1	5884	M	2426	9	15	0.25	7107	94.6	7512	30050			
5	1	5884	M	2523	10	15	0.25	9466	94.6	10011	40043	278.1	1978	2.367
5	1	5884	M	2524	10	15	0.25	9991	94.5	10570	42280			
5	1	5884	M	2619	11	15	0.25	4004	94.5	4236	16944	115.2	2141	2.562
5	1	5884	M	2620	11	15	0.25	4052	94.5	4286	17144			
5	1	5884	M	2715	12	15	0.25	5149	94.7	5436	21746	148.0	2108	2.523
5	1	5884	M	2716	12	15	0.25	5226	94.7	5518	22074			
5	1	5884	M	2811	13	15	0.25	2761	94.8	2914	11655	78.7	2177	2.606
5	1	5884	M	2812	13	15	0.25	2753	94.7	2908	11633			
5	1	5889	M	1626	0	15	0.25	5356	94.6	5663	22651	153.4	2097	2.510
5	1	5889	M	1627	0	15	0.25	5379	94.6	5689	22756			
5	1	5889	M	1678	1	15	0.25	3789	94.5	4010	16039	108.8	2141	2.563
5	1	5889	M	1679	1	15	0.25	3816	94.5	4039	16154			
5	1	5889	M	1742	2	15	0.25	5161	94.7	5450	21801	145.8	2104	2.519
5	1	5889	M	1743	2	15	0.25	5050	94.7	5336	21343			
5	1	5889	M	1840	3	15	0.25	4524	94.7	4779	19115	129.8	2120	2.538
5	1	5889	M	1841	3	15	0.25	4569	94.7	4824	19296			
5	1	5889	M	1936	4	15	0.25	13369	94.7	14121	56483	382.2	1868	2.236
5	1	5889	M	1937	4	15	0.25	13421	94.8	14159	56636			
5	1	5889	M	2032	5	15	0.25	4667	94.6	4934	19734	133.8	2116	2.533
5	1	5889	M	2033	5	15	0.25	4703	94.6	4971	19883			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5889	M	2128	6	15	0.25	7872	94.7	8312	33249	225.3	2025	2.424
5	1	5889	M	2129	6	15	0.25	7914	94.7	8361	33443			
5	1	5889	M	2235	7	15	0.25	8734	94.7	9228	36912	248.7	2007	2.403
5	1	5889	M	2236	7	15	0.25	8686	94.7	9174	36697			
5	1	5889	M	2331	8	15	0.25	7206	94.5	7624	30495	205.0	2051	2.455
5	1	5889	M	2332	8	15	0.25	7130	94.5	7547	30187			
5	1	5889	M	2427	9	15	0.25	7384	94.6	7805	31219	214.7	2041	2.443
5	1	5889	M	2428	9	15	0.25	7640	94.6	8080	32318			
5	1	5889	M	2525	10	15	0.25	11758	94.5	12437	49749	333.5	1923	2.301
5	1	5889	M	2526	10	15	0.25	11580	94.6	12238	48953			
5	1	5889	M	2621	11	15	0.25	5237	94.6	5538	22153	149.3	2107	2.522
5	1	5889	M	2622	11	15	0.25	5212	94.6	5511	22043			
5	1	5889	M	2717	12	15	0.25	3929	94.7	4148	16593	111.4	2145	2.567
5	1	5889	M	2718	12	15	0.25	3878	94.7	4096	16385			
5	1	5889	M	2813	13	15	0.25	2919	94.7	3081	12325	83.9	2172	2.600
5	1	5889	M	2814	13	15	0.25	2961	94.7	3126	12505			
5	1	5896	F	1628	0	15	0.25	3453	94.6	3649	14595	98.0	2152	2.576
5	1	5896	F	1629	0	15	0.25	3405	94.6	3600	14399			
5	1	5896	F	1680	1	15	0.25	3258	94.5	3448	13792	94.1	2156	2.581
5	1	5896	F	1681	1	15	0.25	3318	94.5	3512	14049			
5	1	5896	F	1744	2	15	0.25	4627	94.7	4888	19552	131.9	2118	2.535
5	1	5896	F	1745	2	15	0.25	4614	94.6	4876	19504			
5	1	5896	F	1842	3	15	0.25	4609	94.8	4864	19455	130.4	2120	2.537
5	1	5896	F	1843	3	15	0.25	4533	94.7	4787	19150			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5896	F	1938	4	15	0.25	2066	94.8	2180	8719	57.7	2192	2.624
5	1	5896	F	1939	4	15	0.25	1980	94.7	2090	8362			
5	1	5896	F	2034	5	15	0.25	4288	94.6	4532	18129	122.1	2128	2.547
5	1	5896	F	2035	5	15	0.25	4260	94.7	4501	18005			
5	1	5896	F	2130	6	15	0.25	6234	94.7	6584	26335	176.8	2073	2.482
5	1	5896	F	2131	6	15	0.25	6155	94.7	6500	25999			
5	1	5896	F	2237	7	15	0.25	11502	94.7	12147	48590	327.2	1929	2.309
5	1	5896	F	2238	7	15	0.25	11424	94.7	12066	48265			
5	1	5896	F	2333	8	15	0.25	4424	94.6	4678	18713	127.1	2129	2.548
5	1	5896	F	2334	8	15	0.25	4467	94.5	4726	18905			
5	1	5896	F	2429	9	15	0.25	5813	94.6	6145	24581	160.4	2096	2.508
5	1	5896	F	2430	9	15	0.25	5415	94.6	5722	22887			
5	1	5896	F	2527	10	15	0.25	9278	94.6	9809	39236	263.0	1993	2.386
5	1	5896	F	2528	10	15	0.25	9130	94.6	9651	38605			
5	1	5896	F	2623	11	15	0.25	5225	94.8	5513	22053	148.8	2107	2.522
5	1	5896	F	2624	11	15	0.25	5208	94.8	5497	21986			
5	1	5896	F	2719	12	15	0.25	10222	94.7	10792	43169	293.6	1962	2.349
5	1	5896	F	2720	12	15	0.25	10358	94.7	10934	43735			
5	1	5896	F	2815	13	15	0.25	2366	94.8	2497	9987	67.5	2188	2.619
5	1	5896	F	2816	13	15	0.25	2371	94.8	2502	10007			
5	1	5899	F	1630	0	15	0.25	4789	94.6	5061	20245	136.4	2114	2.530
5	1	5899	F	1631	0	15	0.25	4759	94.6	5031	20124			
5	1	5899	F	1682	1	15	0.25	4335	94.5	4588	18353	123.5	2127	2.546
5	1	5899	F	1683	1	15	0.25	4300	94.5	4551	18202			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5899	F	1746	2	15	0.25	5909	94.7	6243	24972	168.9	2081	2.491
5	1	5899	F	1747	2	15	0.25	5919	94.7	6253	25010			
5	1	5899	F	1844	3	15	0.25	4578	94.7	4836	19343	131.4	2119	2.536
5	1	5899	F	1845	3	15	0.25	4626	94.6	4889	19556			
5	1	5899	F	1940	4	15	0.25	2136	94.8	2254	9015	59.6	2191	2.622
5	1	5899	F	1941	4	15	0.25	2044	94.7	2158	8631			
5	1	5899	F	2036	5	15	0.25	3826	94.6	4045	16179	108.8	2141	2.563
5	1	5899	F	2037	5	15	0.25	3790	94.6	4006	16024			
5	1	5899	F	2132	6	15	0.25	7489	94.8	7903	31611	213.4	2037	2.438
5	1	5899	F	2133	6	15	0.25	7463	94.6	7886	31543			
5	1	5899	F	2239	7	15	0.25	6010	94.7	6347	25388	170.3	2086	2.497
5	1	5899	F	2240	7	15	0.25	5917	94.6	6255	25018			
5	1	5899	F	2335	8	15	0.25	6077	94.6	6426	25703	173.4	2083	2.493
5	1	5899	F	2336	8	15	0.25	6059	94.6	6408	25631			
5	1	5899	F	2431	9	15	0.25	5706	94.6	6034	24137	158.7	2097	2.510
5	1	5899	F	2432	9	15	0.25	5405	94.6	5712	22850			
5	1	5899	F	2529	10	15	0.25	5733	94.6	6059	24235	162.2	2094	2.506
5	1	5899	F	2530	10	15	0.25	5620	94.5	5947	23786			
5	1	5899	F	2625	11	15	0.25	5205	94.8	5493	21970	148.0	2108	2.523
5	1	5899	F	2626	11	15	0.25	5175	94.8	5458	21831			
5	1	5899	F	2721	12	15	0.25	4049	94.6	4279	17115	117.0	2139	2.560
5	1	5899	F	2722	12	15	0.25	4146	94.7	4377	17509			
5	1	5899	F	2817	13	15	0.25	3634	94.6	3840	15360	103.7	2152	2.576
5	1	5899	F	2818	13	15	0.25	3634	94.7	3836	15343			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5900	F	1632	0	15	0.25	2895	94.6	3061	12242	83.1	2167	2.594
5	1	5900	F	1633	0	15	0.25	2921	94.6	3089	12355			
5	1	5900	F	1684	1	15	0.25	3184	94.5	3368	13471	90.8	2159	2.585
5	1	5900	F	1685	1	15	0.25	3170	94.5	3353	13412			
5	1	5900	F	1748	2	15	0.25	5308	94.7	5605	22420	151.7	2099	2.512
5	1	5900	F	1749	2	15	0.25	5320	94.7	5619	22476			
5	1	5900	F	1846	3	15	0.25	4672	94.8	4931	19725	134.2	2116	2.533
5	1	5900	F	1847	3	15	0.25	4735	94.7	5001	20005			
5	1	5900	F	1942	4	15	0.25	1831	94.7	1933	7732	52.1	2198	2.631
5	1	5900	F	1943	4	15	0.25	1819	94.7	1922	7686			
5	1	5900	F	2038	5	15	0.25	3981	94.6	4207	16827	113.2	2137	2.558
5	1	5900	F	2039	5	15	0.25	3942	94.6	4167	16668			
5	1	5900	F	2134	6	15	0.25	6723	94.6	7107	28428	192.1	2058	2.463
5	1	5900	F	2135	6	15	0.25	6725	94.6	7111	28444			
5	1	5900	F	2241	7	15	0.25	5199	94.6	5496	21982	148.4	2108	2.523
5	1	5900	F	2242	7	15	0.25	5192	94.6	5487	21949			
5	1	5900	F	2337	8	15	0.25	5130	94.5	5428	21711	146.7	2109	2.525
5	1	5900	F	2338	8	15	0.25	5125	94.5	5425	21700			
5	1	5900	F	2433	9	15	0.25	8240	94.6	8708	34832	233.8	2022	2.421
5	1	5900	F	2434	9	15	0.25	8124	94.6	8592	34367			
5	1	5900	F	2531	10	15	0.25	5205	94.6	5505	22018	150.3	2106	2.520
5	1	5900	F	2532	10	15	0.25	5306	94.5	5614	22458			
5	1	5900	F	2627	11	15	0.25	4799	94.7	5066	20262	135.6	2120	2.538
5	1	5900	F	2628	11	15	0.25	4708	94.7	4969	19877			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5900	F	2723	12	15	0.25	4459	94.7	4711	18842	127.2	2129	2.548
5	1	5900	F	2724	12	15	0.25	4453	94.7	4704	18815			
5	1	5900	F	2819	13	15	0.25	3086	94.7	3259	13034	88.1	2168	2.595
5	1	5900	F	2820	13	15	0.25	3093	94.8	3263	13051			
5	1	5921	F	1634	0	15	0.25	3310	94.6	3498	13994	94.3	2156	2.581
5	1	5921	F	1635	0	15	0.25	3292	94.6	3479	13917			
5	1	5921	F	1686	1	15	0.25	3316	94.5	3509	14036	95.2	2155	2.579
5	1	5921	F	1687	1	15	0.25	3340	94.5	3534	14136			
5	1	5921	F	1750	2	15	0.25	3683	94.7	3889	15556	104.8	2145	2.568
5	1	5921	F	1751	2	15	0.25	3661	94.6	3869	15475			
5	1	5921	F	1848	3	15	0.25	4239	94.8	4472	17889	120.9	2129	2.549
5	1	5921	F	1849	3	15	0.25	4236	94.7	4474	17898			
5	1	5921	F	1944	4	15	0.25	1961	94.7	2071	8285	56.7	2194	2.626
5	1	5921	F	1945	4	15	0.25	2008	94.6	2123	8492			
5	1	5921	F	2040	5	15	0.25	3556	94.7	3757	15028	100.8	2149	2.573
5	1	5921	F	2041	5	15	0.25	3504	94.6	3703	14811			
5	1	5921	F	2136	6	15	0.25	9265	94.6	9795	39181	265.8	1984	2.375
5	1	5921	F	2137	6	15	0.25	9333	94.5	9872	39487			
5	1	5921	F	2243	7	15	0.25	8315	94.6	8791	35162	237.5	2019	2.416
5	1	5921	F	2244	7	15	0.25	8305	94.6	8782	35129			
5	1	5921	F	2339	8	15	0.25	4112	94.5	4350	17399	117.6	2138	2.560
5	1	5921	F	2340	8	15	0.25	4116	94.5	4354	17416			
5	1	5921	F	2435	9	15	0.25	5207	94.6	5505	22021	150.5	2106	2.520
5	1	5921	F	2436	9	15	0.25	5326	94.6	5630	22518			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	1	5921	F	2533	10	15	0.25	8569	94.6	9061	36243	246.6	2009	2.405
5	1	5921	F	2534	10	15	0.25	8685	94.5	9191	36762			
5	1	5921	F	2629	11	15	0.25	3640	94.8	3841	15364	104.8	2151	2.575
5	1	5921	F	2630	11	15	0.25	3711	94.7	3918	15671			
5	1	5921	F	2725	12	15	0.25	3817	94.6	4033	16133	108.3	2148	2.571
5	1	5921	F	2726	12	15	0.25	3766	94.6	3981	15924			
5	1	5921	F	2821	13	15	0.25	3360	94.8	3544	14178	95.1	2161	2.587
5	1	5921	F	2822	13	15	0.25	3308	94.7	3493	13971			
6	1	5867	M	1704	0	15	0.25	3260	94.6	3448	13790	92.1	2133	8.509
6	1	5867	M	1705	0	15	0.25	3183	94.6	3365	13462			
6	1	5867	M	1768	1	15	0.25	6101	94.6	6448	25794	169.5	2055	8.201
6	1	5867	M	1769	1	15	0.25	5762	94.6	6091	24365			
6	1	5867	M	1866	2	15	0.25	5181	94.7	5469	21875	148.3	2077	8.285
6	1	5867	M	1867	2	15	0.25	5213	94.7	5503	22014			
6	1	5867	M	1962	3	15	0.25	2310	94.7	2439	9754	64.6	2160	8.619
6	1	5867	M	1963	3	15	0.25	2214	94.7	2339	9356			
6	1	5867	M	2058	4	15	0.25	5057	94.7	5341	21363	143.8	2081	8.303
6	1	5867	M	2059	4	15	0.25	5019	94.6	5304	21216			
6	1	5867	M	2165	5	15	0.25	8186	94.7	8648	34591	231.1	1994	7.955
6	1	5867	M	2166	5	15	0.25	8003	94.7	8454	33816			
6	1	5867	M	2261	6	15	0.25	6687	94.5	7077	28309	189.7	2035	8.120
6	1	5867	M	2262	6	15	0.25	6579	94.5	6964	27857			
6	1	5867	M	2357	7	15	0.25	4186	94.5	4428	17713	119.2	2140	8.540
6	1	5867	M	2358	7	15	0.25	4150	94.5	4389	17558			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5867	M	2453	8	15	0.25	7108	94.6	7516	30063	206.3	2053	8.192
6	1	5867	M	2454	8	15	0.25	7332	94.6	7754	31015			
6	1	5867	M	2551	9	15	0.25	8071	94.6	8529	34115	229.9	2030	8.098
6	1	5867	M	2552	9	15	0.25	8024	94.6	8483	33933			
6	1	5867	M	2647	10	15	0.25	8419	94.7	8889	35556	238.1	2021	8.065
6	1	5867	M	2648	10	15	0.25	8269	94.7	8730	34918			
6	1	5867	M	2743	11	15	0.25	8264	94.7	8728	34911	235.6	2024	8.075
6	1	5867	M	2744	11	15	0.25	8247	94.7	8708	34831			
6	1	5867	M	2839	12	15	0.25	2913	94.8	3072	12289	83.9	2176	8.681
6	1	5867	M	2840	12	15	0.25	2970	94.8	3133	12531			
6	1	5867	M	3237	13	15	0.25	3956	94.4	4190	16761	113.6	2146	8.562
6	1	5867	M	3238	13	15	0.25	3976	94.3	4214	16857			
6	1	5868	M	1706	0	15	0.25	2730	94.5	2887	11549	77.6	2147	8.567
6	1	5868	M	1707	0	15	0.25	2701	94.6	2854	11417			
6	1	5868	M	1770	1	15	0.25	5038	94.6	5324	21296	143.1	2082	8.306
6	1	5868	M	1771	1	15	0.25	4979	94.6	5263	21052			
6	1	5868	M	1868	2	15	0.25	2452	94.7	2589	10357	68.7	2156	8.603
6	1	5868	M	1869	2	15	0.25	2360	94.7	2493	9972			
6	1	5868	M	1964	3	15	0.25	3154	94.7	3330	13321	90.6	2134	8.515
6	1	5868	M	1965	3	15	0.25	3192	94.7	3371	13482			
6	1	5868	M	2060	4	15	0.25	8705	94.7	9195	36781	247.9	1977	7.888
6	1	5868	M	2061	4	15	0.25	8661	94.7	9147	36588			
6	1	5868	M	2167	5	15	0.25	6471	94.7	6833	27333	183.7	2041	8.144
6	1	5868	M	2168	5	15	0.25	6394	94.6	6757	27029			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5868	M	2263	6	15	0.25	6769	94.5	7166	28666	193.8	2031	8.104
6	1	5868	M	2264	6	15	0.25	6774	94.4	7172	28688			
6	1	5868	M	2359	7	15	0.25	4102	94.4	4344	17378	117.1	2142	8.548
6	1	5868	M	2360	7	15	0.25	4084	94.5	4322	17287			
6	1	5868	M	2455	8	15	0.25	14209	94.6	15022	60088	401.9	1858	7.411
6	1	5868	M	2456	8	15	0.25	13923	94.6	14721	58882			
6	1	5868	M	2553	9	15	0.25	10755	94.6	11370	45482	308.3	1951	7.785
6	1	5868	M	2554	9	15	0.25	10824	94.6	11443	45773			
6	1	5868	M	2649	10	15	0.25	10021	94.7	10584	42335	285.3	1974	7.877
6	1	5868	M	2650	10	15	0.25	9974	94.7	10530	42120			
6	1	5868	M	2745	11	15	0.25	6438	94.7	6798	27191	183.1	2076	8.285
6	1	5868	M	2746	11	15	0.25	6395	94.7	6752	27007			
6	1	5868	M	2841	12	15	0.25	4565	94.7	4820	19278	129.5	2130	8.498
6	1	5868	M	2842	12	15	0.25	4513	94.8	4763	19052			
6	1	5868	M	3239	13	15	0.25	3451	94.4	3657	14629	98.7	2161	8.621
6	1	5868	M	3240	13	15	0.25	3444	94.3	3650	14599			
6	1	5875	M	1708	0	15	0.25	3795	94.5	4014	16056	109.0	2116	8.442
6	1	5875	M	1709	0	15	0.25	3834	94.6	4053	16212			
6	1	5875	M	1772	1	15	0.25	4530	94.6	4789	19154	128.5	2096	8.364
6	1	5875	M	1773	1	15	0.25	4463	94.6	4719	18874			
6	1	5875	M	1870	2	15	0.25	2581	94.7	2725	10900	73.1	2152	8.585
6	1	5875	M	1871	2	15	0.25	2536	94.6	2681	10724			
6	1	5875	M	1966	3	15	0.25	3671	94.6	3879	15514	104.7	2120	8.459
6	1	5875	M	1967	3	15	0.25	3661	94.6	3868	15473			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5875	M	2062	4	15	0.25	5747	94.7	6071	24285	163.8	2061	8.223
6	1	5875	M	2063	4	15	0.25	5729	94.6	6054	24214			
6	1	5875	M	2169	5	15	0.25	6004	94.6	6346	25384	166.9	2058	8.211
6	1	5875	M	2170	5	15	0.25	5680	94.6	6003	24011			
6	1	5875	M	2265	6	15	0.25	7099	94.4	7523	30094	204.4	2020	8.061
6	1	5875	M	2266	6	15	0.25	7173	94.4	7600	30398			
6	1	5875	M	2361	7	15	0.25	5067	94.4	5365	21459	144.6	2115	8.438
6	1	5875	M	2362	7	15	0.25	5039	94.5	5335	21339			
6	1	5875	M	2457	8	15	0.25	8409	94.6	8892	35567	243.5	2016	8.044
6	1	5875	M	2458	8	15	0.25	8636	94.6	9128	36513			
6	1	5875	M	2555	9	15	0.25	9132	94.6	9651	38604	262.4	1997	7.968
6	1	5875	M	2556	9	15	0.25	9237	94.6	9767	39068			
6	1	5875	M	2651	10	15	0.25	8612	94.7	9098	36393	244.3	2015	8.040
6	1	5875	M	2652	10	15	0.25	8507	94.7	8980	35921			
6	1	5875	M	2747	11	15	0.25	6351	94.7	6707	26829	182.0	2077	8.289
6	1	5875	M	2748	11	15	0.25	6406	94.7	6763	27052			
6	1	5875	M	2843	12	15	0.25	4577	94.7	4834	19335	132.8	2127	8.485
6	1	5875	M	2844	12	15	0.25	4728	94.7	4992	19968			
6	1	5875	M	3241	13	15	0.25	5033	94.3	5335	21342	143.7	2116	8.442
6	1	5875	M	3242	13	15	0.25	5001	94.3	5301	21204			
6	1	5881	M	1710	0	15	0.25	3877	94.6	4100	16400	108.2	2117	8.445
6	1	5881	M	1711	0	15	0.25	3691	94.6	3904	15615			
6	1	5881	M	1774	1	15	0.25	4435	94.6	4688	18753	126.8	2098	8.371
6	1	5881	M	1775	1	15	0.25	4445	94.6	4697	18789			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5881	M	1872	2	15	0.25	3807	94.7	4021	16083	109.9	2115	8.438
6	1	5881	M	1873	2	15	0.25	3894	94.7	4112	16449			
6	1	5881	M	1968	3	15	0.25	4751	94.6	5022	20087	136.0	2089	8.334
6	1	5881	M	1969	3	15	0.25	4770	94.7	5039	20155			
6	1	5881	M	2064	4	15	0.25	12160	94.7	12845	51378	348.0	1877	7.488
6	1	5881	M	2065	4	15	0.25	12214	94.6	12908	51631			
6	1	5881	M	2171	5	15	0.25	7473	94.5	7906	31626	213.7	2011	8.024
6	1	5881	M	2172	5	15	0.25	7480	94.6	7906	31623			
6	1	5881	M	2267	6	15	0.25	6608	94.4	6999	27998	190.2	2035	8.118
6	1	5881	M	2268	6	15	0.25	6679	94.4	7074	28296			
6	1	5881	M	2363	7	15	0.25	5037	94.4	5334	21336	143.3	2116	8.443
6	1	5881	M	2364	7	15	0.25	4976	94.4	5269	21075			
6	1	5881	M	2459	8	15	0.25	7911	94.7	8355	33420	224.5	2035	8.119
6	1	5881	M	2460	8	15	0.25	7811	94.6	8257	33028			
6	1	5881	M	2557	9	15	0.25	10263	94.6	10851	43403	292.8	1967	7.847
6	1	5881	M	2558	9	15	0.25	10228	94.6	10816	43264			
6	1	5881	M	2653	10	15	0.25	5723	94.7	6041	24166	162.5	2097	8.367
6	1	5881	M	2654	10	15	0.25	5667	94.8	5981	23924			
6	1	5881	M	2749	11	15	0.25	4168	94.7	4400	17600	119.2	2140	8.540
6	1	5881	M	2750	11	15	0.25	4186	94.7	4419	17677			
6	1	5881	M	2845	12	15	0.25	6027	94.7	6362	25450	170.2	2089	8.336
6	1	5881	M	2846	12	15	0.25	5904	94.7	6233	24932			
6	1	5881	M	3243	13	15	0.25	3772	94.3	3999	15996	108.6	2151	8.582
6	1	5881	M	3244	13	15	0.25	3808	94.3	4037	16147			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5895	F	1712	0	15	0.25	3380	94.5	3576	14304	96.8	2128	8.491
6	1	5895	F	1713	0	15	0.25	3388	94.5	3585	14340			
6	1	5895	F	1776	1	15	0.25	2973	94.6	3143	12571	84.4	2140	8.540
6	1	5895	F	1777	1	15	0.25	2931	94.5	3100	12400			
6	1	5895	F	1874	2	15	0.25	5289	94.7	5587	22349	151.6	2073	8.272
6	1	5895	F	1875	2	15	0.25	5327	94.7	5627	22509			
6	1	5895	F	1970	3	15	0.25	5282	94.6	5581	22325	151.5	2073	8.272
6	1	5895	F	1971	3	15	0.25	5331	94.7	5628	22513			
6	1	5895	F	2066	4	15	0.25	5017	94.7	5301	21202	142.8	2082	8.307
6	1	5895	F	2067	4	15	0.25	4985	94.6	5268	21072			
6	1	5895	F	2173	5	15	0.25	11393	94.6	12037	48149	324.5	1900	7.582
6	1	5895	F	2174	5	15	0.25	11317	94.5	11974	47896			
6	1	5895	F	2269	6	15	0.25	8138	94.4	8616	34464	233.1	1992	7.947
6	1	5895	F	2270	6	15	0.25	8152	94.4	8633	34533			
6	1	5895	F	2365	7	15	0.25	3862	94.5	4087	16349	110.1	2149	8.576
6	1	5895	F	2366	7	15	0.25	3837	94.5	4061	16243			
6	1	5895	F	2461	8	15	0.25	7104	94.6	7514	30056	201.9	2058	8.210
6	1	5895	F	2462	8	15	0.25	7022	94.6	7427	29706			
6	1	5895	F	2559	9	15	0.25	8547	94.6	9037	36149	246.3	2013	8.032
6	1	5895	F	2560	9	15	0.25	8687	94.5	9192	36766			
6	1	5895	F	2655	10	15	0.25	5435	94.7	5737	22950	154.2	2105	8.400
6	1	5895	F	2656	10	15	0.25	5377	94.7	5677	22706			
6	1	5895	F	2751	11	15	0.25	5947	94.7	6279	25115	170.5	2089	8.335
6	1	5895	F	2752	11	15	0.25	5999	94.7	6336	25344			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5895	F	2847	12	15	0.25	4059	94.8	4283	17132	115.1	2144	8.556
6	1	5895	F	2848	12	15	0.25	4011	94.8	4231	16924			
6	1	5895	F	3245	13	15	0.25	3927	94.3	4162	16648	113.2	2146	8.564
6	1	5895	F	3246	13	15	0.25	3974	94.3	4213	16851			
6	1	5907	F	1714	0	15	0.25	2385	94.5	2523	10093	68.1	2157	8.605
6	1	5907	F	1715	0	15	0.25	2376	94.5	2514	10057			
6	1	5907	F	1778	1	15	0.25	3809	94.6	4027	16107	108.7	2116	8.443
6	1	5907	F	1779	1	15	0.25	3800	94.6	4019	16075			
6	1	5907	F	1876	2	15	0.25	3277	94.7	3461	13842	94.7	2130	8.499
6	1	5907	F	1877	2	15	0.25	3361	94.7	3551	14204			
6	1	5907	F	1972	3	15	0.25	2501	94.7	2640	10561	73.3	2151	8.584
6	1	5907	F	1973	3	15	0.25	2637	94.7	2785	11140			
6	1	5907	F	2068	4	15	0.25	7515	94.6	7944	31777	207.0	2018	8.051
6	1	5907	F	2069	4	15	0.25	6983	94.7	7374	29497			
6	1	5907	F	2175	5	15	0.25	5797	94.6	6130	24518	165.6	2059	8.216
6	1	5907	F	2176	5	15	0.25	5794	94.6	6125	24499			
6	1	5907	F	2271	6	15	0.25	6609	94.4	6999	27994	188.6	2036	8.124
6	1	5907	F	2272	6	15	0.25	6568	94.4	6958	27830			
6	1	5907	F	2367	7	15	0.25	5312	94.5	5620	22479	152.6	2107	8.406
6	1	5907	F	2368	7	15	0.25	5355	94.4	5671	22686			
6	1	5907	F	2463	8	15	0.25	6095	94.6	6445	25778	176.0	2084	8.313
6	1	5907	F	2464	8	15	0.25	6220	94.6	6577	26307			
6	1	5907	F	2561	9	15	0.25	9461	94.6	10005	40022	266.4	1993	7.952
6	1	5907	F	2562	9	15	0.25	9175	94.5	9707	38829			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5907	F	2657	10	15	0.25	7730	94.7	8167	32667	221.7	2038	8.131
6	1	5907	F	2658	10	15	0.25	7802	94.7	8239	32956			
6	1	5907	F	2753	11	15	0.25	6608	94.7	6975	27898	189.3	2070	8.260
6	1	5907	F	2754	11	15	0.25	6661	94.7	7035	28141			
6	1	5907	F	2849	12	15	0.25	4162	94.8	4392	17568	118.5	2141	8.542
6	1	5907	F	2850	12	15	0.25	4143	94.7	4374	17497			
6	1	5907	F	3247	13	15	0.25	3909	94.3	4143	16574	111.6	2148	8.570
6	1	5907	F	3248	13	15	0.25	3881	94.3	4116	16463			
6	1	5909	F	1716	0	15	0.25	2896	94.6	3062	12248	82.7	2142	8.547
6	1	5909	F	1717	0	15	0.25	2891	94.5	3060	12239			
6	1	5909	F	1780	1	15	0.25	3960	94.5	4189	16757	113.5	2111	8.424
6	1	5909	F	1781	1	15	0.25	3976	94.5	4207	16829			
6	1	5909	F	1878	2	15	0.25	3442	94.7	3636	14545	98.8	2126	8.483
6	1	5909	F	1879	2	15	0.25	3478	94.7	3672	14687			
6	1	5909	F	1974	3	15	0.25	2193	94.6	2318	9272	62.5	2162	8.627
6	1	5909	F	1975	3	15	0.25	2184	94.7	2307	9227			
6	1	5909	F	2070	4	15	0.25	4459	94.6	4712	18848	127.3	2098	8.369
6	1	5909	F	2071	4	15	0.25	4455	94.7	4705	18819			
6	1	5909	F	2177	5	15	0.25	7779	94.6	8227	32907	222.2	2003	7.990
6	1	5909	F	2178	5	15	0.25	7767	94.5	8215	32860			
6	1	5909	F	2273	6	15	0.25	4873	94.3	5165	20658	140.4	2084	8.317
6	1	5909	F	2274	6	15	0.25	4931	94.4	5222	20888			
6	1	5909	F	2369	7	15	0.25	4009	94.4	4245	16978	114.4	2145	8.559
6	1	5909	F	2370	7	15	0.25	3987	94.5	4220	16879			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5909	F	2465	8	15	0.25	6070	94.6	6414	25655	173.3	2086	8.324
6	1	5909	F	2466	8	15	0.25	6064	94.6	6413	25651			
6	1	5909	F	2563	9	15	0.25	7978	94.6	8431	33723	226.5	2033	8.112
6	1	5909	F	2564	9	15	0.25	7867	94.5	8327	33306			
6	1	5909	F	2659	10	15	0.25	4171	94.7	4406	17624	120.2	2139	8.536
6	1	5909	F	2660	10	15	0.25	4249	94.7	4487	17948			
6	1	5909	F	2755	11	15	0.25	5565	94.8	5872	23487	158.9	2101	8.381
6	1	5909	F	2756	11	15	0.25	5573	94.7	5883	23534			
6	1	5909	F	2851	12	15	0.25	4011	94.8	4232	16928	113.9	2146	8.561
6	1	5909	F	2852	12	15	0.25	3971	94.7	4193	16774			
6	1	5909	F	3249	13	15	0.25	3545	94.3	3758	15034	102.0	2158	8.608
6	1	5909	F	3250	13	15	0.25	3572	94.3	3787	15147			
6	1	5918	F	1718	0	15	0.25	3125	94.5	3306	13224	89.5	2135	8.520
6	1	5918	F	1719	0	15	0.25	3135	94.6	3315	13261			
6	1	5918	F	1782	1	15	0.25	4020	94.5	4252	17010	115.2	2110	8.417
6	1	5918	F	1783	1	15	0.25	4038	94.5	4271	17086			
6	1	5918	F	1880	2	15	0.25	4264	94.6	4506	18023	121.1	2104	8.393
6	1	5918	F	1881	2	15	0.25	4221	94.7	4456	17823			
6	1	5918	F	1976	3	15	0.25	3802	94.7	4017	16066	111.3	2113	8.432
6	1	5918	F	1977	3	15	0.25	3998	94.7	4222	16889			
6	1	5918	F	2072	4	15	0.25	4984	94.7	5265	21062	141.4	2083	8.312
6	1	5918	F	2073	4	15	0.25	4918	94.6	5201	20803			
6	1	5918	F	2179	5	15	0.25	7065	94.6	7470	29881	202.7	2022	8.068
6	1	5918	F	2180	5	15	0.25	7121	94.6	7529	30115			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	1	5918	F	2275	6	15	0.25	7332	94.4	7768	31072	210.4	2014	8.037
6	1	5918	F	2276	6	15	0.25	7366	94.4	7798	31194			
6	1	5918	F	2371	7	15	0.25	3941	94.5	4172	16688	116.2	2143	8.552
6	1	5918	F	2372	7	15	0.25	4179	94.4	4424	17697			
6	1	5918	F	2467	8	15	0.25	7621	94.6	8058	32230	219.2	2040	8.140
6	1	5918	F	2468	8	15	0.25	7718	94.5	8166	32663			
6	1	5918	F	2565	9	15	0.25	6227	94.6	6586	26343	178.6	2081	8.302
6	1	5918	F	2566	9	15	0.25	6272	94.6	6632	26529			
6	1	5918	F	2661	10	15	0.25	6102	94.7	6446	25785	174.5	2085	8.319
6	1	5918	F	2662	10	15	0.25	6121	94.7	6465	25861			
6	1	5918	F	2757	11	15	0.25	5027	94.7	5308	21233	141.3	2118	8.451
6	1	5918	F	2758	11	15	0.25	4879	94.7	5150	20599			
6	1	5918	F	2853	12	15	0.25	3871	94.8	4086	16342	110.2	2149	8.575
6	1	5918	F	2854	12	15	0.25	3859	94.8	4073	16291			
6	1	5918	F	3251	13	15	0.25	5100	94.3	5407	21627	145.9	2114	8.433
6	1	5918	F	3252	13	15	0.25	5087	94.4	5390	21559			
7	1	5872	M	1800	0	15	0.25	5467	94.7	5771	23083	156.1	2017	24.148
7	1	5872	M	1801	0	15	0.25	5477	94.7	5784	23136			
7	1	5872	M	1898	1	15	0.25	7219	94.7	7621	30483	206.4	1967	23.546
7	1	5872	M	1899	1	15	0.25	7253	94.7	7656	30623			
7	1	5872	M	1994	2	15	0.25	3743	94.8	3949	15795	107.5	2066	24.730
7	1	5872	M	1995	2	15	0.25	3798	94.8	4008	16034			
7	1	5872	M	2090	3	15	0.25	6444	94.8	6799	27195	183.3	1990	23.823
7	1	5872	M	2091	3	15	0.25	6412	94.8	6766	27065			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5872	M	2197	4	15	0.25	5941	94.5	6290	25159	172.1	2001	23.957
7	1	5872	M	2198	4	15	0.25	6092	94.5	6448	25792			
7	1	5872	M	2293	5	15	0.25	7018	94.4	7436	29745	200.5	1973	23.618
7	1	5872	M	2294	5	15	0.25	6981	94.4	7398	29592			
7	1	5872	M	2389	6	15	0.25	3945	94.6	4171	16685	112.1	2062	24.676
7	1	5872	M	2390	6	15	0.25	3896	94.5	4122	16489			
7	1	5872	M	2485	7	15	0.25	7454	94.6	7881	31526	212.4	1995	23.883
7	1	5872	M	2486	7	15	0.25	7407	94.6	7833	31331			
7	1	5872	M	2583	8	15	0.25	15012	94.6	15877	63506	423.4	1784	21.356
7	1	5872	M	2584	8	15	0.25	14610	94.5	15456	61824			
7	1	5872	M	2679	9	15	0.25	7500	94.7	7917	31669	211.7	1996	23.891
7	1	5872	M	2680	9	15	0.25	7342	94.8	7745	30981			
7	1	5872	M	2775	10	15	0.25	3828	94.8	4036	16145	107.9	2100	25.134
7	1	5872	M	2776	10	15	0.25	3740	94.8	3945	15779			
7	1	5872	M	2871	11	15	0.25	2712	94.4	2873	11492	77.5	2130	25.497
7	1	5872	M	2872	11	15	0.25	2701	94.4	2860	11441			
7	1	5872	M	3269	12	15	0.25	4092	94.3	4340	17360	116.5	2091	25.030
7	1	5872	M	3270	12	15	0.25	4039	94.3	4282	17129			
7	1	5872	M	3333	13	15	0.25	4530	94.3	4803	19211	129.3	2078	24.876
7	1	5872	M	3334	13	15	0.25	4496	94.3	4769	19076			
7	1	5873	M	1802	0	15	0.25	5905	94.7	6238	24950	168.9	2005	23.995
7	1	5873	M	1803	0	15	0.25	5933	94.7	6263	25052			
7	1	5873	M	1900	1	15	0.25	5443	94.7	5748	22994	155.2	2018	24.160
7	1	5873	M	1901	1	15	0.25	5431	94.7	5735	22942			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5873	M	1996	2	15	0.25	5003	94.7	5285	21140	144.7	2029	24.286
7	1	5873	M	1997	2	15	0.25	5136	94.8	5421	21682			
7	1	5873	M	2092	3	15	0.25	4576	94.7	4830	19320	131.4	2042	24.444
7	1	5873	M	2093	3	15	0.25	4634	94.7	4894	19576			
7	1	5873	M	2199	4	15	0.25	6645	94.4	7039	28155	186.6	1987	23.784
7	1	5873	M	2200	4	15	0.25	6397	94.5	6767	27066			
7	1	5873	M	2295	5	15	0.25	7828	94.4	8297	33188	224.3	1949	23.333
7	1	5873	M	2296	5	15	0.25	7829	94.3	8301	33204			
7	1	5873	M	2391	6	15	0.25	3690	94.5	3903	15612	105.4	2068	24.756
7	1	5873	M	2392	6	15	0.25	3683	94.6	3895	15582			
7	1	5873	M	2487	7	15	0.25	6516	94.6	6889	27556	191.1	2017	24.138
7	1	5873	M	2488	7	15	0.25	6857	94.6	7249	28996			
7	1	5873	M	2585	8	15	0.25	8086	94.5	8555	34221	230.9	1977	23.660
7	1	5873	M	2586	8	15	0.25	8070	94.6	8534	34137			
7	1	5873	M	2681	9	15	0.25	8020	94.7	8469	33874	227.6	1980	23.701
7	1	5873	M	2682	9	15	0.25	7932	94.8	8370	33481			
7	1	5873	M	2777	10	15	0.25	9537	94.8	10061	40245	270.6	1937	23.186
7	1	5873	M	2778	10	15	0.25	9439	94.7	9963	39850			
7	1	5873	M	2873	11	15	0.25	2957	94.4	3133	12531	85.0	2123	25.407
7	1	5873	M	2874	11	15	0.25	2982	94.4	3159	12635			
7	1	5873	M	3271	12	15	0.25	2308	94.3	2447	9788	66.2	2141	25.632
7	1	5873	M	3272	12	15	0.25	2312	94.3	2453	9811			
7	1	5873	M	3335	13	15	0.25	6020	94.3	6382	25528	172.4	2035	24.361
7	1	5873	M	3336	13	15	0.25	6013	94.3	6374	25495			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5874	M	1804	0	15	0.25	7440	94.7	7861	31443	212.0	1962	23.480
7	1	5874	M	1805	0	15	0.25	7410	94.7	7825	31299			
7	1	5874	M	1902	1	15	0.25	4837	94.7	5106	20424	137.4	2036	24.373
7	1	5874	M	1903	1	15	0.25	4795	94.7	5062	20248			
7	1	5874	M	1998	2	15	0.25	3067	94.7	3238	12954	92.0	2082	24.916
7	1	5874	M	1999	2	15	0.25	3381	94.7	3571	14284			
7	1	5874	M	2094	3	15	0.25	6125	94.7	6466	25863	174.3	1999	23.931
7	1	5874	M	2095	3	15	0.25	6094	94.7	6435	25740			
7	1	5874	M	2201	4	15	0.25	3421	94.5	3620	14481	97.4	2076	24.851
7	1	5874	M	2202	4	15	0.25	3390	94.5	3587	14349			
7	1	5874	M	2297	5	15	0.25	4773	94.3	5062	20247	136.4	2037	24.385
7	1	5874	M	2298	5	15	0.25	4742	94.3	5029	20114			
7	1	5874	M	2393	6	15	0.25	3325	94.6	3516	14063	97.0	2077	24.856
7	1	5874	M	2394	6	15	0.25	3462	94.5	3663	14653			
7	1	5874	M	2489	7	15	0.25	5727	94.6	6055	24220	162.8	2045	24.475
7	1	5874	M	2490	7	15	0.25	5669	94.6	5995	23979			
7	1	5874	M	2587	8	15	0.25	5693	94.6	6019	24078	162.2	2045	24.483
7	1	5874	M	2588	8	15	0.25	5660	94.6	5986	23944			
7	1	5874	M	2683	9	15	0.25	6959	94.6	7353	29414	195.3	2012	24.087
7	1	5874	M	2684	9	15	0.25	6727	94.8	7097	28390			
7	1	5874	M	2779	10	15	0.25	3930	94.8	4145	16581	112.9	2095	25.074
7	1	5874	M	2780	10	15	0.25	3988	94.8	4206	16826			
7	1	5874	M	2875	11	15	0.25	3558	94.4	3770	15080	100.6	2107	25.221
7	1	5874	M	2876	11	15	0.25	3467	94.4	3672	14689			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5874	M	3273	12	15	0.25	5150	94.3	5461	21844	139.6	2068	24.753
7	1	5874	M	3274	12	15	0.25	4596	94.3	4873	19491			
7	1	5874	M	3337	13	15	0.25	9044	94.3	9589	38355	260.8	1947	23.303
7	1	5874	M	3338	13	15	0.25	9158	94.3	9710	38842			
7	1	5882	M	1806	0	15	0.25	4730	94.7	4994	19976	134.6	2039	24.407
7	1	5882	M	1807	0	15	0.25	4700	94.7	4963	19852			
7	1	5882	M	1904	1	15	0.25	5384	94.7	5684	22736	153.9	2020	24.175
7	1	5882	M	1905	1	15	0.25	5402	94.7	5703	22813			
7	1	5882	M	2000	2	15	0.25	3820	94.7	4033	16132	108.2	2065	24.722
7	1	5882	M	2001	2	15	0.25	3766	94.7	3976	15905			
7	1	5882	M	2096	3	15	0.25	6203	94.7	6549	26195	176.4	1997	23.906
7	1	5882	M	2097	3	15	0.25	6159	94.7	6505	26020			
7	1	5882	M	2203	4	15	0.25	7287	94.5	7713	30852	208.2	1965	23.526
7	1	5882	M	2204	4	15	0.25	7268	94.5	7691	30765			
7	1	5882	M	2299	5	15	0.25	7955	94.3	8438	33752	228.9	1945	23.278
7	1	5882	M	2300	5	15	0.25	8012	94.3	8499	33997			
7	1	5882	M	2395	6	15	0.25	2565	94.6	2713	10851	73.0	2101	25.144
7	1	5882	M	2396	6	15	0.25	2542	94.5	2689	10756			
7	1	5882	M	2491	7	15	0.25	10922	94.6	11549	46198	310.3	1897	22.711
7	1	5882	M	2492	7	15	0.25	10794	94.6	11410	45638			
7	1	5882	M	2589	8	15	0.25	8060	94.5	8531	34123	229.4	1978	23.679
7	1	5882	M	2590	8	15	0.25	7980	94.5	8445	33780			
7	1	5882	M	2685	9	15	0.25	7441	94.8	7852	31410	212.1	1995	23.885
7	1	5882	M	2686	9	15	0.25	7429	94.7	7845	31382			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5882	M	2781	10	15	0.25	7870	94.8	8306	33223	225.7	1982	23.723
7	1	5882	M	2782	10	15	0.25	7953	94.7	8394	33575			
7	1	5882	M	2877	11	15	0.25	5348	94.4	5667	22666	153.6	2054	24.587
7	1	5882	M	2878	11	15	0.25	5376	94.4	5696	22784			
7	1	5882	M	3275	12	15	0.25	3520	94.3	3732	14929	101.2	2106	25.213
7	1	5882	M	3276	12	15	0.25	3544	94.3	3756	15025			
7	1	5882	M	3339	13	15	0.25	4315	94.3	4577	18307	123.5	2084	24.947
7	1	5882	M	3340	13	15	0.25	4299	94.3	4560	18241			
7	1	5901	F	1808	0	15	0.25	5965	94.7	6301	25204	169.7	2004	23.986
7	1	5901	F	1809	0	15	0.25	5923	94.7	6255	25019			
7	1	5901	F	1906	1	15	0.25	4912	94.7	5187	20749	140.5	2033	24.335
7	1	5901	F	1907	1	15	0.25	4933	94.7	5210	20841			
7	1	5901	F	2002	2	15	0.25	4995	94.7	5274	21095	142.6	2031	24.311
7	1	5901	F	2003	2	15	0.25	4996	94.7	5277	21109			
7	1	5901	F	2098	3	15	0.25	5480	94.8	5784	23136	156.5	2017	24.144
7	1	5901	F	2099	3	15	0.25	5492	94.7	5799	23198			
7	1	5901	F	2205	4	15	0.25	5460	94.5	5777	23107	157.0	2017	24.138
7	1	5901	F	2206	4	15	0.25	5522	94.6	5840	23361			
7	1	5901	F	2301	5	15	0.25	8639	94.3	9164	36657	248.4	1925	23.044
7	1	5901	F	2302	5	15	0.25	8690	94.3	9215	36859			
7	1	5901	F	2397	6	15	0.25	3061	94.6	3236	12945	87.1	2086	24.974
7	1	5901	F	2398	6	15	0.25	3036	94.5	3212	12848			
7	1	5901	F	2493	7	15	0.25	6118	94.6	6465	25860	174.6	2033	24.335
7	1	5901	F	2494	7	15	0.25	6100	94.5	6455	25822			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5901	F	2591	8	15	0.25	6299	94.6	6663	26650	178.1	2030	24.292
7	1	5901	F	2592	8	15	0.25	6160	94.5	6518	26072			
7	1	5901	F	2687	9	15	0.25	9665	94.7	10203	40812	275.9	1932	23.122
7	1	5901	F	2688	9	15	0.25	9671	94.7	10212	40847			
7	1	5901	F	2783	10	15	0.25	7130	94.8	7523	30090	202.4	2005	24.002
7	1	5901	F	2784	10	15	0.25	7059	94.7	7453	29810			
7	1	5901	F	2879	11	15	0.25	4261	94.4	4514	18057	122.8	2085	24.954
7	1	5901	F	2880	11	15	0.25	4318	94.4	4574	18297			
7	1	5901	F	3277	12	15	0.25	3125	94.3	3313	13253	89.5	2118	25.353
7	1	5901	F	3278	12	15	0.25	3121	94.3	3309	13237			
7	1	5901	F	3341	13	15	0.25	3602	94.3	3818	15272	104.0	2104	25.180
7	1	5901	F	3342	13	15	0.25	3656	94.3	3876	15503			
7	1	5902	F	1810	0	15	0.25	6306	94.6	6666	26665	179.1	1995	23.874
7	1	5902	F	1811	0	15	0.25	6231	94.6	6586	26346			
7	1	5902	F	1908	1	15	0.25	4149	94.7	4379	17517	118.4	2055	24.600
7	1	5902	F	1909	1	15	0.25	4147	94.6	4382	17529			
7	1	5902	F	2004	2	15	0.25	3860	94.6	4080	16318	113.3	2060	24.661
7	1	5902	F	2005	2	15	0.25	4077	94.7	4304	17217			
7	1	5902	F	2100	3	15	0.25	7095	94.7	7493	29971	202.5	1971	23.594
7	1	5902	F	2101	3	15	0.25	7092	94.7	7491	29963			
7	1	5902	F	2207	4	15	0.25	4354	94.5	4608	18432	126.7	2047	24.501
7	1	5902	F	2208	4	15	0.25	4502	94.5	4765	19058			
7	1	5902	F	2303	5	15	0.25	7801	94.3	8277	33108	223.9	1950	23.337
7	1	5902	F	2304	5	15	0.25	7816	94.3	8291	33164			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5902	F	2399	6	15	0.25	3978	94.5	4208	16834	114.8	2059	24.643
7	1	5902	F	2400	6	15	0.25	4055	94.6	4287	17149			
7	1	5902	F	2495	7	15	0.25	5565	94.6	5884	23536	155.9	2052	24.559
7	1	5902	F	2496	7	15	0.25	5343	94.6	5650	22600			
7	1	5902	F	2593	8	15	0.25	9364	94.4	9914	39654	267.5	1940	23.223
7	1	5902	F	2594	8	15	0.25	9342	94.5	9882	39528			
7	1	5902	F	2689	9	15	0.25	7205	94.8	7602	30406	203.6	2004	23.987
7	1	5902	F	2690	9	15	0.25	7069	94.7	7465	29861			
7	1	5902	F	2785	10	15	0.25	8304	94.8	8761	35043	236.4	1971	23.595
7	1	5902	F	2786	10	15	0.25	8276	94.8	8733	34933			
7	1	5902	F	2881	11	15	0.25	2566	94.4	2718	10871	73.7	2134	25.542
7	1	5902	F	2882	11	15	0.25	2583	94.4	2736	10945			
7	1	5902	F	3279	12	15	0.25	2729	94.3	2894	11574	77.3	2130	25.499
7	1	5902	F	3280	12	15	0.25	2667	94.3	2827	11307			
7	1	5902	F	3343	13	15	0.25	2786	94.3	2954	11814	80.4	2127	25.462
7	1	5902	F	3344	13	15	0.25	2826	94.3	2997	11986			
7	1	5913	F	1812	0	15	0.25	3939	94.5	4167	16667	112.0	2062	24.677
7	1	5913	F	1813	0	15	0.25	3899	94.6	4123	16490			
7	1	5913	F	1910	1	15	0.25	3810	94.7	4022	16088	108.3	2065	24.721
7	1	5913	F	1911	1	15	0.25	3777	94.7	3990	15958			
7	1	5913	F	2006	2	15	0.25	2870	94.7	3031	12126	78.8	2095	25.074
7	1	5913	F	2007	2	15	0.25	2651	94.8	2798	11194			
7	1	5913	F	2102	3	15	0.25	3655	94.7	3858	15432	104.3	2069	24.769
7	1	5913	F	2103	3	15	0.25	3652	94.7	3857	15426			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5913	F	2209	4	15	0.25	4480	94.5	4739	18955	128.2	2045	24.483
7	1	5913	F	2210	4	15	0.25	4484	94.5	4746	18983			
7	1	5913	F	2305	5	15	0.25	5896	94.2	6256	25025	167.7	2006	24.010
7	1	5913	F	2306	5	15	0.25	5798	94.2	6153	24613			
7	1	5913	F	2401	6	15	0.25	4322	94.6	4572	18287	123.3	2050	24.541
7	1	5913	F	2402	6	15	0.25	4307	94.6	4556	18223			
7	1	5913	F	2497	7	15	0.25	5957	94.6	6298	25193	169.7	2038	24.393
7	1	5913	F	2498	7	15	0.25	5919	94.6	6258	25033			
7	1	5913	F	2595	8	15	0.25	8944	94.5	9464	37857	256.4	1951	23.356
7	1	5913	F	2596	8	15	0.25	8984	94.5	9509	38037			
7	1	5913	F	2691	9	15	0.25	6877	94.7	7259	29037	192.8	2015	24.116
7	1	5913	F	2692	9	15	0.25	6638	94.7	7010	28039			
7	1	5913	F	2787	10	15	0.25	6317	94.8	6667	26666	178.2	2029	24.291
7	1	5913	F	2788	10	15	0.25	6182	94.8	6523	26092			
7	1	5913	F	2883	11	15	0.25	3595	94.4	3808	15232	102.8	2105	25.194
7	1	5913	F	2884	11	15	0.25	3586	94.4	3800	15198			
7	1	5913	F	3281	12	15	0.25	3104	94.3	3291	13164	89.0	2119	25.359
7	1	5913	F	3282	12	15	0.25	3109	94.3	3297	13187			
7	1	5913	F	3345	13	15	0.25	2516	94.3	2670	10679	72.4	2135	25.558
7	1	5913	F	3346	13	15	0.25	2535	94.3	2688	10752			
7	1	5920	F	1814	0	15	0.25	3304	94.6	3494	13974	93.4	2080	24.899
7	1	5920	F	1815	0	15	0.25	3235	94.6	3419	13676			
7	1	5920	F	1912	1	15	0.25	4065	94.7	4291	17164	112.1	2061	24.675
7	1	5920	F	1913	1	15	0.25	3798	94.8	4008	16033			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	1	5920	F	2008	2	15	0.25	3534	94.6	3736	14944	102.0	2072	24.796
7	1	5920	F	2009	2	15	0.25	3612	94.7	3814	15257			
7	1	5920	F	2104	3	15	0.25	3892	94.7	4110	16439	111.0	2063	24.689
7	1	5920	F	2105	3	15	0.25	3887	94.7	4105	16422			
7	1	5920	F	2211	4	15	0.25	5163	94.5	5464	21857	148.2	2025	24.243
7	1	5920	F	2212	4	15	0.25	5199	94.5	5503	22011			
7	1	5920	F	2307	5	15	0.25	5522	94.2	5861	23444	159.4	2014	24.110
7	1	5920	F	2308	5	15	0.25	5589	94.2	5932	23728			
7	1	5920	F	2403	6	15	0.25	3006	94.5	3179	12717	86.1	2087	24.986
7	1	5920	F	2404	6	15	0.25	3022	94.6	3195	12780			
7	1	5920	F	2499	7	15	0.25	6112	94.6	6464	25854	174.4	2033	24.337
7	1	5920	F	2500	7	15	0.25	6096	94.6	6444	25777			
7	1	5920	F	2597	8	15	0.25	6320	94.6	6682	26726	179.6	2028	24.275
7	1	5920	F	2598	8	15	0.25	6252	94.6	6610	26440			
7	1	5920	F	2693	9	15	0.25	6181	94.7	6527	26107	174.0	2034	24.342
7	1	5920	F	2694	9	15	0.25	6009	94.7	6348	25392			
7	1	5920	F	2789	10	15	0.25	6178	94.7	6524	26096	176.1	2032	24.317
7	1	5920	F	2790	10	15	0.25	6163	94.7	6507	26028			
7	1	5920	F	2885	11	15	0.25	2853	94.4	3024	12094	81.5	2126	25.449
7	1	5920	F	2886	11	15	0.25	2839	94.4	3009	12035			
7	1	5920	F	3283	12	15	0.25	2931	94.3	3107	12429	84.1	2124	25.418
7	1	5920	F	3284	12	15	0.25	2939	94.3	3116	12465			
7	1	5920	F	3347	13	15	0.25	2948	94.3	3128	12513	84.2	2123	25.417
7	1	5920	F	3348	13	15	0.25	2927	94.3	3103	12413			

TABLE E2. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (14-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)

Analyses That Were Not Used for Calculations: **Reason for Exclusion:**

5	1	5871	M	1930	4	15	0.25	12271	94.8	12949	51796	Poor replication.
5	1	5871	M	1931	4	15	0.25	9028	94.8	9526	38106	

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5869	M	1636	0	15	0.25	3315	94.6	3505	14022	94.4	2156	2.580
5	2	5869	M	1637	0	15	0.25	3288	94.6	3478	13912			
5	2	5869	M	1688	1	15	0.25	2931	94.5	3101	12406	83.3	2167	2.594
5	2	5869	M	1689	1	15	0.25	2897	94.5	3065	12259			
5	2	5869	M	1752	2	15	0.25	3764	94.7	3977	15907	107.8	2142	2.564
5	2	5869	M	1753	2	15	0.25	3790	94.7	4002	16007			
5	2	5869	M	1850	3	15	0.25	7307	94.7	7714	30856	206.6	2044	2.446
5	2	5869	M	1851	3	15	0.25	7175	94.7	7575	30299			
5	2	5869	M	1946	4	15	0.25	2301	94.7	2431	9723	65.2	2185	2.615
5	2	5869	M	1947	4	15	0.25	2269	94.7	2397	9590			
5	2	5869	M	2042	5	15	0.25	4169	94.7	4405	17618	119.5	2131	2.550
5	2	5869	M	2043	5	15	0.25	4201	94.6	4442	17766			
5	2	5869	M	2138	6	15	0.25	7821	94.6	8270	33078	223.8	2026	2.426
5	2	5869	M	2139	6	15	0.25	7837	94.5	8291	33163			
5	2	5869	M	2245	7	15	0.25	7613	94.6	8047	32188	217.9	2038	2.440
5	2	5869	M	2246	7	15	0.25	7641	94.6	8078	32314			
5	2	5869	M	2341	8	15	0.25	6144	94.5	6504	26016	176.2	2080	2.489
5	2	5869	M	2342	8	15	0.25	6176	94.5	6533	26131			
5	2	5869	M	2437	9	15	0.25	6809	94.6	7197	28790	193.7	2062	2.468
5	2	5869	M	2438	9	15	0.25	6753	94.6	7139	28557			
5	2	5869	M	2535	10	15	0.25	7392	94.5	7819	31278	209.2	2047	2.450
5	2	5869	M	2536	10	15	0.25	7242	94.6	7658	30633			
5	2	5869	M	2631	11	15	0.25	4458	94.7	4710	18838	128.6	2127	2.546
5	2	5869	M	2632	11	15	0.25	4549	94.7	4806	19223			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5869	M	2727	12	15	0.25	5469	94.6	5779	23117	157.2	2099	2.512
5	2	5869	M	2728	12	15	0.25	5538	94.7	5850	23402			
5	2	5869	M	2823	13	15	0.25	3147	94.6	3328	13311	90.0	2166	2.593
5	2	5869	M	2824	13	15	0.25	3147	94.5	3329	13317			
5	2	5869	M	3221	14	15	0.25	4042	94.3	4285	17141	114.8	2111	2.527
5	2	5869	M	3222	14	15	0.25	3967	94.3	4208	16834			
5	2	5869	M	3301	15	15	0.25	4735	94.3	5022	20087	135.5	2090	2.502
5	2	5869	M	3302	15	15	0.25	4719	94.3	5005	20018			
5	2	5869	M	3365	16	15	0.25	3029	94.5	3206	12822	87.3	2138	2.559
5	2	5869	M	3366	16	15	0.25	3072	94.4	3254	13014			
5	2	5869	M	3413	17	15	0.25	6305	94.4	6678	26713	183.3	2042	2.445
5	2	5869	M	3414	17	15	0.25	6501	94.4	6887	27548			
5	2	5869	M	3461	18	15	0.25	6064	94.3	6428	25712	174.1	2051	2.455
5	2	5869	M	3462	18	15	0.25	6094	94.3	6459	25834			
5	2	5869	M	3509	19	15	0.25	13527	94.3	14348	57391	390.0	1836	2.197
5	2	5869	M	3510	19	15	0.25	13679	94.3	14511	58044			
5	2	5869	M	4200	20	15	0.25	3783	94.4	4009	16035	108.5	2117	2.534
5	2	5869	M	4201	20	15	0.25	3793	94.4	4019	16076			
5	2	5869	M	4248	21	15	0.25	3771	94.3	4001	16002	109.2	2116	2.533
5	2	5869	M	4249	21	15	0.25	3846	94.3	4080	16321			
5	2	5869	M	4296	22	15	0.25	4871	94.3	5165	20660	139.3	2086	2.497
5	2	5869	M	4297	22	15	0.25	4849	94.3	5142	20569			
5	2	5869	M	4344	23	15	0.25	2760	94.3	2926	11703	78.5	2147	2.570
5	2	5869	M	4345	23	15	0.25	2722	94.3	2885	11539			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5869	M	4392	24	15	0.25	4257	94.3	4516	18064	122.7	2103	2.517
5	2	5869	M	4393	24	15	0.25	4301	94.3	4562	18249			
5	2	5869	M	4440	25	15	0.25	5709	94.2	6060	24238	164.2	2061	2.467
5	2	5869	M	4441	25	15	0.25	5747	94.3	6093	24373			
5	2	5869	M	4629	26	15	0.25	8130	94.3	8624	34495	231.5	1994	2.387
5	2	5869	M	4630	26	15	0.25	8020	94.3	8507	34029			
5	2	5869	M	4677	27	15	0.25	5434	94.2	5771	23086	155.0	2071	2.478
5	2	5869	M	4678	27	15	0.25	5368	94.2	5699	22796			
5	2	5870	M	1638	0	15	0.25	4147	94.6	4385	17541	117.5	2133	2.553
5	2	5870	M	1639	0	15	0.25	4074	94.6	4306	17226			
5	2	5870	M	1690	1	15	0.25	4556	94.6	4818	19273	129.9	2120	2.538
5	2	5870	M	1691	1	15	0.25	4531	94.5	4792	19170			
5	2	5870	M	1754	2	15	0.25	4228	94.5	4473	17894	121.9	2128	2.548
5	2	5870	M	1755	2	15	0.25	4301	94.7	4544	18175			
5	2	5870	M	1852	3	15	0.25	3451	94.7	3643	14573	100.6	2150	2.573
5	2	5870	M	1853	3	15	0.25	3597	94.7	3798	15190			
5	2	5870	M	1948	4	15	0.25	6177	94.7	6524	26096	178.3	2072	2.480
5	2	5870	M	1949	4	15	0.25	6308	94.6	6669	26677			
5	2	5870	M	2044	5	15	0.25	4688	94.6	4955	19822	133.1	2117	2.534
5	2	5870	M	2045	5	15	0.25	4630	94.6	4892	19569			
5	2	5870	M	2140	6	15	0.25	9827	94.5	10398	41590	286.0	1964	2.351
5	2	5870	M	2141	6	15	0.25	10180	94.5	10769	43077			
5	2	5870	M	2247	7	15	0.25	5112	94.6	5405	21618	145.5	2110	2.526
5	2	5870	M	2248	7	15	0.25	5071	94.5	5364	21454			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5870	M	2343	8	15	0.25	4702	94.5	4974	19897	132.7	2123	2.541
5	2	5870	M	2344	8	15	0.25	4582	94.6	4846	19385			
5	2	5870	M	2439	9	15	0.25	6859	94.6	7248	28994	195.4	2061	2.466
5	2	5870	M	2440	9	15	0.25	6822	94.6	7213	28852			
5	2	5870	M	2537	10	15	0.25	7044	94.6	7449	29796	201.1	2055	2.460
5	2	5870	M	2538	10	15	0.25	7032	94.6	7436	29743			
5	2	5870	M	2633	11	15	0.25	4203	94.7	4439	17754	120.1	2136	2.557
5	2	5870	M	2634	11	15	0.25	4212	94.7	4446	17783			
5	2	5870	M	2729	12	15	0.25	4247	94.6	4489	17954	122.9	2133	2.553
5	2	5870	M	2730	12	15	0.25	4362	94.7	4607	18428			
5	2	5870	M	2825	13	15	0.25	3295	94.6	3483	13933	94.4	2162	2.587
5	2	5870	M	2826	13	15	0.25	3311	94.6	3500	14000			
5	2	5870	M	3223	14	15	0.25	3762	94.3	3989	15954	107.0	2119	2.536
5	2	5870	M	3224	14	15	0.25	3709	94.3	3933	15731			
5	2	5870	M	3303	15	15	0.25	4777	94.3	5067	20267	135.7	2090	2.502
5	2	5870	M	3304	15	15	0.25	4689	94.3	4972	19889			
5	2	5870	M	3367	16	15	0.25	4952	94.4	5245	20981	141.5	2084	2.495
5	2	5870	M	3368	16	15	0.25	4934	94.4	5227	20909			
5	2	5870	M	3415	17	15	0.25	3840	94.4	4068	16270	110.2	2115	2.532
5	2	5870	M	3416	17	15	0.25	3858	94.5	4084	16336			
5	2	5870	M	3463	18	15	0.25	4886	94.3	5180	20719	139.8	2086	2.497
5	2	5870	M	3464	18	15	0.25	4873	94.3	5168	20673			
5	2	5870	M	3511	19	15	0.25	4286	94.3	4548	18192	124.1	2102	2.515
5	2	5870	M	3512	19	15	0.25	4366	94.3	4632	18528			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5870	M	4202	20	15	0.25	4954	94.4	5250	21001	140.4	2085	2.496
5	2	5870	M	4203	20	15	0.25	4845	94.3	5136	20545			
5	2	5870	M	4250	21	15	0.25	10496	94.3	11128	44513	304.1	1921	2.300
5	2	5870	M	4251	21	15	0.25	10722	94.3	11377	45506			
5	2	5870	M	4298	22	15	0.25	4046	94.4	4287	17150	115.5	2110	2.526
5	2	5870	M	4299	22	15	0.25	4018	94.3	4261	17044			
5	2	5870	M	4346	23	15	0.25	4043	94.3	4287	17147	116.2	2109	2.525
5	2	5870	M	4347	23	15	0.25	4063	94.3	4309	17235			
5	2	5870	M	4394	24	15	0.25	4282	94.2	4543	18173	123.3	2102	2.516
5	2	5870	M	4395	24	15	0.25	4321	94.3	4585	18339			
5	2	5870	M	4442	25	15	0.25	11947	94.3	12671	50682	339.5	1886	2.258
5	2	5870	M	4443	25	15	0.25	11743	94.3	12456	49825			
5	2	5870	M	4631	26	15	0.25	8009	94.2	8504	34018	227.3	1998	2.392
5	2	5870	M	4632	26	15	0.25	7836	94.2	8315	33262			
5	2	5870	M	4679	27	15	0.25	3997	94.2	4246	16983	114.8	2111	2.527
5	2	5870	M	4680	27	15	0.25	4002	94.2	4248	16992			
5	2	5888	M	1640	0	15	0.25	3806	94.7	4021	16086	108.4	2142	2.564
5	2	5888	M	1641	0	15	0.25	3788	94.6	4003	16013			
5	2	5888	M	1692	1	15	0.25	2584	94.6	2733	10933	74.0	2176	2.605
5	2	5888	M	1693	1	15	0.25	2591	94.5	2742	10966			
5	2	5888	M	1756	2	15	0.25	3913	94.7	4132	16527	112.5	2138	2.559
5	2	5888	M	1757	2	15	0.25	3970	94.7	4193	16773			
5	2	5888	M	1854	3	15	0.25	5280	94.7	5577	22306	150.9	2099	2.513
5	2	5888	M	1855	3	15	0.25	5296	94.7	5593	22374			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5888	M	1950	4	15	0.25	2589	94.7	2734	10938	73.6	2177	2.605
5	2	5888	M	1951	4	15	0.25	2566	94.7	2710	10840			
5	2	5888	M	2046	5	15	0.25	3890	94.7	4108	16430	111.2	2139	2.560
5	2	5888	M	2047	5	15	0.25	3899	94.6	4121	16484			
5	2	5888	M	2142	6	15	0.25	9118	94.6	9642	38568	259.8	1990	2.382
5	2	5888	M	2143	6	15	0.25	9062	94.6	9584	38335			
5	2	5888	M	2249	7	15	0.25	7261	94.5	7681	30722	203.9	2052	2.456
5	2	5888	M	2250	7	15	0.25	7008	94.6	7409	29635			
5	2	5888	M	2345	8	15	0.25	3744	94.5	3960	15840	107.7	2148	2.571
5	2	5888	M	2346	8	15	0.25	3789	94.5	4008	16034			
5	2	5888	M	2441	9	15	0.25	8969	94.6	9477	37909	249.0	2007	2.402
5	2	5888	M	2442	9	15	0.25	8471	94.6	8951	35805			
5	2	5888	M	2539	10	15	0.25	9997	94.6	10573	42291	282.2	1974	2.363
5	2	5888	M	2540	10	15	0.25	9750	94.6	10310	41240			
5	2	5888	M	2635	11	15	0.25	4811	94.7	5080	20319	138.8	2117	2.534
5	2	5888	M	2636	11	15	0.25	4919	94.7	5193	20773			
5	2	5888	M	2731	12	15	0.25	5754	94.7	6080	24318	163.7	2092	2.504
5	2	5888	M	2732	12	15	0.25	5717	94.7	6037	24147			
5	2	5888	M	2827	13	15	0.25	4579	94.6	4842	19368	131.0	2125	2.544
5	2	5888	M	2828	13	15	0.25	4590	94.6	4851	19406			
5	2	5888	M	3225	14	15	0.25	3337	94.3	3537	14150	95.3	2130	2.550
5	2	5888	M	3226	14	15	0.25	3312	94.3	3513	14051			
5	2	5888	M	3305	15	15	0.25	3877	94.3	4110	16441	109.3	2116	2.533
5	2	5888	M	3306	15	15	0.25	3754	94.3	3981	15922			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5888	M	3369	16	15	0.25	3326	94.4	3522	14087	95.0	2131	2.550
5	2	5888	M	3370	16	15	0.25	3311	94.4	3507	14026			
5	2	5888	M	3417	17	15	0.25	5175	94.4	5482	21927	148.4	2077	2.486
5	2	5888	M	3418	17	15	0.25	5195	94.4	5503	22010			
5	2	5888	M	3465	18	15	0.25	4242	94.2	4504	18016	122.0	2104	2.518
5	2	5888	M	3466	18	15	0.25	4263	94.3	4521	18085			
5	2	5888	M	3513	19	15	0.25	3610	94.3	3830	15321	104.6	2121	2.539
5	2	5888	M	3514	19	15	0.25	3684	94.3	3907	15629			
5	2	5888	M	4204	20	15	0.25	5258	94.3	5576	22303	149.9	2076	2.485
5	2	5888	M	4205	20	15	0.25	5200	94.3	5515	22058			
5	2	5888	M	4252	21	15	0.25	5114	94.3	5425	21700	145.5	2080	2.490
5	2	5888	M	4253	21	15	0.25	5035	94.3	5341	21365			
5	2	5888	M	4300	22	15	0.25	3396	94.3	3600	14402	97.6	2128	2.547
5	2	5888	M	4301	22	15	0.25	3417	94.3	3623	14492			
5	2	5888	M	4348	23	15	0.25	3520	94.3	3733	14933	100.9	2125	2.543
5	2	5888	M	4349	23	15	0.25	3521	94.3	3732	14930			
5	2	5888	M	4396	24	15	0.25	5156	94.3	5470	21881	148.3	2077	2.486
5	2	5888	M	4397	24	15	0.25	5181	94.2	5501	22002			
5	2	5888	M	4444	25	15	0.25	11075	94.3	11738	46951	317.9	1908	2.283
5	2	5888	M	4445	25	15	0.25	11115	94.3	11789	47157			
5	2	5888	M	4633	26	15	0.25	8613	94.3	9136	36543	249.7	1976	2.365
5	2	5888	M	4634	26	15	0.25	8800	94.2	9338	37354			
5	2	5888	M	4681	27	15	0.25	4717	94.2	5006	20026	135.1	2091	2.502
5	2	5888	M	4682	27	15	0.25	4696	94.1	4989	19954			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5893	M	1642	0	15	0.25	2605	94.6	2753	11013	74.2	2176	2.605
5	2	5893	M	1643	0	15	0.25	2591	94.6	2741	10962			
5	2	5893	M	1694	1	15	0.25	2667	94.6	2821	11282	80.2	2170	2.597
5	2	5893	M	1695	1	15	0.25	2943	94.6	3111	12446			
5	2	5893	M	1758	2	15	0.25	2909	94.6	3074	12294	83.0	2167	2.594
5	2	5893	M	1759	2	15	0.25	2905	94.6	3071	12283			
5	2	5893	M	1856	3	15	0.25	4474	94.7	4724	18894	127.2	2123	2.541
5	2	5893	M	1857	3	15	0.25	4441	94.7	4691	18765			
5	2	5893	M	1952	4	15	0.25	1738	94.7	1835	7341	50.0	2200	2.634
5	2	5893	M	1953	4	15	0.25	1762	94.7	1862	7447			
5	2	5893	M	2048	5	15	0.25	3693	94.6	3903	15610	105.1	2145	2.568
5	2	5893	M	2049	5	15	0.25	3664	94.6	3871	15486			
5	2	5893	M	2144	6	15	0.25	6447	94.5	6819	27276	185.8	2064	2.471
5	2	5893	M	2145	6	15	0.25	6554	94.6	6930	27720			
5	2	5893	M	2251	7	15	0.25	6312	94.5	6680	26720	181.0	2075	2.484
5	2	5893	M	2252	7	15	0.25	6344	94.5	6711	26844			
5	2	5893	M	2347	8	15	0.25	4368	94.5	4621	18483	124.2	2132	2.552
5	2	5893	M	2348	8	15	0.25	4322	94.6	4571	18285			
5	2	5893	M	2443	9	15	0.25	5304	94.6	5605	22421	154.5	2101	2.515
5	2	5893	M	2444	9	15	0.25	5512	94.6	5828	23314			
5	2	5893	M	2541	10	15	0.25	10030	94.6	10604	42415	287.6	1968	2.356
5	2	5893	M	2542	10	15	0.25	10105	94.6	10680	42721			
5	2	5893	M	2637	11	15	0.25	4158	94.7	4390	17559	118.4	2138	2.559
5	2	5893	M	2638	11	15	0.25	4142	94.7	4374	17495			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5893	M	2733	12	15	0.25	2915	94.7	3080	12319	82.7	2173	2.601
5	2	5893	M	2734	12	15	0.25	2876	94.6	3040	12159			
5	2	5893	M	2829	13	15	0.25	3010	94.6	3183	12733	85.3	2171	2.598
5	2	5893	M	2830	13	15	0.25	2962	94.6	3132	12530			
5	2	5893	M	3227	14	15	0.25	15599	94.3	16545	66179	444.0	1782	2.132
5	2	5893	M	3228	14	15	0.25	15382	94.3	16313	65253			
5	2	5893	M	3307	15	15	0.25	4447	94.3	4716	18864	127.1	2098	2.512
5	2	5893	M	3308	15	15	0.25	4423	94.3	4692	18767			
5	2	5893	M	3371	16	15	0.25	4197	94.5	4443	17771	119.8	2106	2.520
5	2	5893	M	3372	16	15	0.25	4180	94.4	4426	17704			
5	2	5893	M	3419	17	15	0.25	3553	94.4	3763	15054	101.8	2124	2.542
5	2	5893	M	3420	17	15	0.25	3556	94.4	3767	15068			
5	2	5893	M	3467	18	15	0.25	4294	94.3	4553	18212	123.5	2102	2.516
5	2	5893	M	3468	18	15	0.25	4324	94.3	4582	18330			
5	2	5893	M	3515	19	15	0.25	4031	94.3	4277	17107	116.1	2109	2.525
5	2	5893	M	3516	19	15	0.25	4069	94.3	4317	17266			
5	2	5893	M	4206	20	15	0.25	12282	94.3	13018	52071	353.9	1872	2.240
5	2	5893	M	4207	20	15	0.25	12424	94.3	13174	52695			
5	2	5893	M	5070	21	15	0.25	5230	94.4	5541	22165	148.2	2077	2.487
5	2	5893	M	5071	21	15	0.25	5122	94.4	5427	21709			
5	2	5893	M	4302	22	15	0.25	4122	94.3	4372	17488	118.4	2107	2.522
5	2	5893	M	4303	22	15	0.25	4142	94.3	4392	17568			
5	2	5893	M	4350	23	15	0.25	3179	94.3	3370	13481	90.9	2135	2.555
5	2	5893	M	4351	23	15	0.25	3164	94.3	3357	13427			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5893	M	4398	24	15	0.25	4936	94.3	5237	20949	140.3	2085	2.496
5	2	5893	M	4399	24	15	0.25	4853	94.3	5147	20589			
5	2	5893	M	4446	25	15	0.25	6249	94.3	6627	26509	178.8	2047	2.450
5	2	5893	M	4447	25	15	0.25	6228	94.3	6604	26416			
5	2	5893	M	4635	26	15	0.25	7652	94.3	8119	32477	217.7	2008	2.403
5	2	5893	M	4636	26	15	0.25	7533	94.3	7989	31956			
5	2	5893	M	4683	27	15	0.25	5413	94.2	5749	22994	155.4	2070	2.478
5	2	5893	M	4684	27	15	0.25	5416	94.2	5752	23007			
5	2	5910	F	1644	0	15	0.25	3032	94.6	3205	12822	86.7	2164	2.590
5	2	5910	F	1645	0	15	0.25	3035	94.6	3208	12833			
5	2	5910	F	1696	1	15	0.25	5162	94.5	5460	21840	147.8	2102	2.516
5	2	5910	F	1697	1	15	0.25	5177	94.5	5478	21910			
5	2	5910	F	1760	2	15	0.25	2316	94.6	2448	9790	65.8	2184	2.615
5	2	5910	F	1761	2	15	0.25	2293	94.6	2423	9692			
5	2	5910	F	1858	3	15	0.25	5425	94.7	5728	22910	155.3	2095	2.508
5	2	5910	F	1859	3	15	0.25	5455	94.7	5763	23053			
5	2	5910	F	1954	4	15	0.25	2335	94.7	2466	9865	66.6	2184	2.614
5	2	5910	F	1955	4	15	0.25	2333	94.7	2465	9859			
5	2	5910	F	2050	5	15	0.25	5122	94.7	5411	21645	145.7	2104	2.519
5	2	5910	F	2051	5	15	0.25	5083	94.6	5373	21493			
5	2	5910	F	2146	6	15	0.25	8035	94.6	8495	33979	230.1	2020	2.418
5	2	5910	F	2147	6	15	0.25	8066	94.6	8531	34124			
5	2	5910	F	2253	7	15	0.25	5303	94.6	5606	22425	151.1	2105	2.520
5	2	5910	F	2254	7	15	0.25	5269	94.6	5572	22287			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5910	F	2349	8	15	0.25	5064	94.7	5350	21398	144.6	2111	2.527
5	2	5910	F	2350	8	15	0.25	5063	94.6	5354	21414			
5	2	5910	F	2445	9	15	0.25	6988	94.6	7389	29558	197.2	2059	2.464
5	2	5910	F	2446	9	15	0.25	6812	94.5	7205	28821			
5	2	5910	F	2543	10	15	0.25	6063	94.5	6414	25655	171.7	2084	2.495
5	2	5910	F	2544	10	15	0.25	5953	94.6	6293	25173			
5	2	5910	F	2639	11	15	0.25	5851	94.7	6178	24710	165.8	2090	2.502
5	2	5910	F	2640	11	15	0.25	5773	94.7	6094	24375			
5	2	5910	F	2735	12	15	0.25	2993	94.7	3161	12643	85.3	2171	2.598
5	2	5910	F	2736	12	15	0.25	2985	94.7	3153	12610			
5	2	5910	F	2831	13	15	0.25	4013	94.5	4246	16983	113.2	2143	2.565
5	2	5910	F	2832	13	15	0.25	3910	94.6	4134	16537			
5	2	5910	F	3229	14	15	0.25	4809	94.3	5100	20400	137.9	2088	2.499
5	2	5910	F	3230	14	15	0.25	4819	94.3	5108	20432			
5	2	5910	F	3309	15	15	0.25	4135	94.3	4387	17548	118.2	2107	2.522
5	2	5910	F	3310	15	15	0.25	4112	94.3	4362	17448			
5	2	5910	F	3373	16	15	0.25	6195	94.5	6558	26231	178.1	2048	2.451
5	2	5910	F	3374	16	15	0.25	6249	94.4	6618	26473			
5	2	5910	F	3421	17	15	0.25	5615	94.4	5946	23783	162.1	2063	2.470
5	2	5910	F	3422	17	15	0.25	5711	94.4	6049	24197			
5	2	5910	F	3469	18	15	0.25	10391	94.4	11011	44043	296.1	1930	2.310
5	2	5910	F	3470	18	15	0.25	10282	94.3	10898	43593			
5	2	5910	F	3517	19	15	0.25	4890	94.2	5190	20758	135.0	2091	2.502
5	2	5910	F	3518	19	15	0.25	4522	94.2	4798	19193			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5910	F	4208	20	15	0.25	4495	94.3	4766	19065	127.2	2098	2.512
5	2	5910	F	4209	20	15	0.25	4382	94.3	4647	18589			
5	2	5910	F	4256	21	15	0.25	3970	94.2	4215	16858	113.4	2112	2.528
5	2	5910	F	4257	21	15	0.25	3941	94.3	4181	16723			
5	2	5910	F	4304	22	15	0.25	4009	94.3	4249	16996	114.9	2111	2.526
5	2	5910	F	4305	22	15	0.25	4012	94.4	4252	17010			
5	2	5910	F	4352	23	15	0.25	4202	94.3	4459	17834	120.3	2105	2.520
5	2	5910	F	4353	23	15	0.25	4190	94.3	4445	17778			
5	2	5910	F	4400	24	15	0.25	3325	94.3	3527	14110	95.4	2130	2.550
5	2	5910	F	4401	24	15	0.25	3327	94.3	3529	14114			
5	2	5910	F	4448	25	15	0.25	5123	94.3	5434	21734	145.2	2080	2.490
5	2	5910	F	4449	25	15	0.25	5008	94.3	5312	21246			
5	2	5910	F	4637	26	15	0.25	7065	94.2	7496	29985	204.7	2021	2.419
5	2	5910	F	4638	26	15	0.25	7209	94.2	7652	30609			
5	2	5910	F	4685	27	15	0.25	5665	94.2	6016	24065	161.7	2064	2.470
5	2	5910	F	4686	27	15	0.25	5601	94.2	5946	23783			
5	2	5911	F	1646	0	15	0.25	2889	94.6	3055	12219	83.0	2167	2.594
5	2	5911	F	1647	0	15	0.25	2916	94.5	3085	12340			
5	2	5911	F	1698	1	15	0.25	2618	94.6	2768	11072	75.0	2175	2.604
5	2	5911	F	1699	1	15	0.25	2629	94.6	2781	11122			
5	2	5911	F	1762	2	15	0.25	3162	94.7	3340	13361	90.3	2160	2.585
5	2	5911	F	1763	2	15	0.25	3163	94.7	3341	13365			
5	2	5911	F	1860	3	15	0.25	2862	94.8	3021	12082	80.7	2169	2.597
5	2	5911	F	1861	3	15	0.25	2795	94.7	2951	11803			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5911	F	1956	4	15	0.25	2646	94.7	2795	11180	75.2	2175	2.603
5	2	5911	F	1957	4	15	0.25	2627	94.7	2773	11093			
5	2	5911	F	2052	5	15	0.25	3745	94.6	3957	15829	107.9	2142	2.564
5	2	5911	F	2053	5	15	0.25	3813	94.6	4029	16115			
5	2	5911	F	2148	6	15	0.25	6582	94.6	6958	27831	188.6	2062	2.468
5	2	5911	F	2149	6	15	0.25	6623	94.6	7001	28003			
5	2	5911	F	2255	7	15	0.25	4457	94.6	4712	18848	125.1	2131	2.551
5	2	5911	F	2256	7	15	0.25	4291	94.5	4542	18168			
5	2	5911	F	2351	8	15	0.25	4289	94.5	4537	18149	122.2	2134	2.554
5	2	5911	F	2352	8	15	0.25	4258	94.5	4506	18025			
5	2	5911	F	2447	9	15	0.25	4764	94.6	5038	20152	133.5	2122	2.541
5	2	5911	F	2448	9	15	0.25	4581	94.6	4842	19369			
5	2	5911	F	2545	10	15	0.25	8763	94.6	9265	37058	248.2	2008	2.403
5	2	5911	F	2546	10	15	0.25	8605	94.5	9103	36411			
5	2	5911	F	2641	11	15	0.25	2645	94.7	2793	11170	74.7	2181	2.611
5	2	5911	F	2642	11	15	0.25	2590	94.8	2734	10935			
5	2	5911	F	2737	12	15	0.25	3185	94.7	3362	13447	90.2	2166	2.592
5	2	5911	F	2738	12	15	0.25	3134	94.6	3311	13244			
5	2	5911	F	2833	13	15	0.25	3191	94.6	3375	13500	90.0	2166	2.593
5	2	5911	F	2834	13	15	0.25	3111	94.8	3284	13134			
5	2	5911	F	3231	14	15	0.25	2808	94.3	2977	11908	80.9	2145	2.567
5	2	5911	F	3232	14	15	0.25	2841	94.3	3013	12053			
5	2	5911	F	3311	15	15	0.25	3430	94.3	3638	14553	98.1	2127	2.546
5	2	5911	F	3312	15	15	0.25	3415	94.3	3623	14492			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5911	F	3375	16	15	0.25	3478	94.5	3682	14727	99.2	2126	2.545
5	2	5911	F	3376	16	15	0.25	3461	94.5	3661	14645			
5	2	5911	F	3423	17	15	0.25	4030	94.4	4267	17068	113.9	2112	2.528
5	2	5911	F	3424	17	15	0.25	3931	94.4	4165	16660			
5	2	5911	F	3471	18	15	0.25	8004	94.3	8485	33939	227.3	1998	2.392
5	2	5911	F	3472	18	15	0.25	7860	94.3	8334	33338			
5	2	5911	F	3519	19	15	0.25	3888	94.3	4123	16490	112.6	2113	2.529
5	2	5911	F	3520	19	15	0.25	3971	94.3	4211	16844			
5	2	5911	F	4210	20	15	0.25	4115	94.3	4364	17455	119.1	2106	2.521
5	2	5911	F	4211	20	15	0.25	4197	94.3	4453	17813			
5	2	5911	F	4258	21	15	0.25	2977	94.2	3159	12636	85.9	2140	2.561
5	2	5911	F	4259	21	15	0.25	3012	94.3	3195	12781			
5	2	5911	F	4306	22	15	0.25	2950	94.3	3128	12511	84.6	2141	2.563
5	2	5911	F	4307	22	15	0.25	2952	94.3	3130	12521			
5	2	5911	F	4354	23	15	0.25	3215	94.4	3407	13628	89.2	2136	2.557
5	2	5911	F	4355	23	15	0.25	3015	94.3	3197	12790			
5	2	5911	F	4402	24	15	0.25	3295	94.3	3496	13985	94.5	2131	2.551
5	2	5911	F	4403	24	15	0.25	3297	94.2	3499	13995			
5	2	5911	F	4450	25	15	0.25	12177	94.3	12916	51663	349.0	1877	2.246
5	2	5911	F	4451	25	15	0.25	12165	94.2	12909	51634			
5	2	5911	F	4639	26	15	0.25	6808	94.2	7225	28901	196.4	2029	2.429
5	2	5911	F	4640	26	15	0.25	6891	94.3	7311	29244			
5	2	5911	F	4687	27	15	0.25	9254	94.2	9825	39299	264.8	1961	2.347
5	2	5911	F	4688	27	15	0.25	9208	94.2	9773	39090			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5915	F	1648	0	15	0.25	2544	94.6	2690	10760	72.9	2177	2.606
5	2	5915	F	1649	0	15	0.25	2557	94.6	2703	10813			
5	2	5915	F	1700	1	15	0.25	3840	94.5	4063	16253	108.8	2141	2.563
5	2	5915	F	1701	1	15	0.25	3769	94.5	3988	15951			
5	2	5915	F	1764	2	15	0.25	2682	94.6	2834	11337	76.5	2174	2.602
5	2	5915	F	1765	2	15	0.25	2678	94.7	2830	11318			
5	2	5915	F	1862	3	15	0.25	3153	94.7	3329	13315	88.8	2161	2.587
5	2	5915	F	1863	3	15	0.25	3070	94.8	3240	12960			
5	2	5915	F	1958	4	15	0.25	2449	94.7	2587	10349	69.5	2181	2.610
5	2	5915	F	1959	4	15	0.25	2417	94.7	2552	10210			
5	2	5915	F	2054	5	15	0.25	4020	94.6	4250	17001	114.0	2136	2.557
5	2	5915	F	2055	5	15	0.25	3961	94.6	4187	16749			
5	2	5915	F	2150	6	15	0.25	6416	94.5	6786	27145	184.0	2066	2.473
5	2	5915	F	2151	6	15	0.25	6454	94.5	6827	27307			
5	2	5915	F	2257	7	15	0.25	5701	94.5	6032	24126	160.6	2095	2.508
5	2	5915	F	2258	7	15	0.25	5536	94.5	5856	23424			
5	2	5915	F	2353	8	15	0.25	10265	94.6	10853	43413	294.3	1962	2.348
5	2	5915	F	2354	8	15	0.25	10321	94.5	10925	43698			
5	2	5915	F	2449	9	15	0.25	4150	94.6	4387	17549	118.4	2138	2.559
5	2	5915	F	2450	9	15	0.25	4138	94.6	4375	17500			
5	2	5915	F	2547	10	15	0.25	4896	94.5	5179	20715	139.9	2116	2.533
5	2	5915	F	2548	10	15	0.25	4897	94.6	5177	20710			
5	2	5915	F	2643	11	15	0.25	4568	94.7	4822	19286	129.6	2126	2.545
5	2	5915	F	2644	11	15	0.25	4512	94.7	4766	19065			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5915	F	2739	12	15	0.25	2501	94.6	2642	10570	71.0	2185	2.615
5	2	5915	F	2740	12	15	0.25	2475	94.7	2614	10456			
5	2	5915	F	2835	13	15	0.25	4137	94.8	4366	17463	117.6	2138	2.560
5	2	5915	F	2836	13	15	0.25	4113	94.8	4339	17354			
5	2	5915	F	3233	14	15	0.25	3835	94.3	4069	16276	110.8	2115	2.531
5	2	5915	F	3234	14	15	0.25	3893	94.3	4129	16516			
5	2	5915	F	3313	15	15	0.25	3692	94.3	3916	15663	106.3	2119	2.537
5	2	5915	F	3314	15	15	0.25	3721	94.3	3947	15790			
5	2	5915	F	3377	16	15	0.25	4014	94.5	4249	16995	114.5	2111	2.527
5	2	5915	F	3378	16	15	0.25	3989	94.5	4221	16884			
5	2	5915	F	3425	17	15	0.25	7421	94.4	7863	31450	208.1	2017	2.415
5	2	5915	F	3426	17	15	0.25	7117	94.4	7539	30158			
5	2	5915	F	3473	18	15	0.25	6341	94.3	6723	26893	181.4	2044	2.447
5	2	5915	F	3474	18	15	0.25	6321	94.3	6702	26806			
5	2	5915	F	3521	19	15	0.25	4253	94.3	4511	18044	125.8	2100	2.513
5	2	5915	F	3522	19	15	0.25	4519	94.2	4797	19189			
5	2	5915	F	4212	20	15	0.25	6058	94.3	6426	25704	173.7	2052	2.456
5	2	5915	F	4213	20	15	0.25	6057	94.2	6429	25715			
5	2	5915	F	4260	21	15	0.25	4002	94.2	4247	16986	114.3	2111	2.527
5	2	5915	F	4261	21	15	0.25	3969	94.3	4210	16842			
5	2	5915	F	4308	22	15	0.25	3417	94.3	3623	14490	98.7	2127	2.546
5	2	5915	F	4309	22	15	0.25	3470	94.3	3679	14716			
5	2	5915	F	4356	23	15	0.25	2954	94.3	3133	12533	84.0	2142	2.563
5	2	5915	F	4357	23	15	0.25	2909	94.3	3086	12345			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5915	F	4404	24	15	0.25	3217	94.3	3413	13650	92.0	2134	2.554
5	2	5915	F	4405	24	15	0.25	3202	94.2	3398	13592			
5	2	5915	F	4452	25	15	0.25	5070	94.3	5377	21510	144.6	2081	2.491
5	2	5915	F	4453	25	15	0.25	5016	94.3	5320	21279			
5	2	5915	F	4641	26	15	0.25	4372	94.3	4637	18550	125.3	2100	2.514
5	2	5915	F	4642	26	15	0.25	4367	94.3	4633	18533			
5	2	5915	F	4689	27	15	0.25	6142	94.2	6519	26074	175.6	2050	2.454
5	2	5915	F	4690	27	15	0.25	6095	94.1	6474	25897			
5	2	5916	F	1650	0	15	0.25	3002	94.6	3174	12696	84.7	2166	2.592
5	2	5916	F	1651	0	15	0.25	2923	94.6	3090	12361			
5	2	5916	F	1702	1	15	0.25	3384	94.6	3579	14316	95.7	2154	2.579
5	2	5916	F	1703	1	15	0.25	3315	94.6	3506	14023			
5	2	5916	F	1766	2	15	0.25	3204	94.6	3386	13543	91.2	2159	2.584
5	2	5916	F	1767	2	15	0.25	3181	94.7	3360	13440			
5	2	5916	F	1864	3	15	0.25	5916	94.7	6244	24978	172.4	2078	2.487
5	2	5916	F	1865	3	15	0.25	6171	94.8	6511	26044			
5	2	5916	F	1960	4	15	0.25	4226	94.7	4465	17858	120.7	2130	2.549
5	2	5916	F	1961	4	15	0.25	4229	94.7	4466	17864			
5	2	5916	F	2056	5	15	0.25	3241	94.6	3427	13708	93.1	2157	2.582
5	2	5916	F	2057	5	15	0.25	3277	94.6	3464	13856			
5	2	5916	F	2152	6	15	0.25	8123	94.5	8593	34370	232.8	2017	2.415
5	2	5916	F	2153	6	15	0.25	8167	94.6	8635	34542			
5	2	5916	F	2259	7	15	0.25	6634	94.5	7018	28070	190.9	2065	2.472
5	2	5916	F	2260	7	15	0.25	6727	94.6	7112	28449			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5916	F	2355	8	15	0.25	5490	94.5	5807	23228	158.5	2097	2.511
5	2	5916	F	2356	8	15	0.25	5602	94.6	5925	23698			
5	2	5916	F	2451	9	15	0.25	5598	94.6	5916	23664	158.3	2098	2.511
5	2	5916	F	2452	9	15	0.25	5484	94.6	5800	23199			
5	2	5916	F	2549	10	15	0.25	7755	94.6	8201	32804	223.6	2032	2.433
5	2	5916	F	2550	10	15	0.25	7892	94.6	8345	33378			
5	2	5916	F	2645	11	15	0.25	9315	94.8	9830	39320	265.8	1990	2.382
5	2	5916	F	2646	11	15	0.25	9321	94.7	9839	39358			
5	2	5916	F	2741	12	15	0.25	4627	94.6	4890	19560	132.1	2124	2.542
5	2	5916	F	2742	12	15	0.25	4623	94.6	4886	19543			
5	2	5916	F	2837	13	15	0.25	2182	94.7	2304	9217	62.4	2194	2.626
5	2	5916	F	2838	13	15	0.25	2189	94.8	2310	9238			
5	2	5916	F	3235	14	15	0.25	4429	94.3	4699	18795	127.1	2098	2.512
5	2	5916	F	3236	14	15	0.25	4440	94.3	4710	18841			
5	2	5916	F	3315	15	15	0.25	3293	94.3	3494	13977	94.4	2131	2.551
5	2	5916	F	3316	15	15	0.25	3292	94.3	3493	13973			
5	2	5916	F	3379	16	15	0.25	3717	94.4	3938	15753	106.7	2119	2.536
5	2	5916	F	3380	16	15	0.25	3735	94.4	3955	15822			
5	2	5916	F	3427	17	15	0.25	3614	94.4	3827	15306	102.5	2123	2.541
5	2	5916	F	3428	17	15	0.25	3548	94.4	3758	15032			
5	2	5916	F	3475	18	15	0.25	3267	94.3	3465	13861	92.5	2133	2.553
5	2	5916	F	3476	18	15	0.25	3190	94.3	3383	13531			
5	2	5916	F	3523	19	15	0.25	3831	94.3	4063	16252	108.6	2117	2.534
5	2	5916	F	3524	19	15	0.25	3746	94.3	3974	15894			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
5	2	5916	F	4214	20	15	0.25	5125	94.3	5435	21738	146.4	2079	2.489
5	2	5916	F	4215	20	15	0.25	5091	94.2	5402	21609			
5	2	5916	F	4262	21	15	0.25	3430	94.2	3641	14562	99.0	2127	2.545
5	2	5916	F	4263	21	15	0.25	3471	94.3	3683	14731			
5	2	5916	F	4310	22	15	0.25	3066	94.4	3249	12996	87.7	2138	2.559
5	2	5916	F	4311	22	15	0.25	3052	94.3	3238	12951			
5	2	5916	F	4358	23	15	0.25	4782	94.3	5070	20280	133.2	2092	2.504
5	2	5916	F	4359	23	15	0.25	4517	94.3	4789	19157			
5	2	5916	F	4406	24	15	0.25	2780	94.2	2950	11798	79.7	2146	2.569
5	2	5916	F	4407	24	15	0.25	2778	94.3	2947	11788			
5	2	5916	F	4454	25	15	0.25	4947	94.3	5248	20991	142.0	2084	2.494
5	2	5916	F	4455	25	15	0.25	4956	94.3	5259	21034			
5	2	5916	F	4643	26	15	0.25	5073	94.2	5384	21537	145.8	2080	2.489
5	2	5916	F	4644	26	15	0.25	5094	94.2	5408	21630			
5	2	5916	F	4691	27	15	0.25	3222	94.2	3421	13686	93.2	2132	2.552
5	2	5916	F	4692	27	15	0.25	3274	94.2	3476	13905			
6	2	5880	M	1720	0	15	0.25	2636	94.6	2786	11145	75.6	2149	8.575
6	2	5880	M	1721	0	15	0.25	2654	94.6	2805	11221			
6	2	5880	M	1784	1	15	0.25	3792	94.5	4012	16050	108.4	2116	8.444
6	2	5880	M	1785	1	15	0.25	3790	94.5	4011	16045			
6	2	5880	M	1882	2	15	0.25	3781	94.7	3993	15971	107.7	2117	8.447
6	2	5880	M	1883	2	15	0.25	3761	94.7	3973	15894			
6	2	5880	M	1978	3	15	0.25	4624	94.6	4886	19543	132.5	2092	8.348
6	2	5880	M	1979	3	15	0.25	4661	94.7	4921	19684			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5880	M	2074	4	15	0.25	4484	94.6	4738	18951	128.3	2096	8.365
6	2	5880	M	2075	4	15	0.25	4502	94.6	4760	19038			
6	2	5880	M	2181	5	15	0.25	8313	94.6	8792	35170	237.2	1988	7.930
6	2	5880	M	2182	5	15	0.25	8282	94.6	8757	35029			
6	2	5880	M	2277	6	15	0.25	5194	94.5	5498	21993	146.8	2078	8.291
6	2	5880	M	2278	6	15	0.25	5062	94.4	5364	21458			
6	2	5880	M	2373	7	15	0.25	3572	94.5	3779	15114	101.4	2158	8.611
6	2	5880	M	2374	7	15	0.25	3517	94.5	3722	14886			
6	2	5880	M	2469	8	15	0.25	6297	94.5	6662	26646	180.0	2079	8.297
6	2	5880	M	2470	8	15	0.25	6301	94.6	6661	26644			
6	2	5880	M	2567	9	15	0.25	9426	94.5	9971	39882	269.6	1990	7.939
6	2	5880	M	2568	9	15	0.25	9435	94.6	9979	39915			
6	2	5880	M	2663	10	15	0.25	6032	94.7	6372	25489	169.6	2090	8.339
6	2	5880	M	2664	10	15	0.25	5851	94.7	6176	24705			
6	2	5880	M	2759	11	15	0.25	6550	94.7	6917	27669	184.5	2075	8.279
6	2	5880	M	2760	11	15	0.25	6387	94.8	6738	26950			
6	2	5880	M	2855	12	15	0.25	3782	94.8	3990	15961	107.1	2152	8.588
6	2	5880	M	2856	12	15	0.25	3726	94.7	3935	15740			
6	2	5880	M	3253	13	15	0.25	3780	94.3	4009	16034	108.2	2151	8.584
6	2	5880	M	3254	13	15	0.25	3769	94.3	3996	15984			
6	2	5880	M	3317	14	15	0.25	3611	94.4	3827	15307	102.9	2121	8.464
6	2	5880	M	3318	14	15	0.25	3575	94.4	3789	15154			
6	2	5880	M	3381	15	15	0.25	4293	94.5	4540	18161	123.4	2101	8.382
6	2	5880	M	3382	15	15	0.25	4341	94.5	4595	18378			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5880	M	3429	16	15	0.25	9794	94.4	10375	41500	281.1	1943	7.753
6	2	5880	M	3430	16	15	0.25	9844	94.4	10425	41701			
6	2	5880	M	3477	17	15	0.25	3868	94.3	4101	16404	110.1	2114	8.436
6	2	5880	M	3478	17	15	0.25	3815	94.3	4045	16180			
6	2	5880	M	3525	18	15	0.25	6414	94.3	6799	27196	182.5	2042	8.147
6	2	5880	M	3526	18	15	0.25	6325	94.3	6704	26817			
6	2	5880	M	4216	19	15	0.25	7201	94.3	7636	30545	205.7	2019	8.054
6	2	5880	M	4217	19	15	0.25	7155	94.3	7584	30336			
6	2	5880	M	4264	20	15	0.25	8214	94.3	8715	34860	235.2	1989	7.936
6	2	5880	M	4265	20	15	0.25	8195	94.3	8691	34765			
6	2	5880	M	4312	21	15	0.25	3687	94.3	3909	15636	105.3	2119	8.455
6	2	5880	M	4313	21	15	0.25	3658	94.3	3880	15520			
6	2	5880	M	4360	22	15	0.25	3531	94.3	3745	14980	101.7	2123	8.469
6	2	5880	M	4361	22	15	0.25	3564	94.3	3779	15114			
6	2	5880	M	4408	23	15	0.25	4714	94.3	5000	20000	136.0	2088	8.332
6	2	5880	M	4409	23	15	0.25	4775	94.3	5066	20265			
6	2	5880	M	4456	24	15	0.25	7375	94.2	7829	31314	211.0	2013	8.033
6	2	5880	M	4457	24	15	0.25	7339	94.3	7783	31134			
6	2	5880	M	4645	25	15	0.25	6098	94.2	6476	25904	173.7	2051	8.182
6	2	5880	M	4646	25	15	0.25	6008	94.2	6378	25510			
6	2	5880	M	4693	26	15	0.25	3946	94.2	4189	16756	111.9	2112	8.428
6	2	5880	M	4694	26	15	0.25	3856	94.2	4092	16368			
6	2	5880	M	4725	27	15	0.25	6155	94.3	6530	26119	177.1	2047	8.168
6	2	5880	M	4726	27	15	0.25	6200	94.3	6577	26310			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5885	M	1722	0	15	0.25	3163	94.6	3343	13371	89.9	2135	8.518
6	2	5885	M	1723	0	15	0.25	3134	94.7	3310	13241			
6	2	5885	M	1786	1	15	0.25	2711	94.6	2866	11463	77.3	2147	8.568
6	2	5885	M	1787	1	15	0.25	2703	94.6	2858	11431			
6	2	5885	M	1884	2	15	0.25	2627	94.7	2774	11097	73.8	2151	8.582
6	2	5885	M	1885	2	15	0.25	2546	94.7	2689	10756			
6	2	5885	M	1980	3	15	0.25	3498	94.7	3695	14779	98.8	2126	8.482
6	2	5885	M	1981	3	15	0.25	3426	94.7	3619	14478			
6	2	5885	M	2076	4	15	0.25	3950	94.7	4172	16687	112.4	2112	8.428
6	2	5885	M	2077	4	15	0.25	3924	94.7	4146	16585			
6	2	5885	M	2183	5	15	0.25	4769	94.5	5045	20180	135.5	2089	8.336
6	2	5885	M	2184	5	15	0.25	4717	94.7	4981	19923			
6	2	5885	M	2279	6	15	0.25	7177	94.4	7604	30417	205.3	2020	8.058
6	2	5885	M	2280	6	15	0.25	7163	94.4	7584	30337			
6	2	5885	M	2375	7	15	0.25	4491	94.4	4755	19020	129.2	2130	8.500
6	2	5885	M	2376	7	15	0.25	4543	94.5	4808	19230			
6	2	5885	M	2471	8	15	0.25	6294	94.5	6657	26627	179.3	2080	8.300
6	2	5885	M	2472	8	15	0.25	6250	94.6	6608	26431			
6	2	5885	M	2569	9	15	0.25	6913	94.6	7308	29233	197.0	2063	8.229
6	2	5885	M	2570	9	15	0.25	6876	94.6	7267	29069			
6	2	5885	M	2665	10	15	0.25	4962	94.8	5236	20945	141.9	2118	8.449
6	2	5885	M	2666	10	15	0.25	4991	94.7	5268	21071			
6	2	5885	M	2761	11	15	0.25	7061	94.8	7452	29808	200.2	2059	8.216
6	2	5885	M	2762	11	15	0.25	6979	94.8	7366	29463			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5885	M	2857	12	15	0.25	3075	94.7	3249	12997	87.1	2172	8.667
6	2	5885	M	2858	12	15	0.25	3031	94.7	3199	12796			
6	2	5885	M	3255	13	15	0.25	4646	94.3	4926	19702	134.6	2125	8.478
6	2	5885	M	3256	13	15	0.25	4751	94.3	5037	20149			
6	2	5885	M	3319	14	15	0.25	5715	94.3	6059	24237	163.9	2060	8.221
6	2	5885	M	3320	14	15	0.25	5724	94.4	6066	24266			
6	2	5885	M	3383	15	15	0.25	5383	94.5	5698	22790	154.3	2070	8.259
6	2	5885	M	3384	15	15	0.25	5406	94.5	5723	22890			
6	2	5885	M	3431	16	15	0.25	4358	94.3	4619	18477	124.7	2100	8.377
6	2	5885	M	3432	16	15	0.25	4356	94.4	4612	18446			
6	2	5885	M	3479	17	15	0.25	3610	94.3	3827	15309	103.1	2121	8.464
6	2	5885	M	3480	17	15	0.25	3581	94.3	3799	15195			
6	2	5885	M	3527	18	15	0.25	4958	94.3	5257	21026	146.8	2078	8.289
6	2	5885	M	3528	18	15	0.25	5281	94.2	5605	22420			
6	2	5885	M	4218	19	15	0.25	6127	94.3	6497	25986	175.1	2049	8.176
6	2	5885	M	4219	19	15	0.25	6093	94.3	6461	25845			
6	2	5885	M	4266	20	15	0.25	5731	94.2	6083	24333	163.8	2060	8.221
6	2	5885	M	4267	20	15	0.25	5695	94.3	6042	24166			
6	2	5885	M	4314	21	15	0.25	11033	94.3	11699	46794	314.0	1910	7.622
6	2	5885	M	4315	21	15	0.25	10886	94.3	11541	46164			
6	2	5885	M	4362	22	15	0.25	3493	94.3	3702	14810	99.3	2125	8.479
6	2	5885	M	4363	22	15	0.25	3439	94.3	3647	14589			
6	2	5885	M	4410	23	15	0.25	4403	94.3	4669	18675	126.5	2098	8.370
6	2	5885	M	4411	23	15	0.25	4419	94.3	4689	18755			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5885	M	4458	24	15	0.25	6878	94.2	7300	29198	198.1	2026	8.084
6	2	5885	M	4459	24	15	0.25	6938	94.2	7361	29446			
6	2	5885	M	4647	25	15	0.25	6009	94.3	6374	25496	172.4	2052	8.187
6	2	5885	M	4648	25	15	0.25	6012	94.2	6380	25522			
6	2	5885	M	4695	26	15	0.25	2798	94.2	2969	11878	79.8	2145	8.556
6	2	5885	M	4696	26	15	0.25	2768	94.3	2937	11748			
6	2	5885	M	4727	27	15	0.25	3597	94.3	3815	15260	101.7	2123	8.469
6	2	5885	M	4728	27	15	0.25	3503	94.3	3714	14854			
6	2	5887	M	1724	0	15	0.25	2917	94.6	3085	12338	83.0	2142	8.546
6	2	5887	M	1725	0	15	0.25	2890	94.6	3054	12217			
6	2	5887	M	1788	1	15	0.25	2459	94.5	2602	10406	70.2	2155	8.597
6	2	5887	M	1789	1	15	0.25	2451	94.5	2593	10372			
6	2	5887	M	1886	2	15	0.25	3513	94.7	3709	14835	103.0	2122	8.466
6	2	5887	M	1887	2	15	0.25	3706	94.7	3911	15644			
6	2	5887	M	1982	3	15	0.25	2600	94.6	2747	10988	74.9	2150	8.578
6	2	5887	M	1983	3	15	0.25	2647	94.7	2796	11182			
6	2	5887	M	2078	4	15	0.25	4710	94.7	4976	19902	134.0	2091	8.342
6	2	5887	M	2079	4	15	0.25	4676	94.6	4944	19776			
6	2	5887	M	2185	5	15	0.25	8140	94.6	8608	34431	233.2	1992	7.946
6	2	5887	M	2186	5	15	0.25	8179	94.5	8652	34608			
6	2	5887	M	2281	6	15	0.25	6478	94.4	6861	27442	184.4	2040	8.141
6	2	5887	M	2282	6	15	0.25	6406	94.4	6786	27143			
6	2	5887	M	2377	7	15	0.25	4005	94.5	4237	16949	113.7	2146	8.562
6	2	5887	M	2378	7	15	0.25	3942	94.4	4173	16693			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5887	M	2473	8	15	0.25	5811	94.5	6147	24586	166.3	2093	8.351
6	2	5887	M	2474	8	15	0.25	5827	94.6	6162	24647			
6	2	5887	M	2571	9	15	0.25	12105	94.5	12812	51247	346.1	1913	7.634
6	2	5887	M	2572	9	15	0.25	12099	94.6	12796	51184			
6	2	5887	M	2667	10	15	0.25	3277	94.7	3460	13841	93.2	2166	8.643
6	2	5887	M	2668	10	15	0.25	3256	94.7	3438	13753			
6	2	5887	M	2763	11	15	0.25	4206	94.7	4442	17768	118.7	2141	8.541
6	2	5887	M	2764	11	15	0.25	4115	94.8	4342	17369			
6	2	5887	M	2859	12	15	0.25	5657	94.7	5972	23889	163.0	2096	8.365
6	2	5887	M	2860	12	15	0.25	5768	94.7	6089	24357			
6	2	5887	M	3257	13	15	0.25	2294	94.4	2430	9721	65.3	2194	8.754
6	2	5887	M	3258	13	15	0.25	2270	94.4	2405	9622			
6	2	5887	M	3321	14	15	0.25	6122	94.3	6489	25956	178.7	2046	8.162
6	2	5887	M	3322	14	15	0.25	6350	94.3	6732	26930			
6	2	5887	M	3385	15	15	0.25	5274	94.5	5581	22326	150.3	2074	8.275
6	2	5887	M	3386	15	15	0.25	5233	94.4	5542	22167			
6	2	5887	M	3433	16	15	0.25	5899	94.4	6245	24981	169.7	2055	8.198
6	2	5887	M	3434	16	15	0.25	5953	94.3	6314	25258			
6	2	5887	M	3481	17	15	0.25	5061	94.3	5368	21473	143.9	2080	8.301
6	2	5887	M	3482	17	15	0.25	4977	94.3	5278	21114			
6	2	5887	M	3529	18	15	0.25	4266	94.3	4526	18103	120.3	2104	8.395
6	2	5887	M	3530	18	15	0.25	4128	94.3	4380	17520			
6	2	5887	M	4220	19	15	0.25	10500	94.3	11134	44534	303.6	1921	7.663
6	2	5887	M	4221	19	15	0.25	10693	94.3	11336	45345			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5887	M	4268	20	15	0.25	4707	94.3	4992	19966	134.5	2090	8.338
6	2	5887	M	4269	20	15	0.25	4680	94.3	4965	19858			
6	2	5887	M	4316	21	15	0.25	3605	94.3	3823	15292	103.2	2121	8.463
6	2	5887	M	4317	21	15	0.25	3598	94.3	3817	15268			
6	2	5887	M	4364	22	15	0.25	3582	94.3	3799	15198	102.6	2122	8.465
6	2	5887	M	4365	22	15	0.25	3582	94.4	3796	15183			
6	2	5887	M	4412	23	15	0.25	3261	94.2	3460	13839	92.8	2132	8.505
6	2	5887	M	4413	23	15	0.25	3212	94.3	3407	13628			
6	2	5887	M	4460	24	15	0.25	5891	94.2	6254	25015	168.4	2056	8.203
6	2	5887	M	4461	24	15	0.25	5855	94.3	6210	24842			
6	2	5887	M	4649	25	15	0.25	4494	94.2	4771	19085	127.5	2097	8.366
6	2	5887	M	4650	25	15	0.25	4393	94.2	4663	18651			
6	2	5887	M	4697	26	15	0.25	3469	94.2	3682	14728	100.8	2123	8.472
6	2	5887	M	4698	26	15	0.25	3558	94.1	3780	15120			
6	2	5887	M	4729	27	15	0.25	2800	94.3	2969	11876	79.9	2144	8.556
6	2	5887	M	4730	27	15	0.25	2776	94.3	2945	11779			
6	2	5894	M	1726	0	15	0.25	2001	94.7	2114	8454	56.6	2168	8.651
6	2	5894	M	1727	0	15	0.25	1964	94.7	2073	8293			
6	2	5894	M	1790	1	15	0.25	3352	94.4	3550	14199	96.2	2129	8.493
6	2	5894	M	1791	1	15	0.25	3375	94.6	3569	14278			
6	2	5894	M	1888	2	15	0.25	3405	94.8	3592	14368	97.1	2128	8.489
6	2	5894	M	1889	2	15	0.25	3403	94.7	3592	14368			
6	2	5894	M	1984	3	15	0.25	3476	94.7	3672	14689	98.7	2126	8.483
6	2	5894	M	1985	3	15	0.25	3435	94.7	3629	14514			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5894	M	2080	4	15	0.25	5509	94.7	5817	23268	156.9	2068	8.251
6	2	5894	M	2081	4	15	0.25	5484	94.7	5793	23172			
6	2	5894	M	2187	5	15	0.25	4762	94.6	5036	20145	136.1	2089	8.333
6	2	5894	M	2188	5	15	0.25	4765	94.6	5037	20150			
6	2	5894	M	2283	6	15	0.25	7979	94.4	8456	33824	227.3	1997	7.970
6	2	5894	M	2284	6	15	0.25	7897	94.4	8366	33465			
6	2	5894	M	2379	7	15	0.25	4880	94.4	5166	20665	138.9	2121	8.461
6	2	5894	M	2380	7	15	0.25	4827	94.5	5109	20434			
6	2	5894	M	2475	8	15	0.25	5175	94.6	5468	21873	147.4	2112	8.427
6	2	5894	M	2476	8	15	0.25	5142	94.6	5437	21749			
6	2	5894	M	2573	9	15	0.25	5776	94.5	6109	24436	165.3	2094	8.356
6	2	5894	M	2574	9	15	0.25	5782	94.5	6120	24480			
6	2	5894	M	2669	10	15	0.25	3553	94.6	3754	15016	101.6	2158	8.610
6	2	5894	M	2670	10	15	0.25	3563	94.7	3762	15050			
6	2	5894	M	2765	11	15	0.25	3339	94.8	3524	14095	96.7	2163	8.629
6	2	5894	M	2766	11	15	0.25	3437	94.7	3630	14518			
6	2	5894	M	2861	12	15	0.25	2962	94.7	3129	12514	84.8	2175	8.677
6	2	5894	M	2862	12	15	0.25	2980	94.7	3147	12587			
6	2	5894	M	3259	13	15	0.25	4473	94.4	4740	18961	128.0	2131	8.504
6	2	5894	M	3260	13	15	0.25	4467	94.3	4735	18941			
6	2	5894	M	3323	14	15	0.25	6153	94.3	6522	26089	175.7	2049	8.174
6	2	5894	M	3324	14	15	0.25	6113	94.3	6483	25931			
6	2	5894	M	3387	15	15	0.25	3492	94.5	3696	14785	100.0	2124	8.476
6	2	5894	M	3388	15	15	0.25	3504	94.5	3707	14828			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5894	M	3435	16	15	0.25	4265	94.3	4524	18095	122.8	2102	8.385
6	2	5894	M	3436	16	15	0.25	4301	94.3	4562	18249			
6	2	5894	M	3483	17	15	0.25	4425	94.3	4693	18773	126.2	2098	8.371
6	2	5894	M	3484	17	15	0.25	4379	94.3	4645	18578			
6	2	5894	M	3531	18	15	0.25	5612	94.3	5954	23816	160.1	2064	8.236
6	2	5894	M	3532	18	15	0.25	5557	94.3	5893	23570			
6	2	5894	M	4222	19	15	0.25	6480	94.3	6869	27476	181.8	2043	8.150
6	2	5894	M	4223	19	15	0.25	6206	94.3	6582	26329			
6	2	5894	M	4270	20	15	0.25	5653	94.2	6000	24001	162.4	2062	8.227
6	2	5894	M	4271	20	15	0.25	5675	94.3	6018	24070			
6	2	5894	M	4318	21	15	0.25	3884	94.3	4120	16481	110.4	2114	8.434
6	2	5894	M	4319	21	15	0.25	3814	94.2	4048	16190			
6	2	5894	M	4366	22	15	0.25	3790	94.3	4017	16069	108.1	2116	8.443
6	2	5894	M	4367	22	15	0.25	3757	94.3	3983	15933			
6	2	5894	M	4414	23	15	0.25	3468	94.2	3679	14718	99.2	2125	8.479
6	2	5894	M	4415	23	15	0.25	3450	94.2	3663	14651			
6	2	5894	M	4462	24	15	0.25	6680	94.2	7094	28376	190.8	2034	8.113
6	2	5894	M	4463	24	15	0.25	6620	94.2	7026	28104			
6	2	5894	M	4651	25	15	0.25	8171	94.2	8673	34692	234.5	1990	7.939
6	2	5894	M	4652	25	15	0.25	8173	94.2	8677	34707			
6	2	5894	M	4699	26	15	0.25	3204	94.2	3402	13609	91.8	2133	8.509
6	2	5894	M	4700	26	15	0.25	3192	94.2	3390	13559			
6	2	5894	M	4731	27	15	0.25	5490	94.3	5825	23299	156.0	2068	8.252
6	2	5894	M	4732	27	15	0.25	5392	94.2	5722	22888			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5903	F	1728	0	15	0.25	2528	94.7	2671	10685	72.1	2153	8.589
6	2	5903	F	1729	0	15	0.25	2523	94.6	2666	10666			
6	2	5903	F	1792	1	15	0.25	2396	94.6	2534	10136	68.2	2157	8.605
6	2	5903	F	1793	1	15	0.25	2374	94.5	2513	10051			
6	2	5903	F	1890	2	15	0.25	2884	94.7	3047	12187	79.2	2146	8.561
6	2	5903	F	1891	2	15	0.25	2665	94.7	2815	11259			
6	2	5903	F	1986	3	15	0.25	2173	94.6	2296	9184	59.9	2165	8.638
6	2	5903	F	1987	3	15	0.25	2022	94.7	2136	8543			
6	2	5903	F	2082	4	15	0.25	3958	94.7	4180	16722	112.7	2112	8.427
6	2	5903	F	2083	4	15	0.25	3937	94.7	4158	16634			
6	2	5903	F	2189	5	15	0.25	5435	94.6	5749	22996	155.0	2070	8.258
6	2	5903	F	2190	5	15	0.25	5414	94.7	5719	22877			
6	2	5903	F	2285	6	15	0.25	6382	94.4	6760	27039	184.6	2040	8.140
6	2	5903	F	2286	6	15	0.25	6514	94.4	6898	27590			
6	2	5903	F	2381	7	15	0.25	5003	94.5	5295	21179	142.0	2117	8.448
6	2	5903	F	2382	7	15	0.25	4928	94.5	5215	20861			
6	2	5903	F	2477	8	15	0.25	5970	94.6	6312	25247	169.7	2090	8.338
6	2	5903	F	2478	8	15	0.25	5911	94.6	6247	24988			
6	2	5903	F	2575	9	15	0.25	7796	94.6	8244	32977	223.1	2036	8.125
6	2	5903	F	2576	9	15	0.25	7817	94.6	8266	33064			
6	2	5903	F	2671	10	15	0.25	3073	94.7	3245	12979	87.9	2172	8.665
6	2	5903	F	2672	10	15	0.25	3085	94.7	3258	13031			
6	2	5903	F	2767	11	15	0.25	3305	94.7	3489	13957	94.4	2165	8.638
6	2	5903	F	2768	11	15	0.25	3315	94.8	3498	13990			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5903	F	2863	12	15	0.25	2172	94.8	2292	9167	61.2	2198	8.771
6	2	5903	F	2864	12	15	0.25	2117	94.8	2234	8938			
6	2	5903	F	3261	13	15	0.25	5268	94.3	5585	22338	150.5	2109	8.415
6	2	5903	F	3262	13	15	0.25	5240	94.3	5554	22216			
6	2	5903	F	3325	14	15	0.25	4881	94.3	5174	20697	141.3	2083	8.311
6	2	5903	F	3326	14	15	0.25	4981	94.3	5281	21125			
6	2	5903	F	3389	15	15	0.25	3590	94.4	3803	15210	102.5	2122	8.466
6	2	5903	F	3390	15	15	0.25	3574	94.4	3784	15137			
6	2	5903	F	3437	16	15	0.25	3030	94.3	3214	12854	87.2	2137	8.527
6	2	5903	F	3438	16	15	0.25	3058	94.4	3241	12963			
6	2	5903	F	3485	17	15	0.25	3429	94.2	3639	14557	98.7	2126	8.481
6	2	5903	F	3486	17	15	0.25	3456	94.2	3667	14670			
6	2	5903	F	3533	18	15	0.25	5364	94.3	5688	22752	152.5	2072	8.266
6	2	5903	F	3534	18	15	0.25	5277	94.3	5595	22378			
6	2	5903	F	4224	19	15	0.25	7067	94.3	7494	29978	205.4	2019	8.055
6	2	5903	F	4225	19	15	0.25	7259	94.3	7702	30808			
6	2	5903	F	4272	20	15	0.25	5684	94.3	6031	24125	163.7	2061	8.221
6	2	5903	F	4273	20	15	0.25	5737	94.3	6085	24342			
6	2	5903	F	4320	21	15	0.25	3688	94.3	3911	15646	105.8	2118	8.452
6	2	5903	F	4321	21	15	0.25	3698	94.3	3921	15685			
6	2	5903	F	4368	22	15	0.25	3009	94.3	3190	12760	86.2	2138	8.531
6	2	5903	F	4369	22	15	0.25	3009	94.3	3191	12763			
6	2	5903	F	4416	23	15	0.25	3062	94.2	3249	12995	87.3	2137	8.526
6	2	5903	F	4417	23	15	0.25	3028	94.3	3213	12850			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5903	F	4464	24	15	0.25	5430	94.3	5760	23040	155.0	2069	8.256
6	2	5903	F	4465	24	15	0.25	5382	94.3	5711	22844			
6	2	5903	F	4653	25	15	0.25	4924	94.3	5223	20894	139.9	2084	8.316
6	2	5903	F	4654	25	15	0.25	4835	94.2	5133	20531			
6	2	5903	F	4701	26	15	0.25	5594	94.2	5939	23758	160.1	2064	8.236
6	2	5903	F	4702	26	15	0.25	5566	94.2	5911	23646			
6	2	5903	F	4733	27	15	0.25	4576	94.2	4856	19426	129.7	2095	8.357
6	2	5903	F	4734	27	15	0.25	4470	94.2	4744	18976			
6	2	5912	F	1730	0	15	0.25	2203	94.7	2328	9310	62.9	2162	8.626
6	2	5912	F	1731	0	15	0.25	2201	94.6	2327	9306			
6	2	5912	F	1794	1	15	0.25	4109	94.5	4348	17390	117.4	2107	8.408
6	2	5912	F	1795	1	15	0.25	4100	94.5	4337	17346			
6	2	5912	F	1892	2	15	0.25	2687	94.8	2835	11342	74.8	2150	8.578
6	2	5912	F	1893	2	15	0.25	2559	94.7	2701	10804			
6	2	5912	F	1988	3	15	0.25	2123	94.7	2242	8966	60.9	2164	8.634
6	2	5912	F	1989	3	15	0.25	2146	94.6	2268	9070			
6	2	5912	F	2084	4	15	0.25	4490	94.7	4742	18968	128.8	2096	8.363
6	2	5912	F	2085	4	15	0.25	4537	94.7	4791	19164			
6	2	5912	F	2191	5	15	0.25	4838	94.6	5117	20467	138.2	2087	8.325
6	2	5912	F	2192	5	15	0.25	4832	94.5	5112	20446			
6	2	5912	F	2287	6	15	0.25	5361	94.4	5681	22725	153.8	2071	8.263
6	2	5912	F	2288	6	15	0.25	5379	94.4	5696	22786			
6	2	5912	F	2383	7	15	0.25	3447	94.5	3649	14596	98.3	2161	8.623
6	2	5912	F	2384	7	15	0.25	3427	94.4	3628	14513			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5912	F	2479	8	15	0.25	4110	94.6	4344	17376	116.0	2143	8.552
6	2	5912	F	2480	8	15	0.25	4012	94.6	4243	16973			
6	2	5912	F	2577	9	15	0.25	6617	94.6	6998	27990	188.8	2071	8.262
6	2	5912	F	2578	9	15	0.25	6592	94.6	6972	27887			
6	2	5912	F	2673	10	15	0.25	4106	94.7	4334	17338	117.5	2142	8.546
6	2	5912	F	2674	10	15	0.25	4133	94.7	4362	17450			
6	2	5912	F	2769	11	15	0.25	4150	94.7	4382	17529	118.4	2141	8.543
6	2	5912	F	2770	11	15	0.25	4152	94.7	4383	17530			
6	2	5912	F	2865	12	15	0.25	3092	94.8	3263	13050	89.0	2170	8.660
6	2	5912	F	2866	12	15	0.25	3152	94.8	3325	13302			
6	2	5912	F	3263	13	15	0.25	5879	94.3	6234	24937	167.6	2092	8.346
6	2	5912	F	3264	13	15	0.25	5812	94.3	6166	24665			
6	2	5912	F	3327	14	15	0.25	6050	94.3	6416	25666	172.5	2052	8.187
6	2	5912	F	3328	14	15	0.25	5988	94.3	6349	25395			
6	2	5912	F	3391	15	15	0.25	4297	94.4	4550	18202	122.7	2102	8.385
6	2	5912	F	3392	15	15	0.25	4275	94.5	4526	18103			
6	2	5912	F	3439	16	15	0.25	4075	94.3	4322	17290	115.9	2108	8.412
6	2	5912	F	3440	16	15	0.25	4016	94.3	4257	17028			
6	2	5912	F	3487	17	15	0.25	3171	94.3	3364	13456	91.9	2132	8.508
6	2	5912	F	3488	17	15	0.25	3239	94.2	3437	13746			
6	2	5912	F	3535	18	15	0.25	3430	94.3	3637	14549	96.3	2128	8.490
6	2	5912	F	3536	18	15	0.25	3293	94.3	3492	13970			
6	2	5912	F	4226	19	15	0.25	10419	94.3	11054	44216	304.4	1920	7.660
6	2	5912	F	4227	19	15	0.25	10802	94.2	11471	45886			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5912	F	4274	20	15	0.25	5673	94.3	6019	24076	163.9	2060	8.221
6	2	5912	F	4275	20	15	0.25	5756	94.3	6106	24424			
6	2	5912	F	4322	21	15	0.25	4287	94.3	4549	18194	122.3	2102	8.387
6	2	5912	F	4323	21	15	0.25	4239	94.2	4498	17992			
6	2	5912	F	4370	22	15	0.25	2228	94.3	2362	9447	64.1	2160	8.619
6	2	5912	F	4371	22	15	0.25	2247	94.3	2382	9529			
6	2	5912	F	4418	23	15	0.25	3316	94.2	3520	14081	94.2	2130	8.499
6	2	5912	F	4419	23	15	0.25	3256	94.3	3454	13815			
6	2	5912	F	4466	24	15	0.25	6884	94.2	7306	29226	198.6	2026	8.082
6	2	5912	F	4467	24	15	0.25	6968	94.3	7391	29563			
6	2	5912	F	4655	25	15	0.25	7730	94.2	8205	32818	223.3	2001	7.984
6	2	5912	F	4656	25	15	0.25	7839	94.2	8319	33276			
6	2	5912	F	4703	26	15	0.25	3944	94.2	4186	16744	113.1	2111	8.424
6	2	5912	F	4704	26	15	0.25	3940	94.2	4181	16726			
6	2	5912	F	4735	27	15	0.25	4312	94.3	4575	18300	121.8	2102	8.389
6	2	5912	F	4736	27	15	0.25	4188	94.3	4442	17767			
6	2	5917	F	1732	0	15	0.25	3782	94.6	3997	15988	107.8	2117	8.446
6	2	5917	F	1733	0	15	0.25	3767	94.6	3981	15925			
6	2	5917	F	1796	1	15	0.25	2448	94.5	2590	10360	70.6	2154	8.595
6	2	5917	F	1797	1	15	0.25	2487	94.5	2631	10525			
6	2	5917	F	1894	2	15	0.25	2829	94.7	2988	11953	86.5	2138	8.532
6	2	5917	F	1895	2	15	0.25	3230	94.7	3410	13638			
6	2	5917	F	1990	3	15	0.25	2374	94.7	2508	10032	67.8	2157	8.606
6	2	5917	F	1991	3	15	0.25	2376	94.7	2508	10033			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5917	F	2086	4	15	0.25	6519	94.7	6888	27550	186.2	2039	8.134
6	2	5917	F	2087	4	15	0.25	6518	94.6	6889	27557			
6	2	5917	F	2193	5	15	0.25	6806	94.6	7198	28793	192.3	2032	8.109
6	2	5917	F	2194	5	15	0.25	6648	94.6	7031	28123			
6	2	5917	F	2289	6	15	0.25	6312	94.4	6685	26739	180.9	2044	8.155
6	2	5917	F	2290	6	15	0.25	6324	94.3	6703	26814			
6	2	5917	F	2385	7	15	0.25	3521	94.5	3726	14903	100.1	2159	8.616
6	2	5917	F	2386	7	15	0.25	3482	94.5	3685	14741			
6	2	5917	F	2481	8	15	0.25	7062	94.6	7465	29859	203.0	2057	8.205
6	2	5917	F	2482	8	15	0.25	7145	94.6	7555	30220			
6	2	5917	F	2579	9	15	0.25	5907	94.5	6249	24994	168.6	2091	8.342
6	2	5917	F	2580	9	15	0.25	5888	94.5	6228	24911			
6	2	5917	F	2675	10	15	0.25	2005	94.7	2117	8470	57.0	2202	8.787
6	2	5917	F	2676	10	15	0.25	1993	94.7	2104	8416			
6	2	5917	F	2771	11	15	0.25	3431	94.8	3620	14480	96.3	2163	8.631
6	2	5917	F	2772	11	15	0.25	3320	94.7	3506	14024			
6	2	5917	F	2867	12	15	0.25	3143	94.8	3316	13265	88.9	2171	8.661
6	2	5917	F	2868	12	15	0.25	3088	94.8	3259	13036			
6	2	5917	F	3265	13	15	0.25	3165	94.3	3355	13418	90.3	2169	8.655
6	2	5917	F	3266	13	15	0.25	3141	94.3	3330	13320			
6	2	5917	F	3329	14	15	0.25	3505	94.3	3716	14864	102.1	2122	8.468
6	2	5917	F	3330	14	15	0.25	3619	94.3	3837	15349			
6	2	5917	F	3393	15	15	0.25	4395	94.4	4656	18625	125.1	2099	8.376
6	2	5917	F	3394	15	15	0.25	4343	94.4	4600	18399			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5917	F	3441	16	15	0.25	4252	94.3	4507	18030	121.9	2102	8.388
6	2	5917	F	3442	16	15	0.25	4255	94.3	4514	18054			
6	2	5917	F	3489	17	15	0.25	5449	94.3	5779	23118	156.4	2068	8.251
6	2	5917	F	3490	17	15	0.25	5458	94.2	5792	23167			
6	2	5917	F	3537	18	15	0.25	11608	94.3	12313	49251	332.1	1892	7.550
6	2	5917	F	3538	18	15	0.25	11558	94.2	12265	49061			
6	2	5917	F	4228	19	15	0.25	6938	94.2	7366	29465	197.5	2027	8.087
6	2	5917	F	4229	19	15	0.25	6830	94.2	7247	28989			
6	2	5917	F	4276	20	15	0.25	4247	94.3	4505	18019	121.4	2103	8.390
6	2	5917	F	4277	20	15	0.25	4226	94.3	4481	17926			
6	2	5917	F	4324	21	15	0.25	3506	94.3	3719	14875	100.2	2124	8.475
6	2	5917	F	4325	21	15	0.25	3486	94.2	3699	14798			
6	2	5917	F	4372	22	15	0.25	1890	94.3	2004	8017	53.9	2170	8.660
6	2	5917	F	4373	22	15	0.25	1871	94.3	1984	7937			
6	2	5917	F	4420	23	15	0.25	2961	94.2	3143	12572	84.2	2140	8.539
6	2	5917	F	4421	23	15	0.25	2907	94.2	3085	12340			
6	2	5917	F	4468	24	15	0.25	11341	94.2	12038	48150	323.2	1901	7.585
6	2	5917	F	4469	24	15	0.25	11185	94.2	11877	47509			
6	2	5917	F	4657	25	15	0.25	9891	94.2	10498	41991	285.0	1939	7.738
6	2	5917	F	4658	25	15	0.25	9980	94.2	10593	42374			
6	2	5917	F	4705	26	15	0.25	3103	94.2	3294	13176	87.5	2137	8.526
6	2	5917	F	4706	26	15	0.25	2997	94.2	3181	12724			
6	2	5917	F	4737	27	15	0.25	3808	94.2	4041	16164	110.2	2114	8.435
6	2	5917	F	4738	27	15	0.25	3879	94.3	4115	16461			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5919	F	1734	0	15	0.25	2744	94.6	2900	11602	78.7	2146	8.562
6	2	5919	F	1735	0	15	0.25	2769	94.6	2927	11708			
6	2	5919	F	1798	1	15	0.25	2582	94.6	2730	10921	73.8	2151	8.582
6	2	5919	F	1799	1	15	0.25	2584	94.5	2734	10938			
6	2	5919	F	1896	2	15	0.25	4300	94.7	4538	18153	124.9	2100	8.378
6	2	5919	F	1897	2	15	0.25	4454	94.7	4705	18820			
6	2	5919	F	1992	3	15	0.25	1325	94.5	1401	5605	39.4	2185	8.719
6	2	5919	F	1993	3	15	0.25	1434	94.6	1516	6063			
6	2	5919	F	2088	4	15	0.25	4701	94.7	4967	19868	134.1	2091	8.341
6	2	5919	F	2089	4	15	0.25	4693	94.6	4959	19836			
6	2	5919	F	2195	5	15	0.25	3833	94.6	4053	16210	109.9	2115	8.438
6	2	5919	F	2196	5	15	0.25	3861	94.7	4080	16318			
6	2	5919	F	2291	6	15	0.25	6954	94.4	7364	29457	199.2	2026	8.082
6	2	5919	F	2292	6	15	0.25	6959	94.4	7374	29496			
6	2	5919	F	2387	7	15	0.25	3521	94.5	3726	14905	100.5	2159	8.614
6	2	5919	F	2388	7	15	0.25	3505	94.5	3710	14839			
6	2	5919	F	2483	8	15	0.25	4307	94.6	4553	18213	122.3	2137	8.527
6	2	5919	F	2484	8	15	0.25	4255	94.6	4498	17990			
6	2	5919	F	2581	9	15	0.25	6415	94.6	6785	27140	184.4	2075	8.280
6	2	5919	F	2582	9	15	0.25	6479	94.5	6858	27431			
6	2	5919	F	2677	10	15	0.25	3016	94.7	3185	12741	85.4	2174	8.674
6	2	5919	F	2678	10	15	0.25	2972	94.7	3138	12551			
6	2	5919	F	2773	11	15	0.25	5787	94.7	6109	24435	166.8	2093	8.350
6	2	5919	F	2774	11	15	0.25	5905	94.8	6232	24929			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5919	F	2869	12	15	0.25	2679	94.7	2828	11312	75.8	2184	8.713
6	2	5919	F	2870	12	15	0.25	2632	94.7	2778	11112			
6	2	5919	F	3267	13	15	0.25	3654	94.3	3875	15499	104.8	2155	8.597
6	2	5919	F	3268	13	15	0.25	3663	94.3	3883	15533			
6	2	5919	F	3331	14	15	0.25	4913	94.3	5210	20839	141.7	2083	8.309
6	2	5919	F	3332	14	15	0.25	4977	94.3	5277	21107			
6	2	5919	F	3395	15	15	0.25	3004	94.5	3180	12720	86.2	2138	8.531
6	2	5919	F	3396	15	15	0.25	3021	94.5	3197	12788			
6	2	5919	F	3443	16	15	0.25	4323	94.3	4585	18339	122.6	2102	8.386
6	2	5919	F	3444	16	15	0.25	4234	94.3	4490	17958			
6	2	5919	F	3491	17	15	0.25	5979	94.2	6345	25379	171.1	2053	8.192
6	2	5919	F	3492	17	15	0.25	5953	94.2	6317	25267			
6	2	5919	F	3539	18	15	0.25	3074	94.2	3262	13048	86.4	2138	8.530
6	2	5919	F	3540	18	15	0.25	2949	94.2	3130	12518			
6	2	5919	F	4230	19	15	0.25	4151	94.2	4405	17618	119.3	2105	8.399
6	2	5919	F	4231	19	15	0.25	4168	94.2	4424	17694			
6	2	5919	F	4278	20	15	0.25	5233	94.2	5554	22218	150.2	2074	8.276
6	2	5919	F	4279	20	15	0.25	5239	94.2	5559	22237			
6	2	5919	F	4326	21	15	0.25	4597	94.3	4877	19507	130.3	2094	8.355
6	2	5919	F	4327	21	15	0.25	4495	94.3	4765	19061			
6	2	5919	F	4374	22	15	0.25	2065	94.3	2189	8757	58.4	2166	8.642
6	2	5919	F	4375	22	15	0.25	2012	94.3	2132	8528			
6	2	5919	F	4422	23	15	0.25	2410	94.2	2557	10228	69.6	2155	8.597
6	2	5919	F	4423	23	15	0.25	2446	94.3	2595	10378			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
6	2	5919	F	4470	24	15	0.25	6414	94.2	6813	27252	183.2	2041	8.144
6	2	5919	F	4471	24	15	0.25	6351	94.2	6741	26963			
6	2	5919	F	4659	25	15	0.25	7239	94.2	7684	30736	206.9	2017	8.049
6	2	5919	F	4660	25	15	0.25	7186	94.2	7628	30512			
6	2	5919	F	4707	26	15	0.25	2664	94.2	2829	11315	76.0	2148	8.571
6	2	5919	F	4708	26	15	0.25	2637	94.2	2799	11195			
6	2	5919	F	4739	27	15	0.25	4806	94.2	5099	20398	137.2	2087	8.327
6	2	5919	F	4740	27	15	0.25	4766	94.3	5056	20223			
7	2	5878	M	1816	0	15	0.25	3304	94.6	3492	13968	94.9	2079	24.881
7	2	5878	M	1817	0	15	0.25	3343	94.7	3531	14124			
7	2	5878	M	1914	1	15	0.25	2912	94.7	3076	12305	83.0	2091	25.023
7	2	5878	M	1915	1	15	0.25	2906	94.7	3068	12273			
7	2	5878	M	2010	2	15	0.25	3513	94.7	3712	14847	100.5	2073	24.815
7	2	5878	M	2011	2	15	0.25	3522	94.6	3722	14889			
7	2	5878	M	2106	3	15	0.25	3653	94.7	3857	15429	104.7	2069	24.765
7	2	5878	M	2107	3	15	0.25	3683	94.7	3888	15552			
7	2	5878	M	2213	4	15	0.25	5424	94.5	5742	22968	154.5	2019	24.168
7	2	5878	M	2214	4	15	0.25	5373	94.4	5690	22760			
7	2	5878	M	2309	5	15	0.25	4228	94.3	4483	17934	121.4	2052	24.564
7	2	5878	M	2310	5	15	0.25	4245	94.3	4504	18015			
7	2	5878	M	2405	6	15	0.25	2974	94.5	3146	12584	86.0	2088	24.988
7	2	5878	M	2406	6	15	0.25	3044	94.5	3220	12881			
7	2	5878	M	2501	7	15	0.25	5693	94.6	6018	24070	162.8	2045	24.475
7	2	5878	M	2502	7	15	0.25	5704	94.6	6032	24127			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5878	M	2599	8	15	0.25	8409	94.5	8895	35581	237.8	1970	23.579
7	2	5878	M	2600	8	15	0.25	8224	94.5	8699	34796			
7	2	5878	M	2695	9	15	0.25	3543	94.7	3742	14966	101.5	2106	25.210
7	2	5878	M	2696	9	15	0.25	3566	94.6	3768	15071			
7	2	5878	M	2791	10	15	0.25	6429	94.7	6788	27154	181.9	2026	24.248
7	2	5878	M	2792	10	15	0.25	6319	94.7	6670	26680			
7	2	5878	M	2887	11	15	0.25	2815	94.4	2983	11933	81.3	2126	25.452
7	2	5878	M	2888	11	15	0.25	2860	94.4	3031	12123			
7	2	5878	M	3285	12	15	0.25	1849	94.3	1961	7843	52.6	2155	25.795
7	2	5878	M	3286	12	15	0.25	1818	94.3	1928	7711			
7	2	5878	M	3349	13	15	0.25	7184	94.3	7619	30477	207.3	2000	23.943
7	2	5878	M	3350	13	15	0.25	7281	94.3	7720	30881			
7	2	5878	M	3397	14	15	0.25	3606	94.4	3819	15275	102.7	2116	25.323
7	2	5878	M	3398	14	15	0.25	3570	94.4	3780	15119			
7	2	5878	M	3445	15	15	0.25	8248	94.3	8749	34994	238.0	1980	23.703
7	2	5878	M	3446	15	15	0.25	8361	94.3	8867	35469			
7	2	5878	M	3493	16	15	0.25	4436	94.3	4705	18820	125.9	2092	25.045
7	2	5878	M	3494	16	15	0.25	4352	94.3	4615	18460			
7	2	5878	M	3541	17	15	0.25	5628	94.3	5970	23880	156.7	2062	24.677
7	2	5878	M	3542	17	15	0.25	5301	94.3	5624	22494			
7	2	5878	M	4232	18	15	0.25	6917	94.3	7339	29358	199.8	2018	24.160
7	2	5878	M	4233	18	15	0.25	7022	94.3	7449	29795			
7	2	5878	M	4280	19	15	0.25	8931	94.3	9476	37905	253.1	1965	23.523
7	2	5878	M	4281	19	15	0.25	8723	94.3	9254	37015			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5878	M	4328	20	15	0.25	4575	94.3	4851	19403	130.7	2088	24.988
7	2	5878	M	4329	20	15	0.25	4546	94.3	4819	19275			
7	2	5878	M	4376	21	15	0.25	4436	94.4	4700	18801	127.2	2091	25.030
7	2	5878	M	4377	21	15	0.25	4440	94.3	4710	18839			
7	2	5878	M	4424	22	15	0.25	3366	94.2	3573	14291	97.0	2121	25.391
7	2	5878	M	4425	22	15	0.25	3398	94.3	3605	14418			
7	2	5878	M	4472	23	15	0.25	11076	94.2	11760	47039	314.6	1904	22.787
7	2	5878	M	4473	23	15	0.25	10859	94.3	11520	46079			
7	2	5878	M	4661	24	15	0.25	9325	94.3	9890	39561	267.1	1951	23.355
7	2	5878	M	4662	24	15	0.25	9312	94.3	9876	39502			
7	2	5878	M	4709	25	15	0.25	4366	94.3	4633	18530	122.8	2095	25.082
7	2	5878	M	4710	25	15	0.25	4201	94.3	4457	17827			
7	2	5878	M	4741	26	15	0.25	3401	94.3	3607	14427	97.7	2121	25.383
7	2	5878	M	4742	26	15	0.25	3417	94.3	3624	14495			
7	2	5878	M	4757	27	15	0.25	4600	94.2	4881	19525	131.9	2086	24.973
7	2	5878	M	4758	27	15	0.25	4600	94.3	4880	19518			
7	2	5886	M	1818	0	15	0.25	3173	94.8	3348	13394	91.0	2083	24.929
7	2	5886	M	1819	0	15	0.25	3205	94.7	3383	13532			
7	2	5886	M	1916	1	15	0.25	3450	94.7	3642	14570	95.0	2079	24.881
7	2	5886	M	1917	1	15	0.25	3208	94.8	3384	13536			
7	2	5886	M	2012	2	15	0.25	4669	94.7	4932	19728	133.1	2040	24.424
7	2	5886	M	2013	2	15	0.25	4656	94.7	4919	19677			
7	2	5886	M	2108	3	15	0.25	4418	94.7	4667	18670	126.1	2048	24.508
7	2	5886	M	2109	3	15	0.25	4418	94.7	4664	18656			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5886	M	2215	4	15	0.25	5846	94.5	6187	24750	166.7	2007	24.022
7	2	5886	M	2216	4	15	0.25	5811	94.5	6147	24589			
7	2	5886	M	2311	5	15	0.25	4400	94.2	4670	18678	126.3	2047	24.506
7	2	5886	M	2312	5	15	0.25	4406	94.2	4675	18700			
7	2	5886	M	2407	6	15	0.25	3500	94.6	3699	14798	99.8	2074	24.823
7	2	5886	M	2408	6	15	0.25	3487	94.6	3687	14747			
7	2	5886	M	2503	7	15	0.25	3111	94.6	3288	13152	86.2	2121	25.392
7	2	5886	M	2504	7	15	0.25	2927	94.6	3094	12374			
7	2	5886	M	2601	8	15	0.25	8023	94.5	8492	33969	227.7	1980	23.699
7	2	5886	M	2602	8	15	0.25	7901	94.5	8360	33440			
7	2	5886	M	2697	9	15	0.25	4435	94.7	4682	18728	127.1	2081	24.903
7	2	5886	M	2698	9	15	0.25	4471	94.7	4722	18888			
7	2	5886	M	2793	10	15	0.25	7235	94.7	7640	30561	204.3	2003	23.980
7	2	5886	M	2794	10	15	0.25	7084	94.8	7474	29897			
7	2	5886	M	2889	11	15	0.25	4125	94.4	4369	17477	119.3	2088	24.997
7	2	5886	M	2890	11	15	0.25	4209	94.4	4456	17824			
7	2	5886	M	3287	12	15	0.25	3300	94.3	3498	13994	94.3	2113	25.296
7	2	5886	M	3288	12	15	0.25	3281	94.3	3479	13915			
7	2	5886	M	3351	13	15	0.25	9060	94.3	9608	38432	259.0	1949	23.324
7	2	5886	M	3352	13	15	0.25	9019	94.3	9560	38241			
7	2	5886	M	3399	14	15	0.25	1678	94.4	1778	7112	48.2	2170	25.975
7	2	5886	M	3400	14	15	0.25	1689	94.5	1788	7153			
7	2	5886	M	3447	15	15	0.25	6183	94.3	6558	26232	177.3	2041	24.429
7	2	5886	M	3448	15	15	0.25	6193	94.3	6566	26263			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5886	M	3495	16	15	0.25	4188	94.3	4444	17775	120.6	2098	25.109
7	2	5886	M	3496	16	15	0.25	4220	94.3	4478	17911			
7	2	5886	M	3543	17	15	0.25	3246	94.3	3444	13774	90.6	2128	25.468
7	2	5886	M	3544	17	15	0.25	3072	94.2	3260	13040			
7	2	5886	M	4234	18	15	0.25	8888	94.3	9424	37698	251.0	1967	23.548
7	2	5886	M	4235	18	15	0.25	8626	94.3	9150	36598			
7	2	5886	M	4282	19	15	0.25	5368	94.3	5695	22782	153.5	2065	24.715
7	2	5886	M	4283	19	15	0.25	5342	94.3	5666	22663			
7	2	5886	M	4330	20	15	0.25	4328	94.3	4589	18358	125.2	2093	25.054
7	2	5886	M	4331	20	15	0.25	4404	94.2	4674	18696			
7	2	5886	M	4378	21	15	0.25	3422	94.3	3629	14514	96.9	2121	25.392
7	2	5886	M	4379	21	15	0.25	3342	94.3	3543	14171			
7	2	5886	M	4426	22	15	0.25	3092	94.2	3281	13125	88.5	2130	25.493
7	2	5886	M	4427	22	15	0.25	3080	94.3	3267	13069			
7	2	5886	M	4474	23	15	0.25	8898	94.2	9446	37783	256.0	1962	23.488
7	2	5886	M	4475	23	15	0.25	8949	94.2	9498	37992			
7	2	5886	M	4663	24	15	0.25	8788	94.2	9331	37325	257.3	1961	23.472
7	2	5886	M	4664	24	15	0.25	9152	94.3	9710	38840			
7	2	5886	M	4711	25	15	0.25	3229	94.3	3425	13698	92.1	2126	25.450
7	2	5886	M	4712	25	15	0.25	3200	94.3	3392	13569			
7	2	5886	M	4743	26	15	0.25	3610	94.3	3829	15318	102.5	2116	25.325
7	2	5886	M	4744	26	15	0.25	3543	94.3	3758	15030			
7	2	5886	M	4759	27	15	0.25	3799	94.2	4031	16123	108.8	2109	25.249
7	2	5886	M	4760	27	15	0.25	3792	94.2	4024	16095			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5891	M	1820	0	15	0.25	2182	94.8	2302	9208	61.8	2112	25.278
7	2	5891	M	1821	0	15	0.25	2151	94.7	2271	9085			
7	2	5891	M	1918	1	15	0.25	3501	94.7	3695	14781	101.3	2072	24.805
7	2	5891	M	1919	1	15	0.25	3599	94.7	3800	15200			
7	2	5891	M	2014	2	15	0.25	2664	94.6	2814	11257	77.1	2097	25.095
7	2	5891	M	2015	2	15	0.25	2735	94.7	2889	11555			
7	2	5891	M	2110	3	15	0.25	5535	94.7	5845	23381	158.7	2015	24.118
7	2	5891	M	2111	3	15	0.25	5585	94.7	5896	23585			
7	2	5891	M	2217	4	15	0.25	4913	94.5	5200	20801	140.6	2033	24.334
7	2	5891	M	2218	4	15	0.25	4916	94.4	5207	20828			
7	2	5891	M	2313	5	15	0.25	5408	94.3	5735	22941	155.4	2018	24.158
7	2	5891	M	2314	5	15	0.25	5429	94.2	5761	23044			
7	2	5891	M	2409	6	15	0.25	3732	94.6	3944	15776	106.0	2068	24.749
7	2	5891	M	2410	6	15	0.25	3688	94.6	3900	15599			
7	2	5891	M	2505	7	15	0.25	3268	94.7	3453	13811	93.7	2114	25.303
7	2	5891	M	2506	7	15	0.25	3294	94.6	3482	13926			
7	2	5891	M	2603	8	15	0.25	7475	94.6	7906	31624	213.8	1994	23.866
7	2	5891	M	2604	8	15	0.25	7479	94.5	7912	31650			
7	2	5891	M	2699	9	15	0.25	3365	94.7	3552	14209	95.7	2112	25.278
7	2	5891	M	2700	9	15	0.25	3349	94.8	3533	14133			
7	2	5891	M	2795	10	15	0.25	4850	94.7	5120	20479	136.5	2071	24.790
7	2	5891	M	2796	10	15	0.25	4720	94.7	4985	19939			
7	2	5891	M	2891	11	15	0.25	3282	94.4	3477	13906	93.4	2114	25.307
7	2	5891	M	2892	11	15	0.25	3240	94.4	3431	13726			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5891	M	3289	12	15	0.25	7459	94.3	7908	31633	209.7	1998	23.914
7	2	5891	M	3290	12	15	0.25	7177	94.3	7611	30443			
7	2	5891	M	3353	13	15	0.25	5207	94.3	5521	22083	149.3	2058	24.638
7	2	5891	M	3354	13	15	0.25	5213	94.3	5527	22107			
7	2	5891	M	3401	14	15	0.25	4904	94.4	5196	20783	139.9	2078	24.877
7	2	5891	M	3402	14	15	0.25	4872	94.4	5160	20641			
7	2	5891	M	3449	15	15	0.25	10165	94.3	10777	43108	289.8	1929	23.084
7	2	5891	M	3450	15	15	0.25	10056	94.3	10666	42665			
7	2	5891	M	3497	16	15	0.25	4603	94.3	4882	19529	132.6	2086	24.965
7	2	5891	M	3498	16	15	0.25	4646	94.3	4929	19718			
7	2	5891	M	3545	17	15	0.25	5565	94.2	5909	23634	157.3	2061	24.669
7	2	5891	M	3546	17	15	0.25	5399	94.2	5732	22926			
7	2	5891	M	4236	18	15	0.25	7751	94.2	8227	32907	221.4	1997	23.902
7	2	5891	M	4237	18	15	0.25	7689	94.3	8156	32626			
7	2	5891	M	4284	19	15	0.25	6707	94.3	7114	28458	189.0	2029	24.290
7	2	5891	M	4285	19	15	0.25	6480	94.3	6870	27480			
7	2	5891	M	4332	20	15	0.25	3426	94.3	3634	14537	97.9	2120	25.381
7	2	5891	M	4333	20	15	0.25	3400	94.2	3608	14431			
7	2	5891	M	4380	21	15	0.25	2949	94.3	3126	12504	84.0	2134	25.546
7	2	5891	M	4381	21	15	0.25	2918	94.3	3093	12374			
7	2	5891	M	4428	22	15	0.25	3005	94.2	3190	12759	86.2	2132	25.520
7	2	5891	M	4429	22	15	0.25	3009	94.3	3193	12770			
7	2	5891	M	4476	23	15	0.25	10431	94.2	11070	44281	298.4	1920	22.980
7	2	5891	M	4477	23	15	0.25	10376	94.2	11013	44050			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5891	M	4665	24	15	0.25	8275	94.3	8775	35101	238.4	1980	23.698
7	2	5891	M	4666	24	15	0.25	8359	94.3	8868	35471			
7	2	5891	M	4713	25	15	0.25	2984	94.3	3164	12658	86.0	2132	25.523
7	2	5891	M	4714	25	15	0.25	3017	94.3	3199	12796			
7	2	5891	M	4745	26	15	0.25	4122	94.3	4372	17489	117.2	2101	25.149
7	2	5891	M	4746	26	15	0.25	4058	94.3	4303	17214			
7	2	5891	M	4761	27	15	0.25	2853	94.3	3026	12104	82.3	2136	25.567
7	2	5891	M	4762	27	15	0.25	2887	94.2	3064	12258			
7	2	5892	M	1822	0	15	0.25	3047	94.7	3218	12874	87.6	2086	24.969
7	2	5892	M	1823	0	15	0.25	3092	94.7	3265	13061			
7	2	5892	M	1920	1	15	0.25	2780	94.7	2935	11742	80.9	2093	25.049
7	2	5892	M	1921	1	15	0.25	2888	94.7	3051	12205			
7	2	5892	M	2016	2	15	0.25	2718	94.6	2873	11493	77.2	2096	25.093
7	2	5892	M	2017	2	15	0.25	2689	94.7	2840	11361			
7	2	5892	M	2112	3	15	0.25	4513	94.7	4765	19060	129.1	2045	24.472
7	2	5892	M	2113	3	15	0.25	4531	94.6	4788	19152			
7	2	5892	M	2219	4	15	0.25	4747	94.4	5028	20111	136.6	2037	24.382
7	2	5892	M	2220	4	15	0.25	4800	94.4	5084	20337			
7	2	5892	M	2315	5	15	0.25	9159	94.2	9720	38879	265.3	1908	22.842
7	2	5892	M	2316	5	15	0.25	9340	94.2	9912	39648			
7	2	5892	M	2411	6	15	0.25	3826	94.6	4046	16182	112.5	2061	24.671
7	2	5892	M	2412	6	15	0.25	4045	94.6	4277	17110			
7	2	5892	M	2507	7	15	0.25	4783	94.6	5054	20215	136.4	2071	24.792
7	2	5892	M	2508	7	15	0.25	4766	94.6	5037	20149			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5892	M	2605	8	15	0.25	5203	94.6	5498	21990	147.9	2060	24.655
7	2	5892	M	2606	8	15	0.25	5149	94.6	5445	21778			
7	2	5892	M	2701	9	15	0.25	4695	94.8	4955	19819	132.6	2075	24.837
7	2	5892	M	2702	9	15	0.25	4597	94.7	4857	19427			
7	2	5892	M	2797	10	15	0.25	4172	94.7	4405	17619	117.4	2090	25.019
7	2	5892	M	2798	10	15	0.25	4058	94.8	4281	17126			
7	2	5892	M	2893	11	15	0.25	2211	94.4	2342	9368	63.2	2144	25.668
7	2	5892	M	2894	11	15	0.25	2203	94.4	2334	9336			
7	2	5892	M	3291	12	15	0.25	2405	94.3	2550	10201	69.7	2138	25.590
7	2	5892	M	3292	12	15	0.25	2461	94.3	2608	10433			
7	2	5892	M	3355	13	15	0.25	5860	94.3	6213	24852	168.7	2039	24.405
7	2	5892	M	3356	13	15	0.25	5913	94.3	6269	25078			
7	2	5892	M	3403	14	15	0.25	3237	94.4	3428	13714	92.6	2126	25.444
7	2	5892	M	3404	14	15	0.25	3234	94.4	3425	13699			
7	2	5892	M	3451	15	15	0.25	6330	94.3	6712	26847	179.9	2038	24.399
7	2	5892	M	3452	15	15	0.25	6225	94.3	6602	26406			
7	2	5892	M	3499	16	15	0.25	5763	94.3	6112	24448	163.3	2055	24.598
7	2	5892	M	3500	16	15	0.25	5627	94.2	5971	23884			
7	2	5892	M	3547	17	15	0.25	4908	94.2	5211	20845	139.7	2079	24.880
7	2	5892	M	3548	17	15	0.25	4834	94.3	5129	20515			
7	2	5892	M	4238	18	15	0.25	7047	94.3	7475	29900	200.6	2018	24.152
7	2	5892	M	4239	18	15	0.25	6943	94.2	7367	29467			
7	2	5892	M	4286	19	15	0.25	7159	94.3	7595	30381	205.0	2013	24.099
7	2	5892	M	4287	19	15	0.25	7137	94.2	7573	30292			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5892	M	4334	20	15	0.25	4530	94.3	4806	19225	129.1	2089	25.007
7	2	5892	M	4335	20	15	0.25	4475	94.3	4746	18983			
7	2	5892	M	4382	21	15	0.25	4948	94.3	5246	20986	141.6	2077	24.858
7	2	5892	M	4383	21	15	0.25	4935	94.3	5231	20924			
7	2	5892	M	4430	22	15	0.25	2968	94.3	3149	12595	84.7	2134	25.539
7	2	5892	M	4431	22	15	0.25	2937	94.2	3117	12466			
7	2	5892	M	4478	23	15	0.25	8291	94.2	8800	35200	236.7	1982	23.719
7	2	5892	M	4479	23	15	0.25	8210	94.2	8714	34855			
7	2	5892	M	4667	24	15	0.25	10012	94.2	10629	42516	289.3	1929	23.089
7	2	5892	M	4668	24	15	0.25	10159	94.2	10780	43120			
7	2	5892	M	4715	25	15	0.25	2122	94.3	2251	9002	61.2	2157	25.820
7	2	5892	M	4716	25	15	0.25	2147	94.2	2278	9113			
7	2	5892	M	4747	26	15	0.25	3359	94.3	3563	14252	96.3	2122	25.399
7	2	5892	M	4748	26	15	0.25	3360	94.3	3565	14261			
7	2	5892	M	4763	27	15	0.25	3259	94.2	3459	13836	92.6	2126	25.444
7	2	5892	M	4764	27	15	0.25	3201	94.3	3394	13577			
7	2	5905	F	1824	0	15	0.25	2956	94.7	3123	12491	83.8	2090	25.014
7	2	5905	F	1825	0	15	0.25	2914	94.7	3079	12315			
7	2	5905	F	1922	1	15	0.25	3597	94.7	3799	15196	104.8	2069	24.763
7	2	5905	F	1923	1	15	0.25	3746	94.7	3955	15819			
7	2	5905	F	2018	2	15	0.25	3424	94.7	3616	14464	97.7	2076	24.848
7	2	5905	F	2019	2	15	0.25	3422	94.7	3613	14452			
7	2	5905	F	2114	3	15	0.25	4157	94.7	4389	17557	117.9	2056	24.606
7	2	5905	F	2115	3	15	0.25	4106	94.7	4338	17350			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5905	F	2221	4	15	0.25	4611	94.5	4880	19519	132.2	2041	24.435
7	2	5905	F	2222	4	15	0.25	4632	94.5	4903	19611			
7	2	5905	F	2317	5	15	0.25	4307	86.5	6478	25914	149.9	2024	24.224
7	2	5905	F	2318	5	15	0.25	4347	94.3	4611	18445			
7	2	5905	F	2413	6	15	0.25	4476	94.2	4750	19001	105.2	2068	24.758
7	2	5905	F	2414	6	15	0.25	2872	94.6	3038	12150			
7	2	5905	F	2509	7	15	0.25	4598	94.5	4865	19459	130.6	2077	24.861
7	2	5905	F	2510	7	15	0.25	4539	94.6	4799	19198			
7	2	5905	F	2607	8	15	0.25	5188	94.6	5486	21943	147.1	2060	24.663
7	2	5905	F	2608	8	15	0.25	5107	94.5	5402	21610			
7	2	5905	F	2703	9	15	0.25	4186	94.7	4420	17679	119.9	2088	24.989
7	2	5905	F	2704	9	15	0.25	4218	94.7	4456	17825			
7	2	5905	F	2799	10	15	0.25	5391	94.7	5690	22760	156.1	2051	24.556
7	2	5905	F	2800	10	15	0.25	5554	94.7	5864	23457			
7	2	5905	F	2895	11	15	0.25	4478	94.4	4742	18968	128.2	2079	24.890
7	2	5905	F	2896	11	15	0.25	4476	94.3	4744	18978			
7	2	5905	F	3293	12	15	0.25	5190	94.3	5501	22005	148.4	2059	24.649
7	2	5905	F	3294	12	15	0.25	5166	94.3	5477	21910			
7	2	5905	F	3357	13	15	0.25	4870	94.4	5158	20633	139.4	2068	24.755
7	2	5905	F	3358	13	15	0.25	4877	94.5	5161	20642			
7	2	5905	F	3405	14	15	0.25	8728	94.4	9246	36982	245.6	1973	23.612
7	2	5905	F	3406	14	15	0.25	8434	94.4	8930	35721			
7	2	5905	F	3453	15	15	0.25	4182	94.3	4435	17741	119.2	2099	25.125
7	2	5905	F	3454	15	15	0.25	4137	94.3	4388	17551			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5905	F	3501	16	15	0.25	4964	94.3	5263	21051	142.3	2076	24.848
7	2	5905	F	3502	16	15	0.25	4969	94.3	5271	21083			
7	2	5905	F	3549	17	15	0.25	5331	94.2	5659	22634	156.5	2062	24.679
7	2	5905	F	3550	17	15	0.25	5578	94.2	5922	23687			
7	2	5905	F	4240	18	15	0.25	9643	94.3	10230	40922	271.4	1947	23.304
7	2	5905	F	4241	18	15	0.25	9286	94.2	9854	39416			
7	2	5905	F	4288	19	15	0.25	7499	94.3	7952	31809	214.6	2004	23.984
7	2	5905	F	4289	19	15	0.25	7469	94.2	7926	31704			
7	2	5905	F	4336	20	15	0.25	4404	94.3	4669	18677	126.3	2092	25.041
7	2	5905	F	4337	20	15	0.25	4407	94.3	4675	18700			
7	2	5905	F	4384	21	15	0.25	4486	94.3	4757	19026	127.7	2091	25.024
7	2	5905	F	4385	21	15	0.25	4423	94.3	4691	18764			
7	2	5905	F	4432	22	15	0.25	3003	94.3	3186	12744	85.8	2132	25.525
7	2	5905	F	4433	22	15	0.25	2982	94.3	3164	12656			
7	2	5905	F	4480	23	15	0.25	5902	94.3	6261	25045	166.8	2052	24.556
7	2	5905	F	4481	23	15	0.25	5728	94.2	6081	24325			
7	2	5905	F	4669	24	15	0.25	8934	94.3	9476	37905	254.9	1963	23.502
7	2	5905	F	4670	24	15	0.25	8845	94.3	9384	37535			
7	2	5905	F	4717	25	15	0.25	2480	94.3	2631	10524	69.8	2149	25.717
7	2	5905	F	4718	25	15	0.25	2388	94.3	2532	10127			
7	2	5905	F	4749	26	15	0.25	2471	94.3	2621	10485	70.3	2148	25.711
7	2	5905	F	4750	26	15	0.25	2433	94.3	2581	10324			
7	2	5905	F	4765	27	15	0.25	1954	94.3	2072	8287	55.8	2163	25.885
7	2	5905	F	4766	27	15	0.25	1936	94.2	2054	8216			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5906	F	1826	0	15	0.25	3108	94.6	3286	13144	88.5	2085	24.958
7	2	5906	F	1827	0	15	0.25	3086	94.6	3263	13052			
7	2	5906	F	1924	1	15	0.25	3195	94.7	3374	13495	92.1	2082	24.915
7	2	5906	F	1925	1	15	0.25	3257	94.7	3440	13758			
7	2	5906	F	2020	2	15	0.25	2926	94.6	3092	12367	83.4	2090	25.020
7	2	5906	F	2021	2	15	0.25	2914	94.7	3077	12308			
7	2	5906	F	2116	3	15	0.25	4375	94.6	4623	18493	124.3	2049	24.529
7	2	5906	F	2117	3	15	0.25	4335	94.7	4579	18314			
7	2	5906	F	2223	4	15	0.25	3943	94.4	4175	16700	112.8	2061	24.667
7	2	5906	F	2224	4	15	0.25	3943	94.5	4174	16696			
7	2	5906	F	2319	5	15	0.25	3680	94.2	3908	15630	105.3	2068	24.757
7	2	5906	F	2320	5	15	0.25	3658	94.2	3884	15537			
7	2	5906	F	2415	6	15	0.25	4269	94.5	4518	18070	122.3	2051	24.553
7	2	5906	F	2416	6	15	0.25	4286	94.5	4534	18135			
7	2	5906	F	2511	7	15	0.25	3831	94.6	4049	16196	115.0	2093	25.048
7	2	5906	F	2512	7	15	0.25	4219	94.6	4460	17841			
7	2	5906	F	2609	8	15	0.25	6605	94.5	6988	27951	190.1	2018	24.149
7	2	5906	F	2610	8	15	0.25	6693	94.6	7078	28311			
7	2	5906	F	2705	9	15	0.25	3888	94.7	4105	16419	110.1	2098	25.107
7	2	5906	F	2706	9	15	0.25	3827	94.7	4041	16164			
7	2	5906	F	2801	10	15	0.25	2262	94.7	2389	9557	63.9	2144	25.660
7	2	5906	F	2802	10	15	0.25	2213	94.7	2338	9350			
7	2	5906	F	2897	11	15	0.25	4192	94.4	4440	17758	121.2	2086	24.973
7	2	5906	F	2898	11	15	0.25	4278	94.4	4533	18130			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5906	F	3295	12	15	0.25	4731	94.3	5018	20072	135.3	2072	24.805
7	2	5906	F	3296	12	15	0.25	4708	94.3	4991	19965			
7	2	5906	F	3359	13	15	0.25	3971	94.4	4207	16827	113.7	2094	25.064
7	2	5906	F	3360	13	15	0.25	3974	94.4	4207	16828			
7	2	5906	F	3407	14	15	0.25	4290	94.5	4540	18161	122.9	2095	25.082
7	2	5906	F	3408	14	15	0.25	4300	94.5	4552	18206			
7	2	5906	F	3455	15	15	0.25	7560	94.3	8018	32071	214.4	2004	23.986
7	2	5906	F	3456	15	15	0.25	7403	94.3	7847	31388			
7	2	5906	F	3503	16	15	0.25	10239	94.3	10861	43446	296.7	1922	23.000
7	2	5906	F	3504	16	15	0.25	10469	94.3	11097	44388			
7	2	5906	F	3551	17	15	0.25	3602	94.2	3824	15296	103.0	2115	25.319
7	2	5906	F	3552	17	15	0.25	3578	94.2	3798	15191			
7	2	5906	F	4242	18	15	0.25	13370	94.3	14186	56744	383.4	1835	21.963
7	2	5906	F	4243	18	15	0.25	13374	94.3	14187	56749			
7	2	5906	F	4290	19	15	0.25	7848	94.2	8329	33314	227.7	1991	23.826
7	2	5906	F	4291	19	15	0.25	8035	94.3	8524	34094			
7	2	5906	F	4338	20	15	0.25	4031	94.3	4275	17100	115.6	2103	25.168
7	2	5906	F	4339	20	15	0.25	4036	94.3	4282	17127			
7	2	5906	F	4386	21	15	0.25	3333	94.4	3532	14128	96.2	2122	25.401
7	2	5906	F	4387	21	15	0.25	3382	94.3	3585	14342			
7	2	5906	F	4434	22	15	0.25	3322	94.2	3527	14107	92.8	2125	25.441
7	2	5906	F	4435	22	15	0.25	3150	94.2	3343	13372			
7	2	5906	F	4482	23	15	0.25	7005	94.2	7436	29743	199.5	2019	24.164
7	2	5906	F	4483	23	15	0.25	6905	94.2	7328	29311			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5906	F	4671	24	15	0.25	8741	94.3	9270	37080	252.8	1965	23.526
7	2	5906	F	4672	24	15	0.25	8896	94.2	9440	37760			
7	2	5906	F	4719	25	15	0.25	2141	94.3	2271	9085	61.5	2157	25.816
7	2	5906	F	4720	25	15	0.25	2149	94.3	2279	9116			
7	2	5906	F	4751	26	15	0.25	2738	94.3	2905	11621	78.3	2140	25.615
7	2	5906	F	4752	26	15	0.25	2720	94.2	2888	11551			
7	2	5906	F	4767	27	15	0.25	3106	94.3	3293	13171	89.7	2129	25.478
7	2	5906	F	4768	27	15	0.25	3152	94.2	3347	13387			
7	2	5908	F	1828	0	15	0.25	2166	94.6	2291	9162	62.5	2111	25.269
7	2	5908	F	1829	0	15	0.25	2211	94.6	2337	9346			
7	2	5908	F	1926	1	15	0.25	2685	94.7	2835	11339	77.9	2096	25.085
7	2	5908	F	1927	1	15	0.25	2773	94.6	2931	11722			
7	2	5908	F	2022	2	15	0.25	3137	94.6	3315	13262	89.0	2085	24.952
7	2	5908	F	2023	2	15	0.25	3095	94.6	3271	13083			
7	2	5908	F	2118	3	15	0.25	4480	94.7	4729	18917	128.0	2046	24.485
7	2	5908	F	2119	3	15	0.25	4492	94.7	4745	18979			
7	2	5908	F	2225	4	15	0.25	3265	94.5	3457	13826	93.3	2080	24.900
7	2	5908	F	2226	4	15	0.25	3258	94.4	3449	13795			
7	2	5908	F	2321	5	15	0.25	4228	94.2	4488	17951	119.6	2054	24.586
7	2	5908	F	2322	5	15	0.25	4109	94.2	4363	17453			
7	2	5908	F	2417	6	15	0.25	3395	94.5	3591	14365	96.5	2077	24.863
7	2	5908	F	2418	6	15	0.25	3354	94.6	3547	14188			
7	2	5908	F	2513	7	15	0.25	3998	94.6	4229	16914	112.8	2095	25.074
7	2	5908	F	2514	7	15	0.25	3898	94.6	4119	16477			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5908	F	2611	8	15	0.25	6679	94.5	7067	28268	189.6	2018	24.155
7	2	5908	F	2612	8	15	0.25	6583	94.5	6963	27850			
7	2	5908	F	2707	9	15	0.25	4288	94.7	4527	18107	123.2	2084	24.950
7	2	5908	F	2708	9	15	0.25	4350	94.8	4591	18364			
7	2	5908	F	2803	10	15	0.25	6302	94.7	6654	26617	180.3	2027	24.266
7	2	5908	F	2804	10	15	0.25	6335	94.7	6688	26750			
7	2	5908	F	2899	11	15	0.25	2509	94.4	2658	10633	72.3	2135	25.559
7	2	5908	F	2900	11	15	0.25	2543	94.4	2694	10778			
7	2	5908	F	3297	12	15	0.25	2261	94.3	2397	9588	64.8	2143	25.649
7	2	5908	F	3298	12	15	0.25	2260	94.3	2396	9584			
7	2	5908	F	3361	13	15	0.25	4038	94.5	4275	17101	115.2	2092	25.045
7	2	5908	F	3362	13	15	0.25	4015	94.5	4251	17003			
7	2	5908	F	3409	14	15	0.25	6203	94.4	6568	26274	179.6	2039	24.403
7	2	5908	F	3410	14	15	0.25	6346	94.5	6718	26873			
7	2	5908	F	3457	15	15	0.25	4604	94.3	4882	19527	131.2	2087	24.981
7	2	5908	F	3458	15	15	0.25	4551	94.2	4829	19318			
7	2	5908	F	3505	16	15	0.25	3730	94.3	3957	15829	106.1	2112	25.282
7	2	5908	F	3506	16	15	0.25	3672	94.3	3896	15585			
7	2	5908	F	3553	17	15	0.25	4987	94.2	5291	21166	143.6	2075	24.833
7	2	5908	F	3554	17	15	0.25	5028	94.2	5337	21349			
7	2	5908	F	4244	18	15	0.25	5007	94.3	5311	21245	145.2	2073	24.815
7	2	5908	F	4245	18	15	0.25	5120	94.3	5432	21727			
7	2	5908	F	4292	19	15	0.25	3780	94.3	4010	16038	108.4	2110	25.254
7	2	5908	F	4293	19	15	0.25	3784	94.3	4015	16058			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5908	F	4340	20	15	0.25	5004	94.3	5309	21234	144.0	2074	24.828
7	2	5908	F	4341	20	15	0.25	5043	94.3	5351	21404			
7	2	5908	F	4388	21	15	0.25	2141	94.3	2270	9079	60.7	2158	25.825
7	2	5908	F	4389	21	15	0.25	2096	94.3	2224	8896			
7	2	5908	F	4436	22	15	0.25	3205	94.3	3401	13603	92.3	2126	25.447
7	2	5908	F	4437	22	15	0.25	3233	94.2	3430	13721			
7	2	5908	F	4484	23	15	0.25	8696	94.3	9227	36907	249.9	1968	23.561
7	2	5908	F	4485	23	15	0.25	8726	94.2	9264	37054			
7	2	5908	F	4673	24	15	0.25	7303	94.3	7741	30962	209.5	2009	24.045
7	2	5908	F	4674	24	15	0.25	7316	94.3	7760	31041			
7	2	5908	F	4721	25	15	0.25	3076	94.3	3262	13049	87.3	2131	25.507
7	2	5908	F	4722	25	15	0.25	3017	94.3	3200	12799			
7	2	5908	F	4753	26	15	0.25	2862	94.3	3037	12147	81.4	2137	25.577
7	2	5908	F	4754	26	15	0.25	2819	94.3	2990	11959			
7	2	5908	F	4769	27	15	0.25	3583	94.3	3802	15206	102.9	2115	25.320
7	2	5908	F	4770	27	15	0.25	3594	94.2	3814	15256			
7	2	5914	F	1830	0	15	0.25	2035	94.6	2152	8607	57.8	2116	25.326
7	2	5914	F	1831	0	15	0.25	2009	94.6	2124	8497			
7	2	5914	F	1928	1	15	0.25	3929	94.7	4150	16602	110.8	2063	24.692
7	2	5914	F	1929	1	15	0.25	3831	94.7	4045	16181			
7	2	5914	F	2024	2	15	0.25	4014	94.7	4240	16959	114.2	2059	24.650
7	2	5914	F	2025	2	15	0.25	3986	94.6	4212	16847			
7	2	5914	F	2120	3	15	0.25	4201	94.7	4438	17753	119.1	2054	24.591
7	2	5914	F	2121	3	15	0.25	4144	94.7	4378	17510			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5914	F	2227	4	15	0.25	3559	94.4	3769	15074	102.0	2072	24.796
7	2	5914	F	2228	4	15	0.25	3572	94.4	3782	15130			
7	2	5914	F	2323	5	15	0.25	5841	94.2	6198	24793	168.3	2005	24.003
7	2	5914	F	2324	5	15	0.25	5888	94.2	6253	25012			
7	2	5914	F	2419	6	15	0.25	3214	94.6	3399	13594	92.4	2081	24.911
7	2	5914	F	2420	6	15	0.25	3253	94.6	3440	13760			
7	2	5914	F	2515	7	15	0.25	3767	94.6	3983	15932	107.4	2100	25.139
7	2	5914	F	2516	7	15	0.25	3752	94.6	3966	15865			
7	2	5914	F	2613	8	15	0.25	4858	94.6	5137	20546	138.8	2069	24.763
7	2	5914	F	2614	8	15	0.25	4854	94.5	5135	20539			
7	2	5914	F	2709	9	15	0.25	2711	94.7	2864	11455	76.7	2131	25.506
7	2	5914	F	2710	9	15	0.25	2663	94.7	2813	11251			
7	2	5914	F	2805	10	15	0.25	2970	94.8	3134	12536	84.2	2123	25.417
7	2	5914	F	2806	10	15	0.25	2931	94.7	3094	12377			
7	2	5914	F	2901	11	15	0.25	9164	94.4	9710	38839	264.9	1943	23.254
7	2	5914	F	2902	11	15	0.25	9341	94.4	9891	39566			
7	2	5914	F	3299	12	15	0.25	3861	94.3	4095	16379	110.6	2097	25.100
7	2	5914	F	3300	12	15	0.25	3864	94.4	4093	16371			
7	2	5914	F	3363	13	15	0.25	3299	94.4	3495	13980	94.4	2113	25.295
7	2	5914	F	3364	13	15	0.25	3295	94.5	3488	13953			
7	2	5914	F	3411	14	15	0.25	4158	94.4	4404	17615	118.6	2100	25.133
7	2	5914	F	3412	14	15	0.25	4129	94.4	4372	17489			
7	2	5914	F	3459	15	15	0.25	4741	94.3	5029	20117	136.6	2082	24.917
7	2	5914	F	3460	15	15	0.25	4790	94.3	5081	20322			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
7	2	5914	F	3507	16	15	0.25	5720	94.3	6068	24274	164.5	2054	24.583
7	2	5914	F	3508	16	15	0.25	5755	94.3	6106	24423			
7	2	5914	F	3555	17	15	0.25	3841	94.2	4079	16316	108.4	2110	25.254
7	2	5914	F	3556	17	15	0.25	3717	94.2	3944	15777			
7	2	5914	F	4246	18	15	0.25	5536	94.2	5875	23500	157.4	2061	24.669
7	2	5914	F	4247	18	15	0.25	5438	94.3	5770	23080			
7	2	5914	F	4294	19	15	0.25	6521	94.3	6917	27667	186.2	2032	24.324
7	2	5914	F	4295	19	15	0.25	6465	94.2	6862	27447			
7	2	5914	F	4342	20	15	0.25	4048	94.2	4296	17183	116.4	2102	25.159
7	2	5914	F	4343	20	15	0.25	4073	94.3	4320	17281			
7	2	5914	F	4390	21	15	0.25	2687	94.3	2850	11399	76.6	2142	25.635
7	2	5914	F	4391	21	15	0.25	2659	94.2	2822	11288			
7	2	5914	F	4438	22	15	0.25	3822	94.3	4055	16219	107.6	2111	25.265
7	2	5914	F	4439	22	15	0.25	3681	94.2	3906	15626			
7	2	5914	F	4486	23	15	0.25	7162	94.3	7598	30391	205.5	2013	24.092
7	2	5914	F	4487	23	15	0.25	7171	94.2	7612	30448			
7	2	5914	F	4675	24	15	0.25	8827	94.3	9365	37458	252.9	1965	23.526
7	2	5914	F	4676	24	15	0.25	8808	94.2	9348	37391			
7	2	5914	F	4723	25	15	0.25	2721	94.3	2886	11543	78.6	2140	25.612
7	2	5914	F	4724	25	15	0.25	2761	94.3	2929	11716			
7	2	5914	F	4755	26	15	0.25	3588	94.3	3807	15229	103.1	2115	25.318
7	2	5914	F	4756	26	15	0.25	3604	94.2	3825	15301			
7	2	5914	F	4771	27	15	0.25	2576	94.3	2733	10932	73.6	2145	25.671
7	2	5914	F	4772	27	15	0.25	2560	94.2	2716	10864			

TABLE E3. Liquid Scintillation Analyses of Pipet Washes and Calculation of Dose Applied (28-Day Repeated Dose Test)

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Dose Day	Samp. Size (mL)	Aliquot Size (mL)	cpm	Count. Eff. (%)	dpm	dpm/mL	Total Activity (nCi)	Actual Dose Applied (nCi)	Actual Dose Applied (mg)
Analyses That Were Not Used for Calculations:														**Reason for Exclusion:**
5	2	5893	M	4254	21	15	0.25	5002	94.2	5310	21240			Poor replication.
5	2	5893	M	4255	21	15	0.25	8888	93.9	9461	37842			

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix F

Liquid Scintillation Analyses of Individual Samples

Liquid Scintillation Analyses of Individual Samples

The following equations were used in calculation of the amount of radioactivity in the various samples (Total Activity), the total test article equivalents (Total Cmpd.), concentration (Conc.), and the percent of actual dose:

$$(1) \quad \text{dpm / g} = \frac{\text{dpm} \times \text{F-factor}^{*}}{\text{Aliquot Size (g)}}$$

$$(2) \quad \text{Total Activity (nCi)} = \frac{\frac{\text{Mean dpm}}{\text{g}} \times \text{Sample Size (g)}^{**}}{2220 \text{ dpm / nCi}}$$

$$(3) \quad \text{Total Cmpd. } (\mu\text{g}) = \frac{\text{Total Activity (nCi)} \times 1\ \mu\text{Ci / 1000 nCi}}{\text{Spec. Act. } (\mu\text{Ci / mg})^{***} \times 1000\ \mu\text{g / mg}}$$

$$(4) \quad \text{\% of Actual Dose} = 100 \times \frac{\text{Total Activity (nCi)}}{\text{Actual Dose Applied (nCi)}^{\dagger}}$$

$$(5) \quad \text{Conc. } (\mu\text{g / g}) = \frac{\text{Total Cmpd. } (\mu\text{g})}{\text{Sample Size (g)}}$$

Other abbreviations used in the tables in this appendix include:

Grp. No. = Group Number
Anim. No. = Animal Number
Collect. = Collection
Count. Eff. = Counting Efficiency
Nec = Necropsy
N/A = Not Applicable

* If applicable, see Sections IX.B. and C.
** For skin digests, use Digest Size.
*** Specific Activity from Table C1 or C2 (Appendix C).
† Actual Dose Applied from Tables E1–E3 (Appendix E).

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	1	5331	M	615	Nec	131.469	0.5764	8763	94.9	9236	16023	932.92	444.92	17.17
1	1	5331	M	616	Nec	131.469	0.5519	8112	94.9	8546	15484			
1	1	5339	M	617	Nec	132.880	0.6318	15768	94.8	16635	26330	1550.73	739.57	28.15
1	1	5339	M	618	Nec	132.880	0.6342	15311	94.7	16163	25485			
1	1	5340	M	619	Nec	131.933	0.6282	16093	94.8	16973	27019	1601.98	764.01	30.02
1	1	5340	M	620	Nec	131.933	0.5828	14863	94.8	15673	26893			
1	1	5355	F	621	Nec	131.476	0.6471	18543	94.7	19573	30247	1768.59	843.47	32.52
1	1	5355	F	622	Nec	131.476	0.6372	17793	94.7	18784	29479			
1	1	5356	F	623	Nec	131.726	0.6469	19674	94.7	20770	32106	1902.30	907.24	34.74
1	1	5356	F	624	Nec	131.726	0.6497	19708	94.8	20799	32013			
1	1	5362	F	625	Nec	131.410	0.6476	8165	94.7	8619	13309	776.13	370.15	14.50
1	1	5362	F	626	Nec	131.410	0.6511	7965	94.7	8409	12915			
1	2	5332	M	627	Nec	131.548	0.6493	61	94.7	64	99	5.94	2.83	0.11
1	2	5332	M	628	Nec	131.548	0.6431	62	94.8	65	102			
1	2	5342	M	629	Nec	131.099	0.6364	3251	94.8	3431	5392	315.57	150.50	5.69
1	2	5342	M	630	Nec	131.099	0.6506	3265	94.8	3446	5296			
1	2	5343	M	631	Nec	131.286	0.6413	7643	94.8	8065	12576	743.08	354.39	13.48
1	2	5343	M	632	Nec	131.286	0.6300	7495	94.8	7909	12554			
1	2	5349	F	633	Nec	132.079	0.6460	3785	94.8	3995	6184	368.21	175.61	6.70
1	2	5349	F	634	Nec	132.079	0.6406	3759	94.7	3968	6194			
1	2	5350	F	635	Nec	130.598	0.6438	9231	94.7	9747	15139	891.28	425.06	16.48
1	2	5350	F	636	Nec	130.598	0.6443	9257	94.8	9769	15162			
1	2	5363	F	637	Nec	131.692	0.6337	12827	94.8	13533	21355	1263.18	602.43	22.93
1	2	5363	F	638	Nec	131.692	0.6405	12890	94.8	13600	21233			
1	3	5327	M	639	Nec	131.674	0.6385	203	94.8	214	335	20.01	9.54	0.36
1	3	5327	M	640	Nec	131.674	0.6533	211	94.7	222	340			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	3	5330	M	641	Nec	131.946	0.6351	596	94.8	629	990	60.14	28.68	1.10
1	3	5330	M	642	Nec	131.946	0.6444	631	94.8	666	1034			
1	3	5334	M	643	Nec	131.401	0.6420	23	94.8	24	37	2.21	1.05	0.04
1	3	5334	M	644	Nec	131.401	0.6418	23	94.8	24	37			
1	3	5347	F	645	Nec	132.648	0.6420	19	94.8	20	31	1.61	0.77	0.03
1	3	5347	F	646	Nec	132.648	0.6373	14	94.8	15	23			
1	3	5348	F	647	Nec	132.722	0.6383	958	94.8	1011	1584	94.77	45.20	1.74
1	3	5348	F	648	Nec	132.722	0.6338	953	94.8	1005	1586			
1	3	5352	F	649	Nec	132.922	0.6425	550	94.8	581	904	55.65	26.54	1.01
1	3	5352	F	650	Nec	132.922	0.6358	575	94.8	607	955			
1	4	5328	M	651	Nec	131.747	0.6405	6	94.7	6	10	0.86	0.41	0.02
1	4	5328	M	652	Nec	131.747	0.6473	12	94.7	12	19			
1	4	5336	M	653	Nec	132.406	0.6401	7	94.7	8	12	1.05	0.50	0.02
1	4	5336	M	654	Nec	132.406	0.6390	14	94.7	15	23			
1	4	5344	M	655	Nec	131.774	0.6387	10	94.7	10	16	1.12	0.54	0.02
1	4	5344	M	656	Nec	131.774	0.6440	14	94.7	14	22			
1	4	5345	M	657	Nec	131.592	0.6437	16	94.7	17	27	1.68	0.80	0.03
1	4	5345	M	658	Nec	131.592	0.6497	19	94.7	20	30			
1	4	5351	F	659	Nec	131.608	0.6439	20	94.7	21	33	2.24	1.07	0.04
1	4	5351	F	660	Nec	131.608	0.6407	26	94.8	27	43			
1	4	5353	F	661	Nec	131.163	0.6462	10	94.8	11	16	1.46	0.70	0.03
1	4	5353	F	662	Nec	131.163	0.6411	20	94.8	21	33			
1	4	5359	F	663	Nec	133.313	0.6419	23	94.8	25	38	3.78	1.80	0.07
1	4	5359	F	664	Nec	133.313	0.6363	53	94.8	56	88			
1	4	5365	F	665	Nec	132.864	0.6440	18	94.8	19	29	1.61	0.77	0.03
1	4	5365	F	666	Nec	132.864	0.6182	14	94.8	15	24			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	5	5329	M	667	Nec	132.359	0.6324	5	94.8	5	8	0.27	0.13	0.00
1	5	5329	M	668	Nec	132.359	0.6326	1	94.8	1	1			
1	5	5333	M	669	Nec	132.075	0.6317	4	94.8	4	7	0.35	0.16	0.01
1	5	5333	M	670	Nec	132.075	0.6426	3	94.8	3	5			
1	5	5341	M	671	Nec	131.774	0.6333	2	94.8	2	4	0.25	0.12	0.00
1	5	5341	M	672	Nec	131.774	0.6333	3	94.7	3	5			
1	5	5360	F	673	Nec	131.806	0.6418	5	94.8	6	9	0.33	0.16	0.01
1	5	5360	F	674	Nec	131.806	0.6396	1	94.8	1	2			
1	5	5364	F	675	Nec	130.900	0.6324	5	94.8	5	8	0.59	0.28	0.01
1	5	5364	F	676	Nec	130.900	0.6417	8	94.8	8	12			
1	5	5366	F	677	Nec	130.813	0.6361	3	94.7	3	5	0.41	0.19	0.01
1	5	5366	F	678	Nec	130.813	0.6344	5	94.7	6	9			
2	1	5836	M	1417	Nec	130.929	0.6086	22050	94.6	23300	38285	2282.77	3628.97	42.04
2	1	5836	M	1418	Nec	130.929	0.6191	22930	94.7	24223	39127			
2	1	5841	M	1419	Nec	130.459	0.6499	27227	94.6	28773	44273	2583.03	4106.30	47.91
2	1	5841	M	1420	Nec	130.459	0.6304	26032	94.6	27509	43637			
2	1	5844	M	1421	Nec	128.975	0.6444	18696	94.6	19760	30665	1780.73	2830.86	32.74
2	1	5844	M	1422	Nec	128.975	0.6321	18329	94.6	19366	30638			
2	1	5853	F	1423	Nec	132.755	0.6209	17670	94.7	18667	30064	1787.06	2840.92	32.63
2	1	5853	F	1424	Nec	132.755	0.6111	17192	94.7	18152	29704			
2	1	5855	F	1425	Nec	129.119	0.6351	16726	94.7	17667	27817	1654.96	2630.93	31.64
2	1	5855	F	1426	Nec	129.119	0.6345	17475	94.7	18459	29092			
2	1	5863	F	1427	Nec	128.541	0.6534	25494	94.6	26950	41246	2385.85	3792.84	43.69
2	1	5863	F	1428	Nec	128.541	0.6402	24949	94.7	26354	41165			
2	2	5832	M	1429	Nec	128.809	0.6413	17397	94.6	18383	28665	1659.85	2638.70	30.72
2	2	5832	M	1430	Nec	128.809	0.6319	17076	94.7	18040	28549			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	2	5834	M	1431	Nec	130.568	0.6596	20254	94.6	21408	32456	1912.61	3040.51	35.25
2	2	5834	M	1432	Nec	130.568	0.6358	19607	94.7	20716	32583			
2	2	5845	M	1433	Nec	131.269	0.6410	14721	94.7	15546	24253	1449.33	2304.03	26.55
2	2	5845	M	1434	Nec	131.269	0.6493	15221	94.6	16082	24769			
2	2	5846	F	1435	Nec	129.084	0.6504	21317	94.6	22534	34647	2015.67	3204.36	36.93
2	2	5846	F	1436	Nec	129.084	0.6504	21347	94.6	22559	34685			
2	2	5858	F	1437	Nec	132.382	0.6226	16272	94.6	17201	27627	1663.11	2643.89	30.47
2	2	5858	F	1438	Nec	132.382	0.6352	16925	94.7	17882	28152			
2	2	5860	F	1439	Nec	130.966	0.6372	17357	94.6	18344	28789	1696.66	2697.22	31.15
2	2	5860	F	1440	Nec	130.966	0.6311	17164	94.7	18133	28732			
2	3	5715	M	1441	Nec	128.950	0.6552	10700	94.7	11298	17244	1000.79	1590.98	18.28
2	3	5715	M	1442	Nec	128.950	0.6479	10561	94.7	11154	17215			
2	3	5831	M	1443	Nec	129.241	0.6289	3160	94.6	3339	5309	306.85	487.80	5.65
2	3	5831	M	1444	Nec	129.241	0.6267	3105	94.7	3279	5232			
2	3	5837	M	1445	Nec	127.115	0.6415	4136	94.7	4368	6809	393.35	625.32	7.19
2	3	5837	M	1446	Nec	127.115	0.6505	4267	94.7	4508	6930			
2	3	5847	F	1447	Nec	128.019	0.6427	8978	94.7	9480	14751	858.81	1365.27	15.62
2	3	5847	F	1448	Nec	128.019	0.6520	9281	94.7	9803	15035			
2	3	5850	F	1449	Nec	128.684	0.6455	7042	94.7	7434	11517	668.50	1062.73	12.15
2	3	5850	F	1450	Nec	128.684	0.6425	7026	94.7	7420	11549			
2	3	5864	F	1451	Nec	129.297	0.6357	5848	94.7	6174	9712	575.47	914.84	10.52
2	3	5864	F	1452	Nec	129.297	0.6317	6015	94.8	6348	10049			
2	4	5713	M	1453	Nec	130.616	0.6400	14	94.8	15	24	1.54	2.45	0.03
2	4	5713	M	1454	Nec	130.616	0.6502	18	94.7	19	29			
2	4	5829	M	1455	Nec	129.434	0.6499	6	94.7	6	10	0.60	0.96	0.01
2	4	5829	M	1456	Nec	129.434	0.6512	7	94.7	7	11			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	4	5830	M	1457	Nec	133.553	0.6427	35	94.7	37	58	3.04	4.83	0.06
2	4	5830	M	1458	Nec	133.553	0.6421	26	94.8	28	43			
2	4	5839	M	1459	Nec	134.784	0.6024	5	94.8	5	9	0.75	1.19	0.01
2	4	5839	M	1460	Nec	134.784	0.6336	10	94.8	10	16			
2	4	5851	F	1461	Nec	133.295	0.6422	179	94.8	189	294	17.31	27.52	0.32
2	4	5851	F	1462	Nec	133.295	0.6506	174	94.8	184	282			
2	4	5852	F	1463	Nec	132.094	0.6425	226	94.8	238	371	22.21	35.30	0.40
2	4	5852	F	1464	Nec	132.094	0.6407	228	94.8	241	376			
2	4	5857	F	1465	Nec	131.501	0.6470	738	94.7	779	1204	73.87	117.44	1.35
2	4	5857	F	1466	Nec	131.501	0.6412	784	94.8	827	1290			
2	4	5861	F	1467	Nec	133.752	0.6279	101	94.8	106	169	9.85	15.65	0.18
2	4	5861	F	1468	Nec	133.752	0.5944	89	94.8	94	158			
2	5	5720	M	1469	Nec	135.099	0.6290	0	94.8	0	0	0.00	0.00	0.00
2	5	5720	M	1470	Nec	135.099	0.6187	0	94.9	0	0			
2	5	5828	M	1471	Nec	132.591	0.6462	0	94.8	0	0	0.00	0.00	0.00
2	5	5828	M	1472	Nec	132.591	0.6495	0	94.8	0	0			
2	5	5840	M	1473	Nec	134.011	0.6286	1	94.9	1	2	0.12	0.18	0.00
2	5	5840	M	1474	Nec	134.011	0.6348	1	94.9	1	2			
2	5	5848	F	1475	Nec	133.459	0.6386	0	94.8	0	0	0.00	0.00	0.00
2	5	5848	F	1476	Nec	133.459	0.6377	0	94.8	0	0			
2	5	5854	F	1477	Nec	132.862	0.6175	0	94.8	0	0	0.00	0.00	0.00
2	5	5854	F	1478	Nec	132.862	0.6431	0	94.8	0	0			
2	5	5862	F	1479	Nec	133.564	0.6429	0	94.8	0	0	0.00	0.00	0.00
2	5	5862	F	1480	Nec	133.564	0.6312	0	94.9	0	0			
3	1	5723	M	807	Nec	129.473	0.6120	21649	95.0	22792	37242	2188.30	10436.38	41.29
3	1	5723	M	808	Nec	129.473	0.6395	22868	94.6	24174	37801			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	1	5733	M	809	Nec	127.484	0.6530	20814	94.6	21996	33685	1944.33	9272.86	36.27
3	1	5733	M	810	Nec	127.484	0.6334	20453	94.9	21556	34032			
3	1	5736	M	811	Nec	126.882	0.6095	16702	95.0	17583	28849	1654.77	7891.85	30.73
3	1	5736	M	812	Nec	126.882	0.6425	17663	94.6	18669	29057			
3	1	5741	F	813	Nec	129.149	0.6250	15921	94.9	16773	26836	1549.56	7390.12	28.86
3	1	5741	F	814	Nec	129.149	0.6220	15600	94.9	16443	26436			
3	1	5744	F	815	Nec	128.387	0.6256	21936	94.7	23176	37046	2155.94	10282.05	39.89
3	1	5744	F	816	Nec	128.387	0.6336	22496	94.7	23768	37512			
3	1	5762	F	817	Nec	128.056	0.6371	27171	94.8	28673	45005	2607.44	12435.30	48.60
3	1	5762	F	818	Nec	128.056	0.6338	27230	94.6	28775	45400			
3	2	5722	M	819	Nec	133.497	0.6271	21825	94.9	22999	36675	2199.02	10487.48	41.33
3	2	5722	M	820	Nec	133.497	0.6339	21935	94.9	23113	36462			
3	2	5734	M	821	Nec	130.389	0.6318	27094	94.6	28644	45337	2674.79	12756.50	50.11
3	2	5734	M	822	Nec	130.389	0.6451	27924	94.6	29510	45744			
3	2	5737	M	823	Nec	127.257	0.6269	17793	94.7	18784	29964	1716.32	8185.42	32.37
3	2	5737	M	824	Nec	127.257	0.6272	17785	94.8	18765	29918			
3	2	5746	F	825	Nec	130.415	0.6258	20646	94.7	21797	34831	2033.39	9697.55	40.05
3	2	5746	F	826	Nec	130.415	0.6485	21116	94.7	22306	34396			
3	2	5751	F	827	Nec	131.273	0.6393	12089	94.7	12763	19964	1182.70	5640.51	22.44
3	2	5751	F	828	Nec	131.273	0.6500	12325	94.6	13025	20039			
3	2	5761	F	829	Nec	133.626	0.6359	20773	94.7	21933	34491	2068.93	9867.07	38.79
3	2	5761	F	830	Nec	133.626	0.6241	20298	94.9	21377	34253			
3	3	5716	M	831	Nec	129.065	0.6421	13036	94.8	13758	21427	1240.27	5915.07	23.74
3	3	5716	M	832	Nec	129.065	0.6273	12648	94.9	13324	21240			
3	3	5717	M	833	Nec	128.556	0.6315	21208	94.7	22397	35466	2049.65	9775.15	38.29
3	3	5717	M	834	Nec	128.556	0.6231	20839	94.7	22010	35324			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	3	5726	M	835	Nec	130.239	0.6397	12097	94.7	12774	19969	1170.08	5580.29	21.74
3	3	5726	M	836	Nec	130.239	0.6389	12059	94.8	12727	19920			
3	3	5739	F	837	Nec	129.654	0.6370	16080	94.7	16972	26644	1552.25	7402.93	29.08
3	3	5739	F	838	Nec	129.654	0.6491	16298	94.7	17209	26513			
3	3	5750	F	839	Nec	128.033	0.6230	17080	94.7	18029	28939	1671.50	7971.64	30.97
3	3	5750	F	840	Nec	128.033	0.6320	17382	94.8	18345	29026			
3	3	5752	F	841	Nec	133.166	0.6374	6062	94.8	6394	10032	603.54	2878.38	11.34
3	3	5752	F	842	Nec	133.166	0.6444	6159	94.7	6503	10091			
3	4	5724	M	843	Nec	130.695	0.6394	15	94.8	16	24	1.60	7.65	0.03
3	4	5724	M	844	Nec	130.695	0.6287	18	94.8	19	30			
3	4	5725	M	845	Nec	128.688	0.6397	3956	94.6	4180	6534	379.30	1808.94	7.10
3	4	5725	M	846	Nec	128.688	0.6159	3826	94.8	4035	6552			
3	4	5727	M	847	Nec	130.281	0.6347	2770	94.8	2922	4604	269.84	1286.93	5.01
3	4	5727	M	848	Nec	130.281	0.6372	2772	94.7	2926	4592			
3	4	5735	M	849	Nec	131.233	0.5830	7321	95.0	7707	13219	779.15	3715.91	14.63
3	4	5735	M	850	Nec	131.233	0.6045	7540	94.9	7944	13142			
3	4	5740	F	851	Nec	132.632	0.5659	463	95.1	487	861	52.03	248.13	0.99
3	4	5740	F	852	Nec	132.632	0.6378	533	94.8	562	881			
3	4	5742	F	853	Nec	131.274	0.6414	5851	94.8	6175	9627	570.19	2719.33	10.64
3	4	5742	F	854	Nec	131.274	0.6314	5787	94.9	6098	9658			
3	4	5753	F	855	Nec	129.637	0.6480	9169	94.7	9681	14939	876.05	4178.01	16.43
3	4	5753	F	856	Nec	129.637	0.6290	8982	94.8	9476	15065			
3	4	5756	F	857	Nec	130.231	0.6210	5021	94.7	5304	8541	499.73	2383.30	9.26
3	4	5756	F	858	Nec	130.231	0.6194	4991	94.8	5262	8496			
3	5	5721	M	859	Nec	131.244	0.6201	9	94.9	9	15	0.86	4.10	0.02
3	5	5721	M	860	Nec	131.244	0.6268	9	94.7	9	14			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	5	5728	M	861	Nec	127.484	0.6317	14	94.7	15	24	1.61	7.69	0.03
3	5	5728	M	862	Nec	127.484	0.6234	19	94.6	20	32			
3	5	5732	M	863	Nec	129.385	0.6402	11	94.8	12	18	1.11	5.31	0.02
3	5	5732	M	864	Nec	129.385	0.6149	12	94.7	12	20			
3	5	5738	F	865	Nec	128.695	0.6346	10	94.7	10	16	0.90	4.28	0.02
3	5	5738	F	866	Nec	128.695	0.6409	9	94.8	10	15			
3	5	5758	F	867	Nec	129.336	0.6449	8	94.6	8	13	0.46	2.21	0.01
3	5	5758	F	868	Nec	129.336	0.6484	2	94.7	2	3			
3	5	5760	F	869	Nec	127.696	0.6354	9	94.7	10	15	0.97	4.61	0.02
3	5	5760	F	870	Nec	127.696	0.6348	11	94.7	12	18			
4	NA	5714	M	999	Nec	129.382	0.6770	63	94.6	66	98	5.82	27.32	0.12
4	NA	5714	M	1000	Nec	129.382	0.6070	59	94.7	62	102			
4	NA	5718	M	1001	Nec	130.387	0.6236	9	94.7	9	15	0.89	4.16	0.02
4	NA	5718	M	1002	Nec	130.387	0.6233	9	94.6	9	15			
4	NA	5719	M	1003	Nec	130.698	0.6153	21	94.7	22	36	1.98	9.30	0.04
4	NA	5719	M	1004	Nec	130.698	0.6151	18	94.7	19	31			
4	NA	5730	M	1005	Nec	130.463	0.6143	28	94.7	29	48	3.13	14.71	0.06
4	NA	5730	M	1006	Nec	130.463	0.6217	35	94.7	37	59			
4	NA	5743	F	1007	Nec	130.190	0.6362	841	94.6	888	1396	81.49	382.67	1.65
4	NA	5743	F	1008	Nec	130.190	0.6268	821	94.7	867	1383			
4	NA	5745	F	1009	Nec	129.705	0.6305	359	94.7	379	602	35.71	167.70	0.71
4	NA	5745	F	1010	Nec	129.705	0.6218	365	94.7	386	621			
4	NA	5748	F	1011	Nec	130.648	0.6137	538	94.7	568	926	54.56	256.19	1.10
4	NA	5748	F	1012	Nec	130.648	0.5957	524	94.7	553	928			
4	NA	5754	F	1013	Nec	130.243	0.6385	350	94.6	369	579	34.01	159.70	0.68
4	NA	5754	F	1014	Nec	130.243	0.6325	348	94.6	367	581			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	1	5871	M	3615	Nec	127.810	0.6371	52	94.4	56	87	4.72	5.65	0.02
5	1	5871	M	3616	Nec	127.810	0.6311	46	94.4	48	77			
5	1	5883	M	3617	Nec	131.268	0.6407	42	94.4	45	70	4.38	5.24	0.01
5	1	5883	M	3618	Nec	131.268	0.6493	48	94.4	51	79			
5	1	5884	M	3619	Nec	128.953	0.6434	59	94.4	62	96	5.08	6.09	0.02
5	1	5884	M	3620	Nec	128.953	0.6326	47	94.4	50	79			
5	1	5889	M	3621	Nec	126.953	0.6413	29	94.4	31	48	2.10	2.51	0.01
5	1	5889	M	3622	Nec	126.953	0.6516	16	94.4	16	25			
5	1	5896	F	3623	Nec	128.133	0.6618	4	94.4	4	7	0.29	0.35	0.00
5	1	5896	F	3624	Nec	128.133	0.6478	2	94.3	2	3			
5	1	5899	F	3625	Nec	127.743	0.6517	23	94.4	25	38	2.55	3.06	0.01
5	1	5899	F	3626	Nec	127.743	0.6419	31	94.4	33	51			
5	1	5900	F	3627	Nec	127.413	0.6422	29	94.4	31	48	2.25	2.69	0.01
5	1	5900	F	3628	Nec	127.413	0.6522	19	94.3	20	30			
5	1	5921	F	3629	Nec	127.041	0.6315	20	94.4	22	34	2.11	2.52	0.01
5	1	5921	F	3630	Nec	127.041	0.6444	24	94.4	25	39			
5	2	5869	M	3647	14	126.511	0.6579	40	94.3	43	65	3.91	4.68	0.01
5	2	5869	M	3648	14	126.511	0.6600	45	94.4	48	73			
5	2	5869	M	4900	Nec	122.675	0.6646	53	94.4	56	84	4.56	5.46	0.01
5	2	5869	M	4901	Nec	122.675	0.6229	48	94.4	51	81			
5	2	5870	M	3649	14	127.660	0.6760	58	94.3	62	92	5.99	7.17	0.01
5	2	5870	M	3650	14	127.660	0.6917	76	94.3	81	117			
5	2	5870	M	4902	Nec	122.314	0.6324	40	94.4	43	68	3.51	4.20	0.01
5	2	5870	M	4903	Nec	122.314	0.6378	36	94.4	38	60			
5	2	5888	M	3651	14	127.689	0.6511	24	94.4	25	38	2.30	2.75	0.00
5	2	5888	M	3652	14	127.689	0.6801	27	94.3	28	42			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5888	M	4904	Nec	125.727	0.6198	31	94.4	33	53	2.93	3.51	0.01
5	2	5888	M	4905	Nec	125.727	0.6398	30	94.4	32	50			
5	2	5893	M	3653	14	127.226	0.6695	36	94.3	39	58	2.72	3.26	0.00
5	2	5893	M	3654	14	127.226	0.6743	24	94.3	25	37			
5	2	5893	M	4906	Nec	122.162	0.6296	28	94.4	30	48	2.58	3.09	0.00
5	2	5893	M	4907	Nec	122.162	0.6341	28	94.4	29	46			
5	2	5910	F	3655	14	126.616	0.6855	16	94.3	17	25	1.46	1.75	0.00
5	2	5910	F	3656	14	126.616	0.6855	17	94.3	18	26			
5	2	5910	F	4908	Nec	126.655	0.6263	28	94.4	30	48	2.46	2.94	0.00
5	2	5910	F	4909	Nec	126.655	0.6164	22	94.5	23	38			
5	2	5911	F	3657	14	125.996	0.6695	65	94.3	69	103	4.37	5.23	0.01
5	2	5911	F	3658	14	125.996	0.6713	33	94.4	34	51			
5	2	5911	F	4910	Nec	125.539	0.6755	31	94.4	33	49	2.68	3.21	0.00
5	2	5911	F	4911	Nec	125.539	0.6523	28	94.4	30	46			
5	2	5915	F	3659	14	124.299	0.6679	40	94.3	42	64	3.27	3.91	0.01
5	2	5915	F	3660	14	124.299	0.6643	33	94.3	35	53			
5	2	5915	F	4912	Nec	125.537	0.6385	21	94.4	23	35	2.15	2.58	0.00
5	2	5915	F	4913	Nec	125.537	0.6534	25	94.4	27	41			
5	2	5916	F	3661	14	125.383	0.6842	30	94.3	32	46	3.35	4.01	0.01
5	2	5916	F	3662	14	125.383	0.6446	44	94.4	47	72			
5	2	5916	F	4914	Nec	125.960	0.6448	24	94.4	25	39	2.37	2.84	0.00
5	2	5916	F	4915	Nec	125.960	0.6389	27	94.4	28	44			
6	1	5867	M	3746	Nec	128.923	0.6429	0	94.3	0	0	0.00	0.00	0.00
6	1	5867	M	3747	Nec	128.923	0.6352	0	94.4	0	0			
6	1	5868	M	3748	Nec	130.477	0.6355	29	94.3	31	49	2.74	10.95	0.01
6	1	5868	M	3749	Nec	130.477	0.6623	28	94.3	30	45			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5875	M	3750	Nec	128.053	0.6469	11	94.3	12	18	1.19	4.76	0.00
6	1	5875	M	3751	Nec	128.053	0.6439	14	94.3	15	23			
6	1	5881	M	3752	Nec	127.983	0.6360	0	94.3	0	0	0.00	0.00	0.00
6	1	5881	M	3753	Nec	127.983	0.6546	0	94.3	0	0			
6	1	5895	F	3754	Nec	127.956	0.6446	3	94.3	3	5	0.26	1.05	0.00
6	1	5895	F	3755	Nec	127.956	0.6367	3	94.3	3	5			
6	1	5907	F	3756	Nec	129.680	0.6370	0	94.3	0	0	0.00	0.00	0.00
6	1	5907	F	3757	Nec	129.680	0.6392	0	94.4	0	0			
6	1	5909	F	3758	Nec	127.149	0.6561	0	94.3	0	0	0.07	0.29	0.00
6	1	5909	F	3759	Nec	127.149	0.6553	2	94.3	2	3			
6	1	5918	F	3760	Nec	130.079	0.6446	1	94.3	1	1	0.21	0.85	0.00
6	1	5918	F	3761	Nec	130.079	0.6440	4	94.3	4	6			
6	2	5880	M	3778	14	129.147	0.6949	49	94.3	52	75	4.47	17.85	0.01
6	2	5880	M	3779	14	129.147	0.6895	51	94.3	54	79			
6	2	5880	M	4932	Nec	125.308	0.6102	21	94.5	23	37	1.82	7.25	0.00
6	2	5880	M	4933	Nec	125.308	0.5943	15	94.5	16	27			
6	2	5885	M	3780	14	129.805	0.6862	69	94.4	73	106	5.58	22.26	0.01
6	2	5885	M	3781	14	129.805	0.6393	51	94.4	54	85			
6	2	5885	M	4934	Nec	125.002	0.6434	17	94.5	18	28	1.61	6.44	0.00
6	2	5885	M	4935	Nec	125.002	0.6347	18	94.4	19	29			
6	2	5887	M	3782	14	129.469	0.6884	465	94.3	493	717	42.54	169.73	0.07
6	2	5887	M	3783	14	129.469	0.7117	498	94.3	528	742			
6	2	5887	M	4936	Nec	123.660	0.6182	19	94.4	20	33	1.68	6.71	0.00
6	2	5887	M	4937	Nec	123.660	0.6189	16	94.5	17	28			
6	2	5894	M	3784	14	129.072	0.7088	79	94.3	84	118	7.12	28.41	0.01
6	2	5894	M	3785	14	129.072	0.7147	85	94.4	91	127			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	2	5894	M	4938	Nec	125.793	0.6189	767	94.5	812	1312	74.46	297.09	0.13
6	2	5894	M	4939	Nec	125.793	0.6162	766	94.5	811	1316			
6	2	5903	F	3786	14	130.387	0.6495	38	94.4	40	62	3.71	14.79	0.01
6	2	5903	F	3787	14	130.387	0.6797	41	94.3	44	64			
6	2	5903	F	4940	Nec	122.047	0.6271	35	94.5	37	59	3.41	13.61	0.01
6	2	5903	F	4941	Nec	122.047	0.6105	38	94.4	40	65			
6	2	5912	F	3788	14	133.166	0.6884	11	94.4	12	17	1.11	4.43	0.00
6	2	5912	F	3789	14	133.166	0.6607	13	94.4	13	20			
6	2	5912	F	4942	Nec	125.257	0.6193	22	94.4	23	37	2.38	9.51	0.00
6	2	5912	F	4943	Nec	125.257	0.5794	26	94.5	28	48			
6	2	5917	F	3790	14	128.518	0.6698	60	94.4	64	96	5.47	21.84	0.01
6	2	5917	F	3791	14	128.518	0.6804	60	94.4	64	94			
6	2	5917	F	4944	Nec	124.410	0.6472	34	94.4	36	55	3.04	12.14	0.01
6	2	5917	F	4945	Nec	124.410	0.6443	33	94.4	34	54			
6	2	5919	F	3792	14	128.164	0.6721	53	94.3	56	84	4.72	18.83	0.01
6	2	5919	F	3793	14	128.164	0.6696	50	94.4	53	80			
6	2	5919	F	4946	Nec	125.372	0.6252	10	94.4	11	17	1.04	4.15	0.00
6	2	5919	F	4947	Nec	125.372	0.6284	12	94.5	12	19			
7	1	5872	M	4120	Nec	130.821	0.6363	24	94.5	26	40	2.48	29.74	0.01
7	1	5872	M	4121	Nec	130.821	0.6339	26	94.5	28	44			
7	1	5873	M	4122	Nec	129.988	0.6468	4	94.5	4	6	0.43	5.14	0.00
7	1	5873	M	4123	Nec	129.988	0.6529	5	94.5	5	8			
7	1	5874	M	4124	Nec	126.024	0.6506	84	94.5	88	136	7.97	95.35	0.03
7	1	5874	M	4125	Nec	126.024	0.6469	89	94.4	94	145			
7	1	5882	M	4126	Nec	128.090	0.6412	21	94.5	22	34	2.11	25.27	0.01
7	1	5882	M	4127	Nec	128.090	0.6459	24	94.5	25	39			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5901	F	4128	Nec	131.624	0.6549	1665	94.5	1763	2691	163.46	1956.61	0.58
7	1	5901	F	4129	Nec	131.624	0.6523	1740	94.5	1841	2823			
7	1	5902	F	4130	Nec	127.157	0.6650	2495	94.4	2641	3972	228.83	2738.97	0.80
7	1	5902	F	4131	Nec	127.157	0.6571	2494	94.4	2641	4018			
7	1	5913	F	4132	Nec	127.373	0.6558	198	94.5	210	320	18.79	224.89	0.07
7	1	5913	F	4133	Nec	127.373	0.6267	199	94.5	210	335			
7	1	5920	F	4134	Nec	135.052	0.5472	955	94.6	1010	1845	113.82	1362.42	0.42
7	1	5920	F	4135	Nec	135.052	0.6475	1160	94.4	1228	1897			
7	2	5878	M	4101	14	126.714	0.6599	17	94.5	17	26	1.40	16.73	0.00
7	2	5878	M	4102	14	126.714	0.6354	14	94.5	14	22			
7	2	5878	M	5004	Nec	125.263	0.6369	457	94.4	484	760	42.76	511.83	0.07
7	2	5878	M	5005	Nec	125.263	0.6088	434	94.4	460	756			
7	2	5886	M	4103	14	129.003	0.6120	15	94.5	16	26	1.27	15.22	0.00
7	2	5886	M	4104	14	129.003	0.5201	9	94.6	9	17			
7	2	5886	M	5006	Nec	126.149	0.6473	0	94.4	0	0	0.00	0.00	0.00
7	2	5886	M	5007	Nec	126.149	0.6419	0	94.4	0	0			
7	2	5891	M	4105	14	130.065	0.6656	1445	94.4	1530	2299	135.19	1618.19	0.23
7	2	5891	M	4106	14	130.065	0.6521	1427	94.5	1510	2316			
7	2	5891	M	5008	Nec	125.329	0.6424	250	94.4	265	412	23.20	277.70	0.04
7	2	5891	M	5009	Nec	125.329	0.6363	246	94.4	261	410			
7	2	5892	M	4107	14	128.439	0.5907	6	94.5	7	11	0.42	4.97	0.00
7	2	5892	M	4108	14	128.439	0.6534	2	94.5	2	3			
7	2	5892	M	5010	Nec	127.084	0.6239	0	94.4	0	0	0.00	0.00	0.00
7	2	5892	M	5011	Nec	127.084	0.6443	0	94.4	0	0			
7	2	5905	F	4109	14	130.474	0.6624	14	94.5	15	22	1.13	13.53	0.00
7	2	5905	F	4110	14	130.474	0.6380	10	94.5	10	16			

TABLE F1. Liquid Scintillation Analyses of Soap Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5905	F	5012	Nec	125.210	0.6458	0	94.3	0	0	0.00	0.00	0.00
7	2	5905	F	5013	Nec	125.210	0.6482	0	94.3	0	0			
7	2	5906	F	4111	14	130.153	0.6688	5	94.5	5	7	0.23	2.73	0.00
7	2	5906	F	4112	14	130.153	0.6550	0	94.5	0	0			
7	2	5906	F	5014	Nec	125.580	0.6380	0	94.4	0	0	0.00	0.00	0.00
7	2	5906	F	5015	Nec	125.580	0.6265	0	94.4	0	0			
7	2	5908	F	4113	14	128.319	0.6661	3	94.4	4	5	0.18	2.16	0.00
7	2	5908	F	4114	14	128.319	0.6501	1	94.5	1	1			
7	2	5908	F	5016	Nec	125.899	0.6407	0	94.4	0	0	0.00	0.00	0.00
7	2	5908	F	5017	Nec	125.899	0.6474	0	94.4	0	0			
7	2	5914	F	4115	14	128.719	0.6339	255	94.5	270	425	24.43	292.46	0.04
7	2	5914	F	4116	14	128.719	0.6543	258	94.5	273	418			
7	2	5914	F	5018	Nec	125.074	0.6260	12	94.4	13	21	1.08	12.90	0.00
7	2	5914	F	5019	Nec	125.074	0.6323	10	94.4	11	17			

Analyses That Were Not Used for Calculations:

												Reason for Exclusion:
1	2	5332	M	6605	Nec	131.548	0.6268	56	94.5	60	95	Confirmatory.
1	2	5332	M	6606	Nec	131.548	0.6259	54	94.5	57	91	
3	4	5724	M	6607	Nec	130.695	0.6468	16	94.5	17	26	Confirmatory.
3	4	5724	M	6608	Nec	130.695	0.6220	13	94.5	14	23	

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	1	5331	M	679	Nec	131.977	0.6343	2941	94.7	3106	4897	284.73	135.79	5.24
1	1	5331	M	680	Nec	131.977	0.6335	2809	94.7	2966	4682			
1	1	5339	M	4522	Nec	131.183	0.6398	1833	94.7	1935	3025	177.87	84.83	3.23
1	1	5339	M	4523	Nec	131.183	0.6401	1816	94.7	1917	2995			
1	1	5340	M	683	Nec	129.919	0.6439	1987	94.7	2097	3257	186.87	89.12	3.50
1	1	5340	M	684	Nec	129.919	0.6413	1900	94.7	2007	3130			
1	1	5355	F	685	Nec	130.135	0.6445	2331	94.7	2461	3819	221.98	105.86	4.08
1	1	5355	F	686	Nec	130.135	0.6406	2278	94.7	2405	3755			
1	1	5356	F	687	Nec	130.060	0.5463	1648	95.1	1733	3171	183.60	87.56	3.35
1	1	5356	F	688	Nec	130.060	0.6338	1858	94.7	1962	3096			
1	1	5362	F	689	Nec	129.453	0.6397	1381	94.7	1458	2279	134.31	64.05	2.51
1	1	5362	F	690	Nec	129.453	0.6419	1415	94.7	1494	2327			
1	2	5332	M	691	Nec	130.320	0.6372	31	94.7	33	51	3.25	1.55	0.06
1	2	5332	M	692	Nec	130.320	0.6137	35	94.8	36	59			
1	2	5342	M	693	Nec	130.262	0.6436	667	94.8	703	1093	62.43	29.77	1.13
1	2	5342	M	694	Nec	130.262	0.6423	629	94.6	665	1035			
1	2	5343	M	695	Nec	130.917	0.6405	917	94.7	968	1512	89.33	42.60	1.62
1	2	5343	M	696	Nec	130.917	0.6254	899	94.7	949	1518			
1	2	5349	F	697	Nec	130.575	0.6377	725	94.7	765	1200	70.43	33.59	1.28
1	2	5349	F	698	Nec	130.575	0.6329	716	94.6	756	1195			
1	2	5350	F	699	Nec	129.372	0.6472	1769	94.6	1869	2888	168.93	80.57	3.12
1	2	5350	F	700	Nec	129.372	0.6582	1813	94.7	1915	2909			
1	2	5363	F	701	Nec	129.923	0.5492	1567	95.2	1646	2997	175.52	83.71	3.19
1	2	5363	F	702	Nec	129.923	0.6296	1790	94.7	1890	3001			
1	3	5327	M	703	Nec	130.886	0.6305	223	94.7	235	373	22.17	10.57	0.40
1	3	5327	M	704	Nec	130.886	0.6121	220	94.8	232	379			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	3	5330	M	705	Nec	130.162	0.6508	1467	94.7	1550	2381	140.62	67.06	2.57
1	3	5330	M	706	Nec	130.162	0.6145	1406	94.7	1484	2416			
1	3	5334	M	707	Nec	130.933	0.6458	14	94.7	15	24	1.77	0.84	0.03
1	3	5334	M	708	Nec	130.933	0.5963	21	94.9	22	36			
1	3	5347	F	709	Nec	131.180	0.6265	16	94.7	17	27	1.14	0.54	0.02
1	3	5347	F	710	Nec	131.180	0.5945	7	94.9	7	12			
1	3	5348	F	4524	Nec	130.894	0.6419	210	94.7	222	345	20.31	9.69	0.37
1	3	5348	F	4525	Nec	130.894	0.6356	207	94.7	219	344			
1	3	5352	F	713	Nec	130.723	0.6405	87	94.7	92	143	8.40	4.01	0.15
1	3	5352	F	714	Nec	130.723	0.6430	87	94.7	91	142			
1	4	5328	M	715	Nec	131.279	0.6411	3	94.7	3	5	0.30	0.14	0.01
1	4	5328	M	716	Nec	131.279	0.6720	3	94.7	3	5			
1	4	5336	M	717	Nec	130.852	0.6302	3	94.7	3	4	0.21	0.10	0.00
1	4	5336	M	718	Nec	130.852	0.6209	2	94.8	2	3			
1	4	5344	M	719	Nec	131.620	0.6410	0	94.7	0	0	0.17	0.08	0.00
1	4	5344	M	720	Nec	131.620	0.6374	3	94.8	3	5			
1	4	5345	M	721	Nec	131.067	0.6180	4	94.8	4	7	0.41	0.20	0.01
1	4	5345	M	722	Nec	131.067	0.6468	5	94.7	5	7			
1	4	5351	F	723	Nec	130.902	0.6478	16	94.7	17	26	1.56	0.74	0.03
1	4	5351	F	724	Nec	130.902	0.6487	16	94.7	17	27			
1	4	5353	F	725	Nec	130.485	0.5427	0	95.2	0	0	0.43	0.21	0.01
1	4	5353	F	726	Nec	130.485	0.6102	9	94.7	9	15			
1	4	5359	F	727	Nec	131.194	0.5791	9	94.9	10	17	0.91	0.44	0.02
1	4	5359	F	728	Nec	131.194	0.6659	9	94.7	9	14			
1	4	5365	F	729	Nec	131.336	0.6493	9	94.7	9	14	0.89	0.43	0.02
1	4	5365	F	730	Nec	131.336	0.6371	10	94.7	10	16			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	5	5329	M	731	Nec	131.708	0.6451	3	94.7	3	4	0.35	0.17	0.01
1	5	5329	M	732	Nec	131.708	0.6574	5	94.6	5	8			
1	5	5333	M	733	Nec	131.410	0.6543	1	94.6	1	2	0.08	0.04	0.00
1	5	5333	M	734	Nec	131.410	0.6537	1	94.7	1	1			
1	5	5341	M	735	Nec	130.905	0.6432	0	94.7	0	0	0.00	0.00	0.00
1	5	5341	M	736	Nec	130.905	0.6449	0	94.7	0	0			
1	5	5360	F	737	Nec	130.470	0.6385	2	94.7	2	3	0.28	0.13	0.01
1	5	5360	F	738	Nec	130.470	0.6520	4	94.7	4	6			
1	5	5364	F	739	Nec	130.556	0.6506	0	94.7	0	0	0.08	0.04	0.00
1	5	5364	F	740	Nec	130.556	0.6527	2	94.7	2	3			
1	5	5366	F	741	Nec	130.991	0.6482	6	94.7	7	10	0.49	0.23	0.01
1	5	5366	F	742	Nec	130.991	0.6348	4	94.7	4	6			
2	1	5836	M	1481	Nec	132.759	0.6447	3892	94.5	4120	6390	381.96	607.22	7.03
2	1	5836	M	1482	Nec	132.759	0.6437	3885	94.6	4109	6384			
2	1	5841	M	1483	Nec	132.363	0.6399	2820	94.6	2981	4658	278.76	443.15	5.17
2	1	5841	M	1484	Nec	132.363	0.6363	2827	94.7	2986	4692			
2	1	5844	M	1485	Nec	132.338	0.6293	1658	94.7	1751	2783	166.72	265.04	3.06
2	1	5844	M	1486	Nec	132.338	0.6276	1670	94.7	1764	2811			
2	1	5853	F	1487	Nec	132.910	0.6219	2025	94.6	2141	3442	207.99	330.64	3.80
2	1	5853	F	1488	Nec	132.910	0.6342	2104	94.6	2224	3506			
2	1	5855	F	1489	Nec	129.734	0.6406	2322	94.6	2453	3829	221.00	351.33	4.23
2	1	5855	F	1490	Nec	129.734	0.6375	2253	94.7	2381	3734			
2	1	5863	F	1491	Nec	132.269	0.6164	3226	94.6	3410	5532	330.18	524.89	6.05
2	1	5863	F	1492	Nec	132.269	0.6175	3244	94.6	3428	5551			
2	2	5832	M	1493	Nec	133.491	0.6321	1512	94.6	1599	2529	152.44	242.34	2.82
2	2	5832	M	1494	Nec	133.491	0.6319	1519	94.6	1606	2541			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	2	5834	M	1495	Nec	131.541	0.6327	2252	94.6	2380	3762	223.59	355.44	4.12
2	2	5834	M	1496	Nec	131.541	0.6337	2270	94.6	2399	3785			
2	2	5845	M	1497	Nec	131.836	0.6356	2837	94.8	2992	4707	278.64	442.97	5.10
2	2	5845	M	1498	Nec	131.836	0.6362	2822	94.8	2976	4678			
2	2	5846	F	1499	Nec	130.481	0.6313	2077	94.8	2190	3469	204.07	324.42	3.74
2	2	5846	F	1500	Nec	130.481	0.6425	2117	94.8	2232	3475			
2	2	5858	F	1501	Nec	129.648	0.6396	2006	94.9	2114	3306	194.95	309.91	3.57
2	2	5858	F	1502	Nec	129.648	0.6365	2035	94.9	2145	3370			
2	2	5860	F	1503	Nec	131.295	0.6391	1488	94.9	1567	2452	145.73	231.67	2.68
2	2	5860	F	1504	Nec	131.295	0.6470	1521	95.0	1602	2476			
2	3	5715	M	1505	Nec	130.453	0.6471	1577	94.9	1661	2566	150.06	238.56	2.74
2	3	5715	M	1506	Nec	130.453	0.6467	1559	94.9	1643	2541			
2	3	5831	M	1507	Nec	129.549	0.6374	557	94.9	587	921	54.66	86.89	1.01
2	3	5831	M	1508	Nec	129.549	0.6377	577	94.9	608	953			
2	3	5837	M	1509	Nec	131.414	0.6379	567	94.9	598	937	55.84	88.78	1.02
2	3	5837	M	1510	Nec	131.414	0.6425	579	94.9	610	950			
2	3	5847	F	1511	Nec	128.417	0.6479	930	95.0	978	1510	87.11	138.48	1.58
2	3	5847	F	1512	Nec	128.417	0.6406	914	95.0	962	1501			
2	3	5850	F	1513	Nec	130.713	0.6479	552	95.0	582	898	52.21	83.00	0.95
2	3	5850	F	1514	Nec	130.713	0.6369	530	94.9	558	876			
2	3	5864	F	1515	Nec	130.619	0.6363	926	95.0	974	1531	89.47	142.23	1.64
2	3	5864	F	1516	Nec	130.619	0.6364	912	95.0	961	1510			
2	4	5713	M	1517	Nec	129.458	0.6326	6	95.0	6	9	0.49	0.77	0.01
2	4	5713	M	1518	Nec	129.458	0.6291	4	94.9	5	7			
2	4	5829	M	1519	Nec	130.728	0.6386	7	95.0	7	11	0.42	0.67	0.01
2	4	5829	M	1520	Nec	130.728	0.6355	2	95.0	2	3			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	4	5830	M	1521	Nec	132.388	0.6358	8	95.1	8	13	0.65	1.03	0.01
2	4	5830	M	1522	Nec	132.388	0.6364	5	95.1	6	9			
2	4	5839	M	1523	Nec	133.107	0.6323	9	95.0	10	15	1.13	1.79	0.02
2	4	5839	M	1524	Nec	133.107	0.6331	13	95.2	14	22			
2	4	5851	F	1525	Nec	131.072	0.6362	162	95.1	171	268	15.16	24.10	0.28
2	4	5851	F	1526	Nec	131.072	0.6242	146	95.0	153	246			
2	4	5852	F	1527	Nec	130.100	0.6384	66	94.9	70	110	6.03	9.59	0.11
2	4	5852	F	1528	Nec	130.100	0.6406	59	95.1	62	96			
2	4	5857	F	1529	Nec	130.374	0.6363	120	95.1	127	199	12.43	19.76	0.23
2	4	5857	F	1530	Nec	130.374	0.6468	138	95.1	145	224			
2	4	5861	F	1531	Nec	130.115	0.6379	53	95.1	55	87	5.27	8.38	0.10
2	4	5861	F	1532	Nec	130.115	0.6419	57	95.1	60	93			
2	5	5720	M	1533	Nec	132.524	0.6460	0	95.1	0	0	0.14	0.23	0.00
2	5	5720	M	1534	Nec	132.524	0.6504	3	95.1	3	5			
2	5	5828	M	1535	Nec	131.005	0.6454	4	95.1	4	7	0.37	0.60	0.01
2	5	5828	M	1536	Nec	131.005	0.6459	4	95.1	4	6			
2	5	5840	M	1537	Nec	130.387	0.6378	4	94.8	4	6	0.33	0.52	0.01
2	5	5840	M	1538	Nec	130.387	0.6410	3	95.0	3	5			
2	5	5848	F	1539	Nec	129.698	0.6438	1	95.1	1	2	0.09	0.14	0.00
2	5	5848	F	1540	Nec	129.698	0.6502	1	95.1	1	1			
2	5	5854	F	1541	Nec	132.035	0.6361	0	95.1	0	0	0.00	0.00	0.00
2	5	5854	F	1542	Nec	132.035	0.6417	0	95.1	0	0			
2	5	5862	F	1543	Nec	132.578	0.6254	0	95.1	0	0	0.00	0.00	0.00
2	5	5862	F	1544	Nec	132.578	0.6176	0	95.1	0	0			
3	1	5723	M	871	Nec	132.098	0.6397	3762	94.7	3971	6208	369.83	1763.78	6.98
3	1	5723	M	872	Nec	132.098	0.6371	3754	94.7	3964	6223			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	1	5733	M	873	Nec	129.914	0.6358	3881	94.7	4099	6447	379.69	1810.83	7.08
3	1	5733	M	874	Nec	129.914	0.6429	3976	94.7	4198	6530			
3	1	5736	M	875	Nec	130.574	0.6452	3058	94.7	3229	5005	294.21	1403.16	5.46
3	1	5736	M	876	Nec	130.574	0.6383	3022	94.7	3191	4999			
3	1	5741	F	877	Nec	131.221	0.6360	1741	94.7	1839	2891	171.22	816.57	3.19
3	1	5741	F	878	Nec	131.221	0.6211	1708	94.7	1803	2903			
3	1	5744	F	879	Nec	132.494	0.6379	2640	94.8	2786	4368	260.92	1244.36	4.83
3	1	5744	F	880	Nec	132.494	0.6339	2628	94.7	2774	4376			
3	1	5762	F	881	Nec	132.303	0.6396	2613	94.7	2759	4313	254.39	1213.25	4.74
3	1	5762	F	882	Nec	132.303	0.6380	2553	94.7	2695	4224			
3	2	5722	M	883	Nec	133.931	0.6305	2172	94.7	2293	3636	219.47	1046.69	4.13
3	2	5722	M	884	Nec	133.931	0.6293	2169	94.7	2290	3640			
3	2	5734	M	885	Nec	131.840	0.6389	2122	94.8	2239	3504	207.20	988.16	3.88
3	2	5734	M	886	Nec	131.840	0.6321	2080	94.7	2196	3474			
3	2	5737	M	887	Nec	131.514	0.6417	1665	94.8	1757	2738	159.57	761.04	3.01
3	2	5737	M	888	Nec	131.514	0.6425	1612	94.7	1702	2649			
3	2	5746	F	889	Nec	132.522	0.6309	1935	94.7	2042	3237	192.77	919.37	3.80
3	2	5746	F	890	Nec	132.522	0.6421	1960	94.8	2069	3222			
3	2	5751	F	891	Nec	132.662	0.6322	990	94.8	1045	1652	97.89	466.86	1.86
3	2	5751	F	892	Nec	132.662	0.6325	973	94.7	1027	1624			
3	2	5761	F	893	Nec	133.180	0.6314	2883	94.8	3040	4815	287.42	1370.75	5.39
3	2	5761	F	894	Nec	133.180	0.6210	2806	94.8	2960	4767			
3	3	5716	M	895	Nec	131.611	0.6618	1280	94.7	1352	2043	123.43	588.65	2.36
3	3	5716	M	896	Nec	131.611	0.6358	1278	94.7	1349	2121			
3	3	5717	M	897	Nec	131.678	0.6414	2125	94.8	2242	3496	203.26	969.39	3.80
3	3	5717	M	898	Nec	131.678	0.5710	1818	94.8	1917	3358			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	3	5726	M	899	Nec	131.348	0.6489	1994	94.7	2105	3244	190.86	910.22	3.55
3	3	5726	M	900	Nec	131.348	0.6459	1962	94.7	2071	3207			
3	3	5739	F	901	Nec	131.794	0.6517	2326	94.7	2456	3769	223.52	1065.99	4.19
3	3	5739	F	902	Nec	131.794	0.6455	2300	94.7	2428	3761			
3	3	5750	F	903	Nec	131.700	0.6597	2440	94.7	2576	3905	230.59	1099.74	4.27
3	3	5750	F	904	Nec	131.700	0.6447	2363	94.8	2494	3869			
3	3	5752	F	905	Nec	132.627	0.6558	771	94.7	814	1241	73.44	350.25	1.38
3	3	5752	F	906	Nec	132.627	0.6550	756	94.7	798	1218			
3	4	5724	M	907	Nec	131.818	0.6432	8	94.8	8	13	0.79	3.76	0.01
3	4	5724	M	908	Nec	131.818	0.6345	8	94.8	9	13			
3	4	5725	M	909	Nec	131.888	0.6405	902	94.8	952	1487	87.94	419.38	1.65
3	4	5725	M	910	Nec	131.888	0.6344	886	94.8	935	1473			
3	4	5727	M	911	Nec	132.119	0.6391	316	94.8	333	522	32.15	153.35	0.60
3	4	5727	M	912	Nec	132.119	0.6390	338	94.8	357	559			
3	4	5735	M	913	Nec	132.429	0.6340	701	94.7	740	1168	69.09	329.52	1.30
3	4	5735	M	914	Nec	132.429	0.6305	687	94.8	724	1149			
3	4	5740	F	915	Nec	131.956	0.6314	60	94.8	63	100	5.80	27.65	0.11
3	4	5740	F	916	Nec	131.956	0.6440	58	94.7	61	95			
3	4	5742	F	917	Nec	132.275	0.6412	557	94.8	587	916	54.41	259.49	1.02
3	4	5742	F	918	Nec	132.275	0.6309	544	94.8	574	910			
3	4	5753	F	919	Nec	131.993	0.6334	976	94.8	1030	1626	96.90	462.11	1.82
3	4	5753	F	920	Nec	131.993	0.6380	987	94.7	1042	1634			
3	4	5756	F	921	Nec	133.113	0.6376	759	94.8	800	1255	75.15	358.39	1.39
3	4	5756	F	922	Nec	133.113	0.6386	758	94.8	799	1251			
3	5	5721	M	923	Nec	129.228	0.6406	2	94.7	2	3	0.33	1.59	0.01
3	5	5721	M	924	Nec	129.228	0.6346	5	94.8	5	8			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	5	5728	M	925	Nec	130.118	0.6407	7	94.7	8	12	0.86	4.11	0.02
3	5	5728	M	926	Nec	130.118	0.6449	11	94.8	11	17			
3	5	5732	M	927	Nec	130.109	0.6460	6	94.8	6	10	0.34	1.62	0.01
3	5	5732	M	928	Nec	130.109	0.6520	1	94.6	1	2			
3	5	5738	F	929	Nec	130.963	0.6468	12	94.6	12	19	0.90	4.28	0.02
3	5	5738	F	930	Nec	130.963	0.6251	7	94.9	7	11			
3	5	5758	F	931	Nec	130.236	0.6298	2	94.6	2	3	0.20	0.94	0.00
3	5	5758	F	932	Nec	130.236	0.6279	2	94.7	2	4			
3	5	5760	F	933	Nec	130.766	0.6230	5	94.8	5	8	0.43	2.04	0.01
3	5	5760	F	934	Nec	130.766	0.6270	4	94.9	4	7			
4	NA	5714	M	1015	Nec	131.242	0.6337	21	94.6	22	35	1.99	9.36	0.04
4	NA	5714	M	1016	Nec	131.242	0.6317	19	94.7	20	32			
4	NA	5718	M	1017	Nec	130.718	0.6328	0	94.8	0	0	0.19	0.88	0.00
4	NA	5718	M	1018	Nec	130.718	0.6274	4	94.7	4	6			
4	NA	5719	M	1019	Nec	133.047	0.6244	16	94.8	17	27	1.51	7.07	0.03
4	NA	5719	M	1020	Nec	133.047	0.6272	14	94.8	15	23			
4	NA	5730	M	1021	Nec	130.895	0.6188	15	94.7	16	26	1.44	6.77	0.03
4	NA	5730	M	1022	Nec	130.895	0.6304	14	94.7	14	23			
4	NA	5743	F	1023	Nec	129.867	0.6287	171	94.8	181	287	17.39	81.66	0.35
4	NA	5743	F	1024	Nec	129.867	0.6327	184	94.7	194	307			
4	NA	5745	F	1025	Nec	129.891	0.6281	98	94.7	104	165	9.88	46.37	0.20
4	NA	5745	F	1026	Nec	129.891	0.6166	101	94.7	107	173			
4	NA	5748	F	1027	Nec	129.962	0.6109	100	94.8	106	173	10.12	47.51	0.20
4	NA	5748	F	1028	Nec	129.962	0.6087	100	94.7	105	173			
4	NA	5754	F	4526	Nec	129.367	0.6427	94	94.7	99	155	8.90	41.80	0.18
4	NA	5754	F	4527	Nec	129.367	0.6237	89	94.7	94	151			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	1	5871	M	3599	Nec	128.726	0.6590	22	94.4	23	35	2.15	2.58	0.01
5	1	5871	M	3600	Nec	128.726	0.6568	24	94.4	26	39			
5	1	5883	M	3601	Nec	132.152	0.6827	66	94.3	70	103	5.76	6.90	0.02
5	1	5883	M	3602	Nec	132.152	0.6687	57	94.3	61	91			
5	1	5884	M	3603	Nec	130.187	0.6664	38	94.4	40	61	3.59	4.29	0.01
5	1	5884	M	3604	Nec	130.187	0.6570	38	94.4	41	62			
5	1	5889	M	3605	Nec	131.452	0.6425	30	94.4	32	50	3.04	3.64	0.01
5	1	5889	M	3606	Nec	131.452	0.6623	33	94.4	35	52			
5	1	5896	F	3607	Nec	129.496	0.6920	5	94.3	5	8	0.33	0.40	0.00
5	1	5896	F	3608	Nec	129.496	0.6595	2	94.3	2	3			
5	1	5899	F	3609	Nec	132.650	0.6619	18	94.3	19	29	1.79	2.14	0.01
5	1	5899	F	3610	Nec	132.650	0.6750	20	94.3	21	31			
5	1	5900	F	3611	Nec	131.889	0.6698	22	94.3	24	35	2.13	2.55	0.01
5	1	5900	F	3612	Nec	131.889	0.6740	23	94.3	25	36			
5	1	5921	F	3613	Nec	133.321	0.6742	9	94.4	10	14	1.18	1.41	0.00
5	1	5921	F	3614	Nec	133.321	0.6645	16	94.3	17	25			
5	2	5869	M	3631	14	126.104	0.6738	27	94.3	28	42	2.49	2.97	0.00
5	2	5869	M	3632	14	126.104	0.6665	29	94.3	30	45			
5	2	5869	M	4884	Nec	126.185	0.6514	45	94.4	48	73	4.05	4.85	0.01
5	2	5869	M	4885	Nec	126.185	0.6534	43	94.4	45	69			
5	2	5870	M	3633	14	126.214	0.6506	29	94.3	31	47	2.58	3.09	0.00
5	2	5870	M	3634	14	126.214	0.6539	27	94.3	28	44			
5	2	5870	M	4886	Nec	127.542	0.6349	42	94.5	45	70	4.10	4.91	0.01
5	2	5870	M	4887	Nec	127.542	0.6492	44	94.5	47	72			
5	2	5888	M	3635	14	126.939	0.6505	18	94.4	19	29	1.28	1.53	0.00
5	2	5888	M	3636	14	126.939	0.6200	9	94.4	10	16			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5888	M	4888	Nec	127.170	0.6435	37	94.4	39	61	3.55	4.25	0.01
5	2	5888	M	4889	Nec	127.170	0.6389	38	94.4	40	63			
5	2	5893	M	3637	14	129.669	0.6629	11	94.3	12	18	1.23	1.47	0.00
5	2	5893	M	3638	14	129.669	0.7046	16	94.3	17	24			
5	2	5893	M	4890	Nec	126.989	0.5053	30	94.6	32	63	3.20	3.83	0.01
5	2	5893	M	4891	Nec	126.989	0.5843	27	94.7	28	48			
5	2	5910	F	3639	14	124.296	0.6497	6	94.4	6	10	0.40	0.48	0.00
5	2	5910	F	3640	14	124.296	0.6698	3	94.3	3	5			
5	2	5910	F	4892	Nec	124.530	0.6543	27	94.4	29	44	2.46	2.95	0.00
5	2	5910	F	4893	Nec	124.530	0.6534	27	94.4	29	44			
5	2	5911	F	3641	14	127.263	0.6745	26	94.3	27	40	2.37	2.84	0.00
5	2	5911	F	3642	14	127.263	0.6698	27	94.3	28	42			
5	2	5911	F	4894	Nec	125.483	0.6478	43	94.4	46	70	3.97	4.76	0.01
5	2	5911	F	4895	Nec	125.483	0.6527	43	94.4	46	70			
5	2	5915	F	3643	14	128.035	0.6417	19	94.4	20	32	1.64	1.96	0.00
5	2	5915	F	3644	14	128.035	0.6561	16	94.3	16	25			
5	2	5915	F	4896	Nec	127.363	0.6598	36	94.4	38	57	3.17	3.80	0.01
5	2	5915	F	4897	Nec	127.363	0.6791	34	94.4	36	54			
5	2	5916	F	3645	14	127.022	0.6291	9	94.4	9	14	0.97	1.16	0.00
5	2	5916	F	3646	14	127.022	0.6346	12	94.4	12	19			
5	2	5916	F	4898	Nec	125.258	0.6518	29	94.4	30	47	2.97	3.55	0.01
5	2	5916	F	4899	Nec	125.258	0.6591	36	94.4	39	58			
6	1	5867	M	3730	Nec	128.993	0.6449	2	94.3	2	3	0.09	0.35	0.00
6	1	5867	M	3731	Nec	128.993	0.6066	0	94.4	0	0			
6	1	5868	M	3732	Nec	131.013	0.6497	32	94.4	34	52	3.19	12.73	0.01
6	1	5868	M	3733	Nec	131.013	0.6360	33	94.4	35	56			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5875	M	3734	Nec	128.807	0.6417	18	94.4	19	29	1.70	6.77	0.01
6	1	5875	M	3735	Nec	128.807	0.6402	18	94.4	19	29			
6	1	5881	M	3736	Nec	128.868	0.6514	0	94.4	0	0	0.00	0.00	0.00
6	1	5881	M	3737	Nec	128.868	0.6481	0	94.4	0	0			
6	1	5895	F	3738	Nec	128.535	0.6635	17	94.4	18	28	1.30	5.21	0.00
6	1	5895	F	3739	Nec	128.535	0.6433	10	94.4	11	17			
6	1	5907	F	3740	Nec	128.428	0.6507	0	94.4	0	0	0.00	0.00	0.00
6	1	5907	F	3741	Nec	128.428	0.6514	0	94.4	0	0			
6	1	5909	F	3742	Nec	126.759	0.6476	9	94.4	10	15	0.82	3.27	0.00
6	1	5909	F	3743	Nec	126.759	0.6228	8	94.4	9	14			
6	1	5918	F	3744	Nec	125.573	0.6365	13	94.4	14	21	1.03	4.13	0.00
6	1	5918	F	3745	Nec	125.573	0.6381	9	94.4	10	15			
6	2	5880	M	3762	14	130.527	0.6371	31	94.5	33	51	2.91	11.60	0.00
6	2	5880	M	3763	14	130.527	0.6519	29	94.5	31	48			
6	2	5880	M	4916	Nec	124.995	0.6597	16	94.4	16	25	1.38	5.50	0.00
6	2	5880	M	4917	Nec	124.995	0.6497	15	94.4	16	24			
6	2	5885	M	3764	14	129.080	0.6822	55	94.4	58	85	4.78	19.08	0.01
6	2	5885	M	3765	14	129.080	0.6736	51	94.4	54	80			
6	2	5885	M	4918	Nec	126.032	0.6386	26	94.4	28	44	2.35	9.39	0.00
6	2	5885	M	4919	Nec	126.032	0.6423	24	94.4	25	39			
6	2	5887	M	3766	14	130.927	0.6381	201	94.5	213	334	19.19	76.56	0.03
6	2	5887	M	3767	14	130.927	0.6550	196	94.4	208	317			
6	2	5887	M	4920	Nec	125.024	0.6259	24	94.4	26	41	2.52	10.07	0.00
6	2	5887	M	4921	Nec	125.024	0.6315	29	94.4	30	48			
6	2	5894	M	3768	14	131.906	0.6566	70	94.4	74	112	6.54	26.09	0.01
6	2	5894	M	3769	14	131.906	0.6498	66	94.5	70	108			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	2	5894	M	4922	Nec	125.773	0.6329	260	94.4	276	436	24.16	96.41	0.04
6	2	5894	M	4923	Nec	125.773	0.6470	255	94.4	270	417			
6	2	5903	F	3770	14	127.356	0.6629	32	94.4	34	51	2.96	11.81	0.01
6	2	5903	F	3771	14	127.356	0.6585	33	94.4	34	52			
6	2	5903	F	4924	Nec	124.065	0.6492	47	94.4	50	77	4.41	17.59	0.01
6	2	5903	F	4925	Nec	124.065	0.6463	49	94.4	52	81			
6	2	5912	F	3772	14	132.039	0.6723	23	94.4	25	37	1.99	7.93	0.00
6	2	5912	F	3773	14	132.039	0.6684	19	94.4	20	30			
6	2	5912	F	4926	Nec	125.104	0.6232	21	94.5	22	36	2.29	9.13	0.00
6	2	5912	F	4927	Nec	125.104	0.6087	26	94.4	28	45			
6	2	5917	F	3774	14	134.605	0.6560	47	94.3	50	76	4.66	18.59	0.01
6	2	5917	F	3775	14	134.605	0.6496	48	94.5	51	78			
6	2	5917	F	4928	Nec	125.138	0.6437	23	94.4	24	38	2.21	8.83	0.00
6	2	5917	F	4929	Nec	125.138	0.6432	25	94.4	26	41			
6	2	5919	F	3776	14	129.364	0.6632	20	94.3	21	31	1.87	7.47	0.00
6	2	5919	F	3777	14	129.364	0.6620	21	94.4	22	33			
6	2	5919	F	4930	Nec	124.486	0.6312	19	94.3	20	31	1.55	6.19	0.00
6	2	5919	F	4931	Nec	124.486	0.6373	14	94.4	15	24			
7	1	5872	M	4152	Nec	130.737	0.6509	15	94.5	15	24	1.40	16.73	0.00
7	1	5872	M	4153	Nec	130.737	0.6377	19	94.5	20	31			
7	1	5873	M	4154	Nec	130.038	0.6513	12	94.5	12	19	1.02	12.18	0.00
7	1	5873	M	4155	Nec	130.038	0.6396	9	94.4	10	16			
7	1	5874	M	4156	Nec	130.819	0.6534	42	94.5	44	68	4.00	47.82	0.01
7	1	5874	M	4157	Nec	130.819	0.6567	42	94.5	45	68			
7	1	5882	M	4158	Nec	129.374	0.5974	13	94.5	14	23	1.39	16.59	0.00
7	1	5882	M	4159	Nec	129.374	0.6518	15	94.5	16	24			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5901	F	4160	Nec	130.810	0.6545	785	94.5	830	1269	74.64	893.46	0.26
7	1	5901	F	4161	Nec	130.810	0.6533	781	94.5	826	1265			
7	1	5902	F	4162	Nec	128.486	0.6485	662	94.5	701	1081	62.83	752.03	0.22
7	1	5902	F	4163	Nec	128.486	0.6143	633	94.5	670	1090			
7	1	5913	F	4164	Nec	128.136	0.6523	173	94.4	183	281	16.19	193.80	0.06
7	1	5913	F	4165	Nec	128.136	0.6504	172	94.4	182	280			
7	1	5920	F	4166	Nec	130.299	0.6565	428	94.5	453	690	40.56	485.51	0.15
7	1	5920	F	4167	Nec	130.299	0.6566	429	94.5	454	692			
7	2	5878	M	4136	14	129.065	0.6469	28	94.5	30	46	2.93	35.09	0.01
7	2	5878	M	4137	14	129.065	0.6381	33	94.5	35	54			
7	2	5878	M	4988	Nec	125.748	0.6366	347	94.4	368	578	33.12	396.44	0.06
7	2	5878	M	4989	Nec	125.748	0.6341	354	94.4	375	592			
7	2	5886	M	4138	14	128.445	0.6638	21	94.5	22	33	1.90	22.77	0.00
7	2	5886	M	4139	14	128.445	0.6496	20	94.5	21	33			
7	2	5886	M	4990	Nec	124.191	0.6252	0	94.4	0	0	0.00	0.00	0.00
7	2	5886	M	4991	Nec	124.191	0.6302	0	94.5	0	0			
7	2	5891	M	4140	14	128.160	0.6557	687	94.5	727	1109	63.72	762.75	0.11
7	2	5891	M	4141	14	128.160	0.6343	658	94.5	697	1098			
7	2	5891	M	4992	Nec	125.053	0.6549	237	94.4	251	383	21.11	252.72	0.04
7	2	5891	M	4993	Nec	125.053	0.6569	227	94.4	241	367			
7	2	5892	M	4142	14	130.771	0.6522	6	94.5	7	10	0.51	6.14	0.00
7	2	5892	M	4143	14	130.771	0.6488	4	94.5	5	7			
7	2	5892	M	4994	Nec	126.699	0.6439	0	94.4	0	0	0.00	0.00	0.00
7	2	5892	M	4995	Nec	126.699	0.6620	0	94.4	0	0			
7	2	5905	F	4144	14	128.826	0.6533	19	94.5	20	30	1.78	21.34	0.00
7	2	5905	F	4145	14	128.826	0.6527	19	94.4	20	31			

TABLE F2. Liquid Scintillation Analyses of Water Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (Day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5905	F	4996	Nec	125.787	0.6353	0	94.4	0	0	0.00	0.00	0.00
7	2	5905	F	4997	Nec	125.787	0.6469	0	94.4	0	0			
7	2	5906	F	4146	14	130.867	0.5264	5	94.6	5	10	0.96	11.52	0.00
7	2	5906	F	4147	14	130.867	0.6714	15	94.4	15	23			
7	2	5906	F	4998	Nec	125.881	0.6499	0	94.4	0	0	0.00	0.00	0.00
7	2	5906	F	4999	Nec	125.881	0.6506	0	94.4	0	0			
7	2	5908	F	4148	14	128.563	0.5625	16	94.5	17	30	1.15	13.73	0.00
7	2	5908	F	4149	14	128.563	0.6643	6	94.5	6	10			
7	2	5908	F	5000	Nec	124.668	0.6375	0	94.4	0	0	0.00	0.00	0.00
7	2	5908	F	5001	Nec	124.668	0.6443	0	94.4	0	0			
7	2	5914	F	4150	14	129.153	0.6509	440	94.5	465	715	41.45	496.18	0.07
7	2	5914	F	4151	14	129.153	0.6332	425	94.5	450	710			
7	2	5914	F	5002	Nec	123.711	0.6278	1	94.4	1	2	0.27	3.29	0.00
7	2	5914	F	5003	Nec	123.711	0.6350	5	94.4	5	8			

Analyses That Were Not Used for Calculations:

												Reason for Exclusion:
1	1	5339	M	681	Nec	131.183	0.6706	3046	94.6	3219	4801	Poor replication.
1	1	5339	M	682	Nec	131.183	0.6336	2035	94.7	2148	3390	
1	3	5348	F	711	Nec	130.894	0.5631	222	95.1	233	414	Poor replication.
1	3	5348	F	712	Nec	130.894	0.6586	213	94.7	225	341	
4	NA	5754	F	1029	Nec	129.367	0.6248	81	94.7	86	137	No weight for 2nd aliquot.
4	NA	5754	F	1030	Nec	129.367	0.0000	89	94.7	94	NA	

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	1	5331	M	743	0.6808	10.8048	0.0347	8202	93.7	8756	252329	1223.17	583.35	856.86	22.51
1	1	5331	M	744	0.6808	10.8048	0.0386	9034	93.5	9662	250308				
1	1	5339	M	745	0.7274	11.8374	0.0584	6262	93.5	6696	114659	614.91	293.26	403.16	11.16
1	1	5339	M	746	0.7274	11.8374	0.0566	6139	93.5	6565	115983				
1	1	5340	M	747	0.5971	9.9671	0.0448	9033	93.9	9620	214729	978.42	466.62	781.49	18.34
1	1	5340	M	748	0.5971	9.9671	0.0523	10826	93.6	11565	221123				
1	1	5355	F	749	0.4791	9.4621	0.0557	10408	92.8	11211	201270	855.03	407.78	851.14	15.72
1	1	5355	F	750	0.4791	9.4621	0.0567	10517	92.8	11337	199946				
1	1	5356	F	751	0.5896	10.8726	0.0464	7603	93.7	8111	174804	859.20	409.77	694.99	15.69
1	1	5356	F	752	0.5896	10.8726	0.0506	8350	93.7	8909	176063				
1	1	5362	F	753	0.9678	14.0558	0.0472	6451	93.3	6912	146441	916.01	436.86	451.39	17.11
1	1	5362	F	754	0.9678	14.0558	0.0567	7554	93.2	8103	142910				
1	2	5332	M	755	0.7711	13.1991	0.0561	859	93.6	919	16374	98.29	46.88	60.79	1.77
1	2	5332	M	756	0.7711	13.1991	0.0565	881	93.5	943	16689				
1	2	5342	M	757	0.7078	12.1858	0.0576	3053	93.2	3277	56886	311.93	148.76	210.18	5.62
1	2	5342	M	758	0.7078	12.1858	0.0604	3191	93.1	3429	56768				
1	2	5343	M	759	1.0635	14.5645	0.0527	3523	94.8	3718	70556	457.02	217.96	204.95	8.29
1	2	5343	M	760	1.0635	14.5645	0.0453	2953	94.8	3115	68768				
1	2	5349	F	761	0.5630	10.2870	0.0556	3550	93.6	3793	68221	316.57	150.98	268.17	5.76
1	2	5349	F	762	0.5630	10.2870	0.0517	3312	93.6	3537	68417				
1	2	5350	F	763	0.6005	10.2305	0.0438	9681	93.3	10378	236931	1095.13	522.28	869.75	20.25
1	2	5350	F	764	0.6005	10.2305	0.0497	11030	93.1	11846	238351				
1	2	5363	F	765	1.0237	14.7637	0.0445	4910	93.8	5232	117571	780.26	372.12	363.50	14.16
1	2	5363	F	766	1.0237	14.7637	0.0593	6493	93.5	6943	117082				
1	3	5327	M	767	0.8390	12.8060	0.0539	1048	94.0	1114	20675	119.12	56.81	67.71	2.17
1	3	5327	M	768	0.8390	12.8060	0.0504	977	94.0	1039	20625				
1	3	5330	M	769	0.7144	12.9004	0.0524	1947	93.9	2074	39581	229.53	109.47	153.23	4.19
1	3	5330	M	770	0.7144	12.9004	0.0534	1976	93.9	2105	39417				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	3	5334	M	771	0.7781	11.4411	0.0516	379	93.5	405	7843	39.86	19.01	24.43	0.73
1	3	5334	M	772	0.7781	11.4411	0.0489	349	93.6	373	7624				
1	3	5347	F	773	0.6043	9.0793	0.0460	464	93.3	497	10811	44.32	21.14	34.98	0.80
1	3	5347	F	774	0.6043	9.0793	0.0461	467	93.3	501	10862				
1	3	5348	F	775	0.7261	9.1661	0.0514	1130	92.9	1216	23665	99.09	47.26	65.09	1.82
1	3	5348	F	776	0.7261	9.1661	0.0503	1138	93.0	1224	24335				
1	3	5352	F	777	1.0289	13.4739	0.0505	638	94.0	679	13444	81.33	38.79	37.70	1.47
1	3	5352	F	778	1.0289	13.4739	0.0472	593	94.1	630	13356				
1	4	5328	M	779	0.8520	9.7830	0.0525	255	94.7	269	5129	22.11	10.54	12.38	0.40
1	4	5328	M	780	0.8520	9.7830	0.0414	193	94.8	203	4905				
1	4	5336	M	781	0.7191	10.1121	0.0572	253	94.0	269	4705	21.17	10.10	14.04	0.39
1	4	5336	M	782	0.7191	10.1121	0.0570	246	94.0	262	4591				
1	4	5344	M	783	0.8129	12.8169	0.0539	187	93.2	201	3727	21.32	10.17	12.51	0.39
1	4	5344	M	784	0.8129	12.8169	0.0586	200	93.1	214	3660				
1	4	5345	M	785	0.7204	9.7214	0.0507	223	93.2	239	4714	20.57	9.81	13.62	0.37
1	4	5345	M	786	0.7204	9.7214	0.0459	200	93.3	215	4681				
1	4	5351	F	787	0.9726	12.5856	0.0533	466	93.2	500	9386	53.27	25.41	26.12	0.97
1	4	5351	F	788	0.9726	12.5856	0.0543	476	93.2	511	9408				
1	4	5353	F	789	0.7836	10.0266	0.0515	331	94.2	352	6835	30.89	14.73	18.80	0.56
1	4	5353	F	790	0.7836	10.0266	0.0511	329	94.2	350	6846				
1	4	5359	F	791	0.8922	12.1022	0.0575	461	94.9	486	8454	45.51	21.71	24.33	0.82
1	4	5359	F	792	0.8922	12.1022	0.0574	449	94.9	473	8243				
1	4	5365	F	793	0.8371	11.7111	0.0549	819	94.3	868	15811	83.87	40.00	47.78	1.53
1	4	5365	F	794	0.8371	11.7111	0.0559	843	94.3	894	15986				
1	5	5329	M	795	0.7977	10.1677	0.0468	159	93.8	170	3630	16.60	7.92	9.93	0.31
1	5	5329	M	796	0.7977	10.1677	0.0510	173	93.8	185	3619				
1	5	5333	M	797	0.8533	11.5923	0.0507	147	95.0	155	3055	16.00	7.63	8.94	0.29
1	5	5333	M	798	0.8533	11.5923	0.0516	151	95.0	159	3074				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	5	5341	M	799	0.8088	10.2188	0.0536	169	94.9	178	3315	15.02	7.16	8.86	0.28
1	5	5341	M	800	0.8088	10.2188	0.0542	165	95.0	174	3212				
1	5	5360	F	801	0.7023	10.8383	0.0503	163	94.7	172	3420	16.55	7.89	11.24	0.30
1	5	5360	F	802	0.7023	10.8383	0.0516	164	94.8	173	3361				
1	5	5364	F	803	0.9385	12.3965	0.0496	278	95.0	293	5911	33.65	16.05	17.10	0.62
1	5	5364	F	804	0.9385	12.3965	0.0567	331	94.9	348	6142				
1	5	5366	F	805	0.7415	11.3635	0.0495	269	94.9	283	5714	29.59	14.11	19.03	0.54
1	5	5366	F	806	0.7415	11.3635	0.0517	287	94.9	302	5847				
2	1	5836	M	1545	0.9227	10.4977	0.0437	6079	93.4	6510	148979	696.79	1107.71	1200.51	12.83
2	1	5836	M	1546	0.9227	10.4977	0.0547	7419	93.1	7971	145729				
2	1	5841	M	1547	1.0682	13.0652	0.0572	4802	93.3	5146	89962	529.75	842.15	788.38	9.82
2	1	5841	M	1548	1.0682	13.0652	0.0580	4873	93.3	5224	90064				
2	1	5844	M	1549	0.7332	8.6522	0.0486	6450	92.8	6951	143028	553.96	880.65	1201.10	10.18
2	1	5844	M	1550	0.7332	8.6522	0.0539	7050	92.6	7613	141246				
2	1	5853	F	1551	0.5546	7.4226	0.0465	5469	92.6	5904	126961	426.64	678.24	1222.94	7.79
2	1	5853	F	1552	0.5546	7.4226	0.0394	4695	92.9	5053	128245				
2	1	5855	F	1553	0.7347	9.3587	0.0521	5459	92.9	5877	112810	476.01	756.73	1029.98	9.10
2	1	5855	F	1554	0.7347	9.3587	0.0558	5851	92.8	6307	113022				
2	1	5863	F	1555	1.0360	13.7710	0.0595	4780	94.3	5071	85230	535.51	851.32	821.74	9.81
2	1	5863	F	1556	1.0360	13.7710	0.0617	5083	94.2	5394	87429				
2	2	5832	M	1557	1.0164	13.2714	0.0499	4947	95.0	5209	104396	625.65	994.61	978.56	11.58
2	2	5832	M	1558	1.0164	13.2714	0.0484	4823	95.0	5078	104917				
2	2	5834	M	1559	1.0678	13.7148	0.0530	3255	94.7	3439	64878	402.22	639.42	598.82	7.41
2	2	5834	M	1560	1.0678	13.7148	0.0538	3327	94.6	3515	65336				
2	2	5845	M	1561	1.0548	13.6078	0.0487	4479	94.9	4720	96915	596.88	948.87	899.57	10.93
2	2	5845	M	1562	1.0548	13.6078	0.0520	4828	94.9	5088	97837				
2	2	5846	F	1563	0.6695	9.2135	0.0527	3985	94.8	4204	79781	330.34	525.15	784.39	6.05
2	2	5846	F	1564	0.6695	9.2135	0.0542	4077	94.7	4304	79411				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	2	5858	F	1565	0.5695	8.6245	0.0553	5038	93.6	5383	97343	377.28	599.76	1053.14	6.91
2	2	5858	F	1566	0.5695	8.6245	0.0566	5131	93.6	5484	96883				
2	2	5860	F	1567	0.4251	7.6651	0.0518	9515	92.7	10269	198252	685.42	1089.62	2563.21	12.58
2	2	5860	F	1568	0.4251	7.6651	0.0523	9622	92.6	10396	198774				
2	3	5715	M	1569	0.6627	9.3177	0.0522	5510	95.0	5798	111080	462.64	735.47	1109.81	8.45
2	3	5715	M	1570	0.6627	9.3177	0.0491	5104	95.0	5370	109375				
2	3	5831	M	1571	0.7279	13.0359	0.0496	1521	95.1	1599	32243	190.68	303.12	416.43	3.51
2	3	5831	M	1572	0.7279	13.0359	0.0466	1449	95.1	1524	32701				
2	3	5837	M	1573	0.8162	13.6962	0.0556	1910	95.1	2008	36123	222.45	353.63	433.27	4.07
2	3	5837	M	1574	0.8162	13.6962	0.0555	1897	95.0	1997	35990				
2	3	5847	F	1575	0.5441	9.8821	0.0477	3961	95.1	4166	87332	388.43	617.50	1134.90	7.06
2	3	5847	F	1576	0.5441	9.8821	0.0511	4234	95.0	4455	87189				
2	3	5850	F	1577	0.9218	13.9218	0.0543	1882	94.9	1984	36535	230.14	365.87	396.90	4.18
2	3	5850	F	1578	0.9218	13.9218	0.0588	2056	94.8	2168	36863				
2	3	5864	F	1579	0.8261	12.0601	0.0524	2590	94.6	2738	52256	280.80	446.39	540.36	5.13
2	3	5864	F	1580	0.8261	12.0601	0.0515	2493	94.7	2633	51120				
2	4	5713	M	1581	0.9752	14.1072	0.0577	293	93.4	314	5434	35.26	56.05	57.47	0.64
2	4	5713	M	1582	0.9752	14.1072	0.0604	319	93.3	342	5663				
2	4	5829	M	1583	0.8662	13.3002	0.0560	291	93.2	312	5578	34.71	55.19	63.71	0.62
2	4	5829	M	1584	0.8662	13.3002	0.0577	323	93.2	347	6011				
2	4	5830	M	1585	1.1116	16.5636	0.0501	174	94.2	185	3694	27.52	43.76	39.36	0.50
2	4	5830	M	1586	1.1116	16.5636	0.0584	202	94.1	215	3684				
2	4	5839	M	1587	1.2089	17.6889	0.0552	188	94.7	198	3593	29.36	46.67	38.61	0.54
2	4	5839	M	1588	1.2089	17.6889	0.0591	211	94.6	223	3776				
2	4	5851	F	1589	0.5297	9.9257	0.0544	638	93.0	685	12596	57.10	90.78	171.38	1.06
2	4	5851	F	1590	0.5297	9.9257	0.0573	690	93.0	742	12948				
2	4	5852	F	1591	0.5500	10.7560	0.0568	357	95.0	376	6618	31.60	50.23	91.33	0.57
2	4	5852	F	1592	0.5500	10.7560	0.0562	343	95.1	361	6426				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5857	F	1593	0.6191	13.1921	0.0579	301	93.3	322	5568	33.85	53.82	86.93	0.62
2	4	5857	F	1594	0.6191	13.1921	0.0571	310	93.3	333	5826				
2	4	5861	F	1595	0.5852	10.0952	0.0546	481	94.3	510	9339	42.26	67.18	114.80	0.78
2	4	5861	F	1596	0.5852	10.0952	0.0559	487	94.2	517	9248				
2	5	5720	M	1597	1.0862	15.1882	0.0481	119	93.6	127	2639	16.89	26.85	24.72	0.31
2	5	5720	M	1598	1.0862	15.1882	0.0526	113	93.7	121	2297				
2	5	5828	M	1599	1.0886	14.9326	0.0539	135	93.6	144	2671	17.23	27.40	25.17	0.31
2	5	5828	M	1600	1.0886	14.9326	0.0580	133	93.5	142	2453				
2	5	5840	M	1601	0.7780	11.8130	0.0502	221	93.6	236	4710	25.65	40.78	52.41	0.47
2	5	5840	M	1602	0.7780	11.8130	0.0532	246	93.6	262	4931				
2	5	5848	F	1603	0.5918	9.8248	0.0519	125	93.2	134	2591	11.90	18.92	31.98	0.22
2	5	5848	F	1604	0.5918	9.8248	0.0560	145	93.1	156	2789				
2	5	5854	F	1605	0.7407	12.2077	0.0534	159	95.0	167	3134	17.85	28.38	38.31	0.33
2	5	5854	F	1606	0.7407	12.2077	0.0528	168	95.0	177	3359				
2	5	5862	F	1607	0.8235	13.3255	0.0545	139	93.3	149	2725	16.83	26.75	32.48	0.31
2	5	5862	F	1608	0.8235	13.3255	0.0577	155	93.2	166	2881				
3	1	5723	M	935	0.6502	8.2282	0.0524	4334	93.0	4662	88969	333.27	1589.42	2444.51	6.29
3	1	5723	M	936	0.6502	8.2282	0.0495	4189	93.1	4498	90866				
3	1	5733	M	937	0.8346	9.7496	0.0432	7891	93.7	8421	194940	859.11	4097.26	4909.25	16.03
3	1	5733	M	938	0.8346	9.7496	0.0478	8788	93.7	9383	196303				
3	1	5736	M	939	1.0057	11.6957	0.0433	4622	94.8	4875	112579	588.52	2806.77	2790.86	10.93
3	1	5736	M	940	1.0057	11.6957	0.0480	5045	94.8	5320	110841				
3	1	5741	F	941	0.6790	9.4720	0.0422	7037	94.2	7473	177075	762.57	3636.84	5356.17	14.20
3	1	5741	F	942	0.6790	9.4720	0.0470	7977	94.1	8478	180382				
3	1	5744	F	943	0.9147	11.5147	0.0437	3531	94.6	3733	85424	445.78	2125.98	2324.23	8.25
3	1	5744	F	944	0.9147	11.5147	0.0529	4323	94.5	4574	86464				
3	1	5762	F	945	0.7987	9.9527	0.0415	4449	94.7	4700	113254	509.84	2431.49	3044.31	9.50
3	1	5762	F	946	0.7987	9.9527	0.0488	5270	94.6	5572	114189				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	2	5722	M	947	1.0147	11.8137	0.0421	2098	95.0	2208	52439	277.68	1324.28	1305.10	5.22
3	2	5722	M	948	1.0147	11.8137	0.0525	2588	95.0	2726	51921				
3	2	5734	M	949	0.9846	12.8776	0.0464	3049	95.0	3211	69195	399.85	1906.97	1936.79	7.49
3	2	5734	M	950	0.9846	12.8776	0.0479	3123	94.9	3289	68669				
3	2	5737	M	951	0.9336	11.8966	0.0446	2021	95.0	2127	47692	256.32	1222.45	1309.39	4.83
3	2	5737	M	952	0.9336	11.8966	0.0518	2359	94.9	2485	47972				
3	2	5746	F	953	1.0369	13.0709	0.0473	2272	94.9	2393	50586	299.28	1427.32	1376.52	5.89
3	2	5746	F	954	1.0369	13.0709	0.0484	2348	95.0	2472	51075				
3	2	5751	F	955	0.5758	6.8698	0.0425	2181	92.9	2348	55246	172.33	821.89	1427.38	3.27
3	2	5751	F	956	0.5758	6.8698	0.0496	2577	92.6	2784	56134				
3	2	5761	F	957	0.8613	9.0023	0.0448	4842	93.2	5198	116019	472.43	2253.09	2615.92	8.86
3	2	5761	F	958	0.8613	9.0023	0.0493	5368	93.1	5767	116986				
3	3	5716	M	959	0.9641	12.2991	0.0459	2051	93.6	2192	47766	265.39	1265.70	1312.83	5.08
3	3	5716	M	960	0.9641	12.2991	0.0528	2368	93.3	2537	48041				
3	3	5717	M	961	1.0895	13.4035	0.0479	3150	93.6	3367	70291	424.52	2024.61	1858.29	7.93
3	3	5717	M	962	1.0895	13.4035	0.0514	3378	93.4	3615	70334				
3	3	5726	M	963	0.8682	10.5422	0.0443	3301	94.1	3509	79214	378.65	1805.86	2080.00	7.04
3	3	5726	M	964	0.8682	10.5422	0.0490	3695	94.0	3933	80261				
3	3	5739	F	965	0.7753	9.4033	0.0443	5278	94.1	5608	126588	537.83	2565.01	3308.41	10.07
3	3	5739	F	966	0.7753	9.4033	0.0506	6059	94.0	6445	127362				
3	3	5750	F	967	0.6403	10.3763	0.0467	4929	93.3	5285	113162	527.69	2516.66	3930.44	9.78
3	3	5750	F	968	0.6403	10.3763	0.0489	5140	93.3	5508	112638				
3	3	5752	F	969	0.5921	8.9341	0.0463	1741	94.9	1834	39607	160.75	766.66	1294.82	3.02
3	3	5752	F	970	0.5921	8.9341	0.0514	1965	94.9	2071	40283				
3	4	5724	M	971	0.9885	10.6385	0.0435	95	95.0	100	2303	11.24	53.61	54.24	0.21
3	4	5724	M	972	0.9885	10.6385	0.0532	121	95.0	127	2388				
3	4	5725	M	973	1.3667	14.7157	0.0451	1326	94.9	1397	30981	204.53	975.44	713.72	3.83
3	4	5725	M	974	1.3667	14.7157	0.0480	1399	94.8	1475	30730				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	4	5727	M	975	0.7932	9.5122	0.0436	926	94.8	976	22396	96.24	458.97	578.63	1.79
3	4	5727	M	976	0.7932	9.5122	0.0466	996	94.8	1050	22525				
3	4	5735	M	977	0.9980	10.3350	0.0395	1441	94.9	1519	38445	177.15	844.86	846.55	3.33
3	4	5735	M	978	0.9980	10.3350	0.0395	1413	95.0	1488	37660				
3	4	5740	F	979	0.8295	10.1505	0.0438	198	94.8	209	4761	21.98	104.80	126.34	0.42
3	4	5740	F	980	0.8295	10.1505	0.0563	259	94.8	273	4851				
3	4	5742	F	981	0.8654	9.6244	0.0443	1037	94.9	1092	24653	107.01	510.35	589.73	2.00
3	4	5742	F	982	0.8654	9.6244	0.0509	1194	94.9	1258	24715				
3	4	5753	F	983	0.7022	9.0772	0.0443	1710	94.6	1807	40793	167.51	798.88	1137.69	3.14
3	4	5753	F	984	0.7022	9.0772	0.0497	1935	94.6	2045	41142				
3	4	5756	F	985	0.5980	8.3130	0.0440	1574	94.8	1661	37752	141.76	676.07	1130.56	2.63
3	4	5756	F	986	0.5980	8.3130	0.0469	1688	94.8	1780	37962				
3	5	5721	M	987	0.8531	8.8881	0.0428	78	94.8	82	1922	7.53	35.93	42.12	0.14
3	5	5721	M	988	0.8531	8.8881	0.0388	68	94.8	71	1841				
3	5	5728	M	989	0.8016	9.2946	0.0394	89	94.9	94	2378	10.07	48.05	59.94	0.19
3	5	5728	M	990	0.8016	9.2946	0.0454	105	94.9	111	2435				
3	5	5732	M	991	0.6041	8.5421	0.0407	133	94.8	140	3446	13.94	66.49	110.06	0.26
3	5	5732	M	992	0.6041	8.5421	0.0474	171	94.8	180	3800				
3	5	5738	F	993	0.9017	10.7577	0.0454	179	94.9	189	4160	20.34	97.00	107.57	0.38
3	5	5738	F	994	0.9017	10.7577	0.0506	203	94.9	214	4234				
3	5	5758	F	995	0.6458	9.6118	0.0427	78	95.0	82	1924	8.66	41.30	63.95	0.16
3	5	5758	F	996	0.6458	9.6118	0.0459	90	94.9	95	2076				
3	5	5760	F	997	0.6096	8.7476	0.0415	94	95.0	98	2373	10.04	47.88	78.54	0.19
3	5	5760	F	998	0.6096	8.7476	0.0471	122	94.9	128	2723				
4	NA	5714	M	1031	0.6023	10.5673	0.0532	179	93.0	192	3612	16.65	78.20	129.83	0.34
4	NA	5714	M	1032	0.6023	10.5673	0.0507	160	93.2	172	3385				
4	NA	5718	M	1033	1.0494	15.1044	0.0495	85	94.8	90	1814	12.56	58.99	56.21	0.25
4	NA	5718	M	1034	1.0494	15.1044	0.0515	92	94.8	97	1879				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5719	M	1035	0.9632	14.8764	0.0539	500	94.2	531	9850	66.55	312.52	324.46	1.37
4	NA	5719	M	1036	0.9632	14.8764	0.0521	491	94.1	522	10013				
4	NA	5730	M	1037	0.8695	13.1985	0.0536	148	94.2	157	2929	16.96	79.63	91.58	0.34
4	NA	5730	M	1038	0.8695	13.1985	0.0585	153	94.1	162	2776				
4	NA	5743	F	1039	0.7950	12.5760	0.0548	3452	94.7	3645	66517	372.77	1750.43	2201.80	7.56
4	NA	5743	F	1040	0.7950	12.5760	0.0550	3389	94.7	3580	65089				
4	NA	5745	F	1041	0.6563	11.0943	0.0555	3244	94.0	3449	62152	310.21	1456.70	2219.57	6.20
4	NA	5745	F	1042	0.6563	11.0943	0.0564	3285	93.9	3497	61998				
4	NA	5748	F	1043	0.8464	13.1604	0.0533	1060	94.7	1119	20995	125.03	587.14	693.69	2.53
4	NA	5748	F	1044	0.8464	13.1604	0.0541	1086	94.8	1146	21189				
4	NA	5754	F	1045	0.6736	11.0396	0.0497	1028	93.0	1105	22228	110.95	521.01	773.47	2.22
4	NA	5754	F	1046	0.6736	11.0396	0.0520	1083	93.0	1165	22395				
5	1	5871	M	4543	0.8305	11.5535	0.4833	7633	90.3	8451	17486	91.01	108.93	131.16	0.32
5	1	5871	M	4544	0.8305	11.5535	0.5417	8562	90.4	9473	17487				
5	1	5883	M	4545	1.7000	18.7660	0.4826	4978	92.7	5371	11130	94.20	112.76	66.33	0.32
5	1	5883	M	4546	1.7000	18.7660	0.5577	5756	92.5	6223	11157				
5	1	5884	M	4547	0.7572	9.8252	0.5001	8849	92.9	9529	19054	84.35	100.96	133.34	0.29
5	1	5884	M	4548	0.7572	9.8252	0.5267	9316	92.8	10040	19062				
5	1	5889	M	4549	0.8312	12.3202	0.4981	3851	88.4	4354	8740	48.38	57.91	69.67	0.17
5	1	5889	M	4550	0.8312	12.3202	0.5307	4085	88.5	4615	8696				
5	1	5896	F	4551	0.9771	10.5071	0.4864	5225	92.3	5664	11644	55.42	66.33	67.88	0.19
5	1	5896	F	4552	0.9771	10.5071	0.5159	5590	92.0	6074	11773				
5	1	5899	F	4553	0.9349	14.8449	0.5002	5238	91.7	5710	11416	77.00	92.17	98.58	0.26
5	1	5899	F	4554	0.9349	14.8449	0.5040	5364	91.6	5853	11613				
5	1	5900	F	4555	0.9248	10.9408	0.4996	7879	92.0	8564	17142	84.35	100.97	109.18	0.28
5	1	5900	F	4556	0.9248	10.9408	0.5272	8278	91.9	9010	17091				
5	1	5921	F	4557	1.0200	14.8550	0.5077	5314	93.3	5694	11215	75.15	89.95	88.19	0.25
5	1	5921	F	4558	1.0200	14.8550	0.5359	5619	93.2	6027	11246				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	2	5869	M	5020	1.4647	17.5897	0.4996	8380	93.6	8953	17921	141.58	169.47	115.70	0.24
5	2	5869	M	5021	1.4647	17.5897	0.4845	8081	93.6	8633	17818				
5	2	5870	M	5022	1.9542	21.9162	0.4522	4631	93.7	4941	10925	107.71	128.93	65.98	0.18
5	2	5870	M	5023	1.9542	21.9162	0.4882	4985	93.7	5319	10896				
5	2	5888	M	5024	1.3522	16.3562	0.4636	8950	93.9	9527	20550	150.89	180.61	133.57	0.26
5	2	5888	M	5025	1.3522	16.3562	0.4709	9029	93.9	9611	20411				
5	2	5893	M	5026	1.3014	17.1844	0.4512	5416	93.8	5772	12793	99.35	118.92	91.38	0.17
5	2	5893	M	5027	1.3014	17.1844	0.4871	5878	93.7	6273	12878				
5	2	5910	F	5028	1.4413	17.8893	0.4386	4656	93.8	4963	11316	91.49	109.51	75.98	0.16
5	2	5910	F	5029	1.4413	17.8893	0.4726	5049	93.8	5384	11391				
5	2	5911	F	5030	1.5122	17.7952	0.4441	7659	93.7	8171	18400	146.69	175.58	116.11	0.25
5	2	5911	F	5031	1.5122	17.7952	0.4890	8337	93.7	8900	18200				
5	2	5915	F	5032	1.2156	15.4646	0.4464	9437	93.8	10058	22531	157.55	188.58	155.13	0.27
5	2	5915	F	5033	1.2156	15.4646	0.4614	9828	93.8	10474	22702				
5	2	5916	F	5034	1.3052	17.3552	0.4420	7123	93.8	7592	17176	134.38	160.85	123.24	0.23
5	2	5916	F	5035	1.3052	17.3552	0.4716	7608	93.8	8113	17203				
6	1	5867	M	4559	0.7874	9.1358	0.4906	6384	93.7	6813	13887	57.36	228.84	290.63	0.20
6	1	5867	M	4560	0.7874	9.1358	0.5252	6880	93.7	7346	13988				
6	1	5868	M	4561	1.0502	13.1062	0.5001	5852	87.5	6687	13370	79.05	315.39	300.32	0.27
6	1	5868	M	4562	1.0502	13.1062	0.5106	5952	86.9	6846	13409				
6	1	5875	M	4563	0.7625	10.3985	0.4984	6563	93.2	7039	14122	66.28	264.45	346.83	0.23
6	1	5875	M	4564	0.7625	10.3985	0.5231	6909	93.2	7417	14179				
6	1	5881	M	4565	0.8198	11.6088	0.5026	3434	92.6	3710	7382	38.58	153.93	187.76	0.13
6	1	5881	M	4566	0.8198	11.6088	0.5199	3552	92.7	3834	7374				
6	1	5895	F	4567	0.8231	10.1431	0.4989	6235	79.8	7815	15665	70.84	282.63	343.37	0.24
6	1	5895	F	4568	0.8231	10.1431	0.5309	6442	79.1	8145	15342				
6	1	5907	F	4569	0.8142	12.2562	0.4941	2772	83.0	3341	6762	37.35	149.04	183.05	0.13
6	1	5907	F	4570	0.8142	12.2562	0.5286	2937	82.1	3578	6770				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	1	5909	F	4571	0.8326	11.6026	0.4986	5070	92.6	5475	10981	57.24	228.40	274.32	0.19
6	1	5909	F	4572	0.8326	11.6026	0.5231	5288	92.5	5715	10925				
6	1	5918	F	4573	0.9065	13.4205	0.5041	5569	93.9	5929	11761	71.08	283.60	312.86	0.23
6	1	5918	F	4574	0.9065	13.4205	0.5144	5683	94.0	6047	11755				
6	2	5880	M	5036	1.2857	10.3327	0.4194	6413	93.9	6827	16277	75.75	302.23	235.07	0.13
6	2	5880	M	5037	1.2857	10.3327	0.4664	7126	93.9	7589	16272				
6	2	5885	M	5038	1.5277	18.9787	0.4660	4035	93.9	4299	9225	78.97	315.08	206.25	0.13
6	2	5885	M	5039	1.5277	18.9787	0.4870	4227	93.8	4505	9250				
6	2	5887	M	5040	1.4110	17.4490	0.4329	5579	93.9	5938	13717	107.96	430.74	305.27	0.18
6	2	5887	M	5041	1.4110	17.4490	0.4406	5702	94.1	6060	13754				
6	2	5894	M	5042	1.8027	17.2567	0.4142	8007	93.8	8541	20621	160.33	639.71	354.86	0.27
6	2	5894	M	5043	1.8027	17.2567	0.4637	8964	93.7	9567	20631				
6	2	5903	F	5044	1.3597	14.3157	0.4380	8332	94.1	8857	20222	130.14	519.25	381.88	0.22
6	2	5903	F	5045	1.3597	14.3157	0.4377	8294	94.1	8816	20141				
6	2	5912	F	5046	1.2581	13.2411	0.4103	5450	93.9	5803	14144	84.01	335.21	266.44	0.14
6	2	5912	F	5047	1.2581	13.2411	0.4480	5898	93.9	6284	14027				
6	2	5917	F	5048	1.2512	14.1222	0.4461	7710	93.9	8211	18406	117.31	468.07	374.09	0.20
6	2	5917	F	5049	1.2512	14.1222	0.4960	8601	93.8	9165	18477				
6	2	5919	F	5050	1.2972	12.1522	0.4088	4305	94.0	4581	11207	61.54	245.55	189.29	0.10
6	2	5919	F	5051	1.2972	12.1522	0.4393	4651	93.9	4955	11279				
7	1	5872	M	4575	1.6234	18.4734	0.5003	1599	93.9	1703	3404	28.08	336.08	207.03	0.10
7	1	5872	M	4576	1.6234	18.4734	0.5136	1613	93.9	1718	3345				
7	1	5873	M	4577	1.1830	14.0820	0.5011	1306	93.8	1391	2777	17.42	208.53	176.27	0.06
7	1	5873	M	4578	1.1830	14.0820	0.5057	1289	93.8	1373	2716				
7	1	5874	M	4579	0.7055	11.8035	0.4975	5862	93.5	6271	12604	67.18	804.10	1139.76	0.23
7	1	5874	M	4580	0.7055	11.8035	0.5139	6081	93.4	6509	12665				
7	1	5882	M	4581	1.1848	14.7208	0.5014	2399	93.8	2558	5103	33.55	401.57	338.94	0.12
7	1	5882	M	4582	1.1848	14.7208	0.5179	2436	93.8	2598	5016				

TABLE F3. Liquid Scintillation Analyses of Skin Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Digest Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
7	1	5901	F	4583	1.4282	14.6672	0.5050	21493	93.6	22961	45468	298.80	3576.48	2504.19	1.05
7	1	5901	F	4584	1.4282	14.6672	0.5055	21281	93.6	22739	44983				
7	1	5902	F	4585	0.9999	10.9909	0.4962	18951	93.8	20214	40738	201.88	2416.43	2416.68	0.71
7	1	5902	F	4586	0.9999	10.9909	0.5110	19576	93.9	20857	40815				
7	1	5913	F	4587	1.0127	13.6627	0.4958	4172	93.7	4452	8980	55.44	663.55	655.23	0.19
7	1	5913	F	4588	1.0127	13.6627	0.5101	4321	93.8	4609	9035				
7	1	5920	F	4589	0.8648	11.1938	0.5081	10077	93.5	10780	21217	100.34	1201.03	1388.80	0.37
7	1	5920	F	4590	0.8648	11.1938	0.5157	8964	93.5	9583	18582				
7	2	5878	M	5052	1.1833	13.1593	0.4219	22290	94.2	23672	56109	333.26	3989.03	3371.11	0.58
7	2	5878	M	5053	1.1833	13.1593	0.4607	24414	94.1	25953	56335				
7	2	5886	M	5054	1.2254	10.2204	0.4272	5567	94.0	5920	13858	63.84	764.16	623.60	0.11
7	2	5886	M	5055	1.2254	10.2204	0.5281	6883	93.9	7328	13876				
7	2	5891	M	5056	1.4000	13.9800	0.4660	15680	94.0	16673	35780	225.90	2703.93	1931.38	0.39
7	2	5891	M	5057	1.4000	13.9800	0.4828	16324	94.0	17364	35965				
7	2	5892	M	5058	1.2634	10.2494	0.4653	2677	94.0	2848	6121	28.28	338.53	267.95	0.05
7	2	5892	M	5059	1.2634	10.2494	0.4500	2593	94.0	2759	6131				
7	2	5905	F	5060	1.1428	13.3348	0.5234	4108	94.0	4370	8349	50.00	598.50	523.71	0.09
7	2	5905	F	5061	1.1428	13.3348	0.5141	4012	94.0	4267	8299				
7	2	5906	F	5062	1.0096	10.8872	0.5089	4878	93.8	5203	10224	50.25	601.45	595.73	0.09
7	2	5906	F	5063	1.0096	10.8872	0.4861	4685	93.9	4991	10268				
7	2	5908	F	5064	1.3333	10.6483	0.4471	4939	94.0	5254	11752	56.30	673.92	505.45	0.10
7	2	5908	F	5065	1.3333	10.6483	0.4596	5063	94.0	5388	11724				
7	2	5914	F	5066	0.9403	8.1713	0.4332	5819	93.9	6194	14299	52.77	631.67	671.78	0.09
7	2	5914	F	5067	0.9403	8.1713	0.5190	6999	93.8	7461	14376				

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	1	5331	M	152	Nec	124.7	0.7660	6675	93.7	7123	9299	522.78	249.32	9.62
1	1	5331	M	153	Nec	124.7	0.7765	6777	93.7	7233	9315			
1	1	5339	M	154	Nec	107.7	0.7613	7382	93.7	7877	10347	503.60	240.18	9.14
1	1	5339	M	155	Nec	107.7	0.7769	7577	93.6	8091	10414			
1	1	5340	M	156	Nec	140.4	0.7692	5805	93.7	6199	8059	511.11	243.76	9.58
1	1	5340	M	157	Nec	140.4	0.7805	5923	93.6	6326	8105			
1	1	5355	F	158	Nec	139.7	0.7603	5904	93.7	6303	8290	525.73	250.73	9.67
1	1	5355	F	159	Nec	139.7	0.7788	6141	93.7	6557	8419			
1	1	5356	F	160	Nec	124.9	0.7666	8211	93.7	8765	11433	640.63	305.53	11.70
1	1	5356	F	161	Nec	124.9	0.7839	8324	93.6	8889	11340			
1	1	5362	F	162	Nec	139.7	0.7617	10475	93.7	11183	14682	920.96	439.22	17.20
1	1	5362	F	163	Nec	139.7	0.7767	10618	93.7	11331	14589			
1	2	5332	M	242	Nec	95.4	0.7621	10572	93.7	11288	14811	637.43	304.00	11.51
1	2	5332	M	243	Nec	95.4	0.7940	11047	93.7	11795	14855			
1	2	5342	M	244	Nec	99.5	0.7979	8665	93.5	9264	11610	523.49	249.66	9.44
1	2	5342	M	245	Nec	99.5	0.7748	8523	93.6	9104	11750			
1	2	5343	M	246	Nec	93.9	0.7583	7051	93.6	7531	9931	420.61	200.60	7.63
1	2	5343	M	247	Nec	93.9	0.7511	7004	93.7	7479	9957			
1	2	5349	F	248	Nec	86.1	0.7533	10371	93.6	11078	14706	571.33	272.47	10.40
1	2	5349	F	249	Nec	86.1	0.7616	10528	93.7	11238	14756			
1	2	5350	F	250	Nec	93.9	0.7504	4949	93.7	5282	7039	297.41	141.84	5.50
1	2	5350	F	251	Nec	93.9	0.7572	4976	93.6	5318	7023			
1	2	5363	F	252	Nec	87.8	0.7433	5295	93.7	5654	7607	303.81	144.89	5.51
1	2	5363	F	253	Nec	87.8	0.7666	5567	93.6	5946	7756			
1	3	5327	M	202	Nec	103.7	0.7560	8753	93.8	9334	12346	573.71	273.61	10.45
1	3	5327	M	203	Nec	103.7	0.7880	9025	93.7	9628	12218			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	3	5330	M	204	Nec	103.6	0.6559	6879	93.9	7328	11172	517.86	246.98	9.46
1	3	5330	M	205	Nec	103.6	0.7935	8192	93.7	8746	11022			
1	3	5334	M	206	Nec	123.4	0.7461	8172	93.8	8710	11674	649.58	309.80	11.82
1	3	5334	M	207	Nec	123.4	0.7580	8305	93.7	8867	11698			
1	3	5347	F	208	Nec	108.3	0.7379	12320	93.7	13142	17809	871.12	415.45	15.79
1	3	5347	F	209	Nec	108.3	0.7588	12734	93.7	13585	17904			
1	3	5348	F	210	Nec	111.3	0.7367	10781	93.8	11497	15606	784.19	373.99	14.38
1	3	5348	F	211	Nec	111.3	0.7245	10657	93.8	11358	15677			
1	3	5352	F	212	Nec	108.4	0.7462	10996	93.7	11733	15724	765.74	365.19	13.84
1	3	5352	F	213	Nec	108.4	0.7668	11237	93.7	11993	15640			
1	4	5328	M	254	Nec	106.1	0.7497	5496	93.5	5877	7839	372.66	177.73	6.75
1	4	5328	M	255	Nec	106.1	0.7207	5233	93.6	5589	7756			
1	4	5336	M	256	Nec	125.1	0.7479	4404	93.6	4705	6291	350.03	166.93	6.48
1	4	5336	M	257	Nec	125.1	0.7492	4301	93.6	4594	6132			
1	4	5344	M	258	Nec	106.1	0.7592	4900	93.6	5237	6898	329.02	156.92	6.03
1	4	5344	M	259	Nec	106.1	0.7717	4964	93.6	5302	6871			
1	4	5345	M	260	Nec	106.9	0.7477	4998	93.6	5340	7142	341.88	163.05	6.15
1	4	5345	M	261	Nec	106.9	0.7728	5104	93.6	5455	7058			
1	4	5351	F	262	Nec	108.7	0.7398	9771	93.6	10439	14110	689.54	328.86	12.58
1	4	5351	F	263	Nec	108.7	0.7714	10147	93.6	10842	14055			
1	4	5353	F	264	Nec	109.0	0.7449	7452	93.6	7961	10687	522.09	248.99	9.40
1	4	5353	F	265	Nec	109.0	0.7507	7434	93.6	7942	10580			
1	4	5359	F	266	Nec	142.2	0.7400	11960	93.6	12778	17268	1100.33	524.77	19.83
1	4	5359	F	267	Nec	142.2	0.7404	11841	93.6	12652	17089			
1	4	5365	F	268	Nec	99.5	0.7305	6730	93.6	7190	9843	436.08	207.97	7.93
1	4	5365	F	269	Nec	99.5	0.7435	6694	93.6	7150	9616			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	5	5329	M	270	Nec	97.7	0.7300	4208	93.7	4494	6156	270.05	128.79	5.02
1	5	5329	M	271	Nec	97.7	0.7188	4116	93.6	4397	6117			
1	5	5333	M	272	Nec	96.1	0.7446	5761	93.6	6154	8265	358.02	170.75	6.54
1	5	5333	M	273	Nec	96.1	0.7726	5981	93.6	6394	8276			
1	5	5341	M	274	Nec	100.0	0.7448	5451	93.6	5826	7822	351.83	167.80	6.48
1	5	5341	M	275	Nec	100.0	0.7142	5215	93.6	5571	7800			
1	5	5360	F	276	Nec	96.7	0.7402	15580	93.5	16670	22521	981.20	467.95	18.04
1	5	5360	F	277	Nec	96.7	0.6725	14189	93.6	15152	22531			
1	5	5364	F	278	Nec	94.9	0.7373	14308	93.6	15287	20734	885.46	422.29	16.26
1	5	5364	F	279	Nec	94.9	0.7171	13889	93.6	14839	20693			
1	5	5366	F	280	Nec	106.5	0.7327	18318	93.5	19590	26737	1283.29	612.02	23.26
1	5	5366	F	281	Nec	106.5	0.7692	19256	93.5	20586	26763			
2	1	5836	M	1342	Nec	108.2	0.7582	6198	93.7	6617	8727	422.02	670.90	7.77
2	1	5836	M	1343	Nec	108.2	0.9056	7268	93.4	7780	8591			
2	1	5841	M	1344	Nec	105.1	0.7445	4985	93.6	5325	7153	339.62	539.90	6.30
2	1	5841	M	1345	Nec	105.1	0.7754	5219	93.6	5579	7195			
2	1	5844	M	1346	Nec	107.0	0.7559	7050	93.6	7531	9963	479.46	762.20	8.81
2	1	5844	M	1347	Nec	107.0	0.7766	7217	93.6	7713	9932			
2	1	5853	F	1348	Nec	107.4	0.6878	5673	93.7	6057	8806	429.46	682.73	7.84
2	1	5853	F	1349	Nec	107.4	0.7538	6314	93.6	6745	8949			
2	1	5855	F	1350	Nec	109.6	0.7535	9812	93.7	10476	13903	684.12	1087.57	13.08
2	1	5855	F	1351	Nec	109.6	0.7403	9579	93.7	10225	13812			
2	1	5863	F	1352	Nec	190.1	0.7619	4899	93.7	5231	6866	586.86	932.95	10.75
2	1	5863	F	1353	Nec	190.1	0.7731	4949	93.6	5289	6841			
2	2	5832	M	1354	Nec	103.6	0.7534	8837	93.6	9438	12527	586.67	932.65	10.86
2	2	5832	M	1355	Nec	103.6	0.7683	9074	93.6	9693	12616			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	2	5834	M	1356	Nec	105.7	0.7479	5203	93.6	5560	7434	353.75	562.37	6.52
2	2	5834	M	1357	Nec	105.7	0.7489	5208	93.7	5561	7426			
2	2	5845	M	1358	Nec	104.0	0.7513	8043	93.6	8590	11434	538.80	856.54	9.87
2	2	5845	M	1359	Nec	104.0	0.7556	8181	93.6	8741	11568			
2	2	5846	F	1360	Nec	103.5	0.7489	8853	93.6	9455	12625	584.27	928.83	10.70
2	2	5846	F	1361	Nec	103.5	0.7706	8970	93.6	9586	12439			
2	2	5858	F	1362	Nec	105.0	0.7277	9493	93.6	10144	13940	657.99	1046.02	12.06
2	2	5858	F	1363	Nec	105.0	0.7384	9594	93.6	10252	13884			
2	2	5860	F	1364	Nec	107.1	0.7051	7667	93.7	8183	11605	560.39	890.87	10.29
2	2	5860	F	1365	Nec	107.1	0.6967	7588	93.7	8101	11627			
2	3	5715	M	1382	Nec	107.5	0.7183	6352	93.8	6773	9430	460.57	732.18	8.41
2	3	5715	M	1383	Nec	107.5	0.7737	6948	93.6	7422	9593			
2	3	5831	M	1384	Nec	103.3	0.7417	9685	93.7	10337	13937	649.80	1033.01	11.96
2	3	5831	M	1385	Nec	103.3	0.7903	10346	93.6	11058	13993			
2	3	5837	M	1386	Nec	107.7	0.7552	10679	93.7	11401	15097	732.88	1165.07	13.39
2	3	5837	M	1387	Nec	107.7	0.7636	10809	93.6	11543	15116			
2	3	5847	F	1388	Nec	106.0	0.7524	8743	93.6	9337	12410	593.97	944.25	10.80
2	3	5847	F	1389	Nec	106.0	0.7630	8911	93.7	9515	12470			
2	3	5850	F	1390	Nec	110.0	0.7362	8113	93.7	8663	11767	585.80	931.27	10.65
2	3	5850	F	1391	Nec	110.0	0.7638	8491	93.6	9072	11878			
2	3	5864	F	1392	Nec	108.2	0.7354	7546	93.7	8057	10956	532.45	846.45	9.74
2	3	5864	F	1393	Nec	108.2	0.7510	7659	93.6	8181	10893			
2	4	5713	M	1366	Nec	120.3	0.7335	7821	93.7	8346	11379	617.40	981.49	11.25
2	4	5713	M	1367	Nec	120.3	0.6675	7139	93.8	7615	11408			
2	4	5829	M	1368	Nec	119.6	0.7595	9161	93.6	9790	12890	693.54	1102.54	12.32
2	4	5829	M	1369	Nec	119.6	0.7806	9389	93.6	10036	12857			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	4	5830	M	1370	Nec	121.1	0.6987	8736	93.7	9323	13344	732.64	1164.70	13.40
2	4	5830	M	1371	Nec	121.1	0.7706	9754	93.6	10417	13518			
2	4	5839	M	1372	Nec	117.2	0.7355	5805	93.7	6197	8426	446.02	709.05	8.15
2	4	5839	M	1373	Nec	117.2	0.7334	5822	93.7	6213	8471			
2	4	5851	F	1374	Nec	119.3	0.6932	8841	93.7	9437	13613	731.84	1163.42	13.59
2	4	5851	F	1375	Nec	119.3	0.7220	9219	93.7	9836	13623			
2	4	5852	F	1376	Nec	120.8	0.7050	5652	93.7	6030	8554	464.50	738.43	8.45
2	4	5852	F	1377	Nec	120.8	0.7609	6068	93.6	6482	8519			
2	4	5857	F	1378	Nec	116.9	0.6906	11920	93.7	12722	18422	965.55	1534.96	17.65
2	4	5857	F	1379	Nec	116.9	0.7512	12840	93.7	13710	18251			
2	4	5861	F	1380	Nec	119.1	0.7115	4971	93.7	5303	7454	400.44	636.58	7.37
2	4	5861	F	1381	Nec	119.1	0.6653	4663	93.8	4973	7474			
2	5	5720	M	1394	Nec	110.9	0.7360	7024	93.6	7504	10195	509.11	809.35	9.39
2	5	5720	M	1395	Nec	110.9	0.7541	7191	93.6	7682	10187			
2	5	5828	M	1396	Nec	108.5	0.7473	5664	93.5	6056	8103	397.14	631.34	7.24
2	5	5828	M	1397	Nec	108.5	0.7725	5885	93.5	6294	8148			
2	5	5840	M	1398	Nec	117.2	0.7411	5794	93.6	6190	8353	440.38	700.08	8.12
2	5	5840	M	1399	Nec	117.2	0.7543	5881	93.6	6284	8330			
2	5	5848	F	1400	Nec	108.6	0.7417	7652	93.6	8175	11023	535.28	850.95	9.83
2	5	5848	F	1401	Nec	108.6	0.7626	7747	93.5	8283	10862			
2	5	5854	F	1402	Nec	116.4	0.7382	8764	93.6	9359	12678	661.11	1050.98	12.18
2	5	5854	F	1403	Nec	116.4	0.7259	8523	93.6	9103	12540			
2	5	5862	F	1404	Nec	106.3	0.7242	5355	93.7	5716	7893	375.57	597.05	6.83
2	5	5862	F	1405	Nec	106.3	0.7021	5124	93.6	5472	7794			
3	1	5723	M	563	Nec	101.0	0.7667	13474	93.6	14389	18768	852.27	4064.61	16.08
3	1	5723	M	564	Nec	101.0	0.8049	14084	93.6	15050	18698			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	1	5733	M	565	Nec	114.1	0.7486	11414	93.6	12195	16290	845.49	4032.27	15.77
3	1	5733	M	566	Nec	114.1	0.7967	12387	93.6	13234	16611			
3	1	5736	M	567	Nec	103.1	0.7637	11999	93.6	12817	16782	781.03	3724.86	14.50
3	1	5736	M	568	Nec	103.1	0.7721	12183	93.6	13012	16853			
3	1	5741	F	569	Nec	112.3	0.7533	10211	93.6	10905	14476	685.75	3270.48	12.77
3	1	5741	F	570	Nec	112.3	0.8605	10185	93.7	10874	12637			
3	1	5744	F	571	Nec	107.4	0.7497	8781	93.7	9375	12505	602.75	2874.60	11.15
3	1	5744	F	572	Nec	107.4	0.7820	9087	93.6	9707	12413			
3	1	5762	F	573	Nec	112.8	0.6991	5763	93.7	6149	8795	428.93	2045.65	7.99
3	1	5762	F	574	Nec	112.8	0.7788	5897	93.6	6299	8089			
3	2	5722	M	575	Nec	106.4	0.7905	13198	93.7	14090	17824	855.11	4078.17	16.07
3	2	5722	M	576	Nec	106.4	0.7958	13299	93.6	14212	17859			
3	2	5734	M	577	Nec	103.2	0.6769	7778	93.8	8294	12253	567.60	2706.98	10.63
3	2	5734	M	578	Nec	103.2	0.7838	8931	93.7	9537	12167			
3	2	5737	M	579	Nec	109.6	0.7226	11968	93.7	12768	17669	876.47	4180.04	16.53
3	2	5737	M	580	Nec	109.6	0.7621	12728	93.6	13594	17837			
3	2	5746	F	581	Nec	103.9	0.7166	17732	93.6	18938	26427	1237.71	5902.84	24.38
3	2	5746	F	582	Nec	103.9	0.7778	19275	93.6	20584	26465			
3	2	5751	F	583	Nec	106.2	0.6974	15074	93.8	16073	23047	1096.04	5227.19	20.79
3	2	5751	F	584	Nec	106.2	0.7525	16042	93.6	17139	22777			
3	2	5761	F	585	Nec	107.8	0.6932	9985	93.8	10650	15363	742.64	3541.77	13.92
3	2	5761	F	586	Nec	107.8	0.7776	11080	93.6	11839	15224			
3	3	5716	M	587	Nec	114.8	0.7952	8002	93.5	8555	10758	556.36	2653.37	10.65
3	3	5716	M	588	Nec	114.8	0.7728	7777	93.5	8315	10760			
3	3	5717	M	589	Nec	123.1	0.7469	4363	93.6	4662	6242	348.06	1659.97	6.50
3	3	5717	M	590	Nec	123.1	0.7210	4261	93.6	4551	6312			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	3	5726	M	591	Nec	121.7	0.7495	5019	93.5	5367	7161	394.17	1879.88	7.32
3	3	5726	M	592	Nec	121.7	0.7739	5226	93.5	5588	7220			
3	3	5739	F	593	Nec	106.8	0.7577	3724	93.5	3983	5256	251.02	1197.14	4.70
3	3	5739	F	594	Nec	106.8	0.7675	3718	93.6	3975	5179			
3	3	5750	F	595	Nec	127.9	0.7066	6831	93.6	7297	10327	595.79	2841.44	11.04
3	3	5750	F	596	Nec	127.9	0.7870	7624	93.5	8150	10356			
3	3	5752	F	597	Nec	116.8	0.7337	11559	93.6	12345	16825	878.17	4188.16	16.50
3	3	5752	F	598	Nec	116.8	0.7767	12029	93.5	12860	16557			
3	4	5724	M	599	Nec	101.5	0.7751	12812	93.5	13703	17679	804.33	3835.98	15.00
3	4	5724	M	600	Nec	101.5	0.7548	12357	93.5	13213	17505			
3	4	5725	M	601	Nec	121.3	0.7839	9562	93.6	10221	13039	712.38	3397.46	13.34
3	4	5725	M	602	Nec	121.3	0.7754	9458	93.6	10109	13037			
3	4	5727	M	603	Nec	115.3	0.7625	10382	93.6	11095	14551	757.75	3613.82	14.06
3	4	5727	M	604	Nec	115.3	0.7789	10658	93.5	11394	14629			
3	4	5735	M	605	Nec	120.1	0.7626	9585	93.5	10247	13437	728.86	3476.05	13.68
3	4	5735	M	606	Nec	120.1	0.7643	9653	93.5	10324	13508			
3	4	5740	F	607	Nec	108.2	0.7202	12359	93.6	13204	18334	900.58	4295.03	17.10
3	4	5740	F	608	Nec	108.2	0.7469	13009	93.5	13908	18621			
3	4	5742	F	609	Nec	100.1	0.7353	12573	93.6	13437	18275	821.20	3916.43	15.32
3	4	5742	F	610	Nec	100.1	0.7700	13079	93.6	13976	18150			
3	4	5753	F	611	Nec	109.4	0.7559	10760	93.5	11505	15220	748.96	3571.90	14.05
3	4	5753	F	612	Nec	109.4	0.7710	10947	93.6	11701	15176			
3	4	5756	F	613	Nec	111.8	0.7348	14424	93.6	15416	20980	1053.31	5023.40	19.53
3	4	5756	F	614	Nec	111.8	0.7817	15243	93.5	16299	20851			
3	5	5721	M	1079	Nec	116.1	0.7634	4155	93.6	4441	5817	302.16	1441.06	5.78
3	5	5721	M	1080	Nec	116.1	0.7610	4086	93.6	4367	5739			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	5	5728	M	1081	Nec	114.1	0.7084	7691	93.6	8216	11598	593.82	2832.02	11.20
3	5	5728	M	1082	Nec	114.1	0.7756	8354	93.6	8927	11509			
3	5	5732	M	1083	Nec	115.8	0.7252	5407	93.6	5778	7967	414.74	1977.98	7.65
3	5	5732	M	1084	Nec	115.8	0.7812	5796	93.5	6199	7935			
3	5	5738	F	1085	Nec	130.3	0.7222	6184	93.6	6608	9150	539.54	2573.17	10.03
3	5	5738	F	1086	Nec	130.3	0.7892	6813	93.5	7288	9235			
3	5	5758	F	1087	Nec	114.9	0.7146	6124	93.6	6540	9152	473.49	2258.14	8.91
3	5	5758	F	1088	Nec	114.9	0.7793	6666	93.5	7127	9145			
3	5	5760	F	1089	Nec	118.5	0.7783	9708	93.5	10380	13337	707.63	3374.81	13.73
3	5	5760	F	1090	Nec	118.5	0.7650	9421	93.5	10080	13176			
4	NA	5714	M	1091	Nec	130.9	0.7326	8520	93.6	9103	12425	731.96	3437.12	14.99
4	NA	5714	M	1092	Nec	130.9	0.7684	8910	93.5	9530	12402			
4	NA	5718	M	1093	Nec	134.6	0.7086	8038	93.6	8584	12114	738.77	3469.10	14.96
4	NA	5718	M	1094	Nec	134.6	0.7561	8672	93.6	9266	12255			
4	NA	5719	M	1095	Nec	123.9	0.7567	6253	93.5	6685	8834	494.23	2320.79	10.15
4	NA	5719	M	1096	Nec	123.9	0.7448	6185	93.6	6611	8876			
4	NA	5730	M	1097	Nec	127.2	0.7032	9018	93.6	9636	13704	780.17	3663.52	15.75
4	NA	5730	M	1098	Nec	127.2	0.7637	9660	93.5	10332	13529			
4	NA	5743	F	1099	Nec	128.5	0.7293	13732	93.5	14686	20137	1166.37	5477.02	23.67
4	NA	5743	F	1100	Nec	128.5	0.7566	14264	93.5	15256	20164			
4	NA	5745	F	1101	Nec	119.9	0.7111	13541	93.6	14466	20344	1097.95	5155.76	21.95
4	NA	5745	F	1102	Nec	119.9	0.7064	13432	93.6	14350	20314			
4	NA	5748	F	1103	Nec	115.9	0.7423	11651	93.6	12450	16772	873.85	4103.44	17.68
4	NA	5748	F	1104	Nec	115.9	0.7151	11184	93.6	11946	16705			
4	NA	5754	F	1105	Nec	125.0	0.6971	9188	93.6	9815	14079	790.56	3712.33	15.83
4	NA	5754	F	1106	Nec	125.0	0.6889	9036	93.7	9646	14001			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	1	5871	M	3674	Nec	154.7	0.7045	9300	93.5	9949	14122	980.79	1173.98	3.42
5	1	5871	M	3675	Nec	154.7	0.7572	9928	93.5	10622	14028			
5	1	5883	M	3676	Nec	128.3	0.6645	16950	93.4	18154	27320	1562.84	1870.67	5.32
5	1	5883	M	3677	Nec	128.3	0.7657	19105	93.2	20493	26764			
5	1	5884	M	3678	Nec	168.4	0.7407	9805	93.4	10495	14169	1081.68	1294.74	3.68
5	1	5884	M	3679	Nec	168.4	0.5844	7856	93.7	8386	14351			
5	1	5889	M	3680	Nec	131.7	0.7597	16827	93.4	18014	23712	1409.71	1687.37	4.87
5	1	5889	M	3681	Nec	131.7	0.7552	16796	93.4	17984	23813			
5	1	5896	F	3682	Nec	154.0	0.6347	9324	93.5	9973	15714	1044.87	1250.68	3.56
5	1	5896	F	3683	Nec	154.0	0.7720	10380	93.3	11125	14411			
5	1	5899	F	3684	Nec	159.5	0.7685	11714	93.4	12546	16325	1184.79	1418.16	4.01
5	1	5899	F	3685	Nec	159.5	0.7496	11675	93.5	12485	16656			
5	1	5900	F	3686	Nec	155.4	0.7500	13386	93.4	14325	19100	1341.33	1605.52	4.52
5	1	5900	F	3687	Nec	155.4	0.7459	13401	93.5	14339	19223			
5	1	5921	F	3688	Nec	154.5	0.7627	18059	93.3	19354	25376	1741.73	2084.79	5.88
5	1	5921	F	3689	Nec	154.5	0.7647	17606	93.3	18871	24678			
5	2	5869	M	3866	14	117.9	0.6793	19698	93.3	21105	31068	1662.18	1989.58	2.84
5	2	5869	M	3867	14	117.9	0.6611	19466	93.4	20843	31528			
5	2	5869	M	4828	Nec	101.0	0.6916	16288	93.4	17429	25202	1139.73	1364.22	1.95
5	2	5869	M	4829	Nec	101.0	0.7193	16722	93.4	17911	24901			
5	2	5870	M	3868	14	139.9	0.6533	19045	93.5	20361	31166	1961.35	2347.68	3.36
5	2	5870	M	3869	14	139.9	0.5909	17192	93.6	18366	31082			
5	2	5870	M	4830	Nec	103.4	0.7673	11637	93.3	12474	16257	752.95	901.25	1.29
5	2	5870	M	4831	Nec	103.4	0.6758	10156	93.5	10863	16074			
5	2	5888	M	3870	14	120.9	0.7616	14171	93.3	15182	19934	1078.60	1291.05	1.84
5	2	5888	M	3871	14	120.9	0.7646	14046	93.4	15045	19677			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5888	M	4832	Nec	99.1	0.7726	20303	93.3	21765	28171	1260.86	1509.21	2.15
5	2	5888	M	4833	Nec	99.1	0.7601	20088	93.3	21526	28319			
5	2	5893	M	3872	14	120.5	0.7638	20104	93.3	21544	28207	1544.97	1849.27	2.64
5	2	5893	M	3873	14	120.5	0.7739	20736	93.3	22226	28720			
5	2	5893	M	4834	Nec	103.6	0.7705	13966	93.2	14978	19439	900.71	1078.12	1.54
5	2	5893	M	4835	Nec	103.6	0.7691	13748	93.3	14738	19163			
5	2	5910	F	3874	14	133.4	0.6930	21827	93.4	23365	33716	2032.67	2433.04	3.46
5	2	5910	F	3875	14	133.4	0.7555	23935	93.3	25640	33938			
5	2	5910	F	4836	Nec	109.7	0.7307	19494	93.3	20906	28611	1395.11	1669.90	2.38
5	2	5910	F	4837	Nec	109.7	0.7253	18845	93.3	20203	27855			
5	2	5911	F	3876	14	122.1	0.7498	21555	93.3	23106	30816	1695.19	2029.09	2.87
5	2	5911	F	3877	14	122.1	0.7555	21719	93.3	23290	30827			
5	2	5911	F	4838	Nec	116.5	0.5923	13865	93.5	14835	25047	1303.08	1559.74	2.20
5	2	5911	F	4839	Nec	116.5	0.5504	12680	93.6	13548	24615			
5	2	5915	F	3878	14	117.5	0.6975	23190	93.4	24826	35593	1886.26	2257.79	3.19
5	2	5915	F	3879	14	117.5	0.6804	22695	93.5	24279	35684			
5	2	5915	F	4840	Nec	106.3	0.7630	21240	93.3	22774	29848	1383.56	1656.07	2.34
5	2	5915	F	4841	Nec	106.3	0.7452	19433	93.3	20822	27941			
5	2	5916	F	3880	14	128.9	0.6692	19765	93.5	21146	31599	1836.26	2197.95	3.11
5	2	5916	F	3881	14	128.9	0.7402	21867	93.3	23429	31652			
5	2	5916	F	4842	Nec	99.4	0.5893	10947	93.4	11716	19881	873.46	1045.51	1.48
5	2	5916	F	4843	Nec	99.4	0.7643	13640	93.3	14625	19135			
6	1	5867	M	3794	Nec	112.9	0.6991	9700	93.6	10364	14825	757.96	3024.19	2.60
6	1	5867	M	3795	Nec	112.9	0.7182	10061	93.5	10761	14983			
6	1	5868	M	3796	Nec	115.4	0.7572	9530	93.5	10193	13462	702.22	2801.76	2.43
6	1	5868	M	3797	Nec	115.4	0.7632	9672	93.5	10346	13556			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5875	M	3798	Nec	121.0	0.6906	5544	93.6	5924	8579	470.01	1875.30	1.62
6	1	5875	M	3799	Nec	121.0	0.7659	6207	93.5	6639	8668			
6	1	5881	M	3800	Nec	133.2	0.7411	11004	93.5	11767	15877	961.30	3835.49	3.32
6	1	5881	M	3801	Nec	133.2	0.7503	11343	93.5	12130	16166			
6	1	5895	F	3802	Nec	133.4	0.7379	9437	93.6	10087	13670	826.11	3296.10	2.84
6	1	5895	F	3803	Nec	133.4	0.7371	9529	93.5	10191	13826			
6	1	5907	F	3804	Nec	130.7	0.7513	14564	93.5	15581	20739	1211.75	4834.75	4.14
6	1	5907	F	3805	Nec	130.7	0.7461	14249	93.5	15239	20425			
6	1	5909	F	3806	Nec	131.3	0.7581	10681	93.4	11433	15081	898.26	3583.97	3.04
6	1	5909	F	3807	Nec	131.3	0.7707	11008	93.4	11787	15294			
6	1	5918	F	3808	Nec	119.9	0.7470	9735	93.5	10414	13942	750.89	2995.96	2.40
6	1	5918	F	3809	Nec	119.9	0.7693	9964	93.4	10666	13864			
6	2	5880	M	4168	14	107.3	0.7421	5339	93.6	5706	7689	371.19	1481.01	0.64
6	2	5880	M	4169	14	107.3	0.7639	5476	93.5	5860	7671			
6	2	5880	M	4868	Nec	114.5	0.8189	19811	93.3	21235	25931	1338.18	5339.20	2.30
6	2	5880	M	4869	Nec	114.5	0.7939	19235	93.3	20609	25960			
6	2	5885	M	4170	14	107.2	0.8109	7942	93.4	8506	10489	505.19	2015.67	0.86
6	2	5885	M	4171	14	107.2	0.8334	8122	93.4	8696	10435			
6	2	5885	M	4870	Nec	101.0	0.7723	17045	93.1	18312	23711	1077.83	4300.41	1.84
6	2	5885	M	4871	Nec	101.0	0.8175	18019	93.1	19351	23671			
6	2	5887	M	4172	14	101.8	0.7550	8365	93.4	8953	11858	544.19	2171.27	0.93
6	2	5887	M	4173	14	101.8	0.7517	8347	93.5	8928	11877			
6	2	5887	M	4872	Nec	93.2	0.7570	17732	93.4	18991	25087	1041.70	4156.27	1.78
6	2	5887	M	4873	Nec	93.2	0.7768	17810	93.4	19062	24539			
6	2	5894	M	4174	14	104.8	0.7470	5261	93.5	5627	7533	353.99	1412.40	0.60
6	2	5894	M	4175	14	104.8	0.7169	5006	93.6	5351	7464			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	2	5894	M	4874	Nec	97.9	0.7953	18577	93.3	19922	25050	1102.07	4397.12	1.87
6	2	5894	M	4875	Nec	97.9	0.7865	18294	93.3	19608	24931			
6	2	5903	F	4176	14	109.6	0.6739	7179	93.6	7669	11380	563.92	2249.98	0.95
6	2	5903	F	4177	14	109.6	0.7102	7622	93.6	8143	11465			
6	2	5903	F	4876	Nec	91.3	0.7580	13681	93.3	14667	19350	785.55	3134.26	1.33
6	2	5903	F	4877	Nec	91.3	0.7658	13479	93.4	14437	18852			
6	2	5912	F	4178	14	111.5	0.6848	5753	93.6	6148	8977	450.92	1799.13	0.77
6	2	5912	F	4179	14	111.5	0.7614	6386	93.4	6836	8979			
6	2	5912	F	4878	Nec	101.0	0.7668	11902	93.2	12766	16649	749.61	2990.86	1.27
6	2	5912	F	4879	Nec	101.0	0.7872	11978	93.3	12835	16305			
6	2	5917	F	4180	14	107.5	0.7555	12338	93.3	13229	17510	847.71	3382.26	1.45
6	2	5917	F	4181	14	107.5	0.7761	12667	93.3	13584	17502			
6	2	5917	F	4880	Nec	113.3	0.7628	19631	93.4	21028	27566	1414.54	5643.88	2.41
6	2	5917	F	4881	Nec	113.3	0.7736	20118	93.3	21558	27867			
6	2	5919	F	4182	14	102.3	0.7069	4203	93.6	4493	6355	291.48	1162.97	0.49
6	2	5919	F	4183	14	102.3	0.7682	4519	93.4	4836	6295			
6	2	5919	F	4882	Nec	108.6	0.7627	10765	93.4	11526	15112	735.22	2933.46	1.24
6	2	5919	F	4883	Nec	108.6	0.7792	10871	93.3	11647	14947			
7	1	5872	M	3850	Nec	150.6	0.7667	9973	93.5	10665	13911	953.58	11414.03	3.38
7	1	5872	M	3851	Nec	150.6	0.8049	10687	93.5	11432	14203			
7	1	5873	M	3852	Nec	162.7	0.7799	22229	93.2	23852	30584	2238.03	26788.51	7.92
7	1	5873	M	3853	Nec	162.7	0.8156	23168	93.2	24869	30491			
7	1	5874	M	3854	Nec	129.4	0.7732	14128	93.3	15138	19578	1136.53	13603.85	3.96
7	1	5874	M	3855	Nec	129.4	0.7946	14393	93.3	15430	19419			
7	1	5882	M	3856	Nec	137.9	0.7686	18278	93.4	19577	25471	1571.93	18815.54	5.58
7	1	5882	M	3857	Nec	137.9	0.7858	18447	93.4	19756	25141			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5901	F	3858	Nec	125.1	0.7770	14447	93.4	15467	19906	1105.52	13232.66	3.89
7	1	5901	F	3859	Nec	125.1	0.8332	15024	93.3	16106	19331			
7	1	5902	F	3860	Nec	135.9	0.7661	19570	93.3	20965	27366	1667.27	19956.65	5.84
7	1	5902	F	3861	Nec	135.9	0.7802	19741	93.3	21147	27105			
7	1	5913	F	3862	Nec	142.0	0.7641	30005	93.3	32164	42094	2662.82	31873.14	9.24
7	1	5913	F	3863	Nec	142.0	0.7617	29268	93.3	31356	41166			
7	1	5920	F	3864	Nec	145.9	0.7568	13082	93.4	14000	18499	1208.86	14469.72	4.51
7	1	5920	F	3865	Nec	145.9	0.7901	13495	93.4	14450	18289			
7	2	5878	M	4184	14	103.0	0.7717	5197	93.5	5559	7204	332.50	3979.95	0.58
7	2	5878	M	4185	14	103.0	0.7457	4970	93.5	5316	7129			
7	2	5878	M	4972	Nec	90.0	0.7464	25131	93.4	26912	36055	1461.21	17490.16	2.54
7	2	5878	M	4973	Nec	90.0	0.7918	26641	93.4	28529	36031			
7	2	5886	M	4186	14	106.0	0.7326	7032	93.5	7523	10268	491.27	5880.37	0.85
7	2	5886	M	4187	14	106.0	0.7572	7295	93.4	7806	10310			
7	2	5886	M	4974	Nec	92.7	0.7768	17322	93.3	18556	23888	986.32	11805.89	1.71
7	2	5886	M	4975	Nec	92.7	0.7855	17130	93.4	18344	23353			
7	2	5891	M	4188	14	102.2	0.7552	7619	93.4	8154	10797	497.54	5955.33	0.86
7	2	5891	M	4189	14	102.2	0.7554	7640	93.5	8172	10818			
7	2	5891	M	4976	Nec	108.7	0.8246	19427	93.3	20834	25266	1231.15	14736.40	2.13
7	2	5891	M	4977	Nec	108.7	0.8097	18900	93.3	20260	25022			
7	2	5892	M	4190	14	119.6	0.7339	5129	93.5	5488	7478	403.13	4825.36	0.70
7	2	5892	M	4191	14	119.6	0.7571	5296	93.4	5669	7488			
7	2	5892	M	4978	Nec	95.9	0.7862	25803	93.3	27645	35163	1511.56	18092.88	2.61
7	2	5892	M	4979	Nec	95.9	0.7884	25632	93.4	27452	34820			
7	2	5905	F	4192	14	128.6	0.7396	9635	93.5	10306	13934	812.23	9722.10	1.40
7	2	5905	F	4193	14	128.6	0.7385	9735	93.4	10419	14109			

TABLE F4. Liquid Scintillation Analyses of Cage Wash Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (day)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5905	F	4980	Nec	108.9	0.7569	17852	93.4	19121	25262	1233.61	14765.92	2.13
7	2	5905	F	4981	Nec	108.9	0.7846	18334	93.3	19641	25034			
7	2	5906	F	4194	14	107.9	0.7591	9634	93.5	10306	13577	659.45	7893.42	1.14
7	2	5906	F	4195	14	107.9	0.7522	9529	93.4	10199	13559			
7	2	5906	F	4982	Nec	113.0	0.7595	19537	93.4	20918	27541	1386.50	16596.00	2.40
7	2	5906	F	4983	Nec	113.0	0.7836	19710	93.4	21108	26937			
7	2	5908	F	4196	14	109.3	0.7604	11870	93.4	12712	16718	823.37	9855.42	1.41
7	2	5908	F	4197	14	109.3	0.6310	9875	93.6	10556	16729			
7	2	5908	F	4984	Nec	121.6	0.7639	24601	93.4	26346	34489	1878.69	22487.27	3.22
7	2	5908	F	4985	Nec	121.6	0.7743	24676	93.4	26410	34108			
7	2	5914	F	4198	14	106.7	0.7554	5176	93.4	5543	7338	352.50	4219.34	0.63
7	2	5914	F	4199	14	106.7	0.7532	5156	93.4	5521	7330			
7	2	5914	F	4986	Nec	112.9	0.7690	12839	93.2	13770	17906	902.02	10796.85	1.61
7	2	5914	F	4987	Nec	112.9	0.7661	12559	93.3	13458	17568			

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	1	5331	M	95	0.0661	0.0661	1399	92.7	1509	22834	0.68	0.324	4.91	0.01
1	1	5339	M	96	0.2293	0.2293	5406	89.3	6052	26391	2.73	1.300	5.67	0.05
1	1	5340	M	97	0.2017	0.2017	3655	92.6	3945	19561	1.78	0.848	4.20	0.03
1	1	5355	F	98	0.1614	0.1614	2759	91.0	3031	18781	1.37	0.651	4.03	0.03
1	1	5356	F	99	0.1080	0.1080	2411	91.3	2641	24450	1.19	0.567	5.25	0.02
1	1	5362	F	100	0.1862	0.1862	5390	91.7	5879	31571	2.65	1.263	6.78	0.05
1	2	5332	M	101	0.1351	0.1351	675	92.5	730	5401	0.33	0.157	1.16	0.01
1	2	5342	M	102	0.2077	0.2077	2467	91.6	2694	12973	1.21	0.579	2.79	0.02
1	2	5343	M	103	0.1098	0.1097	1026	92.8	1106	10085	0.50	0.238	2.17	0.01
1	2	5349	F	104	0.1319	0.1320	2679	92.9	2885	21855	1.30	0.619	4.70	0.02
1	2	5350	F	105	0.0967	0.0967	1790	94.0	1904	19690	0.86	0.409	4.23	0.02
1	2	5363	F	106	0.1557	0.1557	2883	92.8	3105	19941	1.40	0.667	4.28	0.03
1	3	5327	M	107	0.2180	0.2180	1310	93.9	1395	6401	0.63	0.300	1.38	0.01
1	3	5330	M	108	0.2215	0.2215	1597	93.3	1711	7725	0.77	0.368	1.66	0.01
1	3	5334	M	109	0.1600	0.1602	206	92.9	222	1383	0.10	0.048	0.30	0.00
1	3	5347	F	110	0.1341	0.1341	216	93.2	232	1732	0.10	0.050	0.37	0.00
1	3	5348	F	111	0.1678	0.1679	929	93.6	993	5913	0.45	0.213	1.27	0.01
1	3	5352	F	112	0.1488	0.1488	560	93.5	599	4026	0.27	0.129	0.86	0.00
1	4	5328	M	113	0.2008	0.2007	144	91.8	157	782	0.07	0.034	0.17	0.00
1	4	5336	M	114	0.1215	0.1214	86	91.8	94	774	0.04	0.020	0.17	0.00
1	4	5344	M	115	0.2874	0.2874	291	92.5	315	1095	0.14	0.068	0.24	0.00
1	4	5345	M	116	0.0534	0.0534	44	93.0	47	883	0.02	0.010	0.19	0.00
1	4	5351	F	117	0.0536	0.0536	65	94.0	70	1299	0.03	0.015	0.28	0.00
1	4	5353	F	118	0.0319	0.0320	19	92.6	20	640	0.01	0.004	0.14	0.00
1	4	5359	F	119	0.0590	0.0589	84	92.6	91	1543	0.04	0.020	0.33	0.00
1	4	5365	F	120	0.0658	0.0657	80	93.8	86	1302	0.04	0.018	0.28	0.00

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	5	5329	M	121	0.2067	0.2069	50	82.8	61	294	0.03	0.013	0.06	0.00
1	5	5333	M	122	0.1544	0.1544	57	94.1	60	391	0.03	0.013	0.08	0.00
1	5	5341	M	123	0.1841	0.1840	65	93.8	69	377	0.03	0.015	0.08	0.00
1	5	5360	F	124	0.0633	0.0633	53	93.4	57	903	0.03	0.012	0.19	0.00
1	5	5364	F	125	0.0234	0.0234	14	94.5	14	617	0.01	0.003	0.13	0.00
1	5	5366	F	126	0.0370	0.0369	45	93.0	48	1312	0.02	0.010	0.28	0.00
2	1	5836	M	1107	0.1920	0.1920	2503	92.6	2704	14084	1.22	1.936	10.09	0.02
2	1	5841	M	1108	0.2471	0.2471	2123	91.9	2311	9351	1.04	1.655	6.70	0.02
2	1	5844	M	1109	0.1682	0.1683	2979	91.5	3258	19356	1.47	2.331	13.86	0.03
2	1	5853	F	1110	0.1904	0.1904	4358	92.5	4709	24733	2.12	3.372	17.71	0.04
2	1	5855	F	1111	0.2016	0.2016	5516	93.8	5881	29174	2.65	4.212	20.89	0.05
2	1	5863	F	1112	0.0821	0.0821	1125	93.6	1202	14643	0.54	0.861	10.49	0.01
2	2	5832	M	1113	0.2085	0.2086	2789	92.8	3004	14402	1.35	2.150	10.31	0.03
2	2	5834	M	1114	0.2062	0.2062	1289	92.2	1399	6783	0.63	1.002	4.86	0.01
2	2	5845	M	1115	0.2556	0.2557	2381	92.8	2566	10035	1.16	1.837	7.19	0.02
2	2	5846	F	1116	0.1313	0.1313	1415	92.5	1529	11645	0.69	1.095	8.34	0.01
2	2	5858	F	1117	0.2307	0.2308	2284	92.7	2463	10672	1.11	1.763	7.64	0.02
2	2	5860	F	1118	0.0948	0.0949	790	93.2	848	8934	0.38	0.606	6.40	0.01
2	3	5715	M	1119	0.1998	0.2000	1565	93.2	1679	8395	0.76	1.201	6.01	0.01
2	3	5831	M	1120	0.1429	0.1431	832	92.4	900	6290	0.40	0.644	4.50	0.01
2	3	5837	M	1121	0.1432	0.1431	578	92.2	628	4386	0.28	0.450	3.14	0.01
2	3	5847	F	1122	0.0927	0.0927	836	93.6	893	9636	0.40	0.640	6.90	0.01
2	3	5850	F	1123	0.1235	0.1236	1053	93.8	1122	9076	0.50	0.803	6.50	0.01
2	3	5864	F	1124	0.1726	0.1727	1130	92.6	1221	7070	0.55	0.874	5.06	0.01
2	4	5713	M	1071	0.1782	0.1782	152	93.3	162	911	0.07	0.116	0.65	0.00
2	4	5829	M	1072	0.2178	0.2178	189	91.1	207	953	0.09	0.149	0.68	0.00

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5830	M	1073	0.1968	0.1968	258	93.1	277	1409	0.12	0.199	1.01	0.00
2	4	5839	M	1074	0.0531	0.0531	82	92.8	88	1654	0.04	0.063	1.18	0.00
2	4	5851	F	1075	0.1545	0.1545	846	93.5	905	5860	0.41	0.648	4.20	0.01
2	4	5852	F	1076	0.0966	0.0965	294	93.9	313	3245	0.14	0.224	2.32	0.00
2	4	5857	F	1077	0.1225	0.1225	302	92.1	328	2674	0.15	0.235	1.91	0.00
2	4	5861	F	1078	0.1260	0.1259	251	92.8	270	2147	0.12	0.194	1.54	0.00
2	5	5720	M	1125	0.2551	0.2552	112	91.8	123	480	0.06	0.088	0.34	0.00
2	5	5828	M	1126	0.2263	0.2264	80	89.9	89	394	0.04	0.064	0.28	0.00
2	5	5840	M	1127	0.1815	0.1815	108	92.3	117	644	0.05	0.084	0.46	0.00
2	5	5848	F	1128	0.2103	0.2105	119	90.6	131	621	0.06	0.094	0.44	0.00
2	5	5854	F	1129	0.2782	0.2782	136	92.7	147	527	0.07	0.105	0.38	0.00
2	5	5862	F	1130	0.1185	0.1187	60	93.2	64	541	0.03	0.046	0.39	0.00
3	1	5723	M	451	0.2477	0.2477	1605	92.9	1729	6979	0.78	3.713	14.99	0.01
3	1	5733	M	452	0.1550	0.1549	540	90.8	594	3837	0.27	1.278	8.24	0.00
3	1	5736	M	453	0.0419	0.0420	459	93.8	489	11654	0.22	1.049	25.04	0.00
3	1	5741	F	454	0.1483	0.1480	2655	92.0	2885	19494	1.30	6.211	41.88	0.02
3	1	5744	F	455	0.1661	0.1660	1267	93.5	1356	8168	0.61	2.915	17.55	0.01
3	1	5762	F	456	0.2231	0.2231	1386	92.9	1491	6683	0.67	3.203	14.36	0.01
3	2	5722	M	457	0.1724	0.1723	1363	92.9	1467	8516	0.66	3.154	18.30	0.01
3	2	5734	M	458	0.1209	0.1212	349	93.2	374	3085	0.17	0.801	6.63	0.00
3	2	5737	M	459	0.2228	0.2229	1344	93.1	1444	6477	0.65	3.100	13.91	0.01
3	2	5746	F	460	0.0602	0.0602	509	93.7	544	9028	0.24	1.168	19.40	0.00
3	2	5751	F	461	0.0811	0.0812	695	94.0	739	9104	0.33	1.586	19.56	0.01
3	2	5761	F	462	0.1157	0.1158	604	93.9	642	5548	0.29	1.379	11.92	0.01
3	3	5716	M	463	0.1062	0.1062	332	93.3	356	3349	0.16	0.764	7.19	0.00
3	3	5717	M	464	0.2611	0.2611	669	93.3	717	2747	0.32	1.541	5.90	0.01

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	3	5726	M	465	0.1340	0.1340	387	91.0	425	3172	0.19	0.913	6.81	0.00
3	3	5739	F	466	0.1315	0.1315	437	93.6	467	3553	0.21	1.004	7.63	0.00
3	3	5750	F	467	0.1246	0.1247	452	92.8	487	3905	0.22	1.045	8.39	0.00
3	3	5752	F	468	0.1227	0.1228	546	94.0	580	4725	0.26	1.246	10.15	0.00
3	4	5724	M	469	0.1928	0.1928	194	93.2	208	1078	0.09	0.447	2.32	0.00
3	4	5725	M	470	0.1611	0.1611	432	93.8	460	2857	0.21	0.989	6.14	0.00
3	4	5727	M	471	0.1283	0.1282	478	93.4	512	3990	0.23	1.100	8.57	0.00
3	4	5735	M	472	0.1580	0.1582	386	92.8	416	2630	0.19	0.893	5.65	0.00
3	4	5740	F	473	0.0954	0.0954	249	93.6	266	2786	0.12	0.571	5.98	0.00
3	4	5742	F	474	0.1368	0.1369	453	93.6	484	3536	0.22	1.039	7.60	0.00
3	4	5753	F	475	0.0966	0.0966	292	92.9	314	3256	0.14	0.676	6.99	0.00
3	4	5756	F	476	0.0893	0.0894	416	93.1	446	4994	0.20	0.958	10.73	0.00
3	5	5721	M	477	0.0650	0.0652	16	93.9	17	261	0.01	0.036	0.56	0.00
3	5	5728	M	478	0.1311	0.1311	107	92.8	115	879	0.05	0.248	1.89	0.00
3	5	5732	M	479	0.1186	0.1187	51	94.0	54	457	0.02	0.117	0.98	0.00
3	5	5738	F	480	0.1578	0.1577	136	94.0	145	916	0.07	0.311	1.97	0.00
3	5	5758	F	481	0.1064	0.1067	74	94.2	79	738	0.04	0.169	1.59	0.00
3	5	5760	F	482	0.1048	0.1047	61	93.2	66	630	0.03	0.142	1.35	0.00
4	NA	5714	M	1063	0.1919	0.1919	286	91.8	312	1626	0.14	0.660	3.44	0.00
4	NA	5718	M	1064	0.1944	0.1944	140	93.1	151	775	0.07	0.319	1.64	0.00
4	NA	5719	M	1065	0.0947	0.0946	103	93.5	110	1162	0.05	0.233	2.46	0.00
4	NA	5730	M	1066	0.2317	0.2317	288	93.7	308	1328	0.14	0.651	2.81	0.00
4	NA	5743	F	1067	0.1396	0.1397	539	94.2	572	4094	0.26	1.209	8.66	0.01
4	NA	5745	F	1068	0.1134	0.1134	321	93.2	344	3036	0.16	0.728	6.42	0.00
4	NA	5748	F	1069	0.0835	0.0835	306	93.8	327	3913	0.15	0.691	8.28	0.00
4	NA	5754	F	1070	0.1309	0.1309	329	93.2	353	2696	0.16	0.746	5.70	0.00

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	1	5871	M	3559	0.1459	0.1461	229	91.9	250	1708	0.11	0.134	0.92	0.00
5	1	5883	M	3560	0.2321	0.2321	396	91.5	433	1864	0.19	0.233	1.00	0.00
5	1	5884	M	3561	0.2004	0.2004	363	93.3	389	1939	0.18	0.210	1.05	0.00
5	1	5889	M	3562	0.2158	0.2158	180	92.2	195	904	0.09	0.105	0.49	0.00
5	1	5896	F	3563	0.1679	0.1682	164	93.2	176	1046	0.08	0.095	0.56	0.00
5	1	5899	F	3564	0.2189	0.2189	262	93.2	281	1282	0.13	0.151	0.69	0.00
5	1	5900	F	3565	0.1021	0.1022	154	92.8	166	1622	0.07	0.089	0.87	0.00
5	1	5921	F	3566	0.1539	0.1539	245	93.6	261	1699	0.12	0.141	0.92	0.00
5	2	5869	M	4820	0.0792	0.0792	66	92.7	71	893	0.03	0.038	0.48	0.00
5	2	5870	M	4821	0.1365	0.1365	104	93.3	111	815	0.05	0.060	0.44	0.00
5	2	5888	M	4822	0.1006	0.1005	105	92.9	113	1126	0.05	0.061	0.61	0.00
5	2	5893	M	4823	0.0120	0.0120	0	93.8	0	0	0.00	0.000	0.00	0.00
5	2	5910	F	4824	0.2331	0.2333	252	92.6	272	1167	0.12	0.147	0.63	0.00
5	2	5911	F	4825	0.1485	0.1486	140	92.8	151	1015	0.07	0.081	0.55	0.00
5	2	5915	F	4826	0.1622	0.1624	224	92.1	244	1500	0.11	0.131	0.81	0.00
5	2	5916	F	4827	0.1897	0.1897	220	92.8	238	1252	0.11	0.128	0.68	0.00
6	1	5867	M	3690	0.1990	0.1991	133	92.4	144	725	0.06	0.259	1.30	0.00
6	1	5868	M	3691	0.1401	0.1404	60	93.7	65	459	0.03	0.116	0.83	0.00
6	1	5875	M	3692	0.1236	0.1237	64	93.6	69	555	0.03	0.123	1.00	0.00
6	1	5881	M	3693	0.1474	0.1475	111	93.7	119	804	0.05	0.213	1.45	0.00
6	1	5895	F	3694	0.0826	0.0826	56	93.5	60	724	0.03	0.107	1.30	0.00
6	1	5907	F	3695	0.1584	0.1585	130	93.6	139	875	0.06	0.249	1.57	0.00
6	1	5909	F	3696	0.0783	0.0784	70	93.8	75	951	0.03	0.134	1.71	0.00
6	1	5918	F	3697	0.1395	0.1394	124	93.0	133	957	0.06	0.240	1.72	0.00
6	2	5880	M	4844	0.2036	0.2043	135	93.2	145	709	0.07	0.260	1.28	0.00
6	2	5885	M	4845	0.2185	0.2185	186	92.6	200	917	0.09	0.360	1.65	0.00

TABLE F5. Liquid Scintillation Analyses of Plasma Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	2	5887	M	4846	0.1969	0.1972	122	92.2	132	669	0.06	0.237	1.20	0.00
6	2	5894	M	4847	0.2061	0.2060	313	91.9	340	1652	0.15	0.612	2.97	0.00
6	2	5903	F	4848	0.2140	0.2140	246	91.4	269	1257	0.12	0.484	2.26	0.00
6	2	5912	F	4849	0.2727	0.2728	244	92.7	263	966	0.12	0.473	1.74	0.00
6	2	5917	F	4850	0.1231	0.1230	129	93.1	138	1125	0.06	0.249	2.02	0.00
6	2	5919	F	4851	0.1831	0.1832	123	92.8	132	721	0.06	0.237	1.30	0.00
7	1	5872	M	3810	0.2249	0.2250	159	88.8	179	796	0.08	0.965	4.29	0.00
7	1	5873	M	3811	0.3124	0.3121	122	91.4	133	427	0.06	0.719	2.30	0.00
7	1	5874	M	3812	0.1320	0.1320	251	93.2	270	2043	0.12	1.454	11.01	0.00
7	1	5882	M	3813	0.2110	0.2109	86	89.9	96	454	0.04	0.517	2.45	0.00
7	1	5901	F	3814	0.2386	0.2387	328	92.6	354	1483	0.16	1.908	8.00	0.00
7	1	5902	F	3815	0.1703	0.1703	502	92.6	543	3186	0.24	2.926	17.18	0.00
7	1	5913	F	3816	0.1813	0.1812	131	93.1	141	776	0.06	0.758	4.18	0.00
7	1	5920	F	3817	0.2419	0.2419	652	92.5	705	2913	0.32	3.799	15.70	0.00
7	2	5878	M	4948	0.2058	0.2059	320	92.5	346	1681	0.16	1.865	9.06	0.00
7	2	5886	M	4949	0.1985	0.1985	130	92.5	140	707	0.06	0.756	3.81	0.00
7	2	5891	M	4950	0.1585	0.1586	446	91.7	487	3070	0.22	2.624	16.56	0.00
7	2	5892	M	4951	0.1490	0.1490	97	92.0	105	707	0.05	0.568	3.81	0.00
7	2	5905	F	4952	0.2600	0.2600	236	91.5	258	993	0.12	1.392	5.35	0.00
7	2	5906	F	4953	0.1081	0.1081	95	92.6	103	954	0.05	0.556	5.14	0.00
7	2	5908	F	4954	0.4080	0.4080	302	92.9	325	796	0.15	1.750	4.29	0.00
7	2	5914	F	4955	0.1317	0.1317	73	88.2	83	630	0.04	0.447	3.40	0.00

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	1	5331	M	2946	0.1508	0.0947	1.05	834	84.0	993	11012	0.75	0.36	2.37	0.01
1	1	5339	M	2947	0.3822	0.1313	1.05	915	83.5	1096	8764	1.51	0.72	1.88	0.03
1	1	5340	M	2948	0.3194	0.2576	1.05	1392	83.3	1671	6811	0.98	0.47	1.46	0.02
1	1	5355	F	2949	0.3102	0.2517	1.05	1152	83.9	1373	5730	0.80	0.38	1.23	0.01
1	1	5356	F	2950	0.2572	0.1952	1.05	1292	84.2	1535	8258	0.96	0.46	1.77	0.02
1	1	5362	F	2951	0.3114	0.2345	1.05	1713	83.9	2041	9139	1.28	0.61	1.96	0.02
1	2	5332	M	2952	0.3787	0.2836	1.05	386	83.8	461	1706	0.29	0.14	0.37	0.01
1	2	5342	M	2953	0.3444	0.2091	1.05	671	83.9	799	4014	0.62	0.30	0.86	0.01
1	2	5343	M	2954	0.1858	0.1498	1.05	502	83.7	600	4207	0.35	0.17	0.90	0.01
1	2	5349	F	2955	0.3032	0.2714	1.05	1840	83.6	2203	8521	1.16	0.56	1.83	0.02
1	2	5350	F	2956	0.2605	0.2275	1.05	1363	83.4	1634	7542	0.88	0.42	1.62	0.02
1	2	5363	F	2957	0.3029	0.2659	1.05	1588	83.4	1904	7520	1.03	0.49	1.62	0.02
1	3	5327	M	2958	0.3202	0.2836	1.05	419	84.8	494	1828	0.26	0.13	0.39	0.00
1	3	5330	M	2959	0.3285	0.2913	1.05	543	83.9	647	2332	0.35	0.16	0.50	0.01
1	3	5334	M	2960	0.2938	0.2595	1.05	75	83.2	90	366	0.05	0.02	0.08	0.00
1	3	5347	F	2961	0.2092	0.1746	1.05	147	82.4	179	1076	0.10	0.05	0.23	0.00
1	3	5348	F	2962	0.2601	0.2275	1.05	269	83.7	322	1486	0.17	0.08	0.32	0.00
1	3	5352	F	2963	0.2513	0.2166	1.05	361	84.0	430	2084	0.24	0.11	0.45	0.00
1	4	5328	M	2964	0.3721	0.3356	1.05	66	83.8	79	246	0.04	0.02	0.05	0.00
1	4	5336	M	2965	0.3200	0.1891	1.05	77	83.6	92	511	0.07	0.04	0.11	0.00
1	4	5344	M	2966	0.4604	0.3741	1.05	147	83.2	176	494	0.10	0.05	0.11	0.00
1	4	5345	M	2967	0.3099	0.2602	1.05	137	84.3	162	655	0.09	0.04	0.14	0.00
1	4	5351	F	2968	0.2348	0.1944	1.05	87	82.9	104	564	0.06	0.03	0.12	0.00
1	4	5353	F	2969	0.1720	0.1143	1.05	43	82.9	52	479	0.04	0.02	0.10	0.00
1	4	5359	F	2970	0.1680	0.1206	1.05	107	83.5	128	1118	0.08	0.04	0.24	0.00
1	4	5365	F	2971	0.2592	0.1914	1.05	77	83.9	91	502	0.06	0.03	0.11	0.00
1	5	5329	M	2972	0.3903	0.3108	1.05	60	83.7	71	240	0.04	0.02	0.05	0.00

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	5	5333	M	2973	0.5008	0.3969	1.05	130	83.2	156	414	0.09	0.04	0.09	0.00
1	5	5341	M	2974	0.3861	0.3124	1.05	148	82.9	178	599	0.10	0.05	0.13	0.00
1	5	5360	F	2975	0.2365	0.1659	1.05	133	83.2	160	1013	0.11	0.05	0.22	0.00
1	5	5364	F	2976	0.2724	0.2262	1.05	243	83.3	291	1353	0.17	0.08	0.29	0.00
1	5	5366	F	2977	0.2261	0.1876	1.05	130	83.6	155	870	0.09	0.04	0.19	0.00
2	1	5836	M	3018	0.3624	0.3334	1.07	1454	84.7	1717	5511	0.90	1.43	3.95	0.02
2	1	5841	M	3019	0.4000	0.3706	1.07	997	84.6	1178	3403	0.61	0.97	2.44	0.01
2	1	5844	M	3020	0.3455	0.3145	1.07	1809	84.3	2145	7299	1.14	1.81	5.23	0.02
2	1	5853	F	3021	0.2965	0.2655	1.07	1590	84.2	1887	7606	1.02	1.61	5.45	0.02
2	1	5855	F	3022	0.3098	0.2878	1.07	1798	84.9	2118	7873	1.10	1.75	5.64	0.02
2	1	5863	F	3023	0.2340	0.2075	1.07	905	84.8	1067	5502	0.58	0.92	3.94	0.01
2	2	5832	M	3024	0.3438	0.3115	1.07	872	84.4	1034	3551	0.55	0.87	2.54	0.01
2	2	5834	M	3025	0.0311	0.2796	1.07	523	84.3	620	2374	0.03	0.05	1.70	0.00
2	2	5845	M	3026	0.4303	0.3941	1.07	1001	84.9	1180	3203	0.62	0.99	2.29	0.01
2	2	5846	F	3027	0.2549	0.2309	1.07	561	86.4	649	3007	0.35	0.55	2.15	0.01
2	2	5858	F	3028	0.3577	0.3218	1.07	840	83.7	1003	3336	0.54	0.85	2.39	0.01
2	2	5860	F	3029	0.1662	0.1414	1.07	310	84.5	367	2776	0.21	0.33	1.99	0.00
2	3	5715	M	3030	0.3152	0.2873	1.07	825	84.0	981	3655	0.52	0.82	2.62	0.01
2	3	5831	M	3031	0.2477	0.2196	1.07	502	84.2	596	2904	0.32	0.52	2.08	0.01
2	3	5837	M	3032	0.2413	0.2166	1.07	411	85.1	483	2385	0.26	0.41	1.71	0.00
2	3	5847	F	3033	0.1788	0.1531	1.07	441	84.4	523	3655	0.29	0.47	2.62	0.01
2	3	5850	F	3034	0.2033	0.1785	1.07	464	84.3	550	3295	0.30	0.48	2.36	0.01
2	3	5864	F	3035	0.2412	0.2163	1.07	467	84.2	555	2743	0.30	0.47	1.96	0.01
2	4	5713	M	3036	0.2966	0.2673	1.07	169	84.5	200	799	0.11	0.17	0.57	0.00
2	4	5829	M	3037	0.3007	0.2685	1.07	55	84.1	65	259	0.04	0.06	0.19	0.00
2	4	5830	M	3038	0.3486	0.3206	1.07	232	85.0	273	910	0.14	0.23	0.65	0.00
2	4	5839	M	3039	0.1017	0.0779	1.07	40	84.0	48	659	0.03	0.05	0.47	0.00

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5851	F	3040	0.2260	0.1963	1.07	335	84.0	399	2174	0.22	0.35	1.56	0.00
2	4	5852	F	3041	0.2069	0.1773	1.07	193	83.9	230	1386	0.13	0.21	0.99	0.00
2	4	5857	F	3042	0.2360	0.2070	1.07	112	84.3	132	684	0.07	0.12	0.49	0.00
2	4	5861	F	3043	0.1937	0.1655	1.07	70	84.4	83	539	0.05	0.07	0.39	0.00
2	5	5720	M	3044	0.4117	0.3757	1.07	34	83.9	41	116	0.02	0.03	0.08	0.00
2	5	5828	M	3045	0.3859	0.3339	1.07	31	83.5	37	119	0.02	0.03	0.09	0.00
2	5	5840	M	3046	0.2718	0.2361	1.07	66	84.0	78	355	0.04	0.07	0.25	0.00
2	5	5848	F	3047	0.3300	0.2909	1.07	211	83.6	253	930	0.14	0.22	0.67	0.00
2	5	5854	F	3048	0.3730	0.3383	1.07	184	83.7	219	693	0.12	0.19	0.50	0.00
2	5	5862	F	3049	0.1698	0.1380	1.07	75	83.9	90	695	0.05	0.08	0.50	0.00
3	1	5723	M	3090	0.3194	0.2786	1.06	477	84.3	566	2152	0.31	1.48	4.62	0.01
3	1	5733	M	3091	0.2744	0.2258	1.06	279	84.5	330	1548	0.19	0.91	3.33	0.00
3	1	5736	M	3092	0.1094	0.0848	1.06	265	84.0	315	3938	0.19	0.93	8.46	0.00
3	1	5741	F	3093	0.2587	0.2197	1.06	943	84.5	1116	5386	0.63	2.99	11.57	0.01
3	1	5744	F	3094	0.2903	0.2425	1.06	500	85.0	588	2569	0.34	1.60	5.52	0.01
3	1	5762	F	3095	0.3345	0.2828	1.06	513	85.3	601	2252	0.34	1.62	4.84	0.01
3	2	5722	M	3096	0.2970	0.2415	1.06	466	84.7	550	2413	0.32	1.54	5.18	0.01
3	2	5734	M	3097	0.2191	0.1725	1.06	174	84.7	206	1264	0.12	0.59	2.72	0.00
3	2	5737	M	3098	0.3639	0.3120	1.06	566	84.4	671	2279	0.37	1.78	4.90	0.01
3	2	5746	F	3099	0.1614	0.0787	1.06	397	84.8	468	6305	0.46	2.19	13.55	0.01
3	2	5751	F	3100	0.2107	0.1813	1.06	561	84.3	666	3891	0.37	1.76	8.36	0.01
3	2	5761	F	3101	0.2698	0.1980	1.06	311	83.9	371	1987	0.24	1.15	4.27	0.00
3	3	5716	M	3102	0.2057	0.1768	1.06	226	84.3	269	1611	0.15	0.71	3.46	0.00
3	3	5717	M	3103	0.3529	0.3085	1.06	368	84.1	438	1504	0.24	1.14	3.23	0.00
3	3	5726	M	3104	0.2957	0.2371	1.06	343	84.8	404	1806	0.24	1.15	3.88	0.00
3	3	5739	F	3105	0.2608	0.2185	1.06	191	84.4	226	1096	0.13	0.61	2.35	0.00
3	3	5750	F	3106	0.5075	0.1985	1.06	225	84.7	266	1418	0.32	1.55	3.05	0.01

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	3	5752	F	3107	0.2393	0.1925	1.06	274	84.1	325	1792	0.19	0.92	3.85	0.00
3	4	5724	M	3108	0.0313	0.2570	1.06	93	84.6	110	454	0.01	0.03	0.98	0.00
3	4	5725	M	3109	0.2912	0.2238	1.06	201	84.5	238	1128	0.15	0.71	2.42	0.00
3	4	5727	M	3110	0.2044	0.1705	1.06	226	84.1	269	1674	0.15	0.73	3.60	0.00
3	4	5735	M	3111	0.3240	0.2783	1.06	233	85.6	273	1039	0.15	0.72	2.23	0.00
3	4	5740	F	3112	0.2257	0.1934	1.06	215	84.5	254	1391	0.14	0.67	2.99	0.00
3	4	5742	F	3113	0.2813	0.2323	1.06	163	85.2	191	871	0.11	0.53	1.87	0.00
3	4	5753	F	3114	0.1758	0.1326	1.06	178	84.7	210	1676	0.13	0.63	3.60	0.00
3	4	5756	F	3115	0.2153	0.1569	1.06	223	84.3	265	1789	0.17	0.83	3.84	0.00
3	5	5721	M	3116	0.2276	0.1812	1.06	24	85.0	28	165	0.02	0.08	0.35	0.00
3	5	5728	M	3117	0.2879	0.2232	1.06	45	83.9	53	252	0.03	0.16	0.54	0.00
3	5	5732	M	3118	0.0346	0.2827	1.06	38	84.4	45	169	0.00	0.01	0.36	0.00
3	5	5738	F	3119	0.2715	0.2206	1.06	91	84.8	107	516	0.06	0.30	1.11	0.00
3	5	5758	F	3120	0.1936	0.1570	1.06	95	85.1	112	757	0.07	0.31	1.63	0.00
3	5	5760	F	3121	0.2305	0.1819	1.06	150	84.4	177	1034	0.11	0.51	2.22	0.00
4	NA	5714	M	3162	0.3307	0.2963	1.02	227	84.6	269	926	0.14	0.65	1.96	0.00
4	NA	5718	M	3163	0.2965	0.2674	1.02	112	84.3	133	509	0.07	0.32	1.08	0.00
4	NA	5719	M	3164	0.1728	0.1341	1.02	83	83.9	99	756	0.06	0.28	1.60	0.00
4	NA	5730	M	3165	0.3064	0.2767	1.02	73	84.4	86	317	0.04	0.21	0.67	0.00
4	NA	5743	F	3166	0.2409	0.2130	1.02	287	84.3	340	1627	0.18	0.83	3.44	0.00
4	NA	5745	F	3167	0.2440	0.2145	1.02	256	84.4	303	1440	0.16	0.74	3.05	0.00
4	NA	5748	F	3168	0.1878	0.1649	1.02	253	84.1	301	1860	0.16	0.74	3.93	0.00
4	NA	5754	F	3169	0.2469	0.2201	1.02	275	85.0	324	1500	0.17	0.78	3.17	0.00
5	1	5871	M	6157	0.2431	0.1967	1.04	179	85.4	209	1105	0.12	0.14	0.60	0.00
5	1	5883	M	6158	0.4193	0.3799	1.04	277	85.3	324	887	0.17	0.20	0.48	0.00
5	1	5884	M	6159	0.3260	0.2829	1.04	125	86.8	144	530	0.08	0.09	0.29	0.00
5	1	5889	M	6160	0.3351	0.2985	1.04	90	85.7	105	365	0.06	0.07	0.20	0.00

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	1	5896	F	6161	0.3050	0.2707	1.04	194	85.8	226	867	0.12	0.14	0.47	0.00
5	1	5899	F	6162	0.3516	0.3099	1.04	75	85.8	88	294	0.05	0.06	0.16	0.00
5	1	5900	F	6163	0.1944	0.1327	1.04	237	85.6	277	2169	0.19	0.23	1.17	0.00
5	1	5921	F	6164	0.2565	0.2019	1.04	209	85.4	245	1260	0.15	0.17	0.68	0.00
5	2	5869	M	6165	0.1469	0.1033	1.04	25	85.3	30	299	0.02	0.02	0.16	0.00
5	2	5870	M	6166	0.2258	0.1833	1.04	102	85.6	120	679	0.07	0.08	0.37	0.00
5	2	5888	M	6167	0.1579	0.1056	1.04	257	85.4	301	2967	0.21	0.25	1.60	0.00
5	2	5893	M	6168	0.0547	0.0368	1.04	30	86.7	34	961	0.02	0.03	0.52	0.00
5	2	5910	F	6169	0.3905	0.3510	1.04	325	85.6	379	1124	0.20	0.24	0.61	0.00
5	2	5911	F	6170	0.2614	0.2171	1.04	251	85.3	294	1407	0.17	0.20	0.76	0.00
5	2	5915	F	6171	0.2604	0.1976	1.04	592	85.4	693	3646	0.43	0.51	1.97	0.00
5	2	5916	F	6172	0.3090	0.2693	1.04	95	87.3	109	420	0.06	0.07	0.23	0.00
6	1	5867	M	6173	0.3762	0.3279	1.07	187	84.8	220	719	0.12	0.49	1.29	0.00
6	1	5868	M	6174	0.2462	0.2154	1.07	29	85.8	34	170	0.02	0.08	0.31	0.00
6	1	5875	M	6175	0.2271	0.1845	1.07	191	85.7	222	1290	0.13	0.53	2.32	0.00
6	1	5881	M	6176	0.2582	0.2203	1.07	106	85.6	124	604	0.07	0.28	1.08	0.00
6	1	5895	F	6177	0.1764	0.1167	1.07	121	85.6	141	1294	0.10	0.41	2.33	0.00
6	1	5907	F	6178	0.2399	0.2107	1.07	37	86.2	43	219	0.02	0.09	0.39	0.00
6	1	5909	F	6179	0.1483	0.1066	1.07	66	85.5	77	776	0.05	0.21	1.39	0.00
6	1	5918	F	6180	0.2484	0.2222	1.07	258	85.6	301	1451	0.16	0.65	2.61	0.00
6	2	5880	M	6181	0.3254	0.2946	1.07	57	85.6	66	240	0.04	0.14	0.43	0.00
6	2	5885	M	6182	0.2872	0.2375	1.07	116	85.1	136	614	0.08	0.32	1.10	0.00
6	2	5887	M	6183	0.2519	0.2091	1.07	153	85.3	179	915	0.10	0.41	1.65	0.00
6	2	5894	M	6184	0.3040	0.2678	1.07	174	84.8	205	819	0.11	0.45	1.47	0.00
6	2	5903	F	6185	0.3111	0.2737	1.07	163	85.1	191	747	0.10	0.42	1.34	0.00
6	2	5912	F	6186	0.3385	0.3058	1.07	152	84.7	179	626	0.10	0.38	1.13	0.00
6	2	5917	F	6187	0.1890	0.1389	1.07	186	85.4	218	1678	0.14	0.57	3.02	0.00

TABLE F6. Liquid Scintillation Analyses of Blood Cellular Fraction Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	2	5919	F	6188	0.2909	0.2519	1.07	217	85.3	254	1080	0.14	0.56	1.94	0.00
7	1	5872	M	6189	0.3556	0.3088	1.07	126	85.1	148	514	0.08	0.99	2.77	0.00
7	1	5873	M	6190	0.4649	0.4046	1.07	119	84.2	141	373	0.08	0.93	2.01	0.00
7	1	5874	M	6191	0.2754	0.2302	1.07	282	85.3	330	1535	0.19	2.28	8.28	0.00
7	1	5882	M	6192	0.3628	0.2984	1.07	98	85.0	115	413	0.07	0.81	2.23	0.00
7	1	5901	F	6193	0.3449	0.2972	1.07	262	84.9	308	1110	0.17	2.06	5.99	0.00
7	1	5902	F	6194	0.3204	0.2709	1.07	313	84.8	369	1458	0.21	2.52	7.86	0.00
7	1	5913	F	6195	0.2896	0.2468	1.07	40	85.3	47	203	0.03	0.32	1.09	0.00
7	1	5920	F	6196	0.4340	0.3654	1.07	351	84.3	416	1219	0.24	2.85	6.57	0.00
7	2	5878	M	6197	0.3395	0.3118	1.07	93	84.7	110	377	0.06	0.69	2.04	0.00
7	2	5886	M	6198	0.3049	0.2608	1.07	264	85.0	311	1274	0.17	2.09	6.87	0.00
7	2	5891	M	6199	0.2265	0.1907	1.07	169	85.4	198	1112	0.11	1.36	6.00	0.00
7	2	5892	M	6200	0.2726	0.2278	1.07	148	85.1	174	816	0.10	1.20	4.40	0.00
7	2	5905	F	6201	0.3515	0.3144	1.07	62	84.8	73	249	0.04	0.47	1.34	0.00
7	2	5906	F	6202	0.1817	0.1500	1.07	64	85.4	75	537	0.04	0.53	2.89	0.00
7	2	5908	F	6203	0.5094	0.4310	1.07	56	84.5	66	163	0.04	0.45	0.88	0.00
7	2	5914	F	6204	0.2286	0.1883	1.07	103	85.4	120	682	0.07	0.84	3.68	0.00

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	4	5328	M	2978	1.7534	0.5341	1.05	405	83.8	483	950	0.70	0.34	0.19	0.01
1	4	5328	M	2979	1.7534	0.5500	1.05	368	84.5	435	831				
1	4	5336	M	2980	1.9967	0.4727	1.05	337	84.8	397	882	0.84	0.40	0.20	0.02
1	4	5336	M	2981	1.9967	0.4493	1.05	356	85.4	417	975				
1	4	5344	M	2982	2.1838	0.5405	1.05	412	85.3	483	938	0.94	0.45	0.20	0.02
1	4	5344	M	2983	2.1838	0.5559	1.05	430	84.0	512	967				
1	4	5345	M	2984	1.9103	0.5302	1.05	325	85.8	379	750	0.67	0.32	0.17	0.01
1	4	5345	M	2985	1.9103	0.5514	1.05	355	84.5	420	799				
1	4	5351	F	2986	1.0875	0.4152	1.05	312	84.8	368	931	0.44	0.21	0.19	0.01
1	4	5351	F	2987	1.0875	0.4768	1.05	339	85.8	395	871				
1	4	5353	F	2988	1.3317	0.4824	1.05	401	85.5	468	1019	0.56	0.27	0.20	0.01
1	4	5353	F	2989	1.3317	0.4803	1.05	329	84.7	389	850				
1	4	5359	F	2990	1.4788	0.4033	1.05	380	84.2	451	1173	0.77	0.36	0.25	0.01
1	4	5359	F	2991	1.4788	0.3990	1.05	364	85.3	427	1124				
1	4	5365	F	2992	1.1931	0.4328	1.05	391	84.8	461	1118	0.63	0.30	0.25	0.01
1	4	5365	F	2993	1.1931	0.3596	1.05	361	85.3	424	1237				
2	4	5713	M	3050	1.6675	0.5183	1.07	561	83.5	672	1388	1.03	1.64	0.98	0.02
2	4	5713	M	3051	1.6675	0.5171	1.07	548	83.2	659	1363				
2	4	5829	M	3052	1.6359	0.5005	1.07	524	83.1	630	1348	0.95	1.51	0.93	0.02
2	4	5829	M	3053	1.6359	0.5146	1.07	497	83.5	595	1237				
2	4	5830	M	3054	1.7670	0.5075	1.07	530	84.4	628	1325	1.04	1.65	0.93	0.02
2	4	5830	M	3055	1.7670	0.4966	1.07	500	84.2	593	1279				
2	4	5839	M	3056	1.8836	0.4951	1.07	703	84.9	828	1790	1.52	2.42	1.29	0.03
2	4	5839	M	3057	1.8836	0.4843	1.07	683	83.6	817	1804				
2	4	5851	F	3058	1.1220	0.3925	1.07	1058	84.3	1256	3423	1.69	2.69	2.40	0.03
2	4	5851	F	3059	1.1220	0.3986	1.07	1026	84.0	1222	3280				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5852	F	3060	1.2536	0.4019	1.07	705	83.2	847	2255	1.31	2.08	1.66	0.02
2	4	5852	F	3061	1.2536	0.4148	1.07	776	84.2	921	2376				
2	4	5857	F	3062	1.4076	0.4742	1.07	546	83.5	653	1474	0.97	1.54	1.09	0.02
2	4	5857	F	3063	1.4076	0.4913	1.07	608	83.6	727	1583				
2	4	5861	F	3064	1.1282	0.3270	1.07	420	84.0	500	1637	0.92	1.46	1.30	0.02
2	4	5861	F	3065	1.1282	0.3490	1.07	547	84.3	649	1989				
3	4	5724	M	3122	1.6678	0.5044	1.08	530	83.6	634	1358	0.97	4.62	2.77	0.02
3	4	5724	M	3123	1.6678	0.4992	1.08	476	84.3	564	1220				
3	4	5725	M	3124	1.7732	0.5381	1.08	706	83.9	841	1689	1.64	7.84	4.42	0.03
3	4	5725	M	3125	1.7732	0.5384	1.08	1003	82.8	1211	2429				
3	4	5727	M	3126	1.6627	0.5013	1.08	803	84.3	954	2054	1.56	7.45	4.48	0.03
3	4	5727	M	3127	1.6627	0.5009	1.08	827	84.3	981	2116				
3	4	5735	M	3128	1.8936	0.5548	1.08	613	83.8	731	1423	1.28	6.09	3.21	0.02
3	4	5735	M	3129	1.8936	0.5333	1.08	650	83.9	775	1569				
3	4	5740	F	3130	1.2230	0.3986	1.08	552	83.7	660	1788	1.00	4.78	3.91	0.02
3	4	5740	F	3131	1.2230	0.4372	1.08	624	83.3	749	1851				
3	4	5742	F	3132	1.1827	0.3723	1.08	729	83.5	872	2531	1.27	6.04	5.11	0.02
3	4	5742	F	3133	1.1827	0.4250	1.08	733	83.8	875	2225				
3	4	5753	F	3134	0.9725	0.4691	1.08	825	84.1	981	2259	1.32	6.31	6.48	0.02
3	4	5753	F	3135	0.9725	0.3946	1.08	1150	83.3	1380	3777				
3	4	5756	F	3136	1.0284	0.4057	1.08	902	84.3	1071	2850	1.26	5.99	5.82	0.02
3	4	5756	F	3137	1.0284	0.4276	1.08	855	83.9	1019	2572				
4	NA	5714	M	3170	1.5353	0.4892	1.02	613	83.9	730	1523	1.03	4.84	3.15	0.02
4	NA	5714	M	3171	1.5353	0.4377	1.02	527	84.2	626	1459				
4	NA	5718	M	3172	1.8047	0.5148	1.02	413	84.9	486	963	0.78	3.66	2.03	0.02
4	NA	5718	M	3173	1.8047	0.5062	1.02	399	84.2	475	956				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5719	M	3174	2.0470	0.5273	1.02	733	84.7	865	1674	1.77	8.32	4.06	0.04
4	NA	5719	M	3175	2.0470	0.5077	1.02	899	83.3	1079	2168				
4	NA	5730	M	3176	1.6547	0.4968	1.02	410	84.8	484	993	0.81	3.79	2.29	0.02
4	NA	5730	M	3177	1.6547	0.5109	1.02	493	83.9	587	1172				
4	NA	5743	F	3178	1.0147	0.4675	1.02	773	84.4	916	1998	0.94	4.40	4.33	0.02
4	NA	5743	F	3179	1.0147	0.2912	1.02	507	84.6	599	2100				
4	NA	5745	F	3180	1.2993	0.4226	1.02	866	84.2	1028	2482	1.46	6.84	5.26	0.03
4	NA	5745	F	3181	1.2993	0.5051	1.02	1045	84.5	1236	2496				
4	NA	5748	F	3182	1.1498	0.3337	1.02	539	84.1	641	1960	1.00	4.69	4.08	0.02
4	NA	5748	F	3183	1.1498	0.4502	1.02	703	84.0	837	1897				
4	NA	5754	F	3184	1.3829	0.4372	1.02	522	84.5	617	1441	0.90	4.25	3.07	0.02
4	NA	5754	F	3185	1.3829	0.4392	1.02	528	83.7	630	1464				
5	1	5871	M	5272	1.8055	0.5390	1.04	749	87.0	861	1660	1.42	1.70	0.94	0.00
5	1	5871	M	5273	1.8055	0.5280	1.04	791	84.8	932	1836				
5	1	5883	M	5274	1.7453	0.5223	1.04	706	86.0	821	1634	1.31	1.57	0.90	0.00
5	1	5883	M	5275	1.7453	0.5050	1.04	712	86.5	823	1694				
5	1	5884	M	5276	1.3976	0.5105	1.04	798	86.6	922	1879	1.11	1.33	0.95	0.00
5	1	5884	M	5277	1.3976	0.5031	1.04	685	85.3	803	1660				
5	1	5889	M	5278	1.6088	0.5483	1.04	437	85.2	513	974	0.71	0.84	0.52	0.00
5	1	5889	M	5279	1.6088	0.5457	1.04	439	86.0	511	973				
5	1	5896	F	5280	1.3144	0.5345	1.04	424	85.3	497	967	0.62	0.74	0.56	0.00
5	1	5896	F	5281	1.3144	0.5241	1.04	482	85.3	565	1122				
5	1	5899	F	5282	1.5222	0.4965	1.04	453	85.1	532	1115	0.76	0.91	0.60	0.00
5	1	5899	F	5283	1.5222	0.5071	1.04	452	84.8	533	1093				
5	1	5900	F	5284	1.4098	0.5197	1.04	538	85.3	631	1263	0.88	1.05	0.75	0.00
5	1	5900	F	5285	1.4098	0.5321	1.04	641	83.3	770	1504				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	1	5921	F	5286	1.3320	0.5479	1.04	743	86.2	862	1636	0.92	1.10	0.83	0.00
5	1	5921	F	5287	1.3320	0.5037	1.04	595	85.4	696	1437				
5	2	5869	M	5394	1.4396	0.5399	1.07	774	86.6	894	1771	1.06	1.27	0.88	0.00
5	2	5869	M	5395	1.4396	0.5463	1.07	660	85.8	769	1506				
5	2	5870	M	5396	1.6942	0.5315	1.07	493	86.3	571	1150	0.90	1.08	0.64	0.00
5	2	5870	M	5397	1.6942	0.5194	1.07	505	86.2	586	1208				
5	2	5888	M	5398	1.3243	0.5029	1.07	595	85.9	693	1474	0.87	1.04	0.78	0.00
5	2	5888	M	5399	1.3243	0.5202	1.07	600	86.2	696	1432				
5	2	5893	M	5400	1.7259	0.5463	1.07	460	85.9	535	1049	0.88	1.05	0.61	0.00
5	2	5893	M	5401	1.7259	0.5280	1.07	512	86.2	594	1203				
5	2	5910	F	5402	1.4147	0.5203	1.07	545	85.9	634	1303	0.79	0.95	0.67	0.00
5	2	5910	F	5403	1.4147	0.5084	1.07	485	86.3	562	1182				
5	2	5911	F	5404	1.1184	0.5227	1.07	623	85.9	725	1484	0.94	1.12	1.00	0.00
5	2	5911	F	5405	1.1184	0.4025	1.07	728	86.8	839	2231				
5	2	5915	F	5406	1.0269	0.5118	1.07	693	86.6	800	1673	0.79	0.95	0.92	0.00
5	2	5915	F	5407	1.0269	0.4744	1.07	664	85.5	776	1751				
5	2	5916	F	5408	1.3372	0.5411	1.07	616	85.4	722	1427	0.86	1.03	0.77	0.00
5	2	5916	F	5409	1.3372	0.5431	1.07	624	85.4	731	1441				
6	1	5867	M	5312	1.5689	0.5177	1.10	566	85.7	660	1403	0.92	3.66	2.33	0.00
6	1	5867	M	5313	1.5689	0.5380	1.10	496	85.2	582	1190				
6	1	5868	M	5314	1.9644	0.5041	1.10	414	86.1	481	1050	0.89	3.53	1.80	0.00
6	1	5868	M	5315	1.9644	0.5179	1.10	382	85.1	448	952				
6	1	5875	M	5316	1.4504	0.5403	1.10	495	85.4	580	1180	0.78	3.11	2.14	0.00
6	1	5875	M	5317	1.4504	0.5291	1.10	489	84.6	579	1203				
6	1	5881	M	5318	1.6216	0.5083	1.10	441	85.6	515	1114	0.84	3.34	2.06	0.00
6	1	5881	M	5319	1.6216	0.4991	1.10	457	85.5	535	1179				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	1	5895	F	5320	1.3704	0.5109	1.10	501	85.1	588	1266	0.80	3.19	2.33	0.00
6	1	5895	F	5321	1.3704	0.5402	1.10	556	85.3	652	1328				
6	1	5907	F	5322	1.4396	0.5310	1.10	517	85.1	608	1259	0.76	3.04	2.11	0.00
6	1	5907	F	5323	1.4396	0.5194	1.10	441	85.5	516	1093				
6	1	5909	F	5324	1.5052	0.5004	1.10	469	85.0	551	1212	1.03	4.12	2.74	0.00
6	1	5909	F	5325	1.5052	0.5387	1.10	762	84.8	899	1836				
6	1	5918	F	5326	1.4608	0.5291	1.10	481	84.8	567	1179	0.75	3.01	2.06	0.00
6	1	5918	F	5327	1.4608	0.5189	1.10	452	86.1	525	1113				
6	2	5880	M	5434	1.6381	0.5386	1.03	582	86.3	674	1289	0.92	3.68	2.25	0.00
6	2	5880	M	5435	1.6381	0.5223	1.03	544	88.6	614	1211				
6	2	5885	M	5436	1.8963	0.5411	1.03	563	86.1	654	1245	1.07	4.26	2.25	0.00
6	2	5885	M	5437	1.8963	0.5132	1.03	538	86.1	625	1255				
6	2	5887	M	5438	1.8088	0.5354	1.03	495	85.8	577	1110	0.90	3.58	1.98	0.00
6	2	5887	M	5439	1.8088	0.5314	1.03	488	86.5	564	1094				
6	2	5894	M	5440	1.9360	0.5443	1.03	1014	86.4	1174	2222	1.79	7.13	3.68	0.00
6	2	5894	M	5441	1.9360	0.5337	1.03	839	86.3	972	1875				
6	2	5903	F	5442	1.4616	0.5415	1.03	583	85.7	680	1294	0.88	3.50	2.40	0.00
6	2	5903	F	5443	1.4616	0.5005	1.03	576	86.4	667	1372				
6	2	5912	F	5444	1.4960	0.5084	1.03	465	85.6	543	1101	0.74	2.96	1.98	0.00
6	2	5912	F	5445	1.4960	0.5118	1.03	473	86.4	547	1102				
6	2	5917	F	5446	1.4663	0.5130	1.03	581	85.7	678	1360	0.86	3.42	2.33	0.00
6	2	5917	F	5447	1.4663	0.5211	1.03	535	85.5	626	1237				
6	2	5919	F	5448	1.5225	0.5386	1.03	454	86.1	528	1009	0.69	2.73	1.80	0.00
6	2	5919	F	5449	1.5225	0.5399	1.03	444	85.6	518	989				
7	1	5872	M	5352	1.8073	0.5087	1.04	489	86.0	568	1162	0.91	10.84	6.00	0.00
7	1	5872	M	5353	1.8073	0.5225	1.04	456	85.4	534	1063				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
7	1	5873	M	5354	1.7026	0.5050	1.04	275	86.3	319	657	0.50	6.03	3.54	0.00
7	1	5873	M	5355	1.7026	0.5081	1.04	278	86.8	320	656				
7	1	5874	M	5356	1.0714	0.5075	1.04	331	85.3	388	795	0.38	4.60	4.29	0.00
7	1	5882	M	5358	1.4080	0.5176	1.04	483	86.5	558	1121	0.69	8.23	5.85	0.00
7	1	5882	M	5359	1.4080	0.5373	1.04	464	85.6	542	1048				
7	1	5901	F	5360	1.7180	0.5110	1.04	501	86.1	582	1184	0.87	10.38	6.04	0.00
7	1	5901	F	5361	1.7180	0.5318	1.04	464	85.9	541	1057				
7	1	5902	F	5362	1.1368	0.5371	1.04	851	86.3	986	1909	0.97	11.66	10.26	0.00
7	1	5902	F	5363	1.1368	0.4983	1.04	775	85.4	908	1895				
7	1	5913	F	5364	1.4262	0.5290	1.04	462	86.6	534	1049	0.63	7.52	5.28	0.00
7	1	5913	F	5365	1.4262	0.5208	1.04	391	86.0	455	908				
7	1	5920	F	5366	1.3551	0.5226	1.04	756	86.4	874	1740	1.02	12.18	8.99	0.00
7	1	5920	F	5367	1.3551	0.5145	1.04	684	86.7	789	1595				
7	2	5878	M	5470	1.2480	0.5064	1.05	954	86.4	1104	2289	1.23	14.73	11.80	0.00
7	2	5878	M	5471	1.2480	0.5308	1.05	905	85.7	1056	2090				
7	2	5886	M	5472	1.3721	0.5305	1.05	545	86.2	631	1250	0.79	9.41	6.85	0.00
7	2	5886	M	5473	1.3721	0.5424	1.05	576	86.3	668	1293				
7	2	5891	M	5474	1.7240	0.5459	1.05	1347	86.9	1551	2983	2.25	26.88	15.59	0.00
7	2	5891	M	5475	1.7240	0.5003	1.05	1155	86.5	1335	2801				
7	2	5892	M	5477	1.5913	0.5183	1.05	530	85.6	619	1254	0.90	10.76	6.76	0.00
7	2	5905	F	5478	1.4063	0.5240	1.05	441	86.3	511	1023	0.68	8.08	5.75	0.00
7	2	5905	F	5479	1.4063	0.5299	1.05	484	86.5	560	1109				
7	2	5906	F	5480	1.2982	0.5228	1.05	444	86.6	513	1029	0.58	6.96	5.36	0.00
7	2	5906	F	5481	1.2982	0.5368	1.05	422	86.1	490	959				
7	2	5908	F	5482	1.3760	0.5155	1.05	439	86.2	509	1037	0.66	7.94	5.77	0.00
7	2	5908	F	5483	1.3760	0.5106	1.05	461	85.8	537	1104				

TABLE F7. Liquid Scintillation Analyses of Liver Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
7	2	5914	F	5484	1.5226	0.5385	1.05	422	86.0	491	958	0.64	7.65	5.03	0.00
7	2	5914	F	5485	1.5226	0.5341	1.05	398	86.2	462	907				

Analyses That Were Not Used for Calculations:

												Reason for Exclusion:
7	1	5874	M	5357	1.0714	0.4481	1.04	1478	87.0	1699	3943	Inconsistent with group.
7	2	5892	M	5476	1.5913	0.5453	1.05	65	86.5	76	145	Inconsistent with group.

TABLE F8. Liquid Scintillation Analyses of Kidney Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	4	5328	M	2994	0.5840	0.5493	1.05	2596	84.8	3061	5851	1.54	0.73	1.26	0.03
1	4	5336	M	2995	0.6789	0.5340	1.05	3360	85.6	3924	7716	2.36	1.13	1.66	0.04
1	4	5344	M	2996	0.6720	0.5404	1.05	4520	85.7	5274	10248	3.10	1.48	2.20	0.06
1	4	5345	M	2997	0.5851	0.5519	1.05	1810	85.5	2117	4027	1.06	0.51	0.87	0.02
1	4	5351	F	2998	0.3195	0.3018	1.05	1369	84.7	1617	5625	0.81	0.39	1.21	0.01
1	4	5353	F	2999	0.4020	0.3822	1.05	613	85.3	719	1974	0.36	0.17	0.42	0.01
1	4	5359	F	3000	0.3942	0.3718	1.05	861	85.6	1006	2840	0.50	0.24	0.61	0.01
1	4	5365	F	3001	0.3629	0.3551	1.05	602	84.6	712	2105	0.34	0.16	0.45	0.01
2	4	5713	M	3066	0.6879	0.5055	1.07	2166	84.2	2573	5446	1.69	2.68	3.90	0.03
2	4	5829	M	3067	0.5013	0.4915	1.07	1075	83.3	1290	2808	0.63	1.01	2.01	0.01
2	4	5830	M	3068	0.4532	0.4465	1.07	1868	83.8	2229	5343	1.09	1.73	3.83	0.02
2	4	5839	M	3069	0.5947	0.5359	1.07	4831	84.2	5740	11461	3.07	4.88	8.21	0.06
2	4	5851	F	3070	0.3658	0.3512	1.07	3245	84.4	3846	11718	1.93	3.07	8.39	0.04
2	4	5852	F	3071	0.3874	0.3820	1.07	1897	84.1	2255	6318	1.10	1.75	4.52	0.02
2	4	5857	F	3072	0.4031	0.3954	1.07	1471	83.9	1754	4746	0.86	1.37	3.40	0.02
2	4	5861	F	3073	0.2857	0.2748	1.07	1152	85.0	1355	5278	0.68	1.08	3.78	0.01
3	4	5724	M	3138	0.5147	0.4867	1.08	3318	84.3	3936	8734	2.02	9.66	18.76	0.04
3	4	5725	M	3139	0.6186	0.4556	1.08	5054	84.0	6016	14261	3.97	18.95	30.64	0.07
3	4	5727	M	3140	0.4922	0.4620	1.08	4678	84.3	5547	12968	2.88	13.71	27.86	0.05
3	4	5735	M	3141	0.5257	0.5085	1.08	4157	83.6	4974	10565	2.50	11.93	22.70	0.05
3	4	5740	F	3142	0.3743	0.3575	1.08	2295	84.6	2714	8199	1.38	6.59	17.61	0.03
3	4	5742	F	3143	0.3601	0.3339	1.08	2382	84.3	2826	9141	1.48	7.07	19.64	0.03
3	4	5753	F	3144	0.3064	0.2933	1.08	2210	84.0	2632	9693	1.34	6.38	20.82	0.03
3	4	5756	F	3145	0.3393	0.3175	1.08	2716	84.4	3220	10953	1.67	7.98	23.53	0.03
4	NA	5714	M	3186	0.4701	0.4427	1.06	2082	84.4	2468	5909	1.25	5.88	12.50	0.03
4	NA	5718	M	3187	0.5729	0.5491	1.06	2625	84.1	3121	6026	1.55	7.30	12.75	0.03
4	NA	5719	M	3188	0.5407	0.5074	1.06	2046	85.3	2399	5013	1.22	5.73	10.60	0.03

TABLE F8. Liquid Scintillation Analyses of Kidney Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5730	M	3189	0.5048	0.4739	1.06	2059	83.8	2455	5492	1.25	5.86	11.62	0.03
4	NA	5743	F	3190	0.3729	0.3545	1.06	2476	84.8	2919	8727	1.47	6.88	18.46	0.03
4	NA	5745	F	3191	0.3957	0.3762	1.06	1831	84.7	2163	6095	1.09	5.10	12.89	0.02
4	NA	5748	F	3192	0.3989	0.3776	1.06	2625	83.7	3138	8808	1.58	7.43	18.63	0.03
4	NA	5754	F	3193	0.3610	0.3438	1.06	1749	84.7	2064	6363	1.03	4.86	13.46	0.02
5	1	5871	M	5264	0.6358	0.5204	1.03	2859	85.8	3332	6594	1.89	2.26	3.56	0.01
5	1	5883	M	5265	0.6594	0.5335	1.03	4512	88.0	5129	9903	2.94	3.52	5.34	0.01
5	1	5884	M	5266	0.5396	0.5234	1.03	3207	85.5	3751	7382	1.79	2.15	3.98	0.01
5	1	5889	M	5267	0.4760	0.4641	1.03	1469	85.7	1715	3806	0.82	0.98	2.05	0.00
5	1	5896	F	5268	0.4272	0.4182	1.03	808	86.0	939	2314	0.45	0.53	1.25	0.00
5	1	5899	F	5269	0.3787	0.3726	1.03	1062	85.7	1239	3424	0.58	0.70	1.85	0.00
5	1	5900	F	5270	0.3930	0.3776	1.03	1320	85.9	1537	4192	0.74	0.89	2.26	0.00
5	1	5921	F	5271	0.3879	0.3759	1.03	1135	85.7	1325	3631	0.63	0.76	1.96	0.00
5	2	5869	M	5386	0.5503	0.5345	1.07	2140	85.9	2491	4986	1.24	1.48	2.69	0.00
5	2	5870	M	5387	0.5804	0.5320	1.07	1503	85.9	1751	3521	0.92	1.10	1.90	0.00
5	2	5888	M	5388	0.5301	0.5119	1.07	1556	86.5	1799	3761	0.90	1.07	2.03	0.00
5	2	5893	M	5389	0.6748	0.5345	1.07	1783	86.2	2070	4144	1.26	1.51	2.23	0.00
5	2	5910	F	5390	0.3788	0.3685	1.07	753	86.0	876	2544	0.43	0.52	1.37	0.00
5	2	5911	F	5391	0.3597	0.3405	1.07	761	86.2	883	2775	0.45	0.54	1.50	0.00
5	2	5915	F	5392	0.3575	0.3427	1.07	1013	86.3	1175	3668	0.59	0.71	1.98	0.00
5	2	5916	F	5393	0.3857	0.3694	1.07	859	86.0	999	2894	0.50	0.60	1.56	0.00
6	1	5867	M	5304	0.5856	0.5419	1.04	2074	84.9	2441	4686	1.24	4.93	8.42	0.00
6	1	5868	M	5305	0.7143	0.5063	1.04	1035	85.6	1210	2485	0.80	3.19	4.47	0.00
6	1	5875	M	5306	0.4845	0.4773	1.04	905	85.8	1055	2300	0.50	2.00	4.13	0.00
6	1	5881	M	5307	0.4858	0.4794	1.04	1112	85.4	1302	2825	0.62	2.47	5.08	0.00
6	1	5895	F	5308	0.4745	0.4645	1.04	826	85.7	964	2158	0.46	1.84	3.88	0.00
6	1	5907	F	5309	0.3816	0.3728	1.04	635	85.2	746	2080	0.36	1.43	3.74	0.00

TABLE F8. Liquid Scintillation Analyses of Kidney Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	1	5909	F	5310	0.3783	0.3723	1.04	642	85.7	750	2094	0.36	1.42	3.76	0.00
6	1	5918	F	5311	0.4188	0.4103	1.04	489	84.7	578	1464	0.28	1.10	2.63	0.00
6	2	5880	M	5426	0.5520	0.5339	1.03	1009	85.6	1179	2275	0.57	2.26	4.09	0.00
6	2	5885	M	5427	0.4990	0.4871	1.03	1407	86.1	1634	3455	0.78	3.10	6.21	0.00
6	2	5887	M	5428	0.5947	0.5409	1.03	1381	85.6	1614	3074	0.82	3.29	5.52	0.00
6	2	5894	M	5429	0.5691	0.5527	1.03	3352	85.3	3929	7323	1.88	7.49	13.16	0.00
6	2	5903	F	5430	0.3802	0.3676	1.03	692	86.1	804	2253	0.39	1.54	4.05	0.00
6	2	5912	F	5431	0.4253	0.4151	1.03	729	86.2	846	2100	0.40	1.61	3.77	0.00
6	2	5917	F	5432	0.4089	0.4017	1.03	926	86.4	1071	2746	0.51	2.02	4.94	0.00
6	2	5919	F	5433	0.3823	0.3702	1.03	433	85.6	505	1405	0.24	0.97	2.53	0.00
7	1	5872	M	5344	0.6721	0.5290	1.07	2200	85.6	2571	5201	1.57	18.85	28.04	0.01
7	1	5873	M	5345	0.5434	0.5255	1.07	737	85.0	867	1765	0.43	5.17	9.51	0.00
7	1	5874	M	5346	0.4347	0.4222	1.07	412	85.7	480	1217	0.24	2.85	6.56	0.00
7	1	5882	M	5347	0.4444	0.4332	1.07	627	84.9	738	1823	0.36	4.37	9.83	0.00
7	1	5901	F	5348	0.3862	0.3659	1.07	1021	85.2	1198	3503	0.61	7.29	18.89	0.00
7	1	5902	F	5349	0.3427	0.3167	1.07	2628	85.4	3079	10403	1.61	19.22	56.09	0.01
7	1	5913	F	5350	0.4458	0.4261	1.07	910	85.2	1068	2683	0.54	6.45	14.46	0.00
7	1	5920	F	5351	0.3776	0.3390	1.07	2287	85.1	2687	8482	1.44	17.27	45.73	0.01
7	2	5878	M	5956	0.4385	0.4237	1.05	1715	86.1	1991	4935	0.97	11.67	26.61	0.00
7	2	5886	M	5957	0.4813	0.4688	1.05	807	85.8	941	2108	0.46	5.47	11.37	0.00
7	2	5891	M	5958	0.4792	0.4628	1.05	4665	86.4	5401	12253	2.64	31.66	66.07	0.00
7	2	5892	M	5959	0.4583	0.4497	1.05	778	86.2	902	2107	0.43	5.21	11.36	0.00
7	2	5905	F	5960	0.3815	0.3729	1.05	614	86.0	713	2009	0.35	4.13	10.83	0.00
7	2	5906	F	5961	0.3377	0.3226	1.05	776	86.2	901	2931	0.45	5.34	15.80	0.00
7	2	5908	F	5962	0.3991	0.3838	1.05	543	85.6	634	1735	0.31	3.73	9.35	0.00
7	2	5914	F	5963	0.3985	0.3897	1.05	469	86.3	544	1466	0.26	3.15	7.91	0.00

TABLE F9. Liquid Scintillation Analyses of Brain Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	4	5328	M	3002	0.4661	0.4385	1.05	73	85.5	85	204	0.04	0.02	0.04	0.00
1	4	5336	M	3003	0.4973	0.4603	1.05	52	85.9	61	139	0.03	0.01	0.03	0.00
1	4	5344	M	3004	0.4813	0.4456	1.05	30	85.1	36	84	0.02	0.01	0.02	0.00
1	4	5345	M	3005	0.4022	0.3582	1.05	44	84.3	52	152	0.03	0.01	0.03	0.00
1	4	5351	F	3006	0.4378	0.4228	1.05	70	85.4	82	205	0.04	0.02	0.04	0.00
1	4	5353	F	3007	0.4821	0.4616	1.05	92	85.0	108	245	0.05	0.03	0.05	0.00
1	4	5359	F	3008	0.3742	0.3251	1.05	59	85.1	69	224	0.04	0.02	0.05	0.00
1	4	5365	F	3009	0.3767	0.3676	1.05	60	85.4	70	200	0.03	0.02	0.04	0.00
2	4	5713	M	3074	0.4425	0.4122	1.05	87	86.3	100	256	0.05	0.08	0.18	0.00
2	4	5829	M	3075	0.3740	0.3635	1.05	62	85.7	72	209	0.04	0.06	0.15	0.00
2	4	5830	M	3076	0.3516	0.3270	1.05	59	85.7	69	222	0.04	0.06	0.16	0.00
2	4	5839	M	3077	0.3358	0.3229	1.05	56	84.9	66	215	0.03	0.05	0.15	0.00
2	4	5851	F	3078	0.3760	0.3572	1.05	118	85.1	138	406	0.07	0.11	0.29	0.00
2	4	5852	F	3079	0.2997	0.2785	1.05	85	85.1	99	375	0.05	0.08	0.27	0.00
2	4	5857	F	3080	0.3051	0.2867	1.05	50	84.9	58	214	0.03	0.05	0.15	0.00
2	4	5861	F	3081	0.3018	0.2936	1.05	37	85.2	44	156	0.02	0.03	0.11	0.00
3	4	5724	M	3146	0.4114	0.3608	1.08	113	84.9	133	399	0.07	0.35	0.86	0.00
3	4	5725	M	3147	0.4687	0.3637	1.08	102	84.5	120	357	0.08	0.36	0.77	0.00
3	4	5727	M	3148	0.4194	0.3964	1.08	125	84.8	147	401	0.08	0.36	0.86	0.00
3	4	5735	M	3149	0.4263	0.4033	1.08	105	85.1	123	330	0.06	0.30	0.71	0.00
3	4	5740	F	3150	0.5106	0.4926	1.08	129	84.8	152	333	0.08	0.37	0.72	0.00
3	4	5742	F	3151	0.4964	0.4808	1.08	126	85.1	148	334	0.07	0.36	0.72	0.00
3	4	5753	F	3152	0.3208	0.2822	1.08	101	85.6	118	450	0.06	0.31	0.97	0.00
3	4	5756	F	3153	0.3954	0.3607	1.08	194	84.3	230	689	0.12	0.59	1.48	0.00
4	NA	5714	M	3194	0.3592	0.3420	1.06	82	85.2	97	300	0.05	0.23	0.63	0.00
4	NA	5718	M	3195	0.5117	0.4500	1.06	152	85.8	177	416	0.10	0.45	0.88	0.00
4	NA	5719	M	3196	0.4696	0.4116	1.06	171	84.3	203	522	0.11	0.52	1.10	0.00

TABLE F9. Liquid Scintillation Analyses of Brain Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5730	M	3197	0.4768	0.4380	1.06	76	85.9	89	215	0.05	0.22	0.46	0.00
4	NA	5743	F	3198	0.4256	0.3982	1.06	136	85.7	159	423	0.08	0.38	0.89	0.00
4	NA	5745	F	3199	0.4775	0.4362	1.06	145	85.2	170	414	0.09	0.42	0.88	0.00
4	NA	5748	F	3200	0.4391	0.3527	1.06	117	85.3	137	413	0.08	0.38	0.87	0.00
4	NA	5754	F	3201	0.3884	0.3381	1.06	85	85.6	99	310	0.05	0.26	0.66	0.00
5	1	5871	M	5256	0.3153	0.2997	1.03	200	85.8	233	800	0.11	0.14	0.43	0.00
5	1	5883	M	5257	0.4027	0.3966	1.03	150	86.3	174	451	0.08	0.10	0.24	0.00
5	1	5884	M	5258	0.3269	0.3166	1.03	113	85.3	133	433	0.06	0.08	0.23	0.00
5	1	5889	M	5259	0.2994	0.2767	1.03	119	85.7	139	517	0.07	0.08	0.28	0.00
5	1	5896	F	5260	0.3715	0.3437	1.03	25	86.2	29	86	0.01	0.02	0.05	0.00
5	1	5899	F	5261	0.4109	0.4043	1.03	160	85.9	186	474	0.09	0.11	0.26	0.00
5	1	5900	F	5262	0.4567	0.4468	1.03	167	85.9	194	447	0.09	0.11	0.24	0.00
5	1	5921	F	5263	0.4423	0.4288	1.03	198	85.7	231	556	0.11	0.13	0.30	0.00
5	2	5869	M	5378	0.3533	0.3446	1.07	281	85.7	327	1017	0.16	0.19	0.55	0.00
5	2	5870	M	5379	0.3583	0.3500	1.07	167	86.3	193	590	0.10	0.11	0.32	0.00
5	2	5888	M	5380	0.3377	0.3309	1.07	163	86.0	189	611	0.09	0.11	0.33	0.00
5	2	5893	M	5381	0.3465	0.3366	1.07	163	86.0	190	603	0.09	0.11	0.33	0.00
5	2	5910	F	5382	0.3529	0.3424	1.07	134	86.0	156	487	0.08	0.09	0.26	0.00
5	2	5911	F	5383	0.3778	0.3699	1.07	173	85.8	202	584	0.10	0.12	0.31	0.00
5	2	5915	F	5384	0.2795	0.2730	1.07	165	85.7	193	756	0.10	0.11	0.41	0.00
5	2	5916	F	5385	0.3372	0.3272	1.07	170	85.8	198	647	0.10	0.12	0.35	0.00
6	1	5867	M	5296	0.4540	0.4472	1.04	121	86.3	141	327	0.07	0.27	0.59	0.00
6	1	5868	M	5297	0.4218	0.4152	1.04	71	86.2	82	206	0.04	0.16	0.37	0.00
6	1	5875	M	5298	0.4341	0.4242	1.04	134	85.7	157	384	0.08	0.30	0.69	0.00
6	1	5881	M	5299	0.4228	0.4103	1.04	95	86.3	110	280	0.05	0.21	0.50	0.00
6	1	5895	F	5300	0.4034	0.3906	1.04	118	86.2	137	365	0.07	0.26	0.66	0.00
6	1	5907	F	5301	0.4298	0.4176	1.04	138	86.0	160	398	0.08	0.31	0.72	0.00

TABLE F9. Liquid Scintillation Analyses of Brain Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	1	5909	F	5302	0.4632	0.4442	1.04	115	86.6	132	310	0.06	0.26	0.56	0.00
6	1	5918	F	5303	0.4188	0.4079	1.04	101	85.8	118	300	0.06	0.23	0.54	0.00
6	2	5880	M	5418	0.3360	0.3173	1.07	393	86.6	454	1532	0.23	0.93	2.75	0.00
6	2	5885	M	5419	0.3406	0.3287	1.07	74	86.3	85	278	0.04	0.17	0.50	0.00
6	2	5887	M	5420	0.3701	0.3621	1.07	130	85.9	152	448	0.07	0.30	0.81	0.00
6	2	5894	M	5421	0.3529	0.3432	1.07	93	85.6	109	340	0.05	0.22	0.61	0.00
6	2	5903	F	5422	0.3529	0.3460	1.07	60	86.0	70	217	0.03	0.14	0.39	0.00
6	2	5912	F	5423	0.3436	0.3368	1.07	126	86.0	146	464	0.07	0.29	0.83	0.00
6	2	5917	F	5424	0.3670	0.3569	1.07	82	86.2	95	284	0.05	0.19	0.51	0.00
6	2	5919	F	5425	0.3678	0.3583	1.07	85	87.9	97	290	0.05	0.19	0.52	0.00
7	1	5872	M	5336	0.3475	0.3252	1.10	77	85.8	89	303	0.05	0.57	1.63	0.00
7	1	5873	M	5337	0.3598	0.3472	1.10	66	86.2	77	243	0.04	0.47	1.31	0.00
7	1	5874	M	5338	0.3115	0.3011	1.10	128	86.3	148	541	0.08	0.91	2.92	0.00
7	1	5882	M	5339	0.3043	0.2761	1.10	70	86.0	82	325	0.04	0.53	1.75	0.00
7	1	5901	F	5340	0.4234	0.3839	1.10	82	86.3	95	273	0.05	0.62	1.47	0.00
7	1	5902	F	5341	0.3592	0.3422	1.10	143	85.9	167	536	0.09	1.04	2.89	0.00
7	1	5913	F	5342	0.3718	0.3643	1.10	139	85.9	162	489	0.08	0.98	2.64	0.00
7	1	5920	F	5343	0.3710	0.3579	1.10	80	85.9	93	286	0.05	0.57	1.54	0.00
7	2	5878	M	5458	0.3405	0.3291	1.03	109	86.3	126	395	0.06	0.73	2.13	0.00
7	2	5886	M	5459	0.3205	0.3079	1.03	87	86.2	101	336	0.05	0.58	1.81	0.00
7	2	5891	M	5460	0.3516	0.3396	1.03	75	86.5	86	262	0.04	0.50	1.41	0.00
7	2	5892	M	5461	0.3456	0.3356	1.03	92	86.1	106	327	0.05	0.61	1.76	0.00
7	2	5905	F	5462	0.3436	0.3348	1.03	65	85.9	76	233	0.04	0.43	1.26	0.00
7	2	5906	F	5463	0.3621	0.3435	1.03	72	86.1	84	252	0.04	0.49	1.36	0.00
7	2	5908	F	5464	0.3466	0.3347	1.03	44	86.0	51	156	0.02	0.29	0.84	0.00
7	2	5914	F	5465	0.3638	0.3523	1.03	80	86.1	93	271	0.04	0.53	1.46	0.00

TABLE F10. Liquid Scintillation Analyses of Tongue Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	4	5328	M	3010	0.0800	0.0732	1.05	268	85.1	315	4515	0.16	0.08	0.97	0.00
1	4	5336	M	3011	0.0779	0.0711	1.05	404	85.2	474	6999	0.25	0.12	1.50	0.00
1	4	5344	M	3012	0.0712	0.0633	1.05	292	84.0	347	5759	0.18	0.09	1.24	0.00
1	4	5345	M	3013	0.0570	0.0393	1.05	191	84.5	226	6034	0.15	0.07	1.30	0.00
1	4	5351	F	3014	0.0625	0.0569	1.05	366	85.1	430	7938	0.22	0.11	1.71	0.00
1	4	5353	F	3015	0.0645	0.0508	1.05	303	84.9	357	7375	0.21	0.10	1.58	0.00
1	4	5359	F	3016	0.0600	0.0446	1.05	243	85.0	286	6733	0.18	0.09	1.45	0.00
1	4	5365	F	3017	0.0733	0.0549	1.05	290	84.5	343	6555	0.22	0.10	1.41	0.00
2	4	5713	M	3082	0.0713	0.0557	1.05	475	85.0	558	10524	0.34	0.54	7.54	0.01
2	4	5829	M	3083	0.0656	0.0612	1.05	321	84.8	379	6503	0.19	0.31	4.66	0.00
2	4	5830	M	3084	0.0413	0.0302	1.05	225	84.7	266	9247	0.17	0.27	6.62	0.00
2	4	5839	M	3085	0.0472	0.0407	1.05	315	84.7	372	9592	0.20	0.32	6.87	0.00
2	4	5851	F	3086	0.0424	0.0316	1.05	328	85.3	384	12754	0.24	0.39	9.13	0.00
2	4	5852	F	3087	0.0432	0.0348	1.05	291	84.7	343	10350	0.20	0.32	7.41	0.00
2	4	5857	F	3088	0.0443	0.0388	1.05	279	86.2	324	8772	0.18	0.28	6.28	0.00
2	4	5861	F	3089	0.0326	0.0256	1.05	183	85.1	215	8825	0.13	0.21	6.32	0.00
3	4	5724	M	3154	0.0621	0.0468	1.08	252	84.1	300	6923	0.19	0.92	14.87	0.00
3	4	5725	M	3155	0.0581	0.0516	1.08	253	84.1	301	6305	0.17	0.79	13.54	0.00
3	4	5727	M	3156	0.0584	0.0502	1.08	226	83.6	271	5826	0.15	0.73	12.52	0.00
3	4	5735	M	3157	0.0542	0.0458	1.08	216	83.7	258	6092	0.15	0.71	13.09	0.00
3	4	5740	F	3158	0.0623	0.0491	1.08	275	84.0	328	7207	0.20	0.96	15.48	0.00
3	4	5742	F	3159	0.0611	0.0555	1.08	204	84.3	242	4699	0.13	0.62	10.10	0.00
3	4	5753	F	3160	0.0515	0.0374	1.08	177	84.8	209	6030	0.14	0.67	12.95	0.00
3	4	5756	F	3161	0.0472	0.0377	1.08	153	84.1	182	5206	0.11	0.53	11.18	0.00
4	NA	5714	M	3202	0.0572	0.0530	1.06	177	84.8	209	4186	0.11	0.51	8.85	0.00
4	NA	5718	M	3203	0.0519	0.0464	1.06	125	84.6	147	3369	0.08	0.37	7.13	0.00
4	NA	5719	M	3204	0.0666	0.0612	1.06	166	84.7	196	3403	0.10	0.48	7.20	0.00

TABLE F10. Liquid Scintillation Analyses of Tongue Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5730	M	3205	0.0548	0.0354	1.06	190	85.7	222	6648	0.16	0.77	14.06	0.00
4	NA	5743	F	3206	0.0580	0.0406	1.06	180	84.9	213	5552	0.15	0.68	11.74	0.00
4	NA	5745	F	3207	0.0516	0.0379	1.06	252	85.3	295	8253	0.19	0.90	17.46	0.00
4	NA	5748	F	3208	0.0631	0.0533	1.06	579	85.0	681	13548	0.39	1.81	28.66	0.01
4	NA	5754	F	3209	0.0615	0.0412	1.06	184	85.6	215	5541	0.15	0.72	11.72	0.00
5	1	5871	M	5248	0.0475	0.0411	1.03	221	85.8	257	6442	0.14	0.16	3.47	0.00
5	1	5883	M	5249	0.0484	0.0369	1.03	261	85.9	304	8483	0.18	0.22	4.57	0.00
5	1	5884	M	5250	0.0537	0.0461	1.03	323	87.4	369	8244	0.20	0.24	4.45	0.00
5	1	5889	M	5251	0.0443	0.0307	1.03	250	85.6	292	9802	0.20	0.23	5.28	0.00
5	1	5896	F	5252	0.0729	0.0637	1.03	253	85.7	295	4768	0.16	0.19	2.57	0.00
5	1	5899	F	5253	0.0420	0.0354	1.03	162	85.2	190	5536	0.10	0.13	2.98	0.00
5	1	5900	F	5254	0.0462	0.0387	1.03	209	85.5	245	6523	0.14	0.16	3.52	0.00
5	1	5921	F	5255	0.0543	0.0442	1.03	236	85.1	278	6477	0.16	0.19	3.49	0.00
5	2	5869	M	5370	0.0719	0.0635	1.04	375	85.9	436	7147	0.23	0.28	3.85	0.00
5	2	5870	M	5371	0.0593	0.0506	1.04	266	85.7	310	6376	0.17	0.20	3.44	0.00
5	2	5888	M	5372	0.0587	0.0518	1.04	185	85.7	216	4336	0.11	0.14	2.34	0.00
5	2	5893	M	5373	0.0511	0.0442	1.04	182	85.5	213	5005	0.12	0.14	2.70	0.00
5	2	5910	F	5374	0.0609	0.0538	1.04	202	85.7	235	4550	0.12	0.15	2.45	0.00
5	2	5911	F	5375	0.0528	0.0434	1.04	170	86.0	198	4738	0.11	0.13	2.55	0.00
5	2	5915	F	5376	0.0558	0.0461	1.04	240	85.8	280	6310	0.16	0.19	3.40	0.00
5	2	5916	F	5377	0.0561	0.0466	1.04	174	85.7	203	4539	0.11	0.14	2.45	0.00
6	1	5867	M	5288	0.0702	0.0663	1.04	253	85.6	296	4639	0.15	0.59	8.34	0.00
6	1	5868	M	5289	0.0647	0.0612	1.04	162	85.6	190	3223	0.09	0.37	5.79	0.00
6	1	5875	M	5290	0.0588	0.0412	1.04	273	85.0	321	8113	0.21	0.86	14.58	0.00
6	1	5881	M	5291	0.0623	0.0444	1.04	179	85.2	210	4926	0.14	0.55	8.85	0.00
6	1	5895	F	5292	0.0703	0.0477	1.04	264	85.3	309	6746	0.21	0.85	12.12	0.00
6	1	5907	F	5293	0.0611	0.0572	1.04	193	85.2	227	4126	0.11	0.45	7.42	0.00

TABLE F10. Liquid Scintillation Analyses of Tongue Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	1	5909	F	5294	0.0651	0.0472	1.04	191	85.3	224	4933	0.14	0.58	8.87	0.00
6	1	5918	F	5295	0.0589	0.0465	1.04	256	84.9	302	6749	0.18	0.71	12.13	0.00
6	2	5880	M	5410	0.0568	0.0509	1.07	201	85.6	235	4931	0.13	0.50	8.86	0.00
6	2	5885	M	5411	0.0525	0.0476	1.07	205	85.1	241	5414	0.13	0.51	9.73	0.00
6	2	5887	M	5412	0.0517	0.0414	1.07	202	85.7	236	6096	0.14	0.57	10.96	0.00
6	2	5894	M	5413	0.0550	0.0478	1.07	317	86.2	368	8235	0.20	0.81	14.80	0.00
6	2	5903	F	5414	0.0506	0.0435	1.07	170	85.5	199	4887	0.11	0.44	8.78	0.00
6	2	5912	F	5415	0.0510	0.0386	1.07	152	85.5	177	4915	0.11	0.45	8.83	0.00
6	2	5917	F	5416	0.0478	0.0378	1.07	190	85.8	222	6271	0.14	0.54	11.27	0.00
6	2	5919	F	5417	0.0557	0.0464	1.07	163	85.5	191	4404	0.11	0.44	7.92	0.00
7	1	5872	M	5328	0.0446	0.0356	1.10	147	85.4	172	5311	0.11	1.28	28.64	0.00
7	1	5873	M	5329	0.0392	0.0347	1.10	74	85.3	87	2755	0.05	0.58	14.85	0.00
7	1	5874	M	5330	0.0353	0.0322	1.10	82	85.2	97	3297	0.05	0.63	17.77	0.00
7	1	5882	M	5331	0.0410	0.0285	1.10	108	85.7	126	4869	0.09	1.08	26.25	0.00
7	1	5901	F	5332	0.0522	0.0309	1.10	132	85.7	154	5484	0.13	1.54	29.57	0.00
7	1	5902	F	5333	0.0374	0.0266	1.10	95	85.6	111	4607	0.08	0.93	24.84	0.00
7	1	5913	F	5334	0.0434	0.0355	1.10	111	85.4	130	4016	0.08	0.94	21.65	0.00
7	1	5920	F	5335	0.0448	0.0391	1.10	179	85.1	210	5907	0.12	1.43	31.85	0.00
7	2	5878	M	5450	0.0491	0.0332	1.03	253	85.7	296	9177	0.20	2.43	49.48	0.00
7	2	5886	M	5451	0.0499	0.0366	1.03	133	86.7	154	4331	0.10	1.17	23.35	0.00
7	2	5891	M	5452	0.0382	0.0266	1.03	154	85.6	179	6948	0.12	1.43	37.46	0.00
7	2	5892	M	5453	0.0647	0.0510	1.03	299	85.5	350	7059	0.21	2.46	38.06	0.00
7	2	5905	F	5454	0.0484	0.0343	1.03	156	85.7	182	5464	0.12	1.43	29.46	0.00
7	2	5906	F	5455	0.0400	0.0296	1.03	536	86.0	623	21674	0.39	4.67	116.86	0.00
7	2	5908	F	5456	0.0545	0.0457	1.03	143	86.2	166	3736	0.09	1.10	20.14	0.00
7	2	5914	F	5457	0.0497	0.0402	1.03	115	85.5	135	3448	0.08	0.92	18.59	0.00

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	1	5331	M	23	3	3.5893	0.4979	142192	94.1	151102	303478	491.2	234.3	9.04
1	1	5331	M	24	3	3.5893	0.5035	144152	94.1	153158	304186			
1	1	5339	M	25	3	3.6241	0.4944	316669	93.9	337183	682003	1120.3	534.3	20.34
1	1	5339	M	26	3	3.6241	0.4952	321276	94.0	341929	690486			
1	1	5340	M	27	3	5.5510	0.4918	65051	94.2	69069	140441	351.7	167.8	6.59
1	1	5340	M	28	3	5.5510	0.5035	66837	94.2	70945	140905			
1	1	5355	F	29	3	5.3475	0.4932	145609	94.1	154818	313905	756.3	360.7	13.91
1	1	5355	F	30	3	5.3475	0.4996	147626	94.1	156914	314079			
1	1	5356	F	31	3	3.4444	0.4913	188628	94.0	200623	408351	633.1	301.9	11.56
1	1	5356	F	32	3	3.4444	0.4936	189188	94.0	201232	407682			
1	1	5362	F	33	3	4.3709	0.4933	273876	94.2	290837	589575	1159.4	552.9	21.65
1	1	5362	F	34	3	4.3709	0.4928	272716	94.1	289821	588110			
1	2	5332	M	35	6	5.0946	0.5022	585733	94.0	623047	1240636	2846.9	1357.7	51.41
1	2	5332	M	36	6	5.0946	0.5044	588383	94.0	625686	1240456			
1	2	5342	M	37	6	3.0845	0.5028	552003	93.8	588219	1169886	1622.0	773.5	29.25
1	2	5342	M	38	6	3.0845	0.5036	550743	93.9	586624	1164860			
1	2	5343	M	39	6	11.6315	0.4955	86283	94.2	91621	184906	972.0	463.6	17.63
1	2	5343	M	40	6	11.6315	0.5037	88345	94.2	93756	186135			
1	2	5349	F	41	6	7.0178	0.4984	168021	94.2	178441	358028	1125.5	536.8	20.48
1	2	5349	F	42	6	7.0178	0.5134	171161	94.2	181768	354048			
1	2	5350	F	43	6	2.4320	0.4959	293579	94.0	312213	629589	688.5	328.3	12.73
1	2	5350	F	44	6	2.4320	0.5004	295046	94.0	313923	627345			
1	2	5363	F	45	6	5.0596	0.4947	197341	94.2	209603	423697	969.1	462.2	17.59
1	2	5363	F	46	6	5.0596	0.5031	201973	94.1	214683	426720			
1	3	5327	M	47	12	3.4085	0.4962	659326	93.5	705154	1421107	2188.9	1043.9	39.87
1	3	5327	M	48	12	3.4085	0.5056	675876	93.5	723109	1430200			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	3	5330	M	49	12	3.4577	0.4849	520616	93.6	556025	1146680	1781.4	849.6	32.55
1	3	5330	M	50	12	3.4577	0.5022	536016	93.6	572885	1140751			
1	3	5334	M	51	12	4.7221	0.4931	489506	93.6	523195	1061032	2256.5	1076.2	41.06
1	3	5334	M	52	12	4.7221	0.5001	496276	93.6	530433	1060655			
1	3	5347	F	53	12	2.7837	0.4949	607746	93.5	650032	1313461	1659.7	791.5	30.08
1	3	5347	F	54	12	2.7837	0.5068	632126	93.5	675945	1333750			
1	3	5348	F	55	12	3.9665	0.4891	304522	93.8	324474	663410	1189.0	567.1	21.81
1	3	5348	F	56	12	3.9665	0.5026	314956	93.9	335510	667549			
1	3	5352	F	57	12	2.8716	0.4919	451676	93.6	482530	980951	1274.4	607.8	23.03
1	3	5352	F	58	12	2.8716	0.5012	464316	93.6	495962	989549			
1	4	5328	M	127	24	6.2047	0.4968	402766	92.5	435238	876082	2453.4	1170.0	44.45
1	4	5328	M	128	24	6.2047	0.5105	415356	92.5	448991	879511			
1	4	5336	M	129	24	5.8038	0.5131	503506	93.0	541556	1055459	2761.3	1316.9	51.09
1	4	5336	M	130	24	5.8038	0.5133	504746	93.0	542545	1056975			
1	4	5344	M	131	24	8.8778	0.4979	271636	93.2	291551	585561	2335.3	1113.7	42.79
1	4	5344	M	132	24	8.8778	0.5097	276583	93.2	296838	582377			
1	4	5345	M	133	24	14.2253	0.4979	122610	93.6	130979	263063	1681.0	801.7	30.26
1	4	5345	M	134	24	14.2253	0.5011	122693	93.6	131086	261597			
1	4	5351	F	135	24	6.4097	0.5042	324469	93.4	347424	689060	1987.5	947.9	36.25
1	4	5351	F	136	24	6.4097	0.5082	326203	93.3	349470	687662			
1	4	5353	F	137	24	5.8128	0.5068	463796	92.9	499197	984997	2572.4	1226.8	46.30
1	4	5353	F	138	24	5.8128	0.5145	468526	92.9	504143	979869			
1	4	5359	F	139	24	9.5055	0.4986	226846	93.5	242687	486736	2083.1	993.5	37.54
1	4	5359	F	140	24	9.5055	0.5042	229206	93.5	245183	486281			
1	4	5365	F	141	24	4.7932	0.5079	302049	92.8	325532	640937	1381.9	659.1	25.14
1	4	5365	F	142	24	4.7932	0.5194	307889	92.7	331986	639173			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	5	5329	M	59	24	13.4372	0.5017	200001	93.8	213223	425001	2560.5	1221.2	47.59
1	5	5329	M	60	24	13.4372	0.5074	200448	93.8	213646	421061			
1	5	5329	M	83	48	8.3274	0.5003	41793	93.3	44787	89521	335.9	160.2	6.24
1	5	5329	M	84	48	8.3274	0.5016	41912	93.3	44919	89552			
1	5	5333	M	61	24	6.4761	0.5044	357386	93.3	382886	759092	2209.7	1053.9	40.36
1	5	5333	M	62	24	6.4761	0.5059	357033	93.4	382407	755894			
1	5	5333	M	85	48	9.8756	0.4950	35792	93.5	38293	77359	344.3	164.2	6.29
1	5	5333	M	86	48	9.8756	0.5055	36592	93.5	39143	77434			
1	5	5341	M	63	24	6.7353	0.5065	404513	93.4	433245	855370	2584.3	1232.5	47.60
1	5	5341	M	64	24	6.7353	0.5154	408343	93.4	437178	848231			
1	5	5341	M	87	48	10.8343	0.4923	24760	93.5	26494	53816	263.2	125.5	4.85
1	5	5341	M	88	48	10.8343	0.5077	25624	93.4	27437	54042			
1	5	5360	F	65	24	7.7808	0.5086	199769	93.5	213554	419887	1479.7	705.7	27.20
1	5	5360	F	66	24	7.7808	0.5079	201723	93.6	215609	424510			
1	5	5360	F	89	48	11.0082	0.4952	30874	93.0	33183	67009	332.4	158.5	6.11
1	5	5360	F	90	48	11.0082	0.4986	31116	93.0	33442	67072			
1	5	5364	F	67	24	7.3281	0.5073	250513	93.4	268313	528904	1751.0	835.1	32.16
1	5	5364	F	68	24	7.3281	0.5084	252558	93.4	270471	532004			
1	5	5364	F	91	48	9.1846	0.4964	35565	92.9	38276	77107	318.2	151.8	5.85
1	5	5364	F	92	48	9.1846	0.4957	35332	92.9	38038	76735			
1	5	5366	F	69	24	5.1619	0.4997	211068	93.2	226467	453206	1053.2	502.3	19.09
1	5	5366	F	70	24	5.1619	0.5147	217023	93.2	232985	452662			
1	5	5366	F	93	48	4.4347	0.4431	68089	92.8	73357	165554	332.2	158.4	6.02
1	5	5366	F	94	48	4.4347	0.4657	72051	92.7	77770	166996			
2	1	5836	M	1131	3	4.8803	0.4978	54411	94.0	57869	116250	257.5	409.4	4.74
2	1	5836	M	1132	3	4.8803	0.4979	55263	94.0	58773	118043			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	1	5841	M	1133	3	4.7477	0.5004	99744	93.6	106532	212894	452.3	719.0	8.39
2	1	5841	M	1134	3	4.7477	0.5033	99048	93.7	105739	210092			
2	1	5844	M	1135	3	4.7394	0.5005	155011	93.8	165259	330189	707.4	1124.5	13.00
2	1	5844	M	1136	3	4.7394	0.5064	157921	93.8	168377	332498			
2	1	5853	F	1137	3	6.5273	0.4995	72151	94.0	76758	153670	450.9	716.8	8.23
2	1	5853	F	1138	3	6.5273	0.5031	72338	94.0	76986	153024			
2	1	5855	F	1139	3	5.3738	0.4972	127320	94.0	135492	272510	658.2	1046.4	12.58
2	1	5855	F	1140	3	5.3738	0.5137	130966	94.0	139387	271339			
2	1	5863	F	1141	3	3.9007	0.4980	76920	93.9	81948	164554	287.7	457.3	5.27
2	1	5863	F	1142	3	3.9007	0.5072	77587	93.9	82615	162883			
2	2	5832	M	1143	6	2.9201	0.4972	295795	93.6	315958	635474	835.4	1328.1	15.46
2	2	5832	M	1144	6	2.9201	0.5120	304141	93.6	325023	634810			
2	2	5834	M	1145	6	3.2868	0.5019	279181	93.6	298262	594266	882.4	1402.8	16.26
2	2	5834	M	1146	6	3.2868	0.5052	282661	93.6	302007	597796			
2	2	5845	M	1147	6	2.9465	0.4991	303408	93.6	324208	649585	860.3	1367.6	15.76
2	2	5845	M	1148	6	2.9465	0.5095	308401	93.6	329532	646775			
2	2	5846	F	1149	6	3.9735	0.4972	168583	93.7	179886	361799	649.2	1032.1	11.89
2	2	5846	F	1150	6	3.9735	0.5054	172207	93.7	183796	363664			
2	2	5858	F	1151	6	3.2882	0.4969	306801	93.5	328232	660560	975.6	1551.0	17.88
2	2	5858	F	1152	6	3.2882	0.5161	316688	93.4	338996	656841			
2	2	5860	F	1153	6	3.5819	0.4968	192919	93.8	205662	413974	670.2	1065.4	12.30
2	2	5860	F	1154	6	3.5819	0.5130	200395	93.7	213812	416787			
2	3	5715	M	1155	12	5.5843	0.4930	196088	93.7	209236	424414	1069.7	1700.5	19.54
2	3	5715	M	1156	12	5.5843	0.4986	198952	93.7	212453	426099			
2	3	5831	M	1157	12	4.4106	0.5017	412406	93.5	441103	879216	1748.8	2780.1	32.19
2	3	5831	M	1158	12	4.4106	0.5083	418596	93.4	447945	881261			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	3	5837	M	1159	12	3.8406	0.5016	495306	93.2	531506	1059620	1825.4	2901.8	33.36
2	3	5837	M	1160	12	3.8406	0.4984	488246	93.2	523627	1050617			
2	3	5847	F	1161	12	5.7282	0.4995	305476	93.7	326008	652668	1685.0	2678.7	30.64
2	3	5847	F	1162	12	5.7282	0.5008	306556	93.7	327217	653388			
2	3	5850	F	1163	12	7.5007	0.4993	250371	93.6	267437	535624	1805.2	2869.8	32.80
2	3	5850	F	1164	12	7.5007	0.4974	247996	93.6	265099	532970			
2	3	5864	F	1165	12	8.4494	0.5012	217516	93.7	232243	463375	1768.2	2811.0	32.34
2	3	5864	F	1166	12	8.4494	0.5010	218481	93.6	233365	465798			
2	4	5713	M	1179	24	3.6673	0.5085	452786	92.1	491449	966468	1600.0	2543.6	29.16
2	4	5713	M	1180	24	3.6673	0.5179	462996	92.1	502708	970666			
2	4	5829	M	1181	24	4.0542	0.5120	534096	92.3	578550	1129981	2056.5	3269.3	36.53
2	4	5829	M	1182	24	4.0542	0.5203	538806	92.3	583913	1122262			
2	4	5830	M	1183	24	6.4090	0.5004	325850	93.1	350075	699591	2017.4	3207.1	36.91
2	4	5830	M	1184	24	6.4090	0.4945	321516	93.2	345177	698033			
2	4	5839	M	1185	24	5.8882	0.5024	449086	92.3	486442	968236	2573.9	4091.7	47.05
2	4	5839	M	1186	24	5.8882	0.5070	455026	92.3	493103	972589			
2	4	5851	F	1187	24	4.2677	0.4992	484186	93.1	519862	1041390	2006.1	3189.1	37.24
2	4	5851	F	1188	24	4.2677	0.5111	497546	93.1	534442	1045671			
2	4	5852	F	1189	24	5.6655	0.5042	383396	93.0	412378	817886	2095.4	3331.0	38.12
2	4	5852	F	1190	24	5.6655	0.4976	381636	93.1	410138	824232			
2	4	5857	F	1191	24	6.0033	0.4986	314156	93.0	337724	677344	1829.4	2908.2	33.44
2	4	5857	F	1192	24	6.0033	0.5130	322296	93.0	346607	675647			
2	4	5861	F	1193	24	4.8952	0.4988	393330	93.0	422739	847512	1866.8	2967.7	34.34
2	4	5861	F	1194	24	4.8952	0.5088	400516	93.1	430295	845706			
2	5	5720	M	1167	24	5.1694	0.5070	426056	92.5	460627	908534	2106.3	3348.5	38.84
2	5	5720	M	1168	24	5.1694	0.5007	417146	92.5	450920	900580			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	5	5720	M	1195	48	7.5724	0.5211	35449	90.5	39173	75173	253.9	403.7	4.68
2	5	5720	M	1196	48	7.5724	0.5118	34202	90.7	37725	73711			
2	5	5828	M	1169	24	4.8260	0.5073	463086	92.7	499759	985135	2128.7	3384.1	38.81
2	5	5828	M	1170	24	4.8260	0.5154	465166	92.7	501650	973322			
2	5	5828	M	1197	48	7.4779	0.5031	47267	93.2	50718	100812	339.6	539.8	6.19
2	5	5828	M	1198	48	7.4779	0.5051	47455	93.2	50915	100802			
2	5	5840	M	1171	24	4.0193	0.5296	500206	92.6	540076	1019781	1850.8	2942.3	34.11
2	5	5840	M	1172	24	4.0193	0.5185	492546	92.7	531329	1024743			
2	5	5840	M	1199	48	9.1384	0.5037	81834	92.8	88203	175110	718.9	1142.8	13.25
2	5	5840	M	1200	48	9.1384	0.5205	84094	92.8	90651	174162			
2	5	5848	F	1173	24	3.3583	0.5156	575756	92.8	620623	1203691	1818.9	2891.6	33.39
2	5	5848	F	1174	24	3.3583	0.5223	582306	92.8	627351	1201131			
2	5	5848	F	1201	48	7.8801	0.5020	65344	93.1	70195	139830	493.5	784.6	9.06
2	5	5848	F	1202	48	7.8801	0.5029	64679	93.0	69529	138257			
2	5	5854	F	1175	24	3.0025	0.5321	501356	91.9	545587	1025346	1381.9	2196.9	25.46
2	5	5854	F	1176	24	3.0025	0.5167	483886	92.0	526114	1018219			
2	5	5854	F	1203	48	9.0377	0.4990	53727	93.1	57709	115650	470.7	748.3	8.67
2	5	5854	F	1204	48	9.0377	0.5171	55575	93.0	59774	115595			
2	5	5862	F	1177	24	9.3959	0.5033	232266	93.2	249247	495225	2099.8	3338.2	38.21
2	5	5862	F	1178	24	9.3959	0.5139	237921	93.1	255432	497046			
2	5	5862	F	1205	48	6.6842	0.4979	41963	93.2	45039	90459	273.1	434.1	4.97
2	5	5862	F	1206	48	6.6842	0.5264	44582	93.1	47868	90935			
3	1	5723	M	375	3	3.2422	0.5180	81393	94.0	86612	167205	241.7	1152.6	4.56
3	1	5723	M	376	3	3.2422	0.4951	76172	93.9	81075	163756			
3	1	5733	M	377	3	3.6954	0.4949	40646	94.1	43203	87297	145.2	692.5	2.71
3	1	5733	M	378	3	3.6954	0.5007	41007	94.0	43643	87164			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	1	5736	M	379	3	4.2882	0.4990	78728	94.0	83744	167823	327.6	1562.6	6.08
3	1	5736	M	380	3	4.2882	0.3882	62658	94.2	66545	171419			
3	1	5741	F	381	3	4.3251	0.4900	90897	93.9	96829	197611	384.4	1833.1	7.16
3	1	5741	F	382	3	4.3251	0.4945	91472	93.9	97400	196966			
3	1	5744	F	383	3	5.6909	0.5071	36590	94.0	38936	76783	197.1	940.1	3.65
3	1	5744	F	384	3	5.6909	0.5032	36414	94.0	38749	77004			
3	1	5762	F	385	3	2.7005	0.4997	56307	94.0	59887	119846	147.1	701.5	2.74
3	1	5762	F	386	3	2.7005	0.4974	57063	94.0	60683	122000			
3	2	5722	M	387	6	4.9488	0.4902	85236	93.8	90850	185332	409.1	1951.1	7.69
3	2	5722	M	388	6	4.9488	0.4868	83016	93.8	88463	181723			
3	2	5734	M	389	6	4.0619	0.4926	73391	93.6	78438	159233	293.6	1400.4	5.50
3	2	5734	M	390	6	4.0619	0.4969	75176	93.5	80371	161746			
3	2	5737	M	391	6	3.7046	0.4935	170206	93.6	181779	368345	614.3	2929.5	11.59
3	2	5737	M	392	6	3.7046	0.4966	171146	93.7	182674	367848			
3	2	5746	F	393	6	3.8108	0.4885	144968	94.0	154270	315804	542.2	2585.8	10.68
3	2	5746	F	394	6	3.8108	0.4930	146328	93.9	155745	315913			
3	2	5751	F	395	6	4.9549	0.4882	183914	93.9	195854	401176	892.3	4255.5	16.93
3	2	5751	F	396	6	4.9549	0.4972	186078	93.9	198081	398392			
3	2	5761	F	397	6	3.1158	0.4876	112845	93.8	120357	246836	346.4	1652.0	6.49
3	2	5761	F	398	6	3.1158	0.4962	114681	93.7	122444	246764			
3	3	5716	M	399	12	5.6407	0.5023	126977	93.6	135659	270076	691.8	3299.5	13.24
3	3	5716	M	400	12	5.6407	0.5082	130503	93.6	139500	274498			
3	3	5717	M	401	12	7.5871	0.4932	107865	93.7	115170	233515	795.3	3792.8	14.86
3	3	5717	M	402	12	7.5871	0.4986	108300	93.7	115617	231883			
3	3	5726	M	403	12	3.2374	0.5046	295271	93.0	317541	629292	921.4	4394.3	17.12
3	3	5726	M	404	12	3.2374	0.4955	292551	93.1	314336	634380			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	3	5739	F	405	12	4.9672	0.4997	125949	93.7	134438	269037	603.7	2879.1	11.31
3	3	5739	F	406	12	4.9672	0.5037	127540	93.6	136288	270574			
3	3	5750	F	407	12	4.5416	0.4950	90406	93.8	96383	194714	398.5	1900.6	7.38
3	3	5750	F	408	12	4.5416	0.4861	88865	93.8	94736	194890			
3	3	5752	F	409	12	4.9089	0.5010	248552	93.6	265505	529951	1173.3	5595.9	22.05
3	3	5752	F	410	12	4.9089	0.5068	252082	93.6	269269	531312			
3	4	5724	M	423	24	9.1046	0.5014	235692	93.1	253251	505088	2063.8	9842.5	38.49
3	4	5724	M	424	24	9.1046	0.4975	232117	93.1	249420	501347			
3	4	5725	M	425	24	9.6303	0.4979	196225	92.7	211600	424986	1829.6	8725.8	34.26
3	4	5725	M	426	24	9.6303	0.4988	193729	92.8	208773	418551			
3	4	5727	M	427	24	6.7427	0.4981	228262	92.9	245573	493019	1496.1	7135.0	27.75
3	4	5727	M	428	24	6.7427	0.5062	231347	92.9	249112	492121			
3	4	5735	M	429	24	5.0851	0.5123	262737	92.2	284853	556028	1276.2	6086.3	23.96
3	4	5735	M	430	24	5.0851	0.5083	261777	92.3	283762	558256			
3	4	5740	F	431	24	6.5010	0.4942	248542	91.8	270850	548058	1594.7	7605.3	30.28
3	4	5740	F	432	24	6.5010	0.5072	251977	91.8	274427	541062			
3	4	5742	F	433	24	7.9574	0.4968	158917	93.3	170343	342881	1228.9	5861.1	22.93
3	4	5742	F	434	24	7.9574	0.4981	159254	93.3	170767	342837			
3	4	5753	F	435	24	6.6838	0.4931	180521	93.3	193373	392158	1185.7	5654.6	22.23
3	4	5753	F	436	24	6.6838	0.5029	185481	93.3	198879	395464			
3	4	5756	F	437	24	5.4614	0.4940	224147	93.2	240622	487089	1201.4	5729.7	22.27
3	4	5756	F	438	24	5.4614	0.5037	229687	93.1	246628	489633			
3	5	5721	M	411	24	3.5125	0.5154	574577	92.6	620619	1204150	1905.2	9086.4	36.41
3	5	5721	M	412	24	3.5125	0.5247	584637	92.5	631838	1204188			
3	5	5721	M	439	48	7.9312	0.5034	58478	93.0	62895	124940	443.0	2112.7	8.47
3	5	5721	M	440	48	7.9312	0.5134	58736	93.0	63177	123056			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	5	5728	M	413	24	4.2939	0.5096	273097	92.8	294379	577668	1115.4	5319.7	21.04
3	5	5728	M	414	24	4.2939	0.5153	275151	92.7	296675	575732			
3	5	5728	M	441	48	6.9142	0.5021	107275	92.9	115439	229913	714.0	3405.3	13.47
3	5	5728	M	442	48	6.9142	0.5081	107940	92.9	116151	228599			
3	5	5732	M	415	24	3.8241	0.5047	449927	93.3	482470	955954	1639.3	7817.9	30.25
3	5	5732	M	416	24	3.8241	0.5164	456047	93.2	489199	947326			
3	5	5732	M	443	48	5.0271	0.5020	109173	92.7	117807	234676	530.1	2528.1	9.78
3	5	5732	M	444	48	5.0271	0.5006	108435	92.8	116891	233502			
3	5	5738	F	417	24	6.4464	0.4983	174241	93.5	186346	373963	1085.3	5175.9	20.17
3	5	5738	F	418	24	6.4464	0.5060	176753	93.5	189005	373527			
3	5	5738	F	445	48	6.1355	0.4993	90127	93.2	96680	193630	536.5	2558.8	9.97
3	5	5738	F	446	48	6.1355	0.5147	93382	93.2	100174	194627			
3	5	5758	F	419	24	3.9789	0.5080	295031	93.2	316604	623236	1117.6	5329.8	21.04
3	5	5758	F	420	24	3.9789	0.5090	295704	93.1	317529	623830			
3	5	5758	F	447	48	6.6577	0.5000	128781	93.1	138265	276530	824.6	3932.8	15.52
3	5	5758	F	448	48	6.6577	0.5143	130826	93.0	140615	273410			
3	5	5760	F	421	24	7.5924	0.4979	193909	93.2	207958	417670	1425.3	6797.5	27.65
3	5	5760	F	422	24	7.5924	0.5030	195081	93.3	209166	415837			
3	5	5760	F	449	48	4.7123	0.4996	74780	92.7	80676	161482	344.2	1641.5	6.68
3	5	5760	F	450	48	4.7123	0.5056	76291	92.7	82320	162817			
4	NA	5714	M	1047	24	6.0115	0.5025	395505	93.0	425368	846504	2294.6	10775.0	47.01
4	NA	5714	M	1048	24	6.0115	0.5018	395485	92.9	425658	848262			
4	NA	5718	M	1049	24	5.2827	0.5063	483228	92.5	522378	1031756	2462.7	11564.3	49.86
4	NA	5718	M	1050	24	5.2827	0.5176	496948	92.5	537318	1038095			
4	NA	5719	M	1051	24	8.0468	0.5004	291645	92.9	313816	627130	2268.8	10653.9	46.57
4	NA	5719	M	1052	24	8.0468	0.5087	295438	93.0	317803	624735			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
4	NA	5730	M	1053	24	7.2485	0.5075	321911	92.9	346646	683045	2237.8	10508.5	45.17
4	NA	5730	M	1054	24	7.2485	0.5061	323058	92.8	348059	687728			
4	NA	5743	F	1055	24	4.9570	0.4969	242658	93.0	260927	525110	1171.1	5499.3	23.77
4	NA	5743	F	1056	24	4.9570	0.4951	241133	93.0	259358	523850			
4	NA	5745	F	1057	24	5.7306	0.5030	357898	92.9	385306	766016	1967.2	9237.6	39.34
4	NA	5745	F	1058	24	5.7306	0.5098	358785	92.8	386508	758156			
4	NA	5748	F	1059	24	9.7251	0.4994	221483	93.4	237005	474579	2073.3	9735.7	41.96
4	NA	5748	F	1060	24	9.7251	0.5001	220528	93.4	236037	471980			
4	NA	5754	F	1061	24	5.4050	0.5035	402908	93.1	432641	859267	2084.7	9789.4	41.75
4	NA	5754	F	1062	24	5.4050	0.5157	409568	93.1	440019	853246			
5	1	5871	M	3583	Pool	130.9114	0.5101	116359	92.6	125678	246380	14482.3	17334.8	50.44
5	1	5871	M	3584	Pool	130.9114	0.4963	112650	92.7	121495	244802			
5	1	5871	M	3567	Day 14	12.1251	0.5087	118245	92.6	127768	251165	1375.5	1646.4	4.79
5	1	5871	M	3568	Day 14	12.1251	0.4958	115979	92.6	125198	252517			
5	1	5883	M	3585	Pool	100.5349	0.5067	143595	92.3	155577	307040	13963.7	16714.1	47.52
5	1	5883	M	3586	Pool	100.5349	0.4990	142769	92.4	154515	309649			
5	1	5883	M	3569	Day 14	10.7542	0.5014	96366	92.9	103761	206943	1005.0	1203.0	3.42
5	1	5883	M	3570	Day 14	10.7542	0.5206	100552	92.9	108280	207991			
5	1	5884	M	3587	Pool	105.8579	0.5054	139109	92.7	150127	297045	14144.1	16930.0	48.14
5	1	5884	M	3588	Pool	105.8579	0.4845	133079	92.7	143510	296201			
5	1	5884	M	3571	Day 14	9.8724	0.5041	115685	92.8	124610	247192	1105.4	1323.2	3.76
5	1	5884	M	3572	Day 14	9.8724	0.4970	115431	92.9	124232	249964			
5	1	5889	M	3589	Pool	122.9772	0.5006	114485	92.4	123894	247490	13403.7	16043.8	46.35
5	1	5889	M	3590	Pool	122.9772	0.4962	108505	92.5	117323	236442			
5	1	5889	M	3573	Day 14	11.7918	0.5059	119351	92.4	129195	255377	1349.2	1614.9	4.67
5	1	5889	M	3574	Day 14	11.7918	0.5005	116902	92.5	126439	252625			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	1	5896	F	3591	Pool	146.1807	0.5011	116382	92.8	125410	250269	16523.3	19777.8	56.31
5	1	5896	F	3592	Pool	146.1807	0.5050	118008	92.9	127057	251598			
5	1	5896	F	3575	Day 14	28.7872	0.4991	68696	92.6	74164	148595	1945.6	2328.8	6.63
5	1	5896	F	3576	Day 14	28.7872	0.5128	71886	92.5	77678	151479			
5	1	5899	F	3593	Pool	154.2312	0.4999	92060	92.6	99369	198778	13614.2	16295.7	46.04
5	1	5899	F	3594	Pool	154.2312	0.4900	87754	92.7	94642	193146			
5	1	5899	F	3577	Day 14	11.3941	0.5018	92031	92.6	99343	197973	1014.0	1213.7	3.43
5	1	5899	F	3578	Day 14	11.3941	0.4973	90868	92.7	98043	197151			
5	1	5900	F	3595	Pool	88.9254	0.5064	186006	92.1	201872	398642	15980.7	19128.4	53.81
5	1	5900	F	3596	Pool	88.9254	0.5126	188674	92.2	204665	399268			
5	1	5900	F	3579	Day 14	13.1871	0.5097	128202	92.8	138120	270982	1620.1	1939.3	5.46
5	1	5900	F	3580	Day 14	13.1871	0.5068	129159	92.8	139121	274508			
5	1	5921	F	3597	Pool	88.8404	0.4678	153889	92.0	167311	357654	14314.9	17134.4	48.29
5	1	5921	F	3598	Pool	88.8404	0.4982	163914	92.0	178238	357765			
5	1	5921	F	3581	Day 14	11.5152	0.5039	136636	92.5	147702	293117	1509.2	1806.5	5.09
5	1	5921	F	3582	Day 14	11.5152	0.5030	134436	92.6	145265	288797			
5	2	5869	M	5072	Pool	296.3662	0.5035	118565	92.8	127749	253722	33938.0	40622.7	58.08
5	2	5869	M	5073	Pool	296.3662	0.5284	124876	92.8	134594	254719			
5	2	5869	M	4804	Day 28	5.4950	0.5089	231166	92.3	250384	492010	1219.5	1459.7	2.09
5	2	5869	M	4805	Day 28	5.4950	0.5097	232151	92.3	251459	493346			
5	2	5870	M	5074	Pool	310.3045	0.5034	103106	93.0	110886	220275	30325.2	36298.3	51.94
5	2	5870	M	5075	Pool	310.3045	0.5034	99979	93.0	107544	213634			
5	2	5870	M	4806	Day 28	9.2885	0.4944	138935	92.6	149980	303357	1268.1	1517.8	2.17
5	2	5870	M	4807	Day 28	9.2885	0.5004	140418	92.7	151520	302797			
5	2	5888	M	5076	Pool	278.5903	0.5082	109531	92.8	117989	232170	29187.3	34936.2	49.88
5	2	5888	M	5077	Pool	278.5903	0.5180	111971	92.8	120693	232998			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5888	M	4808	Day 28	10.1255	0.4171	104911	93.0	112853	270565	1223.4	1464.4	2.09
5	2	5888	M	4809	Day 28	10.1255	0.5076	125180	92.8	134970	265898			
5	2	5893	M	5078	Pool	272.6644	0.5126	132879	92.9	142999	278968	34203.7	40940.7	58.44
5	2	5893	M	5079	Pool	272.6644	0.5071	131067	93.0	140972	277996			
5	2	5893	M	4810	Day 28	9.5105	0.4922	168207	92.9	181124	367989	1572.5	1882.2	2.69
5	2	5893	M	4811	Day 28	9.5105	0.5052	171507	92.7	184961	366114			
5	2	5910	F	5080	Pool	296.8085	0.5123	127850	92.9	137671	268731	35814.8	42869.2	61.05
5	2	5910	F	5081	Pool	296.8085	0.5104	126593	92.9	136291	267027			
5	2	5910	F	4812	Day 28	8.9268	0.4974	158548	92.7	171001	343790	1375.8	1646.8	2.35
5	2	5910	F	4813	Day 28	8.9268	0.5099	160927	92.7	173621	340500			
5	2	5911	F	5082	Pool	355.6220	0.5132	100121	93.0	107653	209768	33674.3	40307.1	56.98
5	2	5911	F	5083	Pool	355.6220	0.5110	100090	93.0	107648	210662			
5	2	5911	F	4814	Day 28	10.6566	0.4703	85799	92.7	92573	196839	939.1	1124.0	1.59
5	2	5911	F	4815	Day 28	10.6566	0.5001	90033	92.6	97225	194410			
5	2	5915	F	5084	Pool	257.3074	0.5029	127190	92.9	136956	272333	31363.8	37541.4	53.07
5	2	5915	F	5085	Pool	257.3074	0.5092	127156	92.9	136908	268869			
5	2	5915	F	4816	Day 28	6.2729	0.4871	177763	92.4	192306	394797	1115.5	1335.3	1.89
5	2	5915	F	4817	Day 28	6.2729	0.5168	188467	92.4	204026	394788			
5	2	5916	F	5086	Pool	294.5427	0.5198	94028	92.7	101451	195173	25941.5	31051.1	43.92
5	2	5916	F	5087	Pool	294.5427	0.5166	93803	92.7	101189	195875			
5	2	5916	F	4818	Day 28	9.7750	0.4984	106974	92.8	115328	231396	1019.4	1220.2	1.73
5	2	5916	F	4819	Day 28	9.7750	0.5030	108039	92.7	116522	231654			
6	1	5867	M	3714	Pool	90.6608	0.5025	200426	91.6	218703	435229	17593.6	70196.4	60.41
6	1	5867	M	3715	Pool	90.6608	0.4984	194891	91.7	212514	426393			
6	1	5867	M	3698	Day 14	10.7239	0.5219	131474	92.4	142254	272569	1352.2	5395.3	4.64
6	1	5867	M	3699	Day 14	10.7239	0.5084	135136	92.5	146063	287299			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5868	M	3716	Pool	109.8625	0.5030	205361	92.1	222882	443106	21936.8	87525.3	76.01
6	1	5868	M	3717	Pool	109.8625	0.4822	197323	92.3	213832	443450			
6	1	5868	M	3700	Day 14	11.6006	0.5011	141679	92.6	153028	305384	1588.4	6337.4	5.50
6	1	5868	M	3701	Day 14	11.6006	0.5144	144033	92.6	155629	302545			
6	1	5875	M	3718	Pool	98.3990	0.4435	183811	92.6	198565	447722	19877.8	79310.1	68.34
6	1	5875	M	3719	Pool	98.3990	0.5042	209301	92.4	226492	449211			
6	1	5875	M	3702	Day 14	8.8464	0.5041	213963	92.7	230942	458126	1823.7	7276.5	6.27
6	1	5875	M	3703	Day 14	8.8464	0.5183	219593	92.7	236968	457202			
6	1	5881	M	3720	Pool	115.6249	0.5034	170747	92.7	184290	366090	19019.0	75883.7	65.73
6	1	5881	M	3721	Pool	115.6249	0.5064	170947	92.7	184451	364240			
6	1	5881	M	3704	Day 14	12.1728	0.5004	132900	93.1	142777	285325	1561.9	6232.0	5.40
6	1	5881	M	3705	Day 14	12.1728	0.5065	134193	93.2	144043	284389			
6	1	5895	F	3722	Pool	95.6101	0.5040	184407	92.2	199930	396687	17064.2	68084.3	58.65
6	1	5895	F	3723	Pool	95.6101	0.4972	181643	92.3	196767	395751			
6	1	5895	F	3706	Day 14	10.3199	0.5045	149119	92.9	160473	318082	1474.8	5884.2	5.07
6	1	5895	F	3707	Day 14	10.3199	0.5065	148949	92.9	160267	316421			
6	1	5907	F	3724	Pool	91.2817	0.5015	180451	92.2	195653	390135	16018.5	63912.1	54.77
6	1	5907	F	3725	Pool	91.2817	0.4981	178771	92.3	193769	389015			
6	1	5907	F	3708	Day 14	9.8318	0.5066	170179	92.3	184424	364043	1606.9	6411.2	5.49
6	1	5907	F	3709	Day 14	9.8318	0.4459	149179	92.5	161243	361612			
6	1	5909	F	3726	Pool	109.6033	0.5028	173067	92.0	188076	374057	18391.3	73379.1	62.27
6	1	5909	F	3727	Pool	109.6033	0.4890	167167	92.2	181403	370968			
6	1	5909	F	3710	Day 14	11.0326	0.5204	110298	92.8	118913	228503	1143.0	4560.6	3.87
6	1	5909	F	3711	Day 14	11.0326	0.5082	109115	92.8	117649	231501			
6	1	5918	F	3728	Pool	108.3057	0.5027	165043	92.3	178814	355707	17430.8	69547.1	55.64
6	1	5918	F	3729	Pool	108.3057	0.4959	164215	92.3	177964	358872			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5918	F	3712	Day 14	8.6034	0.5043	186255	92.9	200536	397651	1535.2	6125.3	4.90
6	1	5918	F	3713	Day 14	8.6034	0.5030	184339	92.9	198499	394631			
6	2	5880	M	5088	Pool	315.1407	0.5092	121059	93.0	130151	255598	36216.3	144498.9	62.21
6	2	5880	M	5089	Pool	315.1407	0.5211	123405	93.0	132699	254651			
6	2	5880	M	4852	Day 28	9.9291	0.5086	160939	92.4	174102	342316	1526.5	6090.5	2.62
6	2	5880	M	4853	Day 28	9.9291	0.5155	162223	92.5	175413	340278			
6	2	5885	M	5090	Pool	385.2702	0.5115	93879	93.0	100898	197259	34210.2	136494.9	58.43
6	2	5885	M	5091	Pool	385.2702	0.5213	95470	93.0	102692	196992			
6	2	5885	M	4854	Day 28	14.2128	0.4995	83989	92.6	90723	181627	1151.5	4594.5	1.97
6	2	5885	M	4855	Day 28	14.2128	0.5038	83029	92.5	89729	178104			
6	2	5887	M	5092	Pool	288.3532	0.5219	128187	93.0	137801	264037	34441.3	137417.2	58.77
6	2	5887	M	5093	Pool	288.3532	0.5188	128522	93.0	138148	266283			
6	2	5887	M	4856	Day 28	9.4172	0.5225	195843	92.9	210838	403518	1708.5	6816.9	2.92
6	2	5887	M	4857	Day 28	9.4172	0.5184	193815	93.0	208407	402019			
6	2	5894	M	5094	Pool	299.4438	0.5261	129153	92.9	138970	264150	35402.4	141251.8	60.23
6	2	5894	M	5095	Pool	299.4438	0.5215	126425	93.0	135996	260779			
6	2	5894	M	4858	Day 28	8.2533	0.5031	125666	92.6	135656	269640	1003.7	4004.7	1.71
6	2	5894	M	4859	Day 28	8.2533	0.5231	130988	92.6	141405	270322			
6	2	5903	F	5096	Pool	283.8716	0.5242	129062	92.6	139398	265925	34039.9	135815.4	57.64
6	2	5903	F	5097	Pool	283.8716	0.5160	127365	92.6	137508	266489			
6	2	5903	F	4860	Day 28	6.1156	0.5038	163875	92.1	178005	353324	969.5	3868.2	1.64
6	2	5903	F	4861	Day 28	6.1156	0.5091	164155	92.0	178462	350545			
6	2	5912	F	5098	Pool	474.5406	0.5284	84883	93.1	91155	172512	36912.7	147277.6	62.68
6	2	5912	F	5099	Pool	474.5406	0.5219	84037	93.2	90215	172859			
6	2	5912	F	4862	Day 28	8.8010	0.5015	138223	92.8	148990	297088	1179.1	4704.4	2.00
6	2	5912	F	4863	Day 28	8.8010	0.4965	137109	92.8	147831	297747			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	2	5917	F	5100	Pool	271.6011	0.5231	133356	92.9	143472	274272	33665.4	134321.5	57.42
6	2	5917	F	5101	Pool	271.6011	0.5205	133579	93.0	143696	276074			
6	2	5917	F	4864	Day 28	7.1335	0.5048	167787	92.6	181214	358981	1147.6	4578.8	1.96
6	2	5917	F	4865	Day 28	7.1335	0.5133	168791	92.6	182380	355309			
6	2	5919	F	5102	Pool	335.5700	0.5247	127156	93.0	136753	260630	39222.6	156493.9	66.26
6	2	5919	F	5103	Pool	335.5700	0.5223	125545	93.1	134927	258333			
6	2	5919	F	4866	Day 28	20.1447	0.4997	83959	93.2	90063	180234	1631.9	6511.2	2.76
6	2	5919	F	4867	Day 28	20.1447	0.5024	84077	93.3	90157	179452			
7	1	5872	M	3834	Pool	90.8234	0.5049	161579	92.0	175613	347818	14063.5	168335.5	49.80
7	1	5872	M	3835	Pool	90.8234	0.5015	157095	92.2	170356	339692			
7	1	5872	M	3818	Day 14	10.9754	0.4896	67730	93.3	72613	148312	736.0	8809.1	2.61
7	1	5872	M	3819	Day 14	10.9754	0.4835	67424	93.3	72241	149412			
7	1	5873	M	3836	Pool	87.7300	0.5055	158749	91.4	173638	343498	13500.0	161590.3	47.76
7	1	5873	M	3837	Pool	87.7300	0.4925	153329	91.6	167319	339733			
7	1	5873	M	3820	Day 14	14.8975	0.4981	63299	92.9	68137	136793	912.4	10920.8	3.23
7	1	5873	M	3821	Day 14	14.8975	0.4987	62632	92.9	67388	135127			
7	1	5874	M	3838	Pool	102.6913	0.5084	155285	92.5	167851	330154	15224.8	182235.4	53.11
7	1	5874	M	3839	Pool	102.6913	0.5073	154032	92.5	166450	328109			
7	1	5874	M	3822	Day 14	6.5437	0.5042	178699	92.7	192866	382519	1232.8	14756.3	4.30
7	1	5874	M	3823	Day 14	6.5437	0.5056	211809	92.3	229522	453960			
7	1	5882	M	3840	Pool	89.1606	0.5073	145669	92.2	158033	311518	12483.3	149421.2	44.28
7	1	5882	M	3841	Pool	89.1606	0.5124	146559	92.2	158907	310123			
7	1	5882	M	3824	Day 14	15.2165	0.5010	71897	93.1	77190	154071	1048.3	12548.0	3.72
7	1	5882	M	3825	Day 14	15.2165	0.5104	72234	93.2	77487	151816			
7	1	5901	F	3842	Pool	120.4085	0.5067	137329	92.6	148316	292709	15736.8	188364.4	55.39
7	1	5901	F	3843	Pool	120.4085	0.5030	133875	92.6	144651	287577			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5901	F	3826	Day 14	18.2322	0.5019	72739	93.2	78058	155526	1282.0	15344.9	4.51
7	1	5901	F	3827	Day 14	18.2322	0.4967	72535	93.2	77818	156670			
7	1	5902	F	3844	Pool	79.5082	0.5023	165495	91.7	180474	359295	12768.9	152839.5	44.71
7	1	5902	F	3845	Pool	79.5082	0.5101	165447	91.7	180454	353762			
7	1	5902	F	3828	Day 14	13.4833	0.4937	91832	92.3	99437	201413	1216.5	14560.5	4.26
7	1	5902	F	3829	Day 14	13.4833	0.4998	91910	92.3	99541	199161			
7	1	5913	F	3846	Pool	71.8030	0.5096	207719	91.7	226618	444697	14325.4	171470.9	49.74
7	1	5913	F	3847	Pool	71.8030	0.5110	207014	91.8	225417	441129			
7	1	5913	F	3830	Day 14	10.3691	0.4933	120487	93.0	129548	262614	1233.0	14758.6	4.28
7	1	5913	F	3831	Day 14	10.3691	0.5078	125259	93.0	134746	265352			
7	1	5920	F	3848	Pool	89.0803	0.5055	171923	91.6	187776	371466	14780.2	176914.2	55.10
7	1	5920	F	3849	Pool	89.0803	0.5114	171099	91.6	186773	365219			
7	1	5920	F	3832	Day 14	12.1642	0.4938	91605	92.8	98718	199916	1090.2	13048.8	4.06
7	1	5920	F	3833	Day 14	12.1642	0.4985	91545	92.8	98701	197996			
7	2	5878	M	5104	Pool	290.9798	0.5189	117414	93.0	126272	243346	31630.8	378610.3	54.92
7	2	5878	M	5105	Pool	290.9798	0.5101	113526	93.0	122068	239302			
7	2	5878	M	4956	Day 28	7.3122	0.4981	148806	93.0	160013	321247	1059.8	12685.0	1.84
7	2	5878	M	4957	Day 28	7.3122	0.5042	151003	92.9	162476	322245			
7	2	5886	M	5106	Pool	264.3093	0.5219	142661	92.9	153483	294084	35025.5	419244.3	60.60
7	2	5886	M	5107	Pool	264.3093	0.5218	142801	93.0	153562	294292			
7	2	5886	M	4958	Day 28	10.2664	0.4932	115660	93.1	124184	251792	1156.1	13837.6	2.00
7	2	5886	M	4959	Day 28	10.2664	0.5033	116300	93.1	124908	248179			
7	2	5891	M	5108	Pool	273.8523	0.5297	128577	92.9	138418	261314	32025.6	383336.0	55.49
7	2	5891	M	5109	Pool	273.8523	0.5111	122526	92.9	131824	257921			
7	2	5891	M	4960	Day 28	8.5281	0.5028	149236	92.9	160676	319563	1219.8	14601.2	2.11
7	2	5891	M	4961	Day 28	8.5281	0.5277	154473	92.8	166504	315528			

TABLE F11. Liquid Scintillation Analyses of Urine Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5892	M	5110	Pool	285.5993	0.5213	102141	92.9	109899	210818	26827.3	321114.4	46.34
7	2	5892	M	5111	Pool	285.5993	0.5202	99809	93.0	107290	206247			
7	2	5892	M	4962	Day 28	6.1732	0.5097	204418	92.5	221065	433716	1191.3	14259.6	2.06
7	2	5892	M	4963	Day 28	6.1732	0.5122	200508	92.5	216722	423121			
7	2	5905	F	5112	Pool	397.2485	0.5172	82977	93.2	89070	172215	30919.8	370099.7	53.44
7	2	5905	F	5113	Pool	397.2485	0.5206	84097	93.2	90257	173372			
7	2	5905	F	4964	Day 28	17.4279	0.5014	92683	93.4	99228	197902	1555.9	18624.2	2.69
7	2	5905	F	4965	Day 28	17.4279	0.5087	94196	93.3	100975	198497			
7	2	5906	F	5114	Pool	292.8970	0.5207	120020	93.2	128758	247278	32573.9	389898.5	56.34
7	2	5906	F	5115	Pool	292.8970	0.5077	116637	93.2	125151	246507			
7	2	5906	F	4966	Day 28	10.5005	0.5015	121723	93.2	130654	260525	1226.4	14679.3	2.12
7	2	5906	F	4967	Day 28	10.5005	0.5034	120980	93.1	129893	258032			
7	2	5908	F	5116	Pool	270.1066	0.5166	127631	92.9	137345	265864	32185.1	385244.9	55.15
7	2	5908	F	5117	Pool	270.1066	0.5171	126460	92.9	136097	263193			
7	2	5908	F	4968	Day 28	5.6932	0.5083	205703	92.4	222562	437855	1117.0	13369.9	1.91
7	2	5908	F	4969	Day 28	5.6932	0.5173	207028	92.4	224121	433251			
7	2	5914	F	5118	Pool	557.8791	0.5141	65502	93.3	70200	136549	34350.4	411162.9	61.28
7	2	5914	F	5119	Pool	557.8791	0.5147	65711	93.3	70430	136836			
7	2	5914	F	4970	Day 28	13.4991	0.4976	97680	93.0	104986	210984	1266.5	15159.7	2.26
7	2	5914	F	4971	Day 28	13.4991	0.5058	96818	93.1	103985	205585			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	1	5331	M	3882	3	0.3936	0.3771	1.02	77210	85.7	90058	243594	43.19	20.60	0.79
1	1	5339	M	3883	3	0.1733	0.1564	1.02	729	85.3	854	5570	0.43	0.21	0.01
1	1	5340	M	3884	3	0.1526	0.1360	1.02	1239	85.6	1448	10856	0.75	0.36	0.01
1	1	5355	F	3885	3	0.4135	0.4007	1.02	1231	86.4	1424	3625	0.68	0.32	0.01
1	1	5356	F	3886	3	0.2948	0.2772	1.02	6916	85.6	8083	29742	3.95	1.88	0.07
1	1	5362	F	3887	3	0.1802	0.1715	1.02	1962	85.0	2307	13722	1.11	0.53	0.02
1	2	5332	M	3888	6	0.4829	0.4759	1.02	5768	86.7	6654	14262	3.10	1.48	0.06
1	2	5342	M	3889	6	0.5550	0.5102	1.02	6030	85.8	7028	14050	3.51	1.68	0.06
1	2	5343	M	3890	6	0.2770	0.2538	1.02	448	85.9	522	2099	0.26	0.12	0.00
1	2	5349	F	3891	6	0.6921	0.6624	1.02	5126	85.9	5969	9191	2.87	1.37	0.05
1	2	5350	F	3892	6	0.3781	0.3724	1.02	3501	85.3	4104	11240	1.91	0.91	0.04
1	2	5363	F	3893	6	0.4363	0.4092	1.02	14822	85.7	17290	43098	8.47	4.04	0.15
1	3	5327	M	3894	12	0.9205	0.3839	1.02	18593	86.0	21625	57457	24.23	11.55	0.44
1	3	5327	M	3895	12	0.9205	0.4405	1.02	22069	86.0	25653	59401			
1	3	5330	M	3896	12	0.8055	0.3957	1.02	9469	85.8	11035	28444	10.98	5.24	0.20
1	3	5330	M	3897	12	0.8055	0.3422	1.02	9255	85.9	10770	32103			
1	3	5334	M	3898	12	0.7116	0.2766	1.02	13637	86.1	15833	58385	17.83	8.50	0.32
1	3	5334	M	3899	12	0.7116	0.3829	1.02	17213	86.8	19839	52850			
1	3	5347	F	3900	12	1.1663	0.4983	1.02	192223	86.7	221690	453791	228.45	108.95	4.14
1	3	5347	F	3901	12	1.1663	0.4895	1.02	172075	86.2	199582	415881			
1	3	5348	F	3902	12	0.6769	0.6487	1.02	25540	85.6	29821	46889	14.30	6.82	0.26
1	3	5352	F	3903	12	0.5536	0.5401	1.02	13903	86.9	15995	30207	7.53	3.59	0.14
1	4	5328	M	3904	24	1.9754	0.5594	1.02	23229	86.6	26820	48903	43.15	20.58	0.78
1	4	5328	M	3905	24	1.9754	0.5575	1.02	22828	86.9	26282	48085			
1	4	5336	M	3906	24	2.5670	0.5472	1.02	23463	86.7	27075	50469	59.42	28.34	1.10
1	4	5336	M	3907	24	2.5670	0.5576	1.02	24857	86.9	28596	52309			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	4	5344	M	3908	24	3.1462	0.4762	1.02	11099	86.1	12893	27617	37.63	17.94	0.69
1	4	5344	M	3909	24	3.1462	0.4705	1.02	10116	86.1	11754	25482			
1	4	5345	M	3910	24	3.0145	0.4798	1.02	12015	86.2	13934	29622	40.72	19.42	0.73
1	4	5345	M	3911	24	3.0145	0.5065	1.02	13077	86.8	15073	30355			
1	4	5351	F	3912	24	2.1769	0.4859	1.02	34611	86.1	40222	84434	88.60	42.25	1.62
1	4	5351	F	3913	24	2.1769	0.5285	1.02	43147	86.5	49882	96271			
1	4	5353	F	3914	24	2.2459	0.5140	1.02	10505	87.3	12035	23883	22.34	10.65	0.40
1	4	5353	F	3915	24	2.2459	0.4985	1.02	8516	85.9	9913	20283			
1	4	5359	F	3916	24	2.8727	0.5272	1.02	15900	86.3	18420	35639	44.48	21.21	0.80
1	4	5359	F	3917	24	2.8727	0.5230	1.02	14707	86.6	16975	33107			
1	4	5365	F	3918	24	2.6383	0.5156	1.02	7759	86.0	9024	17852	21.89	10.44	0.40
1	4	5365	F	3919	24	2.6383	0.5050	1.02	8075	85.9	9399	18983			
1	5	5329	M	3920	24	3.4342	0.4821	1.02	13902	86.3	16102	34068	54.43	25.96	1.01
1	5	5329	M	3921	24	3.4342	0.4914	1.02	15041	86.0	17489	36301			
1	5	5329	M	3932	48	2.9433	0.4884	1.05	4304	86.5	4973	10692	14.15	6.75	0.26
1	5	5329	M	3933	48	2.9433	0.4889	1.05	4273	86.1	4961	10655			
1	5	5333	M	3922	24	2.1443	0.5041	1.02	7724	86.1	8973	18157	17.75	8.46	0.32
1	5	5333	M	3923	24	2.1443	0.5167	1.02	8109	86.1	9419	18593			
1	5	5333	M	3934	48	3.2585	0.4849	1.05	80418	85.9	93571	202617	306.90	146.37	5.61
1	5	5333	M	3935	48	3.2585	0.4891	1.05	86908	86.6	100412	215563			
1	5	5341	M	3924	24	3.5616	0.4975	1.02	14308	86.2	16596	34025	53.16	25.35	0.98
1	5	5341	M	3925	24	3.5616	0.5048	1.02	13702	85.9	15956	32241			
1	5	5341	M	3936	48	3.7562	0.5039	1.05	3203	86.7	3696	7701	13.07	6.23	0.24
1	5	5341	M	3937	48	3.7562	0.4969	1.05	3149	85.9	3666	7747			
1	5	5360	F	3926	24	1.6811	0.5009	1.02	5979	85.9	6963	14179	11.81	5.63	0.22
1	5	5360	F	3927	24	1.6811	0.5028	1.02	7285	86.9	8387	17015			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
1	5	5360	F	3938	48	2.1330	0.5043	1.05	2280	86.0	2651	5520	5.23	2.50	0.10
1	5	5360	F	3939	48	2.1330	0.4976	1.05	2189	85.9	2547	5375			
1	5	5364	F	3928	24	2.6131	0.5038	1.02	5728	86.2	6644	13451	16.09	7.67	0.30
1	5	5364	F	3929	24	2.6131	0.4871	1.02	5691	85.8	6629	13881			
1	5	5364	F	3940	48	2.8126	0.4982	1.05	2902	85.9	3379	7121	9.39	4.48	0.17
1	5	5364	F	3941	48	2.8126	0.4907	1.05	3123	86.7	3603	7710			
1	5	5366	F	3930	24	1.1385	0.5013	1.02	13196	85.3	15465	31467	16.33	7.79	0.30
1	5	5366	F	3931	24	1.1385	0.4841	1.02	13184	86.2	15295	32227			
1	5	5366	F	3942	48	2.5428	0.5017	1.05	6176	86.0	7185	15037	16.83	8.03	0.31
1	5	5366	F	3943	48	2.5428	0.4817	1.05	5670	86.1	6587	14357			
2	1	5836	M	3944	3	0.4832	0.4611	1.05	109563	86.0	127376	290055	63.13	100.36	1.16
2	1	5841	M	3945	3	0.3289	0.3033	1.05	1823	85.9	2122	7347	1.09	1.73	0.02
2	1	5844	M	3946	3	0.8435	0.3363	1.05	14533	86.0	16891	52736	17.07	27.13	0.31
2	1	5844	M	3947	3	0.8435	0.3516	1.05	10663	85.8	12425	37106			
2	1	5853	F	3948	3	0.7123	0.3051	1.05	9382	85.4	10981	37792	12.42	19.74	0.23
2	1	5853	F	3949	3	0.7123	0.3120	1.05	10092	85.8	11769	39606			
2	1	5855	F	3950	3	0.0936	0.0832	1.05	10051	85.2	11798	148888	6.28	9.98	0.12
2	1	5863	F	3951	3	0.2853	0.2672	1.05	2135	85.7	2491	9787	1.26	2.00	0.02
2	2	5832	M	3952	6	0.4838	0.4589	1.04	7070	86.8	8149	18468	4.02	6.40	0.07
2	2	5834	M	3953	6	0.5125	0.4929	1.04	7336	86.2	8508	17952	4.14	6.59	0.08
2	2	5845	M	3954	6	0.8413	0.3594	1.04	4317	86.2	5006	14485	5.32	8.45	0.10
2	2	5845	M	3955	6	0.8413	0.3422	1.04	3838	85.9	4466	13572			
2	2	5846	F	3956	6	0.3062	0.2818	1.04	9655	86.0	11223	41418	5.71	9.08	0.10
2	2	5858	F	3957	6	0.5578	0.5319	1.04	10953	86.7	12630	24695	6.20	9.86	0.11
2	2	5860	F	3958	6	0.7473	0.3421	1.04	51716	86.5	59803	181803	57.53	91.45	1.06
2	2	5860	F	3959	6	0.7473	0.3526	1.04	47035	86.7	54240	159981			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	3	5715	M	3960	12	0.6667	0.3143	1.04	31048	86.8	35769	118357	34.26	54.46	0.63
2	3	5715	M	3961	12	0.6667	0.3143	1.04	28462	85.8	33177	109781			
2	3	5831	M	3962	12	1.3268	0.5192	1.04	27236	86.0	31679	63457	30.32	48.19	0.56
2	3	5831	M	3963	12	1.3268	0.5579	1.04	17614	86.4	20381	37993			
2	3	5837	M	3964	12	0.8381	0.3786	1.04	17743	86.9	20427	56112	23.00	36.56	0.42
2	3	5837	M	3965	12	0.8381	0.4013	1.04	21979	86.7	25363	65730			
2	3	5847	F	3966	12	0.7979	0.2849	1.04	21806	86.3	25257	92200	21.44	34.09	0.39
2	3	5847	F	3967	12	0.7979	0.3040	1.04	6830	86.2	7929	27124			
2	3	5850	F	3968	12	1.0166	0.4721	1.04	7135	86.2	8277	18234	14.69	23.35	0.27
2	3	5850	F	3969	12	1.0166	0.4747	1.04	18181	86.8	20956	45911			
2	3	5864	F	3970	12	1.5348	0.4742	1.04	18169	86.7	20962	45972	40.89	65.01	0.75
2	3	5864	F	3971	12	1.5348	0.4854	1.04	29141	86.3	33756	72324			
2	4	5713	M	3972	24	2.0341	0.4863	1.04	18982	86.8	21874	46781	43.31	68.85	0.79
2	4	5713	M	3973	24	2.0341	0.5035	1.04	20080	86.8	23121	47757			
2	4	5829	M	3974	24	3.2141	0.5094	1.04	7099	86.7	8189	16720	24.59	39.09	0.44
2	4	5829	M	3975	24	3.2141	0.5166	1.04	7443	86.9	8569	17251			
2	4	5830	M	3976	24	2.0366	0.4995	1.04	21991	86.6	25403	52891	50.55	80.36	0.92
2	4	5830	M	3977	24	2.0366	0.5044	1.04	24189	87.0	27794	57307			
2	4	5839	M	3978	24	2.9435	0.4654	1.04	15302	86.4	17701	39554	53.02	84.29	0.97
2	4	5839	M	3979	24	2.9435	0.4732	1.04	15925	86.6	18392	40421			
2	4	5851	F	3980	24	1.6575	0.5186	1.04	26739	86.9	30779	61725	45.64	72.55	0.85
2	4	5851	F	3981	24	1.6575	0.4938	1.04	25011	87.0	28736	60521			
2	4	5852	F	3982	24	1.9539	0.4769	1.04	25697	86.7	29657	64674	57.77	91.84	1.05
2	4	5852	F	3983	24	1.9539	0.4994	1.04	27617	86.3	31981	66600			
2	4	5857	F	3984	24	2.3952	0.5254	1.04	17584	87.0	20215	40014	42.29	67.23	0.77
2	4	5857	F	3985	24	2.3952	0.4903	1.04	15639	86.4	18097	38386			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
2	4	5861	F	3986	24	3.3036	0.4803	1.04	53801	86.6	62144	134561	193.20	307.13	3.55
2	4	5861	F	3987	24	3.3036	0.5166	1.04	53761	86.5	62139	125095			
2	5	5720	M	3988	24	1.3676	0.4606	1.04	33827	87.0	38876	87780	54.89	87.27	1.01
2	5	5720	M	3989	24	1.3676	0.4981	1.04	37349	86.2	43314	90437			
2	5	5720	M	4000	48	1.3908	0.4753	1.05	27448	86.0	31928	70534	44.00	69.94	0.81
2	5	5720	M	4001	48	1.3908	0.4670	1.05	26672	85.8	31099	69923			
2	5	5828	M	3990	24	2.0416	0.5369	1.04	15163	86.9	17452	33804	31.73	50.45	0.58
2	5	5828	M	3991	24	2.0416	0.5312	1.04	15730	87.5	17985	35211			
2	5	5828	M	4002	48	1.7181	0.4717	1.05	13848	85.6	16171	35996	28.12	44.70	0.51
2	5	5828	M	4003	48	1.7181	0.4924	1.05	14687	85.4	17197	36671			
2	5	5840	M	3992	24	4.4655	0.5416	1.04	14101	86.2	16365	31425	61.96	98.50	1.14
2	5	5840	M	3993	24	4.4655	0.5580	1.04	14031	86.6	16195	30184			
2	5	5840	M	4004	48	4.3958	0.4611	1.05	15023	86.2	17438	39708	76.19	121.12	1.40
2	5	5840	M	4005	48	4.3958	0.4811	1.05	14788	86.6	17067	37249			
2	5	5848	F	3994	24	2.2392	0.5267	1.04	14744	86.2	17100	33765	34.57	54.95	0.63
2	5	5848	F	3995	24	2.2392	0.5200	1.04	14997	86.3	17388	34776			
2	5	5848	F	4006	48	2.9830	0.4941	1.05	11549	86.4	13370	28412	38.63	61.41	0.71
2	5	5848	F	4007	48	2.9830	0.4985	1.05	11895	86.1	13811	29090			
2	5	5854	F	3996	24	3.9621	0.5158	1.04	22123	86.1	25696	51809	95.19	151.32	1.75
2	5	5854	F	3997	24	3.9621	0.5035	1.04	22851	86.0	26559	54859			
2	5	5854	F	4008	48	2.8967	0.5012	1.05	107122	86.6	123663	259069	316.41	503.01	5.83
2	5	5854	F	4009	48	2.8967	0.5045	1.05	94277	86.8	108551	225924			
2	5	5862	F	3998	24	4.7392	0.4453	1.04	6414	85.7	7487	17485	37.67	59.89	0.69
2	5	5862	F	3999	24	4.7392	0.4638	1.04	6828	86.0	7942	17808			
2	5	5862	F	4010	48	2.1222	0.4965	1.05	17677	86.7	20399	43140	41.79	66.43	0.76
2	5	5862	F	4011	48	2.1222	0.4626	1.05	16889	86.6	19514	44292			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	1	5723	M	4012	3	0.4665	0.4371	1.03	95212	86.3	110331	259987	54.63	260.55	1.03
3	1	5733	M	4013	3	0.3538	0.2870	1.03	64297	85.0	75626	271409	43.25	206.29	0.81
3	1	5736	M	4014	3	0.4227	0.3822	1.03	80849	86.0	94014	253362	48.24	230.07	0.90
3	1	5741	F	4015	3	0.4997	0.4703	1.03	73751	86.9	84882	185899	41.84	199.56	0.78
3	1	5744	F	4016	3	0.2990	0.2736	1.03	149898	85.4	175573	660964	89.02	424.56	1.65
3	1	5762	F	4017	3	0.2153	0.2019	1.03	74554	85.1	87588	446836	43.34	206.67	0.81
3	2	5722	M	4018	6	0.3429	0.3303	1.03	153972	86.2	178620	557005	86.03	410.31	1.62
3	2	5734	M	4019	6	0.6263	0.3057	1.03	106003	85.6	123834	417235	118.71	566.16	2.22
3	2	5734	M	4020	6	0.6263	0.2731	1.03	96501	85.8	112513	424345			
3	2	5737	M	4021	6	0.7176	0.3331	1.03	144415	86.0	168005	519500	166.65	794.76	3.14
3	2	5737	M	4022	6	0.7176	0.3453	1.03	147618	86.1	171505	511585			
3	2	5746	F	4023	6	0.1573	0.1316	1.03	48142	85.9	56062	438786	31.09	148.28	0.61
3	2	5751	F	4024	6	0.3451	0.3095	1.03	92863	86.6	107288	357048	55.50	264.70	1.05
3	2	5761	F	4025	6	0.3493	0.3158	1.03	55838	86.0	64913	211716	33.31	158.87	0.62
3	3	5716	M	4026	12	1.0188	0.4895	1.03	186009	86.2	215913	454321	206.06	982.71	3.94
3	3	5716	M	4027	12	1.0188	0.4738	1.03	176265	86.4	204093	443681			
3	3	5717	M	4028	12	0.7597	0.2929	1.03	39666	85.5	46372	163068	53.75	256.33	1.00
3	3	5717	M	4029	12	0.7597	0.4220	1.03	53326	86.2	61889	151056			
3	3	5726	M	4030	12	0.8044	0.3600	1.03	127442	85.7	148787	425696	159.31	759.78	2.96
3	3	5726	M	4031	12	0.8044	0.3933	1.03	149338	86.2	173222	453645			
3	3	5739	F	4032	12	1.0581	0.4686	1.03	175113	86.6	202118	444262	215.82	1029.29	4.04
3	3	5739	F	4033	12	1.0581	0.4901	1.03	190549	86.8	219530	461366			
3	3	5750	F	4034	12	0.3128	0.2844	1.03	132459	86.1	153928	557476	78.55	374.61	1.46
3	3	5752	F	4035	12	0.9578	0.4404	1.03	149488	86.1	173588	405985	179.99	858.42	3.38
3	3	5752	F	4036	12	0.9578	0.4495	1.03	160389	85.8	186956	428397			
3	4	5724	M	4037	24	1.5606	0.5258	1.02	87516	87.1	100434	194832	135.93	648.28	2.54
3	4	5724	M	4038	24	1.5606	0.5501	1.02	89302	86.3	103495	191902			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	4	5725	M	4039	24	2.0625	0.5102	1.02	84560	86.8	97455	194833	173.60	827.94	3.25
3	4	5725	M	4040	24	2.0625	0.5387	1.02	81656	86.4	94476	178886			
3	4	5727	M	4041	24	2.4404	0.5237	1.02	31905	86.3	36952	71971	81.37	388.08	1.51
3	4	5727	M	4042	24	2.4404	0.5327	1.02	34307	86.3	39731	76077			
3	4	5735	M	4043	24	2.6569	0.5478	1.02	95933	86.1	111371	207371	250.08	1192.69	4.70
3	4	5735	M	4044	24	2.6569	0.5554	1.02	98699	86.1	114646	210548			
3	4	5740	F	4045	24	1.7465	0.5176	1.02	108592	85.9	126344	248978	193.47	922.67	3.67
3	4	5740	F	4046	24	1.7465	0.5340	1.02	110182	86.7	127143	242858			
3	4	5742	F	4047	24	1.0720	0.4836	1.02	97517	86.5	112679	237660	110.20	525.54	2.06
3	4	5742	F	4048	24	1.0720	0.5403	1.02	100317	86.6	115871	218745			
3	4	5753	F	4049	24	1.3606	0.5233	1.02	100447	86.5	116070	226240	137.81	657.23	2.58
3	4	5753	F	4050	24	1.3606	0.5365	1.02	100989	85.9	117537	223463			
3	4	5756	F	4051	24	1.1481	0.5156	1.02	90186	86.2	104669	207064	107.76	513.93	2.00
3	4	5756	F	4052	24	1.1481	0.5071	1.02	89766	86.1	104240	209673			
3	5	5721	M	4053	24	2.6345	0.5021	1.02	79665	86.3	92287	187478	221.61	1056.91	4.24
3	5	5721	M	4054	24	2.6345	0.5111	1.02	80440	86.3	93207	186013			
3	5	5721	M	4065	48	2.3558	0.5063	1.05	14044	86.3	16269	33739	39.16	186.78	0.75
3	5	5721	M	4066	48	2.3558	0.5265	1.05	17262	85.9	20095	40076			
3	5	5728	M	4055	24	2.2592	0.5494	1.02	91828	86.3	106413	197563	193.66	923.62	3.65
3	5	5728	M	4056	24	2.2592	0.5443	1.02	84336	86.3	97678	183045			
3	5	5728	M	4067	48	2.0928	0.5170	1.05	40017	85.3	46919	95291	87.46	417.11	1.65
3	5	5728	M	4068	48	2.0928	0.5221	1.05	38302	85.3	44881	90261			
3	5	5732	M	4057	24	0.8371	0.4044	1.02	113727	86.0	132226	333508	127.23	606.79	2.35
3	5	5732	M	4058	24	0.8371	0.4207	1.02	120879	85.9	140785	341337			
3	5	5732	M	4069	48	0.7406	0.3484	1.05	27910	85.7	32584	98202	33.06	157.66	0.61
3	5	5732	M	4070	48	0.7406	0.3837	1.05	31420	86.0	36538	99987			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
3	5	5738	F	4059	24	1.8450	0.5090	1.02	53590	86.6	61902	124047	102.90	490.73	1.91
3	5	5738	F	4060	24	1.8450	0.5096	1.02	53514	86.7	61739	123575			
3	5	5738	F	4071	48	2.7828	0.5349	1.05	43255	86.1	50248	98635	122.65	584.93	2.28
3	5	5738	F	4072	48	2.7828	0.5408	1.05	42910	85.8	49987	97053			
3	5	5758	F	6327	24	2.7753	0.5168	1.04	99448	86.8	114503	230424	278.16	1326.60	5.24
3	5	5758	F	6328	24	2.7753	0.5198	1.04	93262	87.0	107252	214586			
3	5	5758	F	4073	48	3.5530	0.5037	1.05	47820	85.6	55846	116416	189.96	905.95	3.58
3	5	5758	F	4074	48	3.5530	0.5231	1.05	51897	86.1	60264	120967			
3	5	5760	F	4063	24	1.5753	0.5364	1.02	137785	85.9	160375	304963	214.35	1022.29	4.16
3	5	5760	F	4064	24	1.5753	0.5463	1.02	138452	86.4	160246	299196			
3	5	5760	F	4075	48	1.7043	0.5325	1.05	32527	85.9	37850	74635	54.68	260.77	1.06
3	5	5760	F	4076	48	1.7043	0.5522	1.05	30658	86.0	35664	67814			
4	NA	5714	M	4077	24	2.1515	0.5220	1.05	28313	85.9	32940	66258	63.36	297.52	1.30
4	NA	5714	M	4078	24	2.1515	0.5170	1.05	27345	86.1	31757	64496			
4	NA	5718	M	4079	24	2.5486	0.5320	1.05	23310	86.0	27115	53516	67.36	316.29	1.36
4	NA	5718	M	4080	24	2.5486	0.5240	1.05	27391	86.0	31853	63827			
4	NA	5719	M	4081	24	2.1663	0.5274	1.05	29557	86.4	34219	68127	61.24	287.58	1.26
4	NA	5719	M	4082	24	2.1663	0.5229	1.05	24631	86.2	28581	57392			
4	NA	5730	M	4083	24	2.5857	0.5138	1.05	17050	85.4	19958	40785	51.46	241.66	1.04
4	NA	5730	M	4084	24	2.5857	0.5295	1.05	20674	86.2	23996	47584			
4	NA	5743	F	4085	24	1.7958	0.5284	1.05	43232	85.9	50353	100057	77.70	364.85	1.58
4	NA	5743	F	4086	24	1.7958	0.5106	1.05	38292	85.6	44759	92042			
4	NA	5745	F	4087	24	2.3625	0.5288	1.05	32846	86.2	38107	75666	79.40	372.83	1.59
4	NA	5745	F	4088	24	2.3625	0.5369	1.05	32405	86.2	37608	73549			
4	NA	5748	F	4089	24	2.9597	0.5285	1.05	20016	86.3	23181	46056	65.12	305.78	1.32
4	NA	5748	F	4090	24	2.9597	0.5314	1.05	22564	86.4	26129	51629			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
4	NA	5754	F	4091	24	3.3191	0.5338	1.05	56783	86.0	66012	129848	181.95	854.41	3.64
4	NA	5754	F	4092	24	3.3191	0.5366	1.05	50118	86.4	58030	113552			
5	1	5871	M	5152	Pool	51.5554	0.4871	1.05	31745	86.6	36678	79064	1792.80	2145.92	6.24
5	1	5871	M	5153	Pool	51.5554	0.4908	1.05	30426	86.4	35213	75333			
5	1	5871	M	5990	Day 14	4.6475	0.4954	1.04	12927	88.4	14627	30708	63.44	75.93	0.22
5	1	5871	M	5991	Day 14	4.6475	0.4934	1.04	12284	86.6	14184	29897			
5	1	5883	M	5154	Pool	64.2197	0.4922	1.05	33166	86.4	38399	81915	2402.70	2875.95	8.18
5	1	5883	M	5155	Pool	64.2197	0.4822	1.05	33298	86.1	38669	84202			
5	1	5883	M	5992	Day 14	4.9149	0.4999	1.04	11507	86.7	13277	27621	60.45	72.36	0.21
5	1	5883	M	5993	Day 14	4.9149	0.5023	1.04	11313	86.8	13037	26993			
5	1	5884	M	5156	Pool	65.1958	0.4930	1.05	14950	86.4	17305	36856	1028.33	1230.88	3.50
5	1	5884	M	5157	Pool	65.1958	0.4925	1.05	13401	86.1	15561	33176			
5	1	5884	M	6308	Day 14	4.5441	0.5041	1.04	15186	86.7	17525	36156	72.86	87.21	0.25
5	1	5884	M	6309	Day 14	4.5441	0.5086	1.04	14781	86.3	17134	35037			
5	1	5889	M	5158	Pool	48.9094	0.5059	1.05	14499	86.6	16742	34748	790.42	946.11	2.73
5	1	5889	M	5159	Pool	48.9094	0.5020	1.05	15280	86.4	17692	37006			
5	1	5889	M	6310	Day 14	4.9182	0.5124	1.04	7696	86.4	8910	18084	40.52	48.50	0.14
5	1	5889	M	6311	Day 14	4.9182	0.5213	1.04	8014	86.4	9271	18496			
5	1	5896	F	6288	Pool	68.7316	0.5221	1.04	18880	86.2	21899	43621	1348.45	1614.05	4.60
5	1	5896	F	6289	Pool	68.7316	0.5282	1.04	19053	86.3	22087	43488			
5	1	5896	F	5998	Day 14	3.9385	0.4961	1.04	3607	86.6	4166	8733	16.72	20.02	0.06
5	1	5896	F	5999	Day 14	3.9385	0.4914	1.04	4136	86.5	4782	10120			
5	1	5899	F	5162	Pool	60.7448	0.5091	1.05	22789	86.5	26349	54345	1536.94	1839.67	5.20
5	1	5899	F	5163	Pool	60.7448	0.5130	1.05	24349	85.9	28334	57995			
5	1	5899	F	6000	Day 14	4.3769	0.4881	1.04	9139	86.6	10558	22496	46.18	55.28	0.16
5	1	5899	F	6001	Day 14	4.3769	0.5019	1.04	10226	87.0	11751	24351			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	1	5900	F	5164	Pool	59.0508	0.5033	1.05	19106	86.2	22164	46240	1264.02	1512.99	4.26
5	1	5900	F	5165	Pool	59.0508	0.4957	1.05	19817	86.0	23039	48801			
5	1	5900	F	6002	Day 14	4.9988	0.5038	1.04	6430	87.2	7375	15224	33.41	39.99	0.11
5	1	5900	F	6003	Day 14	4.9988	0.4998	1.04	6015	86.6	6946	14453			
5	1	5921	F	5166	Pool	64.9536	0.5170	1.05	36606	86.2	42490	86295	2607.88	3121.54	8.80
5	1	5921	F	5167	Pool	64.9536	0.5077	1.05	38187	85.9	44470	91970			
5	1	5921	F	6004	Day 14	5.3406	0.5097	1.04	8974	86.6	10360	21138	50.67	60.65	0.17
5	1	5921	F	6005	Day 14	5.3406	0.5001	1.04	8732	86.5	10092	20986			
5	2	5869	M	5168	Pool	132.2795	0.5059	1.03	10605	86.2	12297	25036	1465.62	1754.30	2.51
5	2	5869	M	5169	Pool	132.2795	0.4938	1.03	10002	86.4	11582	24158			
5	2	5869	M	5813	Day 28	3.8475	0.5315	1.05	7755	85.9	9026	17831	31.59	37.81	0.05
5	2	5869	M	5814	Day 28	3.8475	0.5229	1.05	8061	86.9	9276	18626			
5	2	5870	M	5170	Pool	113.0380	0.5103	1.03	6707	86.2	7786	15715	865.34	1035.78	1.48
5	2	5870	M	5171	Pool	113.0380	0.5086	1.03	7787	86.3	9024	18275			
5	2	5870	M	5815	Day 28	3.4952	0.5255	1.05	5728	87.1	6577	13142	20.30	24.30	0.03
5	2	5870	M	5816	Day 28	3.4952	0.5080	1.05	5307	86.7	6120	12649			
5	2	5888	M	5172	Pool	133.7225	0.5206	1.03	10718	86.0	12458	24648	1624.30	1944.23	2.78
5	2	5888	M	5173	Pool	133.7225	0.5220	1.03	12754	85.9	14841	29284			
5	2	5888	M	5817	Day 28	3.0932	0.5320	1.05	6897	86.9	7941	15672	21.83	26.13	0.04
5	2	5888	M	5818	Day 28	3.0932	0.5273	1.05	6771	86.1	7868	15667			
5	2	5893	M	5174	Pool	102.1064	0.5005	1.03	19365	86.2	22454	46210	2121.23	2539.04	3.62
5	2	5893	M	5175	Pool	102.1064	0.4925	1.03	18929	86.0	22009	46030			
5	2	5893	M	5819	Day 28	2.3827	0.5241	1.05	11179	86.7	12888	25821	29.76	35.62	0.05
5	2	5893	M	5820	Day 28	2.3827	0.5283	1.05	12886	86.4	14909	29632			
5	2	5910	F	5176	Pool	111.7635	0.5014	1.03	12109	86.2	14054	28871	1576.12	1886.57	2.69
5	2	5910	F	5177	Pool	111.7635	0.5024	1.03	14153	86.0	16459	33744			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5910	F	6314	Day 28	3.6514	0.5277	1.04	16631	86.7	19186	37813	57.15	68.41	0.10
5	2	5910	F	6315	Day 28	3.6514	0.5197	1.04	13682	86.4	15832	31683			
5	2	5911	F	5178	Pool	124.9713	0.4876	1.03	14390	86.2	16698	35273	1879.92	2250.20	3.18
5	2	5911	F	5179	Pool	124.9716	0.4812	1.03	12683	86.1	14724	31517			
5	2	5911	F	5823	Day 28	3.1269	0.5105	1.05	6757	86.3	7829	16104	24.24	29.01	0.04
5	2	5911	F	5824	Day 28	3.1269	0.5347	1.05	8062	86.4	9325	18313			
5	2	5915	F	5180	Pool	100.3572	0.5075	1.03	24233	86.3	28063	56956	2630.80	3148.99	4.45
5	2	5915	F	5181	Pool	100.3572	0.5135	1.03	25511	86.1	29631	59435			
5	2	5915	F	5825	Day 28	3.0891	0.5127	1.05	7092	86.6	8194	16781	23.50	28.12	0.04
5	2	5915	F	5826	Day 28	3.0891	0.5138	1.05	7195	86.5	8314	16991			
5	2	5916	F	5182	Pool	127.0427	0.4993	1.03	26361	86.1	30601	63126	3534.51	4230.70	5.98
5	2	5916	F	5183	Pool	127.0427	0.4879	1.03	24696	86.3	28612	60402			
5	2	5916	F	5827	Day 28	4.5066	0.5230	1.05	7101	86.4	8221	16505	32.62	39.05	0.06
5	2	5916	F	5828	Day 28	4.5066	0.5122	1.05	6600	86.5	7628	15636			
6	1	5867	M	5184	Pool	74.3124	0.5203	1.03	60701	86.5	70205	138980	4755.56	18974.17	16.33
6	1	5867	M	5185	Pool	74.3124	0.5185	1.03	62952	86.2	73070	145154			
6	1	5867	M	6006	Day 14	3.5367	0.5049	1.04	9831	86.8	11324	23326	37.00	147.63	0.13
6	1	5867	M	6007	Day 14	3.5367	0.5051	1.04	9719	86.5	11231	23125			
6	1	5868	M	5186	Pool	59.3191	0.5219	1.03	19566	86.7	22559	44521	1152.94	4600.09	3.99
6	1	5868	M	5187	Pool	59.3191	0.5145	1.03	17986	86.2	20867	41775			
6	1	5868	M	6008	Day 14	4.2728	0.5082	1.04	5780	87.0	6643	13594	26.08	104.06	0.09
6	1	5868	M	6009	Day 14	4.2728	0.4963	1.04	5590	86.7	6445	13507			
6	1	5875	M	5188	Pool	49.8989	0.5099	1.03	13811	86.3	16001	32321	694.23	2769.91	2.39
6	1	5875	M	5189	Pool	49.8989	0.5221	1.03	12866	86.2	14929	29452			
6	1	5875	M	6306	Day 14	3.9268	0.5159	1.04	8596	86.5	9940	20038	35.55	141.83	0.12
6	1	5875	M	6307	Day 14	3.9268	0.5165	1.04	8624	86.2	10010	20156			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	1	5881	M	6286	Pool	52.1811	0.5319	1.04	9181	86.3	10634	20793	473.23	1888.12	1.64
6	1	5881	M	6287	Pool	52.1811	0.5298	1.04	8583	86.5	9920	19473			
6	1	5881	M	6012	Day 14	3.3425	0.5059	1.04	8433	86.6	9740	20023	30.18	120.42	0.10
6	1	5881	M	6013	Day 14	3.3425	0.5155	1.04	8609	86.6	9946	20066			
6	1	5895	F	5192	Pool	61.8500	0.5222	1.03	14125	86.2	16381	32310	847.75	3382.43	2.91
6	1	5895	F	5193	Pool	61.8500	0.5122	1.03	12231	86.2	14196	28547			
6	1	5895	F	6312	Day 14	2.8200	0.5107	1.04	37471	86.7	43241	88056	116.17	463.49	0.40
6	1	5895	F	6313	Day 14	2.8200	0.5039	1.04	39790	86.6	45954	94845			
6	1	5907	F	5194	Pool	45.2936	0.5316	1.03	22721	86.0	26414	51177	1078.20	4301.92	3.69
6	1	5907	F	5195	Pool	45.2936	0.5223	1.03	23853	86.3	27644	54516			
6	1	5907	F	6016	Day 14	2.6281	0.5140	1.04	15905	86.6	18368	37166	40.89	163.13	0.14
6	1	5907	F	6017	Day 14	2.6281	0.5104	1.04	13603	86.9	15659	31907			
6	1	5909	F	5196	Pool	54.4849	0.5421	1.03	33110	86.1	38464	73081	1795.72	7164.72	6.08
6	1	5909	F	5197	Pool	54.4849	0.5197	1.03	31752	85.9	36961	73253			
6	1	5909	F	6018	Day 14	3.0369	0.5076	1.04	10495	86.6	12114	24820	33.70	134.46	0.11
6	1	5909	F	6019	Day 14	3.0369	0.5064	1.04	10315	86.7	11905	24449			
6	1	5918	F	5198	Pool	65.8794	0.5042	1.03	21241	86.8	24467	49982	1524.27	6081.66	4.87
6	1	5918	F	5199	Pool	65.8794	0.5255	1.03	23275	86.5	26911	52747			
6	1	5918	F	6020	Day 14	5.0572	0.5146	1.04	5371	86.4	6219	12568	27.85	111.11	0.09
6	1	5918	F	6021	Day 14	5.0572	0.5011	1.04	4978	86.9	5724	11881			
6	2	5880	M	5200	Pool	126.1011	0.5302	1.04	8888	86.5	10275	20154	1120.24	4469.63	1.92
6	2	5880	M	5201	Pool	126.1011	0.5382	1.04	8600	86.2	9982	19289			
6	2	5880	M	5829	Day 28	4.3652	0.5082	1.05	8888	86.6	10268	21214	39.30	156.79	0.07
6	2	5880	M	5830	Day 28	4.3652	0.5169	1.05	7967	86.3	9233	18756			
6	2	5885	M	6298	Pool	114.0523	0.5178	1.04	23589	86.2	27382	54996	2627.14	10482.00	4.49
6	2	5885	M	6299	Pool	114.0523	0.5131	1.04	20194	86.6	23325	47277			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
6	2	5885	M	5831	Day 28	3.6602	0.5462	1.05	6991	86.6	8075	15523	25.65	102.35	0.04
6	2	5885	M	5832	Day 28	3.6602	0.5418	1.05	7109	88.3	8047	15595			
6	2	5887	M	5204	Pool	122.0257	0.5045	1.04	15904	86.1	18472	38080	2216.38	8843.13	3.78
6	2	5887	M	5205	Pool	122.0257	0.5254	1.04	18604	86.5	21504	42565			
6	2	5887	M	5833	Day 28	4.4874	0.5235	1.05	8149	86.8	9388	18831	36.42	145.32	0.06
6	2	5887	M	5834	Day 28	4.4874	0.5288	1.05	7472	86.2	8665	17206			
6	2	5894	M	5206	Pool	107.7122	0.5222	1.04	17763	86.4	20551	40928	1902.38	7590.28	3.24
6	2	5894	M	5207	Pool	107.7122	0.5379	1.04	16729	86.3	19390	37490			
6	2	5894	M	5835	Day 28	4.0653	0.5290	1.05	9331	86.4	10801	21439	37.85	151.04	0.06
6	2	5894	M	5836	Day 28	4.0653	0.5136	1.05	8411	86.4	9736	19904			
6	2	5903	F	6302	Pool	128.4412	0.5283	1.04	25561	86.0	29715	58496	3371.27	13450.99	5.71
6	2	5903	F	6303	Pool	128.4412	0.5270	1.04	25420	86.4	29412	58043			
6	2	5903	F	5837	Day 28	5.4258	0.5272	1.05	9400	86.2	10910	21728	52.16	208.12	0.09
6	2	5903	F	5838	Day 28	5.4258	0.5306	1.05	9188	86.8	10591	20957			
6	2	5912	F	5210	Pool	171.4577	0.5307	1.04	12282	86.3	14232	27891	2087.30	8328.12	3.54
6	2	5912	F	5211	Pool	171.4577	0.5322	1.04	11526	86.1	13388	26161			
6	2	5912	F	5839	Day 28	3.8159	0.5074	1.05	7773	86.7	8961	18545	30.27	120.79	0.05
6	2	5912	F	5840	Day 28	3.8159	0.5219	1.05	7154	86.3	8291	16681			
6	2	5917	F	5212	Pool	131.2308	0.5256	1.04	13663	86.7	15752	31168	1920.72	7663.45	3.28
6	2	5917	F	5213	Pool	131.2308	0.5224	1.04	14656	86.3	16986	33816			
6	2	5917	F	5841	Day 28	6.8229	0.5187	1.05	6287	86.9	7235	14645	43.94	175.31	0.07
6	2	5917	F	5842	Day 28	6.8229	0.5478	1.05	6259	86.0	7277	13948			
6	2	5919	F	5214	Pool	137.6597	0.5167	1.04	11052	86.3	12814	25792	1676.29	6688.21	2.83
6	2	5919	F	5215	Pool	137.6597	0.5259	1.04	12268	85.8	14297	28274			
6	2	5919	F	5843	Day 28	5.7065	0.5261	1.05	4922	86.3	5705	11386	30.78	122.80	0.05
6	2	5919	F	5844	Day 28	5.7065	0.5161	1.05	5334	86.4	6174	12561			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5872	M	5216	Pool	56.0180	0.5206	1.03	24785	86.8	28558	56501	1503.67	17998.42	5.32
7	1	5872	M	5217	Pool	56.0180	0.5191	1.03	27319	86.5	31590	62680			
7	1	5872	M	6022	Day 14	3.6837	0.5203	1.05	26528	87.4	30355	61258	106.59	1275.84	0.38
7	1	5872	M	6023	Day 14	3.6837	0.5009	1.05	27803	86.7	32065	67215			
7	1	5873	M	5218	Pool	48.4773	0.5243	1.03	46215	87.2	52976	104072	2516.27	30118.93	8.90
7	1	5873	M	5219	Pool	48.4773	0.5100	1.03	54228	86.7	62582	126391			
7	1	5873	M	6024	Day 14	3.7624	0.5119	1.05	19845	86.7	22888	46947	78.47	939.29	0.28
7	1	5873	M	6025	Day 14	3.7624	0.5052	1.05	19157	87.2	21968	45658			
7	1	5874	M	6284	Pool	61.4091	0.5086	1.04	11795	86.5	13637	27886	799.49	9569.62	2.79
7	1	5874	M	6285	Pool	61.4091	0.5060	1.04	12538	86.1	14557	29918			
7	1	5874	M	6026	Day 14	1.5268	0.5107	1.05	27946	87.8	31837	65457	37.87	453.29	0.13
7	1	5874	M	6027	Day 14	1.5268	0.5171	1.05	19187	87.2	21999	44671			
7	1	5882	M	5222	Pool	60.7293	0.5225	1.03	13792	86.6	15918	31378	821.99	9838.98	2.92
7	1	5882	M	5223	Pool	60.7293	0.5237	1.03	12645	86.6	14602	28718			
7	1	5882	M	6028	Day 14	4.3781	0.4825	1.05	29260	86.5	33838	73637	151.24	1810.31	0.54
7	1	5882	M	6029	Day 14	4.3781	0.4941	1.05	32486	86.6	37525	79743			
7	1	5901	F	6548	Pool	62.7911	0.5087	1.07	16398	87.6	18723	39381	1082.99	12963.02	3.81
7	1	5901	F	6549	Pool	62.7911	0.5486	1.07	16695	87.5	19072	37198			
7	1	5901	F	6030	Day 14	4.9014	0.4832	1.05	13619	86.3	15772	34273	73.52	880.00	0.26
7	1	5901	F	6031	Day 14	4.9014	0.4932	1.05	13146	86.6	15184	32325			
7	1	5902	F	6292	Pool	48.0493	0.5373	1.04	31868	86.3	36926	71474	1502.85	17988.65	5.26
7	1	5902	F	6293	Pool	48.0493	0.5311	1.04	29634	86.1	34418	67397			
7	1	5902	F	6032	Day 14	2.3711	0.5126	1.05	109010	86.6	125824	257735	286.24	3426.17	1.00
7	1	5902	F	6033	Day 14	2.3711	0.4982	1.05	115118	87.2	132027	278259			
7	1	5913	F	5228	Pool	53.0897	0.5215	1.03	32162	86.6	37144	73362	1906.13	22815.71	6.62
7	1	5913	F	5229	Pool	53.0897	0.5115	1.03	36881	86.3	42733	86051			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	1	5913	F	6034	Day 14	4.3734	0.5133	1.05	23927	86.5	27658	56577	110.57	1323.47	0.38
7	1	5913	F	6035	Day 14	4.3734	0.4992	1.05	22987	86.8	26470	55675			
7	1	5920	F	6294	Pool	51.2619	0.5233	1.04	27698	86.5	32015	63626	1548.94	18540.28	5.77
7	1	5920	F	6295	Pool	51.2619	0.5178	1.04	30363	86.5	35118	70533			
7	1	5920	F	6036	Day 14	3.4048	0.5018	1.05	13469	86.8	15511	32455	48.68	582.73	0.18
7	1	5920	F	6037	Day 14	3.4048	0.5094	1.05	13026	86.5	15054	31030			
7	2	5878	M	6296	Pool	108.1988	0.5311	1.04	56061	86.8	64546	126394	5673.85	67914.17	9.85
7	2	5878	M	6297	Pool	108.1988	0.5373	1.04	47600	86.6	54988	106435			
7	2	5878	M	5845	Day 28	2.7834	0.5100	1.05	43586	86.4	50423	103812	127.93	1531.30	0.22
7	2	5878	M	5846	Day 28	2.7834	0.5017	1.05	41400	86.4	47906	100261			
7	2	5886	M	5234	Pool	103.5701	0.5091	1.03	26891	86.4	31119	62960	2865.80	34302.74	4.96
7	2	5886	M	5235	Pool	103.5701	0.5211	1.03	26207	86.5	30303	59896			
7	2	5886	M	5847	Day 28	2.3874	0.5167	1.05	26591	86.9	30601	62185	64.90	776.80	0.11
7	2	5886	M	5848	Day 28	2.3874	0.5144	1.05	24788	86.5	28663	58508			
7	2	5891	M	6300	Pool	124.1244	0.5219	1.04	22627	86.3	26204	52217	2911.28	34847.07	5.04
7	2	5891	M	6301	Pool	124.1244	0.5211	1.04	22446	86.3	26016	51921			
7	2	5891	M	6385	Day 28	3.3273	0.4958	1.04	26319	88.2	29836	62584	95.33	1141.12	0.17
7	2	5891	M	6386	Day 28	3.3273	0.5116	1.04	28053	88.2	31794	64631			
7	2	5892	M	5238	Pool	127.5106	0.5031	1.03	24074	86.4	27873	57065	3404.05	40745.36	5.88
7	2	5892	M	5239	Pool	127.5106	0.5100	1.03	26339	86.5	30434	61466			
7	2	5892	M	5851	Day 28	3.1715	0.4950	1.05	40821	86.3	47279	100288	135.89	1626.60	0.23
7	2	5892	M	5852	Day 28	3.1715	0.5046	1.05	37312	86.3	43231	89958			
7	2	5905	F	5240	Pool	129.6663	0.4954	1.03	31886	86.0	37095	77125	4465.67	53452.57	7.72
7	2	5905	F	5241	Pool	129.6663	0.4836	1.03	30783	86.5	35583	75787			
7	2	5905	F	5853	Day 28	3.8561	0.5154	1.05	43473	87.5	49685	101220	168.22	2013.53	0.29
7	2	5905	F	5854	Day 28	3.8561	0.5187	1.05	39333	86.1	45681	92472			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5906	F	5242	Pool	108.3829	0.5047	1.03	32715	86.4	37881	77307	3582.84	42885.38	6.20
7	2	5906	F	5243	Pool	108.3829	0.5097	1.03	29744	86.5	34376	69467			
7	2	5906	F	5855	Day 28	3.8086	0.4957	1.05	62923	86.3	72895	154408	280.02	3351.73	0.48
7	2	5906	F	5856	Day 28	3.8086	0.4896	1.05	69366	86.5	80216	172033			
7	2	5908	F	6304	Pool	107.6442	0.5091	1.04	19818	86.3	22967	46917	2378.88	28474.38	4.08
7	2	5908	F	6305	Pool	107.6442	0.5097	1.04	21753	86.7	25095	51205			
7	2	5908	F	5857	Day 28	3.1771	0.5079	1.05	48112	86.4	55663	115074	180.02	2154.81	0.31
7	2	5908	F	5858	Day 28	3.1771	0.4907	1.05	55126	86.4	63794	136507			
7	2	5914	F	5246	Pool	117.9921	0.5196	1.03	32275	86.0	37538	74412	3933.89	47087.34	7.02
7	2	5914	F	5247	Pool	117.9921	0.5289	1.03	32710	86.5	37803	73619			
7	2	5914	F	5859	Day 28	3.2473	0.4930	1.05	11802	86.4	13662	29097	41.45	496.19	0.07
7	2	5914	F	5860	Day 28	3.2473	0.5076	1.05	11468	86.0	13334	27583			

Analyses That Were Not Used for Calculations:

													Reason for Exclusion:
3	5	5758	F	4061	24	2.7753	0.5211	1.02	12195	85.2	14322	28034	Poor replication.
3	5	5758	F	4062	24	2.7753	0.5615	1.02	103129	86.4	119409	216913	
5	1	5884	M	5994	Day 14	4.5441	0.4947	1.04	15673	86.9	18044	37934	Poor replication.
5	1	5884	M	5995	Day 14	4.5441	0.5035	1.04	7209	86.2	8367	17283	
5	1	5889	M	5996	Day 14	4.9182	0.4942	1.04	4664	86.2	5408	11380	Poor replication.
5	1	5889	M	5997	Day 14	4.9182	0.4998	1.04	6631	87.1	7610	15836	
5	1	5896	F	5160	Pool	68.7316	0.5054	1.05	17139	86.1	19905	41354	Poor replication.
5	1	5896	F	5161	Pool	68.7316	0.4830	1.05	20442	86.2	23706	51535	

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
5	2	5910	F	5821	Day 28	3.6514	0.5219	1.05	20488	87.1	23530	47339	Poor replication.		
5	2	5910	F	5822	Day 28	3.6514	0.5031	1.05	15806	86.7	18223	38032			
6	1	5875	M	6010	Day 14	3.9268	0.4994	1.04	6361	86.8	7324	15253	Poor replication.		
6	1	5875	M	6011	Day 14	3.9268	0.5001	1.04	8342	86.7	9623	20012			
6	1	5881	M	5190	Pool	52.1811	0.5363	1.03	11460	86.4	13268	25483	Poor replication.		
6	1	5881	M	5191	Pool	52.1811	0.5163	1.03	7095	86.5	8202	16364			
6	1	5895	F	6014	Day 14	2.8200	0.4933	1.04	38989	86.8	44921	94705	Poor replication.		
6	1	5895	F	6015	Day 14	2.8200	0.4868	1.04	30985	86.7	35727	76328			
6	2	5885	M	5202	Pool	114.0523	0.5351	1.04	24858	86.5	28741	55861	Poor replication.		
6	2	5885	M	5203	Pool	114.0523	0.5229	1.04	20383	89.4	22787	45321			
6	2	5903	F	5208	Pool	128.4412	0.5361	1.04	32017	86.3	37088	71949	Poor replication.		
6	2	5903	F	5209	Pool	128.4412	0.5430	1.04	24556	86.3	28457	54504			
7	1	5874	M	5220	Pool	61.4091	0.5105	1.03	11754	86.6	13570	27379	Poor replication.		
7	1	5874	M	5221	Pool	61.4091	0.5173	1.03	14948	86.8	17223	34293			
7	1	5901	F	5224	Pool	62.7911	0.5322	1.03	14740	86.5	17042	32983	Poor replication.		
7	1	5901	F	5225	Pool	62.7911	0.5369	1.03	28902	86.3	33480	64228			
7	1	5901	F	6290	Pool	62.7911	0.5288	1.04	23322	86.2	27065	53228	Poor replication.		
7	1	5901	F	6291	Pool	62.7911	0.5293	1.04	15456	86.3	17904	35179			
7	1	5902	F	5226	Pool	48.0493	0.5143	1.03	34788	86.5	40226	80562	Poor replication.		
7	1	5902	F	5227	Pool	48.0493	0.5365	1.03	29053	86.5	33573	64456			
7	1	5920	F	5230	Pool	51.2619	0.5371	1.03	35772	86.4	41408	79409	Poor replication.		
7	1	5920	F	5231	Pool	51.2619	0.5204	1.03	27028	86.4	31294	61939			
7	2	5878	M	5232	Pool	108.1988	0.5237	1.03	48447	86.7	55854	109853	Poor replication.		
7	2	5878	M	5233	Pool	108.1988	0.5254	1.03	39422	86.5	45583	89362			
7	2	5891	M	5236	Pool	124.1244	0.5058	1.03	18568	86.3	21502	43786	Poor replication.		
7	2	5891	M	5237	Pool	124.1244	0.5105	1.03	24099	86.5	27854	56198			

TABLE F12. Liquid Scintillation Analyses of Feces Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Collect. Time (hr)	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	% of Actual Dose
7	2	5891	M	5849	Day 28	3.3273	0.5025	1.05	21693	86.5	25087	52420	Poor replication.		
7	2	5891	M	5850	Day 28	3.3273	0.5004	1.05	26996	86.4	31261	65596			
7	2	5908	F	5244	Pool	107.6442	0.4965	1.03	30953	86.8	35678	74015	Poor replication.		
7	2	5908	F	5245	Pool	107.6442	0.4933	1.03	19672	86.7	22703	47403			

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	1	5331	M	5582	29.5	0.5463	1.05	21898	86.9	25203	48440	633.51	302.1	10.24	11.66
1	1	5331	M	5583	29.5	0.5456	1.05	21275	87.3	24375	46908				
1	1	5339	M	5584	28.8	0.5438	1.05	15323	86.5	17709	34193	475.27	226.7	7.87	8.63
1	1	5339	M	5585	28.8	0.5341	1.05	17130	86.2	19877	39077				
1	1	5340	M	6261	26.3	0.5263	1.04	20981	86.1	24378	48172	594.92	283.7	10.79	11.15
1	1	5340	M	6262	26.3	0.5119	1.04	22152	86.1	25724	52262				
1	1	5355	F	5588	21.1	0.5162	1.05	11498	86.7	13267	26987	251.21	119.8	5.68	4.62
1	1	5355	F	5589	21.1	0.5335	1.05	11380	86.6	13146	25874				
1	1	5356	F	5590	22.2	0.5443	1.05	11459	87.0	13175	25415	249.49	119.0	5.36	4.56
1	1	5356	F	5591	22.2	0.5427	1.05	10987	86.8	12654	24482				
1	1	5362	F	5592	22.0	0.5021	1.05	12912	86.8	14884	31126	311.08	148.4	6.74	5.81
1	1	5362	F	5593	22.0	0.5382	1.05	14038	86.5	16225	31655				
1	2	5332	M	5594	27.7	0.5493	1.05	12268	86.9	14113	26977	335.86	160.2	5.78	6.07
1	2	5332	M	5595	27.7	0.5010	1.05	11109	86.7	12816	26859				
1	2	5342	M	6263	30.0	0.5099	1.04	7079	86.2	8212	16750	232.17	110.7	3.69	4.19
1	2	5342	M	6264	30.0	0.5203	1.04	7604	86.3	8811	17611				
1	2	5343	M	5598	28.4	0.5126	1.05	10744	87.0	12353	25304	315.88	150.6	5.30	5.73
1	2	5343	M	5599	28.4	0.5476	1.05	10878	86.6	12558	24080				
1	2	5349	F	5600	19.7	0.5487	1.05	13175	87.0	15144	28980	235.31	112.2	5.70	4.28
1	2	5349	F	5601	19.7	0.5215	1.05	10373	86.8	11947	24054				
1	2	5350	F	6265	20.7	0.5079	1.04	10265	86.8	11829	24223	220.72	105.3	5.09	4.08
1	2	5350	F	6266	20.7	0.5058	1.04	9766	86.8	11245	23121				
1	2	5363	F	6267	25.7	0.5251	1.04	7022	86.1	8158	16158	204.10	97.3	3.79	3.70
1	2	5363	F	6268	25.7	0.5271	1.04	8346	86.2	9682	19103				
1	3	5327	M	5606	26.9	0.5189	1.05	4487	86.9	5163	10448	129.23	61.6	2.29	2.35
1	3	5327	M	5607	26.9	0.5029	1.05	4515	86.6	5212	10882				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	3	5330	M	5608	27.4	0.5043	1.05	8389	86.9	9657	20107	242.16	115.5	4.22	4.43
1	3	5330	M	5609	27.4	0.5104	1.05	8050	86.6	9301	19134				
1	3	5334	M	5610	29.7	0.5177	1.05	4969	86.6	5740	11641	158.80	75.7	2.55	2.89
1	3	5334	M	5611	29.7	0.5169	1.05	5157	86.6	5956	12099				
1	3	5347	F	6506	25.0	0.5023	1.05	4273	86.6	4936	10319	122.34	58.3	2.33	2.22
1	3	5347	F	6507	25.0	0.4911	1.05	4608	86.3	5336	11409				
1	3	5348	F	5614	20.6	0.5085	1.05	5210	87.0	5990	12368	105.49	50.3	2.44	1.93
1	3	5348	F	5615	20.6	0.5148	1.05	4410	86.8	5083	10368				
1	3	5352	F	5616	20.7	0.4981	1.05	3838	86.8	4423	9323	85.39	40.7	1.97	1.54
1	3	5352	F	5617	20.7	0.5154	1.05	3817	86.5	4414	8992				
1	4	5328	M	6269	27.9	0.5334	1.04	3301	87.2	3787	7384	102.15	48.7	1.75	1.85
1	4	5328	M	6270	27.9	0.5238	1.04	3893	87.1	4468	8872				
1	4	5336	M	6271	27.5	0.5000	1.04	3544	87.2	4066	8456	109.43	52.2	1.90	2.02
1	4	5336	M	6272	27.5	0.5017	1.04	3868	87.1	4444	9212				
1	4	5344	M	5622	26.8	0.5010	1.03	2615	86.5	3024	6216	76.16	36.3	1.36	1.40
1	4	5344	M	5623	26.8	0.4922	1.03	2651	86.7	3059	6402				
1	4	5345	M	5624	24.8	0.5200	1.03	2909	86.5	3361	6658	71.62	34.2	1.38	1.29
1	4	5345	M	5625	24.8	0.5255	1.03	2732	86.9	3145	6164				
1	4	5351	F	5626	18.4	0.4971	1.03	2889	87.0	3322	6883	60.05	28.6	1.56	1.10
1	4	5351	F	5627	18.4	0.4987	1.03	3174	86.2	3684	7608				
1	4	5353	F	6275	20.9	0.5305	1.04	3549	87.1	4075	7990	81.88	39.1	1.87	1.47
1	4	5353	F	6276	20.9	0.5306	1.04	4198	87.5	4799	9406				
1	4	5359	F	5630	23.7	0.4984	1.03	3268	86.5	3776	7805	76.25	36.4	1.53	1.37
1	4	5359	F	5631	23.7	0.4979	1.03	2715	86.7	3132	6479				
1	4	5365	F	5632	21.3	0.5042	1.03	3623	86.7	4182	8543	87.18	41.6	1.95	1.59
1	4	5365	F	5633	21.3	0.5181	1.03	4218	87.1	4844	9631				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	5	5329	M	5634	30.6	0.4986	1.03	1337	86.6	1543	3188	45.24	21.6	0.71	0.84
1	5	5329	M	5635	30.6	0.5194	1.03	1476	86.7	1703	3377				
1	5	5333	M	6500	29.3	0.4945	1.05	1224	86.6	1414	3002	39.20	18.7	0.64	0.72
1	5	5333	M	6501	29.3	0.5035	1.05	1216	86.3	1409	2938				
1	5	5341	M	N/A	28.5	------See end of table for analyses.------						43.17	20.6	0.72	0.80
1	5	5341	M	N/A	28.5	------See end of table for analyses.------									
1	5	5360	F	5640	22.1	0.5005	1.03	2098	86.3	2432	5005	48.27	23.0	1.04	0.89
1	5	5360	F	5641	22.1	0.5082	1.03	2001	86.4	2315	4692				
1	5	5364	F	6504	25.2	0.4983	1.05	1893	86.3	2193	4622	56.96	27.2	1.08	1.05
1	5	5364	F	6505	25.2	0.5149	1.05	2287	86.2	2655	5414				
1	5	5366	F	5644	22.3	0.5100	1.03	3294	86.4	3812	7699	73.73	35.2	1.58	1.34
1	5	5366	F	5645	22.3	0.4975	1.03	2916	86.5	3372	6981				
2	1	5836	M	6318	27.1	0.5252	1.08	19294	85.7	22521	46311	530.27	843.0	31.11	9.76
2	1	5836	M	6319	27.1	0.5183	1.08	16908	86.8	19469	40568				
2	1	5841	M	5648	29.6	0.5131	1.04	12719	87.0	14622	29637	412.45	655.7	22.15	7.65
2	1	5841	M	5649	29.6	0.5124	1.04	13758	86.6	15879	32229				
2	1	5844	M	5650	26.4	0.5094	1.04	27844	86.9	32028	65389	731.28	1162.5	44.04	13.44
2	1	5844	M	5651	26.4	0.5006	1.04	24191	87.3	27725	57599				
2	1	5853	F	N/A	20.1	------See end of table for analyses.------						619.14	984.3	48.97	11.30
2	1	5853	F	N/A	20.1	------See end of table for analyses.------									
2	1	5855	F	5654	21.6	0.5219	1.04	21801	87.1	25024	49867	465.90	740.7	34.29	8.91
2	1	5855	F	5655	21.6	0.4984	1.04	19151	87.1	21998	45902				
2	1	5863	F	6324	22.0	0.5225	1.08	21439	86.7	24723	51103	508.60	808.5	36.75	9.31
2	1	5863	F	6325	22.0	0.5184	1.08	21491	86.9	24740	51543				
2	2	5832	M	6510	24.5	0.5168	1.05	14207	86.9	16351	33220	346.77	551.3	22.50	6.42
2	2	5832	M	6511	24.5	0.5164	1.05	12633	86.7	14568	29622				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	2	5834	M	5660	26.8	0.4978	1.04	9680	86.7	11161	23316	267.61	425.4	15.87	4.93
2	2	5834	M	5661	26.8	0.4933	1.04	8697	87.2	9970	21018				
2	2	5845	M	5662	27.3	0.5147	1.04	13566	87.3	15532	31384	403.77	641.9	23.51	7.40
2	2	5845	M	5663	27.3	0.5062	1.04	14473	86.7	16687	34284				
2	2	5846	F	5664	23.0	0.5066	1.04	14503	87.1	16644	34170	354.04	562.8	24.47	6.49
2	2	5846	F	5665	23.0	0.5125	1.04	14679	87.2	16841	34175				
2	2	5858	F	5666	22.7	0.5197	1.04	13542	86.4	15665	31348	338.33	537.8	23.69	6.20
2	2	5858	F	5667	22.7	0.5182	1.04	14986	86.4	17353	34826				
2	2	5860	F	6322	17.7	0.5072	1.08	21831	87.1	25063	53367	409.51	651.0	36.78	7.52
2	2	5860	F	6323	17.7	0.5069	1.08	20155	87.0	23166	49357				
2	3	5715	M	6569	25.7	0.4873	1.08	13948	85.8	16249	36013	407.13	647.2	25.18	7.44
2	3	5715	M	6570	25.7	0.5031	1.08	13713	85.8	15989	34324				
2	3	5831	M	5672	30.3	0.5056	1.05	7371	87.0	8474	17597	242.15	385.0	12.70	4.46
2	3	5831	M	5673	30.3	0.4969	1.05	7375	87.1	8465	17886				
2	3	5837	M	5674	27.0	0.502	1.05	7776	87.2	8913	18643	220.00	349.7	12.95	4.02
2	3	5837	M	5675	27.0	0.5108	1.05	7411	86.9	8530	17535				
2	3	5847	F	5676	23.1	0.5037	1.05	5111	87.2	5858	12211	135.46	215.3	9.32	2.46
2	3	5847	F	5677	23.1	0.499	1.05	5724	87.1	6570	13825				
2	3	5850	F	5678	19.9	0.502	1.05	21166	87.3	24242	50705	433.99	689.9	34.67	7.89
2	3	5850	F	5679	19.9	0.5032	1.05	19195	86.8	22105	46124				
2	3	5864	F	5680	21.5	0.5124	1.05	14244	87.3	16326	33454	330.40	525.2	24.43	6.04
2	3	5864	F	5681	21.5	0.5179	1.05	14983	87.3	17153	34776				
2	4	5713	M	6508	26.0	0.5196	1.05	5443	86.5	6294	12719	142.57	226.6	8.72	2.60
2	4	5713	M	6509	26.0	0.5276	1.05	5074	86.8	5842	11627				
2	4	5829	M	5684	23.6	0.5113	1.05	2925	87.3	3350	6880	75.58	120.1	5.09	1.34
2	4	5829	M	5685	23.6	0.5097	1.05	3104	87.1	3563	7339				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5830	M	6389	24.4	0.5355	1.08	3516	86.7	4053	8175	98.04	155.8	6.39	1.79
2	4	5830	M	6390	24.4	0.5176	1.08	3983	86.0	4632	9664				
2	4	5839	M	5688	26.5	0.5	1.05	3395	87.2	3891	8172	92.77	147.5	5.56	1.70
2	4	5839	M	5689	26.5	0.5166	1.05	3158	87.1	3626	7371				
2	4	5851	F	6391	20.0	0.5171	1.08	7617	86.2	8843	18468	178.35	283.5	14.18	3.31
2	4	5851	F	6392	20.0	0.4974	1.08	8413	86.5	9730	21126				
2	4	5852	F	N/A	21.7	------See end of table for analyses.------						121.82	193.7	8.92	2.22
2	4	5852	F	N/A	21.7	------See end of table for analyses.------									
2	4	5857	F	6573	22.8	0.5236	1.08	5275	85.4	6178	12744	136.65	217.2	9.53	2.50
2	4	5857	F	6574	22.8	0.5177	1.08	5715	86.0	6647	13866				
2	4	5861	F	5696	16.6	0.5018	1.05	4895	86.7	5646	11815	81.09	128.9	7.77	1.49
2	4	5861	F	5697	16.6	0.4997	1.05	4078	86.8	4699	9875				
2	5	5720	M	6397	29.4	0.5121	1.08	2601	85.3	3049	6430	84.63	134.5	4.58	1.56
2	5	5720	M	6398	29.4	0.4940	1.08	2514	86.6	2905	6351				
2	5	5828	M	5700	28.1	0.5048	1.05	1605	87.3	1838	3823	52.05	82.7	2.94	0.95
2	5	5828	M	5701	28.1	0.5081	1.05	1865	87.6	2130	4401				
2	5	5840	M	5702	27.0	0.5029	1.05	1908	87.2	2187	4567	54.66	86.9	3.22	1.01
2	5	5840	M	5703	27.0	0.5097	1.05	1878	87.5	2146	4421				
2	5	5848	F	5704	21.7	0.5044	1.05	1578	87.4	1806	3759	34.20	54.4	2.51	0.63
2	5	5848	F	5705	21.7	0.5013	1.05	1356	87.7	1547	3240				
2	5	5854	F	6401	23.0	0.5117	1.08	2967	86.9	3416	7210	73.38	116.6	5.07	1.35
2	5	5854	F	6402	23.0	0.5106	1.08	2862	87.1	3288	6955				
2	5	5862	F	6575	23.3	0.4916	1.08	2332	86.1	2710	5953	65.32	103.8	4.46	1.19
2	5	5862	F	6576	23.3	0.4989	1.08	2578	85.9	3000	6494				
3	1	5723	M	6369	25.2	0.5025	1.04	10504	87.3	12030	24897	266.76	1272.2	50.48	5.03
3	1	5723	M	6370	25.2	0.4988	1.04	9262	87.4	10601	22104				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	1	5733	M	N/A	26.5	------See end of table for analyses.------						310.83	1482.4	55.94	5.80
3	1	5733	M	N/A	26.5	------See end of table for analyses.------									
3	1	5736	M	6373	27.0	0.5340	1.04	14688	88.4	16623	32374	385.04	1836.3	68.01	7.15
3	1	5736	M	6374	27.0	0.5082	1.04	13222	87.4	15121	30944				
3	1	5741	F	N/A	20.2	------See end of table for analyses.------						422.00	2012.6	99.63	7.86
3	1	5741	F	N/A	20.2	------See end of table for analyses.------									
3	1	5744	F	5718	25.6	0.5232	1.05	9279	84.9	10932	21938	258.39	1232.3	48.14	4.78
3	1	5744	F	5719	25.6	0.4955	1.05	9204	85.3	10795	22875				
3	1	5762	F	5720	20.9	0.5039	1.05	8176	85.2	9597	19998	203.79	971.9	46.50	3.80
3	1	5762	F	5721	20.9	0.5076	1.05	9660	85.8	11262	23296				
3	2	5722	M	6347	25.3	0.5170	1.04	9595	87.0	11030	22189	265.12	1264.4	49.98	4.98
3	2	5722	M	6348	25.3	0.5176	1.04	10506	86.7	12113	24338				
3	2	5734	M	5724	27.5	0.5079	1.05	8706	85.4	10197	21081	247.22	1179.0	42.87	4.63
3	2	5734	M	5725	27.5	0.5101	1.05	7859	85.9	9150	18834				
3	2	5737	M	5726	28.0	0.5073	1.05	8822	86.2	10236	21187	286.07	1364.3	48.73	5.40
3	2	5737	M	5727	28.0	0.5089	1.05	10014	85.5	11717	24176				
3	2	5746	F	5728	22.0	0.5001	1.05	16415	86.3	19013	39920	364.73	1739.4	79.07	7.18
3	2	5746	F	5729	22.0	0.4931	1.05	13637	86.2	15821	33689				
3	2	5751	F	6518	18.6	0.5101	1.05	14230	86.3	16499	33962	294.77	1405.8	75.58	5.59
3	2	5751	F	6519	18.6	0.5330	1.05	15960	86.4	18479	36403				
3	2	5761	F	6351	20.5	0.5063	1.04	12328	87.4	14101	28965	270.18	1288.5	62.86	5.07
3	2	5761	F	6352	20.5	0.5020	1.04	12400	86.9	14264	29551				
3	3	5716	M	5734	23.2	0.4838	1.04	4226	85.9	4920	10576	107.44	512.4	22.09	2.06
3	3	5716	M	5735	23.2	0.5026	1.04	4192	86.9	4826	9987				
3	3	5717	M	6417	25.7	0.4993	1.04	3092	87.9	3519	7329	84.66	403.8	15.71	1.58
3	3	5717	M	6418	25.7	0.5319	1.04	3262	87.4	3732	7297				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	3	5726	M	5738	25.7	0.5253	1.04	4545	84.9	5353	10597	113.20	539.9	21.01	2.10
3	3	5726	M	5739	25.7	0.5288	1.04	3848	84.5	4556	8959				
3	3	5739	F	5740	24.4	0.4908	1.04	2903	85.5	3395	7194	79.78	380.5	15.59	1.49
3	3	5739	F	5741	24.4	0.5215	1.04	3158	86.0	3672	7323				
3	3	5750	F	6419	21.1	0.5368	1.04	10217	88.6	11528	22334	201.10	959.1	45.45	3.73
3	3	5750	F	6420	21.1	0.5037	1.04	8493	87.8	9678	19982				
3	3	5752	F	5744	20.8	0.4834	1.04	3053	85.1	3586	7714	68.41	326.3	15.69	1.29
3	3	5752	F	5745	20.8	0.4951	1.04	2803	85.5	3280	6890				
3	4	5724	M	N/A	23.9	------See end of table for analyses.------						99.54	474.7	19.86	1.86
3	4	5724	M	N/A	23.9	------See end of table for analyses.------									
3	4	5725	M	5748	23.3	0.5232	1.02	2479	85.9	2885	5625	55.90	266.6	11.44	1.05
3	4	5725	M	5749	23.3	0.5055	1.02	2143	86.0	2492	5028				
3	4	5727	M	6353	22.7	0.5194	1.04	3262	87.3	3736	7480	80.16	382.3	16.84	1.49
3	4	5727	M	6354	22.7	0.4964	1.04	3393	86.7	3913	8198				
3	4	5735	M	6355	25.5	0.5134	1.04	5185	87.6	5922	11996	131.20	625.7	24.54	2.46
3	4	5735	M	6356	25.5	0.5144	1.04	4668	87.0	5365	10847				
3	4	5740	F	6357	19.1	0.4978	1.04	4377	86.8	5041	10531	100.36	478.6	25.06	1.91
3	4	5740	F	6358	19.1	0.4996	1.04	5321	86.6	6148	12799				
3	4	5742	F	5756	20.9	0.4967	1.02	4320	85.6	5049	10369	89.67	427.7	20.46	1.67
3	4	5742	F	5757	20.9	0.5053	1.02	3710	86.3	4301	8681				
3	4	5753	F	5758	20.0	0.4928	1.02	3196	86.3	3706	7670	65.30	311.4	15.57	1.22
3	4	5753	F	5759	20.0	0.4994	1.02	2884	86.3	3342	6826				
3	4	5756	F	N/A	18.0	------See end of table for analyses.------						88.13	420.3	23.35	1.63
3	4	5756	F	N/A	18.0	------See end of table for analyses.------									
3	5	5721	M	N/A	28.7	------See end of table for analyses.------						52.36	249.7	8.70	1.00
3	5	5721	M	N/A	28.7	------See end of table for analyses.------									

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	5	5728	M	6363	24.6	0.5006	1.04	2625	87.2	3011	6255	73.54	350.7	14.26	1.39
3	5	5728	M	6364	24.6	0.5230	1.04	3077	87.2	3529	7018				
3	5	5732	M	5766	21.9	0.4967	1.02	1459	85.7	1703	3496	33.26	158.6	7.24	0.61
3	5	5732	M	5767	21.9	0.4948	1.02	1361	86.4	1575	3246				
3	5	5738	F	5768	19.8	0.4925	1.02	2423	85.4	2839	5880	53.05	253.0	12.78	0.99
3	5	5738	F	5769	19.8	0.5055	1.02	2560	85.8	2982	6017				
3	5	5758	F	6365	19.8	0.5245	1.04	1623	87.5	1854	3676	35.21	167.9	8.48	0.66
3	5	5758	F	6366	19.8	0.4993	1.04	1765	87.2	2025	4218				
3	5	5760	F	6579	22.2	0.5152	1.08	2878	85.3	3373	7071	67.31	321.0	14.46	1.31
3	5	5760	F	6580	22.2	0.5123	1.08	2618	86.3	3031	6390				
4	NA	5714	M	5973	23.0	0.5096	1.06	4904	87.1	5630	11712	127.81	600.2	26.10	2.62
4	NA	5714	M	5974	23.0	0.5198	1.06	5543	87.2	6356	12962				
4	NA	5718	M	5975	25.7	0.5104	1.06	7473	88.5	8444	17536	187.38	879.9	34.24	3.79
4	NA	5718	M	5976	25.7	0.4906	1.06	5989	87.2	6866	14835				
4	NA	5719	M	6339	25.6	0.4910	1.04	7848	87.7	8947	18952	242.26	1137.6	44.44	4.97
4	NA	5719	M	6340	25.6	0.5166	1.04	10099	88.1	11458	23066				
4	NA	5730	M	6516	23.5	0.5268	1.05	5923	86.5	6846	13645	137.91	647.6	27.56	2.78
4	NA	5730	M	6517	23.5	0.4941	1.05	5058	86.6	5841	12412				
4	NA	5743	F	5981	18.4	0.4888	1.06	17096	87.2	19609	42524	364.94	1713.7	93.13	7.41
4	NA	5743	F	5982	18.4	0.5023	1.06	18911	87.6	21579	45537				
4	NA	5745	F	5983	19.6	0.4895	1.06	19670	86.5	22729	49219	437.13	2052.7	104.73	8.74
4	NA	5745	F	5984	19.6	0.5218	1.06	21239	86.6	24517	49805				
4	NA	5748	F	6343	24.6	0.5063	1.04	12698	86.8	14632	30056	342.14	1606.6	65.31	6.92
4	NA	5748	F	6344	24.6	0.5089	1.04	13658	88.1	15510	31696				
4	NA	5754	F	6345	19.8	0.5177	1.04	11545	87.1	13255	26627	250.50	1176.3	59.41	5.02
4	NA	5754	F	6346	19.8	0.5237	1.04	13001	87.4	14878	29545				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	1	5871	M	5486	25.7	0.5449	1.02	7571	85.8	8825	16519	208.08	249.1	9.69	0.72
5	1	5871	M	5487	25.7	0.5454	1.02	8931	86.0	10390	19430				
5	1	5883	M	5488	26.5	0.5007	1.02	5902	86.2	6846	13946	168.07	201.2	7.59	0.57
5	1	5883	M	5489	26.5	0.5004	1.02	6042	86.7	6973	14214				
5	1	5884	M	5490	22.5	0.5379	1.02	6151	86.6	7106	13475	147.70	176.8	7.86	0.50
5	1	5884	M	5491	22.5	0.5476	1.02	7257	86.3	8413	15671				
5	1	5889	M	5492	24.2	0.5078	1.02	5088	86.4	5891	11833	139.00	166.4	6.88	0.48
5	1	5889	M	5493	24.2	0.5095	1.02	5906	86.5	6828	13670				
5	1	5896	F	6379	21.4	0.5095	1.04	3729	86.8	4297	8771	84.94	101.7	4.75	0.29
5	1	5896	F	6380	21.4	0.5169	1.04	3862	87.8	4400	8852				
5	1	5899	F	6381	19.4	0.5232	1.04	6774	87.9	7706	15319	142.47	170.5	8.79	0.48
5	1	5899	F	6382	19.4	0.5023	1.04	7342	87.9	8350	17289				
5	1	5900	F	6383	21.0	0.5359	1.04	5646	87.8	6434	12487	121.58	145.5	6.93	0.41
5	1	5900	F	6384	21.0	0.5097	1.04	5708	88.1	6478	13218				
5	1	5921	F	5500	19.1	0.5132	1.02	6647	86.1	7717	15338	134.58	161.1	8.43	0.45
5	1	5921	F	5501	19.1	0.5333	1.02	7167	86.0	8338	15947				
5	2	5869	M	5502	26.7	0.4944	1.04	6407	87.8	7297	15350	185.49	222.0	8.32	0.32
5	2	5869	M	5503	26.7	0.5111	1.04	6625	87.0	7615	15496				
5	2	5870	M	5504	28.8	0.5368	1.04	5678	87.3	6505	12602	164.66	197.1	6.84	0.28
5	2	5870	M	5505	28.8	0.5061	1.04	5386	86.6	6220	12782				
5	2	5888	M	5506	27.2	0.4993	1.04	5738	86.8	6609	13765	170.49	204.1	7.50	0.29
5	2	5888	M	5507	27.2	0.5521	1.04	6471	86.7	7467	14065				
5	2	5893	M	5508	26.6	0.4515	1.04	5351	87.1	6145	14154	164.89	197.4	7.42	0.28
5	2	5893	M	5509	26.6	0.5204	1.04	5765	86.2	6689	13368				
5	2	5910	F	5510	22.6	0.5558	1.04	6414	87.6	7320	13696	137.24	164.3	7.27	0.23
5	2	5910	F	5511	22.6	0.5392	1.04	5995	87.2	6878	13267				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	2	5911	F	6409	20.8	0.5073	1.04	6084	87.1	6984	14317	126.31	151.2	7.27	0.21
5	2	5911	F	6410	20.8	0.5246	1.04	5614	88.0	6378	12644				
5	2	5915	F	5514	19.5	0.5468	1.04	9735	87.2	11168	21241	185.75	222.3	11.40	0.31
5	2	5915	F	5515	19.5	0.4935	1.04	8748	87.6	9990	21052				
5	2	5916	F	5516	20.4	0.4909	1.04	9167	86.9	10546	22342	198.61	237.7	11.65	0.34
5	2	5916	F	5517	20.4	0.4508	1.04	7927	87.6	9053	20886				
6	1	5867	M	5518	26.6	0.4977	1.04	3618	87.2	4149	8670	102.85	410.4	15.43	0.35
6	1	5867	M	5519	26.6	0.51	1.04	3650	87.6	4167	8497				
6	1	5868	M	5520	29.1	0.5534	1.04	4289	87.0	4928	9261	122.52	488.9	16.80	0.42
6	1	5868	M	5521	29.1	0.4885	1.04	3877	87.5	4431	9433				
6	1	5875	M	5522	25.0	0.5201	1.04	6478	87.4	7416	14828	169.36	675.7	27.03	0.58
6	1	5875	M	5523	25.0	0.4894	1.04	6269	87.3	7177	15251				
6	1	5881	M	5524	23.6	0.4951	1.04	5292	87.4	6053	12714	140.45	560.4	23.75	0.49
6	1	5881	M	5525	23.6	0.4956	1.04	5751	88.0	6533	13710				
6	1	5895	F	5526	22.5	0.5018	1.04	6005	87.5	6865	14228	134.90	538.2	23.92	0.46
6	1	5895	F	5527	22.5	0.5367	1.04	5621	87.9	6395	12392				
6	1	5907	F	5528	19.4	0.485	1.04	8224	87.0	9450	20264	162.21	647.2	33.36	0.55
6	1	5907	F	5529	19.4	0.513	1.04	7257	87.3	8316	16860				
6	1	5909	F	6528	19.9	0.5001	1.07	4626	88.6	5220	11169	103.57	413.2	20.76	0.35
6	1	5909	F	6529	19.9	0.4975	1.07	4886	88.0	5551	11938				
6	1	5918	F	5532	21.4	0.5094	1.04	4860	87.2	5574	11380	112.27	447.9	20.93	0.36
6	1	5918	F	5533	21.4	0.5444	1.04	5497	88.2	6236	11913				
6	2	5880	M	5534	27.8	0.4979	1.02	6111	86.8	7040	14423	189.56	756.3	27.21	0.33
6	2	5880	M	5535	27.8	0.5861	1.02	7871	86.4	9109	15852				
6	2	5885	M	5536	26.5	0.5213	1.02	5247	87.1	6024	11787	141.77	565.6	21.35	0.24
6	2	5885	M	5537	26.5	0.5338	1.02	5458	87.2	6262	11966				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
6	2	5887	M	5538	25.8	0.5403	1.02	5836	86.9	6717	12680	150.89	602.0	23.33	0.26
6	2	5887	M	5539	25.8	0.523	1.02	5918	86.9	6813	13288				
6	2	5894	M	5540	29.1	0.4881	1.02	6770	86.0	7869	16444	206.71	824.7	28.34	0.35
6	2	5894	M	5541	29.1	0.4945	1.02	6342	86.7	7318	15095				
6	2	5903	F	6542	22.5	0.5575	1.07	6321	86.8	7282	13977	141.06	562.8	25.01	0.24
6	2	5903	F	6543	22.5	0.5271	1.07	5968	87.4	6827	13858				
6	2	5912	F	6544	21.4	0.5243	1.07	3881	87.6	4429	9038	93.26	372.1	17.39	0.16
6	2	5912	F	6545	21.4	0.5493	1.07	4624	87.4	5293	10311				
6	2	5917	F	6546	22.3	0.4961	1.07	7724	87.3	8847	19082	193.20	770.9	34.57	0.33
6	2	5917	F	6547	22.3	0.4941	1.07	7779	86.9	8952	19385				
6	2	5919	F	5548	23.4	0.5064	1.02	5361	87.1	6154	12396	120.54	481.0	20.55	0.20
6	2	5919	F	5549	23.4	0.5477	1.02	4893	87.0	5625	10476				
7	1	5872	M	5550	26.7	0.5032	1.07	10131	87.1	11632	24733	285.08	3412.3	127.80	1.01
7	1	5872	M	5551	26.7	0.4986	1.07	9118	86.3	10565	22674				
7	1	5873	M	5552	24.9	0.5122	1.07	2984	85.8	3477	7264	85.58	1024.4	41.14	0.30
7	1	5873	M	5553	24.9	0.5101	1.07	3285	86.2	3812	7996				
7	1	5874	M	6530	18.9	0.5204	1.07	9834	87.4	11255	23141	197.78	2367.4	125.26	0.69
7	1	5874	M	6531	18.9	0.5235	1.07	9916	86.9	11410	23321				
7	1	5882	M	6581	22.7	0.4956	1.08	7556	86.0	8791	19157	178.62	2138.0	94.19	0.63
7	1	5882	M	6582	22.7	0.5066	1.08	6337	85.6	7402	15781				
7	1	5901	F	6583	22.8	0.5127	1.08	6866	84.5	8130	17126	177.59	2125.7	93.23	0.63
7	1	5901	F	6584	22.8	0.5144	1.08	7119	85.6	8315	17459				
7	1	5902	F	6596	16.2	0.4978	1.07	14341	86.2	16635	35755	240.26	2875.9	177.52	0.84
7	1	5902	F	6597	16.2	0.4925	1.07	11941	86.2	13852	30095				
7	1	5913	F	5562	20.3	0.5068	1.07	7930	86.5	9169	19358	187.53	2244.7	110.57	0.65
7	1	5913	F	5563	20.3	0.5304	1.07	9308	86.7	10736	21658				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
7	1	5920	F	5564	18.9	0.5384	1.07	21451	86.3	24856	49398	415.58	4974.4	263.20	1.55
7	1	5920	F	5565	18.9	0.5244	1.07	20482	86.7	23638	48232				
7	2	5878	M	6534	23.2	0.4991	1.07	8128	87.0	9344	20032	213.61	2556.9	110.21	0.37
7	2	5878	M	6535	23.2	0.5387	1.07	9086	86.6	10496	20849				
7	2	5886	M	5568	23.3	0.5125	1.08	9130	85.2	10711	22571	259.23	3102.9	133.17	0.45
7	2	5886	M	5569	23.3	0.531	1.08	11374	86.2	13190	26827				
7	2	5891	M	5570	25.3	0.5202	1.08	9727	86.4	11251	23359	248.56	2975.1	117.59	0.43
7	2	5891	M	5571	25.3	0.5305	1.08	8494	85.3	9952	20261				
7	2	5892	M	5572	25.8	0.5086	1.08	8428	85.7	9837	20889	257.40	3081.0	119.42	0.44
7	2	5892	M	5573	25.8	0.5258	1.08	9772	85.8	11396	23408				
7	2	5905	F	6536	21.3	0.5119	1.07	7245	87.3	8300	17350	151.98	1819.1	85.40	0.26
7	2	5905	F	6537	21.3	0.5214	1.07	6109	87.5	6983	14330				
7	2	5906	F	5576	21.5	0.5303	1.08	10461	85.8	12195	24836	219.36	2625.6	122.12	0.38
7	2	5906	F	5577	21.5	0.5201	1.08	8503	86.3	9855	20464				
7	2	5908	F	6538	22.8	0.5540	1.07	6724	87.2	7712	14895	151.27	1810.6	79.41	0.26
7	2	5908	F	6539	22.8	0.5157	1.07	6118	87.2	7019	14562				
7	2	5914	F	6540	21.6	0.4894	1.07	4382	87.2	5025	10987	104.06	1245.6	57.66	0.19
7	2	5914	F	6541	21.6	0.5104	1.07	4327	87.2	4962	10403				

Analyses That Were Combined for Calculation Owing to Poor Replication of Individual Analyses:

1	5	5341	M	5638	28.5	0.5065	1.03	1522	86.8	1753	3565	43.17	20.6	0.72	0.80
1	5	5341	M	5639	28.5	0.5134	1.03	1896	87.0	2180	4374				
1	5	5341	M	6279	28.5	0.5016	1.04	799	86.7	922	1911				
1	5	5341	M	6280	28.5	0.5130	1.04	1771	86.5	2048	4151				
1	5	5341	M	6502	28.5	0.5122	1.05	1516	86.5	1753	3593				
1	5	5341	M	6503	28.5	0.5417	1.05	1154	86.6	1333	2584				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	1	5853	F	5652	20.1	0.5117	1.04	28742	86.7	33137	67350	619.14	984.3	48.97	11.30
2	1	5853	F	5653	20.1	0.5092	1.04	14965	86.5	17296	35326				
2	1	5853	F	6320	20.1	0.5098	1.08	47494	86.6	54852	116203				
2	1	5853	F	6321	20.1	0.5207	1.08	24662	86.7	28457	59023				
2	1	5853	F	6512	20.1	0.5017	1.05	23858	86.6	27538	57633				
2	1	5853	F	6513	20.1	0.4950	1.05	30417	86.3	35246	74763				
2	4	5852	F	5692	21.7	0.5032	1.05	4702	88.3	5323	11106	121.82	193.7	8.92	2.22
2	4	5852	F	5693	21.7	0.5025	1.05	3757	86.9	4321	9029				
2	4	5852	F	6394	21.7	0.5009	1.08	6185	86.1	7188	15497				
2	4	5852	F	6571	21.7	0.5219	1.08	6559	86.3	7595	15717				
2	4	5852	F	6572	21.7	0.5216	1.08	4539	85.7	5294	10962				
3	1	5733	M	5712	26.5	0.5196	1.05	8228	86.5	9512	19222	310.83	1482.4	55.94	5.80
3	1	5733	M	5713	26.5	0.5585	1.05	15194	86.3	17617	33120				
3	1	5733	M	6371	26.5	0.5321	1.04	10112	87.4	11575	22623				
3	1	5733	M	6372	26.5	0.5060	1.04	14113	88.2	15996	32876				
3	1	5733	M	6524	26.5	0.5259	1.05	8170	86.3	9467	18902				
3	1	5733	M	6525	26.5	0.5305	1.05	12848	86.2	14901	29494				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	1	5741	F	5716	20.2	0.5058	1.05	15133	86.7	17455	36235	422.00	2012.6	99.63	7.86
3	1	5741	F	5717	20.2	0.5073	1.05	27789	86.5	32121	66484				
3	1	5741	F	6375	20.2	0.4991	1.04	21247	87.1	24402	50848				
3	1	5741	F	6376	20.2	0.5043	1.04	13569	87.2	15555	32078				
3	1	5741	F	6526	20.2	0.5389	1.05	18376	86.6	21225	41355				
3	1	5741	F	6527	20.2	0.5206	1.05	21963	86.4	25421	51271				
3	4	5724	M	5746	23.9	0.4919	1.02	2670	85.9	3109	6447	99.54	474.7	19.86	1.86
3	4	5724	M	5747	23.9	0.5235	1.02	2122	86.6	2451	4776				
3	4	5724	M	6514	23.9	0.5043	1.05	6258	86.9	7202	14996				
3	4	5724	M	6515	23.9	0.5116	1.05	3003	86.9	3457	7095				
3	4	5724	M	6577	23.9	0.5116	1.08	3992	85.9	4644	9804				
3	4	5724	M	6578	23.9	0.5110	1.08	5038	86.2	5847	12357				
3	4	5756	F	5760	18.8	0.5037	1.02	3121	85.4	3654	7400	88.13	420.3	22.36	1.63
3	4	5756	F	5761	18.8	0.5184	1.02	4434	85.5	5185	10202				
3	4	5756	F	6359	18.0	0.5322	1.04	1544	86.6	1783	3484				
3	4	5756	F	6360	18.0	0.5278	1.04	6352	86.9	7310	14403				
3	4	5756	F	6520	18.0	0.5056	1.05	7396	87.3	8471	17593				
3	4	5756	F	6521	18.0	0.4935	1.05	3769	85.7	4398	9357				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	5	5721	M	5762	28.7	0.5138	1.02	1824	85.4	2135	4239	52.36	249.7	8.70	1.00
3	5	5721	M	5763	28.7	0.5264	1.02	688	84.9	809	1568				
3	5	5721	M	6361	28.7	0.5407	1.04	2595	87.4	2970	5714				
3	5	5721	M	6362	28.7	0.5328	1.04	1795	86.7	2069	4039				
3	5	5721	M	6522	28.7	0.5072	1.05	1134	86.4	1313	2718				
3	5	5721	M	6523	28.7	0.5454	1.05	2684	85.8	3129	6024				

Analyses That Were Not Used for Calculations: **Reason for Exclusion:**

1	1	5340	M	5586	26.3	0.5335	1.05	16835	86.7	19421	38223	Poor duplication.
1	1	5340	M	5587	26.3	0.5239	1.05	12600	87.0	14485	29031	
1	2	5342	M	5596	30.0	0.5193	1.05	8883	86.8	10232	20689	Poor duplication.
1	2	5342	M	5597	30.0	0.5417	1.05	5741	86.4	6643	12877	
1	2	5350	F	5602	20.7	0.5279	1.05	9341	85.7	10904	21688	Poor duplication.
1	2	5350	F	5603	20.7	0.5407	1.05	14545	87.0	16720	32469	
1	2	5363	F	5604	25.7	0.5190	1.05	9965	87.4	11400	23064	Poor duplication.
1	2	5363	F	5605	25.7	0.5485	1.05	7682	86.7	8858	16956	
1	3	5347	F	5612	25.0	0.4904	1.05	4603	86.3	5334	11421	Poor duplication.
1	3	5347	F	5613	25.0	0.4958	1.05	3405	86.7	3929	8320	
1	3	5347	F	6273	25.0	0.5215	1.04	5780	87.1	6638	13238	Poor duplication.
1	3	5347	F	6274	25.0	0.5250	1.04	4223	87.1	4847	9601	
1	4	5328	M	5618	27.9	0.5286	1.03	3762	86.4	4353	8482	Poor duplication.
1	4	5328	M	5619	27.9	0.5140	1.03	1908	86.7	2202	4413	
1	4	5336	M	5620	27.5	0.5084	1.03	1984	86.6	2293	4645	Poor duplication.
1	4	5336	M	5621	27.5	0.4946	1.03	6465	86.4	7479	15575	

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
1	4	5353	F	5628	20.9	0.5113	1.03	4494	87.0	5167	10409	Poor duplication.			
1	4	5353	F	5629	20.9	0.5199	1.03	3286	86.4	3803	7534				
1	5	5333	M	5636	29.3	0.5113	1.03	1625	87.3	1862	3751	Poor duplication.			
1	5	5333	M	5637	29.3	0.5058	1.03	904	86.6	1044	2126				
1	5	5333	M	6277	29.3	0.5061	1.04	1018	86.3	1179	2422	Poor duplication.			
1	5	5333	M	6278	29.3	0.5176	1.04	809	86.6	934	1877				
1	5	5364	F	5642	25.2	0.5241	1.03	2647	86.5	3059	6012	Poor duplication.			
1	5	5364	F	5643	25.2	0.5298	1.03	2115	86.7	2441	4745				
1	5	5364	F	6281	25.2	0.5319	1.04	2432	86.3	2820	5513	Poor duplication.			
1	5	5364	F	6282	25.2	0.5366	1.04	1961	86.1	2278	4415				
2	1	5836	M	5646	27.1	0.5095	1.04	8740	87.1	10036	20485	Poor duplication.			
2	1	5836	M	5647	27.1	0.5162	1.04	38746	87.0	44533	89722				
2	1	5863	F	5656	22.0	0.5070	1.04	24481	87.1	28115	57672	Poor duplication.			
2	1	5863	F	5657	22.0	0.5029	1.04	35469	86.7	40916	84614				
2	2	5832	M	5658	24.5	0.5132	1.04	12494	87.2	14333	29046	Poor duplication.			
2	2	5832	M	5659	24.5	0.5199	1.04	18826	87.7	21467	42942				
2	2	5832	M	6316	24.5	0.5072	1.08	17641	86.1	20498	43648	Poor duplication.			
2	2	5832	M	6317	24.5	0.5388	1.08	13357	85.8	15564	31198				
2	2	5860	F	5668	17.7	0.5014	1.04	19092	86.7	22014	45661	Poor duplication.			
2	2	5860	F	5669	17.7	0.5029	1.04	15304	86.8	17630	36458				
2	3	5715	M	5670	25.7	0.5001	1.05	14819	87.4	16949	35586	Poor duplication.			
2	3	5715	M	5671	25.7	0.5032	1.05	22468	87.2	25753	53737				
2	3	5715	M	6387	25.7	0.5112	1.08	16703	86.6	19298	40770	Poor duplication.			
2	3	5715	M	6388	25.7	0.5146	1.08	34894	87.4	39910	83760				
2	4	5713	M	5682	26.0	0.4970	1.05	3503	87.6	4001	8453	Poor duplication.			
2	4	5713	M	5683	26.0	0.5059	1.05	2873	87.3	3290	6828				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
2	4	5830	M	5686	24.4	0.5114	1.05	8428	87.3	9657	19827	Poor duplication.			
2	4	5830	M	5687	24.4	0.5177	1.05	3887	86.9	4475	9075				
2	4	5851	F	5690	20.0	0.4915	1.05	11830	87.3	13544	28934	Poor duplication.			
2	4	5851	F	5691	20.0	0.4978	1.05	5428	87.0	6236	13154				
2	4	5852	F	6393	21.7	0.4942	1.08	9872	86.5	11418	24952	Eliminated by Q-test.			
2	4	5857	F	5694	22.8	0.5153	1.05	3845	87.3	4403	8972	Poor duplication.			
2	4	5857	F	5695	22.8	0.5122	1.05	5325	87.3	6099	12504				
2	4	5857	F	6395	22.8	0.5019	1.08	7445	86.5	8608	18523	Poor duplication.			
2	4	5857	F	6396	22.8	0.5210	1.08	5139	86.4	5948	12330				
2	5	5720	M	5698	29.4	0.5136	1.05	1809	87.3	2074	4239	Poor duplication.			
2	5	5720	M	5699	29.4	0.4919	1.05	1334	87.1	1532	3270				
2	5	5840	M	6399	27.0	0.4913	1.08	2466	86.3	2858	6284	Confirmatory.			
2	5	5840	M	6400	27.0	0.5359	1.08	2232	86.6	2576	5192				
2	5	5854	F	5706	23.0	0.5138	1.05	1933	87.6	2206	4507	Poor duplication.			
2	5	5854	F	5707	23.0	0.4921	1.05	2800	87.0	3217	6863				
2	5	5862	F	5708	23.3	0.5285	1.05	4036	87.9	4590	9119	Poor duplication.			
2	5	5862	F	5709	23.3	0.5121	1.05	2683	87.3	3075	6305				
2	5	5862	F	6403	23.3	0.5186	1.08	2326	86.3	2693	5609	Poor duplication.			
2	5	5862	F	6404	23.3	0.5269	1.08	2940	86.6	3396	6961				
3	1	5723	M	5710	25.2	0.5570	1.05	13007	84.9	15317	28875	Poor duplication.			
3	1	5723	M	5711	25.2	0.4984	1.05	9635	86.4	11154	23498				
3	1	5736	M	5714	27.0	0.5144	1.05	25893	87.2	29712	60648	Poor duplication.			
3	1	5736	M	5715	27.0	0.5414	1.05	13550	87.3	15527	30114				
3	2	5722	M	5722	25.3	0.4914	1.05	16578	85.0	19494	41655	Poor duplication.			
3	2	5722	M	5723	25.3	0.4999	1.05	10319	84.7	12182	25587				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
3	2	5751	F	5730	18.6	0.5278	1.05	11697	86.4	13533	26922	Poor duplication.			
3	2	5751	F	5731	18.6	0.5012	1.05	8340	86.4	9649	20214				
3	2	5751	F	6349	18.6	0.5047	1.04	29687	86.8	34187	70446	Poor duplication.			
3	2	5751	F	6350	18.6	0.5112	1.04	9283	87.0	10672	21711				
3	2	5761	F	5732	20.5	0.5187	1.05	11696	86.3	13546	27421	Poor duplication.			
3	2	5761	F	5733	20.5	0.5088	1.05	24191	86.1	28097	57983				
3	3	5717	M	5736	25.7	0.5178	1.04	4739	86.2	5500	11048	Poor duplication.			
3	3	5717	M	5737	25.7	0.5078	1.04	2796	85.9	3256	6667				
3	3	5750	F	5742	21.1	0.5089	1.04	8795	86.0	10231	20908	Poor duplication.			
3	3	5750	F	5743	21.1	0.4892	1.04	5001	86.6	5777	12282				
3	4	5727	M	5750	22.7	0.4995	1.02	5547	85.8	6465	13201	Poor duplication.			
3	4	5727	M	5751	22.7	0.4904	1.02	2902	85.8	3384	7038				
3	4	5735	M	5752	25.5	0.5128	1.02	1963	85.1	2306	4587	Poor duplication.			
3	4	5735	M	5753	25.5	0.4949	1.02	2931	85.7	3421	7050				
3	4	5740	F	5754	19.1	0.5203	1.02	6019	85.4	7046	13813	Poor duplication.			
3	4	5740	F	5755	19.1	0.5027	1.02	4105	85.3	4810	9760				
3	5	5728	M	5764	24.6	0.4997	1.02	2217	86.0	2578	5261	Poor duplication.			
3	5	5728	M	5765	24.6	0.5249	1.02	3761	85.6	4396	8543				
3	5	5758	F	5770	19.8	0.4961	1.02	1658	85.8	1933	3974	Poor duplication.			
3	5	5758	F	5771	19.8	0.5244	1.02	2509	85.8	2923	5685				
3	5	5760	F	5772	22.2	0.5022	1.02	3600	85.3	4223	8577	Poor duplication.			
3	5	5760	F	5773	22.2	0.5023	1.02	833	86.3	965	1959				
3	5	5760	F	6367	22.2	0.5280	1.04	1853	86.5	2142	4218	Poor duplication.			
3	5	5760	F	6368	22.2	0.5373	1.04	3391	87.7	3866	7483				
4	NA	5718	M	6337	25.7	0.5074	1.04	7284	87.2	8353	17120	Confirmatory.			
4	NA	5718	M	6338	25.7	0.5089	1.04	6304	87.3	7217	14749				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
4	NA	5719	M	5977	25.6	0.5162	1.06	5765	86.7	6646	13647	Poor duplication.			
4	NA	5719	M	5978	25.6	0.5171	1.06	7936	87.2	9105	18665				
4	NA	5730	M	5979	23.5	0.5153	1.06	5329	87.4	6099	12546	Poor duplication.			
4	NA	5730	M	5980	23.5	0.515	1.06	6626	86.5	7657	15760				
4	NA	5730	M	6341	23.5	0.5382	1.04	5822	87.3	6666	12881	Poor duplication.			
4	NA	5730	M	6342	23.5	0.5283	1.04	7529	86.7	8683	17093				
4	NA	5748	F	5985	24.6	0.5035	1.06	9045	87.4	10346	21782	Poor duplication.			
4	NA	5748	F	5986	24.6	0.5227	1.06	21689	87.4	24823	50339				
4	NA	5754	F	5987	19.8	0.5288	1.06	15804	86.8	18198	36478	Poor duplication.			
4	NA	5754	F	5988	19.8	0.5288	1.06	12450	86.5	14386	28837				
5	1	5883	M	6377	26.5	0.5340	1.04	6511	87.7	7427	14465	Confirmatory.			
5	1	5883	M	6378	26.5	0.4989	1.04	6648	87.3	7617	15879				
5	1	5896	F	5494	21.4	0.5419	1.02	4247	86.1	4932	9283	Poor duplication.			
5	1	5896	F	5495	21.4	0.5534	1.02	6912	86.5	7989	14725				
5	1	5899	F	5496	19.4	0.5056	1.02	6161	86.0	7163	14452	Poor duplication.			
5	1	5899	F	5497	19.4	0.5244	1.02	8215	86.1	9538	18552				
5	1	5900	F	5498	21.0	0.5326	1.02	7181	86.0	8350	15991	Poor duplication.			
5	1	5900	F	5499	21.0	0.5286	1.02	4019	86.1	4670	9012				
5	2	5888	M	6405	27.2	0.5095	1.04	6574	87.8	7489	15287	Confirmatory.			
5	2	5888	M	6406	27.2	0.5374	1.04	6996	87.6	7987	15457				
5	2	5893	M	6407	26.6	0.4914	1.04	5696	88.1	6464	13680	Confirmatory.			
5	2	5893	M	6408	26.6	0.5248	1.04	6165	87.9	7016	13904				
5	2	5911	F	5512	20.8	0.4834	1.04	5308	88.1	6026	12966	Poor duplication.			
5	2	5911	F	5513	20.8	0.4851	1.04	7031	87.7	8013	17179				
5	2	5915	F	6411	19.5	0.5375	1.04	11362	87.7	12950	25058	Confirmatory.			
5	2	5915	F	6412	19.5	0.5419	1.04	13641	87.3	15619	29975				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
5	2	5916	F	6413	20.4	0.5181	1.04	5710	87.2	6545	13139	Confirmatory.			
5	2	5916	F	6414	20.4	0.4954	1.04	6651	87.3	7617	15991				
6	1	5868	M	6415	29.1	0.5151	1.04	5209	89.0	5850	11811	Confirmatory.			
6	1	5868	M	6416	29.1	0.5140	1.04	4145	87.1	4759	9629				
6	1	5909	F	5530	19.9	0.5666	1.04	4228	86.1	4911	9015	Poor duplication.			
6	1	5909	F	5531	19.9	0.5097	1.04	5761	88.0	6546	13356				
6	2	5903	F	5542	22.5	0.4515	1.02	4981	86.9	5732	12949	Poor duplication.			
6	2	5903	F	5543	22.5	0.5085	1.02	6934	87.0	7967	15980				
6	2	5912	F	5544	21.4	0.5125	1.02	5245	86.7	6048	12037	Poor duplication.			
6	2	5912	F	5545	21.4	0.4979	1.02	3498	86.6	4040	8276				
6	2	5917	F	5546	22.3	0.5301	1.02	8686	86.4	10055	19347	Poor duplication.			
6	2	5917	F	5547	22.3	0.4928	1.02	11704	86.7	13495	27931				
7	1	5874	M	5554	18.9	0.5394	1.07	7899	86.8	9097	18046	Poor duplication.			
7	1	5874	M	5555	18.9	0.5135	1.07	10490	86.6	12110	25234				
7	1	5882	M	5556	22.7	0.5225	1.07	5540	86.4	6413	13132	Poor duplication.			
7	1	5882	M	5557	22.7	0.5009	1.07	7770	86.8	8956	19132				
7	1	5882	M	6532	22.7	0.5114	1.07	9239	87.3	10583	22143	Poor duplication.			
7	1	5882	M	6533	22.7	0.5242	1.07	7410	87.1	8508	17366				
7	1	5901	F	5558	22.8	0.5341	1.07	3194	86.5	3693	7399	Poor duplication.			
7	1	5901	F	5559	22.8	0.5464	1.07	6423	85.7	7493	14674				
7	1	5902	F	5560	16.2	0.5201	1.07	11980	86.8	13795	28380	Poor duplication.			
7	1	5902	F	5561	16.2	0.5226	1.07	9812	86.7	11320	23177				
7	1	5902	F	6585	16.2	0.4907	1.08	6553	85.9	7629	16791	Poor duplication.			
7	1	5902	F	6586	16.2	0.4885	1.08	9720	86.2	11280	24938				
7	2	5878	M	5566	23.2	0.5054	1.08	10519	85.7	12277	26236	Poor duplication.			
7	2	5878	M	5567	23.2	0.5185	1.08	7961	86.3	9219	19202				

TABLE F13. Liquid Scintillation Analyses of Carcass Samples

Grp. No.	Sub-Grp. No.	Anim. No.	Sex	Vial No.	Sample Size (g)	Aliquot Size (g)	F-Factor	cpm	Count. Eff. (%)	dpm	dpm/g	Total Activity (nCi)	Total Cmpd. (µg)	Conc. (µg/g)	% of Actual Dose
7	2	5905	F	5574	21.3	0.5106	1.08	7849	86.6	9063	19169	Poor duplication.			
7	2	5905	F	5575	21.3	0.5106	1.08	6148	86.5	7107	15032				
7	2	5908	F	5578	22.8	0.5131	1.08	8196	85.9	9543	20087	Poor duplication.			
7	2	5908	F	5579	22.8	0.5331	1.08	6391	86.1	7421	15034				
7	2	5914	F	5580	21.6	0.5301	1.08	4873	86.5	5634	11479	Poor duplication.			
7	2	5914	F	5581	21.6	0.5339	1.08	6738	86.1	7828	15836				

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix G

Analysis of Fortified Samples,

Estimation of Quantitation Limits, and Volatility Results

TABLE G1

Analysis Fortified Samples

Sample Type	Vial No.	Sample Size (g)	14C Added (dpm)	Aliquot Size (g)	14C Measured (dpm)	Sample Activity* (dpm)	Mean Recovery** (%)
Soap Wash Gauze	310	130.729	12816128 ***	0.6432	55387 ‡‡	11257204	**87.6**
	311	130.729	12816128 ***	0.6381	54650 ‡‡	11196348	
	330	132.333	12513646 †	0.6466	57604 ‡‡	11789180	**94.2**
	331	132.333	12513646 †	0.6498	57858 ‡‡	11782991	
	338	133.190	3216023 ††	0.6317	14883	3138019	**96.6**
	339	133.190	3216023 ††	0.6319	14575	3072168	
	340	132.461	6432047 †††	0.6426	29944	6172534	**95.5**
	341	132.461	6432047 †††	0.6408	29582	6114923	
Water Wash Gauze	314	129.099	1227526 ‡	0.6381	5987	1211248	**98.0**
	315	129.099	1227526 ‡	0.6390	5914	1194907	
Skin	312	6.5736	12816128 ***	0.0431	85998	13116402	**102**
	313	6.5736	12816128 ***	0.0418	83502	13131752	

$$* \text{ Sample Activity (dpm)} = \frac{^{14}\text{C Measured (dpm)}}{\text{Aliquot Size (g)}} \times \text{Sample Size (g)}$$

$$** \text{ Mean Recovery (\%)} = 100 \times \frac{\text{Mean Sample Activity (dpm)}}{^{14}\text{C Added (dpm)}}$$

*** 40 µL of 304002A1-5-1 (analysis of 9/27/99).
† 40 µL of 304002A1-5-1 (analysis of 10/1/99).
†† 100 µL of 304002A1-20-1.
††† 200 µL of 304002A1-20-1.
‡ 40 µL of 304002A1-17-1.
‡‡ Recount of 10/11/99.

TABLE G1 (cont.)

Analysis Fortified Samples

Sample Type	Vial No.	Aliquot Size (mL or g)	14C Added (dpm)	F-Factor	14C Measured (dpm)	Mean Recovery* (%)
Pipet Wash	296	0.250	10244 **	N/A	10385	**101**
	297	0.250	10244 **	N/A	10347	
Cage Wash	292	1.00	10244 **	N/A	10161	**99.6**
	293	1.00	10244 **	N/A	10237	
Urine (Low Level)	284	0.500	23724 ***	N/A	24917	**106**
	285	0.500	23724 ***	N/A	25226	
Urine (High Level)	288	0.500	623526 †	N/A	624647	**100**
	289	0.500	623526 †	N/A	622530	
Plasma	300	NR	2466 ††	N/A	2001	‡‡
	2917	0.1336	1119 †††	N/A	1156	**103**
Blood Cellular Fraction	4617	0.2501	565 ‡	1.08	524	**100**
	5143	0.2637	565 ‡	1.05	470	**87.4**
	5919	0.3712	565 ‡	1.04	523	**96.3**
Liver	4618	0.5010	565 ‡	1.08	374	**69.5**
	4619	0.5397	565 ‡	1.08	354	
	5136	0.5030	565 ‡	1.05	498	**97.6**
	5137	0.5560	565 ‡	1.05	552	
	5916	0.4976	565 ‡	1.04	532	**99.6**
	5917	0.5060	565 ‡	1.04	550	
Kidney	4620	0.4936	565 ‡	1.08	495	**94.6**
	5142	0.3321	565 ‡	1.05	529	**98.3**

$$* \text{ Mean Recovery (\%)} = 100 \times \frac{\text{Mean } ^{14}\text{C Measured (dpm)}}{^{14}\text{C Added (dpm)}} \times \text{F-Factor (if applicable)}$$

** 400 µL of 304002A1-14-1.
*** 10 µL of 304002A1-11-1.
† 250 µL of 304002A1-11-1.
†† 40 µL of 304002A1-14-1 (Analysis of 9/27/99).
††† 40 µL of 304002A1-14-1 (Analysis of 11/1/99).
‡ 100 µL of 304002A1-61-1.

‡‡ No value calculated owing to inconsistent results for fortification solution.

N/A =Not applicable.
NR =Not recorded.

TABLE G1 (cont.)

Analysis Fortified Samples

Sample Type	Vial No.	Aliquot Size (mL or g)	14C Added (dpm)	F-Factor	14C Measured (dpm)	Mean Recovery* (%)
Brain	4621	0.3959	565 **	1.08	291	**55.6**
	5141	0.3986	565 **	1.05	488	**90.7**
	5918	0.4315	565 **	1.04	532	**98.0**
Tongue	4622	0.0774	565 **	1.08	351	**67.0**
	5140	0.0425	565 **	1.05	446	**82.8**
	5914	0.0915	565 **	1.04	612	**113**
	5915	0.0776	565 **	1.04	574	**106**
Feces	4623	0.4887	565 **	1.08	463	**90.3**
	4624	0.5580	565 **	1.08	482	
	5134	0.4643	565 **	1.05	563	**102**
	5135	0.4030	565 **	1.05	538	
Carcass	5138	0.5076	565 **	1.05	530	**100**
	5139	0.5122	565 **	1.05	547	

$$* \text{ Mean Recovery (\%)} = 100 \times \frac{\text{Mean } ^{14}\text{C Measured (dpm)}}{^{14}\text{C Added (dpm)}} \times \text{F-Factor (if applicable)}$$

** 100 µL of 304002A1-61-1.

TABLE G2

Solutions Used for Matrix Fortifications

Reference No. (304002A1-)	Analysis Date	Aliquot Size (mL)	dpm	dpm	dpm/mL	
5-1	9/27/99	0.040	102464	103187	321329844	
	9/27/99	0.040	102136	101513	318200938	
	9/27/99	0.040	102986	103789	323085938	*
	9/27/99	0.040	102276	101881	318996094	*
				Mean:	**320403203**	
	10/1/99	0.040	99075	100811	312321500	
	10/1/99	0.040	99968	100753	313627078	
	10/1/99	0.040	99456	99939	311555906	*
	10/1/99	0.040	99848	101022	313860156	*
				Mean:	**312841160**	
11-1	9/27/99	0.010	22747	24701	**2372425**	
	9/27/99	0.250	622370	624683	**2494105**	
14-1	9/27/99	0.400	10312	10175	**25609**	
	9/27/99	0.040	2363	2568	**61645**	**
	11/1/99	0.040	1125	1113	**27983**	
17-1	9/27/99	0.040	1219529	1235522	**30688138**	
20-1	10/4/99	0.200	254698	256634	31958269	
	10/4/99	0.200	259018	258777	32362200	
				Mean:	**32160234**	
61-1	11/1/99	0.100	584	546	**5650**	

* Recount of 10/11/99.
** Value inconsistent with other assays. Value not used for recovery calculations.

TABLE G3

Calculation of Approximate Quantitation Limits*

Sample Type	Sample Size** (mL or g)	Aliquot Size** (mL or g)	Min. Sample Activity† (dpm)	Approximate Quantitation Limits†† Group 1 (µg)	Group 1 (% of dose)	Group 2 (µg)	Group 2 (% of dose)	Group 3 (µg)	Group 3 (% of dose)	Group 4 (µg)	Group 4 (% of dose)
Pipet Wash	15	0.25	3000	0.644	0.027	2.15	0.027	6.44	0.027	6.35	0.026
Soap Wash Gauze	129	0.64	10078	2.17	0.090	7.22	0.090	21.7	0.090	21.3	0.089
Water Wash Gauze	130	0.64	10156	2.18	0.091	7.27	0.091	21.8	0.091	21.5	0.090
Skin	12	0.19	3158	0.678	0.028	2.26	0.028	6.78	0.028	6.68	0.028
Cage Wash	115	0.75	7667	1.65	0.069	5.49	0.069	16.5	0.069	16.2	0.068
Plasma	0.16	0.16	50	0.0107	0.00045	0.0358	0.00045	0.107	0.00045	0.106	0.00044
Blood Cellular Fraction	0.28	0.23	61	0.0131	0.00054	0.0436	0.00054	0.131	0.00054	0.129	0.00054
Liver	1.5	0.50	150	0.0322	0.0013	0.107	0.0013	0.322	0.0013	0.317	0.0013
Kidney	0.47	0.43	55	0.0117	0.00049	0.0391	0.00049	0.117	0.00049	0.116	0.00048
Brain	0.39	0.37	53	0.0113	0.00047	0.0377	0.00047	0.113	0.00047	0.111	0.00046
Tongue	0.055	0.045	61	0.0131	0.00055	0.0438	0.00055	0.131	0.00055	0.129	0.00054
Urine	52	0.50	5200	1.12	0.047	3.72	0.047	11.2	0.047	11.0	0.046
Feces	23	0.49	2347	0.504	0.021	1.68	0.021	5.04	0.021	4.96	0.021
Carcass	24	0.51	2353	0.505	0.021	1.68	0.021	5.05	0.021	4.98	0.021

* Based on 50 dpm above background per aliquot assayed; approximately 2x background.

** Approximate mean sample and aliquot sizes. For skin, approximate mean digest and aliquot sizes.

† Minimum Sample Activity (dpm) = $\frac{50 \text{ dpm}}{\text{Aliquot Size (mL or g)}} \times$ Sample (or Digest) Size (mL or g)

†† Quant. Limit (µg) = Sample Activity (dpm) ÷ Specific Activity (dpm / µg) [from Table C1, Appendix C]

Quant. Limit (% of dose) = 100 × Quant. Limit (µg) ÷ Target Dose (µg)

TABLE G3 (cont.)

Calculation of Approximate Quantitation Limits*

Sample Type	Sample Size** (mL or g)	Aliquot Size** (mL or g)	Min. Sample Activity† (dpm)	Approximate Quantitation Limits†† Group 5 (µg)	Group 5 (% of dose)	Group 6 (µg)	Group 6 (% of dose)	Group 7 (µg)	Group 7 (% of dose)
Pipet Wash	15	0.25	3000	1.62	0.0674	5.39	0.0674	16.2	0.0674
Soap Wash Gauze	129	0.64	10078	5.43	0.226	18.1	0.226	54.3	0.226
Water Wash Gauze	130	0.64	10156	5.48	0.228	18.3	0.228	54.8	0.228
Skin	12	0.19	3158	1.70	0.0709	5.68	0.0709	17.0	0.0709
Cage Wash	115	0.75	7667	4.13	0.172	13.8	0.172	41.3	0.172
Plasma	0.16	0.16	50	0.0270	0.00112	0.0899	0.00112	0.270	0.00112
Blood Cellular Fraction	0.28	0.23	61	0.0328	0.00137	0.109	0.00137	0.328	0.00137
Liver	1.5	0.50	150	0.0809	0.00337	0.270	0.00337	0.809	0.00337
Kidney	0.47	0.43	55	0.0295	0.00123	0.0982	0.00123	0.295	0.00123
Brain	0.39	0.37	53	0.0284	0.00118	0.0947	0.00118	0.284	0.00118
Tongue	0.055	0.045	61	0.0329	0.00137	0.110	0.00137	0.329	0.00137
Urine	52	0.50	5200	2.80	0.117	9.35	0.117	28.0	0.117
Feces	23	0.49	2347	1.27	0.0527	4.22	0.0527	12.7	0.0527
Carcass	24	0.51	2353	1.27	0.0529	4.23	0.0529	12.7	0.0529

* Based on 50 dpm above background per aliquot assayed; approximately 2x background.

** Approximate mean sample and aliquot sizes. For skin, approximate mean digest and aliquot sizes.

† Minimum Sample Activity (dpm) = $\frac{50 \text{ dpm}}{\text{Aliquot Size (mL or g)}} \times$ Sample (or Digest) Size (mL or g)

†† Quant. Limit (µg) = Sample Activity (dpm) ÷ Specific Activity (dpm / µg) [from Table C2, Appendix C]

Quant. Limit (% of dose) = 100 × Quant. Limit (µg) ÷ Target Dose (µg)

TABLE G4

Volatility of PCMX*

Time (hr)	Room Temperature Vial No.	dpm	Percent of Time Zero	37°C Vial No.	dpm	Percent of Time Zero
0	6462	1219755		6482	1296300	
	6463	1205548		6483	1288277	
	6464	1209946		6484	1247813	
	Mean:	1211750	N/A	Mean:	1277463	N/A
1	6465	1217545		6485	1277222	
	6466	1213972		6486	1253997	
	6467	1207812		6487	1257143	
	Mean:	1213110	100	Mean:	1262787	98.9
3	6468	1212069		6488	1250043	
	6469	1193091		6489	1210192	
	6470	1187070		6490	1229895	
	Mean:	1197410	98.8	Mean:	1230043	96.3
6	6471	1205936		6491	1222151	
	6472	1207088		6492	1236530	
	6473	1197866		6493	1215350	
	Mean:	1203630	99.3	Mean:	1224677	95.9
12	6474	1188939		6494	1160209	
	6475	1197142		6495	1160286	
	6476	1177461		6496	1178318	
	Mean:	1187847	98.0	Mean:	1166271	91.3
24	6477	1176469		6497	1055473	
	6478	1168691		6498	1051405	
	6479	1143103		6499	1051033	
	Mean:	1162754	96.0	Mean:	1052637	82.4

*10 µL aliquots of a dosing formulation (304002A1-85-1) were placed in scintillation vials and the vials were placed, uncovered, in a fume hood for the indicated length of time under the indicated conditions prior to analysis.

A Dermal Absorption Study with [^{14}C]-labeled PCMX in Mice

Appendix H

Summaries of Individual Animal Data

Summaries of Individual Animal Data

The following equations were used in calculation of total recovery and the amount absorbed (Amt. Abs.):

(1) Total Recovery = $\sum$ Of all sample types

(2) Amt. Abs. (Direct) = $\sum$ Absorbed Samples *

(3) Amt. Abs. (Indirect) = Actual Dose ** - $\sum$ Not Absorbed *** and Absorbable† Samples

Other abbreviations used in the tables in this appendix include:

Anim. No. = Animal Number

N/A = Not applicable

* Cage wash, blood, tissues, urine, feces, and carcass.

** From Tables E1–E3 (Appendix E). For percent of dose, 100%.

*** Soap wash and water wash.

† Skin.

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 1 (3 hr exposure)												
Males												
5331	17.17	5.24	22.51	9.62	0.03	N/A	9.04	0.79	11.66	76.1	31.14	55.08
5339	28.15	3.23	11.16	9.14	0.08	N/A	20.34	0.01	8.63	80.7	38.19	57.46
5340	30.02	3.50	18.34	9.58	0.05	N/A	6.59	0.01	11.15	79.2	27.39	48.14
Mean:	25.11	3.99	17.34	9.45	0.05	N/A	11.99	0.27	10.48	78.7	32.24	53.56
SD:	6.94	1.09	5.74	0.27	0.03	N/A	7.33	0.45	1.62	2.39	5.49	4.84
Females												
5355	32.52	4.08	15.72	9.67	0.04	N/A	13.91	0.01	4.62	80.6	28.24	47.68
5356	34.74	3.35	15.69	11.70	0.04	N/A	11.56	0.07	4.56	81.7	27.93	46.21
5362	14.50	2.51	17.11	17.20	0.07	N/A	21.65	0.02	5.81	78.9	44.76	65.89
Mean:	27.25	3.31	16.17	12.86	0.05	N/A	15.71	0.04	4.99	80.4	33.64	53.26
SD:	11.10	0.79	0.81	3.90	0.02	N/A	5.28	0.03	0.71	1.43	9.63	10.96

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 2 (6 hr exposure)												
Males												
5332	0.11	0.06	1.77	11.51	0.01	N/A	51.41	0.06	6.07	71.0	69.05	98.06
5342	5.69	1.13	5.62	9.44	0.03	N/A	29.25	0.06	4.19	55.4	42.97	87.56
5343	13.48	1.62	8.29	7.63	0.02	N/A	17.63	0.00	5.73	54.4	31.02	76.61
Mean:	6.43	0.94	5.23	9.53	0.02	N/A	32.76	0.04	5.33	60.3	47.68	87.41
SD:	6.72	0.80	3.28	1.94	0.01	N/A	17.16	0.03	1.00	9.30	19.45	10.73
Females												
5349	6.70	1.28	5.76	10.40	0.04	N/A	20.48	0.05	4.28	49.0	35.26	86.26
5350	16.48	3.12	20.25	5.50	0.03	N/A	12.73	0.04	4.08	62.2	22.37	60.15
5363	22.93	3.19	14.16	5.51	0.04	N/A	17.59	0.15	3.70	67.3	27.01	59.72
Mean:	15.37	2.53	13.39	7.14	0.04	N/A	16.93	0.08	4.02	59.5	28.21	68.71
SD:	8.17	1.08	7.27	2.82	0.01	N/A	3.92	0.06	0.29	9.44	6.52	15.20

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 3 (12 hr exposure)												
Males												
5327	0.36	0.40	2.17	10.45	0.02	N/A	39.87	0.44	2.35	56.1	53.13	97.06
5330	1.10	2.57	4.19	9.46	0.02	N/A	32.55	0.20	4.43	54.5	46.66	92.14
5334	0.04	0.03	0.73	11.82	0.00	N/A	41.06	0.32	2.89	56.9	56.09	99.20
Mean:	0.50	1.00	2.36	10.58	0.01	N/A	37.83	0.32	3.22	55.8	51.96	96.13
SD:	0.54	1.37	1.74	1.18	0.01	N/A	4.61	0.12	1.08	1.20	4.82	3.62
Females												
5347	0.03	0.02	0.80	15.79	0.00	N/A	30.08	4.14	2.22	53.1	52.23	99.15
5348	1.74	0.37	1.82	14.38	0.01	N/A	21.81	0.26	1.93	42.3	38.40	96.07
5352	1.01	0.15	1.47	13.84	0.01	N/A	23.03	0.14	1.54	41.2	38.56	97.37
Mean:	0.92	0.18	1.36	14.67	0.01	N/A	24.97	1.51	1.90	45.5	43.06	97.53
SD:	0.86	0.18	0.52	1.01	0.00	N/A	4.46	2.28	0.34	6.56	7.94	1.54

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 4 (24 hr exposure)												
Males												
5328	0.02	0.01	0.40	6.75	0.00	0.04	44.45	0.78	1.85	54.3	53.89	99.58
5336	0.02	0.00	0.39	6.48	0.00	0.06	51.09	1.10	2.02	61.2	60.76	99.58
5344	0.02	0.00	0.39	6.03	0.00	0.08	42.79	0.69	1.40	51.4	50.99	99.59
5345	0.03	0.01	0.37	6.15	0.00	0.03	30.26	0.73	1.29	38.9	38.47	99.59
Mean:	0.02	0.00	0.39	6.35	0.00	0.06	42.15	0.83	1.64	51.4	51.03	99.59
SD:	0.01	0.00	0.01	0.33	0.00	0.02	8.70	0.19	0.35	9.32	9.32	0.01
Females												
5351	0.04	0.03	0.97	12.58	0.00	0.03	36.25	1.62	1.10	52.6	51.57	98.96
5353	0.03	0.01	0.56	9.40	0.00	0.02	46.30	0.40	1.47	58.2	57.59	99.41
5359	0.07	0.02	0.82	19.83	0.00	0.03	37.54	0.80	1.37	60.5	59.58	99.10
5365	0.03	0.02	1.53	7.93	0.00	0.02	25.14	0.40	1.59	36.7	35.08	98.43
Mean:	0.04	0.02	0.97	12.43	0.00	0.02	36.31	0.80	1.38	52.0	50.96	98.97
SD:	0.02	0.01	0.41	5.30	0.00	0.00	8.68	0.57	0.21	10.74	11.11	0.41

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 5 (48 hr exposure)												
Males												
5329	0.00	0.01	0.31	5.02	0.00	N/A	53.84	1.27	0.84	61.3	60.97	99.68
5333	0.01	0.00	0.29	6.54	0.00	N/A	46.65	5.93	0.72	60.1	59.84	99.70
5341	0.00	0.00	0.28	6.48	0.00	N/A	52.45	1.22	0.80	61.2	60.94	99.72
Mean:	0.01	0.00	0.29	6.01	0.00	N/A	50.98	2.81	0.78	60.9	60.59	99.70
SD:	0.00	0.00	0.02	0.86	0.00	N/A	3.81	2.70	0.06	0.65	0.65	0.02
Females												
5360	0.01	0.01	0.30	18.04	0.00	N/A	33.32	0.31	0.89	52.9	52.56	99.68
5364	0.01	0.00	0.62	16.26	0.00	N/A	38.01	0.47	1.05	56.4	55.79	99.37
5366	0.01	0.01	0.54	23.26	0.00	N/A	25.11	0.60	1.34	50.9	50.30	99.45
Mean:	0.01	0.01	0.49	19.19	0.00	N/A	32.14	0.46	1.09	53.4	52.88	99.50
SD:	0.00	0.00	0.16	3.64	0.00	N/A	6.53	0.14	0.23	2.82	2.76	0.16

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 1 (3 hr exposure)												
Males												
5836	42.04	7.03	12.83	7.77	0.04	N/A	4.74	1.16	9.76	85.4	23.48	38.10
5841	47.91	5.17	9.82	6.30	0.03	N/A	8.39	0.02	7.65	85.3	22.39	37.10
5844	32.74	3.06	10.18	8.81	0.05	N/A	13.00	0.31	13.44	81.6	35.62	54.02
Mean:	40.89	5.09	10.95	7.63	0.04	N/A	8.71	0.50	10.29	84.1	27.16	43.07
SD:	7.65	1.99	1.64	1.26	0.01	N/A	4.14	0.59	2.93	2.15	7.35	9.49
Females												
5853	32.63	3.80	7.79	7.84	0.06	N/A	8.23	0.23	11.30	71.9	27.66	55.79
5855	31.64	4.23	9.10	13.08	0.07	N/A	12.58	0.12	8.91	79.7	34.76	55.03
5863	43.69	6.05	9.81	10.75	0.02	N/A	5.27	0.02	9.31	84.9	25.37	40.45
Mean:	35.99	4.69	8.90	10.56	0.05	N/A	8.69	0.12	9.84	78.8	29.27	50.42
SD:	6.69	1.19	1.02	2.62	0.03	N/A	3.68	0.10	1.28	6.57	4.90	8.64

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 2 (6 hr exposure)												
Males												
5832	30.72	2.82	11.58	10.86	0.04	N/A	15.46	0.07	6.42	78.0	32.85	54.87
5834	35.25	4.12	7.41	6.52	0.01	N/A	16.26	0.08	4.93	74.6	27.80	53.22
5845	26.55	5.10	10.93	9.87	0.03	N/A	15.76	0.10	7.40	75.7	33.15	57.42
Mean:	30.84	4.02	9.98	9.08	0.03	N/A	15.83	0.08	6.25	76.1	31.27	55.17
SD:	4.35	1.14	2.24	2.27	0.01	N/A	0.40	0.01	1.24	1.73	3.01	2.12
Females												
5846	36.93	3.74	6.05	10.70	0.02	N/A	11.89	0.10	6.49	75.9	29.21	53.28
5858	30.47	3.57	6.91	12.06	0.03	N/A	17.88	0.11	6.20	77.2	36.28	59.04
5860	31.15	2.68	12.58	10.29	0.01	N/A	12.30	1.06	7.52	77.6	31.18	53.59
Mean:	32.85	3.33	8.52	11.02	0.02	N/A	14.03	0.42	6.73	76.9	32.22	55.31
SD:	3.55	0.57	3.55	0.92	0.01	N/A	3.34	0.55	0.69	0.87	3.65	3.24

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 3 (12 hr exposure)												
Males												
5715	18.28	2.74	8.45	8.41	0.02	N/A	19.54	0.63	7.44	65.5	36.04	70.52
5831	5.65	1.01	3.51	11.96	0.01	N/A	32.19	0.56	4.46	59.3	49.18	89.84
5837	7.19	1.02	4.07	13.39	0.01	N/A	33.36	0.42	4.02	63.5	51.20	87.73
Mean:	10.37	1.59	5.34	11.26	0.02	N/A	28.37	0.53	5.31	62.8	45.48	82.69
SD:	6.89	1.00	2.71	2.56	0.01	N/A	7.66	0.10	1.86	3.14	8.23	10.59
Females												
5847	15.62	1.58	7.06	10.80	0.01	N/A	30.64	0.39	2.46	68.6	44.31	75.74
5850	12.15	0.95	4.18	10.65	0.01	N/A	32.80	0.27	7.89	68.9	51.62	82.72
5864	10.52	1.64	5.13	9.74	0.02	N/A	32.34	0.75	6.04	66.2	48.88	82.71
Mean:	12.76	1.39	5.46	10.39	0.01	N/A	31.93	0.47	5.46	67.9	48.27	80.39
SD:	2.60	0.38	1.47	0.57	0.00	N/A	1.14	0.25	2.76	1.49	3.69	4.03

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 4 (24 hr exposure)												
Males												
5713	0.03	0.01	0.64	11.25	0.00	0.06	29.16	0.79	2.60	44.5	43.86	99.32
5829	0.01	0.01	0.62	12.32	0.00	0.03	36.53	0.44	1.34	51.3	50.66	99.37
5830	0.06	0.01	0.50	13.40	0.00	0.04	36.91	0.92	1.79	53.7	53.08	99.43
5839	0.01	0.02	0.54	8.15	0.00	0.09	47.05	0.97	1.70	58.5	57.96	99.43
Mean:	0.03	0.01	0.57	11.28	0.00	0.05	37.41	0.78	1.86	52.0	51.39	99.39
SD:	0.02	0.01	0.07	2.26	0.00	0.02	7.35	0.24	0.53	5.82	5.86	0.05
Females												
5851	0.32	0.28	1.06	13.59	0.01	0.07	37.24	0.85	3.31	56.7	55.07	98.34
5852	0.40	0.11	0.57	8.45	0.00	0.05	38.12	1.05	2.22	51.0	49.89	98.91
5857	1.35	0.23	0.62	17.65	0.00	0.04	33.44	0.77	2.50	56.6	54.39	97.80
5861	0.18	0.10	0.78	7.37	0.00	0.03	34.34	3.55	1.49	47.8	46.78	98.94
Mean:	0.56	0.18	0.76	11.76	0.01	0.05	35.78	1.56	2.38	53.0	51.54	98.50
SD:	0.53	0.09	0.22	4.77	0.00	0.02	2.25	1.34	0.75	4.38	3.91	0.54

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 5 (48 hr exposure)												
Males												
5720	0.00	0.00	0.31	9.39	0.00	N/A	43.53	1.82	1.56	56.6	56.30	99.69
5828	0.00	0.01	0.31	7.24	0.00	N/A	45.00	1.09	0.95	54.6	54.28	99.68
5840	0.00	0.01	0.47	8.12	0.00	N/A	47.36	2.55	1.01	59.5	59.03	99.52
Mean:	0.00	0.01	0.37	8.25	0.00	N/A	45.30	1.82	1.17	56.9	56.54	99.63
SD:	0.00	0.00	0.09	1.08	0.00	N/A	1.93	0.73	0.34	2.47	2.39	0.09
Females												
5848	0.00	0.00	0.22	9.83	0.00	N/A	42.45	1.34	0.63	54.5	54.25	99.78
5854	0.00	0.00	0.33	12.18	0.00	N/A	34.14	7.58	1.35	55.6	55.26	99.67
5862	0.00	0.00	0.31	6.83	0.00	N/A	43.17	1.45	1.19	52.9	52.64	99.69
Mean:	0.00	0.00	0.28	9.61	0.00	N/A	39.92	3.46	1.06	54.3	54.05	99.71
SD:	0.00	0.00	0.06	2.68	0.00	N/A	5.02	3.57	0.38	1.32	1.32	0.06

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 1 (3 hr exposure)												
Males												
5723	41.29	6.98	6.29	16.08	0.02	N/A	4.56	1.03	5.03	81.3	26.73	45.44
5733	36.27	7.08	16.03	15.77	0.01	N/A	2.71	0.81	5.80	84.5	25.10	40.61
5736	30.73	5.46	10.93	14.50	0.01	N/A	6.08	0.90	7.15	75.8	28.64	52.88
Mean:	36.10	6.51	11.08	15.45	0.01	N/A	4.45	0.91	5.99	80.5	26.82	46.31
SD:	5.28	0.91	4.87	0.84	0.01	N/A	1.69	0.11	1.07	4.41	1.77	6.18
Females												
5741	28.86	3.19	14.20	12.77	0.04	N/A	7.16	0.78	7.86	74.9	28.60	53.75
5744	39.89	4.83	8.25	11.15	0.02	N/A	3.65	1.65	4.78	74.2	21.24	47.04
5762	48.60	4.74	9.50	7.99	0.02	N/A	2.74	0.81	3.80	78.2	15.36	37.16
Mean:	39.11	4.25	10.65	10.64	0.02	N/A	4.52	1.08	5.48	75.8	21.74	45.98
SD:	9.89	0.92	3.14	2.43	0.01	N/A	2.33	0.49	2.12	2.15	6.63	8.35

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 2 (6 hr exposure)												
Males												
5722	41.33	4.13	5.22	16.07	0.02	N/A	7.69	1.62	4.98	81.1	30.38	49.32
5734	50.11	3.88	7.49	10.63	0.01	N/A	5.50	2.22	4.63	84.5	22.99	38.52
5737	32.37	3.01	4.83	16.53	0.02	N/A	11.59	3.14	5.40	76.9	36.68	59.78
Mean:	41.27	3.67	5.85	14.41	0.01	N/A	8.26	2.33	5.00	80.8	30.02	49.21
SD:	8.87	0.59	1.44	3.28	0.01	N/A	3.08	0.77	0.38	3.80	6.85	10.63
Females												
5746	40.05	3.80	5.89	24.38	0.01	N/A	10.68	0.61	7.18	92.6	42.87	50.26
5751	22.44	1.86	3.27	20.79	0.01	N/A	16.93	1.05	5.59	71.9	44.38	72.44
5761	38.79	5.39	8.86	13.92	0.01	N/A	6.49	0.62	5.07	79.2	26.12	46.96
Mean:	33.76	3.68	6.01	19.70	0.01	N/A	11.37	0.76	5.95	81.2	37.79	56.55
SD:	9.83	1.77	2.80	5.31	0.00	N/A	5.25	0.25	1.10	10.49	10.13	13.85

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 3 (12 hr exposure)												
Males												
5716	23.74	2.36	5.08	10.65	0.01	N/A	13.24	3.94	2.06	61.1	29.90	68.82
5717	38.29	3.80	7.93	6.50	0.01	N/A	14.86	1.00	1.58	74.0	23.96	49.98
5726	21.74	3.55	7.04	7.32	0.01	N/A	17.12	2.96	2.10	61.8	29.52	67.67
Mean:	27.93	3.24	6.68	8.16	0.01	N/A	15.07	2.64	1.91	65.6	27.79	62.16
SD:	9.03	0.77	1.46	2.20	0.00	N/A	1.95	1.50	0.29	7.24	3.33	10.56
Females												
5739	29.08	4.19	10.07	4.70	0.01	N/A	11.31	4.04	1.49	64.9	21.55	56.66
5750	30.97	4.27	9.78	11.04	0.01	N/A	7.38	1.46	3.73	68.6	23.62	54.98
5752	11.34	1.38	3.02	16.50	0.01	N/A	22.05	3.38	1.29	59.0	43.22	84.26
Mean:	23.80	3.28	7.62	10.75	0.01	N/A	13.58	2.96	2.17	64.2	29.46	65.30
SD:	10.83	1.65	3.99	5.90	0.00	N/A	7.59	1.34	1.35	4.88	11.96	16.44

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 4 (24 hr exposure)												
Males												
5724	0.03	0.01	0.21	15.00	0.00	0.06	38.49	2.54	1.86	58.2	57.94	99.75
5725	7.10	1.65	3.83	13.34	0.01	0.11	34.26	3.25	1.05	64.6	52.01	87.42
5727	5.01	0.60	1.79	14.06	0.01	0.09	27.75	1.51	1.49	52.3	44.90	92.61
5735	14.63	1.30	3.33	13.68	0.01	0.07	23.96	4.70	2.46	64.1	44.89	80.75
Mean:	6.69	0.89	2.29	14.02	0.01	0.08	31.11	3.00	1.71	59.8	49.93	90.13
SD:	6.07	0.73	1.64	0.72	0.00	0.02	6.50	1.34	0.60	5.79	6.31	8.04
Females												
5740	0.99	0.11	0.42	17.10	0.00	0.05	30.28	3.67	1.91	54.5	53.01	98.48
5742	10.64	1.02	2.00	15.32	0.01	0.06	22.93	2.06	1.67	55.7	42.04	86.35
5753	16.43	1.82	3.14	14.05	0.01	0.05	22.23	2.58	1.22	61.5	40.15	78.61
5756	9.26	1.39	2.63	19.53	0.01	0.06	22.27	2.00	1.63	58.8	45.50	86.71
Mean:	9.33	1.08	2.05	16.50	0.01	0.05	24.43	2.58	1.61	57.6	45.17	87.54
SD:	6.37	0.73	1.18	2.38	0.00	0.00	3.91	0.78	0.28	3.16	5.67	8.20

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 5 (48 hr exposure)												
Males												
5721	0.02	0.01	0.14	5.78	0.00	N/A	44.88	4.98	1.00	56.8	56.64	99.83
5728	0.03	0.02	0.19	11.20	0.00	N/A	34.50	5.30	1.39	52.6	52.39	99.76
5732	0.02	0.01	0.26	7.65	0.00	N/A	40.04	2.96	0.61	51.5	51.26	99.72
Mean:	0.02	0.01	0.20	8.21	0.00	N/A	39.81	4.41	1.00	53.7	53.43	99.77
SD:	0.01	0.01	0.06	2.75	0.00	N/A	5.19	1.27	0.39	2.78	2.84	0.06
Females												
5738	0.02	0.02	0.38	10.03	0.00	N/A	30.14	4.19	0.99	45.8	45.35	99.59
5758	0.01	0.00	0.16	8.91	0.00	N/A	36.56	8.81	0.66	55.1	54.95	99.82
5760	0.02	0.01	0.19	13.73	0.00	N/A	34.33	5.22	1.31	54.8	54.58	99.78
Mean:	0.01	0.01	0.25	10.89	0.00	N/A	33.68	6.07	0.98	51.9	51.63	99.73
SD:	0.01	0.01	0.12	2.52	0.00	N/A	3.26	2.43	0.32	5.32	5.44	0.12

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 4 (24 hr exposure)												
Males												
5714	0.12	0.04	0.34	14.99	0.01	0.05	47.01	1.30	2.62	66.5	65.97	99.50
5718	0.02	0.00	0.25	14.96	0.00	0.05	49.86	1.36	3.79	70.3	70.03	99.72
5719	0.04	0.03	1.37	10.15	0.00	0.07	46.57	1.26	4.97	64.5	63.02	98.56
5730	0.06	0.03	0.34	15.75	0.00	0.05	45.17	1.04	2.78	65.2	64.79	99.57
Mean:	0.06	0.03	0.58	13.96	0.00	0.05	47.15	1.24	3.54	66.6	65.95	99.34
SD:	0.04	0.02	0.53	2.57	0.00	0.01	1.97	0.14	1.09	2.60	2.98	0.53
Females												
5743	1.65	0.35	7.56	23.67	0.01	0.05	23.77	1.58	7.41	66.1	56.48	90.43
5745	0.71	0.20	6.20	21.95	0.01	0.06	39.34	1.59	8.74	78.8	71.68	92.89
5748	1.10	0.20	2.53	17.68	0.01	0.06	41.96	1.32	6.92	71.8	67.95	96.16
5754	0.68	0.18	2.22	15.83	0.01	0.04	41.75	3.64	5.02	69.4	66.29	96.92
Mean:	1.04	0.23	4.63	19.79	0.01	0.05	36.70	2.03	7.02	71.5	65.60	94.10
SD:	0.45	0.08	2.66	3.64	0.00	0.01	8.71	1.08	1.54	5.40	6.48	3.01

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5; SUB-GROUP 1 (14 day exposure)												
Males												
5871	0.02	0.01	0.32	3.42	0.00	0.01	55.23	6.46	0.72	66.2	65.84	99.66
5883	0.01	0.02	0.32	5.32	0.00	0.02	50.94	8.38	0.57	65.6	65.23	99.64
5884	0.02	0.01	0.29	3.68	0.00	0.01	51.90	3.75	0.50	60.2	59.85	99.68
5889	0.01	0.01	0.17	4.87	0.00	0.01	51.02	2.87	0.48	59.4	59.25	99.81
Mean:	0.01	0.01	0.27	4.32	0.00	0.01	52.27	5.37	0.57	62.8	62.54	99.70
SD:	0.00	0.01	0.07	0.92	0.00	0.00	2.02	2.53	0.11	3.53	3.47	0.08
Females												
5896	0.00	0.00	0.19	3.56	0.00	0.00	62.94	4.65	0.29	71.6	71.44	99.81
5899	0.01	0.01	0.26	4.01	0.00	0.01	49.47	5.35	0.48	59.6	59.32	99.72
5900	0.01	0.01	0.28	4.52	0.00	0.01	59.27	4.37	0.41	68.9	68.57	99.70
5921	0.01	0.00	0.25	5.88	0.00	0.01	53.38	8.97	0.45	68.9	68.68	99.74
Mean:	0.01	0.00	0.25	4.49	0.00	0.01	56.27	5.84	0.41	67.3	67.01	99.74
SD:	0.00	0.00	0.04	1.00	0.00	0.00	6.00	2.13	0.08	5.27	5.29	0.05

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5; SUB-GROUP 2 (28 day exposure)												
Males												
5869	0.01	0.01	0.24	4.80	0.00	0.00	60.17	2.56	0.32	68.1	67.85	99.73
5870	0.02	0.01	0.18	4.65	0.00	0.00	54.11	1.52	0.28	60.8	60.57	99.79
5888	0.01	0.01	0.26	4.00	0.00	0.00	51.97	2.81	0.29	59.4	59.08	99.72
5893	0.01	0.01	0.17	4.18	0.00	0.00	61.13	3.68	0.28	69.5	69.27	99.81
Mean:	0.01	0.01	0.21	4.41	0.00	0.00	56.84	2.64	0.29	64.4	64.19	99.76
SD:	0.00	0.00	0.04	0.38	0.00	0.00	4.49	0.89	0.02	5.10	5.11	0.04
Females												
5910	0.01	0.00	0.16	5.84	0.00	0.00	63.40	2.78	0.23	72.4	72.26	99.83
5911	0.01	0.01	0.25	5.07	0.00	0.00	58.57	3.22	0.21	67.3	67.08	99.73
5915	0.01	0.01	0.27	5.53	0.00	0.00	54.96	4.49	0.31	65.6	65.30	99.72
5916	0.01	0.01	0.23	4.59	0.00	0.00	45.65	6.04	0.34	56.9	56.62	99.76
Mean:	0.01	0.01	0.22	5.26	0.00	0.00	55.64	4.13	0.27	65.6	65.31	99.76
SD:	0.00	0.00	0.05	0.55	0.00	0.00	7.51	1.46	0.06	6.48	6.51	0.05

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 6; SUB-GROUP 1 (14 day exposure)												
Males												
5867	0.00	0.00	0.20	2.60	0.00	0.01	65.05	16.46	0.35	84.7	84.47	99.80
5868	0.01	0.01	0.27	2.43	0.00	0.01	81.51	4.09	0.42	88.8	88.46	99.71
5875	0.00	0.01	0.23	1.62	0.00	0.01	74.61	2.51	0.58	79.6	79.32	99.76
5881	0.00	0.00	0.13	3.32	0.00	0.01	71.13	1.74	0.49	76.8	76.68	99.87
Mean:	0.00	0.00	0.21	2.49	0.00	0.01	73.08	6.20	0.46	82.4	82.23	99.78
SD:	0.00	0.01	0.06	0.70	0.00	0.00	6.87	6.91	0.10	5.32	5.26	0.07
Females												
5895	0.00	0.00	0.24	2.84	0.00	0.01	63.72	3.31	0.46	70.6	70.34	99.75
5907	0.00	0.00	0.13	4.14	0.00	0.00	60.26	3.83	0.55	68.9	68.79	99.87
5909	0.00	0.00	0.19	3.04	0.00	0.01	66.14	6.19	0.35	75.9	75.73	99.80
5918	0.00	0.00	0.23	2.40	0.00	0.00	60.54	4.95	0.36	68.5	68.25	99.77
Mean:	0.00	0.00	0.20	3.11	0.00	0.00	62.67	4.57	0.43	71.0	70.78	99.80
SD:	0.00	0.00	0.05	0.74	0.00	0.00	2.80	1.28	0.10	3.42	3.42	0.05

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 6; SUB-GROUP 2 (28 day exposure)												
Males												
5880	0.01	0.01	0.13	2.94	0.00	0.00	64.83	1.99	0.33	70.2	70.09	99.85
5885	0.01	0.01	0.13	2.70	0.00	0.00	60.40	4.53	0.24	68.0	67.88	99.84
5887	0.08	0.04	0.18	2.71	0.00	0.00	61.68	3.84	0.26	68.8	68.50	99.70
5894	0.14	0.05	0.27	2.48	0.00	0.01	61.94	3.30	0.35	68.5	68.07	99.54
Mean:	0.06	0.03	0.18	2.71	0.00	0.00	62.21	3.42	0.29	68.9	68.64	99.73
SD:	0.06	0.02	0.07	0.19	0.00	0.00	1.87	1.08	0.05	0.94	1.00	0.15
Females												
5903	0.01	0.01	0.22	2.29	0.00	0.00	59.28	5.80	0.24	67.9	67.61	99.76
5912	0.01	0.01	0.14	2.04	0.00	0.00	64.68	3.60	0.16	70.6	70.47	99.84
5917	0.01	0.01	0.20	3.86	0.00	0.00	59.37	3.35	0.33	67.1	66.92	99.77
5919	0.01	0.01	0.10	1.73	0.00	0.00	69.02	2.88	0.20	74.0	73.85	99.88
Mean:	0.01	0.01	0.17	2.48	0.00	0.00	63.09	3.91	0.23	69.9	69.71	99.81
SD:	0.00	0.00	0.05	0.95	0.00	0.00	4.69	1.29	0.07	3.10	3.16	0.06

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 1 (14 day exposure)												
Males												
5872	0.01	0.00	0.10	3.38	0.00	0.01	52.41	5.70	1.01	62.6	62.51	99.89
5873	0.00	0.00	0.06	7.92	0.00	0.00	50.99	9.18	0.30	68.5	68.39	99.93
5874	0.03	0.01	0.23	3.96	0.00	0.00	57.41	2.92	0.69	65.3	64.99	99.72
5882	0.01	0.00	0.12	5.58	0.00	0.00	47.99	3.45	0.63	57.8	57.66	99.87
Mean:	0.01	0.01	0.13	5.21	0.00	0.00	52.20	5.31	0.66	63.5	63.39	99.85
SD:	0.01	0.00	0.07	2.03	0.00	0.00	3.93	2.85	0.29	4.51	4.52	0.09
Females												
5901	0.58	0.26	1.05	3.89	0.00	0.01	59.90	4.07	0.63	70.4	68.50	98.11
5902	0.80	0.22	0.71	5.84	0.00	0.01	48.96	6.26	0.84	63.6	61.92	98.27
5913	0.07	0.06	0.19	9.24	0.00	0.00	54.02	7.00	0.65	71.2	70.92	99.69
5920	0.42	0.15	0.37	4.51	0.00	0.01	59.17	5.96	1.55	72.1	71.19	99.05
Mean:	0.47	0.17	0.58	5.87	0.00	0.01	55.51	5.82	0.92	69.4	68.13	98.78
SD:	0.31	0.09	0.38	2.39	0.00	0.00	5.09	1.25	0.43	3.87	4.32	0.73

TABLE H1. Distribution of PCMX Equivalents following Dermal Administration (as Percent of Dose)

	NOT ABSORBED		ABSORBABLE	ABSORBED								
Anim. No.	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Total Recovery	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 2 (28 day exposure)												
Males												
5878	0.08	0.06	0.58	3.11	0.00	0.00	56.76	10.07	0.37	71.0	70.33	99.28
5886	0.00	0.00	0.11	2.56	0.00	0.00	62.60	5.07	0.45	70.8	70.68	99.88
5891	0.27	0.15	0.39	3.00	0.00	0.01	57.61	5.21	0.43	67.1	66.25	99.19
5892	0.00	0.00	0.05	3.31	0.00	0.00	48.40	6.12	0.44	58.3	58.27	99.95
Mean:	0.09	0.05	0.28	2.99	0.00	0.00	56.34	6.62	0.42	66.8	66.38	99.58
SD:	0.13	0.07	0.25	0.32	0.00	0.00	5.89	2.35	0.04	5.94	5.77	0.40
Females												
5905	0.00	0.00	0.09	3.54	0.00	0.00	56.13	8.01	0.26	68.0	67.94	99.91
5906	0.00	0.00	0.09	3.54	0.00	0.00	58.47	6.68	0.38	69.2	69.07	99.91
5908	0.00	0.00	0.10	4.63	0.00	0.00	57.07	4.38	0.26	66.4	66.34	99.90
5914	0.05	0.07	0.09	2.24	0.00	0.00	63.54	7.09	0.19	73.3	73.06	99.79
Mean:	0.01	0.02	0.09	3.49	0.00	0.00	58.80	6.54	0.27	69.2	69.10	99.88
SD:	0.02	0.04	0.01	0.98	0.00	0.00	3.30	1.54	0.08	2.92	2.87	0.06

RECOVERY SUMMARY

	Group:	1	2	3	4	5	6	7	Overall
Males	Minimum:	38.9	44.5	51.5	64.5	59.4	68.0	57.8	38.9
	Maximum:	80.7	85.4	84.5	70.3	69.5	88.8	71.0	88.8
	Mean:	60.8	65.5	67.6	66.6	63.6	75.7	65.2	65.8
	SD:	11.1	12.9	12.0	2.6	4.1	8.1	5.2	10.7
Females	Group:	1	2	3	4	5	6	7	Overall
	Minimum:	36.7	47.8	45.8	66.1	56.9	67.1	63.6	36.7
	Maximum:	81.7	84.9	92.6	78.8	72.4	75.9	73.3	92.6
	Mean:	57.8	65.4	65.6	71.5	66.4	70.4	69.3	65.2
	SD:	13.7	11.8	12.2	5.4	5.5	3.1	3.2	10.9

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 1 (3 hr exposure)												
Males												
5331	2591	445	136	583	249	0.68	N/A	234	20.6	302	807	1427
5339	2627	740	84.8	293	240	2.02	N/A	534	0.21	227	1003	1509
5340	2545	764	89.1	467	244	1.31	N/A	168	0.36	284	697	1225
Mean:	2588	650	103	448	244	1.34	N/A	312	7.05	271	836	1387
SD:	41.2	178	28.3	146	4.61	0.67	N/A	195	11.7	39.3	155	146
Females												
5355	2594	843	106	408	251	1.03	N/A	361	0.32	120	733	1237
5356	2611	907	87.6	410	306	1.02	N/A	302	1.88	119	729	1207
5362	2553	370	64.1	437	439	1.87	N/A	553	0.53	148	1143	1682
Mean:	2586	707	85.8	418	332	1.31	N/A	405	0.91	129	868	1375
SD:	29.7	293	21.0	16.2	97.0	0.49	N/A	131	0.85	16.7	238	266

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 2 (6 hr exposure)												
Males												
5332	2641	445	1.55	46.9	304	0.30	N/A	1358	1.48	160	1824	2148
5342	2645	151	29.8	149	250	0.88	N/A	774	1.68	111	1136	2316
5343	2629	354	42.6	218	201	0.41	N/A	464	0.12	151	815	2014
Mean:	2638	317	24.6	138	251	0.53	N/A	865	1.09	141	1259	2159
SD:	8.37	151	21.0	86.1	51.7	0.31	N/A	454	0.84	26.2	515	151
Females												
5349	2621	176	33.6	151	272	1.17	N/A	537	1.37	112	924	2261
5350	2580	425	80.6	522	142	0.83	N/A	328	0.91	105	577	1552
5363	2627	602	83.7	372	145	1.16	N/A	462	4.04	97.3	710	1569
Mean:	2609	401	66.0	348	186	1.05	N/A	442	2.11	105	737	1794
SD:	25.9	214	28.1	187	74.6	0.19	N/A	106	1.69	7.45	175	404

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 3 (12 hr exposure)												
Males												
5327	2618	9.54	10.6	56.8	274	0.43	N/A	1044	11.6	61.6	1391	2541
5330	2610	28.7	67.1	109	247	0.53	N/A	850	5.24	115	1218	2405
5334	2621	1.05	0.84	19.0	310	0.07	N/A	1076	8.50	75.7	1470	2600
Mean:	2616	13.1	26.2	61.8	277	0.34	N/A	990	8.43	84.3	1360	2515
SD:	5.86	14.2	35.8	45.4	31.5	0.24	N/A	123	3.16	27.9	129	100
Females												
5347	2631	0.77	0.54	21.1	415	0.10	N/A	792	109	58.3	1374	2609
5348	2600	45.2	9.69	47.3	374	0.30	N/A	567	6.82	50.3	998	2498
5352	2639	26.5	4.01	38.8	365	0.24	N/A	608	3.59	40.7	1018	2570
Mean:	2623	24.2	4.75	35.7	385	0.21	N/A	655	39.79	49.8	1130	2559
SD:	20.7	22.3	4.62	13.3	26.8	0.10	N/A	120	59.92	8.82	212	56.4

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 4 (24 hr exposure)												
Males												
5328	2632	0.41	0.14	10.5	178	0.05	1.17	1170	20.6	48.7	1418	2621
5336	2578	0.50	0.10	10.1	167	0.06	1.66	1317	28.3	52.2	1566	2567
5344	2603	0.54	0.08	10.2	157	0.12	2.02	1114	17.9	36.3	1327	2592
5345	2650	0.80	0.20	9.81	163	0.05	0.91	802	19.4	34.2	1019	2639
Mean:	2615	0.56	0.13	10.2	166	0.07	1.44	1101	21.57	42.8	1333	2605
SD:	31.8	0.17	0.05	0.30	8.75	0.03	0.50	217	4.64	8.94	231	31.7
Females												
5351	2614	1.07	0.74	25.4	329	0.04	0.72	948	42.3	28.6	1348	2587
5353	2650	0.70	0.21	14.7	249	0.03	0.57	1227	10.7	39.1	1526	2634
5359	2646	1.80	0.44	21.7	525	0.06	0.71	993	21.2	36.4	1577	2622
5365	2621	0.77	0.43	40.0	208	0.05	0.59	659	10.4	41.6	920	2580
Mean:	2633	1.08	0.45	25.5	328	0.05	0.65	957	21.14	36.4	1343	2606
SD:	17.7	0.51	0.22	10.7	141	0.01	0.08	233	14.95	5.60	298	26.4

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 5 (48 hr exposure)												
Males												
5329	2566	0.13	0.17	7.92	129	0.03	N/A	1381	32.7	21.6	1564	2558
5333	2611	0.16	0.04	7.63	171	0.06	N/A	1218	155	18.7	1562	2603
5341	2589	0.12	0.00	7.16	168	0.06	N/A	1358	31.6	20.6	1578	2582
Mean:	2589	0.14	0.07	7.57	156	0.05	N/A	1319	73.0	20.3	1568	2581
SD:	22.5	0.02	0.09	0.38	23.4	0.02	N/A	88.3	70.8	1.46	8.51	22.7
Females												
5360	2594	0.16	0.13	7.89	468	0.06	N/A	864	8.13	23.0	1363	2586
5364	2597	0.28	0.04	16.0	422	0.08	N/A	987	12.2	27.2	1449	2580
5366	2632	0.19	0.23	14.1	612	0.05	N/A	661	15.8	35.2	1324	2617
Mean:	2607	0.21	0.13	12.7	501	0.07	N/A	837	12.0	28.4	1379	2594
SD:	20.9	0.06	0.10	4.26	99.0	0.01	N/A	165	3.85	6.17	63.8	19.8

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 1 (3 hr exposure)												
Males												
5836	8633	3629	607	1108	671	3.37	N/A	409	100	843	2027	3289
5841	8572	4106	443	842	540	2.63	N/A	719	1.73	656	1919	3180
5844	8648	2831	265	881	762	4.14	N/A	1125	27.1	1163	3081	4671
Mean:	8617	3522	438	944	658	3.38	N/A	751	43.1	887	2342	3713
SD:	40.4	644	171	144	112	0.75	N/A	359	51.2	256	642	831
Females												
5853	8707	2841	331	678	683	4.99	N/A	717	19.7	984	2408	4858
5855	8315	2631	351	757	1088	5.96	N/A	1046	9.98	741	2891	4576
5863	8681	3793	525	851	933	1.78	N/A	457	2.00	809	2203	3511
Mean:	8568	3088	402	762	901	4.24	N/A	740	10.6	844	2501	4315
SD:	219	619	107	86.7	204	2.18	N/A	295	8.88	126	353	710

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 2 (6 hr exposure)												
Males												
5832	8588	2639	242	995	933	3.02	N/A	1328	6.40	551	2821	4712
5834	8626	3041	355	639	562	1.05	N/A	1403	6.59	425	2398	4591
5845	8680	2304	443	949	857	2.82	N/A	1368	8.45	642	2877	4984
Mean:	8631	2661	347	861	784	2.30	N/A	1366	7.15	540	2699	4762
SD:	46.0	369	101	193	196	1.08	N/A	37.4	1.13	109	262	201
Females												
5846	8677	3204	324	525	929	1.64	N/A	1032	9.08	563	2534	4623
5858	8676	2644	310	600	1046	2.62	N/A	1551	9.86	538	3147	5122
5860	8659	2697	232	1090	891	0.94	N/A	1065	91.5	651	2700	4641
Mean:	8671	2848	289	738	955	1.73	N/A	1216	36.8	584	2794	4796
SD:	10.0	309	49.9	307	80.9	0.84	N/A	290	47.3	59	317	283

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 3 (12 hr exposure)												
Males												
5715	8702	1591	239	735	732	2.03	N/A	1701	54.5	647	3136	6137
5831	8636	488	86.9	303	1033	1.16	N/A	2780	48.2	385	4247	7758
5837	8699	625	88.8	354	1165	0.86	N/A	2902	36.6	350	4454	7631
Mean:	8679	901	138	464	977	1.35	N/A	2461	46.4	461	3946	7175
SD:	37.2	601	87.0	236	222	0.60	N/A	661	9.08	163	709	902
Females												
5847	8742	1365	138	617	944	1.11	N/A	2679	34.1	215	3873	6621
5850	8748	1063	83.0	366	931	1.28	N/A	2870	23.3	690	4516	7237
5864	8693	915	142	446	846	1.35	N/A	2811	65.0	525	4249	7190
Mean:	8728	1114	121	477	907	1.25	N/A	2786	40.8	477	4213	7016
SD:	30.1	230	33.2	129	53.1	0.12	N/A	97.9	21.6	241	323	343

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 4 (24 hr exposure)												
Males												
5713	8722	2.45	0.77	56.0	981	0.29	4.94	2544	68.9	227	3826	8663
5829	8951	0.96	0.67	55.2	1103	0.20	2.88	3269	39.1	120	4534	8894
5830	8689	4.83	1.03	43.8	1165	0.43	3.71	3207	80.4	156	4612	8639
5839	8696	1.19	1.79	46.7	709	0.11	7.68	4092	84.3	147	5040	8647
Mean:	8764	2.36	1.07	50.4	989	0.26	4.80	3278	68.1	163	4503	8711
SD:	125	1.77	0.51	6.13	202	0.13	2.10	634	20.4	45.4	503	123
Females												
5851	8563	27.5	24.1	90.8	1163	1.00	6.26	3189	72.5	284	4716	8421
5852	8738	35.3	9.59	50.2	738	0.43	4.23	3331	91.8	194	4360	8643
5857	8698	117	19.8	53.8	1535	0.35	3.24	2908	67.2	217	4731	8507
5861	8643	15.7	8.38	67.2	637	0.27	2.78	2968	307	129	4043	8552
Mean:	8693	49.0	15.5	65.5	1018	0.51	4.13	3099	135	206	4463	8531
SD:	47.6	46.4	7.70	18.4	413	0.33	1.54	196	115	63.9	328	92.5

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 5 (48 hr exposure)												
Males												
5720	8620	0.00	0.23	26.8	809	0.12	N/A	3752	157	135	4853	8593
5828	8720	0.00	0.60	27.4	631	0.10	N/A	3924	95.2	82.7	4733	8692
5840	8625	0.18	0.52	40.8	700	0.15	N/A	4085	220	86.9	5092	8584
Mean:	8655	0.06	0.45	31.7	714	0.12	N/A	3920	157	101	4893	8623
SD:	56.1	0.11	0.20	7.89	89.8	0.03	N/A	166	62.2	28.8	183	59.8
Females												
5848	8660	0.00	0.14	18.9	851	0.31	N/A	3676	116	54.4	4698	8641
5854	8628	0.00	0.00	28.4	1051	0.29	N/A	2945	654	117	4767	8600
5862	8737	0.00	0.00	26.7	597	0.13	N/A	3772	126	104	4600	8711
Mean:	8675	0.00	0.05	24.7	833	0.24	N/A	3465	299	91.6	4688	8650
SD:	56.3	0.00	0.08	5.05	227	0.10	N/A	452	308	32.9	84.3	56.1

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 1 (3 hr exposure)												
Males												
5723	25276	10436	1764	1589	4065	5.19	N/A	1153	261	1272	6755	11486
5733	25564	9273	1811	4097	4032	2.19	N/A	693	206	1482	6416	10383
5736	25681	7892	1403	2807	3725	1.97	N/A	1563	230	1836	7356	13580
Mean:	25507	9200	1659	2831	3941	3.12	N/A	1136	232	1530	6842	11816
SD:	209	1274	223	1254	188	1.80	N/A	435	27.2	285	476	1624
Females												
5741	25609	7390	817	3637	3270	9.20	N/A	1833	200	2013	7325	13765
5744	25777	10282	1244	2126	2875	4.52	N/A	940	425	1232	5476	12125
5762	25588	12435	1213	2431	2046	4.82	N/A	702	207	972	3931	9508
Mean:	25658	10036	1091	2731	2730	6.18	N/A	1158	277	1406	5577	11799
SD:	103.7	2532	239	799	625	2.62	N/A	597	128	542	1699	2147

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 2 (6 hr exposure)												
Males												
5722	25374	10487	1047	1324	4078	4.69	N/A	1951	410	1264	7709	12516
5734	25458	12757	988	1907	2707	1.40	N/A	1400	566	1179	5854	9807
5737	25285	8185	761	1222	4180	4.88	N/A	2929	795	1364	9274	15116
Mean:	25373	10476	932	1485	3655	3.66	N/A	2094	590	1269	7612	12480
SD:	86.6	2286	151	369	823	1.96	N/A	774	193	92.7	1712	2655
Females												
5746	24215	9698	919	1427	5903	3.35	N/A	2586	148	1739	10380	12171
5751	25141	5641	467	822	5227	3.35	N/A	4255	265	1406	11157	18211
5761	25437	9867	1371	2253	3542	2.53	N/A	1652	159	1289	6644	11946
Mean:	24931	8402	919	1501	4891	3.08	N/A	2831	191	1478	9393	14109
SD:	637.5	2393	452	718	1216	0.47	N/A	1319	64.4	234	2413	3554

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 3 (12 hr exposure)												
Males												
5716	24917	5915	589	1266	2653	1.48	N/A	3300	983	512	7449	17148
5717	25526	9775	969	2025	1660	2.68	N/A	3793	256	404	6116	12757
5726	25664	5580	910	1806	1880	2.06	N/A	4394	760	540	7576	17368
Mean:	25369	7090	823	1699	2064	2.07	N/A	3829	666	485	7047	15758
SD:	398	2331	205	391	522	0.60	N/A	548	372	72.0	809	2601
Females												
5739	25461	7403	1066	2565	1197	1.62	N/A	2879	1029	380	5488	14427
5750	25738	7972	1100	2517	2841	2.59	N/A	1901	375	959	6078	14150
5752	25383	2878	350	767	4188	2.17	N/A	5596	858	326	10971	21388
Mean:	25527	6084	839	1949	2742	2.13	N/A	3459	754	555	7512	16655
SD:	187	2791	423	1025	1498	0.49	N/A	1915	340	351	3010	4101

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 4 (24 hr exposure)												
Males												
5724	25573	7.65	3.76	53.6	3836	0.48	15.6	9843	648	475	14818	25507
5725	25473	1809	419	975	3397	1.69	27.9	8726	828	267	13247	22269
5727	25709	1287	153	459	3614	1.83	22.3	7135	388	382	11543	23810
5735	25401	3716	330	845	3476	1.62	19.0	6086	1193	626	11401	20510
Mean:	25539	1705	227	583	3581	1.41	21.2	7947	764	437	12752	23024
SD:	133	1540	185	416	192	0.63	5.26	1665	338	152	1612	2135
Females												
5740	25119	248	27.7	105	4295	1.25	12.7	7605	923	479	13316	24738
5742	25562	2719	259	510	3916	1.57	14.1	5861	526	428	10746	22073
5753	25431	4178	462	799	3572	1.31	13.7	5655	657	311	10210	19992
5756	25724	2383	358	676	5023	1.79	15.1	5730	514	420	11704	22306
Mean:	25459	2382	277	523	4202	1.48	13.9	6213	655	410	11494	22277
SD:	256	1622	186	303	622	0.25	0.99	932	190	70.3	1363	1942

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 5 (48 hr exposure)												
Males												
5721	24953	4.10	1.59	35.9	1441	0.12	N/A	11199	1244	250	14134	24912
5728	25288	7.69	4.11	48.0	2832	0.40	N/A	8725	1341	351	13249	25228
5732	25842	5.31	1.62	66.5	1978	0.13	N/A	10346	764	159	13247	25769
Mean:	25361	5.70	2.44	50.2	2084	0.22	N/A	10090	1116	253	13543	25303
SD:	449	1.82	1.45	15.4	701	0.16	N/A	1257	309	96.1	511	433
Females												
5738	25663	4.28	4.28	97.0	2573	0.61	N/A	7735	1076	253	11637	25557
5758	25337	2.21	0.94	41.3	2258	0.48	N/A	9263	2233	168	13922	25293
5760	24583	4.61	2.04	47.9	3375	0.65	N/A	8439	1283	321	13418	24529
Mean:	25194	3.70	2.42	62.1	2735	0.58	N/A	8479	1530	247	12992	25126
SD:	554	1.30	1.70	30.4	576	0.09	N/A	765	617	76.7	1200	534

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 4 (24 hr exposure)												
Males												
5714	22922	27.3	9.36	78.2	3437	1.31	11.5	10775	298	600	15123	22807
5718	23194	4.16	0.88	59.0	3469	0.64	11.8	11564	316	880	16242	23130
5719	22876	9.30	7.07	313	2321	0.51	15.0	10654	288	1138	14415	22547
5730	23264	14.7	6.77	79.6	3664	0.86	10.6	10508	242	648	15073	23163
Mean:	23064	13.9	6.02	132	3223	0.83	12.2	10875	286	816	15213	22912
SD:	194	9.95	3.62	120	609	0.35	1.94	472	31.7	247	758	291
Females												
5743	23139	383	81.7	1750	5477	2.04	12.3	5499	365	1714	13069	20924
5745	23484	168	46.4	1457	5156	1.47	13.3	9238	373	2053	16834	21813
5748	23204	256	47.5	587	4103	1.43	14.3	9736	306	1607	15767	22313
5754	23448	160	41.8	521	3712	1.53	10.1	9789	854	1176	15544	22726
Mean:	23319	242	54.3	1079	4612	1.62	12.5	8565	474	1637	15304	21944
SD:	173	104	18.4	618	839	0.28	1.80	2059	255	361	1592	776

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5; SUB-GROUP 1 (14 day exposure)												
Males												
5871	34370	5.65	2.58	109	1174	0.28	4.26	18981	2222	249	22631	34253
5883	35175	5.24	6.90	113	1871	0.43	5.41	17917	2948	201	22943	35050
5884	35167	6.09	4.29	101	1295	0.30	3.80	18253	1318	177	21047	35056
5889	34614	2.51	3.64	57.9	1687	0.17	2.14	17659	995	166	20509	34550
Mean:	34831	4.87	4.35	95.1	1507	0.30	3.90	18203	1871	198	21783	34727
SD:	405	1.61	1.84	25.3	327	0.11	1.36	573	886	36.8	1187	395
Females												
5896	35125	0.35	0.40	66.3	1251	0.24	1.48	22107	1634	102	25095	35058
5899	35392	3.06	2.14	92.2	1418	0.21	1.84	17509	1895	171	20995	35294
5900	35545	2.69	2.55	101	1606	0.32	2.21	21068	1553	146	24374	35439
5921	35483	2.52	1.41	90.0	2085	0.32	2.19	18941	3182	161	24371	35389
Mean:	35386	2.15	1.62	87.4	1590	0.27	1.93	19906	2066	145	23709	35295
SD:	185	1.23	0.94	14.8	360	0.06	0.35	2071	758	30.5	1841	169

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 5; SUB-GROUP 2 (28 day exposure)												
Males												
5869	69943	10.1	7.82	169	3354	0.06	3.22	42082	1792	222	47454	69756
5870	69882	11.4	7.99	129	3249	0.14	2.50	37816	1060	197	42325	69734
5888	70041	6.26	5.78	181	2800	0.31	2.36	36401	1970	204	41378	69848
5893	70054	6.35	5.30	119	2927	0.03	2.81	42823	2575	197	48525	69923
Mean:	69980	8.53	6.72	149	3083	0.14	2.72	39780	1849	205	44920	69815
SD:	81.7	2.62	1.39	30.1	261	0.13	0.38	3154	624	11.7	3591	87.3
Females												
5910	70219	4.69	3.43	110	4103	0.38	1.71	44516	1955	164	50740	70101
5911	70742	8.44	7.60	176	3589	0.28	1.91	41431	2279	151	47452	70550
5915	70741	6.49	5.76	189	3914	0.64	1.96	38877	3177	222	46193	70540
5916	70693	6.84	4.71	161	3243	0.20	1.89	32271	4270	238	40024	70521
Mean:	70599	6.62	5.37	159	3712	0.38	1.87	39274	2920	194	46102	70428
SD:	254	1.54	1.76	34.6	378	0.19	0.11	5207	1038	42.6	4483	218

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 6; SUB-GROUP 1 (14 day exposure)												
Males												
5867	116203	0.00	0.35	229	3024	0.75	9.44	75592	19122	410	98158	115974
5868	115151	10.9	12.7	315	2802	0.19	7.26	93863	4704	489	101865	114812
5875	116051	4.76	6.77	264	1875	0.65	6.27	86587	2912	676	92056	115775
5881	115452	0.00	0.00	154	3835	0.49	6.57	82116	2009	560	88527	115298
Mean:	115714	3.93	4.96	241	2884	0.52	7.38	84539	7187	534	95152	115465
SD:	496	5.19	6.04	67.9	806	0.24	1.43	7682	8035	113	5988	519
Females												
5895	116082	1.05	5.21	283	3296	0.52	6.15	73968	3846	538	81655	115793
5907	116695	0.00	0.00	149	4835	0.34	5.23	70323	4465	647	80276	116546
5909	117836	0.29	3.27	228	3584	0.34	6.38	77940	7299	413	89243	117604
5918	141101	0.85	4.13	284	2996	0.89	5.05	75672	6193	448	85315	140813
Mean:	122929	0.54	3.15	236	3678	0.52	5.70	74476	5451	512	84122	122689
SD:	12137	0.49	2.24	63.4	808	0.26	0.66	3211	1583	105	4022	12105

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 6; SUB-GROUP 2 (28 day exposure)												
Males												
5880	232276	25.1	17.1	302	6820	0.40	7.37	150589	4626	756	162800	231931
5885	233586	28.7	28.5	315	6316	0.68	8.04	141089	10584	566	158564	233213
5887	233827	176	86.6	431	6328	0.65	7.73	144234	8988	602	160160	233133
5894	234522	326	122	640	5810	1.06	15.65	145256	7741	825	159649	233435
Mean:	233553	139	63.7	422	6318	0.70	9.70	145292	7985	687	160293	232928
SD:	939	143	49.7	156	413	0.27	3.98	3952	2523	123	1799	677
Females												
5903	235620	28.4	29.4	519	5384	0.90	5.62	139684	13659	563	159296	235043
5912	234976	13.9	17.1	335	4790	0.85	5.30	151982	8449	372	165599	234610
5917	233941	34.0	27.4	468	9026	0.82	6.17	138900	7839	771	156543	233412
5919	236166	23.0	13.7	246	4096	0.80	4.33	163005	6811	481	174399	235884
Mean:	235176	24.8	21.9	392	5824	0.84	5.36	148393	9189	547	163959	234737
SD:	956	8.54	7.70	125	2199	0.04	0.77	11436	3055	169	7925	1030

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 1 (14 day exposure)												
Males												
5872	338012	29.7	16.7	336	11414	1.95	31.5	177145	19274	3412	211279	337630
5873	338327	5.14	12.2	209	26789	1.65	12.3	172511	31058	1024	231396	338101
5874	343114	95.3	47.8	804	13604	3.73	8.98	196992	10023	2367	222999	342166
5882	337481	25.3	16.6	402	18816	1.32	14.2	161969	11649	2138	194588	337037
Mean:	339233	38.9	23.3	438	17655	2.17	16.7	177154	18001	2236	215065	338734
SD:	2610	39.1	16.5	257	6834	1.08	10.1	14671	9594	980	15951	2330
Females												
5901	340060	1957	893	3576	13233	3.97	19.8	203709	13843	2126	232935	333633
5902	341880	2739	752	2416	19957	5.45	32.8	167400	21415	2876	211686	335973
5913	344766	225	194	664	31873	1.07	15.9	186230	24139	2245	244504	343684
5920	321052	1362	486	1201	14470	6.65	31.5	189963	19123	4974	228568	318003
Mean:	336940	1571	581	1964	19883	4.29	25.0	186825	19630	3055	229423	332823
SD:	10768	1060	309	1301	8511	2.40	8.42	14973	4369	1321	13603	10773

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 2 (28 day exposure)												
Males												
5878	689326	529	432	3989	21470	2.56	29.6	391295	69445	2557	484800	684377
5886	691850	15.2	22.8	764	17686	2.85	16.6	433082	35080	3103	488970	691048
5891	690785	1896	1015	2704	20692	3.98	60.5	397937	35988	2975	457657	685169
5892	692890	4.97	6.14	339	22918	1.77	19.0	335374	42372	3081	403766	692541
Mean:	691213	611	369	1949	20692	2.79	31.4	389422	45721	2929	458798	688284
SD:	1524	891	474	1706	2206	0.92	20.2	40428	16146	254	39227	4112
Females												
5905	692523	13.53	21.3	598	24488	1.86	14.1	388724	55466	1819	470513	691890
5906	691992	2.73	11.5	601	24489	1.08	17.5	404578	46237	2626	477949	691376
5908	698518	2.16	13.7	674	32343	2.20	13.1	398615	30629	1811	463413	697829
5914	670928	305	499	632	15016	1.29	12.3	426323	47584	1246	490181	669491
Mean:	688490	80.9	137	626	24084	1.61	14.2	404560	44979	1875	475514	687647
SD:	12077	150	242	35.1	7089	0.51	2.29	15914	10397	568	11438	12453

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 1 (3 hr exposure)												
Males												
5331	5434	933	285	1223	523	1.43	N/A	491	43.2	634	1692	2993
5339	5508	1551	178	615	504	4.23	N/A	1120	0.43	475	2104	3165
5340	5336	1602	187	978	511	2.76	N/A	352	0.75	595	1461	2569
Mean:	5426	1362	216	939	512	2.81	N/A	654	14.8	568	1752	2909
SD:	86.5	372	59.3	306	9.67	1.40	N/A	409	24.6	82.5	325	307
Females												
5355	5439	1769	222	855	526	2.17	N/A	756	0.68	251	1536	2594
5356	5476	1902	184	859	641	2.15	N/A	633	3.95	249	1529	2531
5362	5354	776	134	916	921	3.93	N/A	1159	1.11	311	2396	3528
Mean:	5423	1482	180	877	696	2.75	N/A	850	1.91	271	1821	2884
SD:	62.4	615	43.9	34.1	203	1.02	N/A	275	1.78	35.1	499	558

TABLE H2. Distribution of PCMX Equivalents following Dermal Administration (as Total Micrograms)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 2 (28 day exposure)												
Males												
5878	689326	529	432	3989	21470	2.56	29.6	391295	69445	2557	484800	684377
5886	691850	15.2	22.8	764	17686	2.85	16.6	433082	35080	3103	488970	691048
5891	690785	1896	1015	2704	20692	3.98	60.5	397937	35988	2975	457657	685169
5892	692890	4.97	6.14	339	22918	1.77	19.0	335374	42372	3081	403766	692541
Mean:	691213	611	369	1949	20692	2.79	31.4	389422	45721	2929	458798	688284
SD:	1524	891	474	1706	2206	0.92	20.2	40428	16146	254	39227	4112
Females												
5905	692523	13.53	21.3	598	24488	1.86	14.1	388724	55466	1819	470513	691890
5906	691992	2.73	11.5	601	24489	1.08	17.5	404578	46237	2626	477949	691376
5908	698518	2.16	13.7	674	32343	2.20	13.1	398615	30629	1811	463413	697829
5914	670928	305	499	632	15016	1.29	12.3	426323	47584	1246	490181	669491
Mean:	688490	80.9	137	626	24084	1.61	14.2	404560	44979	1875	475514	687647
SD:	12077	150	242	35.1	7089	0.51	2.29	15914	10397	568	11438	12453

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 2 (6 hr exposure)												
Males												
5332	5537	933	3.25	98.3	637	0.62	N/A	2847	3.10	336	3824	4503
5342	5546	316	62.4	312	523	1.84	N/A	1622	3.51	232	2383	4856
5343	5512	743	89.3	457	421	0.85	N/A	972	0.26	316	1710	4222
Mean:	5532	664	51.7	289	527	1.10	N/A	1814	2.29	295	2639	4527
SD:	17.6	316	44.0	180	108	0.65	N/A	952	1.77	55.0	1080	317
Females												
5349	5496	368	70.4	317	571	2.46	N/A	1125	2.87	235	1937	4740
5350	5409	891	169	1095	297	1.74	N/A	688	1.91	221	1210	3254
5363	5509	1263	176	780	304	2.42	N/A	969	8.47	204	1488	3290
Mean:	5471	841	138	731	391	2.21	N/A	928	4.42	220	1545	3761
SD:	54.3	450	58.9	392	156	0.41	N/A	221	3.54	15.6	367	848

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 3 (12 hr exposure)												
Males												
5327	5490	20.0	22.2	119	574	0.89	N/A	2189	24.2	129	2917	5329
5330	5472	60.1	141	230	518	1.12	N/A	1781	11.0	242	2553	5042
5334	5496	2.21	1.77	39.9	650	0.15	N/A	2256	17.8	159	3083	5452
Mean:	5486	27.5	54.9	130	580	0.72	N/A	2076	17.7	177	2851	5274
SD:	12.3	29.7	75.0	95.3	66.1	0.51	N/A	257	6.62	58.6	271	210
Females												
5347	5518	1.61	1.14	44.3	871	0.21	N/A	1660	228	122	2882	5470
5348	5451	94.8	20.3	99.1	784	0.62	N/A	1189	14.3	105	2094	5237
5352	5533	55.7	8.40	81.3	766	0.51	N/A	1274	7.53	85.4	2134	5388
Mean:	5501	50.7	9.95	74.9	807	0.44	N/A	1374	83.4	104	2370	5365
SD:	43.4	46.8	9.68	27.9	56.3	0.21	N/A	251	126	18.5	444	118

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 4 (24 hr exposure)												
Males												
5328	5519	0.86	0.30	22.1	373	0.11	2.45	2453	43.2	102	2974	5496
5336	5405	1.05	0.21	21.2	350	0.12	3.47	2761	59.4	109	3284	5382
5344	5457	1.12	0.17	21.3	329	0.24	4.24	2335	37.6	76.2	2783	5434
5345	5556	1.68	0.41	20.6	342	0.11	1.91	1681	40.7	71.6	2137	5533
Mean:	5484	1.18	0.27	21.3	348	0.15	3.02	2308	45.2	89.8	2794	5461
SD:	66.7	0.35	0.11	0.63	18.3	0.07	1.04	455	9.73	18.7	484	66.5
Females												
5351	5482	2.24	1.56	53.3	690	0.09	1.51	1987	88.6	60.1	2827	5425
5353	5556	1.46	0.43	30.9	522	0.07	1.19	2572	22.3	81.9	3200	5523
5359	5549	3.78	0.91	45.5	1100	0.13	1.49	2083	44.5	76.2	3306	5499
5365	5497	1.61	0.89	83.9	436	0.10	1.23	1382	21.9	87.2	1928	5410
Mean:	5521	2.27	0.95	53.4	687	0.10	1.35	2006	44.3	76.3	2815	5464
SD:	37.1	1.06	0.46	22.3	295	0.02	0.17	489	31.3	11.7	626	55.3

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 1; SUB-GROUP 5 (48 hr exposure)												
Males												
5329	5380	0.27	0.35	16.6	270	0.07	N/A	2896	68.6	45.2	3280	5363
5333	5475	0.35	0.08	16.0	358	0.12	N/A	2554	325	39.2	3276	5458
5341	5429	0.25	0.00	15.0	352	0.14	N/A	2847	66.2	43.2	3309	5414
Mean:	5428	0.29	0.14	15.9	327	0.11	N/A	2766	153	42.5	3288	5412
SD:	47.3	0.05	0.18	0.80	49.1	0.03	N/A	185	149	3.07	17.8	47.7
Females												
5360	5439	0.33	0.28	16.6	981	0.13	N/A	1812	17.0	48.3	2859	5422
5364	5444	0.59	0.08	33.7	885	0.17	N/A	2069	25.5	57.0	3037	5410
5366	5518	0.41	0.49	29.6	1283	0.11	N/A	1385	33.2	73.7	2776	5487
Mean:	5467	0.44	0.28	26.6	1050	0.14	N/A	1756	25.2	59.7	2891	5440
SD:	43.9	0.13	0.20	8.93	208	0.03	N/A	345	8.06	12.9	134	41.5

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 1 (3 hr exposure)												
Males												
5836	5430	2283	382	697	422	2.12	N/A	258	63.1	530	1275	2069
5841	5392	2583	279	530	340	1.65	N/A	452	1.09	412	1207	2000
5844	5440	1781	167	554	479	2.60	N/A	707	17.1	731	1938	2938
Mean:	5421	2216	276	594	414	2.12	N/A	472	27.1	558	1473	2336
SD:	25.4	405	108	90.3	70.3	0.47	N/A	226	32.2	161	404	523
Females												
5853	5477	1787	208	427	429	3.14	N/A	451	12.4	619	1515	3056
5855	5230	1655	221	476	684	3.75	N/A	658	6.28	466	1818	2878
5863	5460	2386	330	536	587	1.12	N/A	288	1.26	509	1386	2209
Mean:	5389	1943	253	479	567	2.67	N/A	466	6.65	531	1573	2714
SD:	138	389	67.1	54.5	129	1.37	N/A	186	5.59	79.1	222	447

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 2 (6 hr exposure)												
Males												
5832	5402	1660	152	626	587	1.90	N/A	835	4.02	347	1775	2964
5834	5426	1913	224	402	354	0.66	N/A	882	4.14	268	1509	2888
5845	5460	1449	279	597	539	1.78	N/A	860	5.32	404	1810	3135
Mean:	5429	1674	218	542	493	1.45	N/A	859	4.50	339	1698	2996
SD:	28.9	232	63.3	122	123	0.68	N/A	23.5	0.71	68.4	165	127
Females												
5846	5458	2016	204	330	584	1.03	N/A	649	5.71	354	1594	2908
5858	5457	1663	195	377	658	1.65	N/A	976	6.20	338	1980	3222
5860	5447	1697	146	685	560	0.59	N/A	670	57.5	410	1698	2919
Mean:	5454	1792	182	464	601	1.09	N/A	765	23.1	367	1757	3017
SD:	6.28	195	31.4	193	50.9	0.53	N/A	183	29.8	37.4	199	178

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 3 (12 hr exposure)												
Males												
5715	5474	1001	150	463	461	1.27	N/A	1070	34.3	407	1973	3860
5831	5432	307	54.7	191	650	0.73	N/A	1749	30.3	242	2672	4880
5837	5472	393	55.8	222	733	0.54	N/A	1825	23.0	220	2802	4800
Mean:	5459	567	86.9	292	614	0.85	N/A	1548	29.2	290	2482	4513
SD:	23.4	378	54.7	149	140	0.38	N/A	416	5.71	102	446	567
Females												
5847	5499	859	87.1	388	594	0.70	N/A	1685	21.4	135	2437	4165
5850	5503	668	52.2	230	586	0.81	N/A	1805	14.7	434	2841	4552
5864	5468	575	89.5	281	532	0.85	N/A	1768	40.9	330	2673	4523
Mean:	5490	701	76.3	300	571	0.78	N/A	1753	25.7	300	2650	4413
SD:	18.9	144	20.9	80.8	33.4	0.08	N/A	61.6	13.6	152	203	216

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 4 (24 hr exposure)												
Males												
5713	5486	1.54	0.49	35.3	617	0.18	3.11	1600	43.3	143	2407	5449
5829	5630	0.60	0.42	34.7	694	0.13	1.81	2057	24.6	75.6	2852	5595
5830	5466	3.04	0.65	27.5	733	0.27	2.33	2017	50.5	98.0	2901	5435
5839	5470	0.75	1.13	29.4	446	0.07	4.83	2574	53.0	92.8	3171	5439
Mean:	5513	1.48	0.67	31.7	622	0.16	3.02	2062	42.9	102	2833	5479
SD:	78.6	1.12	0.32	3.86	127	0.08	1.32	399	12.9	28.5	317	77.1
Females												
5851	5387	17.3	15.2	57.1	732	0.63	3.94	2006	45.6	178	2966	5297
5852	5497	22.2	6.03	31.6	465	0.27	2.66	2095	57.8	122	2742	5437
5857	5471	73.9	12.4	33.9	966	0.22	2.04	1829	42.3	137	2976	5351
5861	5437	9.8	5.27	42.3	400	0.17	1.75	1867	193	81.1	2543	5379
Mean:	5468	30.8	9.73	41.2	641	0.32	2.60	1949	84.7	129	2807	5366
SD:	30.0	29.2	4.84	11.5	260	0.21	0.97	123	72.6	40.2	206	58.2

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 2; SUB-GROUP 5 (48 hr exposure)												
Males												
5720	5422	0.00	0.14	16.9	509	0.08	N/A	2360	98.9	84.6	3053	5405
5828	5485	0.00	0.37	17.2	397	0.06	N/A	2468	59.9	52.0	2977	5467
5840	5426	0.12	0.33	25.7	440	0.10	N/A	2570	138	54.7	3203	5399
Mean:	5444	0.04	0.28	19.9	449	0.08	N/A	2466	99.0	63.8	3078	5424
SD:	35.3	0.07	0.12	4.96	56.5	0.02	N/A	105	39.2	18.1	115	37.6
Females												
5848	5447	0.00	0.09	11.9	535	0.20	N/A	2312	73.2	34.2	2955	5435
5854	5427	0.00	0.00	17.9	661	0.18	N/A	1853	412	73.4	2999	5409
5862	5496	0.00	0.00	16.8	376	0.08	N/A	2373	79.5	65.3	2893	5479
Mean:	5457	0.00	0.03	15.5	524	0.15	N/A	2179	188	57.6	2949	5441
SD:	35.4	0.00	0.05	3.18	143	0.06	N/A	285	194	20.7	53.0	35.3

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 3; SUB-GROUP 1 (3 hr exposure)												
Males												
5723	5300	2188	370	333	852	1.09	N/A	242	54.6	267	1416	2408
5733	5360	1944	380	859	845	0.46	N/A	145	43.3	311	1345	2177
5736	5385	1655	294	589	781	0.41	N/A	328	48.2	385	1542	2847
Mean:	5348	1929	348	594	826	0.65	N/A	238	48.7	321	1435	2478
SD:	43.7	267	46.8	263	39.3	0.38	N/A	91.3	5.70	59.8	100	340
Females												
5741	5370	1550	171	763	686	1.93	N/A	384	41.8	422	1536	2886
5744	5405	2156	261	446	603	0.95	N/A	197	89.0	258	1148	2542
5762	5365	2607	254	510	429	1.01	N/A	147	43.3	204	824	1994
Mean:	5380	2104	229	573	572	1.30	N/A	243	58.1	295	1169	2474
SD:	21.8	531	50.0	168	131	0.55	N/A	125	26.8	114	356	450

TABLE H3. Distribution of PCMX Equivalents following Dermal Administration (as Total NanoCuries)

		NOT ABSORBED		ABSORBABLE	ABSORBED							
Anim. No.	Actual Dose	Soap Wash	Water Wash	Skin	Cage Wash	Blood	Tissues	Urine	Feces	Carcass	Amt. Absorbed (Direct)	Amt. Absorbed (Indirect)
GROUP 7; SUB-GROUP 2 (28 day exposure)												
Males												
5878	57589	44.2	36.1	333	1794	0.21	2.47	32691	5802	214	40502	57176
5886	57800	1.3	1.90	63.8	1478	0.24	1.39	36182	2931	259	40851	57733
5891	57711	158	84.8	226	1729	0.33	5.05	33245	3007	249	38235	57242
5892	57887	0.42	0.5	28.3	1915	0.15	1.59	28019	3540	257	33732	57858
Mean:	57747	51.1	30.8	163	1729	0.23	2.62	32534	3820	245	38330	57502
SD:	127	74.4	39.6	143	184	0.08	1.68	3378	1349	21.2	3277	344
Females												
5905	57856	1.13	1.78	50.0	2046	0.16	1.18	32476	4634	152	39309	57804
5906	57812	0.23	0.96	50.2	2046	0.09	1.46	33800	3863	219	39930	57761
5908	58357	0.18	1.15	56.3	2702	0.18	1.09	33302	2559	151	38716	58300
5914	56052	25.5	41.73	52.8	1255	0.11	1.02	35617	3975	104	40952	55932
Mean:	57520	6.76	11.41	52.3	2012	0.13	1.19	33799	3758	157	39727	57449
SD:	1009	12.5	20.22	2.93	592	0.04	0.19	1330	869	47.4	956	1040

Ms. Debbie Lumpkins
Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1060
Rockville, MD 20852

FedEx
emp# 203624 24AUG00
** 2DAY **
FRI
TRK# 8198 1600 7164 FORM 0215
Deliver By:
25AUG00
AA
20850 -MD-US
IAD
19 GAIA